# BRAIN METASTASES FROM PRIMARY TUMORS# BRAIN METASTASES FROM PRIMARY TUMORS 

## EPIDEMIOLOGY, BIOLOGY, AND THERAPY OF MELANOMA AND OTHER CANCERS

VOLUME 3

Edited by<br>M.A. Hayat<br>Distinguished Professor<br>Kean University<br>Union, NJ, USA

AMSTERDAM $\cdot$ BOSTON $\cdot$ HEIDELBERG $\cdot$ LONDON NEW YORK $\cdot$ OXFORD $\cdot$ PARIS $\cdot$ SAN DIEGO SAN FRANCISCO $\cdot$ SINGAPORE $\cdot$ SYDNEY $\cdot$ TOKYO

Academic Press is an imprint of Elsevier
![img-0.jpeg](img-0.jpeg)Academic Press is an imprint of Elsevier
125 London Wall, London EC2Y 5AS, UK
525 B Street, Suite 1800, San Diego, CA 92101-4495, USA
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, USA
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK
Copyright © 2016 Elsevier Inc. All rights reserved.
No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

# Notices 

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

## British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library

## Library of Congress Cataloging-in-Publication Data

A catalog record for this book is available from the Library of Congress
ISBN: 978-0-12-803508-5
For information on all Academic Press publications
visit our website at http://www.elsevier.com/
![img-1.jpeg](img-1.jpeg)

Cover image: Figure 3 in Chapter 18: "Treatment of Brain Metastases from Ovarian and Endometrial Carcinomas Using Stereotactic Radiosurgery" by Edward A. Monaco III, Gurpreet S. Gandhoke, Ajay Niranjan, and L. Dade Lunsford, in Brain Metastases from Primary Tumors, Volume 3: Epidemiology, Biology, and Therapy of Melanoma and Other Cancers.

Publisher: Mara Conner
Acquisition Editor: Melanie Tucker
Editorial Project Manager: Kristi Anderson
Production Project Manager: Julia Haynes
Designer: Greg Harris
Typeset by MPS Limited, Chennai, India# Preface 

Metastasis formation is responsible for most cancer deaths. In order to understand brain metastasis from primary cancer, we need to comprehend how cancer cells escape from the primary tumor site, intravasate into blood vessels, accumulate in brain capillaries, survive the hematogenous dissemination to the brain, extravasate and proliferate, and develop angiogenic ability to establish brain metastases. To succeed in finding an effective use of therapeutic drugs, we should understand better the immunologically distinct space that excludes drug macromolecules from the brain. We also need to know the nature of primary tumor cells interaction with the brain microenvironment.

Transfer of primary tumor cells from one organ to another organ is not uncommon. In fact, such transfer of lung cancer, breast cancer, and melanoma to the brain is common. The movement of melanoma, breast cancer, and esophageal cancer (EC) cells to the brain is discussed in this volume of the series Brain Metastases From Primary Tumors: Epidemiology, Biology, and Therapy. The role of melanoma in the development of intracranial cancer is emphasized in this volume. The role of lung cancer in the development of brain metastasis was recently discussed in volume 1 of this series.

Brain metastases, most often from lung cancer, brain cancer, and melanoma, induce a particularly high morbidity and mortality. The incidence rates of melanoma and deaths are increasing. As a result, the death rate due to brain cancer is also increasing. Brain metastasis occurs in $40 \%$ to $60 \%$
of patients with advanced melanoma. Malignant melanoma is the third most common cause of brain metastasis after lung and breast cancer. Approximately, $37 \%$ of patients with stage IV melanoma eventually develop clinically apparent brain metastasis. The prevalence of brain metastasis is $55 \%$ to $75 \%$ of patients who die of melanoma. Brain metastasis typically occurs relatively late in the course of melanoma; approximately 2.2 to 3.8 years after the diagnosis of primary melanoma. Brain metastasis contributes to death in approximately $95 \%$ of patients with cutaneous melanoma with a medium survival of less than 1 year despite treatment. Clinical and molecular factors that predict the development, survival, and treatment outcomes of melanoma patients with brain metastases are explained. Only a few genes associated with melanoma predisposition have been discovered. They are related to cell cycle, DNA damage repair, pigmentation traits, and telomere-regulating pathways. The central role played by the CDKN2A gene within human melanoma families is included in this volume.

Host immune response within the brain is an important factor that has prognostic significance. In this connection, four agents (three targeted therapies against components of the MAPK pathway in BRAFmutant melanomas and one inhibitor of the coinhibitory immune checkpoint protein CTLA4) approved by the FDA have a clinical benefit in patients with active brain metastasis from melanoma, which are explained in this volume.One of the aims in this volume is to analyze prognostic factors, effects of various treatments, and survival outcome in patients with brain metastases arising from melanoma, breast cancer, and EC. The selection of treatment of patients with cerebral metastasis depends on the number and size of lesions and the extracranial extension of the disease.

Despite the introduction and approval of new therapeutic agents, patients with metastatic melanoma still experience poor prognosis. Therefore, it is essential to continue searching for new therapeutic targets and approaches. It is believed that the receptor for advanced glycation end products (RAGE) could be a potential therapeutic target in metastatic melanoma as animal studies show that blocking RAGE with targeted antibodies reduced tumor growth and metastases formation. That RAGE and its ligands contribute to metastatic melanoma is explained in this volume. Another approach to inhibit cancer progression is by using hydrogen sulfide that is known to possess proapoptotic and antiproliferative properties. The synthesis, metabolism, and signaling capacity of this molecule are explained in this volume.

Approximately $10 \%$ to $16 \%$ of breast cancer develops into metastatic brain cancer. The risk of developing this type of metastases is the highest in patients with epidermal growth factor receptor 2 (HER2)-positive breast cancer, followed by triple negative breast tumors. Trastuzumab monoclonal antibody against HER2-positive breast cancer patients can be used, but owing to its high molecular weight, its penetration into the CNS is very low. Alternatively, surgery, stereotactic radiotherapy, and whole brain irradiation can be used (see later). However, there are no uniform recommendations for systemic therapy. Without treatment, the median length of survival following the diagnosis of
brain metastases is approximately 1 month. The development of reliable biomarkers predictive for brain relapse may facilitate selection of new preventive and therapeutic strategies.

The other primary cancer metastatic to brain discussed in this volume is EC. Although this primary cancer metastasizes to lymph nodes, liver, and peritoneum, its ability to metastasize to brain is limited. Brain metastasis from EC has a very poor prognosis, and no clear management has been defined. Possible diagnostic and therapeutic strategies in this situation are explained in this volume.

Intracranial metastases from EC is rare, and the interval between diagnosis of primary lesions and the development of brain metastasis is long in most cases; thus, patients with intracranial metastatic EC survive for a long time. However, after brain metastasis is diagnosed, the prognosis is dismal. Mutations in KIT and PDGFRA genes play an important role in the biology of EC. Chemotherapy is a standard treatment for EC. Imatinib mesylate with activity against these mutations was the first drug approved for the treatment. However, patients with advanced ECs treated with this drug eventually show relapse, and also it cannot pass through the BBB. In spite of its limitations, imatinib is still being used for achieving progression free survival of selected patients of melanoma. The use of this drug in China for treating melanoma patients is discussed in this volume. So, sunitinib was approved as the second-line treatment for EC, which is able to penetrate the BBB. Multimodel combination therapies need to be developed for patients with ECs.

Various treatments applied to patients with brain metastases are discussed in this volume. Surgical resection may immediately relieve significant mass effect in patients with single brain metastasis. Surgery pluswhole-brain radiation therapy (WBRT) shows overall survival benefit. WBRT (30Gy in 10 fractions) is the current standard of cure for patients with five or more brain metastases. Stereotactic radiosurgery (SRS) also has proven to result in excellent local control when used in combination with WBRT. However, the use of WBRT is controversial with respect to neurorecognition. Some studies demonstrate superior outcomes with WBRT, whereas some other studies report negative impact on neurorecognition. It is pointed out in this volume that the choice of WBRT alone, SRS, or surgical resection alone, or the combination of these treatments needs to be individualized based on patients expected overall prognosis.

By bringing together a large number of experts (oncologists, neurosurgeons, physicians, medical research scientists, and pathologists) in the field of brain metastases from primary cancer, it is my hope that substantial progress will be made against this devastating disease inflicting humans. It is difficult for a single author to discuss effectively and comprehensively various aspects of an exceedingly complex process such as brain metastasis from primary cancers of breast, esophagus, and melanoma. Another advantage of involving more than one author is to present different points of view on specific controversial aspects of the advantages and
limitations of various treatments. I hope the information presented in this and other volumes will result in a better understanding of the molecular mechanisms underlying brain metastases and their cure and hopefully their prevention.

This volume was written by 59 contributors representing 9 countries. I am grateful to them for their promptness in accepting my suggestions. Their thoughtful, practical experience highlights the very high quality of their writings, which should build and further the endeavors of the readers in this important medical field. I respect and appreciate the time-consuming hard work invested by the contributors. There exists a tremendous urgent demand by the public and the medical community to address the treatment of this complex disease. In the light of existing disease calamities, government funding must give priority to eradicating deadly malignancies over global military superiority.

I am grateful to Dr Dawood Farahi and Mr Phil Connelly for recognizing the importance of medical research and publishing through an institution of higher education. I am thankful to Elizabeth Shust and my students for their contribution to the final preparation of this volume.
M.A. Hayat

October 2015# Contributors 

![img-2.jpeg](img-2.jpeg)

Érica S.S. Araújo International Research Center, A. C. Camargo Cancer Center, São Paulo, Brazil
![img-3.jpeg](img-3.jpeg)

Mohammad Bashashati Center for Neurogastroenterology and GI Motility, Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX, United States
![img-4.jpeg](img-4.jpeg)

Shivani Bassi Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, United States
![img-5.jpeg](img-5.jpeg)

Giuseppe Cirino Department of Experimental Pharmacology, University of Naples Federico II, Naples, Italy
![img-6.jpeg](img-6.jpeg)

Frances A. Collichio Division of Hematology/ Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
![img-7.jpeg](img-7.jpeg)

Michael A. Davies Melanoma Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States![img-8.jpeg](img-8.jpeg)

Renata Duchnowska Department of Oncology, Military Institute of Medicine, Warsaw, Poland
![img-9.jpeg](img-9.jpeg)

Alexander Engelman Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, United States
![img-10.jpeg](img-10.jpeg)

Majid Esmaeilzadeh Department of Neurosurgery, Hannover Medical School, Hannover, Germany
![img-11.jpeg](img-11.jpeg)

Matthew G. Ewend Division of Hematology/ Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
![img-12.jpeg](img-12.jpeg)

Robert Lance Fine Division of Hematology Oncology, Experimental Therapeutics Section, NYPH Columbia University Medical Center, New York, NY, United States
![img-13.jpeg](img-13.jpeg)

Caterina Fontanella Department of Oncology, University Hospital of Udine, Udine, Italy; Department of Medical and Biological Sciences, University of Udine, Udine, Italy![img-14.jpeg](img-14.jpeg)

Peter A. Forsyth Department of Neurooncology, H. Lee Moffitt Cancer Center \& Research Institute, Tampa, FL, United States
![img-15.jpeg](img-15.jpeg)

Gurpreet S. Gandhoke Center for Image-Guided Neurosurgery, Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, United States
![img-16.jpeg](img-16.jpeg)

Isabella C. Glitza Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
![img-17.jpeg](img-17.jpeg)

Anthony Paul Gulati Division of Hematology Oncology, Experimental Therapeutics Section, NYPH Columbia University Medical Center, New York, NY, United States
![img-18.jpeg](img-18.jpeg)

Jun Guo Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital \& Institute, Beijing, China
![img-19.jpeg](img-19.jpeg)
M.A. Hayat Department of Biology, Kean University, Union, NJ, United States![img-20.jpeg](img-20.jpeg)

Amy Heimberger Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
![img-21.jpeg](img-21.jpeg)

Eirik Helseth Department of Neurosurgery, Oslo University Hospital, Ullevål, Norway
![img-22.jpeg](img-22.jpeg)

Angela M. Hong Melanoma Institute Australia, The Poche Centre, North Sydney, NSW, Australia
![img-23.jpeg](img-23.jpeg)

Angela Ianaro Department of Experimental Pharmacology, University of Naples Federico II, Naples, Italy
![img-24.jpeg](img-24.jpeg)

Jacek Jassem Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
![img-25.jpeg](img-25.jpeg)

Juraj Kavecansky Department of Medical Oncology, New York University School of Medicine, New York, NY, United States![img-26.jpeg](img-26.jpeg)

Damien Kee Division of Cancer Medicine and Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Department of Pathology, University of Melbourne, Parkville, Victoria, Australia
![img-27.jpeg](img-27.jpeg)

Mohammad Reza Keramati Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran
![img-28.jpeg](img-28.jpeg)

Michael N. Khoury Department of Neurooncology, H. Lee Moffitt Cancer Center \& Research Institute, Tampa, FL, United States
![img-29.jpeg](img-29.jpeg)

Ana C.V. Krepischi Department of Genetics and Evolutionary Biology, Institute of Biosciences, University of São Paulo, São Paulo, Brazil
![img-30.jpeg](img-30.jpeg)

Young Kwok Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, United States
![img-31.jpeg](img-31.jpeg)

Peter Lau Division of Cancer Medicine and Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia![img-32.jpeg](img-32.jpeg)

Supriya Lal Neurosurgery Department, Geisinger Health System, Danville, PA, United States
![img-33.jpeg](img-33.jpeg)

Estelle Leclerc Department of Pharmaceutical Sciences, North Dakota State University, Fargo, ND, United States
![img-34.jpeg](img-34.jpeg)

Carrie B. Lee Division of Hematology/ Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
![img-35.jpeg](img-35.jpeg)

Georgina V. Long Melanoma Institute Australia, The Poche Centre, North Sydney, NSW, Australia
![img-36.jpeg](img-36.jpeg)
L. Dade Lunsford Center for Image-Guided Neurosurgery, Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, United States
![img-37.jpeg](img-37.jpeg)

Megan Lyle Melanoma Institute Australia, The Poche Centre, North Sydney, NSW, Australia![img-38.jpeg](img-38.jpeg)

Lili Mao Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital \& Institute, Beijing, China
![img-39.jpeg](img-39.jpeg)

Torstein R. Meling Department of Neurosurgery, The National Hospital, University of Oslo, Oslo, Norway
![img-40.jpeg](img-40.jpeg)

Symeon Missios Department of Neurosurgery, Louisiana State University, LA, United States
![img-41.jpeg](img-41.jpeg)

Edward A. Monaco III Center for Image-Guided Neurosurgery, Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, United States
![img-42.jpeg](img-42.jpeg)

Stergios J. Moschos Division of Hematology/ Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
![img-43.jpeg](img-43.jpeg)

Elizabeth Nichols Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, United States![img-44.jpeg](img-44.jpeg)

Ajay Niranjan Center for Image-Guided Neurosurgery, Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, United States
![img-45.jpeg](img-45.jpeg)

Etin-Osa Osa Department of Radiation Oncology, New York University School of Medicine, New York, NY, United States
![img-46.jpeg](img-46.jpeg)

Anna C. Pavlick Department of Medical Oncology, New York University School of Medicine, New York, NY, United States
![img-47.jpeg](img-47.jpeg)

Dimitrius T. Pramio International Research Center, A. C. Camargo Cancer Center, São Paulo, Brazil
![img-48.jpeg](img-48.jpeg)

Fabio Puglisi Department of Oncology, University Hospital of Udine, Udine, Italy; Department of Medical and Biological Sciences, University of Udine, Udine, Italy
![img-49.jpeg](img-49.jpeg)

Siril G. Rogne Department of Neurosurgery, Oslo University Hospital, Rikshospitalet, Norway![img-50.jpeg](img-50.jpeg)

Brindha Shivalingam Melanoma Institute Australia, The Poche Centre, North Sydney, NSW, Australia
![img-51.jpeg](img-51.jpeg)

Erik P. Sulman Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
![img-52.jpeg](img-52.jpeg)

Konstantina Svokos Philadelphia College of Osteopathic Medicine, Philadelphia, PA, United States; Geisinger Wyoming Valley, Neurosurgery Department, Wilkes Barre, PA, United States
![img-53.jpeg](img-53.jpeg)

Toshihide Tanaka Department of Neurosurgery, Jikei University School of Medicine Kashiwa Hospital, Kashiwa, Chiba, Japan
![img-54.jpeg](img-54.jpeg)

Ahmad A. Tarhini University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, Pittsburgh, PA, United States
![img-55.jpeg](img-55.jpeg)

John F. Thompson Melanoma Institute Australia, The Poche Centre, North Sydney, NSW, Australia![img-56.jpeg](img-56.jpeg)

Steven A. Toms Department of Neurosurgery, Geisinger Health System, Danville, PA, United States
![img-57.jpeg](img-57.jpeg)

Nam D. Tran Department of Neurooncology, H. Lee Moffitt Cancer Center \& Research Institute, Tampa, FL, United States
![img-58.jpeg](img-58.jpeg)

Dimitri Trembath Division of Hematology/ Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
![img-59.jpeg](img-59.jpeg)

Sarah A. Weiss Department of Medical Oncology, New York University School of Medicine, New York, NY, United States
![img-60.jpeg](img-60.jpeg)

Timothy M. Zagar Division of Hematology/ Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States# Volume 1-Contributions 

1. Brain Metastases
2. Epidemiology of Central Nervous System Metastases
3. Involvement of the CXCL12/CXCR4/ CXCR7 Axis in Brain Metastases
4. Non uniform Distribution of Metastatic Intracranial Tumors in Cancer Patients
5. Targeting Angiogenesis, Enhancing Radiosensitization and Crossing the Blood-Brain-Barrier for Brain Metastases
6. Second Malignancies in Children Following Treatment for Neuroblastoma
7. The Role of Chemotherapy in Metastatic Brain Tumors
8. Multiple Metastases to the Brain from Primary Cancers: Whole Brain Radiotherapy
9. Synovial Sarcoma Metastasized to the Brain
10. Multiple Small Brain Metastases with Limited Focal Brain Edema from Non small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations
11. Brain Metastases of Patients with Lung Adenocarcinoma: Epidermal Growth Factor Receptor Mutations and Response to Whole-Brain Radiation Therapy
12. Metastatic Spread of Lung Cancer to Brain and Liver: Role of CX3CR1
13. Solitary Brain Metastasis from Non small Cell Lung Cancer: Treatment with Linac-Based Stereotactic Radiosurgery
14. Brain Metastases from Non small Cell Lung Cancer: Clinical Benefits of Erlotinib and Gefitinib
15. Bispecific Targeted Toxin DTATEGF Against Metastatic NSCLC Brain Tumors
16. Intracranial Disease in Patients with Non small Cell Lung Cancer: Treatment with Erlotinib
17. Radiation Management of Synchronous Brain Metastases from Non small Cell Lung Cancer
18. Brain Metastasis After Prophylactic Cranial Irradiation in Patients with Small Cell Lung Cancer
19. Brain Metastasis from Small Cell Lung Cancer with High Levels of Placental Growth Factor
20. Brain Metastases from Lung Cancer
21. Lambert-Eaton Myesthenic Syndrome and Brain Metastasis from Occult Small Cell Lung Carcinoma: A Clinician's Perspective# Volume 2-Contributions 

1. Brain Metastasis from Solid Tumors
2. The Role of Surgical Resection for Metastatic Brain Tumors
3. Whole-Brain Radiotherapy for Brain Metastases: Is the Therapeutic Window Enlarging?
4. Brain Metastasis in Patients with Non small Cell Lung Cancer: Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
5. Brain Metastasis from Non small Cell Lung Cancer: Use of Epidermal Growth Factor Receptor and HER2 Status for Targeted Therapy
6. Brain Metastases from Non small Cell Lung Cancer: Current Evidence in Management Using Tyrosine Kinase Inhibitor and Whole-Brain Radiation Therapy
7. Brain Metastasis in Patients with Non small Cell Lung Cancer: Immunohistochemical Markers
8. Brain Metastasis from Breast Cancer: Molecular Mechanisms
9. New Targeted Therapies for Brain Metastases from Breast and Lung Cancer and Melanoma
10. Breast Cancers with Brain Metastases
11. Brain Metastases in Melanoma Patients: Treatment with Adjuvant Postoperative Whole-Brain Radiotherapy
12. Melanoma Progression in the Brain: Role of Pericytes, the Basal Lamina, and Endothelial Cells in Tumor Vascularization
13. Brain Metastases from Esophageal Cancer in the Presence of HER-2 Overexpression
14. Brain Metastasis from Renal Carcinoma: Locoregional and Systemic Treatments
15. Gastrointestinal Cancer and Brain Metastasis Outcomes and Management
16. Brain Metastasis of Colorectal Cancer: Microenvironment and Molecular Mechanism
17. Brain Metastasis from Nasopharyngeal Carcinoma# C H A P T E R 

## 1

## Introduction

M.A. Hayat

|  | O U T L I N E |  |  |
| :--: | :--: | :--: | :--: |
| Melanoma | 7 | Esophageal Cancer | 14 |
| Treatment | 8 | Treatment | 15 |
| Breast Cancer | 12 | References | 17 |
| Treatment | 12 |  |  |

In human history, immortality has been one of the most cherished, but unrealistic, wishes of human beings. Indeed, we are still hoping to cure serious diseases to achieve immortality, but medical treatments have been proven to result in less than impressive success. An excessive emphasis on medical therapies has diverted attention from nontherapeutic efforts to prolong healthy life, that is, to slow down the inevitable aging process. In fact, unfortunately some treatments may shorten life instead of prolonging it.

Aging has so permeated our lives that it cannot be stopped, but it can be delayed. Under the circumstances, time is our only friend. Because the aging process is accompanied by disability and disease (e.g., cancer and Alzheimer's and Parkinson's conditions), and cannot be prevented, it seems that slow aging is the only way to have a healthy longer life. In general, aging can be slowed down by not smoking or chewing tobacco, by preventing or minimizing perpetual stress (anger, excessive competition), by abstinence from alcoholic beverages, by having regular exercise and sleep, and by having a healthy diet. There is no doubt that regular physical activity is associated with a reduced risk of mortality, and contributes to the primary and secondary prevention or delay of many types of diseases, including cancer. Discipline is required to attain this goal.

Cancer constitutes a group of diseases characterized by uncontrolled growth and spread of abnormal cells, and if the spread is not controlled, it can result in death. Cancer is caused by both external factors (tobacco, chemicals, radiation, and infectious organisms)and internal factors (inherited mutations, somatic mutations, hormones, and immune conditions) (WHO). Perpetual stress also plays a part in the development of cancer and other diseases. Although anyone can develop cancer, the risk of developing cancer increases substantially with age.

Incidence of cancer is increasing due to aging and growth of the world's population despite the introduction of better and faster diagnosis and more effective treatments. In 2012, 14.1 million new cases of cancer were diagnosed worldwide, and 8.2 million people died; approximately, 32.6 million people were living 5 years after being diagnosed with cancer (Center for Disease Control [CDC]) (Jemal et al., 2010). By 2025, 19.3 million new cases of cancer are expected to be diagnosed each year. In 2012, the most common cancers diagnosed worldwide were 1.8 million (lung cancer), 1.7 million (breast cancer), 1.4 million (colorectal cancer), 1.1 million (prostate cancer), 952,000 (stomach cancer), 782,000 (liver cancer), and 528,000 (cervical cancer). The frequency of cancer varies by geographic areas, especially in developed countries versus developing countries.

A total of 1,658,370 new cancer cases and 589,430 cancer deaths are projected to occur in the United States in 2015 (American Cancer Society, CDC). Cancer is a major public health problem worldwide, and is expected to surpass cardiovascular diseases as the leading cause of death in the next few years.

Estimated new major cancer cases and deaths in the United States in 2015 are (Siegel et al., 2015):

|  | New cases | Deaths |
| :-- | :--: | :--: |
| Genital system | 329,330 | 58,670 |
| Digestive system | 291,150 | 149,300 |
| Respiratory system | 240,390 | 162,460 |
| Breast | 234,190 | 40,730 |
| Melanoma | 73,870 | 9,940 |
| Brain | 22,850 | 15,320 |

The development of cancer requires a series of exceedingly complex multiple steps that may occur during many years. Cancer needs to be diagnosed at an early stage, or even before cells become cancerous (removal of precancerous lesions) when it may be treatable. When cancer becomes metastatic, the treatment becomes difficult. Metastasis formation is responsible for most cancer deaths. Metastatic dissemination is a very complex, slow, and inefficient process. In order to understand brain metastasis from primary cancer, we need to comprehend how cancer cells escape from the primary tumor site, intravasate into blood vessels, accumulate in brain capillaries, survive the hematogenous dissemination to the brain, extravasate and proliferate and develop angiogenic ability to establish brain metastases. A diagrammatic, simplified representation of this process is shown in Fig. 1.1. However, the dissemination cannot be explained simply by blood or lymph drainage from the![img-61.jpeg](img-61.jpeg)

FIGURE 1.1 Simplified, schematic illustration of melanoma brain metastasis. (A) Primary melanoma tumor cells intravasate into blood circulation after escaping from the melanoma tumor. (B) These cells are arrested in the capillary bed. (C) These cells subsequently extravasate into the brain parenchyma cells. Both intravasation and extravasation are mediated by STAT3 and neurotrophin signaling. (D) Melanoma cells either multiply along blood vessels (cooption) and/or establish angiogenesis. (E) Beta 1-integrin and vascular endothelial growth factor-A are associated with this process. Each step is regulated by genes and signaling pathways (Kenchappa et al., 2013).
primary tumor. Metastatic colonization is strongly influenced by the interaction of primary cancer cells with host cells present or recruited to the microenvironment into a structure called the metastatic niche (Ordóñez-Morán and Huelsken, 2014). This local environment is responsible not only for the initial metastatic colonization of the host tissue but also for the progression of the disease. To succeed in finding an effective use of therapeutic drugs, we should also understand better the immunologically distinct space that excludes drug macromolecules from the brain.Brain metastases are the most common intracranial neoplasms in adults, and occur in $20-40 \%$ of cancers. It is estimated that 100,000-170,000 persons are inflicted by metastatic brain cancer per year in the United States. Generally, intracranial metastatic lesions are more common than primary tumors of the brain (Gavrilovic and Posner, 2005). Metastatic brain tumors are 10 times more common than primary brain tumors, and represent $20-40 \%$ of all intracranial neoplasms in adults (Go et al., 2011). Approximately, 10-20\% of all brain metastases are single tumors, and the remaining are multiple tumors. Lung, breast, colon, and kidney cancers and melanoma commonly spread to the brain. Breast and kidney cancers often cause single brain tumors, while lung cancer and melanoma tend to cause multiple brain tumors. Approximately, $85 \%$ of metastatic lesions are located in the cerebrum, while the remaining are located in the cerebellum. Autopsy analyses have shown that the incidence of brain metastases is as high as $30 \%$ in patients with breast cancer, $40 \%$ in those with lung cancer, $75 \%$ in those with melanoma, and $6 \%$ with those with kidney or bladder cancer. Brain metastases are among the most devastating and debilitating complications of lung cancer, breast cancer, unknown cancer, and melanoma. Patients with brain metastases often develop serious deterioration in neurological and neurocognitive functions. Intracranial bleeding is one of the fatal complications encountered in the patients. Treatments for patients with brain cancer are summarized below.

Treatments used for patients with metastatic brain cancer include neurosurgery, stereotactic radiosurgery (SRS), whole brain radiation therapy (WBRT), and chemotherapy; they are used alone or in combination. Neurosurgery is used for patients with a few metastatic lesions provided the lesions are surgically accessible and the patient can tolerate the operation. Surgical resection may immediately eliminate life-threatening or symptom-generating mass effect and eliminate the source of perifocal edema. Surgery is also of value when the diagnosis is uncertain. To reduce the risk of tumor recurrence and leptomeningeal spread "en bloc" approach rather than piecemeal method has been used. SRS has certain advantages: it is largely noninvasive, does not require general anesthesia and is performed on an outpatient basis (Atalar et al., 2013).

SRS is offered as an alternative to neurosurgery for patients with a few lesions which cannot be surgically removed (Yamamoto et al., 2014). WBRT can also be applied in conjunction with neurosurgery or SRS. Surgery plus WBRT shows overall survival benefit (Kocher et al., 2011). WBRT ( 30 Gy in 10 fractions) is the current standard of cure for patients with five or more brain metastases. However, the use of WBRT is controversial. Some studies have demonstrated superior outcomes, whereas some other studies report negative impact on neurorecognition (Brown et al., 2013; Gondi et al., 2013). Typical side effects of WRBT include hair loss, fatigue, memory loss (long-term due to hippocampal neural stem cell injury), headache, skin erythema, serous otitis, leukoencephalopathy, and somnolence (rare). Is WBRT necessary after surgery? Yes, because addition of WBRT even after complete tumor resection decreases intracranial failure and local recurrence. Finally, WBRT retains an important place in the management of brain metastasis (Choi Clara et al., 2012). Advantages and limitations of the WBRT are discussed in this volume. Use of immunotherapy for patients with brain metastasis is also discussed in this volume and by Powell and Dudek (2009).

Primary tumor ulceration is the strongest predictor of brain metastases development, and remains an independent predictor of decreased brain metastasis survival after treatment (Zakrzewski et al., 2011). The importance of determining the characteristics of primary melanoma, especially ulceration, cannot be overemphasized. Such information will help in thedevelopment of risk stratification of a treatment and surveillance protocols early in the clinical course. The information regarding the biology of ulceration and molecular mechanisms underlying its adverse impact on clinical outcome is equally important.

Admittedly, results of standard treatments mentioned above have been less than impressive. However, the situation is not as grim as it seems. It is pointed out that the choice of WBRT alone or SRS or surgical resection alone or combination of these treatments needs to be individualized based on patients overall prognosis. Recently introduced therapies, including multidisciplinary approach, may lead to encouraging positive treatment results.

# MELANOMA 

Between two and three million nonmelanoma skin cancers and 132,000 melanoma skin cancers occur globally each year (WHO). However, the incidence of both of these cancer types has been increasing during the past decades. It is estimated that one in every three cancer types diagnosed is a skin cancer, and one in every five Americans will develop skin cancer in their lifetime. Because ozone levels are depleting, the atmosphere is losing its protective filter function, and thus more solar UV radiation is reaching the surface of the earth. It is estimated that a $10 \%$ decrease in ozone levels will result in an additional 300,000 nonmelanoma and 4000 melanoma skin cancer cases (WHO). For example, the incidence of melanoma increased from 15/100,000 persons in 1986 to more than 25/100,000 persons in 2006 in the United States.

Melanoma is a malignant neoplasm that occurs mostly in adults, and may originate de novo from a pigmented naevi (a benign localized overgrowth of melanin-forming cells of the skin). It can also begin in other pigmented tissues such as in the eye or the intestines. The most aggressive type of skin cancer, melanomas typically grow in densely packed cellular "nests" that contain minimal extracellular matrix (fibronectin, collagen, or laminin). Because of subtle differentiating features, potential for both under- and overdiagnosis of melanoma is not uncommon. This pitfall is especially common in the diagnosis of rare and unusual melanoma variants and melanoma resembling those in typical melanoma. These features include irregular functional components with pagetoid spread, melanocyte atypia, lack of dermal maturation, dermal mitotic activity, intense melanin pigmentation, a desmoplastic stromal response, and dermal regression. Benign melanocytic lesions are difficult to differentiate from naevi. We need improved understanding of the molecular drivers and heterogeneity of this disease.

One of the most common and serious complications of melanoma is the development of central nervous system (CNS) metastases. The frequency of metastasis is estimated to be $40 \%$ or even more in melanoma patients (Soffietti et al., 2002). Primary melanoma tumor ulceration is associated with poor prognosis. Tumor-related inflammation is associated with upregulation of proinflammation cytokines, which is associated with ulceration. Approximately, $75 \%$ of patients with metastatic melanoma develop brain metastases during the course of their disease. Melanoma is the third most common diagnosis among patients with brain metastases, after lung and breast cancer. Spread of melanoma to the brain is an ominous event. Brain metastasis is a major cause of death in melanoma patients, the frequency of which is on the rise. However, despite these poor outcomes, approximately $5 \%$ of patients with brain metastases from melanoma are long-term survivors. The identification of factors that can predict outcomes may benefit the clinical management of these patients.The era, pattern, and timing of melanoma brain metastases have been found to be strongly associated with survival. Other factors involved are less than three parenchymal metastases, leptomeningeal involvement, and the development of brain metastases after prior systemic therapies. A solitary brain lesion, surgical treatment, and a good Karnofsky Performance Status indicate a good prognosis (Celix and Silbergeld, 2014).

Recent developments in melanoma therapy have influenced the management of metastatic melanoma patients. Approximately, $50 \%$ of melanomas have an activating mutation in the gene encoding the serine-threonine protein kinase (BRAF), and approximately $95 \%$ of these mutations result in substitutions of other amino acids at the V600 site, most frequently lysine (V600K). All of these mutations increase the catalytic activity of BRAF. Melanoma patients with brain metastases harboring BRAF mutation are a distinct subgroup with a favorable response to vemurafenib and radiation therapy and acceptable morbidity. Nevertheless, an effective treatment for melanoma brain metastasis is not available. Therefore, it is essential to develop an efficient therapy to prevent such brain metastasis. An essential prerequisite to achieve this goal is to identify molecules expressed by brain-metastasizing melanoma cells, which are involved in the targeted migration of such cells to the brain (Klein et al., 2012). These molecules sustain melanoma cell survival and promote their propagation in the brain. The development of an efficient therapy against brain metastasis will be helped by understanding the interactions of these molecules with the microenvironment of the brain tissue. Chemokines present in the primary tumor cells are thought to be involved in the formation of metastasis. It has been reported that interactions between chemokine receptors CCR3 and CCR4 expressed by brain-metastasizing melanoma cells and the corresponding ligands in the brain tissue may be involved in the targeted migration of tumor cells to the brain (Izraely et al., 2010). It is likely that CCR4 ligands expressed in the brain interact with the CCR4-expressing melanoma cells, thereby directing them to the brain (Klein et al., 2012). It is concluded that the metastatic brain microenvironment plays a part in shaping the malignancy phenotype of melanoma cells.

# Treatment 

A meaningful improvement in overall survival of patients with metastatic melanoma has been an elusive goal. However, the development of new therapies for melanoma has offered new hope to investigators. Examples are BRAF inhibitors and ipilimumab. Nevertheless, treatment of intracranial disease remains a challenge, and there are many unanswered questions. Some of these questions can be answered when targeted therapies are incorporated into the multimodality management of melanoma brain metastasis. Also, improvements in the blood-brain-barrier (BBB) penetrance need to be a priority.

Two therapies against metastatic melanoma approved by the FDA are high dose inter-leukin-2 and dacarbazine; each is associated with response rates of only $10-20 \%$, and a small percentage of complete response (Flaherty et al., 2010). However, neither improves overall survival. The median survival of patients treated with dacarbazine is shorter than 8 months (Bedikian et al., 2006). Most of the standard treatments used against melanoma or brain metastasis from melanoma are summarized below.

1. Neurosurgery or SRS. Neurosurgery is offered to patients with single or a few metastatic lesions, provided brain lesions are surgically accessible and the patient can tolerate theoperation (Staudt et al., 2010). Patients treated with conventional neurosurgery or SRS comprise the group with the highest overall survival, which is comparable with the overall survival of general stage IV melanoma patients (Staudt et al., 2010). Applied treatment and serum lactate dehydrogenase levels are independent predictors of survival of patients with brain metastasis from cutaneous melanoma.
2. Ipilimumab. Ipilimumab is a monoclonal antibody directed against cytotoxic T-lymphocyte antigen 4 (CTLA-4), and improves survival of patients with unresectable stage III and stage IV melanomas (Margolin et al., 2012). This treatment is also effective against brain metastasis from melanoma, especially when metastases are small and asymptomatic. The approved dose of ipilimumab is $3 \mathrm{mg} / \mathrm{kg}$ by intravenous infusion given every 3 weeks for 4 doses (Hodi et al., 2010). No unexpected toxic effects were reported by Margolin et al. (2012). Although this antibody shows a prolonged overall survival of patients with advanced melanoma, its role has decreased with the development of pembrolizumab and nivolumab, which target PD-1; these two antibodies comparatively are more active and show less adverse effects. Ipilimumab is a complex drug with adverse events occurring in $40 \%$ of patients (Eggermont et al., 2014). This antibody shows a wide range of immune-related and other adverse effects, including enterocolitis, dermatitis, endocrinopathies, hepatitis, and hypophysitis (inflammation of the pituitary gland), and other organ systems may also be involved. Ipilimumab has also been used in combination with three other drugs, which are described below.
3. Ipilimumab/Interleukin-2. This is an immune therapy comprising the immune regulatory antibody directed against the cytotoxic T-lymphocyte antigen 4 (CTLA-4 mAb) (Pedersen et al., 2014). Interleukin-2 (IL-2) is an immune stimulatory cytokine that stimulates the proliferation and differentiation of native T cells into antigen-specific effector T cells, triggering the release of other immune-stimulating cytokines (Pedersen et al., 2014).
4. Ipilimumab and vemurafenib. Both ipilimumab and vemurafenib have FDA approval for the treatment of advanced melanoma. The former is an anti-CTLA-4 monoclonal antibody that enhances cellular immunity and reduces tolerance to tumor-associated antigens (Fonkem et al., 2012). Vemurafenib is an inhibitor that blocks the abnormal signaling for melanoma cellular growth in tumors that carry the BRAF $V 600 \mathrm{E}$ mutation (Fonkem et al., 2012).
5. Ipilimumab and nivolumab. According to the study by Larkin et al. (2015), among previously untreated patients with metastatic melanoma, nivolumab combined with ipilimumab resulted in significantly longer progression-free survival than with ipilimumab alone. The negative aspect of using combined treatment with two antibodies apparently consists of more adverse effects.
6. Ipilimumab and gp100 peptide vaccine. Ipilimumab with gp100 peptide improves overall survival of patients with previously treated metastatic melanoma (Hodi et al., 2010). Adverse events can be long-lasting, but most are reversible with appropriate treatment.
7. Nivolumab (Opdivo). Nivolumab is a fully humanized, monoclonal, immunoglobulin G4 (IgG4) antibody that targets a protein called the programmed death-1 (PD-1) receptor (Johnson et al., 2015). This receptor plays an important role in controlling the immune system to prevent inadvertent immune cell activation and autoimmune disease. PD-1 is located on immune cells (T cells), while its ligand PD-L1 is expressed on antigen presenting cells. Binding of PD-L1 to PD-1 inhibits the replication andactivity of immune cells and so prevents an immune response. Melanoma cells express high levels of PD-L1 to avoid immune detection and improve their survival potential. Traditional chemotherapies and targeted anticancer therapies exert their effects by direct cytotoxicity or by tumor growth inhibition. In contrast, nivolumab acts by blocking a negative regulator of T cell activation and response (Pardoll, 2012). This is an example of immune checkpoint blockade.
As mentioned above, PD-1 is a protein on the surface of activated T cells. If another molecule (programmed cell death ligand (PD-L1) or programmed cell death ligand 2 (PD-L2)) binds to PD-1, the T cell becomes inactive. This is one way that the body regulates the immune system to avoid an overreaction. Many cancer cells synthesize PD-L1, inhibiting T cells from attacking the tumor. Nivolumab blocks PD-L1 from binding the PD-1, allowing the T cell to function in defense (Pardoll, 2012). Adverse effects of using nivolumab include fatigue, diarrhea, pruritus, rash, and decreased appetite. The manageable adverse side effects can be reduced by immunomodulatory drugs, although they inflict their own side effects. Nivolumab has been approved by the FDA for treating patients with unresectable or metastatic melanoma and who do not respond to other drugs.
8. Pembrolizumab. Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between programmed cell death-1 protein (PD-1) and its ligand. In other words, pembrolizumab is an anti-PD-1 antibody that prolongs progression-free survival of patients with advanced melanoma (Robert et al., 2014; Ribas et al., 2015). PD-1 is an immune checkpoint receptor expressed by activated T cells. PD-1 binds to its ligands PD-L1 and PD-L2, which are expressed on tumor cells, resulting in the immunosuppression and prevention of the immune system from rejecting the tumor. This function of pembrolizumab has raised its effectiveness as the immunotherapy of choice for most patients with advanced melanoma (Sosman, 2015). The European Commission has approved the use of pembrolizumab in patients with advanced melanoma, unresectable (metastatic) melanoma, and those who are previously treated or untreated. This drug has also received approval for use in the United States, but only for previously treated patients with advanced melanoma. The adverse reactions of pembrolizumab include diarrhea, fatigue, nausea, pruritus (itching), rash, and arthralgia (pain in a joint), leucopenia, neutropenia (abnormally small number of white blood cells), and anemia.
9. Lambrolizumab. Lambrolizumab antibody is an anti-PD-1 antibody that has been used in patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab (Hamid et al., 2013). According to these authors, this treatment resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects.
10. Tremelimumab. Blocking of CTLA-4 with a monoclonal antibody can inhibit immune tolerance and might induce tumor regression. Two such antibodies, tremelimumab and ipilimumab show these effects (Eggermont et al., 2014). Because tremelimumab did not show results superior to dacarbazine, the development of the former antibody was stopped (Ribas et al., 2013).
11. Vemurafenib. Vemurafenib is a BRAF kinase inhibitor that has FDA approval for use in patients with previously untreated, unresectable or metastatic melanomas with the BRAF $V 600 E$ mutation (Gummadi et al., 2015). The brain distribution of this drug is severely restricted at the BBB because of active efflux (Mittapalli et al., 2012).An adjuvant treatment to improve delivery to the brain through efflux inhibition may be a viable option for improving survival. Coadministration of elacridar (a dual inhibitor of P-gp and ABCG2) has been reported to improve the therapeutic efficacy of vemurafenib, especially for brain metastases located behind a functional BBB (Durmus et al., 2012). Oral coadministration of elacridar strongly increased oral availability and brain penetration of vemurafenib in wild-type mice, especially at the clinically more relevant higher vemurafenib dose $(25 \mathrm{mg} / \mathrm{kg})$. Vemurafenib is a more selective BRAF inhibitor, and has nearly 10 -fold greater inhibition of mutant BRAF versus wild-type BRAF (Sullivan and Fisher, 2014). According to Flaherty et al. (2010), treatment of patients with tumors that carry the BRAF $^{\text {V600E }}$ mutation with this antibody may result in complete or partial tumor regression in the majority of cases. Although treatment with vemurafenib leads to improvement in extracranial disease control, existing intracranial disease and survival are not improved (Gummadi et al., 2015).
12. Vemurafenib and radiation. Vemurafenib is an oral BRAF inhibitor and can be used with radiation therapy (Narayana et al., 2013). This synergism from the combination results in the $75 \%$ radiologic response, symptomatic relief in $45 \%$, and a median survival of 13.7 months in patients with BRAF $^{\text {V600E }}$ mutant melanoma metastatic to the brain (Narayana et al., 2013). Safety concerns resulting from this treatment (e.g., radiation necrosis) are yet to be determined. Although it is known that vemurafenib has minimal penetration of the BBB, potential disruption of this barrier may cause a transient disruption by radiation in the BBB, resulting in the uptake of this drug.
13. Lenalidomide and pomalidomide. Lenalidomide and pomalidomide are immunomodulatory drugs that increase $\mathrm{CD} 4^{+}$and $\mathrm{CD}^{+}$T-cell proliferation and cytokine production, enhancing the lytic capacity of cytotoxic T lymphocytes and reducing the suppressive effects of regulatory T cells on $\mathrm{CD}^{+}$T-cell responses (De Keersmaecker et al., 2014). These drugs also add to the potency of dendritic cell (DC)-based vaccine products. Early phase clinical studies can be designed to assess the efficacy of DC-based immunotherapy in combination with posttransplant maintenance treatment with these drugs in multiple melanomas.
14. Intratumoral immunotherapy (ITIT). ITIT empowers the immune system to mount T cell responses against tumor-associated antigens that are most immunogenic (Singh and Overwijk, 2015). This method generates systemic T cell responses that can target distant metastases beyond the initially treated tumor mass. Promising preclinical results and some initial success in clinical trials have been obtained (Singh and Overwijk, 2015). DCs have been used as an effective way of inducing anticancer immune response in vivo.
15. WBRT. Multiple brain metastases from melanoma and omission of upfront WBRT are associated with distant intracranial progression (Dyer et al., 2014). However, as melanoma has traditionally been thought of as radioresistant, the benefit of the use of WBRT alone is unclear. These authors have compared the difference between the treatment with a combination of SRS/WBRT and treatment with SRS alone; the former approach improves freedom from distant progression of the disease. On the other hand, some studies indicate no benefit of WBRT for patients with melanoma brain metastases (Marcus et al., 2014). The application of SRS alone for patients with 1-4 brain lesions and younger than 50 years has been recommended (Sahgal et al., 2015).# BREAST CANCER 

After lung cancer, breast cancer is the second most frequently spread cancer to the brain. During the last three decades a large number of therapeutic agents, including trastuzumab, bevacizumab, pertuzumab, ipilimumab, sorafenib, capecitabine, gemcitabine, lapatinib, vinorelbine, tamoxifen, iniparib, docetaxel, everolimus, eribulin, tanespimycin, and bonemodifying agents, have been used alone or in combination against breast cancer with variable effectiveness and side effects. The applications of these agents are summarized later.

One of the problems encountered in treating a solid tumor is its heterogeneity. Poor (nonuniform) development of vasculature throughout a solid tumor is responsible for inconsistent concentration of oxygen, which results in a significant level of intra- and intertumor heterogeneity. Also, more than one type of gene mutation may be present in a tumor. Phenotypic similarity among tumors does not always mean absence of heterogeneity. Also, substantial phenotypic variation amongst otherwise identical tumor cells is not uncommon (Rouschop and Wouters, 2009).

Some information is available on the differences between relapsed and de novo stage IV breast cancer. Women with de novo stage IV breast cancer had superior outcomes compared with those with relapsed breast cancer (Dawood et al., 2010). Disease-free interval plays an important role in the prognosis for patients with relapsed breast cancer. However, according to Rossi et al. (2014), response rates and progression-free survival to first-line trastuzumabbased therapy did not differ significantly between de novo and recurring stage IV, human epidermal growth factor receptor-2 (HER2)-positive breast cancer. This difference in the overall survival of patients in these two studies may be explained in part whether or not surgery of the primary tumor was used.

## Treatment

Chemotherapeutic agents and antibodies, which have been used for patients with breast cancer, are summarized below.

1. Trastuzumab emtansine (T-DM1). First-line treatment with T-DM1 for patients with HER2-positive metastatic breast cancer provided a significant improvement in progression-free survival, with a favorable safety profile (Hurvitz et al., 2013)
2. Tanespimycin plus trastuzumab. Tanespimycin plus trastuzumab had significant anticancer activity in patients with HER2-positive metastatic breast cancer previously progressing on trastuzumab (Modi et al., 2011). This study shows response evaluation criteria in solid tumors-defined responses for 17-demethoxygeldanamycin in solid tumors. The rationale for using combination of agents is to achieve additive or synergistic effects that may lead to improved outcomes for patients with HER2-amplified breast cancer and other cancer types.
3. Trastuzumab plus Everolimus. Inhibition of mTOR resulted in clinical benefit and disease response in patients with trastuzumab-resistant HER2-overexpressing metastatic breast cancer (Morrow et al., 2011). Everolimus is able to overcome PTEN-mediated trastuzumab resistance through inhibition of the mTOR pathway. Trastuzumab resistance is linked to the activation of phosphoinositol 3-kinase (p13K) pathway.4. Trastuzumab and lapatinib. HER2 status, either gene copy number or the protein expression level, is the best predictive marker for assessing response to trastuzumab and lapatinib (Esteva et al., 2010). Lapatinib prolonged the time to progression and increased the rate of response to capecitabine in patients who had received anthracycline-based and taxanebased chemotherapy, and whose tumors had progressed on trastuzumab. It is important to predict which patients are more likely to benefit from which specific HER2-directed therapies. It is also important to characterize mechanisms of resistance in metastatic tumors.
5. Trastuzumab plus anthracycline. Humanized monoclonal antibody trastuzumab has high affinity for the extracellular domain of HER2 and has been used as a monotherapy for early breast cancer in both first-line and subsequent settings. Incorporation of trastuzumab into anthracycline significantly improved outcomes in HER2-positive early breast cancer (Costa et al., 2010). Treatment of early stage breast cancer reduces the risk of disease recurrence and prolongs overall survival. However, this regimen may accompany toxicity to heart, especially in the form of left ventricular dysfunction. The efficacy of the therapy increases by identifying the subset of the disease.
6. Pertuzumab/trastuzumab/docetaxel. When used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival is achieved with no increase in cardiac toxic effects (Baselga et al., 2012a).
7. Bevacizumab combined with chemotherapy (capecitabine, taxane, or anthracycline). This combination improved clinical benefit in terms of increased progression-free survival in first-line treatment of metastatic breast cancer (Robert et al., 2011).
8. Bevacizumab combined with commonly used chemotherapies (capecitabine, gemcitabine, or vinorelbine). This combination improved clinical benefit in terms of increased progression-free survival (Brufsky et al., 2011). They recommend its use for a second-line cytotoxic therapy for patients with HER2-negative metastatic breast cancer.
9. Glembatumumab vedotin monoclonal antibody. This antibody is well tolerated in heavily pretreated patients with breast cancer (Yardley et al., 2015). The activity of this antibody can be enhanced in patients with glycoprotein NMB-overexpressing tumors and/or triple-negative breast cancer. This antibody is conjugated to potent cytotoxin monomethyl auristatin E, and is specific to this glycoprotein.
10. Sorafenib in combination with capecitabine. The addition of sorafenib to capecitabine improved progression-free survival of patients with HER2-negative advanced breast cancer. However, this treatment resulted in unacceptable toxicity (Baselga et al., 2012b).
11. Fixed-dose capecitabine. Despite the absence of a response reported, a small clinical benefit rate of $19 \%$ was observed in metastatic breast cancer (Rudek et al., 2013).
12. Tamoxifen plus everolimus. This combination increased clinical benefit rate, time to progression, and overall survival compared with tamoxifen alone in postmenopausal women with aromatase resistance metastatic breast cancer (Bachelot et al., 2012).
13. Iniparib plus chemotherapy (gemcitabine-carboplatin). This combination improved the clinical benefit and survival of patients with metastatic triple-negative breast cancer without significantly increased toxic side effects (O'Shaughnessy et al., 2011).
14. Eribulin mesilate monotherapy. Eribulin mesilate monotherapy significantly improved the overall survival ( 2.5 months extension of median survival) of women with heavily pretreated metastatic breast cancer compared with other availablecytotoxicity therapies, including treatment with physician's choice (Cortés et al., 2011). These women had received a median of four previous chemotherapy regimens. Eribulin, in addition, offers a manageable profile of toxic effects. Eribulin has received at least two chemotherapeutic regimens for the treatment of metastatic breast cancer. This study challenges the existing assumption in trial design that extension of overall survival is unrealistic in women with metastatic breast cancer who have been heavily pretreated.
15. Bone-modifying agents (denosumab, pamidronate, zoledronic acid). These agents are recommended for patients with metastatic breast cancer with evidence of bone destruction (Van Poznak et al., 2011). One bone-modifying agent is not preferred over another. All patients should have a dental examination and preventive dentistry before using these agents.

# ESOPHAGEAL CANCER 

In addition to melanoma and breast cancer, esophageal cancer (EC) is discussed in this volume. EC affects more than 450,000 people worldwide, and the incidence is increasing because of its very aggressive nature and poor survival rate (Pennathur et al., 2013). The estimated new cases of breast cancer, EC cancer, and small intestine cancer and deaths in the United States are given below (Siegel et al., 2015).

|  | Breast cancer | Esophageal cancer | Small intestine cancer |
| :-- | :--: | :-- | :-- |
| New cases | 234,190 | 16,980 | 9410 |
| Deaths | 40,730 | 15,590 | 1260 |

EC (squamous cell carcinoma and adenocarcinoma) (malignant neoplasms of epithelial cells) is the fastest growing malignancy in the United States with an annual incidence of $4 / 100,000$ people (Go et al., 2011). In 2010 it was estimated there will be 16,640 new cases of EC and 14,500 deaths from this cancer in the United States. EC is the third most common type of cancer of the digestive tract, and the seventh most common cause of cancer-related mortality worldwide (Spallone and Izzo, 2013). EC is one of the eight most common cancers throughout the world.

EC is 3-4 times more common among men than among women. Smoking and alcohol consumption are the major risk factors for esophageal squamous cell carcinoma (ESCC), while smoking and obesity are the primary risk factors for esophageal adenocarcinoma (EAC) (Engel et al., 2003). Body fatness increases the risk of this disease. Human papilloma virus is also a cause of EC. Eating nonstarchy vegetables, fruits, and foods containing beta-carotene and/or vitamin C protects against this cancer, and meat probably increases the risk of this disease. ESCC arises from the stratified squamous epithelial lining of the organ, whereas EAC affects columnar glandular cells that replace the squamous epithelium (Zhang, 2013). Symptoms of EC are dysphagia (difficulty in swallowing), weight loss, bleeding, epigastric or retrostemal pain, bone pain, hoarseness, and persistent cough.Metastatic spread to the brain is thought to occur via Batson's vertebral venous plexus, which provides communication between the esophagus and CNS (Bartelt et al., 2004). Very low incidence of brain metastasis is found in patients with EC when the primary histological type is squamous cell carcinoma (Smith and Miller, 2011). In contrast, the incidence of brain metastasis is higher when the histological type is adenocarcinoma. Similar pattern is seen in patients with nonsmall cell lung carcinoma, where the incidence of brain metastasis is higher in patients with adenocarcinoma versus squamous cell carcinoma (Mujoomdar et al., 2007). There is a relatively short interval between the diagnosis of the primary esophageal tumor and development of brain metastasis (Smith and Miller, 2011). The median survival of patients with adenocarcinoma of the EC is approximately 13 months.

Brain metastasis from esophageal primary cancer is uncommon; only 1.7-3.6\% of patients with esophageal malignancy show brain metastasis (Smith and Miller, 2011). In fact, the most common sites of distant recurrence of EC, in order of frequency, are lymph nodes, liver, lung, bone, adrenal gland, and brain (Rice et al., 2006). The problem of EC diagnosis is further compounded because this malignancy is devoid of distinctive morphological features. Another problem in deciphering the complexity of esophageal brain metastasis is the presence of carcinoma of unknown primary (CUP) origin. The incidence of CUP in all patients with a malignant disease is $3-15 \%$ (Spallone and Izzo, 2013). This limitation hinders early diagnosis and an effective treatment. CUP requires extensive and expensive diagnostic testing to identify the primary cancer prior to selecting an appropriate therapy. To minimize this problem, a neurosurgical procedure can be used to obtain a definitive diagnosis and an effective treatment (Spallone and Izzo, 2013). Recently, the problem of CUP was reported in a patient with cerebral metastasis without extra-neurological symptoms (Spallone and Izzo, 2013). The CUP was subsequently diagnosed as an esophageal carcinoma. Generally, a CUP remains unknown for a period of time despite complete radiological and instrumental assessments (Pavlidis and Fizazi, 2009).

Takeshima et al. (2001) have suggested that the MRI findings of a cystic tumor with a thin enhancing rim may point to a metastatic brain tumor from the EC, especially in a high risk population. Brain metastatic tumors can be characterized by diffusion-weighted MRI (DWI). These tumors may exhibit different signal intensities on DWI depending on their histology and cellularity. Well-differentiated adenocarcinomas are hypointense, while small and large cell neuroendocrine tumors show hyperintensity (Hayashida et al., 2006).

# Treatment 

Each person's cancer diagnosis is as unique as the person it affects. The length of life and the quality of life are the two most important measures of cancer care, and the treatment must satisfy these requirements. Cancer patients must be explained all available treatment options, and the final decision for treatment needs to be made in consultation with a wellinformed patient. To select the appropriate treatment for patients with EC, it is important to determine the depth of infiltration of the tumor into the esophageal wall, the presence of malignant regional lymph nodes, and distant metastases (van Vliet et al., 2007). Endoscopic ultrasonography is often used to determine the depth of tumor invasion. Both CT and FDGPET can be applied to determine whether or not malignant lymph nodes and/or distant metastases are present.A number of treatments for patients with EC or those with metastatic brain cancer from esophageal primary tumor are available with variability in effectiveness and side effects. The therapeutic options for such patients include neurosurgery, esophagectomy, WBRT, SRS, and chemotherapy (Hasegawa et al., 2003). These treatments have been used alone or in combination. Perfusion-weighted and proton spectroscopy magnetic resonance (MR) can also be used (if available) to differentiate high-grade primary gliomas and solitary metastases on the basis of differences in vascularity and metabolic levels in peritumoral regions (Knopp et al., 1999). Conventional MR and clinical history can be used for this purpose. At diagnosis patients are initially staged for local progression or systemic spread (metastasis) of their disease, both of which determine whether or not a curative therapeutic approach should be considered.

Surgical resectioning is the first option provided the tumor is accessible. Surgical resection of brain metastases can significantly decrease morbidity and prolong survival as compared to nonsurgical approaches (Patel et al., 2012). Generally, surgical excision is preferred in cases with a solitary lesion or adjacent multiple metastases, cases with diagnostic uncertainty, or cases with life-threatening and critically located metastases (Agrawal et al., 2009). In fact, in the majority of cases, complete surgical resection of the primary tumor is the key to attempting curative treatment (Lemke et al., 2014). However, in most cases this treatment is inadequate because the cancer already has metastasized, and therefore, subsequent adjuvant therapy is required. Prognosis of curatively treated patients can be improved by multimodal treatment, including chemotherapy, radiotherapy, and WBRT. Although EC is radiation resistant, it could be applied to control pain as palliative care, without curing. Surgical excision of solitary/single lesion combined with adjuvant WBRT yields a better survival than that with radiotherapy alone (Agrawal et al., 2009).

As emphasized above, surgical resection provides the only chance for cure for patients with EC which, however, is performed in only one-fourth of all patients (Lemke et al., 2014). Patients with nonadjacent multiple or inoperable lesions are usually treated with palliative WBRT. The rationale of adjuvant WBRT is to sterilize the tumor bed that contains microscopic foci.

Chemotherapy is also used for EC patients. The use of sunitinib is preferred compared with imatinib because the latter does not pass through the BBB. Both capecitabine and lapatinib are also known to cross BBB. In the United States, trastuzumab with chemotherapy is the standard treatment for patients with EC overexpressing HER2. The following example indicates the complexity of and difficulty in finding an effective treatment for patients with an advanced HER2-positive EC. The patient initially responded well for 1 year to trastuzumabbased therapy, but subsequently showed liver metastasis, indicating tumor's resistance to this antibody (Niu et al., 2014). The treatment was switched to dual HER2 blockade with trastuzumab and lapatinib in combination with capecitabine. The patient initially responded well with regard to liver metastasis, but subsequently developed multiple brain metastases.

Patients with brain metastases from EC have been treated not only with surgery alone but also with radiation or chemotherapy (cisplatin/paclitaxel or docetaxel) (Celix and Silbergeld, 2014). The clinical study by these authors indicated the following median survival with respect to the treatment modality:

Surgery: 7 months
Radiation therapy: 4 months
Chemotherapy: 1.8 monthsAs stated earlier, presently no reliable treatment has been established for brain metastasis from EC, which can achieve cure or long-term survival. However, some evidence is available indicating that aggressive treatment, including surgical resection may prolong survival in selected patients, particularly those who are diagnosed with solitary brain metastasis disease (Lemke et al., 2014). For example, an aggressive treatment of two patients with esophagogastric junction adenocarcinoma (EGJA) resulted in long-term survival after resection of brain metastasis that was detected 1 year after primary EGJA resection (Matsunaga et al., 2014). Both patients underwent total gastrectomy, middle to lower esophagectomy, and Roux-en Y reconstruction using the jejunum. Intrathoracic anastomosis was performed via right thoracotomy and laparotomy for primary tumor resection as well as brain metastasis resection by CyberKnife irradiation. They remained recurrence-free; one remains alive after $61 / 2$ years, while the other died of myocardial infarction 4 years after surgery. This is a rare case of long-term survival.

I have discussed only one of the gastrointestinal cancers, that is, dissemination of the primary EC to the brain. For information on the brain metastases from other gastrointestinal cancers (gastric, gallbladder, pancreatic, small intestinal), the reader is referred to Go et al. (2011). Lemke et al. (2014) have provided information on the brain cancer from colorectal cancer. For information regarding cancer of the duodenum, colon, and rectum, the reader is referred to Anthony et al. (2004). Cancer of the anus is discussed by Floyd et al. (1966).

# References 

Agrawal, R., Shukla, P., Shukla, V., et al., 2009. Brain metastases from esophageal carcinoma. J. Cancer Res. Therapeut. 5, 137-139.
Anthony, T., Simmang, C., Hyman, N., et al., 2004. Practice parameters for the surveillance and follow-up of patients with colon and rectal cancer. Dis. Colon Rectum 47, 807-817.
Atalar, B., Modlin, L.A., Choi Clara, Y.H., et al., 2013. Risk of leptomeningeal disease in patients treated with stereotactic radiosurgery targeting the postoperative resection cavity for brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 87, 713-718.
Bachelot, T., Bourgier, C., Cropet, C., et al., 2012. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J. Clin. Oncol. 30, 2718-2724.
Bartelt, S., Momm, F., Weissenberger, C., et al., 2004. Patients with brain metastases from gastrointestinal tract cancer treated with whole brain radiation therapy: prognostic factors and survival. World J. Gastroenterol. 10, $3345-3348$.
Baselga, J., Cortés, J., Kim, S.-B., et al., 2012a. Pertizumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366, 109-119.
Baselga, J., Segalla, J.G.M., Roche, H., et al., 2012b. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J. Clin. Oncol. 29, 1484-1491.
Bedikian, A.Y., Millward, M., Pehamberger, M., et al., 2006. Bcl-2 antisence (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J. Clin. Oncol. 24, 4738-4745.
Brown, P.D., Pugh, S., Laack, N.N., et al., 2013. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind placebo-controlled trial. Neuro Oncol. 15, $1429-1437$.
Brufsky, M.A., Hurvitz, S., Perez, E., et al., 2011. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 29, $1255-1263$.Celix, J.M., and Silbergeld, D.L., 2014. Cerebral metastatic disease: applying what we know to rare brain metastases. World Neurosurg. 81, 50-51.
Choi Clara, Y.H., Chang, S.D., Gibbs, I.C., et al., 2012. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases: prospective evaluation of target margin on tumor control. Int. J. Radiat. Oncol. Biol. Phys. $84,336-342$.
Cortés, J., O'Shaughnessy, J., Loesch, D., et al., 2011. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized study. Lancet 377, 914-923.
Costa, R.B., Kurra, G., Greenberg, L., et al., 2010. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann. Oncol. 21, 2153-2160.
Dawood, S., Broglio, K., Ensor, J., et al., 2010. Survival differences among women with de novo stage IV and relapsed breast cancer. Ann. Oncol. 21, 2169-2174.
De Keersmaecker, B., Fostier, K., Corthals, J., et al., 2014. Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation. Cancer Immunol. Immunother. 63, 1023-1036.
Durmus, S., Sparidans, R.W., Wagenaar, E., et al., 2012. Oral availability and brain penetration of the BRAF $V_{\text {WIDE }}$ inhibitor vemurafenib can be enhanced by the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCH2) inhibitor elacridar. Mol. Pharm. 9, 3236-3245.
Dyer, M.A., Arvold, N.D., Chen, Y.-H., et al., 2014. The role of whole brain radiation therapy in the management of melanoma brain metastases. Radiat. Oncol. 9, 143-149. http://dx.doi.org/10.1186/1748-717X-9-143.
Eggermont, A.M.M., Spatz, A., and Robert, C., 2014. Cutaneous melanoma. Lancet 383, 816-827.
Engel, L.S., Chow, W.H., Vaughan, T.L., et al., 2003. Population attributable risks of esophageal and gastric cancers. J. Natl. Cancer Inst. 95, 1404-1413.

Esteva, F.J., Yu, D., Hung, M.-C., et al., 2010. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat. Rev. Clin. Oncol. 7, 98-107.
Flaherty, K.T., Puzanov, M.D., Kim, K.B., et al., 2010. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819.
Floyd, C.E., Stirling, C.T., and Cohn Jr., I., 1966. Cancer of the colon, rectum, and anus: review of 1,687 cases. Ann. Surg. 163, 829-837.
Fonkem, E., Uhlmann, E.J., Floyd, S.R., et al., 2012. Melanoma brain metastasis: overview of current management and emerging targeted therapies. Expert Rev. Neurother. 12, 1207-1215.
Gavrilovic, I.T., and Posner, J.B., 2005. Brain metastases: epidemiology and pathophysiology. J. Neurooncol. 75, 5-14.
Go, P.H., Klaassen, Z., Meadows, M.C., et al., 2011. Gastrointestinal cancer and brain metastasis. Cancer 117, $3630-3640$.
Gondi, V., Mehta, M.P., Pugh, S., et al., 2013. Memory preservation with conformal avoidance of the hippocampus during whole-brain radiation therapy for patients with brain metastases: the Primary Endpoint Results of RTOG 0933. Int. J. Radiat. Oncol. Biol. Phys. 87, 1186. http://dx.doi.org/10.1016/j.ijrobp.2013.10.005.
Gummadi, T., Zhang, B.Y., Valpione, S., et al., 2015. Impact of BRAF mutations and BRAF inhibition on melanoma brain metastases. Melanoma Res. 25, 75-79.
Hamid, O., Robert, S., Daud, A., et al., 2013. Safety and tumor response with lambrolizumab. N. Engl. J. Med. 369, $134-144$.
Hasegawa, T., Kondziolka, D., Flickinger, J.C., et al., 2003. Stereotactic radiosurgery for brain metastases from gastrointestinal tract cancer. Surg. Neurol. 60, 506-514.
Hayashida, Y., Hirai, T., Morishita, S., et al., 2006. Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. Am. J. Neuroradiol. 27, 1419-1425.
Hodi, F.S., O'Day, S.J., McDermott, D.F., et al., 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.
Hurvitz, S.A., Dirix, L., Kocis, J., et al., 2013. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J. Clin. Oncol. 31, 1157-1164.
Izraely, S., Klein, A., Sagi-Assif, O., et al., 2010. Chemokine-chemokine receptor axes in melanoma brain metastasis. Immunol. Lett. 130, 107-114.
Jemal, A., Center, M.M., Desantis, C., et al., 2010. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol. Biomarkers Prev. 19, 1893-1907. http://dx.doi.org/10.1158/1055-9965.EP1-10-0437.Johnson, D.B., Peng, C., and Sosman, J.A., 2015. Nivolumab in melanoma: latest evidence and clinical potential. Ther. Adv. Med. Oncol. 7, 97-106.
Kenchappa, R., Tran, N., Rao, N., et al., 2013. Novel treatments for melanoma brain metastases. Cancer Control 20, 298-306.
Klein, A., Sagi-Assif, O., Izraely, S., et al., 2012. The metastatic microenvironment: brain-derived soluble factors alter the malignant phenotype of cutaneous and brain-metastasizing melanoma cells. Int. J. Cancer 131, 2509-2518.
Knopp, E.A., Cha, S., Johnson, G., et al., 1999. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 211, 791-798.
Kocher, M., Soffietti, R., Abacioglu, U., et al., 2011. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J. Clin. Oncol. 29, 134-141.
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al., 2015. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23-34.
Lemke, J., Scheele, J., Kapapa, T., et al., 2014. Brain metastases in gastrointestinal cancers: is there a role for surgery? Int. J. Mol. Sci. 15, 16816-16830.
Marcus, D.M., Lowe, M., Khan, M.K., et al., 2014. Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma. Am. J. Clin. Oncol. 37, 580-584.
Margolin, K., Ernstoff, M.S., Hamid, O., et al., 2012. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13, 459-465.
Matsunaga, M., Wada, S., Daa, T., et al., 2014. Long-term survival after resection of brain metastases from esophagogastric junction adenocarcinoma: report of two cases and review of the literature. Clin. J. Gastroenterol. 7, $213-218$.
Mittapalli, R.K., Vaidhyanathan, S., Sane, R., et al., 2012. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX-4032). J. Pharmacol. Exp. Ther. 342, 33-44.
Modi, S., Stopeck, A., Linden, H., et al., 2011. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing in trastuzumab. Clin. Cancer Res. 17, 4919-4921.
Morrow, P.K., Wulf, G.M., Ensor, J., et al., 2011. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzamabbased therapy. J. Clin. Oncol. 29, 3126-3132.
Mujoomdar, A., Austin, J.H., Malhotra, R., et al., 2007. Clinical predictors of metastatic decrease to the brain from non-small cell lung carcinoma primary tumor size, cell type and lymph node metastases. Radiology 242, 882-888.
Narayana, A., Mathew, M., Tam, M., et al., 2013. Vemurafenib and radiation therapy in melanoma brain metastases. J. Neurooncol. 113, 411-416.

Niu, J., Gelbspan, D., Weitz, D., et al., 2014. HER2-positive trastuzumab-resistant metastatic esophageal cancer presenting with brain metastasis after durable response to dual HER2 blockade: a case report. J. Gastrointest. Oncol. 5 (6), E103-E108. http://dx.doi.org/10.3978/j.issn.2078-6891.2014.045.
Ordóñez-Morán, P., and Huelsken, J., 2014. Complex metastatic niches: already a target for therapy? Curr. Opin. Cell Biol. 31, 29-38.
O'Shaughnessy, J., Osborne, C., Pippen, J.E., et al., 2011. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med. 364, 205-214.
Pardoll, D.M., 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264.
Patel, T.R., Knisely, J.P., and Chiang, V.L., 2012. Management of brain metastases: surgery, radiation, or both? Oncol. Clin. North Am. 26, 933-947.
Pavlidis, N., and Fizazi, K., 2009. Carcinoma of unknown primary (CUP). Crit. Rev. Oncol. Hematol. 69, 271-278. http://dx.doi.org/10.10106/j.critrevonc.2008.09.005.
Pedersen, P., Andersen, R., Nørgaard, P., et al., 2014. Successful treatment with ipilimumab and interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease. Cancer Immunol. Immunother. 63, $1341-1346$.
Pennathur, A., Gibson, M.K., Jobe, B.A., et al., 2013. Oesophageal carcinoma. Lancet 381, 400-412.
Powell, S., and Dudek, A.Z., 2009. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases. Anticancer Res. 29, 4189-4193.

# I. MOLECULAR MECHANISMSRibas, A., Kefford, R., Marshall, M.A., et al., 2013. Phase III randomized clinical trial comparing tremelimumab with standard of care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31, 616-622.
Ribas, A., Puzanov, I., Dummer, R., et al., 2015. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomized, controlled Phase 2 trial. Lancet Oncol. 16, $908-918$.
Rice, T.W., Khuntia, D., Rybicki, L.A., et al., 2006. Brain metastases from esophageal cancer: a phenomenon of adjuvant therapy? Ann. Thorac. Surg. 82, 2042-2049.
Robert, N.J., Diéras, V., Glaspy, J., et al., 2011. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J. Clin. Oncol. 29, 1252-1260.
Robert, C., Ribas, A., Wolchok, J.D., et al., 2014. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomized dose-comparison cohort of a Phase I trial. Lancet $384,1109-1117$.
Rossi, V., Nole, F., Redana, S., et al., 2014. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy. Breast 23, 44-49.
Rouschop, K.M., and Wouters, B.G., 2009. Regulation of autophagy through multiple independent hypoxic signaling pathways. Curr. Mol. Med. 9, 417-424.
Rudek, M.A., Connolly, R.M., Hoskins, J.M., et al., 2013. Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetics study in metastatic breast cancer. Breast Cancer Res. Treat. 139, 135-143.
Sahgal, A., Aoyama, H., Kocher, M., et al., 2015. Phase 3 trials of stereotactic radiosurgery with or without wholebrain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int. J. Radiat. Oncol. Biol. Phys. 91, 710-714.
Siegel, R.L., Miller, K.D., and Jemal, A., 2015. Cancer statistics. CA Cancer J. Clin. 65, 5-29.
Singh, M., and Overwijk, W.W., 2015. Intratumoral immunotherapy for melanoma. Cancer Immunol. Immunother. $64,911-921$.
Smith, R.S., and Miller, R.C., 2011. Incidence of brain metastasis in patients with esophageal carcinoma. World J. Gastroenterol. 17, 2407-2410.
Soffietti, R., Ruda, R., and Mutani, R., 2002. Management of brain metastases. J. Neurol. 249, 1357-1369.
Sosman, J.A., 2015. Immunotherapy of advanced melanoma with immune checkpoint inhibition. UpToDate. <www.uptodate.com/contents/immunotherapy-of-advanced-melanoma-with-immune-checkpoint-inhibition> (accessed 01.09.15.).
Spallone, A., and Izzo, C., 2013. Esophageal cancer presenting as a brain metastasis: a case report. Oncol. Lett. 6, $722-724$.
Staudt, M., Lasithiotakis, K., Leiter, U., et al., 2010. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br. J. Cancer 102, 1213-1218.
Sullivan, R.J., and Fisher, D.E., 2014. Understanding the biology of melanoma and therapeutic implications. Hematol. Oncol. Clin. North Am. 28, 437-453.
Takeshima, H., Kuratsu, J., Nishi, T., et al., 2001. Metastatic brain tumors from esophageal carcinoma: neuroimaging and clinicopathological characteristics in Japanese patients. Acta Neurovhir. 143, 31-36.
Van Poznak, C.H., Temin, S., Yee, G.C., et al., 2011. American society of clinical oncology executive summary of the clinical practice guidelines update on the role of bone-modifying agents in metastatic breast cancer. J. Clin. Oncol. 29, 1221-1227.
van Vliet, E.P.M., Steyerberg, E.W., Eijkemans, M.J.C., et al., 2007. Detection of distant metastases in patients with oesophageal or gastric cardia cancer: a diagnostic decision analysis. Br. J. Cancer 97, 868-876.
Yamamoto, M., Serizawa, T., Shuto, T., Takabane, A., et al., 2014. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 15, $387-395$.
Yardley, D.A., Weaver, R., Melisko, M.E., et al., April 6, 2015. EMERGE: a randomized phase II study of the anti-body-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancer. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2014.56.2959.
Zakrzewski, J., Geraghty, L.N., Rose, A.E., et al., 2011. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer 117, 1711-1720.
Zhang, Y., 2013. Epidemiology of esophageal cancer. World J. Gastroenterol. 14, 5598-5606.

# I. MOLECULAR MECHANISMS# C H A P T E R 

## 2

## The Management and Biology of Metastatic Cancers to the Brain

Anthony Gulati and Robert Fine

|  | OUTLINE |  |  |
| :--: | :--: | :--: | :--: |
| Introduction | 21 | General Principles | 30 |
| BBB Structure | 22 | Breast Cancer | 30 |
| Molecular Changes in the BBB with |  |  | 31 |
| $\quad$ Metastatic Lesions | 24 | Melanoma | 32 |
| The Role of P-Glycoprotein | 25 | Conclusion | 33 |
| Local and Supportive Treatments | 29 | Acknowledgments | 33 |
| Systemic and Targeted Therapies | 30 | References | 33 |

## INTRODUCTION

Brain metastases are a serious consequence of many solid tumors, which can result in significant morbidity and mortality. Approximately 10-20\% of cancer patients develop brain metastases, and while the actual incidence of brain metastases is somewhat difficult to quantify, it has been estimated that there were between 21,000 and 43,000 cases of brain metastases in the United States in 2010 (Schouten et al., 2002; Fox et al., 2011). The most common primary tumors that metastasize to the brain, in order of incidence, are non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), melanoma, breast cancer, andkidney cancer. Less commonly, gastrointestinal and prostate cancers can spread to the brain as well. In a study published in 2004, the prevalence of brain metastases for all primary sites combined was $9.6 \%$; the greatest of them being lung cancer ( $19.9 \%$ ), followed by melanoma (6.9\%), renal cancer ( $6.5 \%$ ), breast cancer ( $5.1 \%$ ), and colorectal cancer ( $1.8 \%$ ) (BarnholtzSloan et al., 2004). The majority of brain metastases develop through a hematogenous route from the primary tumor site via the arterial circulation. Probably due to the progressive narrowing of the blood vessels that leads to the trapping of embolic tumor cells, the most common sites of metastases to the brain are the gray-white junction and terminal watershed areas at zones between major intracranial arteries (Hwang et al., 1996; Delattre et al., 1988). Approximately two out of three of these brain lesions are symptomatic, and can pose significant problems in terms of management. In this chapter, we will review the function of the blood-brain-barrier (BBB) under normal conditions, and then examine how the BBB becomes disrupted because of brain metastases. Finally, we will analyze some of the potential treatment paradigms for brain metastases, with additional discussions of two seminal studies; each supporting the hypothesis that chemotherapeutic treatment of brain metastases can be based upon the characteristics of the primary tumor.

In most cases, brain metastases are detected after the primary tumor has been diagnosed; uncommonly, a patient may present with symptoms from a brain metastasis first and upon work-up for the brain lesion, the site of origin is revealed. Brain metastases are frequently symptomatic, but can vary in the manner in which they present. Common manifestations include headaches, focal weakness or paralysis, visual field disturbance, cognitive disturbance, altered mental status, ataxia, and seizures. Seizure is the presenting symptom in about $10 \%$ of all cases of brain metastases, and is more common in patients with multiple metastases or when melanoma is the primary tumor. Presentation with neurological symptoms may also be due to hemorrhage, particularly in the case of metastases from a primary renal cell carcinoma or melanoma.

The prognosis for patients with brain metastases is generally poor, with the median overall survival (OS) in the range of 3-9 months. Two well-established prognostic assessments for these patients are currently available; they are the Recursive Partitioning Analysis (RPA) by Gaspar et al. (1997), and the Graded Prognostic Assessment (GPA) from Gaspar et al. (2000). The RPA divides patients into three stratified classes for the purpose of sorting patients into clinical trials by predicted outcome so as to compare patients who have similar disease. The classes are based on the following three positive outcome predictive factors: Age $<65$, Karnofsky Performance Score (KPS) 70 or higher, and controlled primary tumor with no evidence of extracranial metastases. Median OS in patients in Class 1 was 7.1 months, while patients in Class 3 (KPS <70) had an OS of 2.3 months (Gaspar et al., 1997). The GPA system is another prognostic index that separates patients into four groups with assigned scores based on age, KPS, known extracranial metastases, and number of metastases (Gaspar et al., 2000).

# BBB STRUCTURE 

The BBB is a highly specialized structure created by the interaction between astrocytes and vascular endothelial cells. The foot processes of the astrocytes surround over $90 \%$ of small blood vessels, forming tight junctions with minimal fenestrations and minimal![img-62.jpeg](img-62.jpeg)

FIGURE 2.1 Schematic comparison of a brain capillary (B) with a capillary in the periphery (A). Source: From Deeken et al., 2007, CCR Focus.
pinocytotic vesicle activity. Fortifying the BBB is a collagen-rich basal membrane that surrounds the brain capillary endothelial cells. The separation of the blood and brain is further enhanced by the absence of the lymphatic system from the central nervous system (CNS) preventing macromolecules from entering the brain by passive transport, thereby creating an immunologically distinct space. There is also significant regulation of the BBB microenvironment by active transport modulators (active efflux pumps), such as P-glycoprotein (P-gp) and multidrug resistance-associated proteins (MRP), as shown in Fig. 2.1, which will be discussed later. It has been shown by Kroll and colleagues that an intact BBB prevents passage of ionized, water-soluble molecules of $>150$ Daltons, and repels negatively charged ionic compounds due to its negatively charged luminal surface (Kroll and Neuwelt, 1998). Most natural product chemotherapy agents (NPCAs) are charged, have molecular weights from 600 to 1400 Daltons, and account for about half of all traditional chemotherapies (Lo et al., 1994). There are also chemotherapies that are much larger molecules, as they are bound to albumin, which is approximately 66,000 Daltons and are negatively charged. The great majority of chemotherapy drugs are $>150$ Daltons, charged and bound to albumin in the serum ( $50-90 \%$ of the drug is bound to albumin). Notably, topotecan and irinotecan (topoisomerase I inhibitors) are only about $30-35 \%$ bound to albumin, leaving a quantity of free drug to cross the BBB.These free, uncharged camptothecin-derived drugs may partially explain why the topoisomerase I inhibitors, such as topotecan and irinotecan, are useful in gliomas and metastatic tumors to the brain. Certain antimetabolites, including 5-Fluorouracil (5-FU), cytarabine (Ara-C), and gemcitabine, are able to cross the BBB because they are not charged and are relatively small (less than 200 Daltons). Because gadolinium ions are 500-950 Daltons, gadolinium-enhanced Magnetic Resonance Imaging (MRI) is a potential way to evaluate for BBB interruption (Lo et al., 1994). However, a limitation to this method of determining the integrity of the BBB is that it only takes into account molecular size, not charge. Further, Lo et al. (1994) have shown that the amount of "leakage" detected on MRI may not directly correlate with the amount of drug that actually reaches the brain parenchyma.

The BBB in primary CNS cancers (gliomas, etc.) will only be briefly mentioned to serve as a comparison to the BBB in the case of metastases to the brain, as the focus of this chapter is on metastatic lesions to the brain. It is important to note that it has been shown that the BBB is still relatively intact in primary CNS solid tumors, certainly more so than in metastatic brain tumors. This may account for somewhat limited response rates of primary CNS cancers to many different types of chemotherapy, especially if the drug is large ( $>150$ Daltons) and charged, and may explain why synthetic antimetabolite drugs such as Ara-C, methotrexate, 6-MP, and gemcitabine are efficacious in regimens for CNS lymphoma, because they are small and uncharged. In addition, primary CNS lymphomas have high Ki-67's, which are indicative of rapid growth rates. In general, the class of antimetabolites mentioned in the previous sentence is active mainly in $\mathrm{G}_{\mathrm{I}} \mathrm{S}$, these drugs are nonpolar, and have molecular weights $<150$ Daltons. These characteristics make them advantageous to use in rapidly growing CNS lymphomas.

# MOLECULAR CHANGES IN THE BBB WITH METASTATIC LESIONS 

In 1989, the development of metastases in the brain was described by the "seed and soil" hypothesis first described by Paget; he postulated that tumor cells (the "seed") have a specific predilection for certain organs (the "soil"). In a multistep process, tumor cells interact with the brain microenvironment through the secretion of a variety of molecules implicated in cell invasion, such as matrix metalloproteinases (MMP), heparanase (HPSE) and hyaluronidase, in order to cross the endothelium by inducing breakdown of the extracellular matrix (Tosoni et al., 2004). Heparan sulfate proteoglycans are a major constituent of the endothelial cell layer that lines the luminal surface of blood vessels. HPSE is an enzyme that cleaves polymeric heparin sulfate molecules into shorter oligosaccharide chains; therefore, it is an important molecule in the process of penetration through the endothelial basement membrane. It has been shown that HPSE also releases angiogenic factors in the tumor microenvironment and thus can facilitate tumor cell invasion, vascularization, and decreased survival (Vlodavsky et al., 2002). Similarly, Delpech et al. (2002) have shown that levels of hyaluronidase are higher in human brain metastases than in their primary extracranial tumors, indicating that this might be an important aspect of the brain metastatic phenotype, in which the BBB in metastatic brain tumors is less intact than it is in primary gliomas. In the early stages of deposition of brain metastases, it appears that the BBB is still somewhatintact. In mouse xenografts, an intact BBB was seen with brain metastases up to 2 mm in diameter (Zhang et al., 1992). Over time, however, disruption of the foot processes occurs, leading to the breakdown of astrocyte and endothelial cell binding, which increases permeability of the BBB. Animal studies with sodium fluorescein, a marker of BBB permeability, have shown more physical disruption of the interactions between astrocytes and the BBB endothelial cells associated with metastatic lesions than with primary brain tumors. Thus, the BBB in metastatic brain tumors is more disrupted and less organized than the BBB in primary gliomas, which is an important factor when deciding which chemotherapy drug to use therapeutically in that particular patient.

Hypoxia also plays an important role in the pathogenesis of metastatic lesions to the brain. Zhang et al. (1992) have shown that approximately $70 \%$ of metastatic brain tumors that are greater than 0.5 mm in diameter have central necrosis and an ischemic environment. Ischemia leads to the breakdown of the BBB by increasing endothelial pinocytosis, opening tight junctions, and damaging endothelial cells (Dietrich et al., 1990). Hypoxia-inducible factor 1 (HIF-1) is upregulated under hypoxic conditions, and HIF-1 induces overexpression of vascular endothelial growth factor (VEGF) in tumors (Maxwell et al., 1997). The presence of VEGF, which stimulates neoangiogenesis, also makes blood vessels more permeable, and Lee et al. (2003) demonstrated in breast cancer cells that VEGF modulates transendothelial migration and brain endothelial cell permeability. In order to induce angiogenesis, VEGF must create interendothelial cell gaps and fenestrations in the neovascular endothelium, causing subsequent degeneration of the plasma membrane and loss of the integrity of the BBB. Furthermore, newly created vessels (neoangiogenesis) lack the properties of those normal, nontumor related blood vessel endothelial cells in the same area of the brain and can lead to increased leakage through the BBB (Fidler et al., 2002). Thus, blood vessels formed in the environment of metastatic brain tumors $>2 \mathrm{~mm}$ are "leaky" and do not have an intact BBB as in normal brain blood vessels. It has been posited that blocking early VEGF expression may limit BBB breakdown; there are known agents that block VEGF expression, such as bevacizumab, the anti-VEGF antibody, that are in clinical use today.

Currently, the reason for the predilection of some tumors to metastasize to the brain more than others is not completely understood. One theory is that the brain and the organs that form types of cancer that easily metastasize to the brain have the same embryonic neuroectodermal origin; for instance, SCLC and melanoma are derived from tissues that are of embryonic neuroectodermal origin, and they have a high propensity to metastasize to the brain. Another theory has been reported by Hirano and Zimmerman (1972), and posited that the neovasculature in the metastatic brain lesion expresses characteristics of the blood vessels of the primary extracranial tumor. Interestingly, the fenestrations seen in the blood vessel endothelium in renal cell carcinoma metastases to the brain are similar to those seen in the primary tumor. One can hypothesize that the tumor cells secrete or induce molecules that alter the architecture or structural character of the BBB so that it is similar to its tumor of origin.

# THE ROLE OF P-GLYCOPROTEIN 

P-gp (also known as ABCB1) is a product of the MDR1 gene and it is an adenosine triphosphate (ATP)-dependent efflux pump in many organs/tissues that detoxifies theblood and it is located on the luminal surface of BBB endothelial vessel cells and in organs that are vital to detoxification (Fig. 2.1). It plays an important role in the detoxification process of xenotoxins and is expressed in tissues such as the liver, kidney, placenta, colon, BBB, and small intestine. In the capillary endothelial cells of the CNS-BBB, this protein is highly expressed and pumps out many xenotoxins (by hydrolysis of ATP) from the endothelial cells into the capillaries and peripheral circulation. Notably, xenotoxins comprise the great majority of the NPCAs in use today, and they are derived from plants, bacteria, protozoa, and fungi. Half of our chemotherapy drugs are derived from natural sources: from land and marine-based organisms. In general, the majority of NPCAs are not useful in primary brain tumors because they cannot cross the BBB, even if it is only partially intact. Exceptions to this are the topoisomerase I/II inhibitors, such as irinotecan (CPT-11) and etoposide (VP-16), which do cross over the BBB, probably because they are not highly bound to albumin (about $70 \%$ is free drug). This also explains why small lipophilic (nonpolar) synthetic drugs, such as the class of lipophilic alkylators/methylators (temozolomide (TMZ), CCNU, BCNU, Thio-TEPA) are useful in primary brain tumors where the BBB is partially intact and the P-gp expression is high. Lipophilic alkylators/methylators, like TMZ, can cross the BBB into primary brain tumors at $40 \%$ of their plasma concentration. It has been shown in murine knockout models that deletion of P-gp leads to a two- to threefold higher concentration of NPCAs in the brain parenchyma compared with wild-type P-gp mice (Kemper et al., 2004; Gallo et al., 2003). In addition, Toth et al. (1996) demonstrated that P-gp expression in the neovasculature of gliomas is different than that of metastatic brain tumors. In a study of adult surgical brain tumor specimens ( 29 gliomas and 6 metastatic brain lesions), the endothelial cells of newly formed capillaries in nearly $90 \%$ of primary gliomas stained highly positive, by immunohistochemical staining (IHC), for P-gp, whereas only $50 \%$ of metastatic tumors stained highly positive for P-gp. The metastatic brain tumors with high levels of P-gp by IHC were tumors which intrinsically have high P-gp levels in their primary tumors and organs such as colon, kidney, liver, and pancreas. In addition, the expression of P-gp in the neovasculature of the metastatic brain tumor was similar to the P-gp levels found in the primary, extracranial, tumor vasculature. For instance, primary melanomas (which usually have low P-gp levels) and their related brain metastases had similar levels of P-gp in their neovasculature; the level was much lower than would be expected in the normal BBB. Alternatively, the P-gp level in renal cell or hepatocellular carcinoma metastases (normally high P-gp levels) to the brain was similar to that found in the primary tumor organs. Given the finding that the level of P-gp expression is lower or higher in the neovasculature of brain metastases, based upon the expression of P-gp in the primary tumors, one can hypothesize that this can significantly affect the ability of P-gp to block entry of NPCAs into the brain. Of note, this effect is caused more from the expression of P-gp in the neovascular endothelial cells, rather than the expression in the tumor itself. P-gp is one of the primary efflux pumps not only for the great majority of NPCA's, but for many targeted agents as well including axitinib, dasatinib, gefitinib, erlotinib, imatinib, sorafenib, sunitinib, everolimus, and lapatinib (Steeg et al., 2011). This finding is unexpected since many of the targeted agents are of lower molecular weights and some are uncharged.

There are several known P-gp inhibitors. Notable drugs that are used in other clinical situations that also inhibit P-gp include tamoxifen, verapamil, cyclosporine A, and the cardiac antiarrythmic/antihypertensive group called dihydropyridines. Elacridar is an inhibitorof both P-gp and ABCG2 (breast cancer resistance protein), and it was shown by Lagas and colleagues that this agent is almost as effective in increasing levels of sorafenib in the brain as a double knockout of $A b c b 1 ; A b c g 2$ (P-gp) (Lagas et al., 2010). This study is important in that it shows the relative importance of ABCG2 transporter in addition to P-gp alone in pumping out many useful drugs and xenotoxins from the vascular endothelial brain cells. Likewise, Agarwal et al. (2010) found that Elacridar increases brain to plasma ratios of gefitinib in mice despite the presence of intact tight junctions, indicating that gefitinib distribution to the brain is restricted due to active efflux by these pumps. More recently, CBT-1, which is well tolerated and is administered by mouth, has been shown to inhibit P-gp, though more prospective trials are needed to confirm its therapeutic efficacy (Kelly et al., 2012). Tamoxifen penetrates well into brain metastases and therapeutic concentrations can be achieved in both brain tumors and serum (Lien et al., 1991). However, when treated with tamoxifen alone, breast cancer patients who have disease that is only metastatic to the brain rarely achieve long-term remissions of their brain metastases without chemotherapy (Salvati et al., 1993). Based on the theory that tamoxifen might inhibit P-gp, we carried out a laboratory/randomized clinical study of paclitaxel (a NPCA drug) and high dose tamoxifen to assess the ability of tamoxifen to increase paclitaxel intratumoral accumulation in metastatic brain tumors and primary gliomas (Fine et al., 2006). We tested 27 patients who were aged 18-80; they all had recurrence of their histologically documented primary brain glioma, or an initial metastatic brain lesion and their neurosurgeons deemed surgical resection as the next step for treatment. There were two arms in this randomized study; all patients were given $175 \mathrm{mg} / \mathrm{m}^{2}$ paclitaxel infused within a 4 h period just prior to their neurosurgical procedure, or they received the same dose of paclitaxel plus 5 days of tamoxifen (a loading dose followed by $160 \mathrm{mg} / \mathrm{m}^{2}$ twice a day, given orally) starting 5 days prior to the neurosurgical procedure. It was considered safe for these patients to delay their surgery by 5 days, as deemed by the neurosurgeons, and they signed informed consent for this IRB-approved protocol. We analyzed plasma and tissue samples from these patients for paclitaxel levels by high performance liquid chromatography (HPLC). Tumor tissue was resected from the center and periphery of the brain tumor (metastatic or primary glioma) and at the interface with normal brain tissue. In this study the metastatic brain tumors originated from NSCLC, SCLC, and renal cell carcinomas (Fine et al., 2006).

The 5 days of high dose tamoxifen was well tolerated, without any toxicity above grade 2, and there were no complications (i.e., healing of surgical scar) from the interventions. Pharmacokinetic (PK) studies for serum levels of paclitaxel and tamoxifen showed no difference in the levels of paclitaxel in the two groups. There was also no difference in serum/blood tamoxifen levels between metastatic brain tumor and primary glioma patients. After performing a multivariate, linear regression analysis, adjusting for tumor type and other factors, we found that median intracellular paclitaxel concentrations increased significantly from tamoxifen. Paclitaxel concentrations were 3.70 and 2.46 higher in the periphery and tumor-brain interface of metastatic brain lesions, respectively, than in gliomas ( $P=0.01$ ) (Fig. 2.2) (Fine et al., 2006). The median paclitaxel concentrations were 2.68 -fold higher in the center of the tumor ( $P=0.03$ ) (Fig. 2.2). However, the important effect of tamoxifen was that the paclitaxel concentrations were 3.70 and 2.46 -fold higher in the periphery and tumor-normal brain interface of metastatic brain lesions as compared with primary brain tumors. These examinations were derived using HPLC analysis of![img-63.jpeg](img-63.jpeg)

FIGURE 2.2 Paclitaxel tissue concentrations in all primary and metastatic brain tumors. Median tissue concentrations of paclitaxel $(\mathrm{ng} / \mathrm{g})$ in the tumor center, tumor periphery, and surrounding normal brain. Total median paclitaxel concentrations of all patients within each tumor type (primary vs metastatic) who receive paclitaxel alone or with prior tamoxifen. Values are overlaid on an image of a glioblastoma multiforme for the primary brain tumor group and of a melanoma brain metastasis for the metastatic brain tumor group. Source: From Fine et al. (2006).
tissues from the center and periphery of patient's brain tumors. The area of the tumor that is growing in both metastatic and primary brain tumors is the tumor periphery and tumornormal brain interface. These are the important areas to assess because the tumor center is mainly necrotic tissue and is not actively growing. Thus, tamoxifen was able to significantly increase paclitaxel traversement into metastatic brain tumors more so than primary gliomas and it occurred in the growing periphery ( 3.70 fold) and normal brain-tumor interface ( 2.46 fold). This study also showed that baseline penetration and accumulation of paclitaxel alone was higher in metastatic brain tumors as compared to gliomas, which have more intact BBBPgp (Fine et al., 2006).

We also examined the effects of high dose tamoxifen upon the concentration of paclitaxel in the cerebrospinal fluid (CSF) of brain tumor patients. In a prospective, IRB-approved study with informed consent, we randomized 10 patients with either primary or metastatic brain tumors to paclitaxel alone ( $175 \mathrm{mg} / \mathrm{m} 2 / \mathrm{IV}$ ) or a course of tamoxifen (loading dose followed by $160 \mathrm{mg} / \mathrm{m} 2$ PO BID on days $1-5$ prior to surgery for their tumor and 3 h just before surgery) followed by paclitaxel ( $175 \mathrm{mg} / \mathrm{m} 2 / \mathrm{IV}$ ). We obtained CSF and plasma levels of paclitaxel and performed PK studies for tamoxifen and paclitaxel by HPLC (Chen et al., 2006). Unexpectedly, we found a trend toward lower paclitaxel concentrations in CSF when paclitaxel was given together with tamoxifen. For those who received paclitaxel alone, we detected a 2.4 -fold greater mean CSF paclitaxel concentration and a 3.7 -fold higher median CSF to plasma paclitaxel ratio for those who received paclitaxel alone, as compared to those who received both drugs $(P=0.02)$. This finding was consistent with the reported finding that P-gp in the endothelial cells of the choroid plexus pumps NPCA's in an opposite direction and concentrates drugs inside the CSF and out of the brain (Piwnica-Worms et al., 1999). Therefore, it is surmised that agents that inhibit P-gp (such as tamoxifen), may increase effluxof NPCA out of the blood-CSF barrier into the peripheral circulation and, paradoxically, lower the CSF concentrations of these agents. This finding was unexpected, but it implies that P-gp in the brain effluxes NPCA out of the tumor and brain into the CSF where it is partitioned into the bloodstream away from the brain and tumor metastases. The choroid plexus is very high in P-gp content and here the NPCA's are effluxed into the bloodstream in order to protect the tumor and brain. Adding tamoxifen to paclitaxel, in this situation, causes more NPCA to be effluxed out of the CSF and into the peripheral blood circulation resulting in less paclitaxel in the CSF (Chen et al., 2006). The function of P-gp in the choroid plexus is to protect the CSF-BBB-brain from xenotoxins like paclitaxel. Thus, use of P-gp inhibitors for treated carcinomatous meningitis may actually be hindered and paradoxically decrease the efficacy and concentration of the NPCA anticancer drug in the CSF circulation.

# LOCAL AND SUPPORTIVE TREATMENTS 

Since seizures can occur in up to $25 \%$ of patients with brain metastases, antiepileptic drugs (AEDs) are commonly used in treatment and prophylaxis for these patients. However, these medications can have substantial side effects, and can interact with other drugs, such as chemotherapy drugs. Many AEDs are inducers or suppressors of the hepatic cytochrome p450 system that metabolizes many NPCA and non-NPCA drugs. Therefore, serum concentrations of these drugs, both NPCA and non-NPCA may be altered (either increased or decreased) when AEDs are administered. For instance, paclitaxel, cyclophosphamide (active drug is 4-hydroxy-cyclophosphamide, metabolized in the liver), methotrexate, irinotecan (CPT-11), topotecan, navelbine, and doxorubicin are all metabolized by the hepatic cytochrome p450 system, as are several of the newer targeted agents, such as imatinib, gefitinib, and erlotinib. Of note, AEDs that do not induce or suppress the cytochrome p450 system include valproic acid, topiramate, gabapentin, lamotrigine, and, importantly, levitracetam. Phenytoin and phenobarbital can also significantly enhance the catabolism of corticosteroids and vice versa and thus accelerate their breakdown leading to lower serum concentrations of the AED or steroid drug, and reducing their efficacy in the treatment of seizures and CNS edema, respectively. In a meta-analysis and practice guideline paper done by Glantz et al. (2000), it was shown that AEDs did not reduce the frequency of first seizures in patients with brain metastases, and thus they did not recommend this for prophylaxis.

Corticosteroids are often used to reduce CNS edema from brain metastases, and they are critical in reducing the risk of brain stem herniation. Positive effects are usually seen within $8-12 \mathrm{~h}$ of corticosteroid administration, with maximal effect being seen in 3-7 days. The mechanism by which steroids reduce cerebral edema is not completely known; however, it has been shown that corticosteroids restore disrupted capillary permeability (Chumas et al., 1997). Using mouse models, Straathof and colleagues showed that the concentration of cisplatinum in the area of the brain surrounding a tumor is considerably decreased following pretreatment with high dose dexamethasone (Straathof et al., 1998). Therefore, it can be inferred that steroid administration, to patients who are receiving chemotherapy or other targeted agents for their brain tumors, can negatively impact the efficacy of their treatment. For instance, if cisplatinum is given to a patient for the treatment of a brain metastasisfrom NSCLC, while also receiving high dose dexamethasone, and the patient does not have a response to the cisplatinum, the explanation for the lack of response may be that there is accelerated catabolism of cisplatinum due to the impact of the steroid and not due to an intrinsic drug resistance of the tumor. In this situation, switching to another agent active in NSCLC that isn't affected by steroids or increasing the dose of cisplatinum is advisable.

Whole brain radiation therapy (WBRT) is often the treatment of choice for patients who have multiple brain metastases at the time of diagnosis. Median survival after WBRT, when given alone, is estimated to be 3-6 months, and often death is from progression of the primary disease, as opposed to the progression of brain metastases. Generally, a short course of radiation therapy with 30 Gy total cumulative dosage (given in 180-300 cGy fractionated doses, 5 times a week) is administered for brain metastases. Stereotactic radiosurgery (SRS) and surgery are also options for localized treatment of these tumors. SRS is usually reserved for patients with small tumors (less than 3 cm ) and usually having fewer than three CNS lesions. The advantage of SRS is specificity and a high "kill fraction," if other lesions develop after radiosurgery, then WBRT can be administered. The reverse is also true in that SRS can be administered for a singular lesion or fewer than three lesions even when WBRT has been given in the past. Interestingly, these types of radiation induce further breakdown of the BBB by decreasing P-gp content by $\geq 25 \%$ in irradiated brain tumors (Deeken and Loscher, 2007). This effect has not been well studied, but may allow the passage of NPCA and non-NPCAs into the brain lesions more readily. The role of adjuvant WBRT after surgery or SRS is still controversial, and studies are ongoing to understand the role of radiation in this context. If the metastatic brain tumor is in the cerebellum or near the brainstem anatomy, radiation has sometimes been dangerous in that it increases brain edema and intracranial pressures leading to signs of herniation. In these cases, resection may be preferred to radiation as a treatment. In addition, high dose steroids should be considered with the radiation to decrease edema.

# SYSTEMIC AND TARGETED THERAPIES 

## General Principles

At this time, there is no established paradigm for chemotherapy and targeted agents in the systemic treatment of brain metastases; however, the choice of a chemotherapeutic regimen should depend mostly upon the histology of the primary tumor. There are drugs under development that are being designed to improve BBB permeability (Deeken and Loscher, 2007). As mentioned previously, it is important to account for concomitant use of steroids and cytochrome p450 inducers when considering systemic chemotherapies, as these agents may limit the efficacy of chemotherapeutics and their PKs. Next, we will discuss the management of several cancers that are often associated with CNS metastases.

## Breast Cancer

Breast cancer has several commonly used predictive markers to help define treatment, including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2). The humanized monoclonal antibody that blocksHER-2, trastuzumab, has changed the outlook for patients with HER-2 overexpression and it improves OS. HER-2 overexpression is found in $15-20 \%$ of breast cancers, and this patient population is characterized by a higher incidence of brain metastases and prolonged survival, when compared to those patients who are negative for HER-2 overexpression. One possible explanation for this finding is that the BBB penetration of trastuzumab is generally poor and a partially nonfunctioning BBB can allow the brain to become a sanctuary for colonization by metastatic breast cancer cells (Leyland-Jones, 2009). Moreover, the improved survival time in this patient population, due to treatment with new and improved chemotherapy drugs such as trastuzumab, may allow more time for brain metastases to develop and become clinically apparent. More recently, lapatinib, a tyrosine kinase inhibitor (TKI) of both epidermal growth factor receptor (EGFR) and HER-2, has the advantage of being able to penetrate the BBB more effectively than trastuzumab. In a mouse model, Taskar et al. (2012) have shown that the concentration of lapatinib in brain metastases was seven- to ninefold greater than surrounding brain tissue at 2 and 12 h after oral administration of the drug. However, the mean lapatinib concentration in brain metastases was still only about $10-20 \%$ of that found in non-CNS, peripheral metastases. The LANDSCAPE trial was a single arm Phase II trial combining lapatinib with capecitabine in patients with HER-2 overexpressing breast cancer and brain metastases, which demonstrated a $65.9 \%$ CNS response rate and no toxic deaths (Bachelot et al., 2013). Randomized trials of this combination are ongoing in breast cancer patients with CNS metastases.

Another subgroup of breast cancer patients that has a relatively high rate of brain metastases includes those that are negative for ER, PR, and HER-2 overexpression, often referred to as "Triple-negative" breast cancer. This group also carries a poor prognosis overall, but there is growing interest in using Poly-Adenosine Ribose Polymerase (PARP) inhibitors in this patient population since PARP plays an important role in DNA damage repair; drugs that target this enzyme can increase tumor response to chemotherapy (Helleday, 2011). Phase II trials looking at the combination of PARP inhibitors with chemotherapy regimens are ongoing, and the role they may play in the management of brain metastases is under active investigation.

# Lung Adenocarcinoma 

In NSCLC, Crino and colleagues demonstrated that the response rates of brain metastases to gemcitabine and cisplatinum were similar to the response rates seen in the primary and other metastatic lesions (Crino et al., 1999). Similarly, other studies in NSCLC have shown similar results showing that brain metastases are as chemosensitive as their primary tumors to chemotherapy drugs (Bernardo et al., 2002; Cortes et al., 2003). Alternatively, TMZ, a lipophilic methylator commonly used to treat primary brain tumors, has been shown to have relatively low response rates ( $<9 \%$ ) in patients with brain metastases from NSCLC (Abrey et al., 2001). A Phase II study by Dziadziuszko et al. (2003) was closed after no responses were seen (in either primary or metastatic brain lesions) in NSCLC patients treated with single agent TMZ, and it was concluded that, as a single agent, TMZ has no clinical benefit in this disease. This type of therapeutic rationale that chooses a lipophilic drug with no history of efficacy in its primary tumor needs to be reconsidered by the treating oncologist. Thus, even though TMZ might have good penetration across the BBB( $\sim 40 \%$ penetration into the CNS and CSF), since it is not an active agent for primary NSCLC lesions, it has a limited role in the management of brain metastases from NSCLC. However, TMZ has been reported to have significant activity in treating SCLC metastases to the brain and visceral organs. It has been recommended as a good second line drug for SCLC. The standard of care for the systemic treatment of NSCLC patients with brain metastases is platinum-based chemotherapy (in addition to brain radiotherapy as symptomatically indicated). The same chemotherapy drug used for the primary tumor histology should be strongly considered for patients with metastatic brain lesions from the particular primary tumor, chemosensitive primary tumors, and progressive systemic disease.

The use of TKIs targeting the EGFR including gefitinib, erlotinib, and more recently afatinib in the treatment of NSCLC has suggested the possibility of using TKIs for the treatment of brain metastases. Although there is a lack of detailed studies; the BBB permeability of erlotinib is thought to be better than gefitinib since penetration of erlotinib into the CSF has been documented by Masuda et al. (2011). Furthermore afatinib, a second generation EGFR irreversible inhibitor that also acts upon the T790A resistance mutation, was reported to induce the remission of a patient with NSCLC brain metastases (Yap et al., 2010). Other targeted agents that act upon specific and rare mutations found in NSCLC, such as EGF receptor (EGFR) and anaplastic lymphoma kinase (ALK), are in development, and their ability to cross the BBB is under investigation. However, there are increasing case reports of responses in NSCLC brain metastases with an EGFR or ALK mutation to these oral TKIs. Unfortunately, ALK and EGFR mutations each occur only in 4-6\% of the NSCLC population. Overall, the advent of these TKIs is very exciting for the treatment of NSCLC (and its high frequency of metastasizing to the brain), making this area of research very promising. One major limitation to getting these TKIs across the BBB is that many of these molecules are also substrates for ABC transporters such as P-gp and MRP.

# Melanoma 

The treatment of metastatic melanoma has been dramatically improved with the development of BRAF inhibitors and effective immunotherapy with checkpoint inhibition. BRAF mutations are found in about half of melanoma cases, and this mutation leads to stimulation of the mitogen-activated protein kinase pathway responsible for increased tumor survival and progression. While the initial studies with the BRAF inhibitor, vemurafenib, did not include patients with brain metastases, Phase II studies have been initiated to evaluate the efficacy of this and other BRAF inhibitors in patients with brain metastases. In a dose escalation study by Falchook et al. (2012), treatment with the BRAF inhibitor, dabrafenib, induced responses in previously untreated brain metastases in 9 out of 10 melanoma patients.

Melanoma is commonly considered to be an immunogenic cancer similar to renal cell cancer, and there have been great advancements in the field of immunotherapy to treat this disease. The cytotoxic T lymphocyte antigen 4 (CTLA-4) is an inhibitory regulator of T-cells (T-Reg Cells) that is often employed by tumors as a method to evade the immune system. It has been seen in Phase III studies, that ipilimumab increases OS in patients with metastatic melanoma by blocking CTLA-4 (Hodi et al., 2010). Margolin et al. (2012) showed that ipilimumab was tolerable and had activity in patients with advanced melanoma and brain metastases, particularly when the metastases were small and asymptomatic. While furtherrandomized, controlled trials to test efficacy in treating brain metastases from melanoma are needed, the use of immunotherapy in addition to standard chemotherapy and TKIs is very exciting and promising for this aggressive cancer. Again, we see that the treatment of brain metastases in melanoma appears to be based upon using agents known to have historical efficacy against primary melanoma. As a general rule for treating brain metastases, the agents of choice should be taken from those known to be efficacious in treating the primary tumor. This is based upon the prior findings of metastatic brain tumor research, which show significant disruption of the BBB, and enhanced permeability of the BBB to certain non-NPCA, TKIs and immunologic treatments.

# CONCLUSION 

Brain metastases are a serious and often fatal consequence of cancer. Through a complex process that is still being elucidated, microscopic tumor deposits manage to circumvent the BBB and form brain metastases. Understanding how the BBB works can help explain why certain chemotherapeutic agents have limited roles in brain tumors. Understanding the BBB and how it works will lead to other potential areas for study, such as pharmacologic inhibition, as seen with the number of P-gp inhibitors coming to the clinic. Nevertheless, treatment of brain metastases should focus on using local therapies for palliating symptoms in addition to using chemotherapeutics and targeted agents with known efficacy against the primary tumor. When designing new treatment regimens, special thought should be given to the physiology of the functional and semifunctional BBB and how the BBB may hinder or allow the penetration of therapeutic agents into metastatic brain tumors.

## Acknowledgments

We wish to thank our Research Nurse, Dawn Tsushima, BS, RN, for her editing, insightful comments and assistance in making this chapter clear and logical. We also want to thank Tyler Golato and Uri Hochfeld for assistance in the preparation of the chapter.

## References

Abrey, L.E., Olson, J.D., Raizer, J.J., Mack, M., Rodavitch, A., Boutros, D.Y., et al., 2001. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J. Neurooncol. 53 (3), 259-265.

Agarwal, S., Sane, R., Gallardo, J.L., Ohlfest, J.R., and Elmquist, W.F., 2010. Distribution of brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-active efflux. J. Pharmacol. Exp. Ther. 334 (1), 147-155.

Bachelot, T., Romieu, G., Campone, M., et al., 2013. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 14 (1), 64-71.
Barnholtz-Sloan, J.S., Sloan, A.E., Davis, F.G., Vigneau, F.D., Lai, P., and Sawaya, R.E., 2004. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J. Clin. Oncol. 22 (14), 2865-2872.

Bernardo, G., Cuzzoni, Q., Strada, M.R., Bernardo, A., Brunetti, G., Jedrychowska, I., et al., 2002. First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study. Cancer Invest. 20 (3), 293-302.Chen, J., Balmaceda, C., Bruce, J.N., Sisti, M.B., Huang, M., Cheung, Y.K.K., et al., 2006. Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients. J. Neurooncol. 76 (1), 85-92.
Chumas, P., Condon, B., Oluoch-Olunya, D., Griffiths, S., Hadley, D., and Teasdale, G., 1997. Early changes in peritumorous oedema and contralateral white matter after dexamethasone: a study using proton magnetic resonance spectroscopy. J. Neurol. Neurosurg. Psychiatry 62 (6), 590-595.
Cortes, J., Rodriguez, J., Aramendia, J.M., et al., 2003. Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology 64 (1), 28-35.
Crino, L., Scagliotti, G.V., Ricci, S., et al., 1999. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian lung cancer project. J. Clin. Oncol. 17 (11), 3522-3530.
Deeken, J.F., and Loscher, W., 2007. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin. Cancer Res. 13 (6), 1663-1674.
Delattre, J.Y., Krol, G., Thaler, H.T., and Posner, J.B., 1988. Distribution of brain metastases. Arch. Neurol. 45 (7), $741-744$.
Delpech, B., Laquerriere, A., Maingonnat, C., Bertrand, P., and Freger, P., 2002. Hyaluronidase is more elevated in human brain metastases than in primary brain tumours. Anticancer Res. 22 (4), 2423-2427.
Dietrich, W.D., Busto, R., Halley, M., and Valdes, I., 1990. The importance of brain temperature in alterations of the blood-brain barrier following cerebral ischemia. J. Neuropathol. Exp. Neurol. 49 (5), 486-497.
Dziadziuszko, R., Ardizzoni, A., Postmus, P.E., Smit, E.F., Price, A., Debruyne, C., et al., 2003. Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases: a phase II study of the EORTC Lung Cancer Group (08965). Eur. J. Cancer 39 (9), 1271-1276.
Falchook, G.S., Long, G.V., Kurzrock, R., et al., 2012. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379 (9829), 1893-1901.
Fidler, I.J., Yano, S., Zhang, R.D., Fujimaki, T., and Bucana, C.D., 2002. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol. 3 (1), 53-57.
Fine, R.L., Chen, J., Balmaceda, C., Bruce, J.N., Huang, M., Desai, M., et al., 2006. Randomized study of tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors. Clin. Cancer Res. 12 (19), 5770-5776.
Fox, B.D., Cheung, V.J., Patel, A.J., Suki, D., and Rao, G., 2011. Epidemiology of metastatic brain tumors. Neurosurg. Clin. N. Am. 22 (1), 1-6. v.
Gallo, J.M., Li, S., Guo, P., Reed, K., and Ma, J., 2003. The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res. 63 (16), 5114-5117.
Gaspar, L., Scott, C., Rotman, M., Asbell, S., Phillips, T., Wasserman, T., et al., 1997. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int. J. Radiat. Oncol. Biol. Phys. 37 (4), 745-751.
Gaspar, L.E., Scott, C., Murray, K., and Curran, W., 2000. Validation of the RTOG recursive partitioning analysis (GPA) classification for brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 47 (4), 1001-1006.
Glantz, M.J., Cole, B.F., Forsyth, P.A., et al., 2000. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 54 (10), 1886-1893.
Helleday, T., 2011. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol. Oncol. 5 (4), 387-393.
Hirano, A., and Zimmerman, H.M., 1972. Fenestrated blood vessels in a metastatic renal carcinoma in the brain. Lab. Invest. 26 (4), 465-468.
Hodi, F.S., O'Day, S.J., McDermott, D.F., et al., 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363 (8), 711-723.
Hwang, T.L., Close, T.P., Grego, J.M., Brannon, W.L., and Gonzales, F., 1996. Predilection of brain metastasis in gray and white matter junction and vascular border zones. Cancer 77 (8), 1551-1555.
Kelly, R.J., Robey, R.W., Chen, C.C., Draper, D., Luchenko, V., Barnett, D., et al., 2012. A pharmacodynamic study of the P-glycoprotein antagonist CBT-1(R) in combination with paclitaxel in solid tumors. Oncologist 17 (4), 512.
Kemper, E.M., Boogerd, W., Thuis, I., Beijnen, J.H., and van Tellingen, O., 2004. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat. Rev. 30 (5), $415-423$.Kroll, R.A., and Neuwelt, E.A., 1998. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 42 (5), 1083-1099. Discussion 99-100.
Lagas, J.S., van Waterschoot, R.A., Sparidans, R.W., Wagenaar, E., Beijnen, J.H., and Schinkel, H., 2010. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol. Cancer Ther. 9 (2), 319-326.
Lee, T.H., Avraham, H.K., Jiang, S., and Avraham, S., 2003. Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability. J. Biol. Chem. 278 (7), 5277-5284.
Leyland-Jones, B., 2009. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J. Clin. Oncol. 27 (31), 5278-5286.
Lien, E.A., Wester, K., Lonning, P.E., Solheim, E., and Ueland, P.M., 1991. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br. J. Cancer 63 (4), 641-645.
Lo, E.H., Pan, Y., Matsumoto, K., and Kowall, N.W., 1994. Blood-brain barrier disruption in experimental focal ischemia: comparison between in vivo MRI and immunocytochemistry. Magn. Reson. Imaging 12 (3), 403-411.
Margolin, K., Ernstoff, M.S., Hamid, O., et al., 2012. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13 (5), 459-465.
Masuda, T., Hattori, N., Hamada, A., Iwamoto, H., Ohshimo, S., Kanehara, M., et al., 2011. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother. Pharmacol. 67 (6), 1465-1469.
Maxwell, P.H., Dachs, G.U., Gleadle, J.M., Nicholls, L.G., Harris, A.L., Stratford, I.J., et al., 1997. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 94 (15), 8104-8109.
Paget, S., 1989. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev. 8 (2), 98-101.
Piwnica-Worms, D., Rao, V.V., Dahlheimer, J.L., Bardgett, M.E., and Snyder, A.E., 1999. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc. Natl. Acad. Sci. 96 (7), 3900-3905.
Salvati, M., Cervoni, L., Innocenzi, G., and Bardella, L., 1993. Prolonged stabilization of multiple and single brain metastases from breast cancer with tamoxifen. Report of three cases. Tumori 79 (5), 359-362.
Schouten, L.J., Rutten, J., Huveneers, H.A., and Twijnstra, A., 2002. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94 (10), 2698-2705.
Steeg, P.S., Camphausen, K.A., and Smith, Q.R., 2011. Brain metastases as preventive and therapeutic targets. Nat. Rev. Cancer 11 (5), 352-363.
Straathof, C.S., van den Bent, M.J., Ma, J., Schmitz, P.I.M., Kros, J.M., Stoter, G., et al., 1998. The effect of dexamethasone on the uptake of cisplatin in 9L glioma and the area of brain around tumor. J. Neurooncol. 37 (1), 1-8.
Taskar, K.S., Rudraraju, V., Mittapalli, R.K., et al., 2012. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm. Res. 29 (3), 770-781.
Tosoni, A., Ermani, M., and Brandes, A.A., 2004. The pathogenesis and treatment of brain metastases: a comprehensive review. Crit. Rev. Oncol. Hematol. 52 (3), 199-215.
Toth, K., Vaughan, M.M., Peress, N.S., Slocum, H.K., and Rustum, Y.M., 1996. MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. Am. J. Pathol. 149 (3), 853-858.
Vlodavsky, I., Goldshmidt, O., Zcharia, E., Atzmon, R., Rangini-Guatta, Z., Elkin, M., et al., 2002. Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Semin. Cancer Biol. 12 (2), $121-129$.
Yap, T.A., Vidal, L., Adam, J., et al., 2010. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J. Clin. Oncol. 28 (25), 3965-3972.
Zhang, R.D., Price, J.E., Fujimaki, T., Bucana, C.D., and Fidler, I.J., 1992. Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am. J. Pathol. 141 (5), 1115-1124.# C H A P T E R 

## 3

## Melanoma Metastases Are Underrepresented in Cerebellum Compared with Metastases from Colorectal Cancers

Torstein R. Meling, Siril G. Rogne and Eirik Helseth

## O U T L I N E

Introduction 38
Epidemiology 38
The Pathogenesis of Brain Metastasis 38
Histology of Primary Cancer 39
Cerebellar Metastases 40
The Oslo University Hospital
Experience
Clinical Setting
Statistics
Origin of Primary Tumor
Incidence of Cerebellar versus
Supratentorial Brain Metastases

Incidence of Cerebellar Malignant
Melanomas Metastases 42
Incidence of Cerebellar Colorectal
Cancer Metastases 42
Discussion 44
Malignant Melanomas 44
Coloectal Cancers 46
Conclusions 46
References 47# INTRODUCTION 

## Epidemiology

Brain metastases are estimated to be the most common intracranial malignancy in adults (Gavrilovic and Posner, 2005). However, the exact incidence is unknown as epidemiological, clinical, neurosurgical, and autopsy series present different incidence rates due to different patient selections. Autopsy series report the highest incidence rates, as they include asymptomatic metastases in patients with advanced disseminated cancer disease. Autopsy series from the 1970s and 1980s reported that $1 / 6$ to $1 / 4$ of patients with cancer harbored brain metastases at autopsy, and about one-third of these metastases were estimated to be asymptomatic during the patient's lifetime (Chason et al., 1963; Posner, 1978). As fewer patients undergo autopsy today, similar autopsy series with updated data are not available. Population-based series suggest that $8-10 \%$ of adults with cancer will experience symptomatic metastases during their lifetime (Eichler and Loeffler, 2007; Schouten et al., 2002). The incidence rate of brain metastases in population-based series is reported in the range of 8.3-14.3 per 100,000 population (Nayak et al., 2012). However, most of these series are old and outdated.

Incidence rates from epidemiological and clinical series are likely to underestimate the true incidence as a consequence of inadequate reporting (Gavrilovic and Posner, 2005; Suki, 2004). In contrary to primary cancers, which are systematically and compulsorily registered in cancer registries in many western countries, brain metastases are not necessarily registered and may even be omitted from discharge diagnosis code. Furthermore, asymptomatic metastases are not accounted for in most of these series.

Neurosurgical series report incidence rates that are depended upon referral patterns and management strategies of the department. At our department, intracranial metastases constituted $16 \%$ of all intracranial tumor surgeries in adults (unpublished results). In Norway, about 30,000 patients develop cancer annually and the age-standardized incidence rate of all primary cancers is 367 and 296 per 100,000 person-years for men and women, respectively (The Cancer Registry of Norway, http://www.kreftregisteret.no/en/). We have estimated the annual annual incidence of first-time craniotomy for a brain metastasis to be 2.6 per 100,000 people in the south-eastern population of Norway (Rogne et al., 2012). The average annual risk of having a craniotomy for a brain metastasis in cancer patients was $0.48 \%$ (Rogne et al., 2012).

The increased incidence of intracranial metastases observed over the last decades has been attributed improved diagnostic imaging, prolonged survival of cancer patients as a result of better systemic treatment and an altered treatment approach toward an increasingly elderly population (Lassman and DeAngelis, 2003). Many chemotherapeutic agents used for cancer treatment do not cross the blood-brain-barrier, which may leave the brain parenchyma as a sanctuary for growth of metastases (Gavrilovic and Posner, 2005). As cancer patients live longer due to improved therapy, brain metastases are, for certain cancer types, a common first sign of relapse (Smedby et al., 2009).

## The Pathogenesis of Brain Metastasis

The process of metastasis from a primary tumor to the brain parenchyma consists of a series of complex, interactive steps including; genetic alterations, proliferation,transformation, angiogenesis, invasion, spread, tumor cell arrest, and growth in brain microenvironment (Eichler et al., 2011). Metastatic cells most commonly reach the brain parenchyma by hematogenous spread (Gavrilovic and Posner, 2005). Local extension from adjacent cranium metastases is a less common alternative route for central nervous system involvement. Intracranial metastases may be located in intra-axial parenchyma and/ or may involve the leptomeninges.

Parenchymal metastases are often located in the gray-white matter interfaces and the watershed areas. These are areas where the arterioles narrow and may mechanically arrest embolic tumor cells (Delattre et al., 1988). Generally, parenchymal metastases are located in cerebral hemispheres in $80 \%$, cerebellum in $15 \%$, and brain stem in $5 \%$, a distribution that closely parallels the regional blood flows and blood volumes of the respective regions. These observations support Ewing's mechanical hypothesis from 1928, that is, that the pattern of metastasis is sufficiently explained by a mechanical entrapment of tumor cells defined by the vascular anatomy and blood flow between primary tumor and receptive organs (Gavrilovic and Posner, 2005). Other observations supporting this hypothesis are the high occurrence of lung as primary tumor site, and the high occurrence of lung metastases among patients with brain metastases. Primary lung tumors may disseminate in the arterial circulation and thus directly reach the brain parenchyma, whereas metastatic cells from other primary sites might be arrested in the capillary bed of the lung parenchyma before reaching the brain (Lassman and DeAngelis, 2003). However, the mechanical hypothesis fails to fully explain why small cell lung cancer (SCLC) has much higher propensity for brain metastasis than squamous cell carcinoma (Gavrilovic and Posner, 2005). Furthermore, vascular anatomy, blood flow, volume, and number of tumor cells in circulation in clinical and observational series have not been sufficient to explain the variable pattern of brain metastasis from different primary cancers (Fidler, 2003).

Over a century ago, Paget introduced the hypothesis that a metastasis was the result of an interaction between the metastatic tumor cells ("seed") and the host organ microenvironment ("soil") (Paget, 1989). The current conception of this "seed and soil hypothesis" has three defined core principles (Fidler, 2003). First, primary tumors in general and metastatic lesions in particular, are biologically heterogeneous and contain subpopulations of cells with different angiogenic, invasive, and metastatic properties. Second, the process of metastasis is highly selective for cells that can complete all of the steps in the process. Metastases can have a clonal origin, and different metastases can originate from the proliferation of different single cells. Third, the outcome of a metastasis depends on multiple interactions between the metastatic cells and the host's homeostatic mechanisms that include the organ microenvironment which tumor cells exploit for their own gain (Eichler et al., 2011). A newer hypothesis is that primary tumor cells can take with them their own soil to secondary organs (Eichler et al., 2011). However, a detailed review of all molecular steps lies beyond the scope of this chapter.

# Histology of Primary Cancer 

Histology of primary tumor is an important predictor of the incidence and pattern of intracranial metastasis (Suki, 2004). Intracranial metastases can originate from virtually any primary cancer, but different primary tumors may have a variable propensity to metastasizeto the brain. In absolute numbers, the most common primary tumor origins are lung, breast, melanoma, kidney, and colorectal cancer, in that respective order (Suki, 2004). However, when taking the relative incidence of primary tumor into account, melanomas have the greatest propensity to disseminate to the brain (Johnson and Young, 1996; Suki, 2004).

Malignant melanomas represent only $4 \%$ of all cancers, but have the highest propensity for brain metastasis of all primary cancers. Melanoma patients are in clinical series diagnosed with intracranial metastases in $6-43 \%$ and in autopsy series in up to $90 \%$ (Hofmann et al., 2007; Skibber et al., 1996).

Colorectal cancer only metastasize to brain parenchyma in 1-3\% (Go et al., 2011), but as the incidence of colorectal is high, colorectal brain metastases are seen quite often in clinical series. Upper GI cancers, especially gastric cancer, very rarely metastasize to the brain (Rogne et al., 2012).

# Cerebellar Metastases 

The scientific literature review provides only few studies addressing the outcome of cerebellar metastases separate from the more common supratentorial lesions (Ampil et al., 1996; Fadul et al., 1987; Ghods et al., 2011; Javalkar et al., 2010; Kanner et al., 2003; Pompili et al., 2008; Yoshida and Takahashi, 2009). However, different primary cancers are seen to even have different propensity to spread to specific regions within the brain. For instance, leptomeningeal metastases often originate from lung cancers and melanomas, whereas colorectal cancers commonly metastasize to the cerebellum (Delattre et al., 1988).

A metastasis located in the cerebellum has been perceived as an isolated negative prognostic marker for survival (Wronski and Arbit, 1999, 2000). In general, infratentorial tumors are considered more life-threatening than supratentorial ones, as tumors in the confined space of the posterior fossa can result in hydrocephalus, brainstem compression, and tonsillar herniation (Fadul et al., 1987). Gradual onset headache, nausea, and gait instability are the most common presenting symptoms, but some patients might deteriorate rapidly, requiring immediate neurosurgery to prevent a neurological cause of death (Fadul et al., 1987; Ghods et al., 2011).

## THE OSLO UNIVERSITY HOSPITAL EXPERIENCE

Two recent studies by Rogne et al. $(2012,2014)$ addressed the incidence of brain metastases from malignant melanomas and colorectal cancers. The patients included in this study were identified from a consecutive, prospectively collected tumor database, which encompasses all patients with histologically verified intracranial metastases treated surgically at Oslo University Hospital (OUH) in the time period of 2003-2011. The strengths of these studies lie in the setting, design and follow-up. The data were restricted to one health center, thereby reducing the possible confounding effect of differences in the access to health care services between health centers and avoiding the selection bias inherently present in large multicenter studies. Furthermore, the data were prospectively registered and included all craniotomies performed for a histologically verifiable brain tumor, leaving no selection bias. The study is contemporary, thereby reflecting current neurosurgical practice and wasperformed within a relatively short time span, thereby reducing confounding factors as changes in antibiotic prophylaxis regimen or operating theaters. With respect to data, only easily verifiable end points (i.e., mortality) were used. Lastly, follow-up was $100 \%$. The studies were approved by the Data Protection Official at OUH.

# Clinical Setting 

The defined neurosurgical catchment area for OUH is the south and eastern health region of Norway and includes 2.7 million inhabitants ( $56 \%$ of the Norwegian population). From January 2003 until January 2011, primary surgery for parenchymal supratentorial and cerebellar metastases was conducted 627 times. Among these, surgery for cerebellar metastases was undertaken in 140 patients ( $22 \%$ of total), constituting the primary study population. Vital status (deceased/alive) and time of death were retrieved from the Norwegian population registry (Folkeregisteret) at October 15, 2012, hence all patients were observed for at least 9.5 months. Median overall survival was calculated from the time of surgery until the time of death.

## Statistics

To visualize the relative propensity of different primary cancer types to metastasize to the brain, we retrieved the average annual incidence of each primary cancer type for the south-eastern population of Norway between 2003 and 2011 from the Norwegian Cancer Registry. For each primary cancer type, the number of patients undergoing surgery for a cerebellar metastasis was divided by the incidence of that specific primary cancer type in our catchment area population within the study period. For comparison, this calculation was also made for all the supratentorial metastases operated within the same time period.

In order to evaluate whether metastases from different primary cancer types were significantly over- or underrepresented in the cerebellum, we calculated if the proportion of cerebellar metastases were significantly different from the overall proportion of cerebellar metastases undergoing surgery at our department ( $140 / 627=0.223$ ). For each primary cancer, we proposed a null hypothesis $\left(\mathrm{H}_{0}\right)$ that the proportion of cerebellar metastases is not significantly different from $0.223\left(\mathrm{H}_{0} ; P=0.223\right)$, as apposed to the alternative hypothesis $\left(\mathrm{H}_{1}\right)$ that the proportion of cerebellar metastases is significantly different from $0.223\left(\mathrm{H}_{1} ; P \neq 0.223\right)$.

## Origin of Primary Tumor

The origin and histology of a primary tumor are important predictors of the incidence and pattern of intracranial metastasis (Suki, 2004). By retrieving the incidence of primary tumors from the Norwegian Cancer Registry, we were able to show that the risk of undergoing craniotomy for a brain metastasis was highest ( $>1 \%$ ) for melanomas and lung cancers, in contrary to a particularly low risk ( $<0.1 \%$ ) in prostate and upper GI cancers (Attia et al., 2013; Rogne et al., 2012, 2014). However, it is important to note that brain metastases from certain primary tumor sites, such as testicular cancer and hematologic malignancies, are systematically excluded from surgical series as they primarily are enrolled for other treatment modalities.# Incidence of Cerebellar versus Supratentorial Brain Metastases 

In our surgical cohort, $22 \%$ of the intracranial metastases were located in the cerebellum (Rogne et al., 2014). Similar findings can be found in previous surgical series (Chaichana et al., 2014). This percentage is higher than the expected $15 \%$ based on the regional blood flow to and tissue volume of the cerebellum (Gavrilovic and Posner, 2005), which can be explained by a more aggressive surgical approach toward cerebellar lesions to prevent potential life-threatening complications (i.e., hydrocephalus and brainstem compression) (Fadul et al., 1987).

## Incidence of Cerebellar Malignant Melanomas Metastases

Malignant melanomas have the highest propensity for undergoing craniotomy for a brain metastasis (Rogne et al., 2012). Nevertheless, we observed that cerebellar melanoma metastases were exceedingly rare. A larger cohort was therefore constructed to evaluate whether these observations were random, or a pattern of metastasis for melanomas (Rogne et al., 2012).

We have confirmed that melanoma metastases were significantly underrepresented in the cerebellum (5\%) compared to the overall proportion of cerebellar metastases surgically resected ( $22 \%$ ) at our department ( $P<0.05$ ) (Fig. 3.1) (Rogne et al., 2014). Our findings are statistically well-founded, as we included 140 cases and the sample size needed was 23 for a power of 0.8 and $\alpha$ of 0.05 . To further substantiate our findings, we conducted a post hoc one-sample test of proportion to confirm that the proportion of cerebellar melanoma metastases also was significantly underrepresented compared to $15 \%$, the overall expected percentage in accordance to regional blood flow (Gavrilovic and Posner, 2005).

Currently, the mechanism driving this possible predilection is unknown, and addressing possible biological interactions based on contemporary molecular biology lies beyond the scope of this surgical thesis. The interpretation of our findings may be challenged by the inherent selection bias of patients to surgical intervention. Patients with multiple tumors, poor performance status and advanced systemic disease with a limited life expectancy are most likely not considered surgical candidates and referred to other treatment modalities. On the other hand, one can advocate that cerebellar melanoma metastases are likely to be considered for surgery, as they are inherent radioresistant tumors, and other treatment options are scarce. We consider our findings robust, as the percentage of cerebellar melanoma metastases is low (5\%), the total sample size is large $(\mathrm{n}=140)$ and similar observations can be found in prior literature to support our claim. It is, however, only an estimate of the relative biologic propensity of melanomas to metastasize to the supratentorial versus infratentorial compartment in surgical candidates. To reduce the selection bias, our findings need to be verified in other studies.

## Incidence of Cerebellar Colorectal Cancer Metastases

Colorectal cancers had an intermediate risk ( $0.1-1 \%$ ) of undergoing craniotomy for a brain metastasis in our series (Rogne et al., 2012). In contrast to melanomas, we confirmedthat colorectal cancer metastases were significantly overrepresented (38\%) in cerebellum compared to the overall proportion of cerebellar metastases surgically resected ( $22 \%$ ) at our department ( $P<0.05$ ) (Fig. 3.1) (Rogne et al., 2014). Colorectal cancer metastases' predilection for the cerebellum is well-known, and in previous series observed in $32-52 \%$ of the cases (Alden et al., 1996; Delattre et al., 1988; Mongan et al., 2009; Wronski and Arbit, 1999). The etiology for this pattern of metastasis is unknown, but it has been proposed that colorectal cancer metastases may spread to the posterior fossa by retrograde metastasis via the spinal epidural venous plexus (Batsons' plexus). However, an increased incidence of spinal metastases is not observed in these patients, as would be expected.
![img-64.jpeg](img-64.jpeg)
$\alpha=0.05$
FIGURE 3.1 Primary tumor site for cerebellar metastases enrolled for surgery at OUH between 2003 and 2011. For each primary cancer group, the figure illustrates if the metastases were significantly over- or underrepresented in cerebellum compared to 0.223 , red dots indicate significant values at $5 \%$ level. UDL, upper limit; LDL, lower limit.# DISCUSSION 

Primary cancers are thought to metastasize to the brain parenchyma by hematogenous dissemination. Distribution of brain metastases as a result of blood supply and mechanical tumor cell arrest, was first proposed by Ewing in 1928 (Gavrilovic and Posner, 2005). An observation supportive of this hypothesis is that metastatic cells are seen to preferably embed in watershed areas and gray-white matter interfaces, areas where arterioles narrow, resulting in possible mechanical entrapment of metastatic cells. Moreover, parenchymal brain metastases are reported to be located in the cerebellum in about $15 \%$, cerebral hemispheres in $80 \%$, and brain stem in $3-5 \%$, a distribution comparable to the regional blood flow.

However, the distribution of brain metastases cannot be explained by regional blood supply and volume alone (Gavrilovic and Posner, 2005; Lassman and DeAngelis, 2003). Virtually any systemic cancer has the ability to metastasize to brain parenchyma, but the propensity for developing brain metastases varies greatly among different primary cancer types (Suki, 2004). In absolute numbers, the most common primary tumors giving rise to brain metastases are lung, breast, malignant melanoma, colorectal, and kidney cancer (Suki, 2004). Lung cancers may commonly produce brain metastases as they can directly disseminate into the arterial circulation and thereby reach brain parenchyma, whereas metastases from other primaries might be arrested in the capillary pulmonary bed before reaching the systemic arterial circulation. However, this cannot explain why SCLC has a higher propensity for brain metastases than non-SCLC, nor why adenocarcinomas have a higher propensity than squamous cell carcinomas (Gavrilovic and Posner, 2005). Furthermore, anatomical localization of primary tumor site cannot entirely explain why melanomas have the highest propensity to metastasize to the brain, whereas brain metastases from prostate cancer are a rarity (Amer et al., 1978; Eichler and Loeffler, 2007; Gavrilovic and Posner, 2005; Lynes et al., 1986). The variable relative frequency of brain metastases from different primaries can in part be explained by the "seed and soil" hypothesis first proposed by Paget in 1887 (Paget, 1989). The concept of this hypothesis is that metastasis of cancers depends on cross-talk between tumor cells ("seed") and specific host microenvironment ("soil") (Fidler, 2003). In conclusion, both the mechanical and the "seed and soil" hypothesis may be of importance for the distribution of brain metastases (Gavrilovic and Posner, 2005).

In our neurosurgical practice, brain metastases were located in the cerebellum in $22 \%$ of cases. This is higher than the expected $15 \%$ of cases and might reflect a more aggressive neurosurgical approach toward these lesions, as tumor location in posterior fossa is thought to represent a higher risk of developing hydrocephalus, brain stem compression, and herniation than a supratentorial counterpart (Fadul et al., 1987). Furthermore, metastases from certain primary cancer types were significantly over- or underrepresented in cerebellum compared to the supratentorial compartment (Fig. 3.2).

## Malignant Melanomas

Up to $75 \%$ of melanoma patients with metastatic disease develop brain metastases (Hofmann et al., 2007; Skibber et al., 1996). However, in our cohort, cerebellar melanoma metastases were rare with only seven resected lesions, accounting for only $5 \%$ of all the![img-65.jpeg](img-65.jpeg)

FIGURE 3.2 Primary tumor site for cerebellar and supratentorial metastases enrolled for surgery at OUH between 2003 and 2011.
melanoma brain metastases enrolled for surgery in our department. This incidence is statistically significantly lower than the expected $22 \%$ rate (Fig. 3.1). A one-sample test of proportions analysis conducted post hoc confirmed that the incidence of cerebellar melanoma metastases in our cohort was also significantly lower than $15 \%$, which is the expected overall percentage of cerebellar metastases according to regional blood flow.

An apparent aversion of melanomas to metastasize to cerebellum can be observed in former published series, but has not been explicitly pointed out previously. In series exclusively reporting on cerebellar metastasis, melanomas have accounted for $2.3-10 \%$ (Fadul et al., 1987; Ghods et al., 2011; Javalkar et al., 2010; Pompili et al., 2008). In series reporting exclusively on melanoma metastases but addressing different treatment modalities,cerebellar lesions were found in 5.3-9.6\% of the patients (Hofmann et al., 2007; Salvati et al., 2012; Sampson et al., 1998; Staudt et al., 2010; Wronski and Arbit, 2000; Zacest et al., 2002). In two series, melanomas were located both supra- and infratentorially in an additional $15-30 \%$ of patients (Hofmann et al., 2007; Staudt et al., 2010).

Our surgical series consists of a selected group of patients with brain metastases found eligible for surgical treatment. Patients with multiple intracranial metastases with advanced systemic disease and a poor performance status are usually not offered surgery. As many patients with malignant melanoma present with multiple metastases, a surgical series may be subject to a negative selection bias. However, in the case of cerebellar melanomas, the selection bias may as well be in favor of surgery. There are two main reasons for this. First, melanomas are radioresistant and surgery has often been the treatment of choice for these patients. Only in recent years has stereotactic radiosurgery been documented effective for small radioresistant metastases (Selek et al., 2004). Second, due to the poor tolerance of space-occupying lesions in the posterior fossa, a more aggressive neurosurgical practice is often adopted in order to preserve neurological function and prevent a neurological cause of death. Consequently, patients with cerebellar melanomas may well be preferentially referred to surgery, rather than be excluded from it. Since this study includes a large cohort of patients with cerebellar lesions and has a high number of melanoma brain metastases overall, we think our observations are well founded. However, future series verifying these findings in a more general patient selection undergoing different treatment modalities is required.

# Coloectal Cancers 

In clinical series, brain metastases are seen in $3-5 \%$ of patients with colorectal cancer, whereas in autopsy studies, brain metastases are found in an extra $2-3 \%$ of patients who die of colorectal cancer (Go et al., 2011). Colorectal cancer was the second most common primary malignancy among the cerebellar metastases in our series (19\%), only outnumbered by lung cancer (45\%) (Fig. 3.2) (Rogne et al., 2014). These cerebellar metastases accounted for $38 \%$ of all the brain metastases from colorectal cancer undergoing surgery in our department.

The predilection of colorectal cancers to metastasize to cerebellum is well-known. In previous studies, the relative rate of cerebellar metastases has been reported in the range of $32-52 \%$ (Alden et al., 1996; Delattre et al., 1988; Mongan et al., 2009; Wronski and Arbit, 1999). In our studies, metastases from lower GI tract cancers were significantly overrepresented in the cerebellum (Fig. 3.1). Why colorectal cancers commonly metastasize to cerebellum is unclear, but it has been proposed that metastatic cells might reach the brain via retrograde metastasis through the vertebral venous system (Batson's plexus) (Delattre et al., 1988). However, the rarity of spinal cord metastases among these patients with cerebellar metastases argues against this hypothesis (Balasingam and McCutcheon, 2004; Delattre et al., 1988).

## CONCLUSIONS

Cerebellar metastases accounted for $22 \%$ of all parenchymal brain metastases undergoing surgery in our department during the defined time period. Malignant melanoma metastases were statistically significantly underrepresented in cerebellum, accounting for only $5 \%$ ofall the intracranial melanoma metastases resected in our department (Fig. 3.1). Conversely, colorectal cancer metastases were significantly overrepresented in cerebellum (Fig. 3.1).

Our observation may have potential consequences not only for clinicians, but also for more basic research into the "seed and soil" mechanisms of metastases. If malignant melanomas indeed are less frequently located in the cerebellum, there should be a biological mechanism for this pattern of metastasis.

The mechanism driving this possible predilection is unknown, and addressing possible biological interactions based on contemporary molecular biology could be fruitful. Currently, a translational study involving an animal model using nude mice has verified our clinical observations of an apparent aversion of malignant melanomas to metastasize to the cerebellum.

# References 

Alden, T.D., Gianino, J.W., and Saclarides, T.J., 1996. Brain metastases from colorectal cancer. Dis. Colon Rectum 39, $541-545$.
Amer, M.H., Al-Sarraf, M., Baker, L.H., and Vaitkevicius, V.K., 1978. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 42, 660-668.
Ampil, F.L., Nanda, A., Willis, B.K., Nandy, I., and Meehan, R., 1996. Metastatic disease in the cerebellum. The lsu experience in 1981-1993. Am. J. Clin. Oncol. 19, 509-511.
Attia, M., Rachez, C., Avner, P., and Rogner, U.C., 2013. Nucleosome assembly proteins and their interacting proteins in neuronal differentiation. Arch. Biochem. Biophys. 534, 20-26.
Balasingam, V., and McCutcheon, I.E., 2004. Metastatic colorectal carcinoma. In: Sawaya, R. (Ed.), Intracranial Metastases: Current Management Strategies Blackwell Futura, Malden, MA, pp. 279-291.
Chaichana, K.L., Rao, K., Gadkaree, S., Dangelmajer, S., Bettegowda, C., Rigamonti, D., et al., 2014. Factors associated with survival and recurrence for patients undergoing surgery of cerebellar metastases. Neurol. Res. 36, $13-25$.
Chason, J.L., Walker, F.B., and Landers, J.W., 1963. Metastatic carcinoma in the central nervous system and dorsal root ganglia. A prospective autopsy study. Cancer 16, 781-787.
Delattre, J.Y., Krol, G., Thaler, H.T., and Posner, J.B., 1988. Distribution of brain metastases. Arch. Neurol. 45, $741-744$.
Eichler, A.F., and Loeffler, J.S., 2007. Multidisciplinary management of brain metastases. Oncologist 12, 884-898.
Eichler, A.F., Chung, E., Kodack, D.P., Loeffler, J.S., Fukumura, D., and Jain, R.K., 2011. The biology of brain metas-tases-translation to new therapies. Nat. Rev. Clin. Oncol. 8, 344-356.
Fadul, C., Misulis, K.E., and Wiley, R.G., 1987. Cerebellar metastases: diagnostic and management considerations. J. Clin. Oncol. 5, 1107-1115.
Fidler, I.J., 2003. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 3, $453-458$.
Gavrilovic, I.T., and Posner, J.B., 2005. Brain metastases: epidemiology and pathophysiology. J. Neurooncol. 75, $5-14$.
Ghods, A.J., Munoz, and L., Byrne, R., 2011. Surgical treatment of cerebellar metastases. Surg. Neurol. Int. 2, 159.
Go, P.H., Klaassen, Z., Meadows, M.C., and Chamberlain, R.S., 2011. Gastrointestinal cancer and brain metastasis: a rare and ominous sign. Cancer 117, 3630-3640.
Hofmann, M.A., Coll, S.H., Kuchler, I., Kiecker, F., Wurm, R., Sterry, W., et al., 2007. Prognostic factors and impact of treatment in melanoma brain metastases: better prognosis for women? Dermatology 215, 10-16.
Javalkar, V., Cardenas, R., Ampil, F., Ahmed, O., Shi, R., and Nanda, A., 2010. The Louisiana state university experience in the management of single small cerebellar metastasis. Neurosurgery 67, 1515-1522.
Johnson, J.D., and Young, B., 1996. Demographics of brain metastasis. Neurosurg. Clin. N. Am. 7, 337-344.
Kanner, A.A., Suh, J.H., Siomin, V.E., Lee, S.Y., Barnett, G.H., and Vogelbaum, M.A., 2003. Posterior fossa metastases: aggressive treatment improves survival. Stereotact. Funct. Neurosurg. 81, 18-23.
Lassman, A.B., and DeAngelis, L.M., 2003. Brain metastases. Neurol. Clin. 21, 1-23. vii.Lynes, W.L., Bostwick, D.G., Freiha, F.S., and Stamey, T.A., 1986. Parenchymal brain metastases from adenocarcinoma of prostate. Urology 28, 280-287.
Mongan, J.P., Fadul, C.E., Cole, B.F., Zaki, B.I., Suriawinata, A.A., Ripple, G.H., et al., 2009. Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. Clin. Colorectal Cancer 8, 100-105.
Nayak, L., Lee, E.Q., and Wen, P.Y., 2012. Epidemiology of brain metastases. Curr. Oncol. Rep. 14, 48-54.
Paget, S., 1989. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8, $98-101$.
Pompili, A., Carapella, C.M., Cattani, F., Fabi, A., Giannarelli, D., Giovannetti, M., et al., 2008. Metastases to the cerebellum. Results and prognostic factors in a consecutive series of 44 operated patients. J. Neurooncol. 88, $331-337$.
Posner, J.B., 1978. Neurologic complications of systemic cancer. Dis. Mon. 25, 1-60.
Rogne, S.G., Ronning, P., Helseth, E., Johannesen, T.B., Langberg, C.W., Lote, K., et al., 2012. Craniotomy for brain metastases: a consecutive series of 316 patients. Acta Neurol. Scand. 126, 23-31.
Rogne, S.G., Helseth, E., Brandal, P., Scheie, D., and Meling, T.R., 2014. Are melanomas averse to cerebellum? Cerebellar metastases in a surgical series. Acta Neurol. Scand. 130, 1-10.
Salvati, M., Frati, A., D'Elia, A., Pescatori, L., Piccirilli, M., Pietrantonio, A., et al., 2012. Single brain metastases from melanoma: remarks on a series of 84 patients. Neurosurg. Rev. 35, 211-217. discussion 217-218.
Sampson, J.H., Carter Jr., J.H., Friedman, A.H., and Seigler, H.F., 1998. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J. Neurosurg. 88, 11-20.
Schouten, L.J., Rutten, J., Huveneers, H.A., and Twijnstra, A., 2002. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94, 2698-2705.
Selek, U., Chang, E.L., Hassenbusch III, S.J., Shiu, A.S., Lang, F.F., Allen, P., et al., 2004. Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int. J. Radiat. Oncol. Biol. Phys. 59, 1097-1106.
Skibber, J.M., Soong, S.J., Austin, L., Balch, C.M., and Sawaya, R.E., 1996. Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann. Surg. Oncol. 3, 118-123.
Smedby, K.E., Brandt, L., Backlund, M.L., and Blomqvist, P., 2009. Brain metastases admissions in Sweden between 1987 and 2006. Br. J. Cancer 101, 1919-1924.
Staudt, M., Lasithiotakis, K., Leiter, U., Meier, F., Eigentler, T., Bamberg, M., et al., 2010. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br. J. Cancer 102, 1213-1218.
Suki, D., 2004. The epidemiology of brain metastasis. In: Sawaya, R. (Ed.), Intracranial Metastases: Current Management Strategies Blackwell Futura, Malden, MA, pp. 20-34.
Wronski, M., and Arbit, E., 1999. Resection of brain metastases from colorectal carcinoma in 73 patients. Cancer 85, $1677-1685$.
Wronski, M., and Arbit, E., 2000. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J. Neurosurg. 93, 9-18.
Yoshida, S., and Takahashi, H., 2009. Cerebellar metastases in patients with cancer. Surg. Neurol. 71, 184-187. discussion 187 .
Zacest, A.C., Besser, M., Stevens, G., Thompson, J.F., McCarthy, W.H., and Culjak, G., 2002. Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades. J. Neurosurg. 96, 552-558.# Risk Reductions of Recurrence and Mortality in Melanoma Patients Using IFN- $\alpha$ 

Ahmad A. Tarhini

## O U T L I N E

Introduction
Interferon- $\alpha$ : Biology and Clinical Applications in Cancer
Studies of IFN- $\alpha$ in Stage IV Inoperable Melanoma
Adjuvant IFN- $\alpha$ Trials in Melanoma
High Dose IFN- $\alpha$ Trials
Other IFN- $\alpha$ Studies That Evaluated Varying Dose Levels, Routes, and Duration
Meta-analyses of IFN- $\alpha$ Trials

49
Adjuvant Trials Testing IFN- $\alpha$ in Combination 50 Neoadjuvant IFN- $\alpha$ and Other Agents in Melanoma 57 Biomarkers of Clinical Benefit with IFN- $\alpha \quad 58$
Conclusions 60
Acknowledgments 60
References 61

## INTRODUCTION

Melanoma is the fastest growing malignancy in the United States in terms of incidence. In the year 2015, it is estimated that 73,870 men and women will be diagnosed with cutaneous melanoma in the United States and that 9940 will die as a result of this disease (Siegel et al., 2015; Balch et al., 2009).The American Joint Committee on Cancer (AJCC) staging system divides melanoma patients into four stages that correspond to patient prognosis (Balch et al., 2009). Stages I and II constitute melanoma that is limited to the skin and where the risk is defined by the depth of the tumor, the presence or absence of surface ulceration, and the mitotic rate. High mitotic rate (at least 1 mitosis $/ \mathrm{mm}^{2}$ ) correlates with declining survival and has replaced the Clark level of invasion as a complementary criterion to ulceration for differentiating T1a versus T1b primary tumor in the most recent AJCC update (Balch et al., 2009). Every millimeter increase in tumor depth (Breslow's tumor thickness) corresponds to a significant decline in survival; the 10-year survival rate drops from $92 \%$ for T1 tumors (thickness $\leq 1 \mathrm{~mm}$ ) to $50 \%$ with T4 melanoma (thickness $>4 \mathrm{~mm}$ ). Ulceration of the primary tumor leads to proportionately lower survival than nonulcerated melanoma of equivalent T category but is similar to patients with a nonulcerated melanoma of the subsequent T category. For instance, survival rates with T3b and T4a are approximately similar ( $68 \%$ and $71 \%$, respectively), whereas it falls to $53 \%$ in the T4b population (Balch et al., 2009).

AJCC Stage III constitutes melanoma spread to regional lymph nodes and/or the presence of intralymphatic (satellite or in-transit) metastasis. Nodal subclassifications N1a (micrometastasis) and N1b (macrometastasis) are also different by prognosis and prognosis also worsens with the increase in the number of lymph nodes involved (Balch et al., 2009). In-transit lymphatic metastases without and with metastatic lymph nodes are classified as N2c and N3, respectively (Balch et al., 2009). Stage IV consists of distant metastatic spread of melanoma. The number and location of metastasis and lactate dehydrogenase blood levels impact patient prognosis (Balch et al., 2009).

Studies of interferon- $\alpha$ (IFN- $\alpha$ ) adjuvant therapy in melanoma have primarily targeted patients with AJCC stages IIB, IIC, and III, while one study (E2696) also enrolled subjects with surgically resected stage IV. These patients carry an estimated risk of recurrence that exceeds $30 \%$ (ranging from $30 \%$ chance of recurrence for IIB to $89 \%$ chance of recurrence for IIIC) (Balch et al., 2009; Romano et al., 2010). Approximately, this population of patients is 3 times the size of the population with metastatic disease (Balch et al., 2009).

# INTERFERON- $\alpha$ : BIOLOGY AND CLINICAL APPLICATIONS IN CANCER 

IFN- $\alpha$ belongs to the type I IFN family, also including $-\beta,-\delta,-\varepsilon,-\kappa,-\tau$, and $-\omega$ subtypes (Siegal et al., 1999). It was long ago discovered that type I IFN is secreted in response to viral, bacterial, or tumor cell stimuli by leukocytes, and later it was demonstrated that a specific population of $\mathrm{CD} 4^{+} \mathrm{CD} 11 \mathrm{c}^{-}$(plasmacytoid Dendritic cell precursors ( pDCs )) is the predominant producer (Tarhini et al., 2012).

IFN- $\alpha$ has undergone extensive clinical evaluation over the past four decades. Clinically used recombinant formulations of IFN- $\alpha$ exist in three isoforms ( $\alpha 2 \mathrm{a}, \alpha 2 \mathrm{~b}, \alpha 2 \mathrm{c}$ ) and it has regulatory approval for the adjuvant treatment of high-risk melanoma (IFN- $\alpha 2 \mathrm{~b}$, also in its pegylated form), as systemic treatment for metastatic renal cell carcinoma ( $\alpha 2 \mathrm{a}, \alpha 2 \mathrm{~b}$ in combination with bevacizumab), AIDS-related Kaposi's sarcoma ( $\alpha 2 \mathrm{~b}$ ), follicular lymphoma ( $\alpha 2 \mathrm{~b}$ ), hairy cell leukemia ( $\alpha 2 \mathrm{a}, \alpha 2 \mathrm{~b}$ ), chronic myelogenous leukemia ( PH chromosome+, $\alpha 2 \mathrm{a}$ ), condyloma acuminata ( $\alpha 2 \mathrm{~b}$ ), cervical intraepithelial neoplasms ( $\alpha 2 \mathrm{~b}$ ) (Thompson and Allison, 1997).The interferon molecule anticancer activity is thought to be mediated through an immunomodulatory effect primarily, and less so in terms of a directly cytotoxic or antiangiogenic effect (Tarhini et al., 2012). IFN- $\alpha$ has significant immunomodulatory effects where it polarizes the immune response toward Th1, enhances cytotoxicity and survival of NK cells, induces the generation and survival of both cytotoxic T lymphocytes and memory CD8 ${ }^{+}$ T cells, positively regulates antibody production, promotes dendritic cell maturation, chemotaxis and $\mathrm{CD8}^{+}$priming against tumor antigens (Tarhini et al., 2012). Additionally, IFN- $\alpha$ exhibits direct antitumor activity by upregulation of MHC I surface molecules, promotes caspase-dependent apoptosis in certain types of cancer, and has antiangiogenic effects on tumor vasculature (Tarhini et al., 2012).

A study of IFN- $\alpha$ in the melanoma neoadjuvant setting has shown a significant impact of IFN- $\alpha$ on Signal Transducer and Activator of Transcription (STAT) signaling (Moschos et al., 2006). An influx of dendritic cells (DCs) and T lymphocytes into the tumor tissue was shown to result from neoadjuvant IFN- $\alpha$ (Moschos et al., 2006). IFN- $\alpha$ was found to downregulate STAT3 expression in tumor cells and to stimulate the induction of STAT1 that correlated with a reversal in T cell signaling defects (Moschos et al., 2006).

# STUDIES OF IFN- $\alpha$ IN STAGE IV INOPERABLE MELANOMA 

Phase I and II studies that tested IFN- $\alpha$ as systemic therapy for advanced inoperable Stage IV melanoma reported response rates of about $16 \%$. Responses were seen as late as 6 months from the initiation of IFN- $\alpha$ therapy. One-third of the responses were reported as durable, and included complete responses (Creagan et al., 1986a,b). IFN- $\alpha$ was also tested as part of the biochemotherapy (BCT) regimen (consisting of IFN- $\alpha$, interleukin-2, dacarbazine, cisplatin, vinblastine) and has been used, as an off-label systemic therapy, for stage IV inoperable melanoma, both as monotherapy and as part of BCT (Atkins et al., 2008; O'Day et al., 2002; Eton et al., 2002; Tarhini et al., 2012).

## ADJUVANT IFN- $\alpha$ TRIALS IN MELANOMA

Trials testing IFN- $\alpha$ as systemic adjuvant therapy for high risk surgically resected melanoma have evaluated several different regimens. These regimens have varied by the duration of therapy, the route of administration, the dose level and the formulation. The impetus to study IFN- $\alpha$ in the adjuvant setting was the evidence of clinical activity in the more advanced metastatic setting. The series of adjuvant IFN- $\alpha$ trials completed and reported over the years have been pooled in a number of meta-analyses, the largest of which has most recently supported its adjuvant therapeutic efficacy in terms of both disease-free survival and, to a lower extent, overall survival (OS) (Mocellin et al., 2013).

## High Dose IFN- $\alpha$ Trials

The earliest trials that tested adjuvant high dose IFN- $\alpha$ (HDI) (>10 Million Units (MU)/ dose) for high-risk surgically resected melanoma, were the North Central Cancer TreatmentGroup (NCCTG) trial (Creagan et al., 1995), and the Eastern Cooperative Group (ECOG) trial E1684 (Kirkwood et al., 1996).

The ECOG E1684 trial evaluated a regimen consisting of IFN- $\alpha$ given intravenously (IV) as an induction phase at $20 \mathrm{MU} / \mathrm{m}^{2}$ for five consecutive days a week for 4 weeks followed by as maintenance phase where IFN- $\alpha$ is administered subcutaneously (SC) at $10 \mathrm{MU} / \mathrm{m}^{2}$ 3 times a week for 48 weeks. This study was initiated in 1984 and enrolled 287 patients. At a median follow-up of 6.9 years, the study reported a statistically significant difference in relapse-free survival (RFS) and OS in favor of HDI as compared to the observation arm. The 5 -year RFS in the treatment arm was $37 \%$ ( $95 \%$ confidence interval (CI), $30-46 \%$ ) compared to $26 \%$ ( $95 \%$ CI, $19-34 \%$ ) in the observation group. The 5 -year OS was $46 \%$ ( $95 \%$ CI, 39-55\%) and $37 \%$ ( $95 \%$ CI, $30-46 \%$ ) in the treatment and control arms, respectively. Patients with clinically node-negative but pathologically lymph node positive disease (N1) were found to derive the greatest survival benefit. The results of E1684 led to the regulatory approval of HDI in the United States by the Food and Drug Administration in 1995 (Moschos et al., 2006). In terms of safety and tolerability, there was a $67 \%$ incidence for grade 3 toxicity, $9 \%$ incidence for grade 4 toxicity, and 2 early therapy-related hepatotoxic deaths. These factors raised concerns over patients' tolerance and adherence to the regimen and supported the study of other regimens that varied by dose level, duration of therapy, route of administration or formulation.

The ECOG and US Intergroup E1690 trial tested the E1684 HDI regimen and a low-dose regimen of IFN- $\alpha 2$ b (LDI; 3 MU SC 3 times weekly for 2 years) compared to observation. E1690 enrolled subjects between 1991 and 1995, and at 4.3 years median follow-up, the 5 -year RFS rates were $44 \%$ for HDI, $40 \%$ for LDI, and $35 \%$ for the observation arm, respectively (Kirkwood et al., 2000). RFS benefit from HDI was statistical significantly superior to observation (hazards ratio for HDI vs observation was $1.28, P=0.05$; for LDI vs observation $1.19, P=0.17$ ). However, no OS benefit was observed with either HDI or LDI compared to observation (Estimated OS at 5 years: $52 \%$ HDI, $53 \%$ LDI and $55 \%$ observation). Interestingly, there was improved OS of the E1690 observation arm when compared to E1684 observation arm (median 6 years vs 2.8 years). Unlike E1684, subjects in E1690 did not require elective lymph node dissection (LND) and a retrospective analysis found evidence of cross over from the observation arm at regional nodal recurrence to IFN- $\alpha$ salvage therapy that may have affected the survival analysis on this trial.

The US Intergroup E1694 trial compared HDI with the GMK ganglioside vaccine. The GMK vaccine was made of ganglioside GM2 coupled to keyhole limpet hemocyanin and combined with the adjuvant QS-21. This vaccine was considered to be the most optimal vaccine candidate at the time based on earlier studies that supported its immunogenicity and clinical activity. HDI was found to be significantly superior to GMK in terms of RFS (HR $=1.47, P=0.001$ ) and OS (HR $=1.52, P=0.009$ ) (Kirkwood et al., 2001b).

The ECOG later conducted a randomized phase-II trial, E2696, that targeted patients with surgically resected stage IIB, III and IV disease, enrolling 107 patients between 1998 and 2000 (Kirkwood et al., 2001a). This study intended to test the anti-GM2 antibody response induced by the GMK vaccine given with or without IFN- $\alpha$. E2696 included three study arms: arm A (GMK with concurrent HDI), arm B (GMK with sequential HDI), and arm C (GMK alone). The combination regimens reduced the risk of recurrence versus GMK alone (HR 1.75 for arm C vs arm A and 1.96 for C vs B).A pooled analysis of E1684 and E1690 (the observation-controlled trials) was updated through April 2001 and reported continued significant relapse benefits with HDI at a median follow-up of 12.6 years in E1684 and 6.6 years in E1690 (Kirkwood et al., 2004). This analysis failed to show significant evidence of OS benefit, consistent with known outcome of the larger of the two observation-controlled trials (E1690). E1694, where the GMK vaccine served as control, was not included. In addition, the long-term follow-up in E1684 at this time suggests the potential of competing causes of death as confounders of the OS analysis in this study (Kirkwood et al., 1996, 2000, 2001b, 2004). Table 4.1 summarizes adjuvant IFN- $\alpha$ trials that led to regulatory approval in the United States.

TABLE 4.1 Summary of IFN- $\alpha$ Trials Leading to Regulatory Approval in the United States

| Study | Stage | N | Treatment regimen | Median follow-up (year) | Impact on |  | Toxicity attrition rate (\%) | Comment |
| :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: |
|  |  |  |  |  | PFS | OS |  |  |
| E1684 | T4, N+ | 287 | HDI versus Observation | 6.9 | $\begin{aligned} & 0.61 ; \\ & P=0.001 \end{aligned}$ | $\begin{aligned} & 0.67 ; \\ & P=0.01 \end{aligned}$ | 26 | In the later update with a median follow-up of 12.6 years, there is a potential for competing causes of death to impact the OS analysis. |
|  |  |  |  | 12.6 | $\begin{aligned} & 0.72 ; \\ & P=0.02 \end{aligned}$ | $\begin{aligned} & 0.82 ; \\ & P=0.18 \end{aligned}$ |  |  |
| E1690 | T4, N+ | 642 | HDI or LDI versus Observation | 4.3 | $\begin{aligned} & 0.78 ; \\ & P=0.05 \end{aligned}$ | 1.0 | 13 | A retrospective analysis documented cross over of observation patients to standard HDI therapy at nodal relapse ( $n=38$ patients). Such cross-over may have affected the OS analysis in this trial. |
|  |  |  |  | 6.6 | $\begin{aligned} & 0.81 ; \\ & P=0.09 \end{aligned}$ | 1.0 |  |  |
| E1694 | T4, N+ | 880 | HDI versus GMK vaccine for 96 weeks | 1.3 | $\begin{aligned} & 0.67 ; \\ & P=0.0004 \end{aligned}$ | $\begin{aligned} & 0.72 ; \\ & P=0.023 \end{aligned}$ | 10 | E1694 confirmed the OS benefit seen in E1684. RFS benefits in E1694 correlated with the OS benefits (as in E1684). |
|  |  |  |  | 2.1 | $\begin{aligned} & 0.75 ; \\ & P=0.006 \end{aligned}$ | $\begin{aligned} & 0.76 ; \\ & P=0.04 \end{aligned}$ |  |  |
| EORTC <br> 18991 | N1,2 | 1256 | Pegylated IFN- $\alpha$ versus Observation | 3.8 | $\begin{aligned} & 0.82 ; \\ & P=0.011 \end{aligned}$ | 0.98 | 37 | RFS benefit appears to be confined to the N1 population. |
|  |  |  |  | 7.6 | $\begin{aligned} & 0.87 ; \\ & P=0.055 \end{aligned}$ | 0.96 |  | Subgroup analysis suggested greater benefit in the N1 population with an ulcerated primary tumor. <br> Duration of therapy appeared to be feasible to $\sim 1$ year (median duration 14 months). |# Other IFN- $\alpha$ Studies That Evaluated Varying Dose Levels, Routes, and Duration 

Other adjuvant trials varying dosing ranges, routes of administration, duration of therapy, and formulations in the search for more effective and better tolerated regimens. The HDI regimen was further evaluated in the Sunbelt Melanoma Trial that tested LND alone as compared to LND followed by adjuvant HDI and found no statistically significant differences (Chao et al., 2002). The Italian Melanoma Group trial tested a shorter but more intense course of HDI versus the standard 1 year HDI regimen and also reported no significant differences (Chiarion-Sileni et al., 2011).

US Intergroup E1697 trial tested the value of the 1 month high dose intravenous induction phase of HDI as a necessary and sufficient therapy in patients with surgically resected intermediate risk melanoma ( $\geq \mathrm{T} 3$ or any T with microscopic nodal metastasis). This study was activated in 1998 enrolled 1150 patients that were randomized to either 4 weeks of IFN- $\alpha\left(20 \mathrm{MU} / \mathrm{m}^{2} /\right.$ day for 5 days weekly) or to observation (Agarwala et al., 2011). A third interim analysis conducted in 2010 considered the study futile in terms of the efficacy endpoints leading to study closure for further enrollment. A presentation at the 2011 ASCO Annual Meeting reported no benefits in RFS or OS with this 1 month regimen (Agarwala et al., 2011).

The Hellenic Oncology group trial tested the hypothesis that the intravenous induction phase of the HDI regimen was similar in adjuvant therapeutic efficacy to the standard 1 year HDI regimen in patients with high-risk melanoma (Gogas et al., 2004). This phase III study (He 13A/98) randomized patients to a modified induction phase consisting of $15 \mathrm{MU} / \mathrm{m}^{2}$ IFN- $\alpha$ I.V., 5 days a week for 4 weeks only versus the same induction month followed by a modified maintenance phase consisting of 10 MU (flat dose and not per $\mathrm{m}^{2}$ ) 3 times weekly for 11 months with a total of 182 patients per study arm were enrolled between 1998 and 2004. At a median follow-up of 5.25 years, the results as reported in 2009 showed no statistically significant differences between the two study arms in either RFS or OS. However, two factors should be taken into account in evaluating the results of this study. The therapeutic regimen was modified to administer a lower dose overall comparted to standard HDI. Further, the sample size of 182 subjects per study arm may be too small to permit showing a significant and clinically meaningful difference.

Studies testing less intensive regimens of adjuvant IFN- $\alpha$ were also conducted. Very low dose IFN- $\alpha$ regimens ( 1 MU SC every other day) was evaluated in the European Organization for Research and Treatment of Cancer (EORTC) 18871 targeting patients with stage IIB, IIIA (Kleeberg et al., 2004). Low dose IFN- $\alpha$ ( $\leq 3$ MU SC 3 times weekly) was tested in the WHO melanoma trial 16 (stage III) (Cascinelli et al., 1994), E1690 (T4, N1) (Kirkwood et al., 2000), UKCCCR AIM-High trial (stage IIB/III) (Hancock et al., 2004), the Scottish trial (stage IIB, III) (Cameron et al., 2001), and the German DeCOG study (T3anyN) (Hauschild et al., 2010). Intermediate dosing IFN- $\alpha$ regimens ( $5-10 \mathrm{MU} / \mathrm{m}^{2}$ ) were evaluated in the EORTC 18952 (T4 N1-2) (Eggermont et al., 2005) and EORTC 18991 (TxN1) (Eggermont et al., 2008) studies. Overall, these trials reported benefits in RFS with IFN- $\alpha$ that appeared to be degraded with time. Similarly, the French multicenter trial concluded that the RFS adjuvant benefits of IFN- $\alpha$ were lost soon after cessation of treatment (Grob et al., 1998).The EORTC 18952 trial enrolled 1388 patients with stage IIB/III disease (Kirkwood et al., 2004). Patients received 4 weeks of induction IFN- $\alpha$ at 10 MU I.V. 5 times a week, followed by one of two therapeutic maintenance regimens. The first consisted of S.C. IFN- $\alpha$ at 10 MU 3 days a week for 1 year and the second S.C. IFN- $\alpha$ at 5 MU 3 days a week for 2 years. The study included a third arm which was an observation control arm. Subjects were enrolled between the years 1996 and 2000. At a median follow-up of 4.65 years, the study reported a statistically insignificant $7.2 \%$ increase in distant metastasis-free interval (DMFS) in favor of the 2-year regimen ( $47 \%$ 2-year, $43 \%$ 1-year vs $40 \%$ observation). There was a $5.4 \%$ increase in OS in the 2-year arm ( $53 \%$ compared to $48 \%$ each in the 1-year and observation arms). Therefore, the relative improvement in OS was seen only in patients treated for 25 months and not in those treated for 13 months. The results of this study suggested that the duration of therapy might be more important than the dose and supported later trials focusing on duration such as EORTC 18991.

A randomized Phase III Dermatologic Cooperative Group (DeCOG) trial investigated LDI in combination with Dacarbazine (DTIC) chemotherapy versus LDI alone (Garbe et al., 2008). After a median follow-up of 4 years, this study reported improvements in DFS (HR = 0.69) and OS (HR = 0.62) with LDI. In other words, this trial demonstrated that chemotherapy with DTIC does not add therapeutic benefits to treatment with LDI alone. Importantly, earlier trials evaluating LDI, including the Austrian (AMCG) trial and the French (FCGM) trial, have no shown no OS benefits compared to observation (Pehamberger et al., 1998; ChiarionSileni et al., 2011). LDI as adjuvant therapy for stage II melanoma patients has regulatory approval in Europe by the European Medicines Agency (EMEA). Adjuvant IFN- $\alpha$ is used in Europe but regional differences exist in terms of the regimens and dose levels.

The EORTC 18991 trial tested pegylated IFN- $\alpha$ as adjuvant therapy for surgically resected Stage III melanoma (Eggermont et al., 2012b). In pegylated IFN- $\alpha$, sustained absorption and a longer half-life are achieved through the covalent bonding of the IFN molecule and a polyethylene glycol moiety. This study evaluated the efficacy and safety of pegylated IFN- $\alpha 2 \mathrm{~b}$ (peg-IFN) as compared to observation, enrolling 1256 patients from the year 2000 to the year 2002. Study subjects had surgically resected AJCC stage III melanoma that were stratified into N1 (microscopic nodal metastasis as detected by a sentinel lymph node biopsy) and N2 (clinically detectable nodal metastasis). The IFN- $\alpha$ regimen consisted of an induction dose of peg-IFN given S.C. at $6 \mathrm{mcg} / \mathrm{kg}$ a week for 8 weeks. This was followed by a maintenance phase given once weekly S.C. at $3 \mathrm{mcg} / \mathrm{kg}$ for up to 5 years. At the mature median followup of 7.6 years, there was an improvement in RFS (primary endpoint) in favor of the treatment arm (HR $0.87,95 \% \mathrm{CI}, 0.76-1.00, P=0.05$ ). However, no difference was seen in term of OS or DMFS (secondary endpoints) between the treatment and observation arms of the study. This benefit appeared to be confined to the N1 (microscopic nodal disease) population on subgroup analysis where no benefit was reported in the N2 group (including RFS) (Eggermont et al., 2012b). Further subgroup analysis reported that patients with microscopic nodal metastasis who had an ulcerated primary tumor derived significant benefits in RFS, OS and DMFS. These important findings warrant further testing which is ongoing as part of the 18081 trial, although this study is limited to earlier stage subjects and have excluded patients with nodal disease. In terms of toxicity and tolerance, the attrition rate of peg-IFN for toxicity was $37 \%$. The results of this trial led to the regulatory approval of pegylated IFN- $\alpha$ in the United States as adjuvant therapy for patients with lymph node metastases.TABLE 4.2 Four Meta-analyses of All Trials of IFN- $\alpha$ and the Reported RFS and OS Benefits

| Meta-analysis | \#RCT | RFS | OS | Comment |
| :--: | :--: | :--: | :--: | :--: |
| Ives, Cancer Treat Rev. 2003 | 12 | $+$ | $-/+$ | Did not include E1694 |
| Wheatley, ASCO. 2007 | 13 | $\begin{aligned} & + \\ & \text { OR }=0.87,95 \% \mathrm{CI}= \\ & 0.81-0.93, P=0.00006 \end{aligned}$ | $\begin{aligned} & + \\ & \text { OR }=0.9,95 \% \mathrm{CI}= \\ & 0.84-0.97, P=0.008 \end{aligned}$ | OS translates into absolute benefit of $3 \%$ (CI, 1-5\%) at 5 years |
| Mocellin, JNCI. 2010 | 14 | $\begin{aligned} & + \\ & \text { HR }=0.82,95 \% \mathrm{CI}= \\ & 0.77-0.87 ; P<0.001 \end{aligned}$ | $\begin{aligned} & + \\ & \text { HR }=0.89,95 \% \mathrm{CI}= \\ & 0.83-0.96 ; P=0.002 \end{aligned}$ | DFS $18 \%$ risk reduction OS $11 \%$ risk reduction |
| Mocellin, Cochrane. 2013 | 17 | $\begin{aligned} & + \\ & \text { HR }=0.83,95 \% \\ & \text { CI }=0.78-0.87 \\ & P<0.00001(17 \text { RCTs }) \end{aligned}$ | $\begin{aligned} & + \\ & \text { HR }=0.91,95 \% \\ & \text { CI }=0.85-0.97 \\ & P=0.003(15 \text { RCTs }) \end{aligned}$ | Relapse risk reduction 17\% Mortality risk reduction $9 \%$ |

# Meta-analyses of IFN- $\alpha$ Trials 

At least four systematic reviews and meta-analyses (see Table 4.2) of IFN- $\alpha$ adjuvant trials in melanoma were published between 2002 and 2013 (Wheatley et al., 2003, 2007a; Mocellin et al., 2010). The largest and most recent was the 2013 Cochrane database systematic review by Mocellin et al. (2013). This review pooled 18 randomized controlled trials (RCTs) that treated a total of 10,499 patients. Out of these, 17 RCTs reported between 1995 and 2011, were considered suitable for this meta-analysis. This review quantified the therapeutic efficacy of IFN- $\alpha$ as measured by disease-free survival ( 17 trials; 10,345 subjects) and OS (15 trials; 9927 patients) (Mocellin et al., 2013). Overall, there was a significant improvement in RFS with adjuvant IFN- $\alpha$ with a HR of $0.83(95 \% \mathrm{CI}, 0.78-0.87)$ corresponding to a relative reduction in the risk of relapse of $17 \%$. The absolute risk reduction at 5 years was estimated at $50 / 100$ to $44 / 100$ and the number needed to treat (NNT) at 16. A significant improvement in reducing the risk death was also seen with a HR of $0.91(95 \% \mathrm{CI}, 0.85-$ 0.97). The absolute mortality risk reduction at 5 years was estimated at $40 / 100$ to $37 / 100$. Considering the 5-year OS rate for TNM stage II-III cutaneous melanoma at $60 \%$, the metaanalysis estimated the NNT at $35(95 \%$ CI, 21-108) in order to prevent one death (Mocellin et al., 2013).

## Adjuvant Trials Testing IFN- $\alpha$ in Combination

As discussed earlier in this review, a DeCOG trial tested LDI in combination with Dacarbazine (DTIC) chemotherapy versus LDI alone (Garbe et al., 2008). The South West Oncology Group (SWOG) led the investigation of the US Intergroup S0008 trial that tested the adjuvant value of BCT (Flaherty et al., 2012). S0008 was a phase III study in high-risk, lymph node-positive melanoma patients that compared adjuvant BCT administered over 9 weeks versus the standard HDI regimen given over 52 weeks. The BCT regimen utilized three cycles of combination chemotherapy (cisplatin, vinblastine, DTIC) andimmunotherapy (low dose IL-2 and IFN- $\alpha$ ) (Flaherty et al., 2014). At a median follow-up of about 6 years of 203 patients in the HDI arm and 199 patients in the BCT arm, there was significant improvement in RFS for BCT versus HDI (median 4.31 years vs 1.9 years). RFS at 5 years was $47 \%$ with BCT versus $39 \%$ with HDI. However, there was no difference in OS between the groups (OS at 5 years was $56 \%$ for both) (Flaherty et al., 2014). There was a higher rate of grade III/IV adverse events in the BCT arm (76\%) as compared to the HDI arm $(64 \%)$. The expectation that patients on the BCT arm were followed less frequently (every 3 months following completion of the 9 week BCT regimen) when compared to the HDI arm patients (followed more closely as clinically indicated with IFN- $\alpha$ ) raises the question of whether closer follow-up may have affected the RFS analysis.

In summary, studies of adjuvant therapy of high risk surgically resected melanoma with IFN- $\alpha$ have led to the regulatory approval of HDI (stage IIB-III) and peg-IFN (stage III). Benefits were seen in the HDI trials both in terms of RFS (E1684, E1690, E1694) and OS (E1684 and E1694). Peg-IFN was tested in EORTC 18991 demonstrated improvements in RFS that appear to be mainly derived by the microscopic nodal disease population. Survival benefits with peg-IFN were suggested based on subgroup analysis within the microscopic nodal disease and ulcerated primary group of patients.

# NEOADJUVANT IFN- $\alpha$ AND OTHER AGENTS IN MELANOMA 

Preoperative neoadjuvant therapy targets patients with locally-regionally advanced melanoma that carry a high risk of relapse and death despite aggressive surgical management. Reported neoadjuvant studies in melanoma to date evaluated chemotherapy with temozolomide and BCT as well as immunotherapy with IFN- $\alpha$ and ipilimumab CTLA4 blockade therapy. BCT regimens tested three or more cycles of chemotherapy (dacarbazine, cisplatin and vinblastine) combined with interleukin (IL)-2 and IFN- $\alpha$ reporting high objective response rates of about $40 \%$ that included a minority of patients with complete pathologic responses (Buzaid et al., 1998; Shah et al., 2010). However, BCT regimens that are associated with significant toxicity were eventually abandoned with the failure of BCT to deliver survival benefits in randomized trials of metastatic melanoma including the Phase III trials E3695 and EORTC 18951 that compared BCT to chemotherapy alone (Atkins et al., 2008; Keilholz et al., 2005).

Neoadjuvant IFN- $\alpha$ was tested in patients with stage IIIB/C disease who underwent biopsy followed by 1 month of high dose IFN- $\alpha$ (IV $20 \mathrm{MU} / \mathrm{m}^{2} 5$ days a week for 4 weeks) administered prior to completion LND and subsequent maintenance HDI (SC $10 \mathrm{MU} / \mathrm{m}^{2}$ 3 days a week for 48 weeks) after recovery from surgery (Moschos et al., 2006). Amongst 20 patients treated, three were found to have pathologic complete responses and eight had partial responses. There were significantly greater intratumoral $\mathrm{CD}^{+}+\mathrm{T}$ cells and $\mathrm{CD} 11 \mathrm{c}^{+}$ monocyte-derived dendritic cell infiltration in responding patients (Moschos et al., 2006; Tarhini et al., 2011). IFN- $\alpha$ was associated with downregulation of STAT3 expression in tumor cells and stimulated the induction of STAT1 that correlated with a reversal in T cell signaling defects (Moschos et al., 2006). TAP2 was found to be augmented by IFN- $\alpha$ (but not TAP1) (Wang et al., 2007). Further, IFN- $\alpha$ affected MAPK signaling differentially in melanoma tumor cells and host lymphoid cells. It downregulated pSTAT3 ( $P=0.008$ ) and phospho-MEK1/2( $P=0.008$ ) levels significantly in tumor cells. IFN- $\alpha$ downregulated phospho-ERK1/2 in tumor cells ( $P=0.015$ ), while this effect was not seen in lymphoid cells. IFN- $\alpha$ downregulated EGFR ( $P=0.013$ ), while pSTAT3 activation appeared not to be associated with EGFR expression and MEK/ERK MAPK pathway activation, suggesting that independent activation of STAT3 not related to EGFR/MEK/ERK signaling (Wang et al., 2008).

Neoadjuvant ipilimumab given intravenously at $10 \mathrm{mg} / \mathrm{kg}$ was studied by Tarhini et al. (2014a) in patients with locally and regionally advanced melanoma yielding several important clinical and mechanistic findings. This has led to ongoing studies that are currently evaluating neoadjuvant combinations testing IFN- $\alpha$ combined with ipilimumab CTLA4 blockade (UPCI 11-063) and with pembrolizumab PD1 blockade (UPCI 14-102).

# BIOMARKERS OF CLINICAL BENEFIT WITH IFN- $\alpha$ 

Among the 70,000 new cases of invasive melanoma diagnosed, about 30,000 will be surgically operable melanoma that is at intermediate to high risk for recurrence and death and for which adjuvant therapy is indicated. High-dose IFN- $\alpha-2 b$ (HDI) has established but limited efficacy as an adjuvant therapy and is associated with significant toxicity and high cost. The current paradigm of adjuvant therapy in melanoma involves the indiscriminate treatment of all patients clinically considered at high risk for melanoma recurrence and mortality, despite data showing that only a small proportion of patients will benefit. In the adjuvant trial E1684 testing HDI versus observation, the 5-year RFS and OS rates were 37\% versus $26 \%$ and $46 \%$ versus $37 \%$, respectively (Kirkwood et al., 1996). However, we currently have no means to predict which patients will be among the roughly one-third who will benefit and who will be among the two-thirds who could be spared the adverse events and cost due to lack of predicted efficacy. However, several studies have revealed important preliminary data that are the subject of ongoing research.

Among these studies, we reported on serum S100B protein serving as a potential prognostic biomarker for patients with high-risk melanoma (Tarhini et al., 2009). In this study, sera banked at baseline and three additional time points were tested for S100B in 691 patients from E1694 trial by using chemiluminescence. S100B $\geq 0.15 \mu \mathrm{~g} / \mathrm{L}$ significantly correlated with $\mathrm{OS}(P=0.010)$, and a Cox multivariate analysis identified baseline S100B as a significant independent predictor of $\mathrm{OS}(P=0.043)$ after adjusting for significant prognostic factors and treatment (Tarhini et al., 2009). A multiplex analysis of serum cytokines in high-risk melanoma patients treated with HDI in E1694 adjuvant trial showed that baseline pro-inflammatory cytokine levels may predict 5-year RFS with HDI but not GMK vaccine (Yurkovetsky et al., 2007). Luminex multiplex to was used to simultaneously measure the levels of 29 cytokines, chemokines, and angiogenic and growth factors in the sera of 179 patients from E1694 plus sex-matched controls (73-76). Serum concentrations of IL1 $\alpha$, IL1 $\beta$, IL6, IL8, IL12p40, IL13, G-CSF, MCP1, MIP1 $\alpha$, MIP1 $\beta$, IFN- $\alpha$, TNF $\alpha$, EGF, VEGF, and TNFRII were significantly higher among patients with resected high-risk melanoma compared with controls. Serum levels of immune-suppressive angiogenic/growth stimulatory factors (VEGF, EGF, HGF) were significantly decreased by HDI, while levels of antiangiogenic IP-10 and IFN- $\alpha$ were elevated after treatment. Comparing patients according to relapse outcome, the pretreatment levels of pro-inflammatory cytokines IL1 $\beta$, IL1 $\alpha$, IL6, TNF $\alpha$, andchemokines MIP1 $\alpha$, and MIP1 $\beta$ were significantly higher ( $P<0.05$ ) in sera of patients with longer RFS of 1-3 years and $>5$ years, compared with patients who experienced shorter RFS of $<1$ year (Yurkovetsky et al., 2007).

We also reported a four-marker signature of TNF-RII, TGF- $\alpha$, TIMP-1, and CRP that is prognostic of worse survival in high-risk resected melanoma (Tarhini et al., 2014b). We tested banked serum specimens from 40 patients in the vaccine arm of E1694 for prognostic biomarkers. In order to take advantage of the broader array of testable analytes in this platform compared to Luminex, we used Aushon multiplex platform in order to quantitate baseline serum levels of 115 analytes. Four markers that included Tumor Necrosis Factor alpha Receptor II (TNF-RII), Transforming Growth Factor alpha (TGF- $\alpha$ ), Tissue Inhibitor of Metalloproteinases 1 (TIMP-1), and CRP were found to be most informative for the prediction of OS (high levels correlate with worse prognosis). When using the four-marker PH model to predict 5-year OS, we achieved an area under the curve (AUC) $72 \%$ (cross validated). High baseline TNF-RII was also significantly associated with worse RFS. RFS with high (above median) TNF-RII was significantly lower than low TNF-RII ( $P=0.01$ ).

We recently reported that an early on-treatment (1 month) pro-inflammatory cytokines predict 1 year RFS with IFN- $\alpha$ but not observation in E1697 trial (Tarhini et al., 2013). E1697 tested observation (Arm A) versus adjuvant IFN- $\alpha 2$ b for 1 month (Arm B) in patients (pts) with resected intermediate risk stage IIA-B and IIIA melanoma. We evaluated levels of 16 candidate serum biomarkers for their therapeutic predictive or prognostic value in Arm B versus Arm A in 268 pts with banked biospecimens. Luminex multiplex platform was used for serum cytokine tests at baseline and 1 month. Cox PH modeling and Wald tests were used to test the association of each marker and RFS. Similar leave-one-out cross validation strategy was used to avoid over fitting of the data. In the multimarker modeling analysis in Arm B, 1 month IL2R $\alpha$, IL-12p40, and IFN levels significantly predicted 1 year RFS with LOOCV AUC $=83 \%$. The risk score (linear combination of the three markers) separated RFS curves of low and high risk groups well. This model did not hold for Arm A, indicating a marker-treatment (IFN) interaction in Arm B, consistent with our previous data. (Yurkovetsky et al., 2007). Therefore, early on-treatment (1 month) pro-inflammatory serum markers (IL2R $\alpha$, IL-12p40, IFN) significantly predict RFS in pts treated with adjuvant IFN$\alpha 2 b$ and warrant further study.

Clinically, the Wheatley meta-analysis first found an association between primary tumor ulceration and IFN- $\alpha$ benefit (Wheatley et al., 2007b). More recently, subset analysis of EORTC 18991 trial testing peg-IFN reported significant benefits in OS, RFS, and DMFS in patients with ulcerated primary tumors and microscopic nodal disease. These results have led to the ongoing EORTC 18081 trial that is testing peg-IFN for 2 years as compared to observation in patients with an ulcerated primary cutaneous melanoma who have stages T(2-4)b, N0, M0 (Eggermont et al., 2012a).

Autoimmunity as a biomarker associated with IFN- $\alpha$ benefit was first reported in an analysis nested within the Hellenic adjuvant IFN- $\alpha$ trial that reported significant associations between the induction of autoimmunity and RFS and OS benefits (Gogas et al., 2006). We evaluated the prognostic value of autoimmunity in patients enrolled in the E2696 and E1694 trials to further understand the association between IFN- $\alpha$ induced autoimmunity related side effects and improved outcomes with IFN- $\alpha$. In both trials, the presence of autoantibodies in the sera of patients was significantly more frequent in the IFN- $\alpha$ armcompared to the vaccine arm, but the prognostic value was less certain. A landmark analysis of E1694 showed a trend toward a survival advantage associated with HDI-induced autoimmunity in stage III patients. The development of autoimmunity occurred over a period of up to 1 year in our studies. Therefore, as a biomarker serologic evidence of autoimmunity cannot be used as a baseline or early on-treatment predictor of IFN- $\alpha$ therapeutic benefit that may alter patient treatment. (Tarhini et al., 2009, 2014c). We tested immunogenic predictors of autoimmunity associated with IFN- $\alpha$ in the context of the E1697 trial as potential predictors of IFN- $\alpha$ therapeutic benefits including HLA genotypes and polymorphisms in CTLA4 and FOXP3 genes but have found no significant associations (Tarhini et al., 2015). The expression of methylthioadenosine phosphorylase (MTAP) was reported to be association with improved OS and RFS in patients treated with adjuvant IFN- $\alpha$. MTAP plays a role in STAT1 activation (Meyer et al., 2010).

# CONCLUSIONS 

Multiple randomized clinical trials (RCT) and meta-analyses have demonstrated a significant RFS benefit with adjuvant IFN- $\alpha$ therapy after surgical resection of high risk melanoma. Two RCT have supported OS benefit with the HDI regimen when compared to observation (E1684) and the GMK vaccine (E1694). A limited OS benefit from adjuvant IFN- $\alpha$ was also supported by the most recent and largest Cochrane meta-analysis. This meta-analysis of adjuvant IFN- $\alpha$ trials reported an $18 \%$ risk reduction in the risk of recurrence and an $11 \%$ risk reduction in the risk of death (Kleeberg et al., 2004). Pegylated IFN- $\alpha$ received regulatory approval in 2011 as adjuvant therapy in node positive melanoma based on RFS benefits seen in the EORTC 18991 trial.

Ongoing adjuvant trials are testing HDI versus ipilimumab CTLA4 blockade therapy (US Intergroup E1609) and PD1 blockade with pembrolizumab (US Intergroup S1404). E1609 completed subject accrual in August 2014 and earliest results are expected in 2016 while S1404 was activated in the summer of 2015. As adjuvant therapy trials in melanoma, EORTC 18071 has demonstrated significant EFS benefits compared to placebo in stage III disease. Other studies are testing BRAF inhibitors (BRIM-8 and COMBI-AD) and MAGE-A3 vaccine (DERMA). Recent reports from the DERMA trial demonstrated failure in terms of the primary endpoint of RFS. Other adjuvant trials utilizing anti-PD1 antibodies include CheckMate 238 testing nivolumab compared to ipilimumab and KEYNOTE-054 evaluating pembrolizumab versus placebo.

Studies attempting to identify therapeutic predictive biomarkers in the adjuvant and neoadjuvant settings are ongoing and preliminary results are encouraging. Such biomarkers of clinical benefit, that may allow us to target therapy to those likely to benefit while saving others the toxicities and cost due to lack of predicted benefit, are more crucial than ever.

## Acknowledgments

This manuscript was partly supported by NIH award P50CA121973. Its content is solely the responsibility of the author and does not necessarily represent the official views of the National Cancer Institute.# References 

Agarwala, S.S., Lee, S.J., Flaherty, L.E., et al., 2011. Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697), 2011 ASCO Annual Meeting Abstracts. J. Clin. Oncol. 29, 8505. (No 15, suppl. 2011).
Atkins, M.B., Hsu, J., Lee, S., Cohen, G.I., Flaherty, L.E., Sosman, J.A., et al., 2008. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa- $2 b$ with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. 26 (35), 5748-5754.
Balch, C.M., Gershenwald, J.E., Soong, S.J., Thompson, J.F., Atkins, M.B., Byrd, D.R., et al., 2009. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27 (36), 6199-6206.
Buzaid, A.C., Colome, M., Bedikian, A., Eton, O., Legha, S.S., Papadopoulos, N., et al., 1998. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res. 8 (6), 549-556.

Cameron, D.A., Cornbleet, M.C., Mackie, R.M., Hunter, J.A., Gore, M., Hancock, B., et al., 2001. Adjuvant interferon alpha $2 b$ in high risk melanoma-the Scottish study. Br. J. Cancer 84 (9), 1146-1149.
Cassinelli, N., Bufalino, R., Morabito, A., and Mackie, R., 1994. Results of adjuvant interferon study in WHO melanoma programme. Lancet 343 (8902), 913-914.
Chao, C., Wong, S.L., Ross, M.I., Reintgen, D.S., Noyes, R.D., Cerrito, P.B., et al., 2002. Patterns of early recurrence after sentinel lymph node biopsy for melanoma. Am. J. Surg. 184 (6), 520-524. Discussion 525.
Chiarion-Sileni, V., Guida, M., Romanini, A., et al., 2011. Intensified high-dose intravenous interferon alpha 2b (IFN $\mathrm{a} 2 \mathrm{~b}$ ) for adjuvant treatment of stage III melanoma: a randomized phase III Italian Melanoma Intergroup (IMI) trial [ISRCTN75125874]. J. Clin. Oncol. 29 (No 15, suppl. 8506) <http://jco.ascopubs.org/site/misc/ Terms_and_Cond.xhtml>.
Creagan, E.T., Ahmann, D.L., Frytak, S., Long, H.J., Chang, M.N., and Itri, L.M., 1986a. Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients. Cancer Treat. Rep. 70 (5), 619-624.

Creagan, E.T., Ahmann, D.L., Frytak, S., Long, H.J., and Itri, L.M., 1986b. Recombinant leukocyte A interferon (rIFN-alpha A) in the treatment of disseminated malignant melanoma. Analysis of complete and long-term responding patients. Cancer 58 (12), 2576-2578.
Creagan, E.T., Dalton, R.J., Ahmann, D.L., Jung, S.H., Morton, R.F., Langdon, R.M., et al., 1995. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J. Clin. Oncol. 13 (11), 2776-2783.

Eggermont, A.M., Suciu, S., MacKie, R., Ruka, W., Testori, A., Kruit, W., et al., 2005. Post-surgery adjuvant therapy with intermediate doses of interferon alfa $2 b$ versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366 (9492), 1189-1196.
Eggermont, A.M., Suciu, S., Santinami, M., Testori, A., Kruit, W.H., Marsden, J., et al., 2008. Adjuvant therapy with pegylated interferon alfa- $2 b$ versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372 (9633), 117-126.
Eggermont, A.M., Spatz, A., Lazar, V., and Robert, C., 2012a. Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity? Curr. Opin. Oncol. 24 (2), 137-140.
Eggermont, A.M., Suciu, S., Testori, A., Santinami, M., Kruit, W.H., Marsden, J., et al., 2012b. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J. Clin. Oncol. 30 (31), 3810-3818.
Eton, O., Legha, S.S., Bedikian, A.Y., Lee, J.J., Buzaid, A.C., Hodges, C., et al., 2002. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J. Clin. Oncol. 20 (8), 2045-2052.
Flaherty, L.E., Moon, J., Atkins, M.B., et al., 2012. Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): an intergroup study of CALGB, COG, ECOG, and SWOG. 2012 ASCO Annual Meeting 30 (No 15, suppl. 2012), 8504.
Flaherty, L.E., Othus, M., Atkins, M.B., Tuthill, R.J., Thompson, J.A., Vetto, J.T., et al., 2014. Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma-an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. J. Clin. Oncol. 32 (33), 3771-3778.

## I. MOLECULAR MECHANISMSGarbe, C., Radny, P., Linse, R., Dummer, R., Gutzmer, R., Ulrich, J., et al., 2008. Adjuvant low-dose interferon [alpha]2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann. Oncol. 19 (6), 1195-1201.
Gogas, H., Bafaloukos, D., Ioannovich, J., Skarlos, D., Polyzos, A., Fountzilas, G., et al., 2004. Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year-a Hellenic Cooperative Oncology Group study. Anticancer Res. 24 (3b), 1947-1952.
Gogas, H., Ioannovich, J., Dafni, U., Stavropoulou-Giokas, C., Frangia, K., Tsoutsos, D., et al., 2006. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354 (7), 709-718.
Grob, J.J., Dreno, B., de la Salmoniere, P., Delaunay, M., Cupissol, D., Guillot, B., et al., 1998. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 351 (9120), 1905-1910.
Hancock, B.W., Wheatley, K., Harris, S., Ives, N., Harrison, G., Horsman, J.M., et al., 2004. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J. Clin. Oncol. 22 (1), 53-61.
Hauschild, A., Weichenthal, M., Rass, K., Linse, R., Berking, C., Bottjer, J., et al., 2010. Efficacy of low-dose interferon [alpha]2a 18 versus 60 months of treatment in patients with primary melanoma of $>=1.5 \mathrm{~mm}$ tumor thickness: results of a randomized phase III DeCOG trial. J. Clin. Oncol. 28 (5), 841-846.
Keilholz, U., Punt, C.J., Gore, M., Kruit, W., Patel, P., Lienard, D., et al., 2005. Dacarbazine, cisplatin, and inter-feron-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J. Clin. Oncol. 23 (27), 6747-6755.
Kirkwood, J.M., Strawderman, M.H., Ernstoff, M.S., Smith, T.J., Borden, E.C., and Blum, R.H., 1996. Interferon alfa2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14 (1), 7-17.
Kirkwood, J.M., Ibrahim, J.G., Sondak, V.K., Richards, J., Flaherty, L.E., Ernstoff, M.S., et al., 2000. High- and lowdose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J. Clin. Oncol. 18 (12), 2444-2458.
Kirkwood, J.M., Ibrahim, J., Lawson, D.H., Atkins, M.B., Agarwala, S.S., Collins, K., et al., 2001a. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J. Clin. Oncol. 19 (5), 1430-1436.
Kirkwood, J.M., Ibrahim, J.G., Sosman, J.A., Sondak, V.K., Agarwala, S.S., Ernstoff, M.S., et al., 2001b. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 19 (9), 2370-2380.
Kirkwood, J.M., Manola, J., Ibrahim, J., Sondak, V., Ernstoff, M.S., and Rao, U., 2004. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res. 10 (5), 1670-1677.
Kleeberg, U.R., Suciu, S., Brocker, E.B., Ruiter, D.J., Chartier, C., Lienard, D., et al., 2004. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness $>3 \mathrm{~mm}$ ) or regional lymph node metastasis. Eur. J. Cancer 40 (3), 390-402.
Meyer, S., Wild, P.J., Vogt, T., Bataille, F., Ehret, C., Gantner, S., et al., 2010. Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma. Exp. Dermatol. 19 (8), e251-257.
Mocellin, S., Pasquali, S., Rossi, C.R., and Nitti, D., 2010. Interferon alpha adjuvant therapy in patients with highrisk melanoma: a systematic review and meta-analysis. J. Natl. Cancer Inst. 102 (7), 493-501.
Mocellin, S., Lens, M.B., Pasquali, S., Pilati, P., and Chiarion Sileni, V., 2013. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst. Rev. 6, CD008955.
Moschos, S.J., Edington, H.D., Land, S.R., Rao, U.N., Jukic, D., Shipe-Spotloe, J., et al., 2006. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J. Clin. Oncol. 24 (19), 3164-3171.
O'Day, S.J., Boasberg, P.D., Piro, L., Kristedja, T.S., Wang, H.J., Martin, M., et al., 2002. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin. Cancer Res. 8 (9), 2775-2781.

# I. MOLECULAR MECHANISMSPehamberger, H., Soyer, H.P., Steiner, A., Kofler, R., Binder, M., Mischer, P., et al., 1998. Adjuvant interferon alfa2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J. Clin. Oncol. 16 (4), 1425-1429.
Romano, E., Scordo, M., Dusza, S.W., Coit, D.G., and Chapman, P.B., 2010. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J. Clin. Oncol. 28 (18), 3042-3047.
Shah, G.D., Socci, N.D., Gold, J.S., Wolchok, J.D., Carvajal, R.D., Panageas, K.S., et al., 2010. Phase II trial of neoadjuvant temozolomide in resectable melanoma patients. Ann. Oncol. 21 (8), 1718-1722.
Siegal, F.P., Kadowaki, N., Shodell, M., Fitzgerald-Bocarsly, P.A., Shah, K., Ho, S., et al., 1999. The nature of the principal type 1 interferon-producing cells in human blood. Science 284 (5421), 1835-1837.
Siegel, R.L., Miller, K.D., and Jemal, A., 2015. Cancer statistics, 2015. CA. Cancer J. Clin. 65 (1), 5-29.
Tarhini, A.A., Stuckert, J., Lee, S., Sander, C., and Kirkwood, J.M., 2009. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J. Clin. Oncol. 27 (1), 38-44.
Tarhini, A.A., Cherian, J., Moschos, S.J., Tawbi, H.A., Shuai, Y., Gooding, W.E., et al., 2012. Safety and efficacy of combination immunotherapy with interferon alfa- 2 b and tremelimumab in patients with stage IV melanoma. J Clin Oncol 30 (3), 322-328. <http://dx.doi.org/10.1200/JCO.2011.37.5394>. Epub 2011 Dec 19. Erratum in: J Clin Oncol. 2012 Nov 1;30(31):3903.
Tarhini, A.A., Pahuja, S., and Kirkwood, J.M., 2011. Neoadjuvant therapy for high-risk bulky regional melanoma. J. Surg. Oncol. 104 (4), 386-390.

Tarhini, A.A., Gogas, H., and Kirkwood, J.M., 2012. IFN-alpha in the treatment of melanoma. J. Immunol. 189 (8), $3789-3793$.
Tarhini, A.A., Lin, Y., Lee, S.J., Butterfield, L.B., Ringquist, S., Gogas, H., et al. 2013. Biomarkers of outcome after one month of adjuvant IFN- $\alpha 2$ b for intermediate-risk melanoma in E1697, translated by Philadelphia.
Tarhini, A.A., Edington, H., Butterfield, L.H., Lin, Y., Shuai, Y., Tawbi, H., et al., 2014a. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One 9 (2), e87705.
Tarhini, A.A., Lin, Y., Yeku, O., LaFramboise, W.A., Ashraf, M., Sander, C., et al., 2014b. A four-marker signature of TNF-RII, TGF-alpha, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. J. Transl. Med. 12, 19.
Tarhini, A.A., Shin, D., Lee, S.J., Stuckert, J., Sander, C.A., and Kirkwood, J.M., 2014c. Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. Melanoma Res. 24 (2), 150-157.
Tarhini, A.A., Lin, Y., Zahoor, H., Shuai, Y., Butterfield, L.H., Ringquist, S., et al., 2015. Pro-Inflammatory cytokines predict relapse-free survival after one month of interferon-alpha but not observation in intermediate risk melanoma patients. PLoS One 10 (7), e0132745.
Thompson, C.B., and Allison, J.P., 1997. The emerging role of CTLA-4 as an immune attenuator. Immunity 7 (4), $445-450$.
Wang, W., Edington, H.D., Rao, U.N., Jukic, D.M., Land, S.R., Ferrone, S., et al., 2007. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin. Cancer Res. 13 (5), 1523-1531.
Wang, W., Edington, H.D., Jukic, D.M., Rao, U.N., Land, S.R., and Kirkwood, J.M., 2008. Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma. Cancer Immunol. Immunother. 57 (9), 1315-1321.
Wheatley, K., Ives, N., Hancock, B., Gore, M., Eggermont, A., and Suciu, S., 2003. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat. Rev. 29 (4), 241-252.
Wheatley, K., Ives, N., Eggermont, A., and Kirkwood, J.M., 2007a. Interferon- $\alpha$ as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. ASCO Annual Meeting Proceedings Part I. vol. 25, No. 18S (June 20 suppl.), 2007: 8526.
Wheatley, K., Ives, N., Eggermont, A., Kirkwood, J., Cascinelli, N., Markovic, S.N., et al. 2007b. Interferon- $\alpha$ as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials, translated by Oncology, J. o. C., Chicago.
Yurkovetsky, Z.R., Kirkwood, J.M., Edington, H.D., Marrangoni, A.M., Velikokhatnaya, L., Winans, M.T., et al., 2007. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin. Cancer Res. 13 (8), 2422-2428.

# I. MOLECULAR MECHANISMS# C H A P T E R 

## 5

## Brain Metastases from Melanoma

John F. Thompson, Brindha Shivalingam, Angela M. Hong, Megan Lyle and Georgina V. Long

## O U T L I N E

Introduction ..... 66
Surgery for Melanoma Brain Metastases ..... 66
Historical Role of Surgery for
Melanoma Brain Metastases ..... 67
Current Indications for Surgical Management of Melanoma Brain Metastases ..... 68
Technical Aspects of Surgical Resection of Melanoma Brain Metastases ..... 68
Complications Following Surgical Resection of Melanoma Brain Metastases ..... 69
Radiation Therapy for Melanoma Brain Metastases ..... 70
Single Metastasis or Oligometastatic Disease: The Role of Stereotactic Radiosurgery ..... 70
Single Metastases or Oligometastatic Disease: The Role of Whole Brain
Radiation Therapy in Melanoma
After Local Treatment of Metastases ..... 71
Minimizing the Risk of Neurological Deficit Following Whole Brain RadiationTherapy: Hippocampal Sparing73
Multiple Metastases: The Role of
Whole Brain Radiation Therapy ..... 74
The Current Role of Radiation Therapy in Melanoma Brain Metastases ..... 74
Systemic Therapies for Melanoma
Brain Metastases ..... 74
Chemotherapy ..... 75
Small Molecule Targeted Therapies:
BRAF, MEK, and KIT Inhibitors ..... 76
Immunotherapy ..... 78
Suggested Approach to Management ..... 79
Conclusions ..... 80
References ..... 80# INTRODUCTION 

Metastatic melanoma in the brain is a serious event in patients with melanoma because it signifies a poor prognosis and has a potentially severe impact on quality of life. In $20 \%$ of cases, symptomatic metastases represent the initial site of metastatic spread but they may occur at any time during the course of the disease (Choi et al., 1985). Autopsy data indicate that up to $75 \%$ of patients who die of metastatic melanoma have brain metastases (de la Monte et al., 1983; Sampson et al., 1998). In two large single institutional series of 686 and 702 patients (Fife et al., 2004; Sampson et al., 1998), the great majority (up to 95\%) died as a direct result of the brain metastases. The median survival of patients with multiple brain metastases was approximately 3-4 months. There were some differences in survival according to treatment received ( 8.9 months for surgery plus whole brain radiotherapy (WBRT), 8.7 months for surgery alone, 3.4 months for WBRT alone and 2.1 months for supportive care only). However, these differences probably reflect patient selection based on the number of cerebral metastases, performance status, and extent of extracranial metastasis.

Prognostic factors for patients with melanoma brain metastases have been studied extensively. Age $>65$ years and a greater number of neurological symptoms are associated with poorer survival (Zakrzewski et al., 2010). Ulceration and location on the head or neck are the two main primary tumor characteristics associated with poorer survival (Zakrzewski et al., 2010). The number of cerebral metastases is also a significant prognostic factor, with a better prognosis in patients with single cerebral metastases or oligometastatic disease (2-3 metastases). Patients with $>3$ metastases had a median survival of 3.5 months compared with 5.9 months for those with $\leq 3$ metastases ( $P=0.005$ ). More recently, there has been debate on whether it is the number of metastases or the overall intracranial tumor volume that is the relevant factor (Lippitz et al., 2014). The worst outcome is seen in patients with leptomeningeal disease (Groves, 2008). In all large cohorts of patients with melanoma brain metastases the absence of extracranial disease was a positive prognostic factor.

In one study, the outcomes for 743 patients with metastatic melanoma in the brain treated at the MD Anderson Cancer Center between 1986 and 2004 were analyzed (Davies et al., 2011). On multivariate analysis, the date of diagnosis was a prognostic factor. The median survival for patients diagnosed before 1996 was 4.1 months compared with 5.9 months for patients diagnosed in 1996 or later (HR $0.75,95 \% \mathrm{CI}, 0.59-0.95, P=0.02$ ). The increased use of MRI as a screening tool for brain metastases over time may have contributed to this improvement in survival. In addition, earlier diagnosis of patients with smaller, asymptomatic brain metastases might allow for more frequent use of locally directed treatment such as stereotactic radiosurgery (SRS) or surgical excision. A similar study of patients from the Memorial Sloan Kettering Cancer Center noted that age $>65$, presence of extracranial metastases, presence of neurologic symptoms and four or more metastases were predictors for poorer survival, although some of these features were self-predicting in that more aggressive treatment options were less likely to be recommended (Raizer et al., 2008).

## SURGERY FOR MELANOMA BRAIN METASTASES

Surgical resection of melanoma brain metastases was first reported in 1940 (Moersch et al., 1940). Today, surgery is used extensively to provide effective palliation andprolongation of life (McWilliams et al., 2005). However, in the latter part of the 20th century and the first decade of the current century, surgery was usually considered only for patients with a single brain metastasis with controlled or minimal systemic disease. Conservative selection was a result of the potentially high risks of surgical morbidity and mortality (McWilliams et al., 2005).

# Historical Role of Surgery for Melanoma Brain Metastases 

A review of the surgical literature reveals, as expected, a steadily increasing median survival over the last couple of decades, reducing overall morbidity and a gradual trend toward expansion of the indications for surgical resection of melanoma brain metastases.

Sampson et al. (1999) reviewed 702 patients with melanoma brain metastases and showed a doubling of survival time if a metastasis was resected when compared to WBRT alone ( 8.2 months vs 4.2 months). Around $50 \%$ reported improvement of symptoms. However the neurological deficit rate following surgery was $22.4 \%$ and the risk of death within 30 days was $8.6 \%$.

Wronski and Arbit (2000) reported a median survival of 6.7 months after surgical resection in a smaller series of 91 patients. The vast majority of patients had a single lesion $(n=76)$. Median hospital stay was 14 days. However, in the last 3 years of the study, hospital stay had fallen to 7 days (1991-1994). Central nervous system (CNS) complications occurred in $18.7 \%$ of patients and $14.2 \%$ died within 30 days of surgery.

Zacest et al. (2002) reviewed 147 patients. Again, the vast majority had a single metastasis ( $84 \%$ ). Median survival was 8.5 months, comparable to the previous 2 studies. The striking difference was their surgical morbidity of $8 \%$ and 30 day mortality rate of $2 \%$. Around $78 \%$ of patients reported improvement in their symptoms. This group described their surgical technique and stated that in the last 5 years of their study neuronavigation was used routinely, reducing postoperative complications and reducing hospital stay from 14 days to 6 days.

In recent times, there have been few surgical studies pertaining exclusively to melanoma brain metastases. However, surgical techniques for resection of all brain metastases are largely interchangeable. Paek et al. (2005) published the results of surgical management of 208 patients with brain metastases treated between 1998 and 2002. Both the 30 day mortality rate and the neurological complication rate were low ( $1.9 \%$ and $6 \%$ respectively). Median survival time in this mixed group was 8 months.

A study reported in 2004 by Stark et al. is also worthy of note. Again it was a review of a mixed group of tumors. However, the series does provide some insight into expanding patient selection to include the elderly, those with multiple metastases with significant extracranial disease and patients with recurrence of brain metastases. A total of 177 patients were reviewed. None of them had melanoma. Perioperative mortality for those $>70$ years of age was $18.2 \%$, while survival was significantly lower for those $>70$ and for those who had $>3$ lesions. However, reoperation for recurrence was associated with a statistically significantly higher survival.

The surgical literature described above indicates that median survival rates have remained fairly static, at around 8-9 months after surgery. Surgical resection has been repeatedly proven to be superior to WBRT alone. The relatively static survival figures must therefore be due to the lack of progress in controlling extracranial disease. All the studiesshowed a clear-cut advantage for those with single lesions and controlled systemic disease. Although those with multiple lesions and the elderly still have a dismal prognosis, there have certainly been incremental gains with regard to neurological deficits, hospital stay and perioperative mortality as surgical technique and precision have improved.

# Current Indications for Surgical Management of Melanoma Brain Metastases 

In recent times the decision-making climate has changed considerably for the treatment of melanoma brain metastases. Traditionally, patients were usually referred for neurosurgical management when symptoms of the problem became apparent. However, high risk patients now routinely undergo whole body imaging and it is not uncommon for incidental, asymptomatic brain metastases to be discovered. Lesions $<1 \mathrm{~cm}$ in diameter are generally not appropriate for surgical resection due to limitations of stereotactic navigation systems. These small lesions are therefore best targeted with SRS. However, with the advent of several new drug trials for systemic disease, the surgeon may be called upon to resect these lesions in order for the patient to be rendered disease free in the brain, and thereby become eligible to enrol in a trial. Patients with multiple small metastases are often treated with SRS. With increased use of SRS, we are now seeing adverse effects of this treatment more commonly. Surgery is often necessary to deal with these events. The complications include radionecrosis and post-SRS hemorrhage (Long et al., 2010), both of which can cause mass effect and neurological deficit. Progression of disease after SRS is another indication for surgical resection in the current climate. We have recently entered the era of targeted therapies and immune-mediated therapies that may cross the blood-brain-barrier (BBB) and penetrate the CNS, thereby providing an additional modality of treatment. This may reduce the need for surgery for some tumors. However, the complication profile of these new agents is yet to be defined (Shapiro and Samlowski, 2011) and surgery remains the gold standard for treatment of melanoma metastases in the brain.

## Technical Aspects of Surgical Resection of Melanoma Brain Metastases

The single most important factor when considering surgery for metastatic disease in the brain is its precise location. Surgery in eloquent areas of the brain can result in significant neurological deficit that impairs the individual's quality of life, which is of paramount concern since life expectancy is generally limited. Most metastases that cause symptoms such as headache, focal deficit or seizure produce a considerable amount of vasogenic edema with mass effect. It is therefore important that the patient be stabilized with high dose dexamethasone, and anticonvulsants if needed. In those who have not experienced seizures, there appears to be no role for the use of prophylactic anticonvulsants (Cohen et al., 1988; Glantz et al., 1996).

Once the patient is stabilized, adequate imaging is required to accurately delineate the location of the lesion(s). The gold standard is MRI examination with and without contrast. This not only defines the location but also confirms the true number of lesions. Adjuncts to standard MRI are functional MRI (fMRI) and diffusion tensor imaging (DTI). With considerable reliability fMRI can map out the motor cortex and speech areas and their relationship to the tumor (Bizzi et al., 2008). DTI visualizes the deep white matter tracts andtheir relationship to the lesion. In addition, a multiplanar rapid acquisition gradient echo (MPRAGE) sequence is essential for intraoperative neuronavigation. Furthermore, fMRI and DTI images may be fused with MPRAGE images and used intraoperatively to avoid eloquent areas during resection of metastatic lesions (Hamid et al., 2013b; Lyle and Long, 2014).

Most patients may be admitted on the day of surgery. With the use of stereotactic navigation, incorporating the above imaging techniques, it is possible to resect metastatic lesions in a minimally invasive fashion using a small linear incision and mini craniotomy. This technique facilitates the resection of numerous lesions, often under the same anesthetic (Chang and Adler, 2000). After inducing general anesthesia, the patient is positioned on the operating table with the head rigidly secured in pins. The frameless stereotactic system with the preoperative images is then registered. Using the navigation probe, the position of the lesion(s) can be marked on the scalp, followed by an appropriately sized linear incision. A minimal shave is performed, the head is prepared and draped, and sterile components of the frameless navigation system are attached.

A linear incision is made and the pericranium is stripped away. A mini craniotomy is then performed and the dura is opened with a cruciate or curved incision. The operating microscope is then introduced to facilitate microsurgical dissection of the lesion. Stereotactic navigation is indispensable at this stage as it ensures a direct trajectory to the lesion via a safe route that avoids eloquent areas. A microsurgical technique is used to circumferentially dissect the lesion and remove it whole. Melanoma is often highly vascular. Internal debulking therefore can lead to significant blood loss and so should be avoided if possible. However, in lesions into which hemorrhage has occurred, it is often advantageous to first evacuate the clot within and outside the lesion to facilitate circumferential dissection. The most important advantage of circumferential dissection and en bloc resection is that it allows identification and cautery of arterial feeders and draining veins. The plane between brain and tumor is usually quite distinct.

After excision of the lesion, meticulous attention is paid to hemostasis. It is often necessary to line the tumor cavity with Surgicel to achieve hemostasis. In the hemostatic phase of the operation, the anesthetist is also instructed to raise the patient's systolic BP to a level that is approximately 20 mm Hg higher than the resting BP. Closure of the dura is then carried out and the bone flap is secured with titanium plates. Any large areas of bony defect can be further sealed with acrylic cranioplasty to give a better cosmetic result. Finally, the skin is opposed with galeal sutures, and the skin closed with a subcuticular absorbable suture.

When anesthesia is reversed at the conclusion of the procedure, the patient is assessed for possible deficits. The patient is observed in a high dependency environment for the next 24 h , and a CT or MRI performed at this stage to assess for postoperative hematoma, edema and most importantly to confirm complete resection. Most patients who undergo uncomplicated surgery as described above may be discharged home with 2-5 days of their surgery.

# Complications Following Surgical Resection of Melanoma Brain Metastases 

Complications are rare but can be devastating when they do occur. Postoperative mortality may be caused by postoperative hemorrhage in the tumor bed or in a distant fashion from a separate metastasis. Neurological deficit may occur after the resection of tumorsin eloquent areas. However, generally these tumors caused a deficit preoperatively and the deficit improves postoperatively as the mass effect is relieved. Occasionally temporary worsening is noted. Surgery itself can provoke seizures. Again, the seizure tendency is higher preoperatively due to edema and mass effect. Other postoperative complications include infections, hydrocephalus, and general systemic complications that may be associated with operative procedure.

# RADIATION THERAPY FOR MELANOMA BRAIN METASTASES 

The management of metastatic melanoma in the brain depends on the combination of patient, tumor and treatment factors. The dominant factor determining management has been the number of cerebral metastases. With the wider availability of SRS enabling the effective treatment of multiple metastases in a single treatment session, the absolute number of cerebral metastases is now less important than previously. Reports increasingly suggest that the use of SRS to treat multiple metastases may have merit, particularly if there are less than 10 lesions, all under 3 cm in size and with limited edema or mass effect (DiLuna et al., 2007; Groves, 2008; Samlowski et al., 2007). Recent data suggest that the total volume of the metastatic lesions rather than the number of metastases was the limiting factor for SRS technique (Lippitz et al., 2014). The Radiation Therapy Oncology Group (RTOG) Recursive Partitioning Analysis (RPA) Classes have been validated in melanoma (Breneman et al., 1997).

For patients with a single metastases or oligometastases, management depends on age, performance status, neurologic status, characteristics of the metastases (number, size, and location), and the extent of extracranial disease. Patients in the RPA class 3 (performance status, Karnofsky Performance Score $<70 \%$ ) is generally managed with steroids in conjunction with WBRT. Those with more favorable characteristics are considered for more aggressive local treatment of the individual metastasis. The local treatment options are surgical excision or SRS. Surgery has a role in confirming the diagnosis histologically, especially when there is no clear relationship between a primary melanoma and the development of brain metastasis. Surgical excision can also provide quick relief of symptoms associated with disease.

## Single Metastasis or Oligometastatic Disease: The Role of Stereotactic Radiosurgery

The term "radiosurgery" was originally coined by Lars Leksell to describe the use of a multisource cobalt system (Gamma Knife) to deliver radiation to a defined target using stereotactic principles. It aims to deliver a single dose of ablative radiation to the brain metastasis while limiting the dose to surrounding normal tissue. Historically, this has relied on frame-based stereotactic approaches that can accurately localize the tumor and target the beam in three-dimensional space. Options now include frameless, image-guided approaches, such as fixed beam intensity modulated radiotherapy, helically delivered intensity modulated radiotherapy, and image guided robotic radiosurgery. Arc based intensity modulated radiotherapy techniques can also achieve highly conformal image guided treatment in very short treatment times (Mayo et al., 2010). However, there are no randomized data showing clear superiority of any one SRS system.The dose of SRS depends on the size of the target lesion and its location. The RTOG 90-05 study was designed to determine the maximum tolerable dose of SRS in patients with recurrent, previously irradiated brain metastases (excluding lesions in the brain stem) (Shaw et al., 2000). The maximum tolerable doses of single fraction radiosurgery for these patients were $24 \mathrm{~Gy}, 18 \mathrm{~Gy}$, and 15 Gy for tumors $\leq 20 \mathrm{~mm}, 21-30 \mathrm{~mm}$, and $31-40 \mathrm{~mm}$ in maximum diameter, respectively.

Mathieu et al. (2007) from the University of Pittsburgh reviewed their experience with 244 patients who had 754 melanoma metastases treated with Gamma Knife radiosurgery without adjuvant WBRT. Local control was achieved in $86.2 \%$ of the metastases. Overall, 54 patients ( $30.9 \%$ ) had progression of at least one metastasis after radiosurgery. The median time to progression was 2.9 months. Fifty-one patients ( $24.8 \%$ ) underwent WBRT after radiosurgery because of the development of multiple new brain lesions. Multiple lesions and failure to provide systemic immunotherapy were predictors for the occurrence of new brain metastases, which developed in $41.7 \%$ of the patients. Progressive cerebral disease was the cause of death in $40.5 \%$ of the patients. Corticosteroids were not needed or were discontinued after radiosurgery in $52.4 \%$ of the patients. On multivariate analysis, the use of WBRT was not a factor that influenced local control or distant intracranial control ( $P=0.061$ ). A more recent update of the University of Pittsburgh's experience on 333 consecutive patients with 1570 metastatic melanoma lesions treated with Gamma Knife radiosurgery showed the long-term local control rate was $73 \%$ and the actuarial survival rates were $70 \%$ at 3 months, $47 \%$ at 6 months, $25 \%$ at 12 months, and $10 \%$ at 24 months (Liew et al., 2011). About $25 \%$ of 259 patients who had follow-up imaging after SRS had evidence of delayed intratumoral hemorrhage. Factors associated with longer survival included controlled extracranial disease, better performance status, fewer brain metastases, no prior use of WBRT or chemotherapy, treatment with immunotherapy, and no intratumoral hemorrhage before radiosurgery.

The potential morbidity of SRS includes progression or worsening of cerebral edema (symptomatic in 4-6\% of patients within 1-2 weeks of treatment), seizures within 1-2 days (in 2-6\%) and delayed radiation necrosis (in 2-11\%) (Breneman et al., 1997; Shaw et al., 2000; Shiau et al., 1997). This risk of delayed radiation necrosis increases with prior treatment, larger volumes treated (both larger lesions and larger numbers of lesions) and larger doses delivered.

# Single Metastases or Oligometastatic Disease: The Role of Whole Brain Radiation Therapy in Melanoma After Local Treatment of Metastases 

The role of WBRT after surgery or SRS for single metastases or oligometastatic disease is controversial and there is currently no level 1 evidence for guidance. The rationale of WBRT is to treat residual microscopic disease at the site of initial metastasis and elsewhere in the brain, to maintain long-term cerebral control. Adjuvant systemic therapy is generally not used as the brain is considered a sanctuary site for chemotherapy, although this assumption has been challenged recently by responses in the patients with BRAF mutant melanoma treated with BRAF inhibitors (Long et al., 2010). Opponents of WBRT argue that melanoma is radioresistant and that WBRT can potentially cause late neurocognitive deficits. The Australia and New Zealand Melanoma Trials Group (ANZMTG) and the Trans-TasmanRadiation Oncology Group (TROG) are currently conducting a phase 3 randomized trial (WBRTMel trial) to address the role of WBRT after local treatment of 1-3 melanoma brain metastases (Fogarty et al., 2011). Eligible patients are randomized to WBRT ( 30 Gy in 10 fractions) or observation. The primary end point of the trial is intracranial disease control. This trial also includes detailed neurocognitive and quality of life assessments. Until this trial is completed and reported, clinicians will have to rely on data from other randomized trials that included patients with metastatic disease from all histologies.

Several randomized studies including brain metastases from all histologies have provided good evidence for the use of WBRT after local treatment of oligometastases in terms of improved intracranial control. However, the number of patients with melanoma in these trials has been small. Aoyama et al. (2006) compared WBRT and SRS ( 65 patients) to SRS alone in patients with 1-4 brain metastases of any histology. Over $65 \%$ of the patients had metastatic lung cancer, but the number of melanoma patients per arm was not mentioned. The WBRT dose was 30 Gy in 10 fractions over 2 weeks. There was no difference between the two groups with respect to overall survival (OS), neurological toxicity, neurological functional preservation, and neurocognitive function or neurological death. The median survival time was 7.5 months with WBRT plus SRS compared to 8 months with SRS alone. The 12-month actuarial brain tumor local recurrence rate was $46.8 \%$ in the WBRT plus SRS group and $76.4 \%$ in the SRS alone group ( $P=0.001$ ). Fifty-five patients had new brain metastases at distant sites ( 21 in the WBRT plus SRS group and 34 in the SRS-alone group). The 12-month actuarial rate of developing distant brain metastases was $41.5 \%$ in the WBRT plus SRS group and $63.7 \%$ in the SRS-alone group ( $P=0.003$ ). Univariate analysis showed that patients with 2-4 metastases had a higher risk of developing distant intracranial disease than those with single metastasis ( $P=0.03$ ), but this did not reach significance on multivariate analysis $(P=0.06)$.

More recently, the EORTC reported a randomized trial of 359 patients with 1-3 brain metastases from all solid tumor types randomized to either observation or WBRT of 30 Gy in 10 fractions after local treatment (surgery or SRS) (Kocher et al., 2011). The majority of patients ( $53 \%$ ) had primary lung cancer and only $5 \%$ had metastatic melanoma. After surgery, at 2 years, WBRT significantly reduced the probability of relapse at the initial site (from $59 \%$ to $27 \%, P=0.001$ ) and at distant intracranial sites (from $42 \%$ to $23 \%, P=0.008$ ). After SRS, WBRT reduced the probability of relapse at initial sites from $31 \%$ to $19 \%(P=0.04)$ and at distant intracranial sites from $48 \%$ to $33 \%(P=0.023)$ at 2 years. The median progressionfree survival was slightly longer in the WBRT arm compared with the observation arm (4.6 months vs 3.4 months; $P=0.02$ ) but there was no difference in OS between the two arms. Eighty-one percentage of the patients had a single metastasis but there was no analysis of one versus more than one metastasis. This trial included neurocognitive and the quality of life assessments which have not yet been reported.

There are a number of retrospective, single institution series in melanoma patients, with their inherent selection biases. Fife et al. (2004) reviewed the outcomes of 686 patients treated at the Sydney Melanoma Unit (now Melanoma Institute Australia). There was no significant difference in the median survival between the 158 patients treated with surgery and WBRT and the 47 patients treated with surgery alone ( 8.9 months vs 8.7 months, $P=0.21$ ). Sampson et al. (1998) also reported no difference in median survival for patients treated with WBRT after surgery or surgery alone patients (median survival of 9 months,$P=0.99$ ). However, patients treated with WBRT were more likely to remain without neurological deficits or experience an improvement ( $81.7 \%$ ) after completion of therapy than those who did not $(57.7 \%, P=0.01)$.

Selek et al. (2004) reported results for 103 patients with 153 intracranial melanoma metastases treated with SRS. Sixty-one patients (59\%) had a single brain metastasis. Treatment was SRS alone ( 61 patients), SRS with WBRT ( 12 patients) and salvage SRS after WBRT ( 30 patients). The overall incidence of distant brain metastasis-free survival did not differ significantly between the group that received initial SRS alone and the group that received SRS and WBRT ( $17.6 \%$ vs $0 \%, P=0.27$ ). However this study did not have the statistical power to detect a difference in distant brain metastasis-free survival. The initial number of brain lesions (single vs multiple) was the only factor with a significant effect on distant brain metastasis-free survival at 1 year: $23.5 \%$ for single metastases and $0 \%$ for multiple lesions ( $P<0.05$ ). Samlowski et al. (2007) performed a retrospective analysis of 44 patients with melanoma who had $\leq 5$ brain metastases treated with SRS and showed that the addition of WBRT did not improve survival. Buchsbaum et al. (2002) reviewed 74 patients with melanoma brain metastases. Survival analysis showed that combined local treatment and WBRT offered significantly better survival ( $P<0.0001$ ), with a median survival of 8.8 months for the combined therapy group, 4.8 months for the local therapy alone group.

The MD Anderson Cancer Center reported a series of patients with solitary melanoma brain metastases and no extracranial disease (Skibber et al., 1996). Twenty two patients received surgical excision and WBRT and 12 patients were treated with surgery alone. Despite the small sample size, the intracranial recurrence rates favored the combination therapy ( $5 / 22$ vs $9 / 12$ surgery alone, $P=0.01$ ). Median OS was 18 months in the combination therapy group versus 6 months for surgery alone ( $P=0.002$ ). These data indicate that WBRT can decrease intracranial progression and may even convey a survival benefit in patients without active extracranial disease as a competing cause of death.

# Minimizing the Risk of Neurological Deficit Following Whole Brain Radiation Therapy: Hippocampal Sparing 

One of the concerns about delivering WBRT after local treatment of oligometastases is the potential neurological deficit. Preclinical and early clinical evidence suggests that the neural stem cell compartment in the hippocampus is central to the pathogenesis of neurocognitive deficits observed after cranial irradiation. Modern intensity modulated radiotherapy technologies, such as helical tomotherapy and volumetric modulated arc therapy, can conformally avoid the hippocampus during WBRT and therefore potentially reduce the risk of neurocognitive deficit. The RTOG has recently completed a phase II clinical trial (RTOG 0933) that confirmed the benefit of hippocampal sparing during WBRT in patients with brain metastases (Gondi et al., 2013). At 4 months the mean relative decline in HVLTdelayed recall from baseline was $7 \%$ ( $95 \% \mathrm{CI},-4.7$ to $18.7 \%$ ) and this was significantly less than the historical control value of a $30 \%$ decline ( $P=0.0003$ ). This phase 2 trial was based on an estimated risk of a metastasis in the hippocampal region of $8.6 \%$ in 371 patients with $1-10$ metastases from all primary histologies (Gondi et al., 2010). In the study, patients with melanoma $(n=47)$ had a $14.9 \%$ risk of a metastasis within 5 mm of the hippocampi with a trend toward significance $(P=0.06)$ in the logistic regression analysis. Recently, theANZMTG reviewed the location and proximity of 115 metastases in 77 patients who were eligible for the WBRTMel trial. Only four patients ( $5.2 \%$ ) had metastases within 5 mm of the hippocampi and the median distance from metastasis to the nearest hippocampus was 37.2 mm (Hong et al., 2014). Based on the low risk of a melanoma metastasis within the hippocampal region, WBRT with hippocampal sparing is now permitted in the WBRTMel trial.

# Multiple Metastases: The Role of Whole Brain Radiation Therapy 

Patients with multiple melanoma brain metastases are generally not suitable for aggressive local treatment. The prognosis is often poor, with the majority succumbing to progressive intracranial metastases within a few months, irrespective of treatment. Application of the RTOG recursive partitioning analysis to 74 patients with cerebral metastases from melanoma produced median survivals of 10,6 , and 2 months, respectively, for RPA Classes I-III, with a median survival of 5.5 months for the entire group (Buchsbaum et al., 2002).

Initial management includes the use of corticosteroids to reduce cerebral edema, typically $4-16 \mathrm{mg}$ of dexamethasone daily. This results in rapid symptomatic, but often shortterm, improvement in approximately $50 \%$ of patients. WBRT may produce a small survival advantage compared with steroids alone and may allow reduction in the steroid dose. In addition to WBRT, surgical removal or SRS of a dominant or symptomatic lesion should be considered. Conversely, patients with a poor performance status who have not responded to steroids may be better managed with supportive care only.

The technique of WBRT involves a pair of parallel-opposed lateral 6MV photon fields. Commonly used regimens are 20 Gy in 5 fractions and 30 Gy in 10 fractions. For good performance patients with minimal extracranial disease, there might be an advantage for a higher dose of WBRT based on a retrospective study (Rades et al., 2010). Rades et al. (2010) compared the outcomes of 33 patients treated with 30 Gy in 10 fractions with 18 patients treated with higher doses ( 40 Gy in 20 fractions or 45 Gy in 15 fractions). In the multivariate analysis, higher doses $(P=0.010),<4$ brain metastases $(P=0.012)$, no extracranial metastases $(P=0.006)$ and RPA class 1 status $(P=0.005)$ were associated with improved OS.

## The Current Role of Radiation Therapy in Melanoma Brain Metastases

Brain metastasis is a common development in patients with metastatic melanoma. To provide optimal management of the patient with melanoma, the radiation oncologist must be an integral part of the multidisciplinary team. Although there have been no completed, large scale randomized trials in patients with melanoma brain metastases, treatment can be guided by the evidence for the treatment of brain metastases in general. A new approach that delivers radiation therapy while sparing the hippocampi will hopefully improve the therapeutic ratio and minimize potential neurocognitive toxicity.

## SYSTEMIC THERAPIES FOR MELANOMA BRAIN METASTASES

Until recently, systemic therapy had a very limited role in the management of melanoma brain metastases due to a lack of activity. This was partly attributed to the BBB, whichTABLE 5.1 Clinical Trials of New Systemic Therapies in Active Melanoma Brain Metastases

| Trial | Phase | Treatment | Pts with BM (n) |  | Brain ORR (\%) | Median PFS (weeks) ${ }^{a}$ | Median OS (weeks) ${ }^{a}$ |
| :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: |
| Margolin et al. (2012) | 2 | Ipilimumab | Cohort A | 51 | 16 | 6.1 | 30.3 |
|  |  |  | Cohort B | 21 | 5 | 5.2 | 16.0 |
| Long et al. (2012) | 2 | Dabrafenib | Cohort A V600E | 74 | 39 | 16.1 | 33.1 |
|  |  |  | Cohort A V600K | 15 | 7 | 8.1 | 16.3 |
|  |  |  | Cohort B V600E | 65 | 31 | 16.6 | 31.4 |
|  |  |  | Cohort B V600K | 18 | 22 | 15.9 | 21.9 |
| Dummer et al. (2014) | Pilot | Vemurafenib | 24 |  | 16 | 16.9 | 23.0 |
| Kefford et al. (2013) | 2 | Vemurafenib | Cohort 1 | 90 | 18 | 16.0 | 28.0 |
|  |  |  | Cohort 2 | 56 | 20 | 17.5 | 27.8 |

[^0]impairs drug delivery to the brain by acting as a physical barrier and by expression of active efflux transporters, such as $P$-glycoprotein and breast cancer resistance protein (BCRP) (Mittapalli et al., 2013). The lack of activity was also due to the relative resistance of melanoma to chemotherapy, whether the metastases were extracranial or intracranial. Thus, historically, local therapies (neurosurgery, SRS, and WBRT) have been the mainstays of treatment, and systemic therapy has been reserved for patients who have failed local therapy or who have had extensive extracranial disease and/or poor performance status.

The situation has now changed, recent studies having demonstrated the efficacy of newer targeted therapies and immunotherapy in patients with melanoma brain metastases. Now, more than ever, clinical trials are needed in patients with active brain metastases (i.e., untreated or progressing after local treatment) to answer questions regarding combining or sequencing systemic therapies with local therapies. In this section new systemic therapies for metastatic melanoma and their evolving role in the management of brain metastases (see Table 5.1) will be discussed.

# Chemotherapy 

Fotemustine and temozolomide are two chemotherapy agents that were trialed in patients with melanoma brain metastases based on preclinical evidence of their ability to cross the BBB, and their activity in extracranial metastatic melanoma. However, both agents showed disappointing results in these clinical trials. A phase 2 study of temozolomide in 151 patients with melanoma brain metastases, not previously treated with radiotherapy, showed a brain objective response rate (RR) of only 6\% (Agarwala et al., 2004). A randomized phase 3 study of fotemustine including 43 patients with active brain metastases demonstrated a

## I. MOLECULAR MECHANISMS

[^0]:    BM, brain metastases; ORR, objective response rate (i.e., complete response+ partial response); PFS, progression free survival; OS, overall survival.
    ${ }^{a}$ Any survival time reported in months was converted to weeks.brain RR of only $5.9 \%$, which was significantly better than the brain RR of $0 \%$ observed in the dacarbazine arm (Avril et al., 2004).

# Small Molecule Targeted Therapies: BRAF, MEK, and KIT Inhibitors 

Somatic molecular aberrations and oncogenic mutations continue to be identified in melanoma and offer the potential for new drug targets (Hodis et al., 2012). Currently, there are three mutually exclusive mutations for which there are targeted therapies available; BRAF $(\sim 40 \%)$, NRAS ( $\sim 20 \%$ ), and KIT ( $\sim 2 \%$ ) (Long et al., 2011; Menzies et al., 2012; Jakob et al., 2011; Lyle and Long, 2013). These driver oncogenic mutations may predict a higher risk of brain metastases. In a large retrospective study of clinicopathological correlates of melanoma mutations, only $12 \%$ of patients who were wild-type for both BRAF and NRAS had brain metastases at the time of stage IV diagnosis compared with $24 \%$ and $23 \%$ of patients with BRAF or NRAS respectively (Jakob et al., 2012).

Only targeted BRAF inhibitors have been studied specifically in patients with active melanoma brain metastases. Currently, there is no evidence available that KIT inhibitors (including imatinib, nilotinib, and dasatinib) have any activity in brain metastases. MEK inhibitors have not been trialed in patients with active brain metastases, although single agent MEK inhibitor therapy has activity in both BRAF (Kim et al., 2013) and NRAS mutated extracranial metastases (Ascierto et al., 2013).

## BRAF Inhibitors: Dabrafenib and Vemurafenib

A phase 1 study of the BRAF inhibitor dabrafenib included a cohort of 10 patients with untreated, asymptomatic brain metastases; four patients had a brain complete response (CR) and four had a brain partial response (PR) (Falchook et al., 2012). These results led to the BREAK-MB open label, phase 2 trial to further quantify the level of activity in patients with active brain metastases (Long et al., 2012). One hundred and seventy-two patients with BRAF $^{\mathrm{V} 600 \mathrm{E}}$ or BRAF $^{\mathrm{V} 600 \mathrm{~K}}$ mutated metastatic melanoma and at least one measurable brain metastasis ( $5-40 \mathrm{~mm}$ max diameter) were treated with oral dabrafenib 150 mg twice a day. Cohort A included 89 patients who had not received previous local treatment and cohort B enrolled 83 patients whose brain metastases had progressed after prior local treatment. A modified form of Response Evaluation Criteria in Solid Tumors (RECIST) was used to assess response and allowed up to five intracranial and five extracranial target lesions.

The primary endpoint of this study was the intracranial objective RR (CR + PR) in patients with BRAF $^{\mathrm{V} 600 \mathrm{E}}$ mutated melanoma; this was $39 \%(29 / 74)$ in cohort A and $31 \%$ $(20 / 65)$ in cohort B. The RRs were lower for those with V600K mutations; $7 \%(1 / 15)$ and $22 \%(4 / 18)$ for cohorts A and B respectively. The global disease control rate was approximately $80 \%$ for those with V600E and $50 \%$ for patients with V600K mutations. The toxicities were as expected based on previous trials of dabrafenib (Falchook et al., 2012); 26\% of patients experienced pyrexia and $6 \%$ developed cutaneous squamous cell carcinomas. The number of intracranial hemorrhages was lower than the reported rate of spontaneous hemorrhage (up to $40 \%$ ) for melanoma brain metastases (Raizer et al., 2008).

Vemurafenib is another effective BRAF inhibitor (Chapman et al., 2011; Sosman et al., 2012) that has been trialed in patients with Cobas mutation-positive metastatic melanoma, that is, predominantly BRAF $^{\mathrm{V} 600 \mathrm{E}}$. It showed activity in a pilot study of 24 patients withmelanoma brain metastases who were refractory to all previous treatments (Dummer et al., 2014), with an acceptable safety profile (the primary end point). An overall PR was observed in $42 \%$ of patients $(10 / 24)$, and $16 \%$ of evaluable patients $(3 / 19)$ achieved an intracranial objective response.

In a phase 2 study of vemurafenib in 146 patients with Cobas mutation-positive metastatic melanoma and active brain metastases, patients without previous local treatment for brain metastases had an intracranial RECIST RR of $18 \%(16 / 90)$ by independent review (primary endpoint) (Kefford et al., 2013). A similar RR of $20 \%(11 / 56)$ was seen in those who had progressed in brain metastases after prior local therapy. The median progression free survival and OS were 3.7 and 6.5 months respectively in those with no prior local therapy, and 4.0 and 6.4 months in those with prior local therapy. The study showed a safety profile consistent with previous experience with vemurafenib, including toxicities such as arthralgia, rash, cutaneous squamous cell carcinomas, and photosensitivity.

It is important to note that evaluation of vemurafenib in clinical trials has been restricted to patients with a positive Roche Cobas 4800 BRAF V600 mutation test, an allele-specific PCR-based test for the BRAF $^{\mathrm{V} 600 \mathrm{E}}$ mutation, therefore efficacy of this drug in other mutation types is unclear. In contrast, dabrafenib has been studied in patients with both BRAF V600E and BRAF V600K mutations. In a retrospective study, both vemurafenib and dabrafenib have demonstrated activity in the rare BRAF V600R mutation, including responses in brain metastases with dabrafenib (Klein et al., 2013a,b).

In terms of trials of concurrent targeted therapy and local treatments, dabrafenib combined with SRS in BRAF V600E mutated metastatic melanoma is currently under investigation (NCT01721603), and the primary outcome is the 6 month, distant brain metastasis-free survival (Table 5.2). A recently published retrospective series of 12 patients treated with vemurafenib in sequence or conjunction with radiotherapy (SRS and/or WBRT) for melanoma brain metastases, with no evidence of active brain metastases, showed CR or PR in 36 of $48(75 \%)$ index lesions assessed (Narayana et al., 2013). The median survival was 13.7 months and there was one case of radionecrosis. These results must be interpreted with caution as the study was very small, retrospective, and many patients underwent pretreatment with neurosurgery and/or systemic therapy (e.g., with ipiliumumab), without proven evidence of active or progressing brain metastases on commencing vemurafenib. Additionally, radiosensitization and radiation recall have been reported at extracranial sites treated with radiotherapy in patients receiving vemurafenib (Anker et al., 2013; Boussemartet al., 2013), and this raises concerns about the possibility of similar toxicities in the setting of brain metastases.

This impressive clinical activity of BRAF inhibitors in brain metastases has been seen despite preclinical studies showing impaired brain distribution due to active efflux by $P$-glycoprotein and BCRP at the BBB (Mittapalli et al., 2012, 2013). Preclinical studies have demonstrated greater brain penetration of dabrafenib compared with vemurafenib (Mittapalli et al., 2013), although it is unclear if this translates to a difference in the clinical situation.

Superior activity of combined BRAF and MEK inhibition over single agent BRAF inhibition was observed in patients with systemic melanoma metastases in a phase $1 / 2$ study (Flaherty et al., 2012), and the results from phase 3 trials are awaited (NCT01584648, NCT01597908). The combination was approved for use in 2014 for BRAF V600 mutatedTABLE 5.2 Upcoming or Current Clinical Trials of New Systemic Therapies in Active Melanoma Brain Metastases

| NCT | Phase | Treatment | Endpoint(s) |
| :--: | :--: | :--: | :--: |
| NCT01721603 | 2 | Dabrafenib and SRS | 6-month, distant brain metastasis-free survival |
| NCT01978236 | 1 | Neoadjuvant dabrafenib +/- trametinib followed by resection of brain metastasis | Pharmacokinetics, pharmacodynamics, exploratory translational research, and safety endpoints |
| NCT02039947 | 2 | Dabrafenib and trametinib | Safety and efficacy |
| NCT01703507 | 1 | Ipilimumab and WBRT or SRS | Safety and dosing |

[^0]metastatic melanoma and is now a new standard of care. None of the trials to date have included patients with active brain metastases, however a phase 2 trial of combination dabrafenib and trametinib therapy in this setting is planned (Table 5.2). In addition, a translational study will be performed in which patients will be treated with neoadjuvant dabrafenib + / -trametinib, followed by resection of a brain metastasis at day $7-14$ to further understand the activity of these agents in the brain (NCT01978236).

# Immunotherapy 

## Interleukin-2

The role of Interleukin-2 (IL-2) in patients with active melanoma brain metastases appears to be limited, although it has been used in highly selected patients with metastatic melanoma with a good performance status and no brain metastases (Atkins et al., 1999, 2000; Rosenberg et al., 1994). A retrospective series showed some activity in those with pretreated brain metastases but little benefit in a previously untreated cohort (Guirguis et al., 2002). Seven patients with brain metastases at the time of commencement of IL-2 therapy all demonstrated progressive disease as best response in a more recent retrospective series (Chu et al., 2013).

## Check Point Inhibitors: CTLA-4 Inhibition and PD-1/PDL-1 Axis Inhibition

The CTLA-4 antibody ipilimumab improves the OS of patients with metastatic melanoma (Hodi et al., 2010; Robert et al., 2011) and also has activity in active brain metastases (Margolin et al., 2012). In a phase 2 trial 72 patients with melanoma brain metastases were treated with initial induction of four infusions of ipilimumab $10 \mathrm{mg} / \mathrm{kg}$ every 3 weeks followed by 12 weekly maintenance infusions in patients who were clinically stable at 24 weeks (this differs from the currently approved dose and schedule for ipilimumab in many countries). Patients were enrolled in two cohorts; cohort A consisted of patients with asymptomatic brain metastases and cohort B consisted of patients requiring steroid therapy to control neurologic symptoms or cerebral edema. The primary endpoint of the trial was the proportion of patients with global disease control (CR + PR + stable disease (SD))


[^0]:    NCT, National Clinical Trial number (clinicaltrials.gov); N/A, not applicable (no NCT number allocated); SRS, stereotactic radiosurgery; WBRT, whole brain radiotherapy.after 12 weeks, assessed by modified World Health Organization (mWHO) criteria, and the results were $18 \%(9 / 51)$ in cohort A but only $5 \%(1 / 21)$ in cohort B. The RR increased to $25 \%$ $(13 / 51)$ and $10 \%(2 / 21)$ in cohorts A and B, respectively, using the immune-related response criteria (irRC) (Wolchok et al., 2009). The reported brain objective RR was $16 \%(8 / 51)$ in cohort A and only $5 \%(1 / 21)$ in cohort B. The median OS in cohort A was 7.0 months, however the 24 month OS rate was $26 \%$, demonstrating the potential for durable responses as is seen in a subset of ipilimumab-treated patients without brain metastases. In cohort B, median OS and 24 month survival were only 3.7 months and $10 \%$ respectively. The most common adverse events included fatigue, diarrhea, nausea, headache, rash, and pruritus, consistent with previous experience with ipilimumab (Hodi et al., 2010; Robert et al., 2011).

A phase 2 study of ipilimumab combined with fotemustine, including some patients with asymptomatic brain metastases, showed an irRC global disease control rate of $46.5 \%$ $(40 / 86)$ overall and $50 \%(10 / 20)$ in those with brain metastases (Di Giacomo et al., 2012). A randomized phase 3 trial (NIBIT-M2; CA184-192) of this combination is planned. A two arm, phase 1 study to investigate the safety and dosing of ipilimumab in combination with WBRT and SRS in patients with melanoma brain metastases (NCT01703507) is currently underway (Table 5.2).

Anti-PD1 antibodies are a new class of checkpoint inhibitors. These agents act by blocking the interaction between the Programmed Death 1 (PD-1) receptor, expressed on T cells, and a ligand, PD-L1, expressed on tumor cells. Blocking this interaction prevents inactivation of T cells at the tumoral level and augments the antitumor immune response. Two agents in this class, nivolumab (BMS-936558) and MK-3475, have shown promising activity and durable responses in metastatic melanoma (Hamid et al., 2013a; Topalian et al., 2012) and there are ongoing phase 3 studies (NCT01866319, NCT01721772), including a study of nivolumab combined with ipilimumab (NCT01844505). A PD-L1 antibody (MPDL3280A) has also recently shown activity in metastatic melanoma, with a RR of $29 \%$ in a phase 1 study (Hamid et al., 2013a). There are currently no published data on the activity of PD-1 antibodies in active brain metastases, however, trials of these agents in this patient population are planned.

# Suggested Approach to Management 

A suggested approach to management of patients with melanoma brain metastases, incorporating local and systemic therapies, was published recently (Lyle and Long, 2014). Enrolment in a clinical trial, if available, is recommended for all patients with metastatic melanoma. Management should be discussed by a multidisciplinary team, with consultation between surgical oncologists, neurosurgeons, radiation oncologists, medical oncologists, and others involved in patient care. The recommended management of brain metastases should be based on a range of factors including mutation status, performance status, rate of progression, presence of symptoms, and extent of extracranial disease.

The use of targeted BRAF inhibitor therapy in patients with BRAF V600 mutated melanoma can be considered upfront, especially for those with rapidly progressive extracranial disease or multiple brain metastases. Local therapy may be reserved for nonresponsive or progressing metastases. Alternatively, BRAF inhibitor therapy can be considered in patients who have already failed local therapy.For BRAF wild-type patients with no clinical trial option, local therapy remains the firstline treatment of choice for active brain metastases. Ipilimumab could be considered concurrently or soon after local therapy for patients with multiple brain metastases, particularly if treated with WBRT alone, or for patients with coexisting extracranial metastases. However, the potentially negative impact of steroid treatment on the activity of ipilimumab (Margolin et al., 2012) should be noted when planning treatment.

# CONCLUSIONS 

Brain metastases are common in patients with metastatic melanoma, and remain a major clinical problem and an unmet medical need despite the progress made with active systemic therapies in recent years. It is clear that optimal treatment outcomes require Multidisciplinary care, with integrated and appropriate sequencing of surgery, radiation therapy and systemic therapies. More research is required to further improve patient outcomes, and strategies to investigate the activity of new therapies in active brain metastases need to be considered at an early stage in drug development (e.g., in phase 1 clinical trials). Clinical trials for patients with brain metastases must be a priority if we are to make any progress in improving the prognosis for this unfortunate and difficult to manage group of melanoma patients.

## References

Agarwala, S.S., Kirkwood, J.M., Gore, M., et al., 2004. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J. Clin. Oncol. 22, 2101-2107.
Anker, C.J., Ribas, A., Grossmann, A.H., et al., 2013. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J. Clin. Oncol. 31, e283-e287.
Aoyama, H., Shirato, H., Tago, M., et al., 2006. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295, 2483-2491.
Ascierto, P.A., Schadendorf, D., Berking, C., et al., 2013. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 14, 249-256.
Atkins, M.B., Lotze, M.T., Dutcher, J.P., et al., 1999. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105-2116.
Atkins, M.B., Kunkel, L., Sznol, M., and Rosenberg, S.A., 2000. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J. Sci. Am. 6 (Suppl. 1), S11-S14.
Avril, M.F., Aamdal, S., Grob, J.J., et al., 2004. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J. Clin. Oncol. 22, 1118-1125.
Bizzi, A., Blasi, V., Falini, A., et al., 2008. Presurgical functional MR imaging of language and motor functions: validation with intraoperative electrocortical mapping. Radiology 248, 579-589.
Boussemart, L., Boivin, C., Claveau, J., et al., 2013. Vemurafenib and radiosensitization. JAMA Dermatol. 149, 855-857.
Breneman, J.C., Warnick, R.E., Albright Jr., R.E., et al., 1997. Stereotactic radiosurgery for the treatment of brain metastases. Results of a single institution series. Cancer 79, 551-557.
Buchsbaum, J.C., Suh, J.H., Lee, S.Y., et al., 2002. Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer 94, 2265-2272.
Chang, S.D., and Adler Jr., J.R., 2000. Current treatment of patients with multiple brain metastases. Neurosurg. Focus 9, e5.Chapman, P.B., Hauschild, A., Robert, C., et al., 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516.
Choi, K.N., Withers, H.R., and Rotman, M., 1985. Intracranial metastases from melanoma. Clinical features and treatment by accelerated fractionation. Cancer 56, 1-9.
Chu, M.B., Fesler, M.J., Armbrecht, E.S., et al., 2013. High-Dose Interleukin-2 (HD IL-2) therapy should be considered for treatment of patients with melanoma brain metastases. Chemother. Res. Pract. 2013, 726925.
Cohen, N., Strauss, G., Lew, R., et al., 1988. Should prophylactic anticonvulsants be administered to patients with newly-diagnosed cerebral metastases? A retrospective analysis. J. Clin. Oncol. 6, 1621-1624.
Davies, M.A., Liu, P., McIntyre, S., et al., 2011. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117, 1687-1696.
de la Monte, S.M., Moore, G.W., and Hutchins, G.M., 1983. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res. 43, 3427-3433.
Di Giacomo, A.M., Ascierto, P.A., Pilla, L., et al., 2012. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 13, 879-886.
DiLuna, M.L., King Jr., J.T., Knisely, J.P., and Chiang, V.L., 2007. Prognostic factors for survival after stereotactic radiosurgery vary with the number of cerebral metastases. Cancer 109, 135-145.
Dummer, R., Goldinger, S.M., Turtschi, C.P., et al., 2014. Vemurafenib in patients with BRAF(V600) mutationpositive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur. J. Cancer $50,611-621$.
Falchook, G.S., Long, G.V., Kurzrock, R., et al., 2012. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379, 1893-1901.
Fife, K.M., Colman, M.H., Stevens, G.N., et al., 2004. Determinants of outcome in melanoma patients with cerebral metastases. J. Clin. Oncol. 22, 1293-1300.
Flaherty, K.T., Infante, J.R., Daud, A., et al., 2012. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703.
Fogarty, G., Morton, R.L., Vardy, J., et al., 2011. Whole brain radiotherapy after local treatment of brain metastases in melanoma patients-a randomised phase III trial. BMC Cancer 11, 142.
Glantz, M.J., Cole, B.F., Friedberg, M.H., et al., 1996. A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology 46, 985-991.
Gondi, V., Tome, W.A., Marsh, J., et al., 2010. Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: safety profile for RTOG 0933. Radiother. Oncol. 95, $327-331$.
Gondi, V., Mehta, M.P., Pugh, S., et al., 2013. Memory preservation with conformal avoidance of the hippocampus during whole-brain radiation therapy for patients with brain metastases: primary endpoint results of RTOG 0933. Int. J. Radiat. Oncol. Biol. Phys. 87, 1186.

Groves, M.D., 2008. Leptomeningeal metastasis: still a challenge. ASCO Proc. 2008, 80-87.
Guirguis, L.M., Yang, J.C., White, D.E., et al., 2002. Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J. Immuonther. 25, 82-87.
Hamid, O., Robert, C., Daud, A., et al., 2013a. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134-144.
Hamid, O., Sosman, J., Lawrence, D., et al., 2013b. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J. Clin. Oncol. 31 abstr 9010 .
Hodi, F.S., O'Day, S.J., McDermott, D.F., et al., 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.
Hodis, E., Watson, I.R., Kryukov, G.V., et al., 2012. A landscape of driver mutations in melanoma. Cell 150, 251-263.
Hong, A., Chao, S., Valenzuela, M., et al., 2014. Low incidence of melanoma brain metastasis in the hippocampus. Radiother. Oncol. 111, 59-62.
Jakob, J.A., Bassett Jr., R.L., Ng, C.S., et al., 2011. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118, 4014-4023.
Jakob, J.A., Bassett Jr., R.L., Ng, C.S., et al., 2012. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118, 4014-4023.
Kefford, R., Maio, M., Arance, A., et al., 2013. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicenter study. Pigment Cell Melanoma Res. 26, 965.

# I. MOLECULAR MECHANISMSKim, K.B., Kefford, R., Pavlick, A.C., et al., 2013. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J. Clin. Oncol. 31, 482-489.

Klein, O., Clements, A., Menzies, A.M., et al., 2013a. BRAF inhibitor activity in V600R metastatic melanoma. Eur. J. Cancer 49, 1073-1079.
Klein, O., Clements, A., Menzies, A.M., et al., 2013b. BRAF inhibitor activity in V600R metastatic melanomaresponse. Eur. J. Cancer 49, 1797-1798.
Kocher, M., Soffietti, R., Abacioglu, U., et al., 2011. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J. Clin. Oncol. 29, 134-141.

Liew, D.N., Kano, H., Kondziolka, D., et al., 2011. Outcome predictors of Gamma Knife surgery for melanoma brain metastases. J. Neurosurg. 114, 769-779.
Lippitz, B., Lindquist, C., Paddick, I., et al., 2014. Stereotactic radiosurgery in the treatment of brain metastases: the current evidence. Cancer Treat. Rev. 40, 48-59.
Long, G.V., Kefford, R.F., Carr, P.J.A., et al., 2010. Phase 1/2 Study of GSK2118436, a Selective Inhibitor of V600 Mutant (Mut) BRAF kinase: evidence of activity in melanoma brain metastases. Ann. Oncol. 21 viii12.
Long, G.V., Menzies, A.M., Nagrial, A.M., et al., 2011. Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma. J. Clin. Oncol. 29, 1239-1246.
Long, G.V., Trefzer, U., Davies, M.A., et al., 2012. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 13, $1087-1095$.
Lyle, M., and Long, G.V., 2013. Diagnosis and treatment of KIT-mutant metastatic melanoma. J. Clin. Oncol. 31, $3176-3181$.
Lyle, M., and Long, G.V., 2014. The role of systemic therapies in the management of melanoma brain metastases. Curr. Opin. Oncol. 26, 222-229.
Margolin, K., Ernstoff, M.S., Hamid, O., et al., 2012. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13, 459-465.
Mathieu, D., Kondziolka, D., Cooper, P.B., et al., 2007. Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery 60, 471-481.
Mayo, C.S., Ding, L., Addesa, A., et al., 2010. Initial experience with volumetric IMRT (RapidArc) for intracranial stereotactic radiosurgery. Int. J. Radiat. Oncol. Biol. Phys. 78, 1457-1466.
Menzies, A.M., Haydu, L.E., Visintin, L., et al., 2012. Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma. Clin. Cancer. Res. 18, 3242-3249.
McWilliams, R.R., Rao, R.D., Brown, P.D., et al., 2005. Treatment options for brain metastases from melanoma. Expert Rev. Anticancer Ther. 5, 809-820.
Mittapalli, R.K., Vaidhyanathan, S., Sane, R., and Elmquist, W.F., 2012. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J. Pharmacol. Exp. Ther. 342, 33-40.
Mittapalli, R.K., Vaidhyanathan, S., Dudek, A.Z., and Elmquist, W.F., 2013. Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J. Pharmacol. Exp. Ther. 344, 655-664.
Moersch, F.P., Love, J., and Kernohan, J.W., 1940. Melanoma of the central nervous system: report of thirty-four cases, in nineteen of which the diagnosis was verified by operation or necropsy. JAMA 115, 2148-2155.
Narayana, A., Mathew, M., Tam, M., et al., 2013. Vemurafenib and radiation therapy in melanoma brain metastases. J. Neurooncol. 113, 411-416.

Paek, S.H., Audu, P.B., Sperling, M.R., et al., 2005. Reevaluation of surgery for the treatment of brain metastases: review of 208 patients with single or multiple brain metastases treated at one institution with modern neurosurgical techniques. Neurosurgery 56, 1021-1034.
Rades, D., Heisterkamp, C., Huttenlocher, S., et al., 2010. Dose escalation of whole-brain radiotherapy for brain metastases from melanoma. Int. J. Radiat. Oncol. Biol. Phys. 77, 537-541.
Raizer, J.J., Hwu, W.J., Panageas, K.S., et al., 2008. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol. 10, 199-207.
Robert, C., Thomas, L., Bondarenko, I., et al., 2011. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526.

# I. MOLECULAR MECHANISMSRosenberg, S.A., Yang, J.C., Topalian, S.L., et al., 1994. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271, 907-913.
Samlowski, W.E., Watson, G.A., Wang, M., et al., 2007. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS). Cancer 109, 1855-1862.
Sampson, J.H., Carter Jr., J.H., Friedman, A.H., and Seigler, H.F., 1998. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J. Neurosurg. 88, 11-20.
Selek, U., Chang, E.L., Hassenbusch III, S.J., et al., 2004. Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int. J. Radiat. Oncol. Biol. Phys. 59, 1097-1106.
Shapiro, D.G., and Samlowski, W.E., 2011. Management of melanoma brain metastases in the era of targeted therapy. J. Skin Cancer 2011, 845863.
Shaw, E., Scott, C., Souhami, L., et al., 2000. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int. J. Radiat. Oncol. Biol. Phys. 47, 291-298.
Shiau, C.Y., Sneed, P.K., Shu, H.K., et al., 1997. Radiosurgery for brain metastases: relationship of dose and pattern of enhancement to local control. Int. J. Radiat. Oncol. Biol. Phys. 37, 375-383.
Skibber, J.M., Soong, S.J., Austin, L., et al., 1996. Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann. Surg. Oncol. 3, 118-123.
Sosman, J.A., Kim, K.B., Schuchter, L., et al., 2012. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714.
Topalian, S.L., Hodi, F.S., Brahmer, J.R., et al., 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454.
Wolchok, J.D., Hoos, A., O'Day, S., et al., 2009. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412-7420.
Wronski, M., and Arbit, E., 2000. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J. Neurosurg. 93, 9-18.
Zacest, A.C., Besser, M., Stevens, G., et al., 2002. Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades. J. Neurosurg. 96, 552-558.
Zakrzewski, J., Geraghty, L.N., Rose, A.E., et al., 2010. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer 117, $1711-1720$.# C H A P T E R 

## 6

## Pathobiology of Brain Metastases: Molecular Mechanisms

Konstantina Svokos, Supriya Lal and Steven A. Toms

## O U T L I N E

Introduction
Pathobiology of Brain Metastasis
Cellular Heterogeneity and Proliferation
Epithelial-Mesenchymal Transition
Interaction with Tumor Stroma
Local Invasion
E-Cadherin-Catenin Complex and Integrins
Dissemination
Brain's Microenvironment
Reactive Oxygen Species and Brain Metastasis

Contribution of Systemic Immune Cells to Metastasis Proliferation on the Brain
86
86
87
87
88
88
89
89
90

Evolution in Brain Metastasis Animal Models
Genetics in Breast Cancer Brain Metastases
Genetics in Lung Cancer Brain Metastases
Epigenetics in Brain Metastases 94
microRNAs in Brain Metastases 94
Discussion 96
References 97# INTRODUCTION 

Metastatic brain tumors (MBT) arise from cancers outside the central nervous system (CNS). They reach the brain either from hematogenous spread or via direct invasion from adjacent tissues. Brain metastases are the most common brain tumors and occur nearly 200,000 times each year in the USA. They comprise about $25 \%$ of all cancer metastases and may be seen in about $20-40 \%$ of all adult cancer patients. The number of cases for the site of origin is $40-50 \%$ for lung, $15-20 \%$ for breast, $5-10 \%$ for skin, and $4-6 \%$ for the gastrointestinal tract (Barnholtz-Sloan et al., 2004). Brain metastases are the leading cause of morbidity and mortality in cancer patients. Median survival time for untreated patients is 5 weeks; multimodality therapy may extend survival to 3-18 months (McDermott et al., 2013). Recently, an increased incidence of MBTs has been noted likely secondary to improved imaging modalities and possibly more effective systemic treatment of primary tumors (Barajas and Cha, 2012).

The vast majority of MBTs occur in the cerebral hemispheres ( $80 \%$ ) with a much smaller number appearing in the cerebellum ( $15 \%$ ) and the brainstem ( $5 \%$ ). These percentages roughly correspond to the relative tissue volumes of the respective portions of the brain. MBTs tend to distribute along gray-white junctions and watershed vascular distributions where the circulating tumor cells lodge in capillary beds prior to growing into symptomatic lesions (Delattre et al., 1988). MBTs are a major cause of morbidity and mortality in patients with metastatic cancer. The clinical symptoms of MBTs may be nonspecific such as headaches from raised intracranial pressure, cognitive impairment, or more specifically correlated to location and present with seizure or focal neurological deficits (Chang et al., 2007).

The brain, enclosed by the meninges, has a unique perivascular environment thanks to the blood-brain-barrier (BBB), a selectively permeable tissue found around most blood vessels that limits the movement of molecules from the blood, based upon molecular size and charge. The BBB prevents the entry of most hydrophilic chemotherapeutics, thereby acting as a refuge for metastatic tumors (Lockman et al., 2010). Furthermore, the BBB acts as an immune refuge, limiting exposure of the brain parenchymal tissues to circulating antigens.

In addition, the BBB provides a microenvironment that is tightly metabolically regulated for the metastatic cells that have arrested in brain vasculature, extravasated, and begun to proliferate either in the perivascular space or the brain parenchyma. The brain's interstitial fluid has high chloride content enabling clones of neuroepithelial origin, such as small cell carcinoma of the lung or melanoma, to proliferate while sometimes inhibiting the growth of other cancer cell types lacking this predilection (Beasley and Toms, 2011).

This chapter will focus on MBT, the hallmarks of the metastatic cascade, the genetics, and pathobiology of brain metastases. By understanding the molecular events that sustain brain metastases, a foundation may be created to allow the investigation and development of more effective targeted therapies and research directions.

## PATHOBIOLOGY OF BRAIN METASTASIS

Metastases develop when tumor cells manage to evade the homeostatic mechanisms within the host to exploit the cytoprotective features provided by the brain's microenvironment. The "seed-and-soil" hypothesis of metastasis states that the metastatic "seed"from the primary tumor can only grow in appropriate fertile "soil" of the host organ. This implies that the successful outgrowth of deadly metastatic tumors depends on the bidirectional interaction between the metastatic cancer cells and host tissue site-specific microenvironment (Langley and Fidler, 2011). To form a metastasis, a tumor cell must complete a sequential series of steps that begins with its detachment from the primary mass and invasion of the surrounding tissue. The cascade involves two distinct stages: (1) migration which includes intravasation, dissemination, and extravasation; (2) colonization and metastatic proliferation.

# Cellular Heterogeneity and Proliferation 

Tumor cells are genetically heterogeneous, and their potential to metastasize is variable. Tumor cells are able to evade normal tissue organization, survive despite local environmental stresses, such as hypoxia, nutrient deficiency, hypoperfusion, and immune mediation, and have the ability to metastasize to distant sites. In the metastatic process, cancer cells are able to invade adjacent tissues, disseminate, adhere to new tissue substrates, and initiate neoangiogenesis. Malignant cells have the capacity to evade growth suppressors and inhibitors of cell proliferation via mechanisms including the resistance of apoptosis by overexpression of Bcl-2, Bcl-xL, and downregulation of proapoptotic Bax and Bim (Junttila and Evan, 2009).

In normal tissue, epithelial cells are held in tight apposition by proteins involved in the maintenance of structural integrity. Downregulation of one of these proteins, E-cadherin, is correlated with high metastatic potential. Invading tumor cells secrete proteolytic enzymes that degrade the epithelial basement membrane before they penetrate the endothelial basement membrane of thin-walled blood vessels to enter the circulation. Tumor cells arrest in capillary beds and gain access to activated angiogenic programs and develop new vascular networks by recruiting adjacent microvascular endothelial cells as well as bone marrow derived circulating endothelial precursor cells (Lyden et al., 2001).

In primary tumors, there are multiple cell types including cancer stem cells (CSC), partially differentiated progenitor cells, and fully differentiated cancer stromal cells which behave in an uncontrolled manner as compared to normal tissue (Ailles and Weissman, 2007). These CSCs may contribute to the enhanced malignant potential of primary tumors and are able to degrade the extracellular matrix (ECM), invade blood vessels and lymph nodes, migrate, extravasate, and colonize at their new locations (Marcato et al., 2011; Quintana et al., 2008).

## Epithelial-Mesenchymal Transition

Epithelial-mesenchymal transition (EMT) is a temporary, reversible phenomenon where cells can dedifferentiate, migrate to a distant focus, and then redifferentiate to the original cell, forming a new structure (Yilmaz and Christofori, 2009). Signals activating EMT are intrinsic (gene mutations and epigenetic changes) or extrinsic (growth factor signaling and immune modulation). Transdifferentiation is initiated by release of EMT inducing transcription factors that convert epithelial cells into mesenchymal derivatives, giving these cells the capacity to invade, resist apoptosis, and disseminate (Hanahan and Weinberg, 2011; Thieryet al., 2009). EMT enables non-CSCs to resemble a CSC state allowing them to invade and disseminate from the primary tumor to a distant, metastatic focus (Mani et al., 2008).

# Interaction with Tumor Stroma 

Cancer progression involves activation of cells in the adjacent normal tissue stroma via paracrine signaling (Pietras and Ostman, 2010). Cells involved in these interactions may include endothelial cells, pericytes, fibroblasts, and leukocytes with protumorigenic factors to sustain tumor growth. The most prominent cells are the cancer-associated fibroblasts (CAF) and the pericytes. CAFs express high amounts of TGF $\beta$, HGF, EGF, FGF, and IL-6 (Bhowmick et al., 2004). Experimental models suggest that cancer cells release factors, such as CSF-1, which stimulate macrophages in the tumor microenvironment and release EGF promoting tumor proliferation (Qian and Pollard, 2010). The intercellular milieu contributes to stresses on the tumor cells, enhancing genomic instability and epigenetic dysregulation (Bristow and Hill, 2008).

## Local Invasion

Once a phenotypically aggressive clone has developed in a primary cancer, the tumor may spread via invasion of the ECM. Tumor cells may penetrate into the vasculature system and spread hematogenously to the CNS and other organs. The ECM degradation and intravasation into the circulation is dependent on a number of protein complexes that regulate cell-cell interactions as well as proteolytic enzymes responsible for the degradation of the ECM. Combined with the various molecular and cellular events, this begins the process of tumor metastasis.

## E-Cadherin-Catenin Complex and Integrins

The E-cadherin-catenin molecular complex (ECCC) is essential for the maintenance of both normal and tumor cytoarchitecture. It is a mediator of cell-cell adhesion that determines cell polarity and organization (Hirohashi and Kanai, 2003). Cadherin molecules are cell membrane glycoproteins that interact with each other in a homophilic manner with a stable extracellular fragment and a cytoplasmic protein coat, catenin. In tumor metastasis, tumor clones fail to adhere to one another, become disorganized, and are able to separate from the tumor mass. Many malignancies have mutations in the genes for catenins and E-cadherins which correlate with unfavorable prognosis. DNA hypermethylation of E-cadherin's promoter can diminish or silence its expression, disturb the ECCC function, and is a common event in many metastatic cancers (Bremnes et al., 2002). N-cadherin is another molecule connected to the cytoskeleton via $\alpha$-catenin and $\beta$-catenin similar to E-cadherin. Gain-of-function mutations in N-cadherin have been shown to trigger increased migration and invasion in tumors (Hulit et al., 2007).

Integrins are major adhesion and intracellular signaling receptor proteins linking the ECM to the cellular cytoskeleton. They play an important role in mediating cell migration and invasion via signal transduction pathways. In addition, they regulate cytoskeletal organization, influence gene expression, and control rates of proliferation and apoptosis(Hynes, 2002). Integrins induce the release of a key signaling mediator, focal adhesion kinase (FAK). FAK is a ubiquitously expressed nonreceptor cytoplasmic tyrosine kinase and is thought to play a key role in migration and proliferation by providing abnormal signals for survival, EMT, invasion, and angiogenesis (Zhao and Guan, 2011).

The ability of tumor cells to migrate from their primary site is dependent on their ability to remodel the ECM by degrading the ECM via proteolytic enzymes, creating a pathway for invasion. Neurotrophins promote brain invasion by enhancing the production of heparinase, an ECM proteolytic enzyme. Heparinase is a $\beta$-d-glucuronidase, s heparin sulfate degradative enzyme that destroys both the ECM and the BBB (Marchetti and Nicolson, 2001).

# Dissemination 

Once a tumor cell has breached its microenvironment and arrived at the vasculature or lymphatics, it must survive the stressful environment of the circulatory system. Tumor cells respond by reinforcing their cytoskeleton and by adhering to the vascular wall (Davies et al., 2005). By adhering to endothelium of target tissue, the tumor cells behave like macrophages, creating pseudopodia and penetrating the cell-cell junctions (Kumar and Weaver, 2009). Cancer cells appear to attract platelets because of their expressed surface tissue proteins, which protect the cells from the immune system (Nieswandt et al., 1999). Once these mobile cancer cells get arrested in the microvasculature in a secondary organ tissue site, they colonize by cellular diapedesis, extravasation, and proliferation of the tumor cell mass, prior to their rupture into adjacent stroma.

## BRAIN'S MICROENVIRONMENT

The BBB is hypothesized to create and interact with a unique brain microenvironment and to influence metastatic colonization. The BBB consists of capillary endothelial cells that are connected by tight junctions and have no fenestrations. The endothelial cells are lined by pericytes, basement membrane, and astrocytes. There is low permeability to ions and small molecules and almost no permeability to macromolecules and peptides. There is no pinocytosis, a process that facilitates transcytosis. The BBB works with the blood-CSF barrier to protect the neural environment (Weil et al., 2005). Most of the control of solute transport across the BBB is attributed to pericytes, cells that reside in the perivascular space (VirchowRobin space) that are involved in CNS homeostasis: angiogenesis, BBB formation, and maintenance and capillary blood flow regulation (Hamilton and Sibson, 2013).

Metastasis to the brain is facilitated by both endogenous and target site contributions dependent on complex signal interactions between cancer cells and their organ targets (McDermott et al., 2013). When tumor cells invade the BBB to establish a brain metastasis, endothelial cells form a BBB. Many brain metastases are characterized by white matter. The edema is generated by the increased permeability of tumor-associated endothelial cells that permits leakage of proteins and water into brain parenchyma surrounding the tumor (Lesniak and Brem, 2004). Fibroblasts may function as cancer promoters using paracrine signaling pathways (McDermott et al., 2013). These fibroblasts secrete many proteins involved in metastasis, such as VEGF-A, Transforming Growth Factor-Beta, andMMPs. In addition, glial cells provide structural support for neurons and influence brain and BBB integrity, even though they have been traditionally thought to provide neuronal structural support (Weil et al., 2005).

# REACTIVE OXYGEN SPECIES AND BRAIN METASTASIS 

Cells of the systemic immune system produce reactive oxygen species (ROS) and nitric oxide (NO) during phagocytosis. ROS are released in response to activation by TNF. A side effect of the oxidative stress of ROS production may be an increase in the rate of mutation in tumor cells that are able to resist immune mediated cell death (Hamilton and Sibson, 2013). Therefore, even though the systemic immune system is beneficial in destroying some target cancer cells, the local inflammatory response at the tumor site may aid tumor survival (Dvorak, 1986).

Microglia and macrophages secrete multiple cytokines, growth factors, enzymes, and ROS that can directly or indirectly lead to angiogenesis (e.g., VEGF), tumor proliferation (e.g., EGF), and invasion (e.g., metalloproteases) of metastatic cancer cells in the brain (Lorger, 2012). In particular, studies on metastatic breast cancer cells show that their protein expression profile uses enhanced mitochondrial respiratory pathways for energy production and antioxidant defense mechanisms (Chen et al., 2007). The proteins upregulated in the brain metastatic cells show three major changes in the energy metabolism: enhanced glycolysis, increased beta oxidation of fatty acids, and an elevated pentose phosphate pathway (Chen et al., 2007). The cells' metabolic changes reflect adaptation of the tumor cells to the brain microenvironment where a constant high energy demand is met mostly by glucose oxidation (Raichle and Mintun, 2006; Rao et al., 2006).

The reduction-oxidative state of brain metastatic breast cancer cells may provide a link between their energy metabolism and gene regulation (Chen et al., 2007). Recent research provides evidence that brain metastatic breast cancer cells use metabolic pathways distinct from anaerobic glycolysis (Chen et al., 2007). Anaerobic glycolysis is predominant in most cancer cells in oxygen-poor tumor microenvironments. Brain derived cancer cells seem to use mainly aerobic glycolysis, coupled to the TCA cycle, and oxidative phosphorylation to generate energy for cell growth (Chen et al., 2007). This shows the significance of understanding the metabolism of metastatic cells and supports the idea of targeting tumor energy metabolism in brain metastases therapy.

## CONTRIBUTION OF SYSTEMIC IMMUNE CELLS TO METASTASIS PROLIFERATION ON THE BRAIN

For metastatic cancers that have arrested in the brain vasculature, extravasated, and begun to proliferate either in the perivascular space or the brain parenchyma, the BBB provides a microenvironment that is tightly metabolically regulated. Brain metastases are not free from immune surveillance, either from microglia or by exposure to extravasating systemic immune cells. Inflammation has been identified as an enabling characteristic of cancer, and there is a need for tumors to avoid immune destruction both in primary andmetastatic tumors. A better understanding of tumor cell interactions with immune system cells is necessary thanks to an increasing move toward immunotherapy in cancer patients.

Many of the hypotheses relating to mechanisms of metastatic extravasation in the brain have arisen from observations of in vitro and in vivo models (Green et al., 2009; Haddad et al., 2010). First, tumor cells may be able to use similar mechanisms of those used by systemic immune cells to adhere to proteins expressed by endothelial cells allowing them to cross the BBB into the perivascular space. Second, tumor cells adhere to systemic immune cells via receptor-ligand interactions and cross through the BBB with the "hijacked" cells (Munzarova and Kovarik, 1987). Third, tumor cells, mechanically arrested in blood vessels, may be able to modify the endothelial cell wall via expression of MMPs, allowing extravasation into the perivascular space (Kienast et al., 2010).

This section will explore the pathways by which systemic immune cells can control the proliferation of metastatic cells in the CNS.
A. Macrophages: Circulating macrophages maintain a population of resident macrophages in the perivascular space whose primary purpose is the clearance of cellular debris. Their recruitment to specific brain sites is achieved via local expression of colony stimulating factor 1. Tumor associated macrophages (TAMs) have been observed at later stages of metastasis following the extravasation of metastatic cells in the perivascular space. TAMs are responsible for edema at both primary and MBT, and TAM levels correlate with tumor edema (Shinonaga et al., 1988). Macrophage recruitment to metastatic sites may occur prior to metastatic recruitment suggesting a role for inflammatory cells in the adhesion and migration of circulating metastatic cells (Mareel and Madani, 2006).
B. Neutrophils: Neutrophils are the most common white blood cell in mammals and make up $70 \%$ of circulating leukocytes in humans. Although their role has been implicated in cancer progression, their role in metastatic brain disease is poorly understood. A key signaling molecule in neutrophil recruitment is interleukin-8 (IL-8), which has been suggested to play a role in protective inflammation at metastatic sites (Bekes et al., 2011).
C. Natural Killer Cells: Natural Killer (NK) cells are a subset of lymphocytes that play a role in the apoptotic killing of both tumor cells and virus-infected cells (Hamilton and Sibson, 2013). NK cells have two cytotoxic pathways. First, the protease granzyme B is released through perforin proteins, leading to protein degradation at the target cell and apoptotic cell death. Second, TNF family ligands on the cell surface can ligate target cell receptors leading to apoptosis (Rousalova and Krepela, 2010). Research on NK cells has focused on CD57 ${ }^{+}$and IOT-10 expression, two NK-cell markers and the antitumor effect of NK-cells in animal models. They have become a subject of interest for immunotherapy in other organs, but further research is necessary in the field of brain metastasis (Hamilton and Sibson, 2013).
D. T-lymphocytes: T lymphocytes are divided into $\mathrm{CD}^{+}{ }^{+} \mathrm{T}$ helper cells (Th) and $\mathrm{CD}^{+}$ cytotoxic T lymphocytes (CTL) both of which are implicated in brain metastasis. High levels of $\mathrm{CD}^{+}$CTLs are believed to promote tumor destruction, while high levels of $\mathrm{CD} 4^{+} \mathrm{Th}$ are believed to protect tumor development (Gerloni and Zanetti, 2005). Experiments depleting populations of $\mathrm{CD} 4^{+}$or $\mathrm{CD}^{+}{ }^{+} \mathrm{T}$ cells have been shown to cause an increase in brain metastases (Lu et al., 2003). Adoptive transfer of T cells has led to several successes in immunotherapy against brain metastases (Prins and Liau, 2004).E. B-lymphocytes: The role of B lymphocytes in brain metastasis is poorly understood. Experiments of melanoma-induced metastasis to the lung showed a twofold increase in metastatic burden with B cell depletion, a reduction in $\mathrm{CD} 4^{+}$and $\mathrm{CD}^{+}$activation, and a reduction in tumor-specific $\mathrm{CD}^{+}$proliferation (DiLillo et al., 2010). These results suggest an interaction between B cell populations and tumor repression via T cell activation. Information on B cells' role in brain metastasis comes from patients with B cell lymphoma that has migrated to the CNS (Yamazaki et al., 2003). However, the exact mechanism is poorly understood.
F. Platelets: Platelets play an important role in wound healing via blood clotting. Research linking thrombosis and cancer suggest a role for platelets in the development of various cancers and metastases (Erpenbeck and Schon, 2010). Platelet aggregation around tumor cells is thought to aid in tumor survival by protecting them from shear forces inside blood vessels and by avoiding immune system cells, killing by NK cells in particular (Nash et al., 2002).

# EVOLUTION IN BRAIN METASTASIS ANIMAL MODELS 

Progress has been made in modeling human cancer in the mouse which can recapitulate the range of phenotypes seen in primary human cancers. To date, no model of spontaneous brain metastasis has been developed, although cell lines injected intravenously have established tumor foci in brain and other organs (Maher et al., 2009). It has been deduced that the earliest steps of brain metastases rely on the in vivo analyses (Lorger, 2012).

Kang et al. (2003) investigated organ specificity by using an in vivo mouse model to identify MDA-MB-231-derived breast cancer lines with organotropism for bone and lung. On rare occasions, foci of tumors grew in the brain; and after rounds of systemic injection, they were able to isolate outgrowth of cells with increased propensity of brain metastasis.

Kouros-Mehr et al. (2008) described a model system of injecting human breast cells into fat pads of mice with a focus on determining when the cells acquire the ability to disseminate, colonize an organ, and grow. This model enables studying the interaction between tumor and stroma, including the function of microglia and inflammatory cells recruited to the site of tumor cell growth (Maher et al., 2009; Kang et al., 2003; Kouros-Mehr et al., 2008; Rao et al., 2006; Haddad et al., 2010).

Reports in the literature suggest that other cell lines may be capable of brain metastasis in vivo, mimicking the heterogeneity in human cancer. They include a human cell line derived from a brain metastasis (MDA-MB-361), commonly studied lines, such as MDA-MB-468, and rarely cited lines, such as MA11 (Weil et al., 2005). The carotid artery injections of MDA-MB-231 BR1 to BR3 sublines demonstrate that models can be robust enough to provide quantitation of therapeutic effects of compounds that may be used not only in molecular biology but also for preclinical drug development (Weil et al., 2005).

Traditionally, in vitro assays have been used to investigate motility, invasion of ECM, and anchorage-independent colonization. Lee et al. (2004) investigated the invasion of human brain microvascular endothelial cells as a model for invasion of the BBB. Invasion of labeled MDA-MB -231 cells could be measured quickly by assessing in vitro attachment to human brain microvascular endothelial cells and alterations in BBB properties. Additionally, the cell migration is vital to the metastatic cascade. The cells take cue from the concentration,signals, and receptors present in the in vivo model. By tracking the extracellular signals passed and the intracellular pathways signaled, it becomes easier to track metastasis growth. In an in vitro environment, a variety of stimuli can be used to best predict what will cause the tumors to metastasize (Pouliot et al., 2000). Recently, these authors have been working on creating both patient-derived in vivo and in vitro models of brain metastases originating from lung or breast cancer using surgical specimens, which will help identify therapeutically targetable genes.

# GENETICS IN BREAST CANCER BRAIN METASTASES 

There is an urgent need to better understand the mechanisms underlying the pathogenesis of brain metastasis and to identify novel targeted therapies. Gene expression studies using DNA microarrays have identified at least four distinct subtypes of breast cancer, including Luminal A, Luminal B, HER2 $/^{+} / \mathrm{ER}^{-}$, and basal-like subtypes (Perou et al., 2010; Parker et al., 2009). Additional research focusing on the genetic and epigenetic analysis of breast cancer with microarray technology measuring alterations at the level of mRNA expression, DNA copy number, and DNA methylation is underway with collaborators of the authors.

A number of regions of amplifications and deletions have been identified using copy number analysis. The most notable regions of broad gains were $1 \mathrm{q}, 5 \mathrm{p}, 8 \mathrm{q}, 11 \mathrm{q}$, and 20 q . Broad deletions were identified at $8 \mathrm{p}, 17 \mathrm{p}, 21 \mathrm{p}$, and Xq . Studies have shown that invasive breast cancer has shown deletions in 1p, 8p, 11q, 16q, 18q, and 22 (Nikolsky et al., 2008; Yao et al., 2006). This suggests overlap of regions involved in primary breast cancer, pointing toward emergence of chromosomal abnormalities unique to breast cancer metastasis. Breast cancer oncogene such as MYC (8q) was not highly expressed (Salhia et al., 2014). However, ATAD2 (8q24) and DERL1 (8q24) were overexpressed and amplified suggesting a role in breast cancer metastasis. ATAD2 is a transcriptional coactivator of ESR1 required to induce estradiol target gene expression (Raeder et al., 2013). DERL1 is thought to participate in the endoplasmic-reticulum (ER) associated degradation response and proteosomal degradation.

Differential expression analysis revealed significant profiles associated with G2-M checkpoint and proliferation. FOXM1, a transcriptional activator in the G2-M cascade, was overexpressed in a large percentage of breast cancer metastases. FOXM1 regulated many genes involved in the mitotic checkpoint such as AURKA, AURKB, PLK1, and CENPF (Salhia et al., 2014).

## GENETICS IN LUNG CANCER BRAIN METASTASES

Large-scale studies first conducted on mice and then on humans suggest that 24 new tumor suppressor genes (TSGs) were significantly downregulated in hLSCC's or human lung squamous cell carcinomas. One common genetic alteration is one of FGFR1 or fibroblast growth factor receptor 1 that increases FGFR signaling. By isolating a mere 14 of the TSGs, the body strengthens the bronchial epithelial cells and in most cases, causes the TSG's to become responsive to FGFR inhibitors. Thus, FGFR signaling can indicate and encourage tumorigenesis in many hLSCC's that lack mutations or FGFR1 expansion, like ones found in the brain (Lin et al., 2014; Rosenthal et al., 2001). Using immunohistochemistry, a group of researchers isolated the Dishevelled-1 (DVL1), Dishevelled-3 (DVL3), E-cadherin (CDH1), andbeta-catenin (CTNNB1) genes from cells that stemmed from primary lung carcinoma cells and analyzed them in regards to expression in brain metastases. DVL1 and DVL3 were heavily expressed in brain metastasis with percentages reaching $87.1 \%$ and $90.3 \%$, respectively. Betacatenin, the main promoter of the Wnt signaling pathway, reached a regulation barrier of $56 \%$ and resettled to $36 \%$ of the brain metastases. Ergo, mutation of DV1, DVL3, CDH1, and CTNNB1 present in brain metastases suggests that Wnt signaling is important and may contribute to a better understanding of how lung carcinoma can affect brain metastases (Kafka et al., 2014).

# EPIGENETICS IN BRAIN METASTASES 

Cancer-associated localized hypermethylation has been described for CpG islands, DNA sequences of about $1-2 \mathrm{~kb}$ that are $(\mathrm{C}+\mathrm{G})$-rich. When their promoters overlap, CpG islands are usually unmethylated in tissues. Frequent and excessive hypermethylation of CpG islands is observed in many cancers. However, DNA hypomethylation in cancer often affects more of the genome than does hypermethylation so that net losses of genomic 5-methylcytosine are seen in many human cancers (Gama-Sosa et al., 1983).

It is important to consider the contribution of DNA hypomethylation to tumorigenesis in light of cancer therapies aimed at decreasing DNA methylation. Inducing DNAhypomethylation may have short-term effects but may also help speed tumor progression from cancer cells surviving the DNA methylation chemotherapy (Ehrlich, 2002). A recent study has shown increased DNA methylation levels compared to nonneoplastic tissue, which is likely due to amplification and overexpression of DNMT3B and MAT1A (Salhia et al., 2014). Compared to HER2 enriched and luminal B brain metastasis, there was overall decreased methylation in basal-like tumors, consistent with primary breast cancer findings (TCGA) (Cancer Genome Atlas Network, 2012).

## microRNAs IN BRAIN METASTASES

Research on the metastatic cascade has demonstrated the role of incorrectly regulated protein expression. Molecular studies have emphasized the role of microRNAs. They are a large class of small noncoding RNAs, 19-25 nucleotides long, and are produced naturally in cells after being cut into segments from larger strands of RNA. They bind to complementary sites on the 3'UTR of genes and promote the recruitment of protein complexes responsible for impairing translation and/or decreasing the stability of mRNA (Lewis et al., 2005). They are master regulators of the human genome, and their aberrant expression contributes to tumorigenesis, metastasis, and therapeutic resistance. The loss of tumor suppressive microRNAs activates oncogenic pathways to promote the generation of cancer phenotypes, tumor initiation, progression, and metastasis (Melo and Esteller, 2011). Epigenetic alterations of microRNAs are also implicated in tumorigenesis and metastasis since microRNA deregulation promotes generation of a cancer phenotype, tumor initiation, metastatic growth, and development of drug resistance (Aigner, 2011; Calin and Croce, 2006).

MicroRNAs are directly involved in the changes of the brain microenvironment in metastatic tumor cells as many studies have shown that the brain microenvironment changes themicroRNA profile of the tumor cells when compared with the primary tumor. For instance, microRNA-146a was found to be suppressed in brain metastases compared to primary tumors in animal models, associated with decreased $\beta$-catenin protein levels and increased heterogeneous nuclear ribonucleoprotein $\mathrm{C} 1 / \mathrm{C} 2$, contributing to migratory and invasive capabilities (Hwang et al., 2012). In addition, microRNA-768-3p was downregulated in tumor cells and in human brain metastatic tissues from lung cancer, breast cancer, and melanoma when compared to match-paired primary tumors. MiRNA-768-3p downregulation led to an increase in K-ras expression and translated into increased tumor growth and drug resistance (Subramani et al., 2013). These studies demonstrate that the brain microenvironment induces changes in the microRNA of the tumor cells to activate pro-growth signaling pathways leading to more aggressive, drug resistant metastatic lesions.

MicroRNAs are promising in regards to diagnostics, prognostics, and therapeutics ( Lu et al., 2012). MicroRNA-based diagnostics may detect metastatic brain lesions and distinguish primary from metastatic lesions and may eventually aid in clinical decision-making and prognostication (Mueller et al., 2011). Early detection of brain micrometastases may be based upon deregulated microRNAs known to be altered within MBT. Thus, changes in microRNA levels may provide an early signal to prompt aggressive treatment. A single microRNA is capable of regulating multiple genes, making them appealing therapeutic targets (Alsidawi et al., 2014). Two strategies exist for miRNA-based therapeutics: First, a direct approach involving microRNA mimics or microRNA antagomirs. MicroRNA mimics replace the loss of tumor suppressor microRNA while antagomirs are antisense oligonucleotides that block oncogenic microRNAs. A second, an indirect strategy involves identifying agents that modulate the expression and processing of microRNAs in traditional com-pound-library screens (Alsidawi et al., 2014) (Figs. 6.1 and 6.2).
![img-66.jpeg](img-66.jpeg)

FIGURE 6.1 MRI of the brain illustrates the loss of blood-brain-barrier integrity. A 68-year-male patient with lung cancer and metastatic brain lesion in the left occipital lobe (A) T1 axial before contrast (B) T1 axial after contrast.Genetic changes: $\uparrow$ apoptosis resistance genes, angiogenesis, proteases
Epigenetic changes: hypomethylation E-cadherin promoter
![img-67.jpeg](img-67.jpeg)

FIGURE 6.2 Overview of cancer cell interactions with stromal and immune cells, genetic and epigenetic changes of the metastatic cascade.

# DISCUSSION 

The metastatic cascade is a complex, multistep process. Involvement of the CNS in patients with metastatic disease is increasingly more treatable. Brain metastases are becoming increasingly more prevalent as greater control over systemic disease is achieved and large molecules such as antibodies are used in the control of primary cancers. Due both to the BBB and the brain's unique microenvironment, novel approaches for the treatment of brain metastases will be necessary.

Recent advances in animal models of experimental metastases to the brain will facilitate molecular analyses and the development of preclinical studies. It is possible that increased specificity in targeting will lead to increased efficacy and reduced toxicity in the clinical care of those with MBTs. A more thorough understanding of the metastatic process will enable more precise therapeutic targeting of metastases and may lead to earlier detection and improved treatment of brain metastases.# References 

Aigner, A., 2011. MicroRNAs (miRNAs) in cancer invasion and metastasis: therapeutic approaches based on metastasis-related miRNAs. J. Mol. Med. 89, 445-457.
Ailles, L.E., and Weissman, I.L., 2007. Cancer stem cells in solid tumors. Curr. Opin. Biotechnol. 18, 460-466.
Alsidawi, S., Malek, E., and Driscoll, J.J., 2014. MicroRNAs in brain metastases: potential role as diagnostics and therapeutics. Int. J. Mol. Sci. 15, 10508-10526.
Barajas, R.F., Jr., and Cha, S., 2012. Imaging diagnosis of brain metastasis. Prog. Neurol. Surg. 25, 55-73.
Barnholtz-Sloan, J.S., Sloan, A.E., Davis, F.G., Vigneau, F.D., Lai, P., and Sawaya, R.E., 2004. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system. J. Clin. Oncol. 22, 2865-2872.

Beasley, K.D., and Toms, S.A., 2011. The molecular pathobiology of metastasis to the brain: a review. Neurosurg. Clin. N. Am. 22, 7-14.
Bekes, E.M., Schweighofer, B., Kupriyanova, T.A., Zajac, E., Ardi, V.C., Quigley, J.P., et al., 2011. Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor-angiogenesis and effi- $\bar{\varnothing}$ ciency of malignant cell intravasation. Am. J. Pathol. 179, 1455-1470.
Bhowmick, N.A., Neilson, E.G., and Moses, H.L., 2004. Stromal fibroblasts in cancer initiation and progression. Nature 432, 332-337.
Bremnes, R.M., Veve, R., Hirsch, F.R., and Franklin, W.A., 2002. The e-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. Lung Cancer 36, 115-124.
Bristow, R.G., and Hill, R.P., 2008. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat. Rev. Cancer 8, 180-192.
Calin, G.A., and Croce, C.M., 2006. MicroRNA signatures in human cancers. Nat. Rev. Cancer 6, 857-866.
Cancer Genome Atlas Network, 2012. Comprehensive molecular portraits of human breast tumours. Nature 490, $61-70$.
Chang, E.L., Wefel, J.S., Maor, M.H., Hassenbusch, S.J. III, Mahajan, A., Lang, F.F., et al., 2007. A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery 60, 277-283. discussion 283-284.
Chen, E.I., Hewel, J., Krueger, J.S., Tiraby, C., Weber, M.R., Kralli, A., et al., 2007. Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res. 67, 1472-1486.
Davies, P.F., Spaan, J.A., and Krams, R., 2005. Shear stress biology of the endothelium. Ann. Biomed. Eng. 33, $1714-1718$.
Delattre, J.Y., Krol, G., Thaler, H.T., and Posner, J.B., 1988. Distribution of brain metastases. Arch. Neurol. 45, $741-744$.
DiLillo, D.J., Yanaba, K., and Tedder, T.F., 2010. B cells are required for optimal $\mathrm{CD}^{+}$and $\mathrm{CD} 8^{+} \mathrm{T}$ cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J. Immunol. 184, 4006-4016.
Dvorak, H.F., 1986. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315, 1650-1659.
Ehrlich, M., 2002. DNA methylation in cancer: too much, but also too little. Oncogene 21, 5400-5413.
Erpenbeck, L., and Schon, M.P., 2010. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood 115, 3427-3436.
Gama-Sosa, M.A., Slagel, V.A., Trewyn, R.W., Oxenhandler, R., Kuo, K.C., Gehrke, C.W., et al., 1983. The 5methylcytosine content of DNA from human tumors. Nucleic Acids Res. 11, 6883-6894.
Gerloni, M., and Zanetti, M., 2005. CD4 T cells in tumor immunity. Springer Semin. Immunopathol. 27, 37-48.
Green, C.E., Liu, T., Montel, V., Hsiao, G., Lester, R.D., Subramaniam, S., et al., 2009. Chemoattractant signaling between tumor cells and macrophages regulates cancer cell migration, metastasis and neovascularization. PLoS One 4, e6713.
Haddad, O., Chotard-Ghodsnia, R., Verdier, C., and Duperray, A., 2010. Tumor cell/endothelial cell tight contact upregulates endothelial adhesion molecule expression mediated by NFkappaB: differential role of the shear stress. Exp. Cell Res. 316, 615-626.
Hamilton, A., and Sibson, N., 2013. Role of the systemic immune system in brain metastasis. Mol. Cell. Neurosci. $53,42-51$.
Hanahan, D., and Weinberg, R.A., 2011. Hallmarks of cancer: the next generation. Cell 144, 646-674.
Hirohashi, S., and Kanai, Y., 2003. Cell adhesion system and human cancer morphogenesis. Cancer Sci. 94, 575-581.Hulit, J., Suyama, K., Chung, S., Keren, R., Agiostratidou, G., Shan, W., et al., 2007. N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer Res. 67, 3106-3116.
Hwang, S.J., Seol, H.J., Park, Y.M., Kim, K.H., Gorospe, M., Nam, D.H., et al., 2012. MicroRNA-146a suppresses metastatic activity in brain metastasis. Mol. Cells 34, 329-334.
Hynes, R.O., 2002. Integrins: bidirectional, allosteric signaling machines. Cell 110, 673-687.
Junttila, M.R., and Evan, G.I., 2009. P53 - a Jack of all trades but master of none. Nat. Rev. Cancer 9, 821-829.
Kafka, A., Tomas, D., Beros, V., Pecina, H.I., Zeljko, M., and Pecina-Slaus, N., 2014. Brain metastases from lung cancer show increased expression of DVL1, DVL3 and beta-catenin and down-regulation of E-cadherin. Int. J. Mol. Sci. 15, 10635-10651.
Kang, Y., Siegel, P.M., Shu, W., Drobnjak, M., Kakonen, S.M., Cordon-Cardo, C., et al., 2003. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549.
Kienast, Y., von Baumgarten, L., Fuhrmann, M., Klinkert, W.E., Goldbrunner, R., Herms, J., et al., 2010. Real-time imaging reveals the single steps of brain metastasis formation. Nat. Med. 16, 116-122.
Kouros-Mehr, H., Bechis, S.K., Slorach, E.M., Littlepage, L.E., Egeblad, M., Ewald, A.J., et al., 2008. Gata-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 13, 141-152.
Kumar, S., and Weaver, V.M., 2009. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev. 28, 113-127.
Langley, R.R., and Fidler, I.J., 2011. The seed and soil hypothesis revisited-the role of tumor-stroma interactions in metastasis to different organs. Int. J. Cancer 128, 2527-2535.
Lee, B.C., Lee, T.H., Avraham, S., and Avraham, H.K., 2004. Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells. Mol. Cancer Res. 2, 327-338.
Lesniak, M.S., and Brem, H., 2004. Targeted therapy for brain tumours. Nat. Rev. Drug Discov. 3, 499-508.
Lewis, B.P., Burge, C.B., and Bartel, D.P., 2005. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15-20.
Lin, L., Chamberlain, L., Pak, M.L., Nagarajan, A., Gupta, R., Zhu, L.J., et al., 2014. A large-scale RNAi-based mouse tumorigenesis screen identifies new lung cancer tumor suppressors that repress FGFR signaling. Cancer Discov. Pii: CD-13-0747 [Epub ahead of print].
Lockman, P.R., Mittapalli, R.K., Taskar, K.S., Rudraraju, V., Gril, B., Bohn, K.A., et al., 2010. Heterogeneous bloodtumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin. Cancer Res. 16, 5664-5678.
Lorger, M., 2012. Tumor microenvironment in the brain. Cancers 4, 218-243.
Lu, W., Su, J., Kim, L.S., Bucana, C.D., Donawho, C., He, J., et al., 2003. Active specific immunotherapy against occult brain metastasis. Cancer Res. 63, 1345-1350.
Lu, Y., Govindan, R., Wang, L., Liu, P.Y., Goodgame, B., Wen, W., et al., 2012. MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis 33, 1046-1054.
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., et al., 2001. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7, 1194-1201.
Maher, E.A., Mietz, J., Arteaga, C.L., DePinho, R.A., and Mohla, S., 2009. Brain metastasis: opportunities in basic and translational research. Cancer Res. 69, 6015-6020.
Mani, S.A., Guo, W., Liao, M.J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., et al., 2008. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715.
Marcato, P., Dean, C.A., Pan, D., Araslanova, R., Gillis, M., Joshi, M., et al., 2011. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 29, 32-45.
Marchetti, D., and Nicolson, G.L., 2001. Human heparanase: a molecular determinant of brain metastasis. Adv. Enzyme Regul. 41, 343-359.
Mareel, M., and Madani, I., 2006. Tumor-associated host cells participating at invasion and metastasis: targets for therapy? Acta Chir. Belg. 106, 635-640.
McDermott, R., Gabikian, P., Sarvaiya, P., Ulasov, I., and Lesniak, M.S., 2013. MicroRNAs in brain metastases: big things come in small packages. J. Mol. Med. 91, 5-13.
Melo, S.A., and Esteller, M., 2011. Dysregulation of microRNAs in cancer: playing with fire. FEBS Lett. 585, 2087-2099.Mueller, W.C., Spector, Y., Edmonston, T.B., St Cyr, B., Jaeger, D., Lass, U., et al., 2011. Accurate classification of metastatic brain tumors using a novel microRNA-based test. Oncologist 16, 165-174.
Munzarova, M., and Kovarik, J., 1987. Is cancer a macrophage-mediated autoaggressive disease? Lancet 1, 952-954.
Nash, G.F., Turner, L.F., Scully, M.F., and Kakkar, A.K., 2002. Platelets and cancer. Lancet Oncol. 3, 425-430.
Nieswandt, B., Hafner, M., Echtenacher, B., and Mannel, D.N., 1999. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 59, 1295-1300.
Nikolsky, Y., Sviridov, E., Yao, J., Dosymbekov, D., Ustyansky, V., Kaznacheev, V., et al., 2008. Genome-wide functional synergy between amplified and mutated genes in human breast cancer. Cancer Res. 68, 9532-9540.
Parker, J.S., Mullins, M., Cheang, M.C., Leung, S., Voduc, D., Vickery, T., et al., 2009. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160-1167.
Perou, C.M., Parker, J.S., Prat, A., Ellis, M.J., and Bernard, P.S., 2010. Clinical implementation of the intrinsic subtypes of breast cancer. Lancet Oncol. 11, 718-719 (author reply 720-721).
Pietras, K., and Ostman, A., 2010. Hallmarks of cancer: interactions with the tumor stroma. Exp. Cell Res. 316, $1324-1331$.
Pouliot, N., Pearson, H.B., and Burrows, A., 2000. Investigating metastasis using in vitro platforms Madame Curie Bioscience Database [Internet]. Landes Bioscience, Austin (TX), Available from: <http://www.ncbi.nlm.nih. gov/books/NBK5974/>.
Prins, R.M., and Liau, L.M., 2004. Cellular immunity and immunotherapy of brain tumors. Front Biosci. 9, $3124-3136$.
Qian, B.Z., and Pollard, J.W., 2010. Macrophage diversity enhances tumor progression and metastasis. Cell 141, $39-51$.
Quintana, E., Shackleton, M., Sabel, M.S., Fullen, D.R., Johnson, T.M., and Morrison, S.J., 2008. Efficient tumour formation by single human melanoma cells. Nature 456, 593-598.
Raeder, M.B., Birkeland, E., Trovik, J., Krakstad, C., Shehata, S., Schumacher, S., et al., 2013. Integrated genomic analysis of the 8 q 24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLoS One 8, e54873.
Raichle, M.E., and Mintun, M.A., 2006. Brain work and brain imaging. Annu. Rev. Neurosci. 29, 449-476.
Rao, J., Oz, G., and Seaquist, E.R., 2006. Regulation of cerebral glucose metabolism. Minerva Endocrinol. 31, $149-158$.
Rosenthal, R., Thieme, H., and Strauss, O., 2001. Fibroblast growth factor receptor 2 (FGFR2) in brain neurons and retinal pigment epithelial cells act via stimulation of neuroendocrine L-type channels (Ca(v)1.3). FASEB J. 15, $970-977$.
Rousalova, I., and Krepela, E., 2010. Granzyme B-induced apoptosis in cancer cells and its regulation (review). Int. J. Oncol. 37, 1361-1378.

Salhia, B., Kiefer, J., Ross, J.T., Metapally, R., Martinez, R.A., Johnson, K.N., et al., 2014. Integrated genomic and epigenomic analysis of breast cancer brain metastasis. PLoS One 9, e85448.
Shinonaga, M., Chang, C., Suzuki, N., Sato, M., and Kuwubara, T., 1988. Immunohistological evaluation of macrophage infiltrates in brain tumors. Correlation with peritumoral edema. J. Neurosurg. 68, 259-265.
Subramani, A., Alsidawi, S., Jagannathan, S., Sumita, K., Sasaki, A.T., Aronow, B., et al., 2013. The brain microenvironment negatively regulates miRNA-768-3p to promote K-ras expression and lung cancer metastasis. Sci. Rep. 3, 2392.
Thiery, J.P., Acloque, H., Huang, R.Y., and Nieto, M.A., 2009. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890.
Weil, R.J., Palmieri, D.C., Bronder, J.L., Stark, A.M., and Steeg, P.S., 2005. Breast cancer metastasis to the central nervous system. Am. J. Pathol. 167, 913-920.
Yamazaki, H., Hanada, M., Kitada, M., Kuyama, J., Sato, T., Nishikubo, M., et al., 2003. Four cases of central nervous system involvement of breast malignant lymphoma. Jpn. J. Clin. Oncol. 33, 399-403.
Yao, J., Weremowicz, S., Feng, B., Gentleman, R.C., Marks, J.R., Gelman, R., et al., 2006. Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res. 66, 4065-4078.
Yilmaz, M., and Christofori, G., 2009. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 28, $15-33$.
Zhao, X., and Guan, J.L., 2011. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv. Drug Deliv. Rev. 63, 610-615.

# I. MOLECULAR MECHANISMS# Role of CDKN2A Mutations and Other Relevant Genes in Melanoma Predisposition 

Érica S.S. de Araújo, Dimitrius T. Pramio and Ana C.V. Krepischi

## O U T L I N E

Introduction
High-Risk Melanoma Predisposition
Genes
CDKN2A: Identification of the Major
Melanoma Predisposition Gene
CDKN2A Mutations
CDK4
BAP1
Telomere Regulating Genes
TERT
POT1
Other Shelterin Complex Genes
101
102
102
103
105
105
106
107
108

101
MC1R
MITF
Low Evidence Genes
Genome-Wide Association Studies on
Melanoma Predisposition
Perspectives
Acknowledgments
References

109
109
110
110
110
111
111
114

## INTRODUCTION

Melanoma is an aggressive skin cancer and accounts for the majority of skin cancer deaths, according to the American Cancer Society (www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/). The melanoma incidence rate is increasingworldwide, and the disease is among the top 10 in new cancer cases that occur in developed countries (Torre et al., 2015). Although the majority of melanoma cases are sporadic, the risk of developing melanoma rises by 30-70-fold in individuals with a familial history of the disease. However, to date, the etiology of hereditary melanoma has not been fully elucidated. Since the discovery of the high-risk melanoma gene CDKN2A in 1994, few genes have been associated with melanoma predisposition, and most of them have been identified recently through advancements in genome sequencing technologies. In this chapter, we will summarize and discuss the currently recognized genomic architecture that is associated with melanoma risk.

# HIGH-RISK MELANOMA PREDISPOSITION GENES 

## CDKN2A: Identification of the Major Melanoma Predisposition Gene

The first evidence of genetic inheritance of melanoma was produced by the observations of Dr William Norris in 1820. Dr Norris described a male melanoma patient who developed a tumor from a mole; the patient's father had died from a similar disease, and the patient's sons had developed several moles. However, it was not until 1952 that studies of the hereditary aspects of melanoma were resumed, which were reinitiated by the investigations of Cawley et al. (1952) and followed by additional descriptions of melanoma families. At that time, familial melanoma was characterized by an early age of onset and an autosomal dominant pattern of inheritance; however, no "melanoma gene" had been identified.

Succeeding studies suggested that atypical moles, which were defined in relation to color, border, and histological characteristics, are a melanoma risk factor. Thereafter, the search for a melanoma gene has included evaluating the occurrence of both melanoma and dysplastic nevus and has resulted in identifying a candidate locus at chromosome 1p (Bale et al., 1989). However, the association of the 1 p locus with hereditary melanoma was not subsequently validated in additional melanoma families (Cannon-Albright et al., 1990).

Between the 1970s and 1980s, results from experiments conducted on murine and human melanoma cell lines indicated an association between chromosome 9 p and the development of melanoma (Piepkorn, 1994). A candidate 9p21 locus was tested by Cannon-Albright and colleagues using linkage analysis of 11 relatives who presented with invasive melanoma, and these authors delimitated the melanoma susceptibility locus using IFNA and D9S126 probes (Cannon-Albright et al., 1992). The identification of a melanoma patient who was carrying a germline translocation between 5 p and 9 p in association with a deletion of both IFNA and D9S126 markers provided further support for the importance of this genomic region (Petty et al., 1993). After delimitation of the candidate locus, two independent groups (Kamb et al., 1994a; Nobori et al., 1994) demonstrated that this region was frequently altered in melanomas and cell lines, similarly to the previously described p16 locus (also called CDKN2 or MTS1), a gene that had been demonstrated to be associated with control of the cell cycle. Only a low frequency of p16 mutations was subsequently identified in melanoma families (Kamb et al., 1994b). Indeed, germline mutations affecting p16 have been detected in only a portion of the melanoma families that have been studied to date (Hayward, 1996). A description of a homozygous individual who carried a p16 deletion but had notdeveloped melanoma over the course of his life indicated that lack of p16 can be not enough to spur melanoma development (Gruis et al., 1995).

In 1995, two separate groups reported a new transcript for the p16 locus, p14, which partially shares the sequence of the first identified transcript (Duro et al., 1995; Stone et al., 1995). Later, two different germline mutations were identified in an exclusive region of p14: a deletion in one family with melanoma and nervous system tumors (Randerson-Moor et al., 2001), and an insertion in one melanoma patient who had developed multiple melanomas (Rizos et al., 2001). Altogether, the collected family data demonstrated that mutations in both p16 and p14 proteins led to melanoma predisposition, supporting that CDKN2A (the official name of the p16/p14 locus) was the melanoma susceptibility gene located at 9p21.

# CDKN2A Mutations 

The CDKN2A gene encodes two different proteins with distinct functions: p16 and p14. The sequence codifying these two protein isoforms differs within the first exon (exon $1 \alpha$ and exon $1 \beta$ for p16 and for p14, respectively) as a result of alternative splicing and a different reading frame (Stone et al., 1995). The p16 protein acts as a tumor suppressor by inhibiting the CDK4 protein, which impairs the activation of pRb and results in cell arrest at the G1 phase of the cell cycle. The p14 protein also acts a tumor suppressor and inhibits the MDM2 protein, leading to p53 stabilization and G1 cell cycle arrest (Zhang et al., 1998).

Up to $40 \%$ of familial melanoma cases are caused by germline CDKN2A mutations (Aoude et al., 2015a). In contrast, the detection rate of mutations in this gene is low in patients presenting with melanomas during childhood or adolescence (Berg et al., 2004). Several characteristics of melanoma patients and their families, such as $\geq 2$ affected family members, early age at diagnosis, and occurrence of multiple primary melanomas and pancreatic cancer, have been significantly associated with CDKN2A mutations (Pedace et al., 2011). According to the ClinVar database (http://www.ncbi.nlm.nih.gov/clinvar; April 2014), 58 pathogenic genetic alterations have already been reported in the CDKN2A gene, and 20 of them are germline mutations that were identified in melanoma families. In Table 7.1, we have compiled a list of the CDKN2A mutations that have been most frequently associated with hereditary melanoma according to reports published between January 2010 and March 2015. The pathogenic mutations associated with melanoma predisposition have been primarily detected in exons $1 \alpha$ and 2 (Marzuka-alcalá et al., 2014). Mutations affecting the p16 isoform are far more frequent and are predominantly loss-of-function missense mutations, whereas the inactivating mutations that have been reported for the p14 isoform include deletions, insertions and splicing mutations (Aoude et al., 2015a).

An increased CDKN2A penetrance has been identified in select regions of the world that exhibit a high melanoma incidence; however, the overall penetrance of CDKN2A has been estimated to be $30 \%$ by age of 50 and $67 \%$ by age of 80 (Bishop et al., 2002). Additionally, the relative risk of melanoma among carriers of CDKN2A mutations could diverge depending on the pathogenic variant; for instance, the odds ratio associated with the $-34 \mathrm{G}>\mathrm{T}$ mutation was estimated to be 15.3 , whereas missense mutations that affect only p14 were determined to have odds ratios of 0.7 (Berwick et al., 2006). Other genetic variants can also influence CDKN2A penetrance. Variants of the melanocortin-1-receptor (MC1R) gene have been reported to increase CDKN2A penetrance because $81 \%$ of patients carrying both a CDKN2ATABLE 7.1 CDKN2A Variants Associated with Melanoma Predisposition*

| Gene element | Variant |  | SNP ${ }^{g}$ | Clinical significance ${ }^{8}$ | Reference |
| :--: | :--: | :--: | :--: | :--: | :--: |
|  | NM_000077.4(p16) | NM_058195.3 (p14) |  |  |  |
| 5'UTR | c.-34G>T | $-$ | rs1800586 | pathogenic | Maubec et al. (2012); De Ávila et al. (2014); Harland et al. (2014) |
| exon $1 \alpha$ | c.9_32del24 | $-$ | $-$ | $-$ | Harland et al. (2014); <br> Wadt et al. (2015a) |
|  | c.32_33ins9_32 | $-$ | $-$ | $-$ | Harland et al. (2014) |
|  | c.52_57dup | $-$ | $-$ | $-$ | Maubec et al. (2012); <br> Harland et al. (2014) |
|  | c.68G>A | $-$ | $-$ | $-$ | Harland et al. (2014) |
|  | c.71G>C | $-$ | rs104894097 | pathogenic | Nikolaou et al. (2011); <br> Pedace et al. (2011); <br> Maubec et al. (2012); <br> Harland et al. (2014) |
|  | c.95T>C | $-$ | $-$ | $-$ | Harland et al. (2014) |
|  | c.104G>C | $-$ | $-$ | $-$ | Maubec et al. (2012); <br> Harland et al. (2014) |
|  | c.142C>A | $-$ | $-$ | pathogenic | Pedace et al. (2011); <br> Maubec et al. (2012); <br> De Ávila et al. (2014) |
| exon 2 | c.159G>C | c.202G>C | rs104894095 | pathogenic | Maubec et al. (2012); <br> Harland et al. (2014) |
|  | c.176T>G | c.219T>G | rs104894099 | risk factor | Pedace et al. (2011); <br> Maubec et al. (2012); <br> Harland et al. (2014) |
|  | c.194T>C | c.237T>C | $-$ | $-$ | Maubec et al. (2012); <br> Harland et al. (2014) |
|  | c.259C>T | c.302C>T | $-$ | $-$ | Nikolaou et al. (2011); <br> Harland et al. (2014) |
|  | c.301G>T | c.344G>T | rs104894094 | pathogenic | Pedace et al. (2011); <br> Maubec et al. (2012); <br> De Ávila et al. (2014); <br> Harland et al. (2014); <br> Wadt et al. (2015a) |
|  | c.335_337dup | c.379_381dup | $-$ | $-$ | Helgadottir et al. (2014); <br> Wadt et al. (2015a) |
|  | c.442G>A | c.*86G>A | rs3731249 | benign | Bakos et al. (2011); <br> Veinalde et al. (2013) |
| intron 2 | c.458-105A>G | $-$ | $-$ | $-$ | Maubec et al. (2012); <br> Harland et al. (2014) |

${ }^{\circ}$ This table lists only CDKN2A variants that were reported in works published from January 2010 to March 2015 and were found in at least two countries, ${ }^{8}$ ClinVar.
mutation and an $M C 1 R$ variant had developed melanoma before 50 years of age, whereas the estimated penetrance for these patients if they harbored only a CDKN2A mutation would be $57 \%$ (Box et al., 2001). The effect of MC1R on CDKN2A penetrance appears to be stronger in carriers of multiple and red hair color variants (Fargnoli et al., 2010). Conversely,null GSTT1 alleles were described to confer a protective effect with respect to melanoma risk even among carriers of CDKN2A mutations (Chaudru et al., 2009). Regarding environmental factors, contradictory results of both positive and minor effects have been reported with regard to UV exposure (Goldstein et al., 1998; Berwick et al., 2011).

Carriers of CDKN2A mutations have been reported to be predisposed toward developing additional types of cancer, including nervous system tumors and pancreatic cancer (Aoude et al., 2015a). Additionally, patients who smoke and who also carry the CDKN2A p.Arg112dup mutation have been shown to be at high-risk of developing tumors in respiratory and upper digestive tissues (Helgadottir et al., 2014).

Although the importance of CDKN2A mutations in melanoma susceptibility has been well established, there is currently no consensus regarding the indication of genetic screening in melanoma-prone patients, primarily because a positive result for a CDKN2A mutation does not affect clinical care, and data corroborating that such a result improves prevention is insufficient (Glanz et al., 2013). However, the detection of a CDKN2A germline mutation in a melanoma family does enable the identification of family members who are not at risk of developing melanomas and therefore can exclude them from undergoing further surveillance.

# CDK4 

In 1995, a CDK4 mutation (R24C) was identified that impaired the association between $C D K 4$ and p16 and therefore contributed to melanogenesis via the disruption of cell cycle regulation (Wölfel et al., 1995). The same mutation was detected later in two unrelated melanoma families without CDKN2A mutations; following this, a second type of CDK4 mutation (R24H) was discovered in a French melanoma family, strengthening the importance of this locus in melanoma predisposition.

It is noteworthy that in melanoma cells a single mutant CDK4 allele is sufficient to induce deregulation of cell cycle control, whereas both CDKN2A alleles must be mutated to produce similar results. However, no phenotypic differences have been observed when comparing melanoma patients who are carriers of mutations in these genes. Furthermore, it appears that MC1R variants also influence the penetrance of CDK4 mutations because only a low frequency of red hair color variants was detected in unaffected individuals carrying CDK4 mutations (Puntervoll et al., 2013). Although CDK4 can be considered a high-risk melanoma gene, its detection rate is very low; currently, only 17 melanoma families harboring CDK4 mutations have been reported (Aoude et al., 2015a).

## BAP1

The tumor suppressor gene BRCA1-associated protein-1 (BAP1) has been mapped to the cytoband 3p21.3, a region that has been shown to be routinely deleted in several types of cancer. Harbour and colleagues (2010) described for the first time a high frequency of BAP1 mutations in patients presenting with uveal melanoma metastasis; one of the patients carried a germline insertion that caused premature termination of BAP1 protein translation. These findings were further supported by Njauw and colleagues (2012), who identified fouradditional cases of germline BAP1 mutations in association with a metastatic subtype of uveal melanoma.

Notably, cutaneous melanoma cases have also occurred in families with BAP1 germline mutations. Njauw and colleagues (2012) reported a low frequency of BAP1 mutations in cutaneous melanoma families ( $0.52 \%$ ), whereas families exhibiting both cutaneous and uveal melanomas exhibited a frequency of $28.5 \%$. Another recent population-based study that was conducted on a group of Australian cutaneous melanoma patients detected BAP1 missense mutations in $0.63 \%$ of the cases (Aoude et al., 2015a).

Following the first descriptions of an association between BAP1 mutations and melanoma predisposition, several studies have found BAP1 germline mutations that segregate in families with distinct cancer types. Testa and colleagues (2011) described a cancer syndrome that was characterized by uveal melanoma and mesothelioma, whereas Wiesner and colleagues (2011) reported BAP1 germline mutations in two families presenting with melanocytic neoplasms in which several of the affected patients developed uveal or cutaneous melanomas. Moreover, Abdel-Rahman and colleagues (2011) reported one family that exhibited cutaneous and uveal melanomas, meningioma and neuroendocrine carcinoma cases that segregated with BAP1 mutations; another family presented with multiple cases of uveal and cutaneous melanoma, paraganglioma, and breast cancer that were reported to segregate with a BAP1 splice-site mutation (Wadt et al., 2012).

In summary, BAP1 missense mutations have been identified at a low frequency in popula-tion-based samples of cutaneous melanoma and in dense cutaneous melanoma families. It appears that alterations in the BAP1 gene are highly penetrant and result in families who exhibit both uveal and cutaneous melanomas. BAP1 mutations are now related to a phenotype characterized by cutaneous and ocular melanomas, characteristic melanocytic proliferations, and other internal neoplasms that is termed COMMON syndrome (Njauw et al., 2012).

# TELOMERE REGULATING GENES 

Human telomeres are structures that are composed of a repetitive double-stranded sequence of TTAGGG repeats, followed by single-strand DNA (ssDNA) overhangs that are composed of 50-300-nucleotide-long G-rich sequences. Telomeres are crucial to genomic stability because these structures protect chromosome ends from the DNA repair system (Robles-Espinoza et al., 2014a). Telomere length is a feature that has been related to cell viability and aging, as shorter or longer telomeres have been directly associated with cell death control. The mechanism that regulates telomere length and integrity involves two distinct complexes: the telomerase complex and the shelterin complex. The telomerase complex includes a telomerase holoenzyme and several accessory factors that are necessary for assembly and activation. The shelterin complex includes six core proteins (TERF1, TERF2, TINF2, TERF2IP, ACD, and POT1) that interact with each other to maintain telomere length and to protecting it from DNA repair systems; they are also associated with activation of the telomerase complex (Robles-Espinoza et al., 2014a).

Disruptions to the normal expression levels and/or changes affecting the genomic sequences of the components of these two telomere complexes have been previously described in sporadic cancers. Additionally, germline mutations in several of these geneswere recently demonstrated to be associated with cancer predisposition, especially in cutaneous melanoma families (Robles-Espinoza et al., 2014b).

# TERT 

The telomerase reverse transcriptase gene (TERT) has been mapped at 5p15.33 and encodes the catalytic subunit of the TERT holoenzyme. Active TERT is also comprised of an RNA template, encoded by the TERC gene, and has been implicated in the maintenance of telomere length. It is interesting to note that telomere length has been associated with an increase in cutaneous melanoma risk in melanoma families: affected patients without CDKN2A mutations who carried longer telomeres were determined to have an odds ratio of $3.34(95 \% \mathrm{CI}, 1.12-10.00)$ compared to healthy individuals, as described by Burke and colleagues (2013). Considering the relevance of telomere length in triggering apoptotic pathways and cancer development, researchers have (unsuccessfully) searched for TERT mutations in different types of cancer over the past several years. The mystery was solved with the discovery of a mutation in a noncoding region of the TERT gene, which was located in the promoter region at -57 bp from the ATG (adenine-thymine-guanine) start site (Horn et al., 2013). This mutation in the TERT promoter has been identified in a melanoma family, segregating in all four affected members, and in one unaffected member who carried multiple nevi. The T>G mutation at -57 bp from the transcription start site creates a new binding motif for a family of Ets transcription factors, thus upregulating TERT expression in tissues expressing these factors. In a study that was conducted by our group, we did not identify TERT promoter mutations in a cohort of 48 Brazilian melanoma-prone patients (Pramio et al., 2014).

Horn and colleagues also screened TERT promoter mutations in melanoma cell lines and primary melanomas, and alterations were detected at $-124,-125,-138,-139$, and -146 bp from the ATG start site in $74 \%$ of the cell lines and $33 \%$ of the tumors. These findings were further supported by Huang and colleagues, who described a $71 \%$ frequency of TERT promoter mutations in primary cutaneous melanomas (Huang et al., 2013). As expected, TERT promoter mutations were then investigated in other cancer types, and they were detected in $16 \%$ of 150 different cancer cell lines and found to be especially common in bladder and hepatocellular cancer cell lines (Huang et al., 2013).

## POT1

The POT1 gene (protection of telomeres 1), which is mapped at 7q31.33, is a component in the shelterin complex. The POT1 protein has affinity for ssDNA, and its interactions with other shelterin complex proteins results in the formation of a t-loop structure that promotes telomerase accessibility to the $3^{\prime}$ single-stranded regions of telomeres. Two independent studies simultaneously identified rare germline alterations affecting POT1 in familial cutaneous melanoma cases without CDKN2A mutations. Robles-Espinoza and colleagues utilized whole-exome sequencing to screen for germline variants in a group of 184 patients from 105 different pedigrees, and four families were found to carry BAP1 mutations (Robles-Espinoza et al., 2014b). In a fifth family, they detected a Tyr89Cys mutation in the highly conserved N-terminal oligonucleotide-/oligosaccharide-binding (OB) domain of POT1, which is a region that is essential for enabling the protein to bind to ssDNA.In another pedigree, a splice acceptor variant (g.124465412C>T; predicted to be deleterious) was found, and two other families presented with nonsynonymous mutations in the OB domain (g. 124503670G $>$ C, g. 124493077C $>$ A).

The role of POT1 as a melanoma predisposition gene was further supported by a subsequent study. In a study that examined 101 patients from 56 unrelated melanoma families, a variant (g.7:124493086 C $>$ T) that was found in four Italian melanoma families (Shi et al., 2014) was absent in a control group of 2038 Italians. This variant, which is located in the OB2 domain of POT1, was found to be related to increased telomere length and size heterogeneity in the analyzed carriers. Two additional missense variants (p.Gln623His and p.Arg137His) were disclosed in this study on Italian families, and two variants (p.Asp224Asn and p.Ala532Pro) were also discovered in American and Spanish families. Notably, several of the POT1 mutation carriers had developed more than one primary melanoma, and their first- or second-degree relatives were found to be affected by other cancer types (Shi et al., 2014).

# Other Shelterin Complex Genes 

After the reports of POT1 mutations cosegregating in cancer families, the presence of germline alterations were explored in the remaining genes of the shelterin complex ( $A C D$, TERF2IP, TERF1, TERF2, and TINF2) (Aoude et al., 2015b). Among 510 melanoma families, $A C D$ and TERF2IP mutations were identified in six and four families, respectively.

The $A C D$ gene (adrenocortical dysplasia homologue) is located on chromosome 16q22.1, and the encoded protein interacts with POT1 to mediate the control of telomere length and telomere end protection by regulating telomerase accessibility in telomeres. In one of the reported families with $A C D$ mutations, the patients presented a p.Q320X mutation that led to a protein truncation that disrupted the POT1 binding domain and also eliminated the TINF2 binding domain. Interestingly, this family possessed a phenotype of early-onset cutaneous melanoma. Other segregating $A C D$ variants have been described, including p.N249S, which was detected in three families, and p.V272M, which was reported in a single family.

The protein that is encoded by the TERF2IP gene (telomeric repeat binding factor 2, interacting protein; 16q21.3) acts as a component of the shelterin complex through its interactions with the TRF2 protein. TERF2IP is required to prevent homology-directed DNA repair from occurring in telomeres. Two melanoma families presenting germline TERF2IP mutations have been identified, the members of which harbor either p.R364X mutations, which result in protein truncation and disruption of the TERF2 binding domain, or p.Q191R mutations. Two additional TERF2IP variants (p.M5I and p.M10H) have been discovered; however, they were not found to fully segregate in the families in which they were discovered (Aoude et al., 2015b). Following the pattern of telomere-related mutations that impair the functions of telomere regulating genes, several families carrying $A C D$ and TERF2IP germline alterations have exhibited cases of multiple primary melanomas in addition to other tumors, such as those affecting breast, lung, cervix, colon, bowel, ovary, and B cells. This observation reinforces the hypothesis that germline mutations in shelterins confer a predisposition to a broader class of tumors in addition to cutaneous melanomas.# PIGMENTATION TRAIT GENES 

One of the biological functions of melanin is photoprotection, which is best achieved by brown/black eumelanin (Brenner and Hearing, 2008). In contrast to high-risk melanoma genes, which are mostly related to the control of the cell cycle (CDKN2A/CDK4) or linked to DNA repair mechanisms (BAP1), mutations in the genes that act in the pathway of melanin synthesis have been reported as low-to-moderate risk variants. The MC1R and microphthalmia-associated transcription factor (MITF) genes are the best known examples of this category.

## MC1R

MC1R is a receptor expressed in melanocytes that is activated by melanocortins such as $\alpha$-MSH. Upon being stimulated, MC1R increases the levels of intracellular cAMP, which induces melanogenesis. In addition to constitutive pigmentation, facultative pigmentation induced by UV exposure is also controlled by MC1R. MC1R is a highly polymorphic gene, and approximately 200 variants have already been described in its coding region (García-Borrón et al., 2014). The diversity of human pigmentation can be partially explained by MC1R variations; African populations usually exhibit the MC1R consensus sequence, whereas variants of this sequence are common in Eurasians (Harding et al., 2000).

Valverde and colleagues were the first to describe an association of specific MC1R variants with red hair color and fair skin (Valverde et al., 1995). They later reported that several $M C 1 R$ variants are more common in melanoma patients than in the general population, especially the Asp84Glu mutation (Valverde et al., 1996). A meta-analysis showed that in melanoma patients the odds ratios for different MC1R variants ranged from 1.29 to 2.44 (Williams et al., 2011). Importantly, the risk of melanoma is increased by up to fivefold in individuals who carry two separate red hair color variants (Cust et al., 2012). However, not all of the $M C 1 R$ variants that have been associated with melanoma are also associated with red hair and fair skin (Raimondi et al., 2008). Indeed, it has been suggested that individuals with dark hair, eyes, and skin also display an increased melanoma risk if they carry either two low-risk or any high-risk MC1R variants (Kanetsky et al., 2010). Moreover, independent of pigmentation phenotype, MC1R plays a role in DNA repair by enhancing nucleotide excision repair and reducing oxidative stress (Abdel-Malek et al., 2008).

In addition to augmenting cancer risk, several MC1R variants influence the biology of melanomas. Activation of MC1R leads to stimulation of MITF (a transcription factor that targets genes related to the cell cycle, DNA repair, and apoptosis), and the BioGenoMel consortium has tested whether MC1R variants impact patient survival. This investigation revealed that the absence of a consensus allele was associated with a reduced risk of death (Davies et al., 2012).

Although the broad actions of $M C 1 R$ with respect to melanoma origin and development have evidentiary support, genetic testing for this gene remains controversial because acquiring data regarding $M C 1 R$ genotypes does not lead to the development of treatment strategies that could benefit melanoma patients, per se (Glanz et al., 2013).# MITF 

The MITF gene, which has been mapped to 3p14p13, is a major transcription factor that is involved in pigmentation traits. This gene is responsible for melanocyte differentiation and is activated by increases in intracellular cAMP levels, through an interaction between the MSH hormone and the MC1R (García-Borrón et al., 2005).

Two independent studies (Bertolotto et al., 2011; Yokoyama et al., 2011) conducted on melanoma patients have reported the existence of a germline missense substitution in codon 318 (E318K) of MITF; this mutation affects a SUMOylation consensus site and therefore increases its transcriptional activity. Bertolloto and colleagues have reported a higher frequency of this germline E318K mutation in patients who have cutaneous melanoma (OR $=4.78 ; \mathrm{CI}, 95 \%=2.05-11.75)$, renal cell carcinoma ( $\mathrm{OR}=5.19 ; \mathrm{CI}, 95 \%=1.37-16.87)$, or both cancers ( $\mathrm{OR}=14.46 ; \mathrm{CI}, 95 \%=3.74-48.04$ ) compared to controls. They also found the E318K variant to cosegregate with melanoma in three melanoma-prone families. Simultaneously, Yokoyama and colleagues reported segregation of the E318K mutation in one melanoma family; a linkage analysis revealed a log odds ratio score of 2.7, implicating that this MITF alteration serves as a possible intermediate risk variant. They also found this variant to be overrepresented in a replication cohort that included familial melanomas, multiple primary melanomas, or both. In our study of Brazilian melanoma-prone patients, we identified one individual who had multiple primary melanomas and carried the E318K variant $(\mathrm{OR}=2.64, \mathrm{CI}, 95 \%=0.16-43)$ (Pramio et al., 2014).

## LOW EVIDENCE GENES

In recent history, additional studies have reported the existence of novel genes presenting with germline mutations in melanoma families. However, each of these variants has only been described in a single study and therefore further investigation is required. IbarrolaVillava and colleagues performed a case-control study in three distinct, sporadic melanoma series from France, Germany, and Spain, and they found that two different single-nucleotide polymorphisms (SNPs) were significantly associated with the disease: one in an intronic region of the WNT3 gene (rs199524) and one in the 3'UTR of the VPS41 gene (rs11773094) (Ibarrola-Villava et al., 2015). The WNT3 rs199524 SNP demonstrated strong linkage disequilibrium with four other SNPs that are located in the same gene and was associated with the disease at the same order of magnitude in all three phases of the study. After these results were obtained, three French melanoma families were investigated by exome sequencing, and the variant rs147210031 (a nonsynonymous T52R alteration) at VPS41 was found to cosegregate with the phenotypes of these families. Further T52R genotyping in 178 French melanoma families revealed an OR of $4.46(\mathrm{CI}, 95 \%=1.75-11.26)$ compared to controls (Ibarrola-Villava et al., 2015).

A germline heterozygous deletion affecting the MGMT gene was identified by Appelqvist and colleagues in a study that screened a panel of 34 tumor suppressor genes for small copy number alterations in 68 melanoma families using the MLPA (Multiplex ligation-dependent probe amplification) technique (Appelqvist et al., 2014). The MGMT deletion was found to be heterozygous in blood samples and homozygous in tumor samples in two patients of thisfamily (father and daughter); this deletion comprised the promoter region and first exon of MGMT. Further whole MGMT sequencing of the remaining 63 melanoma families revealed the existence of four SNPs, which were also found in the control group and did not segregate with the disease.

Wadt and colleagues employed exome sequencing to study a family with three cases of melanoma; a RAD51B nonsense mutation (c.193C>T) was detected in two sisters who developed melanoma (Wadt et al., 2015b). Although the father also carried the same mutation, he developed a pituitary adenoma and presented no familial history of melanoma. This family was particularly puzzling because the mother also developed a superficial spreading melanoma but did not carry the RAD51B germline alteration, raising the possibility of a phenocopy.

# GENOME-WIDE ASSOCIATION STUDIES ON MELANOMA PREDISPOSITION 

SNPs are the most common type of variation in the human genome. The core basis of genome-wide association studies (GWAS) is the sequencing of huge numbers of SNPs in large cohorts of patients to identify loci associated with diseases. In the case of melanoma, GWAS have been applied as a strategy to clarify the etiology of familial melanoma because until 2011 only two melanoma predisposition genes had been described.

Currently, eight GWAS have been conducted on melanoma, which has resulted in the identification of 28 different SNPs that have been mapped to either within or proximal to 27 different genes (Table 7.2). Some of the highlighted genomic regions harbor genes that have already been associated with melanoma, such as CDKN2A and MC1R. In general, the affected genes are related to proliferation, synthesis of melanin, and DNA repair. However, for the majority of the candidate genes, the relative risk that was conferred by a specific allele was low, and additional studies confirming the pathogenicity of these mutations in melanoma families are scarce. Fang and colleagues (2013) evaluated the joint effects of 11 different SNPs that were previously associated with melanoma by different GWAS and that were mapped to the ARNT, ALS2CR12, LOC402359, LOC100418, MTAP, TYR, ATM, HERC2, CDK10, ASIP, and PLA2G6 genes. In this study, evaluating the combined effects of the SNPs was superior at identifying high-risk melanoma individuals compared to conventional phenotype assessment, which takes into account pale skin and the presence of multiple nevi.

Additional studies are still necessary to validate candidate melanoma genes that have been revealed by GWAS and to clarify their single and synergistic effects on melanoma susceptibility.

## PERSPECTIVES

Understanding the genetic landscape of hereditary melanoma facilitates the early identification of high-risk individuals, improving genetic counseling and potentially resulting in more effective preventive strategies. Currently, we can identify nine well-established and 28 candidate melanoma predisposition genes (Fig. 7.1). However, a substantial fraction of familial melanoma cases still possess unknown etiology, and multiple factors can impactTABLE 7.2 SNPs Associated with Melanoma Risk According to the Catalog of Genome-Wide Association Studies ${ }^{a}$

| Gene name(s) | Mapping | SNP | $P$-Value | OR or beta (95\% CI) |
| :--: | :--: | :--: | :--: | :--: |
| ARNT, SETDB1, LASS2, ANXA9, MCL1, CTSK | 1q21.3 | rs7412746 | 9E-11 | 1.15 |
| ANXA9 | 1q21.3 | rs1722784 | 2E-6 | 1.12 |
| PARP1 | 1q42.12 | rs3219090 | 9E-8 | 1.15 |
| CASP8 | 2q33.1 | rs13016963 | 9E-10 | 1.14 |
| DOCK3 | 3p21.2 | rs1031925 | 8E-6 | 1.15 |
| ACTRT3 | 3q26.2 | rs13097028 | 7E-7 | 1.12 |
| TET2 | 4q24 | rs4698934 | 8E-7 | 1.18 |
| SLC45A2 | 5p13.2 | rs35390 | 2E-7 | 2.78 |
| TERT, CLPTM1L | 5p15.33 | rs401681 | 3E-8 | 1.20 |
| EYS | 6q12 | rs1889497 | 2E-6 | 1.15 |
| ASIP | 6q23.2 | rs228437 | 1E-7 | 1.21 |
| CDKN2A | 9p21.3 | rs7023329 | 4E-7 | 1.18 |
| CDKN2A, MTAP | 9p21.3 | rs7023329 | 7E-9 | 1.20 |
| NR | 10q25.1 | rs17119461 | 7E-12 | 8.40 |
| TYR | 11q14.3 | rs1393350 | 2E-14 | 1.29 |
|  | 11q14.3 | rs1393350 | 2E-13 | 1.30 |
|  | 11q14.3 | rs1847134 | 6E-8 | 1.25 |
| ATM | 11q22.3 | rs1801516 | 3E-9 | 1.19 |
| FTO | 16q12.2 | rs16953002 | 4E-12 | 1.16 |
| MC1R | 16q24.3 | rs258322 | 3E-27 | 1.67 |
|  | 16q24.3 | rs4785763 | 6E-22 | 1.36 |
|  | 16q24.3 | rs258322 | 3E-27 | 1.70 |
|  | 16q24.3 | rs258322 | 2E-9 | 1.50 |
| CDC91L1 | 20q11.22 | rs910873 | 1E-15 | 1.75 |
| MX2 | 21q22.3 | rs45430 | 3E-9 | 1.14 |
| Intergenic | 22q13.1 | rs2284063 | 2E-9 | 1.20 |
| PLA2G6 | 22q13.1 | rs6001027 | 2E-6 | 1.18 |

${ }^{a}$ Hindorff LA, MacArthur J (European Bioinformatics Institute), Morales J (European Bioinformatics Institute), Junkins HA, Hall PN, Klemm AK, and Manolio TA. A Catalog of Published Genome-Wide Association Studies. Available at: www.genome.gov/guastudies. Accessed on 03/26/2015.![img-68.jpeg](img-68.jpeg)

FIGURE 7.1 Genomic map of reported melanoma predisposition genes. Genes are indicated in their respective chromosomal locations and are categorized according to the bottom legend. Genes shown in red are recognized melanoma predisposition genes, and genes shown in black are candidates for melanoma susceptibility (ideogram based on the Genome Decoration Page; http://www.ncbi.nlm.nih.gov/genome/tools/gdp; GRCh37/ resolution: 850).
the occurrence of melanoma in families with missing mutations; such factors may include specific individual or even multiple mutations as well as shared environmental exposures (Aoude et al., 2015a). Recent achievements in the field of genomic sequencing have led to an expansion of the list of melanoma predisposition genes. Since 2011, when the MITF variant E318 was detected, the number of known melanoma predisposition genes has increased from two (CDKN2A and CDK4) to several. Another promising area of research is the field of epigenetics, which involves genomic marks that are not related to changes in the DNA sequence. DNA methylation is the best studied epigenetic marker; however, few groups have explored its potential in melanoma predisposition. Promoter hypermethylation is an alternative mechanism of gene silencing, but investigations of whether this event occurs in the CDKN2A promoter produced negative results in several melanoma families (Araújo et al., 2015). Nevertheless, abnormal DNA methylation levels in TNF and TNFRSF10C genes have been associated with melanoma risk (Hyland et al., 2014; Pergoli et al., 2014), and less conclusive evidence has also suggested that LINE-1 hypermethylation is associated with the development of melanoma (De Araújo et al., 2015). It would be prudent for future studies to also consider potential synergistic effects between already defined genetic variants and environmental factors, which can modulate crucial epigenetic changes. We predict that inthe next few years the perspective in the search for melanoma predisposition genes will probably shift to genome-wide studies that evaluate combined patterns of genetic and epigenetic modifications in families with strong histories of melanoma.

# Acknowledgments 

This work was supported by grants from FAPESP (2012/13963-9; 2013/10785-5 and 2013/07480-8) and CNPq (470446_2013-7).

## References

Abdel-Malek, Z.A., Knittel, J., Kadekaro, A.L., et al., 2008. The melanocortin 1 receptor and the UV response of human melanocytes-a shift in paradigm. Photochem. Photobiol. 84, 501-508.
Abdel-Rahman, M.H., Pilarski, R., Cebulla, C.M., et al., 2011. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J. Med. Genet. 48, 856-859.
Aoude, L.G., Wadt, K.A.W., Pritchard, A.L., et al., 2015a. Genetics of familial melanoma: 20 years after CDKN2A. Pigment Cell Melanoma Res. 28, 148-160.
Aoude, L.G., Pritchard, A.L., Robles-Espinoza, C.D., et al., 2015b. Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma. J. Natl. Cancer Inst. 107, dju408.
Appelqvist, F., Yhr, M., Erlandson, A., Martinsson, T., et al., 2014. Deletion of the MGMT gene in familial melanoma. Genes Chromosomes Cancer 53, 703-711.
Araújo, É.S.S., De, Pramio, D.T., Kashiwabara, A.Y., et al., 2015. DNA Methylation Levels of melanoma risk genes are associated with clinical characteristics of melanoma patients. Biomed. Res. Int. 2015 Article ID 376423.
Bakos, R.M., Besch, R., Zoratto, G.G., et al., 2011. The CDKN2A p.A148T variant is associated with cutaneous melanoma in Southern Brazil. Exp. Dermatol. 20, 890-893.
Bale, S.J., Dracopoli, N.C., Tucker, M.A., et al., 1989. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N. Engl. J. Med. 320, 1367-1372.
Berg, P., Wennberg, A.-M., Tuominen, R., et al., 2004. Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma. Melanoma Res. 14, 251-255.
Bertolotto, C., Lesueur, F., Giuliano, S., et al., 2011. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 480, 94-98.
Berwick, M., Orlow, I., Hummer, A.J., et al., 2006. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol. Biomarkers Prev. 15, 1520-1525.
Berwick, M., Begg, C.B., Armstrong, B.K., et al., 2011. Interaction of CDKN2A and sun exposure in the etiology of melanoma in the general population. J. Invest. Dermatol. 131, 2500-2503.
Bishop, D.T., Demenais, F., Goldstein, A.M., et al., 2002. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J. Natl. Cancer Inst. 94, 894-903.
Box, N.F., Duffy, D.L., Chen, W., et al., 2001. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am. J. Hum. Genet. 69, 765-773.
Brenner, M., and Hearing, V.J., 2008. The protective role of melanin against UV damage in human skin. Photochem. Photobiol. 84, 539-549.
Burke, L.S., Hyland, P.L., Pfeiffer, R.M., et al., 2013. Telomere length and the risk of cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations. PLoS One 8, e71121.
Cannon-Albright, L.A., Goldgar, D.E., Wright, E.C., et al., 1990. Evidence against the reported linkage of the cutaneous melanoma-dysplastic nevus syndrome locus to chromosome Ip36. Am. J. Hum. Genet. 46, 912-918.
Cannon-Albright, L.A., Goldgar, D.E., Meyer, L.J., et al., 1992. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 258, 1148-1152.
Cawley, E.P., Kruse, W.T., and Pinkus, H.K., 1952. Genetic aspects of malignant melanoma. AMA. Arch. Derm. Syphilol. 65, 440-450.Chaudru, V., Lo, M.T., Lesueur, F., et al., 2009. Protective effect of copy number polymorphism of glutathione S-transferase T1 gene on melanoma risk in presence of CDKN2A mutations, MC1R variants and host-related phenotypes. Fam. Cancer 8, 371-377.
Cust, A.E., Goumas, C., Holland, E.A., et al., 2012. MC1R genotypes and risk of melanoma before age 40 years: a population-based case-control-family study. Int. J. Cancer 131, E269-281.
Davies, J.R., Randerson-Moor, J., Kukalizch, K., et al., 2012. Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study. Pigment Cell Melanoma Res. 25, 384-394.
De Araújo, É.S.S., Kashiwabara, A.Y., Achatz, M.I.W., et al., 2015. LINE-1 hypermethylation in peripheral blood of cutaneous melanoma patients is associated with metastasis. Melanoma Res. 25, 173-177.
De Ávila, A.L.R., Krepischi, A.C.V., Moredo, L.F., et al., 2014. Germline CDKN2A mutations in Brazilian patients of hereditary cutaneous melanoma. Fam. Cancer 13, 645-649.
Duro, D., Bernard, O., Della Valle, V., et al., 1995. A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies. Oncogene 11, 21-29.
Fang, S., Han, J., Zhang, M., et al., 2013. Joint effect of multiple common SNPs predicts melanoma susceptibility. PLoS One 8, e85642.
Fargnoli, M.C., Gandini, S., Peris, K., et al., 2010. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis. Eur. J. Cancer 46, 1413-1420.
García-Borrón, J.C., Sánchez-Laorden, B.L., and Jiménez-Cervantes, C., 2005. Melanocortin-1 receptor structure and functional regulation. Pigment Cell Res. 18, 393-410.
García-Borrón, J.C., Abdel-Malek, Z., and Jiménez-Cervantes, C., 2014. MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation. Pigment Cell Melanoma Res. 27, 699-720.
Glanz, K., Volpicelli, K., Kanetsky, P.A., et al., 2013. Melanoma genetic testing, counseling, and adherence to skin cancer prevention and detection behaviors. Cancer Epidemiol. Biomarkers Prev. 22, 607-614.
Goldstein, A.M., Falk, R.T., Fraser, M.C., et al., 1998. Sun-related risk factors in melanoma-prone families with CDKN2A mutations. J. Natl. Cancer Inst. 90, 709-711.
Gruis, N.A., van der Velden, P.A., Sandkuijl, L.A., et al., 1995. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat. Genet. 10, 351-353.
Harbour, J.W., Onken, M.D., Roberson, E.D.O., et al., 2010. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330, 1410-1413.
Harding, R.M., Healy, E., Ray, A.J., et al., 2000. Evidence for variable selective pressures at MC1R. Am. J. Hum. Genet. 66, 1351-1361.
Harland, M., Cust, A.E., Badenas, C., et al., 2014. Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom. Hered. Cancer Clin. Pract 12, 20.
Hayward, N.K., 1996. The current situation with regard to human melanoma and genetic inferences. Curr. Opin. Oncol. 8, 136-142.
Helgadottir, H., Hoiom, V., Jonsson, G., et al., 2014. High risk of tobacco-related cancers in CDKN2A mutationpositive melanoma families. J. Med. Genet. 51, 545-552.
Horn, S., Figl, A., Rachakonda, P.S., Fischer, C., et al., 2013. TERT promoter mutations in familial and sporadic melanoma. Science 339, 959-961.
Huang, F.W., Hodis, E., Xu, M.J., et al., 2013. Highly recurrent TERT promoter mutations in human melanoma. Science 339, 957-959.
Hyland, P.L., Burke, L.S., Pfeiffer, R.M., et al., 2014. Constitutional promoter methylation and risk of familial melanoma. Epigenetics 9, 685-692.
Ibarrola-Villava, M., Kumar, R., Nagore, E., et al., 2015. Genes involved in the WNT and vesicular trafficking pathways are associated with melanoma predisposition. Int. J. Cancer 136, 2109-2119.
Kamb, A., Gruis, N.A., Weaver-Feldhaus, J., et al., 1994a. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264, 436-440.
Kamb, A., Shattuck-Eidens, D., Eeles, R., et al., 1994b. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat. Genet. 8, 23-26.
Kanetsky, P.A., Panossian, S., Elder, D.E., et al., 2010. Does MC1R genotype convey information about melanoma risk beyond risk phenotypes? Cancer 116, 2416-2428.
Marzuka-alcalá, A., Gabree, M.J., and Tsao, H., 2014. Molecular diagnostics for melanoma. Methods Mol. Biol. 1102, $381-393$.Maubec, E., Chaudru, V., Mohamdi, H., et al., 2012. Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family. J. Am. Acad. Dermatol. 67, 1257-1264.
Nikolaou, V., Kang, X., Stratigos, A., et al., 2011. Comprehensive mutational analysis of CDKN2A and CDK4 in Greek patients with cutaneous melanoma. Br. J. Dermatol. 165, 1219-1222.
Njauw, C.-N.J., Kim, I., Piris, A., et al., 2012. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One 7, e35295.
Nobori, T., Miura, K., Wu, D.J., et al., 1994. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368, 753-756.
Norris, W., 1820. Case of fungoid disease. Edinb. Med. Surg. J. 16, 562-565.
Pedace, L., De Simone, P., Castori, M., et al., 2011. Clinical features predicting identification of CDKN2A mutations in Italian patients with familial cutaneous melanoma. Cancer Epidemiol. 35, 116-120.
Pergoli, L., Favero, C., Pfeiffer, R.M., et al., 2014. Blood DNA methylation, nevi number, and the risk of melanoma. Melanoma Res. 24, 480-487.
Petty, E.M., Gibson, L.H., Fountain, J.W., et al., 1993. Molecular definition of a chromosome 9p21 germ-line deletion in a woman with multiple melanomas and a plexiform neurofibroma: implications for 9p tumor-suppressor gene(s). Am. J. Hum. Genet. 53, 96-104.
Piepkorn, M.W., 1994. Genetic basis of susceptibility to melanoma. J. Am. Acad. Dermatol. 31, 1022-1039.
Pramio, D.T., Aguiar, T., Araujo, E.S.S.D., et al., 2014. Low frequency of germline TERT and MITF mutations in Brazilian melanoma-prone patients. Hered. Genet. 3, 3-4.
Puntervoll, H.E., Yang, X.R., Vetti, H.H., et al., 2013. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J. Med. Genet. 50, 264-270.
Raimondi, S., Sera, F., Gandini, S., et al., 2008. MC1R variants , melanoma and red hair color phenotype : a metaanalysis. Int. J. Cancer 122, 2753-2760.
Randerson-Moor, J.A., Harland, M., Williams, S., et al., 2001. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum. Mol. Genet. 10, 55-62.
Rizos, H., Puig, S., Badenas, C., et al., 2001. A melanoma-associated germline mutation in exon 1beta inactivates p14ARF. Oncogene 20, 5543-5547.
Robles-Espinoza, C.D., Del Castillo Velasco-Herrera, M., Hayward, N.K., et al., 2014a. Telomere-regulating genes and the telomere interactome in familial cancers. Mol. Cancer Res. 13, 211-222.
Robles-Espinoza, C.D., Harland, M., Ramsay, A.J., et al., 2014b. POT1 loss-of-function variants predispose to familial melanoma. Nat. Genet. 46, 478-481.
Shi, J., Yang, X.R., Ballew, B., et al., 2014. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat. Genet. 46, 482-486.
Stone, S., Jiang, P., Dayananth, P., et al., 1995. Complex structure and regulation of the P16 (MTS1) locus. Cancer Res. 55, 2988-2994.
Testa, J.R., Cheung, M., Pei, J., et al., 2011. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 43, 1022-1025.
Torre, L.A., Bray, F., Siegel, R.L., et al., 2015. Global cancer statistics. 2012. CA Cancer J. Clin. 65, 87-108.
Valverde, P., Healy, E., Jackson, I., et al., 1995. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat. Genet. 11, 328-330.
Valverde, P., Healy, E., Sikkink, S., et al., 1996. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum. Mol. Genet. 5, 1663-1666.
Veinalde, R., Ozola, A., Azarjana, K., et al., 2013. Analysis of Latvian familial melanoma patients shows novel variants in the noncoding regions of CDKN2A and that the CDK4 mutation R24H is a founder mutation. Melanoma Res. 23, 221-226.
Wadt, K., Choi, J., Chung, J.-Y., et al., 2012. A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma. Pigment Cell Melanoma Res. 25, 815-818.
Wadt, K.A.W., Aoude, L.G., Krogh, L., et al., 2015a. Molecular characterization of melanoma cases in denmark suspected of genetic predisposition. PLoS One 10, e0122662.
Wadt, K.A.W., Aoude, L.G., Golmard, L., et al., 2015b. Germline RAD51B truncating mutation in a family with cutaneous melanoma. Fam. Cancer 14, 337-340.Wiesner, T., Obenauf, A.C., Murali, R., et al., 2011. Germline mutations in BAP1 predispose to melanocytic tumors. Nat. Genet. 43, 1018-1021.
Williams, P.F., Olsen, C.M., Hayward, N.K., et al., 2011. Melanocortin 1 receptor and risk of cutaneous melanoma: a meta-analysis and estimates of population burden. Int. J. Cancer 129, 1730-1740.
Wölfel, T., Hauer, M., Schneider, J., et al., 1995. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281-1284.
Yokoyama, S., Woods, S.L., Boyle, G.M., et al., 2011. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480, 99-103.
Zhang, Y., Xiong, Y., and Yarbrough, W.G., 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92, 725-734.# C H A P T E R 

## 8

## The Role of the Receptor for Advanced Glycation End Products in Malignant Melanoma

## Estelle Leclerc

## O U T L I N E

Introduction ..... 119
Biology of the Receptor for Advanced
Glycation End Products ..... 120
Physiological Role of RAGE ..... 120
RAGE Structure and Isoforms ..... 121
RAGE Signaling ..... 122
RAGE in Melanoma ..... 122
RAGE Ligands in Melanoma ..... 123
Advanced Glycation End Products ..... 124
High Mobility Group Box 1 Protein ..... 125
S100 Proteins ..... 125
S100B ..... 125
S100A2 ..... 126
S100A4 ..... 127
S100A6 ..... 128
S100A8/A9 ..... 129
Other S100 Proteins ..... 129
Conclusion ..... 130
References ..... 130

## INTRODUCTION

Melanoma is a disease of melanocytes, the cells of our skin that produce melanin. Because abnormal growth of melanocytes can be readily followed by visual observation of the skin, early stage melanoma tumors can be easily detected and after surgical resection,patients have a very good prognosis with a 5-year survival of $80-100 \%$. However, once melanoma cells escape the primary tumor and form metastases, the survival rate of patients decreases dramatically with a 10-year survival of less than 10\% (Bhatia et al., 2009). For more than 30 years, the gold standard for treatment of melanoma consisted of the alkylating agent dacarbazine, however, the response rates were low and the survival benefits minimal (Bhatia et al., 2009). Since 2011, several new drugs have been approved by the FDA for the treatment of metastatic melanoma (Trinh and Hagen, 2013). Two drugs, vemurafenib and dabrafenib, are small molecules that target the BRAF enzyme if the enzyme has the V600E mutation, the most frequent mutation of BRAF found in melanoma tumors (Menzies and Long, 2013). Although treatment with the BRAF inhibitors resulted in promising response rates, most patients experience regrowth of drug-resistant tumors within a year of treatment, due to the reactivation of the MEK signaling pathway. To overcome this problem of drug resistance, new combination therapies have been tested in clinical trials (Menzies and Long, 2013). One combination consists of dabrafenib with trametinib, an inhibitor of MEK (Menzies and Long, 2013). Several monoclonal antibodies have also been recently approved for the treatment of metastatic melanoma (Robert et al., 2015). Ipilimumab targets the cytotoxic T-lymphocyte antigen- 4 receptor at the surface of T cells, resulting in suppression of T-cell inhibition (Trinh and Hagen, 2013). Nivolumab and pembrolizumab target the program cell death (PD1) receptor on the surface of T-cells, therefore releasing PD-1-mediated inhibition of the immune response, and resulting in enhanced antitumor immune responses (Robert et al., 2015). Because of their mechanisms of action, these monoclonal antibodies can generate life threatening immune-related adverse events in patients (Robert et al., 2015). In addition, because of the nature of the target cells, the therapeutic efficacy of these antibodies depends on the levels of infiltrated immune cells in the melanoma tumors.

Despite these recent advances in melanoma therapy, it is important to continue searching for novel therapeutic strategies and targets. Recent studies have suggested that the receptor for advanced glycation end products (RAGE) should be evaluated as a therapeutic target in melanoma (Meghnani et al., 2014a; Popa et al., 2014). We will discuss here evidence supporting a role of RAGE and its ligands in the progression of melanoma.

# BIOLOGY OF THE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS 

## Physiological Role of RAGE

RAGE was initially identified as a receptor for advanced glycation end products. Staining for RAGE showed that this receptor is most abundantly expressed in skeletal muscle, lung, and heart. Studies of RAGE knock-out animals revealed that RAGE is not essential for life but that it has a role in innate immunity, peripheral nerve repair, and shows protective effects in the lungs (Sparvero et al., 2009). Behavioral studies showed no changes in spatial memory or anxiety in RAGE knock-out animals and only increased cage activity and sensitivity to auditory stimuli.

Whereas the physiological role of RAGE needs to be further investigated, stronger evidence supports the role of RAGE in multiple diseases. For example, studies have shown that RAGE is involved in complications of diabetes, in Alzheimer's disease, in infectious diseases, and in multiple cancers, including melanoma (Sparvero et al., 2009).# RAGE Structure and Isoforms 

RAGE belongs to the superfamily of immunoglobulin (Ig)-like receptors. It consists of a single transmembrane domain, a large Ig-like extracellular domain and a relatively short intracellular domain (Fig. 8.1) (Fritz, 2011). The extracellular part is the site of interaction with RAGE ligands: it comprises an Ig-like variable (V) domain (residues 23-119) and two Ig-like constant domains (C1: residues 120-233 and C2: residues 234-325) (Fig. 8.1) (Fritz, 2011). Recent studies suggest that RAGE exists as dimers at the surface of cells. However, it is currently not exactly known how the different domains of the receptor interact with each other or with RAGE ligands during signal transduction (Fritz, 2011). Several structural models have recently been proposed, suggesting interactions between RAGE V domains, C1 domain or C2 domain (Yatime and Andersen, 2013). It has been hypothesized that RAGE recognizes similar structural elements or patterns within its numerous ligands and therefore RAGE has been classified as a pattern recognition receptor.

The main form of RAGE is the full-length form described in Fig. 8.1. However, several spliced and proteolytically produced isoforms have been described. The most common isoform of RAGE, besides the full-length RAGE, is the soluble form or sRAGE. sRAGE lacks both the intracellular and transmembrane domains. sRAGE can result either from a splicing event or from the action of a metalloprotease such as ADAM 10 (Sparvero et al., 2009).
sRAGE has been suggested to interact with circulating RAGE ligands and to suppress RAGE signaling by acting as decoy receptor. However, this role for sRAGE is controversial
![img-69.jpeg](img-69.jpeg)

FIGURE 8.1 RAGE structure and signaling. RAGE consists of a single transmembrane domain, a large extracellular domain comprising of one Ig-like variable (V) and two Ig-like constant (C1 and C2) domains. RAGE signaling is complex and is ligand and cell-type dependent. RAGE ligands interact with the V, C1, or C2 domain. RAGE engagement by its ligands leads to the activation of distinct signaling pathways involving PI3K/AKT, RAS/ Erk1/2, or JAK with the downstream activation of several transcription factors, such as NF- $\kappa B, A P-1$, and STAT3. Several adaptor molecules (Dia-1, TIRAP, ERK1/2, and MyD88) interacting with the intracellular domain have been described.because of the low levels of circulating sRAGE (picomolar) compared to the 1000-fold higher levels of RAGE ligands (nanomolar) (Bierhaus and Nawroth, 2009). Recently, the group of Fritz proposed a more attractive role for sRAGE. They suggested that one molecule of sRAGE could form a hetero-complex with one molecule of full-length RAGE, resulting in a nonfunctional RAGE dimer (Fritz, 2011).

Although the role of sRAGE is not fully understood, studies have shown that in certain pathologies, the levels of sRAGE could serve as a biomarker for the progression of the disease. For example, lower levels of sRAGE have been reported in Alzheimer's patients, or patients with certain cancers compared to healthy control individuals. However, in other diseases such as diabetes, the levels of sRAGE does not always correlate with the disease progression (reviewed and discussed in Yan et al., 2010). Other splicing isoforms, such as the one lacking the N -terminal V domain, have been reported but their physiological functions are still not fully understood (Jules et al., 2013).

# RAGE Signaling 

RAGE signaling is complex and the engagement of RAGE by its ligands can result in ligand specific and cell-type specific signaling. Fig. 8.1 illustrates several important kinases (PI3K, AKT, ERK1/2 and JAK), GTPases (Ras), and transcription factors (NF-кB, AP-1, and STAT3) that have been found activated in RAGE dependent manner (Sparvero et al., 2009). In addition, RAGE activation by its ligands often results in the upregulation of the receptor itself, resulting in positive feedback loops (Fig. 8.1).

## RAGE in Melanoma

An increasing amount of evidence supports the hypothesis that RAGE does play a significant role in melanoma progression. The group of Huttunen generated syngeneic tumors in mice using the B16F10 cell line that either expressed full-length RAGE and a form of the receptor lacking the intracellular signaling domain (Huttunen et al., 2002). The authors showed that mice developed a larger number of metastases when injected with cells that were transfected with full-length RAGE than when injected with cells transfected with signal-deficient RAGE mutants. In two independent studies in mice, the growth of human xenograft tumors generated from implanted G361 showed significant reduction in the presence of either anti-RAGE monoclonal antibodies or RAGE targeting aptamers (Abe et al., 2004; Ojima et al., 2014).

We recently showed that the growth of xenograft melanoma tumors could be significantly reduced when mice were treated with the monoclonal anti-RAGE antibody 2A11 (Meghnani et al., 2014a). In our study, we implanted WM115 melanoma cells that overexpressed RAGE. Interestingly, only tumors generated from RAGE overexpressing cells responded to the antibody treatment, and the antibody treatment did not affect the growth of tumors generated from MOCK-transfected WM115 cells. Several studies including ours revealed large variations in RAGE levels among human melanoma tumors. We analyzed a panel of 40 samples of human melanoma tumor cDNA and observed up to 50 -fold differences between samples (Leclerc et al., 2009). These data strongly suggest that targeting RAGE in melanoma tumors could be a valid approach for melanoma tumors that express a high level of the receptor.At the cellular level, we showed that forced expression of RAGE in the WM115 melanoma cell line was sufficient to trigger an increase in cell migration and invasion and resulted in moderate but significant decrease in cell proliferation. Analysis of signaling pathways revealed a decrease in activation levels of Erk1/2 and p38 in the RAGE overexpressing cells compared to the MOCK control cells (Meghnani et al., 2014a). Recently Popa et al. showed that the migration of the two melanoma cell lines MelJuSo and SK-Mel28 was RAGE dependent, albeit to a different extent in the two cell lines, suggesting again that RAGE contribution to melanoma is cell line or tumor specific and cannot be generalized (Popa et al., 2014). Another interesting aspect of the study of Popa et al. is that RAGE localized at different sites within the different cells, with a more dispersed localization of RAGE in the metastatic SK-Mel28 cell line than in the primary tumor MelJuSo cell line, suggesting also complex and distinct functions of RAGE in primary and metastatic tumors (Popa et al., 2014).

# RAGE LIGANDS IN MELANOMA 

RAGE has been classified as a pattern recognition receptor because of the large variety of its ligands: these ligands include advanced glycation end products (AGEs), amyloid forming peptides and proteins, S100 proteins (Fig. 8.2), the high mobility group box 1 (HMGB1) protein, and DNA (Fritz, 2011). Many RAGE ligands form oligomers and Fritz et al. recently discussed the mechanisms of how RAGE can be activated by so many structurally distinct ligands (Fritz, 2011).
![img-70.jpeg](img-70.jpeg)

FIGURE 8.2 RAGE and its S100 protein ligands in melanoma tumors. Cancer tumors consist of multiple cell types, including cancer and stromal cells. In melanoma tumors, stromal cells (i.e., immune cells or fibroblasts) express S100 proteins (i.e., S100A4 or S100A8/A9). Cytoplasmic S100 proteins can interact with nuclear proteins (1) such as p53, leading to the transcription of cancer-related genes. Certain cytoplasmic proteins, such as S100A4, also interact with cytoskelal proteins (2), resulting in modulation of migration and invasion. When released in the extracellular media (3), S100 proteins can interact with RAGE (4), when expressed on the surface of melanoma cells. RAGE activation by S100 proteins can lead to upregulation of the receptor itself, or the secretion of additional S100 proteins (5), such as S100B. Secreted S100s from melanoma cells can act on stromal cells either through RAGE, or through other receptors (6).# Advanced Glycation End Products 

These ligands form themselves into a large group of structurally and functionally diverse proteins. AGEs are the result of covalent reaction between mainly the primary amino groups of proteins and reactive carbonyl groups of carbohydrates. Hemoglobin is an example of an AGE, and in general, any protein that circulates long enough in the body can become an AGE. Because of the nature of the reaction producing AGEs, these ligands are found in higher levels in diabetic patients who poorly control their blood sugar levels. AGEs are also found in large amounts in cancer tissues and in the brain of Alzheimer's disease patients (Sparvero et al., 2009).

Because of their metabolism, melanoma cells generate high levels of reactive carbonyl species, which can produce AGEs and which have been implicated in melanoma cell proliferation and formation of metastases (Wondrak et al., 2006). A study showed stronger staining for AGEs in human melanoma tumor sections than in normal tissue sections (Abe et al., 2004). AGEs were localized in both the cytoplasm of melanoma cells and in the extracellular space whereas RAGE was only located in the cytoplasm of melanoma cells. The group of Abe showed that several preparation of AGEs could stimulate the proliferation and migration of melanoma cells in vitro (Table 8.1) (Abe et al., 2004).

In a recent study, we investigated how the extent of lysine modification and the oligomerization of AGEs influenced the proliferation of melanoma cells (Indurthi et al., 2012).

TABLE 8.1 Relevance of RAGE/Ligands in Melanoma

| Ligand | Role | References |
| :--: | :--: | :--: |
| AGEs | Present in higher levels in human melanoma tissues than control tissues <br> Promotes cell proliferation, migration, and invasion of G361 melanoma cells | Abe et al. (2004) |
| HMGB1 | Promotes melanoma tumor growth in RAGE dependent manner | Tang et al. (2013) |
| S100B | Downregulates p53 in malignant melanoma <br> Serves as prognostic marker <br> Role of RAGE/S100B signaling not yet clearly established S100B levels correlate with RAGE levels | Lin et al. (2010) <br> Donato et al. (2013) <br> Meghnani et al. (2014a,b) |
| S100A2 | Plays the role of tumor suppressor <br> Association between RAGE and S100A4 expression in a mouse xenograft model | Maelandsmo et al. (1997) <br> Meghnani et al. (2014b) |
| S100A4 | Promotes lung colonization of B16F10 melanoma cells in lungs in a RAGE dependent manner <br> Association between RAGE and S100A4 expression in a mouse xenograft model | Haase-Kohn et al. (2014) <br> Meghnani et al. (2014b) |
| S100A6 | Association between RAGE and S100A6 expression in a mouse xenograft model | Meghnani et al. (2014b) |
| S100A8/A9 | RAGE/(S100A8/A9) promotes migration and invasion of melanoma cells in vitro and homing of metastases in mice | Saha et al. (2010) |We showed a strong positive correlation between the degree of oligomerization of the AGEs and melanoma cell proliferation.

# High Mobility Group Box 1 Protein 

HMGB1 is a DNA binding protein with important biological functions including transcriptional regulation and nucleosome stabilization. In addition to its nuclear function, HMGB1 can have the extracellular role of inflammatory cytokine, following active secretion by immune cells or passive release from necrotic cells. HMGB1 has also been shown to be released from melanoma cells, and from keratinocytes following exposure to UV light (Ito et al., 2007; Johnson et al., 2013). Using a genetically engineered mouse model of melanoma, it was shown that UV exposure also promoted metastasis and angiogenesis, through HMGB1 and toll like receptor 4 (TLR 4) signaling (Bald et al., 2014). HMGB1 has been shown to contribute to melanoma malignancy by promoting the transcription of the melanoma inhibitory activity protein. In the two metastatic melanoma cell lines A375 and G361, HMGB1 was also shown to control the proliferation and colony formation, as well as cycle cell arrest and senescence (Li et al., 2014). In the same study, a strong positive correlation was found between the level of HMGB1 in the skin, the progression of melanoma, and poor patient survival.

The RAGE/HMGB1 axis has been studied in many cell types. For example, in neuronal cells, stimulation of cells with HMGB1 has been shown to promote cell outgrowth and cell differentiation, in a RAGE dependent manner. In another study, HMGB1/RAGE was shown to stimulate glioma cell growth and the formation of metastases. RAGE stimulation by HMGB1 has also been shown to contribute to the progression of pancreatic cancer (Kang et al., 2014). In melanoma, blocking the HMGB1/RAGE pathways has been shown to reduce tumor growth and the production of the inflammatory cytokine IL-17 and Il-23 (Tang et al., 2013) supporting an important role of RAGE and this ligand in this disease.

## S100 Proteins

S100 proteins form one of the largest group of RAGE ligands (Fig. 8.2). All the members of the family possess amino acid sequence and structure similarities. S100 proteins are EF-hand calcium binding proteins with high tissue and cell specificity. S100 proteins bind calcium, but can also bind zinc and copper (Donato et al., 2013). S100 proteins are lacking intrinsic function and act by binding to their target proteins, oftentimes following calciuminduced conformational changes (Donato et al., 2013). S100 proteins have both intra- and extracellular targets. In the following sections, we will review the contribution of several S100 proteins to melanoma progression.

## S100B

In stage IV melanoma patients, serum levels of S100B are used as a prognostic marker, high levels of S100B being indicative of a poor prognosis (Balch et al., 2009). S100B is released from melanoma tumors by mechanisms which are not clearly understood (Donato et al., 2013). The role of intracellular S100B is better understood. One intracellular targetprotein of S100B is the tumor suppressor p53 (Lin et al., 2010). S100B has been shown to interact with p53 in melanoma cells and tumors, resulting in p53 inhibition and increased expression of S100B, in a negative feedback loop (Lin et al., 2010). Based on this mechanism, the Weber's group is currently investigating small interfering antisense RNA inhibitors of S100B as inhibitors of melanoma tumor growth.

In melanoma cells, S100B could also contribute to melanoma progression through the interaction with metabolic enzymes which are important for cancer cells. One example is the glycolytic enzyme fructose-1,6-biphosphate aldolase. In vitro, S100B has been shown to interact with and activate this enzyme (Donato et al., 2013). Consequences of this activation could be an increase in melanoma cell metabolism and glycolysis, and inhibiting S100B/fructose-1,6-biphosphate aldolase interaction could be an approach to reduce glycolytic activity in melanoma cells and therefore melanoma progression. Inhibiting melanoma cell metabolism and glycolysis is currently being considered in clinical trials (Hersey et al., 2009).

S100B has other possible relevant targets in melanoma cells. Indeed, S100B interacts with many components of the cytoskeleton, such as tubulin, the actin binding protein caldesmon, or the small GTPase Rac1, and the cdc42 effector IQGAP1 (Donato et al., 2013). All these proteins are important for the motility of melanoma cells and increases in S100B levels could therefore favor increases in cell proliferation, migration, and invasion. S100B has also been shown to interact with and activate the nuclear dbf2-related kinase and the phosphoprotein AHNAK/desmoyokin. However, the relevance to melanoma progression of these interactions has not yet been demonstrated.

Despite the established function of S100B as a prognostic biomarker and the abundant release of S100B by melanoma cells, the role of extracellular S100B is not clearly understood. Many studies have shown that S100B can signal through RAGE when added extracellularly to cells, in vitro (reviewed in Donato et al., 2013). However, S100B has not yet been shown to signal through RAGE in melanoma cells. One role could be to facilitate the translocation and secretion of S100B, as suggested by previous others (Donato et al., 2013). In our recent studies, we showed that forced expression of RAGE in melanoma cells was associated with the upregulation of S100B in both cells and tumors generated from these cells (Meghnani et al., 2014a,b), suggesting a strong association between RAGE and S100B in melanoma.

# S100A2 

S100A2 was described as a nuclear protein but can also be present in the cytoplasm. S100A2 has been shown to play the role of either tumor suppressor or promotor, depending of the type of cancer (Wolf et al., 2011). Even in the same type of cancer such as nonsmall cell lung cancer, conflicting results have been reported.

In melanoma tumors, S100A2 has been shown to be expressed at higher levels in nevi than in primary or metastatic tumors. Other studies reported similar observations. We analyzed a cDNA array established from stage III and IV human melanoma tumors and also observed a significant reduction in S100A2 transcripts in melanoma tumors than in control samples (Leclerc et al., 2009). In addition, a significant upregulation of S100A2 was also observed in metastatic uveal and cutaneous melanoma cells upon treatment with chemotherapeutic agents, supporting the role of S100A2 as tumor suppressor.In the nucleus, S100A2 has been shown to interact with and to modulate the activity of the tumor suppressor p53, in two oral cancer cell lines (Donato et al., 2013). The interaction of S100A2 with p53 has been confirmed in in vitro studies. These studies have also suggested difference in modulation of the transcriptional activity of p53 between S100A2 and S100B, although these two S100 proteins are structurally very similar. S100A2 also interacts with other p53 family members such as p63 and p73, suggesting an additional level of complexity of the S100A2/p53 regulation (Wolf et al., 2011).

We recently demonstrated that in vitro, S100A2 could interact with RAGE (Leclerc et al., 2009). However, signaling by S100A2/RAGE in melanoma cells has not been demonstrated yet. Our most recent study showed an upregulation of S100A2 in xenograft melanoma tumors generated from cells overexpressing RAGE (WM115-RAGE) compared to tumors generated from control cells (WM115-MOCK) (Meghnani et al., 2014b). These data suggest complex regulation of S100A2 in melanoma tumors.

# S100A4 

S100A4 was initially named metastatin because of its selected expression in cancer and tumor cells. Later studies confirmed the role of S100A4 in cancer cell invasiveness and motility. For example, it was shown that tumors derived from metastatic mammary carcinoma cells showed delayed growth when implanted in S100A4 knock-out mice compared to tumors implanted in control mice (Donato et al., 2013).

As observed with S100B, S100A4 possesses both intra- and extracellular functions (reviewed in (Boye and Maelandsmo, 2010)). As a nuclear protein, S100A4 interacts with p53 and modulates its transcriptional activity. In vivo, S100A4 has also been suggested to promote degradation of p53, resulting in increases in tumor growth. Similarly to S100B, S100A4 interacts with many proteins of the cytoskeleton, such as nonmuscle myosin II and tropomyosin, which are involved in cytoskeletal reorganization occurring during cell migration and invasion.

S100A4 is released from both normal cells and tumor cells. Normal cells secreting S100A4 include fibroblasts, leukocytes, and endothelial cells (Boye and Maelandsmo, 2010). A large variety of tumors also secrete S100A4, such as breast cancer, ovarian carcinoma, osteosarcoma, and adenocarcinoma tumors. As an extracellular protein, S100A4 has been shown to promote tumor growth and metastasis neovascularization and angiogenesis (Boye and Maelandsmo, 2010).

Extracellular S100A4 has been shown to interact with Annexin 2 and RAGE. Interaction of S100A4 with Annexin 2 results in the formation of plasmin from plasminogen, resulting in increased mechanisms of angiogenesis, such as the formation of capillary-like tubes by endothelial cells (Boye and Maelandsmo, 2010). RAGE/S100A4 signaling has been shown to enhance motility of pulmonary artery smooth muscle cells, as well as prostate and colorectal cancer tumorigenesis and metastasis.

The role of S100A4 in melanoma is complex. An early study from Maelandsmo et al. (1997) showed no significant differences in S100A4 transcript levels between melanoma tissue samples and control samples. Another study reported complex associations between the levels of S100A4 and patient survival rates during the progression of melanoma: high levels of S100A4 in primary melanoma tumors were associated with low patient survivalrates, whereas high S100A4 levels in metastatic tumors were not associated with patient survival rates. We analyzed 40 samples of stage III and stage IV melanoma tissue samples and observed a significant reduction of S100A4 mRNA in stage IV compared to control samples (Leclerc et al., 2009).

As for the role of RAGE/S100A4 signaling in melanoma, Haase-Kohn et al. (2014) showed that S100A4 derived from macrophages could promote lung colonization of B16F10 melanoma cells in mice, in a RAGE dependent manner. In our most recent study, we also observed that S100A4 levels were significantly higher in melanoma xenograft tumors generated from RAGE overexpressing WM115 cells then from tumors generated from control WM115-MOCK cells (Meghnani et al., 2014b). Further studies are needed to elucidate the role of RAGE/S100A4 signaling in melanoma.

# S100A6 

S100A6 is another member of the S100 family that is relevant to cancer. S100A6 is expressed in both cancer and normal cells. S100A6 is expressed in epithelial cells and fibroblasts, but also in neurons, glial cells, smooth muscle cells, cardiac myocytes, platelets, and lymphocytes (reviewed in Lesniak et al., 2009). In cancer, S100A6 is expressed at high levels in many types of cancer tissues including colorectal, pancreatic, hepatocellular carcinoma, melanoma, lung cancer, and gastric cancer.

In melanoma, metastatic melanoma samples were shown to express higher levels of S100A6 than melanocytic nevi. Maelandsmo also showed a positive correlation between the levels of S100A6 and the severity of melanoma (Maelandsmo et al., 1997). In our analysis of melanoma tissues samples, we found that $43 \%$ of stage III samples had significantly higher levels of S100A6 than control samples (Leclerc et al., 2009). Another study revealed that 33\% of examined melanoma tissue samples showed positive staining for S100A6. In addition, studies have also shown that certain types of benign nevi, such as pigmented spindle cell nevi, and nonmelanoma cutaneous lesions, such as squamous cell carcinoma, can also stain positive for S100A6, making it difficult to use S100A6 as a diagnostic marker for melanoma (Puri et al., 2011).

S100A6 has multiple targets in the cell, both nuclear and cytoplasmic. Inside the nucleus, S100A6 interacts with p53 but this interaction is different from the interaction of p53 with S100B, suggesting different transcriptional regulation of p53 by the different S100 proteins (Lesniak et al., 2009). In the cytoplasm, S100A6 has been suggested to interact with several annexin proteins, but the relevance of these interactions to melanoma still needs to be demonstrated.

Studies have shown that S100A6 can be released in the extracellular media suggesting that extracellular S100A6 could have physiological functions (Leclerc et al., 2007). One of the potential target of extracellular S100A6 is RAGE. We showed that extracellular S100A6 interacts with and signals through RAGE, both in vitro and in neuroblastoma cells. As observed with S100B, S100A2, and S100A6, we measured higher levels of S100A6 in xenograft tumors generated from RAGE overexpressing WM115 melanoma cells than from tumors generated from control cells (Meghnani et al., 2014b). As for the previous S100 proteins mentioned, additional studies need to be performed to clarify the role of RAGE/S100A6 signaling in melanoma.# S100A8/A9 

S100A8 and S100A9 usually form heterodimers. These proteins are expressed abundantly by immune cells, such as monocytes and macrophages, and are often described as cytokinelike proteins because they are released in inflamed tissues (Gebhardt et al., 2006). In the cells constituting the epidermis, including melanocytes, S100A8 and S100A9 are expressed at very low levels (Petersson et al., 2009).

Recent studies have shown that S100A8/A9 are key players in cancer where they promote tumor growth and metastasis, and sustain inflammatory conditions (Grebhardt et al., 2014; Hibino et al., 2013; Khammanivong et al., 2013). Specifically, S100A8/A9 have been shown to stimulate the accumulation of myeloid-derived suppressor cells, thereby facilitating tumor growth (Sinha et al., 2008). Similar roles of S100A8/A9 have been observed in a genetically engineered mouse model of melanoma (Meyer et al., 2011).

Several receptors have been described for extracellular S100A8 and S1009: TLR 4, the scavenger receptor CD36, RAGE, and EMMPIRIN (Ghavami et al., 2008; Hibino et al., 2013; Saha et al., 2010; Vogl et al., 2007). The activation of RAGE by S100A8/A9 has been shown to promote tumorigenesis in a colitis-induced colon cancer mouse model, as well as to increase proliferation of colon and breast cancer cells.

In melanoma, S100A9 has been shown to promote metastases formation in mice through the EMMPIRIN receptor (Hibino et al., 2013). Using a different mouse model, Saha et al. (2010) demonstrated that tail-vein injected RAGE expressing B16F10 melanoma cells were attracted and migrated toward S100A8/A9-abundant lungs of uteroglobin-knockout mice. The same authors showed that S100A8/A9-induced cell migration could be suppressed in vitro using anti-RAGE antibodies. In a different study, S100A8 and S100A9 have been shown to promote cell proliferation, migration, and invasion of melanocytes and of the WC62 melanoma cell line (Shirley et al., 2014). However, the receptor targeted by S100A8 and S100A9 has not been investigated in this study.

## Other S100 Proteins

Other S100 proteins are found in cells of the epidermis and have been associated with melanoma in several studies. For example S100A7, also named psoriasin for its upregulation in psoriasis, has been reported at higher levels in the urine of melanoma patients than in healthy control individuals (Brouard et al., 2002).

S100A10 is another member of the S100 protein family that has been found expressed at various levels in melanoma tumor samples and melanocytes (Leclerc et al., 2009; Petersson et al., 2009). We recently found an association between RAGE overexpression and S100A10 levels in human melanoma xenograft tumors (Meghnani et al., 2014b). We observed higher levels of S100A10 in tumor tissues from mice implanted with RAGE overexpressing WM115 cells than in tumor tissues from mice implanted with control WM115-MOCK cells (Meghnani et al., 2014b), suggesting an association between RAGE and S100A10 in melanoma tumors.

S100A11 is another S100 protein with a potential link to melanoma. In ocular melanoma, the group of Van Ginkel et al. reported higher levels of S100A11 than in normal tissues (Van Ginkel et al., 1998). However, the role of S100A11 in melanoma needs to be further investigated.# CONCLUSION 

In recent years, many studies have demonstrated that RAGE is an important player in melanoma progression. In particular, studies have shown that numerous RAGE ligands such as S100 proteins, AGEs, or HMGB1 are upregulated or abundant in melanoma tissues and participate to melanoma progression. Based on this evidence, it appears thus promising to consider targeting RAGE/ligand complexes in melanoma. This strategy might not be a valid approach for all melanoma patients, since we and others have shown that RAGE expression varies considerably among melanoma tumors. However, in tumors expressing high levels of RAGE, this approach might be successful.

Several RAGE inhibitors have been developed and some are currently being tested in clinical trials. These inhibitors include the soluble form of the receptor (sRAGE), antibodies against RAGE or small molecules (Bierhaus and Nawroth, 2009; Deane et al., 2012). One small molecule inhibitor, TPP488, has been evaluated for safety and efficacy, in a phase 2 study, in mild to moderate Alzheimer's disease patients. We have generated an anti-RAGE antibody (2A11) that can delay xenograft melanoma tumors in mice, suggesting that this approach should be further investigated.

## References

Abe, R., Shimizu, T., Sugawara, H., Watanabe, H., Nakamura, H., Choei, H., et al., 2004. Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J. Invest. Dermatol. 122, 461-467.
Balch, C.M., Gershenwald, J.E., Soong, S.J., Thompson, J.F., Atkins, M.B., Byrd, D.R., et al., 2009. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199-6206.
Bald, T., Quast, T., Landsberg, J., Rogava, M., Glodde, N., Lopez-Ramos, D., et al., 2014. Ultraviolet-radiationinduced inflammation promotes angiotropism and metastasis in melanoma. Nature 507, 109-113.
Bhatia, S., Tykodi, S.S., and Thompson, J.A., 2009. Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 23, 488-496.
Bierhaus, A., and Nawroth, P.P., 2009. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 52, 2251-2263.
Boye, K., and Maelandsmo, G.M., 2010. S100A4 and metastasis: a small actor playing many roles. Am. J. Pathol. $176,528-535$.
Brouard, M.C., Saurat, J.H., Ghanem, G., and Siegenthaler, G., 2002. Urinary excretion of epidermal-type fatty acidbinding protein and S100A7 protein in patients with cutaneous melanoma. Melanoma Res. 12, 627-631.
Deane, R., Singh, I., Sagare, A.P., Bell, R.D., Ross, N.T., LaRue, B., et al., 2012. A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J. Clin. Invest. 122, $1377-1392$.
Donato, R., Cannon, B.R., Sorci, G., Riuzzi, F., Hsu, K., Weber, D.J., et al., 2013. Functions of S100 proteins. Curr. Mol. Med. 13, 24-57.
Fritz, G., 2011. RAGE: a single receptor fits multiple ligands. Trends Biochem. Sci. 36, 625-632.
Gebhardt, C., Nemeth, J., Angel, P., and Hess, J., 2006. S100A8 and S100A9 in inflammation and cancer. Biochem. Pharmacol. 72, 1622-1631.
Ghavami, S., Rashedi, I., Dattilo, B.M., Eshraghi, M., Chazin, W.J., Hashemi, M., et al., 2008. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J. Leukoc. Biol. $83,1484-1492$.
Grebhardt, S., Muller-Decker, K., Bestvater, F., Hershfinkel, M., and Mayer, D., 2014. Impact of S100A8/A9 expression on prostate cancer progression in vitro and in vivo. J. Cell. Physiol. 229, 661-671.Haase-Kohn, C., Wolf, S., Herwig, N., Mosch, B., and Pietzsch, J., 2014. Metastatic potential of B16-F10 melanoma cells is enhanced by extracellular S100A4 derived from RAW264.7 macrophages. Biochem. Biophys. Res. Commun. 446, 143-148.
Hersey, P., Watts, R.N., Zhang, X.D., and Hackett, J., 2009. Metabolic approaches to treatment of melanoma. Clin. Cancer Res. 15, 6490-6494.
Hibino, T., Sakaguchi, M., Miyamoto, S., Yamamoto, M., Motoyama, A., Hosoi, J., et al., 2013. S100A9 is a novel ligand of EMMPRIN that promotes melanoma metastasis. Cancer Res. 73, 172-183.
Huttunen, H.J., Fages, C., Kuja-Panula, J., Ridley, A.J., and Rauvala, H., 2002. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res. $62,4805-4811$.
Indurthi, V.S., Leclerc, E., and Vetter, S.W., 2012. Interaction between glycated serum albumin and AGE-receptors depends on structural changes and the glycation reagent. Arch. Biochem. Biophys. 528, 185-196.
Ito, N., DeMarco, R.A., Mailliard, R.B., Han, J., Rabinowich, H., Kalinski, P., et al., 2007. Cytolytic cells induce HMGB1 release from melanoma cell lines. J. Leukoc. Biol. 81, 75-83.
Johnson, K.E., Wulff, B.C., Oberyszyn, T.M., and Wilgus, T.A., 2013. Ultraviolet light exposure stimulates HMGB1 release by keratinocytes. Arch. Dermatol. Res. 305, 805-815.
Jules, J., Maiguel, D., and Hudson, B.I., 2013. Alternative splicing of the RAGE cytoplasmic domain regulates cell signaling and function. PLoS One 8, e78267.
Kang, R., Tang, D., Schapiro, N.E., Loux, T., Livesey, K.M., Billiar, T.R., et al., 2014. The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. Oncogene 33, $567-577$.
Khammanivong, A., Wang, C., Sorenson, B.S., Ross, K.F., and Herzberg, M.C., 2013. S100A8/A9 (calprotectin) negatively regulates G2/M cell cycle progression and growth of squamous cell carcinoma. PLoS One 8, e69395.
Leclerc, E., Fritz, G., Weibel, M., Heizmann, C.W., and Galichet, A., 2007. S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains. J. Biol. Chem. 282, 31317-31331.
Leclerc, E., Heizmann, C.W., and Vetter, S.W., 2009. RAGE and S100 protein transcription levels are highly variable in human melanoma tumors and cells. Gen. Physiol. Biophys., F65-F75. 28 Spec No Focus.
Lesniak, W., Slomnicki, L.P., and Filipek, A., 2009. S100A6-new facts and features. Biochem. Biophys. Res. Commun. 390, 1087-1092.
Li, Q., Li, J., Wen, T., Zeng, W., Peng, C., Yan, S., et al., 2014. Overexpression of HMGB1 in melanoma predicts patient survival and suppression of HMGB1 induces cell cycle arrest and senescence in association with p21 (Waf1/Cip1) up-regulation via a p53-independent, Sp1-dependent pathway. Oncotarget 5, 6387-6403.
Lin, J., Yang, Q., Wilder, P.T., Carrier, F., and Weber, D.J., 2010. The calcium-binding protein S100B down-regulates p53 and apoptosis in malignant melanoma. J. Biol. Chem. 285, 27487-27498.
Maelandsmo, G.M., Florenes, V.A., Mellingsaeter, T., Hovig, E., Kerbel, R.S., and Fodstad, O., 1997. Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. Int. J. Cancer 74, 464-469.
Meghnani, V., Vetter, S.W., and Leclerc, E., 2014a. RAGE overexpression confers a metastatic phenotype to the WM115 human primary melanoma cell line. Biochim. Biophys. Acta 1842, 1017-1027.
Meghnani, V., Wagh, A., Indurthi, V.S., Koladia, M., Vetter, S.W., Law, B., et al., 2014b. The receptor for advanced glycation end products influences the expression of its S100 protein ligands in melanoma tumors. Int. J. Biochem. Cell. Biol. 57, 54-62.
Menzies, A.M., and Long, G.V., 2013. New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Ther. Adv. Med. Oncol. 5, 278-285.
Meyer, C., Sevko, A., Ramacher, M., Bazhin, A.V., Falk, C.S., Osen, W., et al., 2011. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc. Natl. Acad. Sci. USA 108, 17111-17116.
Ojima, A., Matsui, T., Maeda, S., Takeuchi, M., Inoue, H., Higashimoto, Y., et al., 2014. DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice. Lab. Invest. 94, 422-429.
Petersson, S., Shubbar, E., Enerback, L., and Enerback, C., 2009. Expression patterns of S100 proteins in melanocytes and melanocytic lesions. Melanoma Res. 19, 215-225.Popa, I., Ganea, E., and Petrescu, S.M., 2014. Expression and subcellular localization of RAGE in melanoma cells. Biochem. Cell. Biol. 92, 127-136.
Puri, P.K., Elston, C.A., Tyler, W.B., Ferringer, T.C., and Elston, D.M., 2011. The staining pattern of pigmented spindle cell nevi with S100A6 protein. J. Cutan. Pathol. 38, 14-17.
Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al., 2015. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521-2532.
Saha, A., Lee, Y.C., Zhang, Z.J., Chandra, G., Su, S.B., and Mukherjee, A.B., 2010. Lack of an endogenous antiinflammatory protein in mice enhances colonization of B16F10 melanoma cells in the lungs. J. Biol. Chem. 285, 10822-10831.
Shirley, S.H., von Maltzan, K., Robbins, P.O., and Kusewitt, D.F., 2014. Melanocyte and melanoma cell activation by calprotectin. J. Skin Cancer 2014, 846249.
Sinha, P., Okoro, C., Foell, D., Freeze, H.H., Ostrand-Rosenberg, S., and Srikrishna, G., 2008. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol. 181, 4666-4675.
Sparvero, L.J., Asafu-Adjei, D., Kang, R., Tang, D., Amin, N., Im, J., et al., 2009. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J. Transl. Med. 7, 17.
Tang, Q., Li, J., Zhu, H., Li, P., Zou, Z., and Xiao, Y., 2013. Hmgb1-IL-23-IL-17-IL-6-Stat3 axis promotes tumor growth in murine models of melanoma. Mediators. Inflamm. 2013, 713859.
Trinh, V.A., and Hagen, B., 2013. Ipilimumab for advanced melanoma: a pharmacologic perspective. J. Oncol. Pharm. Pract. 19, 195-201.
Van Ginkel, P.R., Gee, R.L., Walker, T.M., Hu, D.N., Heizmann, C.W., and Polans, A.S., 1998. The identification and differential expression of calcium-binding proteins associated with ocular melanoma. Biochim. Biophys. Acta $1448,290-297$.
Vogl, T., Tenbrock, K., Ludwig, S., Leukert, N., Ehrhardt, C., van Zoelen, M.A., et al., 2007. MRP8 and MRP14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat. Med. 13, $1042-1049$.
Wolf, S., Haase-Kohn, C., and Pietzsch, J., 2011. S100A2 in cancerogenesis: a friend or a foe? Amino Acids 41, 849-861.
Wondrak, G.T., Jacobson, M.K., and Jacobson, E.L., 2006. Antimelanoma activity of apoptogenic carbonyl scavengers. J. Pharmacol. Exp. Ther. 316, 805-814.
Yan, S.F., Ramasamy, R., and Schmidt, A.M., 2010. Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem. Pharmacol. 79, 1379-1386.
Yatime, L., and Andersen, G.R., 2013. Structural insights into the oligomerization mode of the human receptor for advanced glycation end-products. FEBS J. 280, 6556-6568.# 9 

## Hydrogen Sulfide Pathway and Cancer

## Angela Ianaro and Giuseppe Cirino

## O U T L I N E

Introduction
Hydrogen Sulfide
$\mathrm{H}_{2} \mathrm{~S}$ and Cancer
Evidence for a Role of CBS and
CSE in Cancer
133
133
135

CSE and Melanoma
Conclusion
References

138
141
References

142

## INTRODUCTION

## Hydrogen Sulfide

## Hydrogen Sulfide Synthesis, Metabolism, and General Functions

Hydrogen sulfide $\left(\mathrm{H}_{2} \mathrm{~S}\right)$ is a colorless flammable gas with a strong odor of rotten eggs. At physiological $\mathrm{pH}(7.4)$ less than $20 \%$ of $\mathrm{H}_{2} \mathrm{~S}$ exists in solution as the undissociated compound and the rest is dissociated to $\mathrm{HS}^{-}$(hydrosulfide anion) and $\mathrm{H}^{+}$. Further dissociation of $\mathrm{HS}^{-}$to sulfide anion $\left(\mathrm{S}_{2 \cdot}\right)$ occurs only at high pH and does not play any role at physiological pH . Since both $\mathrm{H}_{2} \mathrm{~S}$ and $\mathrm{HS}^{-}$always coexist in aqueous solution, it is not possible to separate their effects and to conclude which of them is involved in signaling processes (Li and Lancaster, 2013).
$\mathrm{H}_{2} \mathrm{~S}$ is a gaseous mediator, soluble in both water and lipids, sharing with nitric oxide and carbon monoxide many physiological and pathophysiological roles (Wang, 2014). $\mathrm{H}_{2} \mathrm{~S}$ is a signaling molecule with a variety of functions. It regulates synaptic transmission, vascular tone, inflammation, transcription, and angiogenesis, protects cells from oxidative stress andischemia-reperfusion injury, and promotes healing of ulcers (Kimura, 2014), moreover, it can bind to hemoglobin (Searcy and Lee, 1998).

In general, the biosynthesis of $\mathrm{H}_{2} \mathrm{~S}$ requires tissue-specific enzymes that generate $\mathrm{H}_{2} \mathrm{~S}$ starting from L-cysteine, a metabolite of dietary methionine. Three such enzymes have been identified: cystathionine $\beta$-synthase (CBS, EC 4.2.1.22) and cystathionine $\gamma$-lyase (CSE, aka CGL, EC 4.4.1.1) that require pyridoxal-5'-phosphate (P5P) as cofactor and use L-cysteine as substrate (Bukovska et al., 1994); and 3-mercaptopyruvate sulfurtransferase (3-MST, EC 2.8.1.2) which produces $\mathrm{H}_{2} \mathrm{~S}$ using 3-mercaptopyruvate, a metabolite of L-cysteine (Shibuya et al., 2009).

Inhibitors of $\mathrm{H}_{2} \mathrm{~S}$ biosynthesis are relatively nonspecific and may be poorly absorbed by tissues (Szabo, 2007; Whiteman et al., 2011). Propargyl glycine (PPG) is an irreversible inhibitor, and $\beta$-cyanoalanine (BCA) a reversible inhibitor of CSE. Aminooxyacetate (AOA) is an irreversible inhibitor of CBS and hydroxylamine (HA) inhibits PLP-dependent enzymes including CBS, CSE, and cysteine aminotransferase (CAT) (although a number of studies claim this is a specific inhibitor of CBS). Pyruvate acid has been used as a competitive inhibitor of 3-MST with limited success (Whiteman et al., 2011).
$\mathrm{H}_{2} \mathrm{~S}$ can also be generated endogenously through nonenzymatic reduction of elemental sulfur in the blood using reducing equivalents supplied through the glycolitic pathway (Searcy and Lee, 1998).

Much of the inactivation of $\mathrm{H}_{2} \mathrm{~S}$ occurs via mitochondrial oxidation (Hildebrandt and Grieshaber, 2008). Two membrane-bound sulfide:quinone oxidoreductases (SQR) oxidize sulfide to elemental sulfur while simultaneously reducing their cysteine disulfides. This produces a persulfide group at each of the SQR cysteines (SQR-SSH). Sulfur dioxygenase (SDO) then oxidizes one of the persulfides to sulfite $\left(\mathrm{H}_{2} \mathrm{SO}_{3}\right)$.

Sulfur from the second persulfide is transferred from the SQR to sulfite by sulfur transferase (ST) producing thiosulfate $\left(\mathrm{H}_{2} \mathrm{~S}_{2} \mathrm{O}_{3}\right)$. Most thiosulfate is further metabolized to sulfate by thiosulfate reductase and sulfite oxidase. One electron from each of the two $\mathrm{H}_{2} \mathrm{~S}$ is fed into the respiratory chain via the quinone pool $(\mathrm{Q})$, and finally transferred to oxygen at complex IV, thereby consuming molecular oxygen and water in the process. Oxygen consumption is obligatory during $\mathrm{H}_{2} \mathrm{~S}$ metabolism and one mole of oxygen is consumed for every mole of $\mathrm{H}_{2} \mathrm{~S}$ oxidized along the electron transport chain (Du et al., 2014).

Reported levels of $\mathrm{H}_{2} \mathrm{~S}$ in serum and tissues vary with differing methods of measurement, but concentrations are generally reported to be between 50 and $160 \mu \mathrm{M}$ in the brain (Abe and Kimura, 1996) and $50 \mu \mathrm{M}$ in serum. It has been argued that these are overestimates, the true concentrations of $\mathrm{H}_{2} \mathrm{~S}$ being three orders of magnitude lower, because of very efficient catabolism of $\mathrm{H}_{2} \mathrm{~S}$ (Furne et al., 2008) and because of the colorimetric methylene blue method used to measure $\mathrm{H}_{2} \mathrm{~S}$ levels which has multiple disadvantages ( Li and Lancaster, 2013). In fact, this method measures not only free $\mathrm{H}_{2} \mathrm{~S} / \mathrm{HS}^{-}$but also other sulfide pools in the sample, including sulfane sulfur and acid-labile sulfur; the latter mostly includes iron-sulfur clusters in proteins (Nagy et al., 2014). However, both these bound sulfur pools are $\mathrm{H}_{2} \mathrm{~S}$ storage forms from which the gasotransmitter may be released and, as stated previously, a fraction of sulfane sulfur may even be directly synthesized by CBS and CSE. Thus, although high micromolar $\mathrm{H}_{2} \mathrm{~S}$ values are clearly overestimated, relative differences in " $\mathrm{H}_{2} \mathrm{~S}$ " concentrations between, for example, control and experimental groups may be of significant relevance for $\mathrm{H}_{2} \mathrm{~S}$ signaling. The true free $\mathrm{H}_{2} \mathrm{~S}$ concentration is low micromolar or even nanomolar (Whitfield et al., 2008).$\mathrm{H}_{2} \mathrm{~S}$ is able to stimulate and inhibit the mitochondrial electron transport, depending on its concentrations. It has been reported to act as both substrate at low concentration ( $<5 \mu \mathrm{M}$ ), and inhibitor at high concentration ( $>20 \mu \mathrm{M}$ ) for the cytochrome oxidase system (Szabo et al., 2014). $\mathrm{H}_{2} \mathrm{~S}$ has also been demonstrated to regulate L and T type calcium channels and open KATP channels (Matsunami et al., 2012; Modis et al., 2013; Zoccali et al., 2009).
$\mathrm{H}_{2} \mathrm{~S}$ also possesses antioxidative properties, increasing superoxide dismutase (SOD) activity, glutathione (GSH) turnover, decreasing reactive oxygen species (ROS) production; several reports have shown that $\mathrm{H}_{2} \mathrm{~S}$ possesses both antiapoptotic properties by inhibiting nuclear factor kappa beta (NF- $\kappa \mathrm{B}$ ) pathways, mitogen-activated protein kinase p38 (MAPK p38), C-Jun N-terminal kinase (JNK), Bcl-2 associated X protein (BAX), and caspase 3, as well as upregulating Bcl (Guo et al., 2013) and proapoptotic and antiproliferative properties (Du et al., 2014; Panza et al., 2015).

# $\mathrm{H}_{2} \mathrm{~S}$ AND CANCER 

Emerging data indicate that $\mathrm{H}_{2} \mathrm{~S}$ plays an important role in the regulation of tumor cell biology. However, the effects of $\mathrm{H}_{2} \mathrm{~S}$ on cancer are controversial and remain unclear. Recently, it has been shown that $\mathrm{H}_{2} \mathrm{~S}$ induces DNA damage and alters the cell cycle in various mammalian cells (Baskar and Bian, 2011). Endogenously produced or exogenously treated $\mathrm{H}_{2} \mathrm{~S}$ has a role in the accumulation or proliferation of cells and, furthermore, may provide for development of a novel therapeutic approach in conditions associated with uncontrolled cell growth. However, the potential biological and clinical significance of $\mathrm{H}_{2} \mathrm{~S}$ has been the subject of intense debate in recent years and despite considerable progress in our understanding about $\mathrm{H}_{2} \mathrm{~S}$, much still needs to be learned about its production at the site of tissue injury and its downstream signaling pathways on cell growth (Baskar and Bian, 2011). It is also important to emphasize that in the recent literature different roles have been attributed in several types of cancer to CBS-derived $\mathrm{H}_{2} \mathrm{~S}$ and to CSE-derived $\mathrm{H}_{2} \mathrm{~S}$. Moreover, many of the biological responses to $\mathrm{H}_{2} \mathrm{~S}$ follow a biphasic dose-response: while low concentrations of $\mathrm{H}_{2} \mathrm{~S}$ are responsible for physiological, cytoprotective effects, high concentrations have cytotoxic results (Hellmich et al., 2015).

## Evidence for a Role of CBS and CSE in Cancer

Several studies suggest increased expression of CBS and/or increased levels of $\mathrm{H}_{2} \mathrm{~S}$ in several types of cancer. Since the early 1960s observations have been made on the potential diagnostic value of cystathionine detection in the urine of cancer patients (Geiser and Efron, 1968; Voute and Wadman, 1968).

In fact, elevated CBS activity in neuroblastoma surgical resection homogenates was reported along with elevated urinary cystathionine levels in patients (Klein et al., 1988). Other studies also confirmed an increase of urinary cystathionine levels in prostate cancer patients correlating with the progression of the disease (Stabler et al., 2011). It has to be considered that cystathionine can be produced by multiple pathways but it is also feasible for a contribution of CBS upregulation in cancer cells even if this hypothesis has to be experimentally verified.Increased levels of exhaled $\mathrm{H}_{2} \mathrm{~S}$ in cancer patients have been detected (Altomare et al., 2013; Yamagishi et al., 2012) even if the biological source was not investigated. Moreover, in a clinical study carried out on prostate cancer patients, elevated urinary levels of thiosulfate (the stable breakdown product of $\mathrm{H}_{2} \mathrm{~S}$ ) were found with levels 50 times higher than in the control group and five times higher than in patients with benign prostatic hyperplasia (Chwatko et al., 2013).

One of the most important and recent report on a role of CBS-derived $\mathrm{H}_{2} \mathrm{~S}$ is the paper by Szabo et al. (2013) demonstrating that CBS is abundantly expressed in human colon cancer cell lines and in human colon cancer tissue specimens, resulting in increased $\mathrm{H}_{2} \mathrm{~S}$ production (Szabo et al., 2013). CBS-derived $\mathrm{H}_{2} \mathrm{~S}$ stimulates tumor cell bioenergetics, proliferation, migration, and invasion. Moreover, by a paracrine action on peritumor/intratumor vascular endothelial cells, $\mathrm{H}_{2} \mathrm{~S}$ promotes tumor angiogenesis (Szabo et al., 2013).

Pharmacological inhibition or stable lentiviral-mediated silencing of CBS resulted in attenuated cellular energetic responses, suppressed cell proliferation and invasion in vitro, and inhibited tumor growth in vivo, suggesting a proliferation-stimulating role for endogenously produced $\mathrm{H}_{2} \mathrm{~S}$ in colon cancer cells (Szabo et al., 2013). Evidence for an autocrine and paracrine function for $\mathrm{H}_{2} \mathrm{~S}$ in cancer has been also shown by Yamagishi et al. (2012).

Bhattacharyya and colleagues (Bhattacharyya et al., 2013) confirmed intracellular localization of CBS in ovarian cancer cells and demonstrated that the downregulation/inhibition of CBS sensitizes the cancer cells to cisplatin. Using patient tissue microarray (TMA), in vitro and in vivo studies, authors have shown that the expression of CBS is common in primary serous ovarian carcinoma. The in vitro effects of CBS silencing can be reversed by exogenous supplementation with GSH or with $\mathrm{H}_{2} \mathrm{~S}$ donors, such as $\mathrm{Na}_{2} \mathrm{~S}$. Silencing CBS in a cisplatin resistant orthotopic model in vivo by nanoliposomal delivery of CBS siRNA inhibits tumor growth, reduces nodule formation, and sensitizes ovarian cancer cells to cisplatin. Furthermore, CBS also regulates bioenergetics of ovarian cancer cells by regulating mitochondrial ROS production, oxygen consumption, and ATP generation. These data define an important role of CBS in promoting ovarian tumor growth and maintaining the drug resistant phenotype through the control of cellular redox behavior and regulation of mitochondrial bioenergetics (Bhattacharyya et al., 2013).

Other lines of evidence show high expression of CBS in prostate cancer cells (Guo et al., 2012) and enhanced production of $\mathrm{H}_{2} \mathrm{~S}$ in tumor-bearing experimental animals and cancer patients (Altomare et al., 2013; Yamagishi et al., 2012), suggesting that cancer cell-derived $\mathrm{H}_{2} \mathrm{~S}$ serves as an autocrine stimulator of tumor growth.

More recently the role of CBS in human glioma cells has been assessed by stably transfecting cells with lentiviral vectors encoding shRNA targeting CBS or a nontargeting control shRNA, and subclones have been injected into immunodeficient mice. Interestingly, decreased CBS expression did not affect proliferation in vitro but decreased the latency period before rapid tumor xenograft growth after subcutaneous injection and increased tumor incidence and volume following orthotopic implantation into the caudate-putamen. Bioinformatic analysis of mRNA expression data from human glioma specimens revealed a significant association between low expression of CBS mRNA and high expression of angi-opoietin-like 4 (ANGPTL4) and vascular endothelial growth factor (VEGF) transcripts suggesting that decreased CBS expression in glioma promotes glioma tumor formation (Takano et al., 2014).All these reports point toward a protumorigenic role of $\mathrm{H}_{2} \mathrm{~S}$. However the role of the $\mathrm{H}_{2} \mathrm{~S}$ pathway varies depending on the type of cancer and organ involved. Indeed, several reports support evidence for antigrowth potential of $\mathrm{H}_{2} \mathrm{~S}$ against a wide variety of human cancer cells (Chattopadhyay et al., 2012b).

In breast cancer cells, $\mathrm{H}_{2} \mathrm{~S}$ has been shown to decrease the in vivo tumor mass through the inhibition of cellular proliferation, induction of apoptosis, and decrease in nuclear factor- $\kappa$ B (NF- $\kappa$ B) levels (Chattopadhyay et al., 2012a).

Furthermore, $\mathrm{H}_{2} \mathrm{~S}$ has been found to inhibit breast cancer-induced osteoclast formation and activity, suppress osteoclastogenesis, and prevent osteolysis (Frantzias et al., 2012). As bone metastases are common in breast cancer, $\mathrm{H}_{2} \mathrm{~S}$ may have inhibitory effects on breast cancer cell invasion and metastasis, thereby suppressing osteoclastogenesis and osteolysis. More recently a beneficial effect for $\mathrm{H}_{2} \mathrm{~S}$ in gastric cancer has been suggested (Zhang et al., 2015). In this paper the authors show that CSE and CBS proteins were expressed in human gastric cancer cells and upregulated in human gastric carcinoma mucosa compared with those in noncancerous gastric samples. Exogenous hydrogen sulfide ( NaHS ) addition induced apoptosis of gastric cancer cells by regulating apoptosis-related proteins and inhibited cancer cell migration and invasion (Zhang et al., 2015).

It has been shown that a reduced $\mathrm{CSE} / \mathrm{H}_{2} \mathrm{~S}$ signaling contributes to antiandrogen-resistant status, and sufficient level of H2S can inhibit androgen receptor (AR) transactivation and treat castration-resistant prostate cancer (Zhao et al., 2014). AR signaling is indispensable for the development of prostate cancer from the initial androgen-dependent state to a later aggressive androgen-resistant state. $\mathrm{H}_{2} \mathrm{~S}$ inhibits cell proliferation of both androgendependent (LNCaP) and antiandrogen-resistant prostate cancer cells (LNCaP-B). The expression of CSE, a major $\mathrm{H}_{2} \mathrm{~S}$ producing enzyme in prostate tissue, was reduced in both human prostate cancer tissues and LNCaP-B cells. Most importantly, this paper showed that $\mathrm{H}_{2} \mathrm{~S}$ significantly represses the expression of prostate-specific antigen (PSA) and TMPRSS2, two AR-targeted genes, as well as AR binding with PSA promoter and androgen-responsive element (ARE) luciferase activity. Moreover, $\mathrm{H}_{2} \mathrm{~S}$ posttranslationally modifies the AR through S-sulfhydration while mutation of cysteine 611 and cysteine 614 in the second zinc finger module of AR-DNA binding domain diminishes the effects of $\mathrm{H}_{2} \mathrm{~S}$ on AR S-sulfhydration and AR dimerization (Zhao et al., 2014). These results clearly indicate that low levels of $\mathrm{H}_{2} \mathrm{~S}$ contribute to antiandrogen-resistant status in prostate cancer cells and that the $\mathrm{CSE} / \mathrm{H}_{2} \mathrm{~S}$ system can serve as a valuable prognosis indicator for treatment of prostate cancer.

In contrast to CBS whose role in colon cancer has been studied in detail, the role, if any, of $\mathrm{CSE} / \mathrm{H}_{2} \mathrm{~S}$ is not very clear. Only in a recent paper has it been demonstrated that CSE gene expression is regulated by the Wnt pathway at the transcriptional level (Fan et al., 2014). Many kinds of tumors are relevant to mutation of members in the Wnt pathway, which is a highly conserved signal transduction pathway and has important roles in multiple developments, metabolism, stem cell self-renewal, and tumorigenesis (Clevers and Nusse, 2012). In the study by Fan et al. (2014) the authors showed that the activation of the Wnt pathway increased CSE mRNA and protein levels, while siRNA-mediated silence of $\beta$-catenin decreased CSE mRNA and protein levels. Either knockdown of CSE by shRNA (shCSE) or its inhibition by PAG decreased SW480 cell proliferation, migration, and tumor xenograft growth in nude mice demonstrating that the Wnt pathway regulates CSE gene expressionat the transcriptional level. Thus the authors conclude that the $\mathrm{CSE} / \mathrm{H}_{2} \mathrm{~S}$ may play a role in colon cancer (Fan et al., 2014).

Hepatocellular carcinoma (HCC) is one of the most malignant and leading causes of cancer death worldwide. No effective therapeutic treatment is currently available, especially when HCC is diagnosed at the advanced stages. Dysregulation of cellular proliferation and apoptosis is closely associated with HCC development and progression. A role for the $\mathrm{H}_{2} \mathrm{~S} /$ CSE pathway has also been demonstrated in epatoma cell lines (Pan et al., 2014). In their paper, the authors showed that CSE is overexpressed in hepatoma HepG2 and PLC/PRF/ 5 cells and that the inhibition of endogenous pathway decreases the proliferation of HepG2 and PLC/PRF/5 cells, enhances ROS production and mitochondrial disruption, as well as DNA damage, and increases apoptosis. This latter effect is associated with the activation of p53 and p21, reduction of Bcl-2/Bax and upregulation of phosphorylated c-Jun N-terminal kinase (JNK) and caspase-3 activity. Moreover, the inhibition of $\mathrm{H}_{2} \mathrm{~S} / \mathrm{CSE}$ system correlated with the blockade of cell mitogenic and survival signal transduction of epidermal growth factor receptor (EGFR) via downregulating the extracellular-signal-regulated kinase $1 / 2$ (ERK1/2) activation (Pan et al., 2014). In conclusion the authors affirm that the $\mathrm{H}_{2} \mathrm{~S} / \mathrm{CSE}$ pathway contribute to the proliferation of hepatoma cells (Pan et al., 2014).

# CSE and Melanoma 

Melanoma has historically been considered a refractory disease with few if any options in the advanced/metastatic setting. Advances in both immune and genetically targeted treatment approaches have revolutionized the spectrum of treatment options for melanoma patients over the last several years (Johnson et al., 2015). However, the overall clinical benefit is limited to either small subgroups of patients who may be cured by immunotherapies or to a subset of patients with BRAF-mutant melanoma. Nevertheless, almost $50 \%$ of the BRAF-mutant melanoma patients develop resistance to the molecularly targeted therapy (Atefi et al., 2011; Hodis et al., 2012). Therefore, drugs are needed that can be added to the current arsenal of compounds for use alone or in combination with agents such as vemurafenib (Villanueva et al., 2011).

It has been shown that CSE is expressed in melanoma cell lines (Jurkowska et al., 2011) but the role of the $\mathrm{H}_{2} \mathrm{~S}$ pathway has never been investigated in detail.

Recently the involvement of the $\mathrm{H}_{2} \mathrm{~S}$ pathway in melanoma has been evaluated (Panza et al., 2015). The immunohistochemical analysis performed on more than 100 human samples demonstrated that CSE expression increased from nevi to primary melanoma, decreased in tissue metastases, and was absent in lymph node metastases. Conversely, analysis of CBS expression revealed that this enzyme was absent in dysplastic nevi. Positive CBS expression was found in only $25 \%$ of the primary melanomas analyzed. Therefore, as opposed to other types of cancer (Bhattacharyya et al., 2013; Szabo et al., 2013), CBS does not appear to play an important role in human melanoma. The expression of 3-MST, the other $\mathrm{H}_{2} \mathrm{~S}$ synthesizing enzyme, was extremely variable in the human specimens analyzed from nevi to metastasis, not allowing any clear conclusion on its involvement in melanoma (Panza et al., 2015).

The finding that CSE expression is higher in primary melanoma than in distant metastatic melanoma, suggests the involvement of this pathway in the progression of melanoma. Several melanoma cell lines, widely used in the relevant literature, have been analyzed,such as A375, SK-MEL5, and SK-MEL28. All the melanoma cells selected expressed CSE, CBS, and 3-MST but to a different extent. CSE expression was higher in all melanoma cells analyzed as compared with normal cells (NHEM), while 3-MST showed a variable pattern of expression among all cell lines. Conversely, CBS expression was enhanced in A375 cells only. This cell line has been studied in order to evaluate the primary role of CSE versus CBS and 3-MST. Overexpression of CSE in A375 inhibited cellular proliferation (50\%) while CBS overexpression caused only a small inhibition of cell proliferation (about 10\%) that was not further increased by the addition of L-cysteine. The same magnitude of effect, about $8 \%$, was observed following 3-MST overexpression. Addition of 3-MP, the enzyme substrate, increased the antiproliferative effect up to $15 \%$. These data support our hypothesis that CSEderived $\mathrm{H}_{2} \mathrm{~S}$ plays a major role in melanoma (Panza et al., 2015). A similar antiproliferative effect for CSE-derived $\mathrm{H}_{2} \mathrm{~S}$ has been also shown by using HEK-293 cells (Yang et al., 2004).

It has been shown that activation of the $\mathrm{H}_{2} \mathrm{~S}$ pathway can exert both pro- and antiapoptotic activity in cultured cells (Hu et al., 2007; Taniguchi et al., 2011). These studies have been conducted on immortalized cell lines mainly using NaHS as the exogenous source of $\mathrm{H}_{2} \mathrm{~S}$. The use of NaHS as donor has two main drawbacks: (1) the fast kinetics of $\mathrm{H}_{2} \mathrm{~S}$ release; and (2) the high concentrations used, often in the mM range. These two issues suggest that discrepancies (e.g., pro- and antiapoptotic effects) may lie in the choice of the $\mathrm{H}_{2} \mathrm{~S}$ donors used. Sulfide salts, such as NaHS and sodium sulfide $\left(\mathrm{Na}_{2} \mathrm{~S}\right)$, on addition of water generate a burst of $\mathrm{H}_{2} \mathrm{~S}$ within a short period as opposed to the organic donors (Lee et al., 2011). Since cell culture takes place over a period of hours or days, it is likely that little, if any, $\mathrm{H}_{2} \mathrm{~S}$ is present in medium within a short time of adding either NaHS or $\mathrm{Na}_{2} \mathrm{~S}$. In a recent comparative study showing differences between fast ( NaHS ) and slow-release (GYY4137) $\mathrm{H}_{2} \mathrm{~S}$ donors, it was demonstrated that only GYY4137 caused a concentration-dependent killing of several human cancer cell lines (Lee et al., 2011). On A375 cells the effect of fast (NaHS) and slow releasers (DATS, GYY4137, thioglycine, and L-thiovaline) has been determined (Panza et al., 2015), both the fast or slow releaser, except NaHS, inhibited cellular proliferation, although with different $\mathrm{IC}_{50}$. The most active among the $\mathrm{H}_{2} \mathrm{~S}$ donors was diallyl trisulfide (DATS). DATS is a donor whose $\mathrm{H}_{2} \mathrm{~S}$-delivering property has been well characterized (Benavides et al., 2007). Cytofluorimetric studies demonstrated that the antiproliferative effect of DATS on A375 was due to its ability to induce apoptosis and cell cycle arrest. The finding that DATS induces caspase-3 activation further confirmed that $\mathrm{H}_{2} \mathrm{~S}$ triggers apoptosis. Many chemotherapeutic agents cause cell cycle arrest but not apoptosis and this is one of the mechanisms leading to chemoresistance. In fact, growth arrest allows cells to repair their DNA and limits the efficacy of chemotherapy. Thus, by overriding tumor resistance to apoptosis, agents such as $\mathrm{H}_{2} \mathrm{~S}$ donors could be of a great potential therapeutic value.

Constitutive activation of NF- $\kappa \mathrm{B}$ and AKT has been described in melanoma (Kantrow et al., 2007). In our study we showed that $\mathrm{H}_{2} \mathrm{~S}$ donors inhibit $\mathrm{I} \kappa \mathrm{B} \alpha$ degradation and this effect is associated with the inhibition of NF- $\kappa$ B nuclear translocation and activation. The issue of whether exogenous $\mathrm{H}_{2} \mathrm{~S}$ inhibits (Fan et al., 2013; Guo et al., 2013; Li and Lancaster, 2013; Pan et al., 2012; Shankar et al., 2008) or activates (Sen et al., 2012) NF- $\kappa$ B signaling pathway is still a matter of debate. However, the different experimental settings (in vitro vs in vivo) coupled to the different stimuli as well as to the protocols used do not allow a clear conclusion to be drawn. It has been shown that the slow-releasing $\mathrm{H}_{2} \mathrm{~S}$ donor derivatives of diclofenac (Frantzias et al., 2012; Li et al., 2007; Wallace et al., 2007) and aspirin(Chattopadhyay et al., 2012a) inhibit NF- $\kappa$ B activation. In addition, it has recently been shown that $\mathrm{H}_{2} \mathrm{~S}$ inhibits NF- $\kappa \mathrm{B}$ activation in ox LDL-induced macrophage inflammation through both sulfhydration of free thiol group on cysteine 38 in p65 subunit and inhibition of IкB $\alpha$ degradation (Du et al., 2014). In melanoma cell line $\mathrm{H}_{2} \mathrm{~S}$ inhibits IкB $\alpha$ degradation, leading to inhibition of NF- $\kappa$ B nuclear translocation. These results are in line with the inhibitory effect of $\mathrm{H}_{2} \mathrm{~S}$ on NF- $\kappa \mathrm{B}$ activation (Fan et al., 2013; Guo et al., 2013; Li and Lancaster, 2013; Pan et al., 2012; Shankar et al., 2008; Sivarajah et al., 2009). The fact that NF- $\kappa \mathrm{B}$ is inhibited by $\mathrm{H}_{2} \mathrm{~S}$ is also supported by the finding that $\mathrm{H}_{2} \mathrm{~S}$ donors greatly decrease the expression of the antiapoptotic proteins c-FLIP, XIAP, and Bcl-2. Indeed, these proteins are known to be transcriptionally regulated by NF- $\kappa$ B (Ben-Neriah and Karin, 2011).

The possible involvement of the MAPK/ERK and the $\mathrm{PI}_{3} \mathrm{~K} / \mathrm{AKT}$ pathways in $\mathrm{H}_{2} \mathrm{~S}$ effect has also been investigated. These pathways are the two most frequently deregulated pathways in melanoma and are also involved in primary and secondary resistance to BRAF inhibitors (Atefi et al., 2011; Hodis et al., 2012). Both DATS and GYY4137 inhibited the phosphorylation of AKT and ERK. Therefore, feeding $\mathrm{H}_{2} \mathrm{~S}$ to melanoma cells leads to downregulation of these two main pathways involved in melanoma resistance. The inhibitory effect of exogenous $\mathrm{H}_{2} \mathrm{~S}$ on both AKT and MAPK pathways has been also shown by others (Guo et al., 2013; Shankar et al., 2008).

In human melanoma A375 cells CSE, but not CBS, overexpression induces spontaneous apoptosis and exogenous $\mathrm{H}_{2} \mathrm{~S}$ induces apoptosis. This apoptotic effect involves: (1) the suppression of prosurvival pathways associated to NF- $\kappa$ B transcription activity, as demonstrated by the decreased expression of c-FLIP, XIAP, and Bcl-2; and (2) the inhibition of the activation of AKT and ERK1/2 downstream signaling pathways. This in vitro data find support in a translational in vivo preclinical study performed in C57BL/6 mice using B16 melanoma cell line. This is a well-established mouse melanoma model that recapitulates human cutaneous melanoma progression (Berkelhammer et al., 1982). L-cysteine, the natural substrate of CSE, significantly reduced tumor volume and this effect was completely abolished by PAG, a selective CSE inhibitor. In this same model, DATS significantly inhibited tumor volume development. These data, together with previous evidence, confirm the involvement of $\mathrm{H}_{2} \mathrm{~S}$ in melanoma progression.

In conclusion, the involvement of the L-cysteine / $\mathrm{CSE} / \mathrm{H}_{2} \mathrm{~S}$ pathway in human melanoma has been demonstrated in human specimens as well as in cell lines and in a mouse model of melanoma. This pathway can be exploited as a potential therapeutic target in melanoma (Panza et al., 2015). It is well known that a majority of human melanomas are found to express a few oncogenic proteins, such as mutant RAS and BRAF variants. However, these oncogenes are also found in nevi, and it is now established that their expression alone leads to senescence. Recently, the question of senescence evasion in melanocytes has been addressed (Leikam et al., 2014). The authors show that the transcription factor v-myc myelocytomatosis viral oncogene homolog (c-MYC), is involved, together with many other oncogenes, in driving the evasion of reactive oxygen stress-induced melanocyte senescence caused by activated receptor tyrosine kinase signaling. On the other hand, the transcription factor MIZ1, the growth suppressing interaction partner of MYC, is involved in mediating melanocyte senescence. Both, MYC overexpression and Miz1 knockdown led to a strong reduction of endogenous ROS, DNA damage, and senescence. The cystathionase (CTH), another name for CSE, gene product was identified as the mediator of the ROS-related MYC and MIZ1 effects. In fact, by blocking CTH enzymatic activity in MYC-overexpressing and Miz1 knockdowncells an increase in intracellular stress and senescence was observed. Pharmacological inhibition of CTH in human melanoma cells also reconstituted senescence in the majority of cell lines, and CTH knockdown reduced tumorigenic effects. This study identifies CSE as a new MYC target gene with an important role in senescence evasion (Leikam et al., 2014)

# CONCLUSION 

Cellular methylation and antioxidant metabolism are linked by the trans-sulfuration pathway, which converts the methionine/cysteine in $\mathrm{H}_{2} \mathrm{~S}$. It is known that substances containing free thiols, such as N -acetylcysteine and disulfiram, have anticancer properties, such as counteraction against mutagens and prevention of tumor progression. Disulfiram has also shown promising beneficial effects in melanoma.

However, so far the beneficial activity of thiol-containing substances has been ascribed solely to the ability of the thiol group to react with oxidizing agents determining cellular redox potential, thereby modulating several biological events. Indeed, melanomas produce many oxidative species which are important mediators of tumor transformation and progression of the disease. At the present stage there is an increasing interest on the role played by the $\mathrm{H}_{2} \mathrm{~S}$ pathway in cancer. An increasing number of studies have recently appeared in the current literature focusing their attention on the role played in cancer by the enzymes CBS and CSE regulating methionine/cysteine metabolism.

The data so far obtained indicate that these enzymes are differentially expressed and generate opposite effects depending on the cancer type and stage. In fact, the actual scenario proposes a procancerogenic role for CBS and CBS-derived $\mathrm{H}_{2} \mathrm{~S}$ in cancer, in particular in both colon and ovarian cancer.

Conversely, there are no data available concerning 3-MST, while the research on CSE is at a very early stage.

As regarding to melanoma the most relevant finding is the observation that CSE expression is higher in primary melanoma than in distant metastatic melanoma, suggesting the involvement of this pathway in the progression of melanoma. As opposed to other types of cancer, CBS does not appear to play an important role in human melanoma. Moreover, the finding that several signaling cascades such as the RAS/RAF/ERK1/2 pathway, the PI3K/AKT and NF-кB pathways, all involved in melanoma initiation and progression, can be modulated by $\mathrm{H}_{2} \mathrm{~S}$ as it opens a new avenue in our understanding on the cause of melanoma development and progression and provides proof-of-principle toward establishing this pathway as a potential therapeutic target in melanoma (Panza et al., 2015). In fact, the myriad of purported biological actions of $\mathrm{H}_{2} \mathrm{~S}$ has led to a growing interest in more precise delivery of this volatile gas to target tissues in the form of $\mathrm{H}_{2} \mathrm{~S}$ "donating" compounds. The progress of these drugs in clinical trials can be accessed from the website "www.clinicaltrials.gov" while a quite dated list of patent applications on $\mathrm{H}_{2} \mathrm{~S}$-releasing molecules and dosages can be found in Bannenberg and La Vieira (Bannenberg and Vieira, 2009).

In conclusion, even if significant progress has been made in recent years in the $\mathrm{H}_{2} \mathrm{~S}$ field, it appears quite evident from the analysis of the current literature that its role in cancer (beneficial vs detrimental) is still controversial and the effect of currently used drugs and natural products on the $\mathrm{H}_{2} \mathrm{~S}$ system is in the early stage of research.# References 

Abe, K., and Kimura, H., 1996. The possible role of hydrogen sulfide as an endogenous neuromodulator. J. Neurosci. 16, 1066-1071.
Altomare, D.F., Di Lena, M., Porcelli, F., Trizio, L., Travaglio, E., Tutino, M., et al., 2013. Exhaled volatile organic compounds identify patients with colorectal cancer. Br. J. Surg. 100, 144-150.
Atefi, M., von Euw, E., Attar, N., Ng, C., Chu, C., Guo, D., et al., 2011. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One 6, e28973.
Bannenberg, G.L., and Vieira, H.L., 2009. Therapeutic applications of the gaseous mediators carbon monoxide and hydrogen sulfide. Expert. Opin. Ther. Pat. 19, 663-682.
Baskar, R., and Bian, J., 2011. Hydrogen sulfide gas has cell growth regulatory role. Eur. J. Pharmacol. 656, 5-9.
Benavides, G.A., Squadrito, G.L., Mills, R.W., Patel, H.D., Isbell, T.S., Patel, R.P., et al., 2007. Hydrogen sulfide mediates the vasoactivity of garlic. Proc. Natl. Acad. Sci. USA. 104, 17977-17982.
Ben-Neriah, Y., and Karin, M., 2011. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat. Immunol. 12, 715-723.
Berkelhammer, J., Oxenhandler, R.W., Hook Jr., R.R., and Hennessy, J.M., 1982. Development of a new melanoma model in C57BL/6 mice. Cancer Res. 42, 3157-3163.
Bhattacharyya, S., Saha, S., Giri, K., Lanza, I.R., Nair, K.S., Jennings, N.B., et al., 2013. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. PLoS One 8, e79167.
Bukovska, G., Kery, V., and Kraus, J.P., 1994. Expression of human cystathionine beta-synthase in Escherichia coli: purification and characterization. Protein Expr. Purif. 5, 442-448.
Chattopadhyay, M., Kodela, R., Nath, N., Barsegian, A., Boring, D., and Kashfi, K., 2012a. Hydrogen sulfide-releasing aspirin suppresses NF-kappaB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo. Biochem. Pharmacol. 83, 723-732.
Chattopadhyay, M., Kodela, R., Nath, N., Dastagirzada, Y.M., Velazquez-Martinez, C.A., Boring, D., et al., 2012b. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect. Biochem. Pharmacol. 83, 715-722.
Chwatko, G., Forma, E., Wilkosz, J., Glowacki, R., Jozwiak, P., Rozanski, W., et al., 2013. Thiosulfate in urine as a facilitator in the diagnosis of prostate cancer for patients with prostate-specific antigen less or equal $10 \mathrm{ng} / \mathrm{mL}$. Clin. Chem. Lab. Med. 51, 1825-1831.
Clevers, H., and Nusse, R., 2012. Wnt/beta-catenin signaling and disease. Cell 149, 1192-1205.
Du, J., Huang, Y., Yan, H., Zhang, Q., Zhao, M., Zhu, M., et al., 2014. Hydrogen sulfide suppresses oxidized lowdensity lipoprotein (ox-LDL)-stimulated monocyte chemoattractant protein 1 generation from macrophages via the nuclear factor kappaB (NF-kappaB) pathway. J. Biol. Chem. 289, 9741-9753.
Fan, H., Guo, Y., Liang, X., Yuan, Y., Qi, X., Wang, M., et al., 2013. Hydrogen sulfide protects against amyloid betapeptide induced neuronal injury via attenuating inflammatory responses in a rat model. J. Biomed. Res. 27, 296-304.
Fan, K., Li, N., Qi, J., Yin, P., Zhao, C., Wang, L., et al., 2014. Wnt/beta-catenin signaling induces the transcription of cystathionine-gamma-lyase, a stimulator of tumor in colon cancer. Cell. Signal. 26, 2801-2808.
Frantzias, J., Logan, J.G., Mollat, P., Sparatore, A., Del Soldato, P., Ralston, S.H., et al., 2012. Hydrogen sulphidereleasing diclofenac derivatives inhibit breast cancer-induced osteoclastogenesis in vitro and prevent osteolysis ex vivo. Br. J. Pharmacol. 165, 1914-1925.
Furne, J., Saeed, A., and Levitt, M.D., 2008. Whole tissue hydrogen sulfide concentrations are orders of magnitude lower than presently accepted values. Am. J. Physiol. Regul. Integr. Comp. Physiol. 295, R1479-1485.
Geiser, C.F., and Efron, M.L., 1968. Cystathioninuria in patients with neuroblastoma or ganglioneuroblastoma. Its correlation to vanilmandelic acid excretion and its value in diagnosis and therapy. Cancer 22, 856-860.
Guo, H., Gai, J.W., Wang, Y., Jin, H.F., Du, J.B., and Jin, J., 2012. Characterization of hydrogen sulfide and its synthases, cystathionine beta-synthase and cystathionine gamma-lyase, in human prostatic tissue and cells. Urology 79 (483), e481-485.
Guo, R., Lin, J., Xu, W., Shen, N., Mo, L., Zhang, C., et al., 2013. Hydrogen sulfide attenuates doxorubicin-induced cardiotoxicity by inhibition of the p38 MAPK pathway in H9c2 cells. Int. J. Mol. Med. 31, 644-650.
Hellmich, M.R., Coletta, C., Chao, C., and Szabo, C., 2015. The therapeutic potential of cystathionine beta-synthetase/hydrogen sulfide inhibition in cancer. Antioxid. Redox Signal. 22, 424-448.Hildebrandt, T.M., and Grieshaber, M.K., 2008. Three enzymatic activities catalyze the oxidation of sulfide to thiosulfate in mammalian and invertebrate mitochondria. FEBS. J. 275, 3352-3361.
Hodis, E., Watson, I.R., Kryukov, G.V., Arold, S.T., Imielinski, M., Theurillat, J.P., et al., 2012. A landscape of driver mutations in melanoma. Cell 150, 251-263.
Hu, L.F., Wong, P.T., Moore, P.K., and Bian, J.S., 2007. Hydrogen sulfide attenuates lipopolysaccharide-induced inflammation by inhibition of p38 mitogen-activated protein kinase in microglia. J. Neurochem. 100, 1121-1128.
Johnson, D.B., Peng, C., and Sosman, J.A., 2015. Nivolumab in melanoma: latest evidence and clinical potential. Ther. Adv. Med. Oncol. 7, 97-106.
Jurkowska, H., Placha, W., Nagahara, N., and Wróbel, M., 2011. The expression and activity of cystathionine- $\gamma$-lyase and 3-mercaptopyruvate sulfurtransferase in human neoplastic cell lines. Amino Acids 41, 151-158.
Kantrow, S.M., Boyd, A.S., Ellis, D.L., Nanney, L.B., Richmond, A., Shyr, Y., et al., 2007. Expression of activated Akt in benign nevi, Spitz nevi and melanomas. J. Cutan. Pathol. 34, 593-596.
Kimura, H., 2014. Production and physiological effects of hydrogen sulfide. Antioxid. Redox Signal. 20, 783-793.
Klein, C.E., Roberts, B., Holcenberg, J., and Glode, L.M., 1988. Cystathionine metabolism in neuroblastoma. Cancer $62,291-298$.
Lee, Z.W., Zhou, J., Chen, C.S., Zhao, Y., Tan, C.H., Li, L., et al., 2011. The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo. PLoS One 6, e21077.
Leikam, C., Hufnagel, A., Walz, S., Kneitz, S., Fekete, A., Muller, M.J., et al., 2014. Cystathionase mediates senescence evasion in melanocytes and melanoma cells. Oncogene 33, 771-782.
Li, L., Rossoni, G., Sparatore, A., Lee, L.C., Del Soldato, P., and Moore, P.K., 2007. Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. Free Radic. Biol. Med. 42, 706-719.
Li, Q., and Lancaster Jr., J.R., 2013. Chemical foundations of hydrogen sulfide biology. Nitric Oxide. 35, 21-34.
Matsunami, M., Kirishi, S., Okui, T., and Kawabata, A., 2012. Hydrogen sulfide-induced colonic mucosal cytoprotection involves T-type calcium channel-dependent neuronal excitation in rats. J. Physiol. Pharmacol. 63, 61-68.
Modis, K., Panopoulos, P., Coletta, C., Papapetropoulos, A., and Szabo, C., 2013. Hydrogen sulfide-mediated stimulation of mitochondrial electron transport involves inhibition of the mitochondrial phosphodiesterase 2A, elevation of cAMP and activation of protein kinase A. Biochem. Pharmacol. 86, 1311-1319.
Nagy, P., Palinkas, Z., Nagy, A., Budai, B., Toth, I., and Vasas, A., 2014. Chemical aspects of hydrogen sulfide measurements in physiological samples. Biochim. Biophys. Acta 1840, 876-891.
Pan, Y., Ye, S., Yuan, D., Zhang, J., Bai, Y., and Shao, C., 2012. Radioprotective role of H(2)S/CSE pathway in Chang liver cells. Mutat. Res. 738-739, 12-18.
Pan, Y., Ye, S., Yuan, D., Zhang, J., Bai, Y., and Shao, C., 2014. Hydrogen sulfide (H2S)/cystathionine gamma-lyase (CSE) pathway contributes to the proliferation of hepatoma cells. Mutat. Res. 763-764, 10-18.
Panza, E., De Cicco, P., Armogida, C., Scognamiglio, G., Gigantino, V., Botti, G., et al., 2015. Role of the cystathionine gamma lyase/hydrogen sulfide pathway in human melanoma progression. Pigment Cell Melanoma Res. $28,61-72$.
Searcy, D.G., and Lee, S.H., 1998. Sulfur reduction by human erythrocytes. J.Exp. Zool. 282, 310-322.
Sen, N., Paul, B.D., Gadalla, M.M., Mustafa, A.K., Sen, T., Xu, R., et al., 2012. Hydrogen sulfide-linked sulfhydration of NF-kappaB mediates its antiapoptotic actions. Mol. Cell. 45, 13-24.
Shankar, S., Chen, Q., Ganapathy, S., Singh, K.P., and Srivastava, R.K., 2008. Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms. Mol. Cancer Ther. 7, 2328-2338.
Shibuya, N., Tanaka, M., Yoshida, M., Ogasawara, Y., Togawa, T., Ishii, K., et al., 2009. 3-Mercaptopyruvate sulfurtransferase produces hydrogen sulfide and bound sulfane sulfur in the brain. Antioxid. Redox Signal. 11, $703-714$.
Sivarajah, A., Collino, M., Yasin, M., Benetti, E., Gallicchio, M., Mazzon, E., et al., 2009. Anti-apoptotic and antiinflammatory effects of hydrogen sulfide in a rat model of regional myocardial I/R. Shock 31, 267-274.
Stabler, S., Koyama, T., Zhao, Z., Martinez-Ferrer, M., Allen, R.H., Luka, Z., et al., 2011. Serum methionine metabolites are risk factors for metastatic prostate cancer progression. PLoS One 6, e22486.
Szabo, C., 2007. Hydrogen sulphide and its therapeutic potential. Nat. Rev. Drug Discov. 6, 917-935.
Szabo, C., Coletta, C., Chao, C., Modis, K., Szczesny, B., Papapetropoulos, A., et al., 2013. Tumor-derived hydrogen sulfide, produced by cystathionine-beta-synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer. Proc. Natl. Acad. Sci. USA 110, 12474-12479.

# I. MOLECULAR MECHANISMSSzabo, C., Ransy, C., Modis, K., Andriamihaja, M., Murghes, B., Coletta, C., et al., 2014. Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part I. Biochemical and physiological mechanisms. Br. J. Pharmacol. 171, 2099-2122.
Takano, N., Sarfraz, Y., Gilkes, D.M., Chaturvedi, P., Xiang, L., Suematsu, M., et al., 2014. Decreased expression of cystathionine beta-synthase promotes glioma tumorigenesis. Mol. Cancer Res. 12, 1398-1406.
Taniguchi, S., Kang, L., Kimura, T., and Niki, I., 2011. Hydrogen sulphide protects mouse pancreatic beta-cells from cell death induced by oxidative stress, but not by endoplasmic reticulum stress. Br. J. Pharmacol. 162, 1171-1178.
Villanueva, J., Vultur, A., and Herlyn, M., 2011. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res. 71, 7137-7140.
Voute Jr., P.A., and Wadman, S., 1968. Cystathioninuria in hepatoblastoma. Clin. Chim. Acta 22, 373-378.
Wallace, J.L., Caliendo, G., Santagada, V., Cirino, G., and Fiorucci, S., 2007. Gastrointestinal safety and antiinflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology 132, $261-271$.
Wang, R., 2014. Gasotransmitters: growing pains and joys. Trends Biochem. Sci. 39, 227-232.
Whiteman, M., Le Trionnaire, S., Chopra, M., Fox, B., and Whatmore, J., 2011. Emerging role of hydrogen sulfide in health and disease: critical appraisal of biomarkers and pharmacological tools. Clin. Sci. (Lond). 121, 459-488.
Whitfield, N.L., Kreimier, E.L., Verdial, F.C., Skovgaard, N., and Olson, K.R., 2008. Reappraisal of H2S/sulfide concentration in vertebrate blood and its potential significance in ischemic preconditioning and vascular signaling. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294, R1930-1937.
Yamagishi, K., Onuma, K., Chiba, Y., Yagi, S., Aoki, S., Sato, T., et al., 2012. Generation of gaseous sulfur-containing compounds in tumour tissue and suppression of gas diffusion as an antitumour treatment. Gut 61, 554-561.
Yang, G., Cao, K., Wu, L., and Wang, R., 2004. Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1. J. Biol. Chem. 279, $49199-49205$.
Zhang, L., Pei, Y., Wang, H., Jin, Z., Liu, Z., Qiao, Z., et al., 2015. Hydrogen sulfide alleviates cadmium-induced cell death through restraining ROS accumulation in roots of Brassica rapa L. ssp. pekinensis. Oxid. Med. Cell. Longev. 5, 804603.
Zhao, K., Li, S., Wu, L., Lai, C., and Yang, G., 2014. Hydrogen sulfide represses androgen receptor transactivation by targeting at the second zinc finger module. J. Biol. Chem. 289, 20824-20835.
Zoccali, C., Catalano, C., and Rastelli, S., 2009. Blood pressure control: hydrogen sulfide, a new gasotransmitter, takes stage. Nephrol. Dial. Transplant. 24, 1394-1396.# C H A P T E R 

## 10

## Brain Metastasis from Esophageal Cancer <br> Mohammad Reza Keramati, Majid Esmaeilzadeh and Mohammad Bashashati

|  | OUTLINE |  |  |
| :--: | :--: | :--: | :--: |
| Introduction | 145 | Treatment | 150 |
| Incidence | 146 | Surgical Resection | 150 |
| Clinical Presentations | 146 | Whole Brain Radiation Therapy | 151 |
| Risk Factors | 148 | Stereotactic Radiosurgery | 151 |
| Histology | 148 | Chemotherapy | 151 |
| Diagnosis and Staging | 148 | Combination Therapies | 151 |
| Oncological Anatomy of Esophageal Cancer | 149 | Prognosis and Survival | 152 |
|  |  | Summary and Future Directions | 152 |
|  | 149 | References | 153 |

## INTRODUCTION

Esophageal cancer (EC) is one of the eight most common cancers throughout the world. The incidence of esophageal cancer varies worldwide with the highest rates in Eastern Asian and Southern African countries and the lowest rates in Western Africa, Central Africa, and Central America (Jemal et al., 2011). The worldwide incidence and the mortality rate of esophageal cancer are $3.2 \%$ and $4.9 \%$, respectively (Ferlay et al., 2013).The most common forms of esophageal cancer are esophageal squamous cell carcinoma (ESCC) and adenocarcinoma (EAC). Clinical outcome of patients with esophageal cancer is greatly affected by the extent of tumor dissemination and metastasis. Lymph nodes (including celiac lymph nodes and supraclavicular lymph nodes), liver, and peritoneum are the most common sites of metastasis from EC (van Vliet et al., 2007). Other rare but important distant metastasis of esophageal cancer to lung, bone, or brain, as well as bone marrow involvement, has also been reported (Madani et al., 2014; Natsugoe et al., 2003).

Although brain metastasis is the most common neurological complication of systemic cancers with a poor prognosis, brain metastasis from esophageal cancer is a rare phenomenon with an incidence of approximately 1-3.6\% (Go et al., 2011; Spallone and Izzo, 2013). On the other hand, the low incidence of brain metastasis from esophageal cancer can be due to underestimation, because brain imaging is not a routine diagnostic procedure in cancer patients without neurological symptoms (Esmaeilzadeh et al., 2014).

Over the recent decades, as a result of advances in diagnostic methods and therapeutic options, management of patients with brain metastasis from primary cancers has improved. However, for the brain metastases from esophageal cancer, basically due to the small number of reported cases, our knowledge is limited and their management is still controversial. In this chapter, we review the available literature on the brain metastasis of esophageal cancer.

# INCIDENCE 

The real incidence of brain metastasis from esophageal cancer is unknown. To date, brain metastasis from esophageal cancer has remained a relatively rare phenomenon with a limited number of reported patients. Its incidence has been suggested to be approximately $0-2 \%$ in clinical studies and $0-5.1 \%$ in autopsies (Go et al., 2011). In a recently published series in 2014 on 1612 EC patients with primary esophageal cancer, $1.61 \%$ had brain metastasis (Song et al., 2014). In another large study published in 2002 by Ogawa et al., $1.4 \%$ of cases out of 2554 patients were identified to have brain metastases (Ogawa et al., 2002). Moreover, in a case series on 1588 patients, the incidence of brain metastasis from esophageal cancer was found to be $1.7 \%$ (Weinberg et al., 2003). A list of published studies on esophageal cancer patients with brain metastases has been summarized in Table 10.1.

## CLINICAL PRESENTATIONS

Esophageal carcinoma is mostly asymptomatic at the beginning. When it becomes symptomatic, the symptoms are categorized into: (1) local tumor effects; (2) invasion to adjacent structures; and (3) distant disease. The most common complaint in patients with esophageal cancer is dysphagia which is due to the stricture of the lumen and is usually progressive. To overcome dysphagia, patients usually change their diet to small bites followed by soft or liquid food in the late stages. Therefore, they may not recognize the presence of any swallowing problem, due to the adaptive change of their diet; however, they may lose weightTABLE 10.1 An Overview of Published Clinical Studies on Brain Metastasis from Esophageal Cancer

| First author | Year of publication | Total number of patients with esophageal cancer | Total number of patients with brain metastasis |
| :--: | :--: | :--: | :--: |
| Spallone and Izzo (2013) | 2013 | 1 (Case report) | 1 |
| Smith and Miller (2011) | 2011 | 53 | 7 |
| Agrawal et al. (2009) | 2009 | 504 | 1 |
| Da Silva et al. (2009) | 2009 | N/A | 5 |
| Kim et al. (2009) | 2009 | N/A | 1 |
| Yoshida (2007) | 2007 | 1141 | 17 |
| Kesler et al. (2006) | 2006 | 1 (Case report) | 1 |
| Bartelt et al. (2004) | 2004 | 916 | 0 |
| Almasi et al. (2004) | 2004 | 301 | 1 |
| Weinberg et al. (2003) | 2003 | 1588 | 27 |
| Ogawa et al. (2002) | 2002 | 2554 | 36 |
| Gabrielsen et al. (1995) | 1995 | 722 | 15 |
| Quint et al. (1995) | 1995 | 147 | 3 |
| Koga et al. (1991) | 1991 | 4 (Case series) | 4 |
| Odaimi and Ajani (1986) | 1986 | 1 (Case report) | 1 |
| Averbuch and Blinder (1983) | 1983 | 1 (Case report) | 1 |

because of the diet changes and lack of energy intake. Chest pain and odynophagia along with cough, regurgitation and salivation, and gastrointestinal (GI) bleeding are other local symptoms. Invasion to adjacent structures may present with respiratory fistula, hoarseness due to recurrent laryngeal nerve invasion, and hiccups as the results of phrenic nerve invasion. Paraneoplastic symptoms (e.g., hypercalcemia majorly in ESCC), pneumonia, and symptoms of the metastasis (e.g., to lung, liver, bone, and brain) are other symptoms of the esophageal cancer. In physical examination, cachexia, supraclavicular lymphadenopathy, pleural effusion, and hepatosplenomegaly may be detected (Absi et al., 2014).

The interval between the diagnosis of the primary tumor in the esophagus to the discovery of brain metastasis, or brain disease-free interval, ranges from 5.6 to 30 months in clinical studies with a median of 13 months (Esmaeilzadeh et al., 2014). A number of neurological symptoms might happen in patients with brain metastasis. Headache, motor deficit, gait disturbance, speech deficit, personality changes, nausea, visual defects, sensory deficit, cranial nerve deficit, and vomiting are the most common symptoms. Increased intracranial pressure as a result of the metastasis can lead to nausea and vomiting which might be mistakenly attributed to the primary tumor in esophagus (Esmaeilzadeh et al., 2014).# RISK FACTORS 

A large number of risk factors have been identified for esophageal cancer. These vary dramatically between EAC and ESCC. Major risk factors for the EAC are Barrett's esophagus, gastroesophageal reflux, and obesity; while tobacco use, alcohol consumption, and nutritional imbalance have been identified as the risk factors of ESCC (Mao et al., 2011). Gastroesophageal reflux alone increases the risk of EAC by three fold, whereas Barrett's esophagus, a metaplastic transformation of the normal stratified squamous esophageal epithelium, increases the risk of EAC by 30 -folds (Mao et al., 2011). Obesity, as a consequence of overnutrition, is a risk factor that may lead to gastroesophageal reflux and subsequent EAC (Murray and Romero, 2009). Nitrosamines, found in salted vegetables and preserved foods, have also been confirmed as powerful carcinogens in esophageal cancer (Abnet, 2007). Human papillomavirus (HPV) is another important risk factor for ESCC (Syrjanen, 1982). Moreover, genetic alteration and abnormalities may lead to esophageal cancer (Kuwano et al., 2005).

Studies have shown that large primary esophageal tumor and advanced stages are two major risk factors in the development of brain metastasis. Ogawa et al. (2002) noted that more than $80 \%$ of brain metastasis from esophageal cancer are found in stages III or higher. Moreover, Weinberg et al. (2003) reported that $70 \%$ of their metastatic patients were in stage IV of esophageal cancer. Similar findings have been reported by Song et al. (2014) indicating more than $70 \%$ of esophageal cancer patients with brain metastasis were in stages III or higher.

Gabrielsen et al. (1995) reported a significant difference between the size of tumor in patients with and without brain metastasis. They showed a mean tumor size of greater than 8.63 cm in patients with brain metastasis compared to a size less than 5.12 cm in patients diagnosed with no metastases. Song et al. (2014) have also found a mean tumor size of 6.0 cm in patients with brain metastasis. They concluded that proper management of the primary esophageal tumor can decrease the rate of brain metastasis and may influence the time to brain metastasis. Despite these reports, our knowledge of the risk factors of brain metastasis from esophageal cancer is restricted. Therefore, more studies on larger databases are necessary.

## HISTOLOGY

Contradictory results have been published on the histology of esophageal carcinoma and its relation to brain metastasis. In Western countries, EAC has been the most prevalent histology in brain metastases from esophageal carcinoma (Weinberg et al., 2003); while in Asian countries such as Japan and China, ESCC is the most common histological type (Ogawa et al., 2002; Yoshida, 2007). These results may be due to the current higher prevalence of EAC in Western countries and ESCC in Asia. It has also been suggested that tumor histology is not an independent risk factor for esophageal brain metastasis (Go et al., 2011). Another reported subtype is basaloid squamous cell carcinoma which has a poor prognosis (Song et al., 2014).# DIAGNOSIS AND STAGING 

The diagnosis of esophageal cancer is based on suspicious GI symptoms which necessitate the evaluation of the upper GI tract by imaging techniques or endoscopy. The diagnosis is confirmed by histological evaluation, and then the patient should be staged for the disease by computerized tomography (CT) scanning. Staging of the esophageal cancer is very important as it helps the physicians in choosing the best therapeutic approach and to predict the prognosis and response to the treatment. Moreover, as indicated, staging can predict the risk of metastasis to the brain (Esmaeilzadeh et al., 2014; Song et al., 2014; Weinberg et al., 2003).

Brain imaging, using CT scanning or magnetic resonance imaging (MRI), is highly recommended in patients with neurological clinical presentations suggestive of CNS involvement. Preoperative neuroimaging has also been suggested in cases with large primary esophageal tumor of greater than 8 cm in diameter (Go et al., 2011). Gabrielsen et al. (1995) have studied the value of routine brain CT scan in patients with esophageal carcinoma and detected brain metastasis in $0 \%$ and $0.8 \%$ of patient who were candidates and were not candidates for esophagectomy, respectively. Considering these findings, routine preoperative neuroimaging has not been recommended as a part of the staging workup to identify occult brain metastasis (Gabrielsen et al., 1995).

## ONCOLOGICAL ANATOMY OF ESOPHAGEAL CANCER

In the case of cancer, understanding the vascular and lymphatic drainage of an organ would be important as it defines the roots of metastasis or dissemination of the tumor as well as the basics of treatment. While ESCC primarily occurs in the upper esophagus, EAC affects the lower esophagus and esophagogastric junction (EGJ).

Anatomically, the esophagus is divided into cervical, thoracic, and abdominal segments. The inferior thyroid artery supplies the cervical esophagus and its drainage is to the inferior thyroid vein. Esophageal and bronchial branches of the thoracic aorta supply the thoracic segment, and the venous drainage of this part is toward the azygos, hemiazygos, intercostal, and bronchial veins. The ascending branches of the left phrenic and left gastric arteries supply the abdominal esophagus and its venous drainage is into the left gastric vein of the portal system. The esophagus has two lymphatic plexus, one in the mucous membrane and the other in the muscular coat. The lymphatic system of esophagus is densely interconnected, which allows easy spreading of the esophageal carcinoma. The lymphatic drainage of cervical esophagus is into the deep cervical nodes, the thoracic part to the posterior mediastinal nodes, and the abdominal part to the left gastric nodes (Viswanatha, 2011).

By understanding the anatomy of esophagus, it becomes clear that there is not a common or joint lymphatic or vascular drainage for the brain and esophagus, suggesting alternative routes for the metastasis of esophageal cancer to the brain. Therefore, two different pathways have been considered for this type of metastasis, although these hypotheses have not been proved yet:
(1) Brain metastasis of esophageal cancer might be due to the metastasis to the lung and subsequent metastasis of secondary lung tumors to the brain. On the other hand, only$15-30 \%$ of patients with brain metastasis had evidence for lung metastasis at the same time. In this case, micrometastasis to the lung might be a possibility as it is not detectable based on routine workups (Almasi et al., 2004; Ogawa et al., 2002; Weinberg et al., 2003). (2) Metastatic spread of esophageal cancer to the brain may occur through the Batson's vertebral venous plexus as a vascular communication between the esophagus and brain (Almasi et al., 2004; Go et al., 2011). As mentioned above, these routes are based on hypotheses, and we do not know exactly how the esophageal cancer metastasizes to the brain.

# TREATMENT 

The treatment of esophageal cancer depends on the stage of the disease and whether it is resectable or not. Localized lesions with or without lymph node involvement, or with pleural, pericardial, or diaphragmatic involvement, but without distant metastasis, are resectable (Stage: T1-T4a). On the other hand, those with invasion to aorta, trachea, and vertebral body or distant metastasis are considered unresectable (Stage $\geq$ T4b) (Keditsu et al., 2013). Neoadjuvant chemoradiotherapy (NACT) is recommended for T3 or N1 tumors. However, due to staging difficulties, it has been also recommended for T2 tumors (Sancheti and Fernandez, 2012). Definitive chemoradiotherapy has been suggested for patients with unresectable disease, or who refuse surgery with a 2-year survival of $40-55 \%$ (Cooper et al., 2012).

There is no clear guideline for the treatment of brain metastasis of esophageal cancer. Therefore, a general approach similar to other tumor metastases to the brain should be followed. For patients with brain metastasis, no clinical trial has been performed and therapeutic approaches should be individualized depending on each patient's condition and prognostic factors (Norden et al., 2005). Two strategies, including supportive or definitive therapy, can be considered. Supportive therapy aims at management of complications caused by the brain lesion. Treatment of the malignancy, improvement of patient survival, and restoration of neurological function can be reached through definitive therapy (Esmaeilzadeh et al., 2014). Although it is not definitive, we outline possible treatment strategies in esophageal cancer with brain metastasis mainly based on the approaches which have been suggested for other GI cancers with brain metastasis.

## Surgical Resection

Local control of the metastatic disease, improvement of neurological symptoms, improvement of survival, and confirmation of histological diagnosis are the main goals of surgical resection (Black and Johnson, 2004). Studies have shown that surgical resection is the method of choice in patients with a solitary metastasis (Norden et al., 2005). Tumor size and location may also influence surgical treatment (Song et al., 2014). Although a large and symptomatic lesion in patients with multiple brain metastases should be resected in order to correct the neurological symptoms, patients with multiple lesions are not appropriates candidates for surgical resection (Esmaeilzadeh et al., 2014). We should bear in mind that "resect or not to resect a metastatic lesion in the brain," also depends on the whole clinical picture of the patient. Therefore, we do not recommend surgical resection in patients with higher stages of disease, who have a lower rate of survival.# Whole Brain Radiation Therapy 

While whole brain radiation therapy (WBRT), due to its toxicity and cognitive complications, has not been recommended as the first-line therapy of brain metastasis (Richards et al., 2007), WBRT is an accepted treatment modality used in poor prognostic patients with active extracranial tumor and/or multiple intracranial metastatic lesions (Song et al., 2014). To be eligible for WBRT, patients should have a Karnofsky performance score (KPS) of greater than 70 and be capable of caring for themselves independently (Yoshida, 2007). Increased survival, local control of the metastasis, improvement in neurological function, and control of undiagnosed micrometastases are observed after WBRT (Andrews et al., 2004; Kondziolka et al., 2005; Roberge et al., 2009).

## Stereotactic Radiosurgery

Stereotactic radiosurgery (SRS) is an external irradiation technique employing multiple convergent beams to deliver a high single dose of radiation to a discrete target. Due to a rapid dose falloff, the risk of damage to normal nervous tissues surrounding the metastasis can be reduced (Soffietti et al., 2008). Because of the small size, spherical shape, and distinct margins, brain metastases are ideal targets for SRS (Baumert et al., 2006). The efficacy of SRS and the required radiation dose are inversely related to the brain tumor's size, including its diameter and volume (Soffietti et al., 2008). Gamma Knife radiosurgery (GKRS) using multiple radioactive cobalt-60 sources and linear particle accelerator (Linac) are two SRS techniques (Esmaeilzadeh et al., 2014). Due to higher probability of recurrence, use of SRS alone for the treatment of large solitary brain metastasis is not recommended; however, it can be used in patients with surgical contraindication. SRS is frequently used as initial treatment in single small lesions or as an adjuvant therapy to surgery (Esmaeilzadeh et al., 2014).

## Chemotherapy

The role of chemotherapy in patients with brain metastasis is controversial. Most of the current chemotherapeutic agents fail to reach the brain because of the blood-brain-barrier. Therefore, they are not effective first-line treatments for the metastatic brain lesions, but can be suggested when other treatments have failed, although improved survival is not guaranteed (Song et al., 2014). Temozolomide has shown good results in recent trials as an effective treatment for metastatic brain lesions from solid tumors, such as lung and breast tumors. It is a prodrug that is administered orally, and is metabolized and activated locally (Song et al., 2014). Whether this helps in brain metastasis from esophageal cancer needs further investigations.

## Combination Therapies

Surgical resection (SR) of the metastasis has been a standard treatment for solitary metastatic lesions, especially in patients with good performance status and limited extracranial disease (Kalkanis et al., 2010); however, a large number of patients who present with other organ involvement are not suitable for surgery. Combination of SR and WBRT has shown a good survival in patients with isolated brain metastases from esophageal cancer (Ogawaet al., 2002; Yoshida, 2007). Contradictory results have been published regarding the combinations of surgical resection and SRS. Some studies report that SRS provides good local control of the brain metastasis after surgical resection, while some other studies indicate equal success rate for these therapeutic methods (Kondziolka et al., 2001).

Adjuvant WBRT after SRS or surgery has been found to be effective in controlling relapses in patients with one to three brain metastases (Kocher et al., 2011). Rades et al. (2007) have also shown that 1-year survival and local tumor control after WBRT plus SRS appeared to be as effective as surgery with WBRT. Aoyama et al. (2006) found a significant difference in local tumor recurrence after 1 year between WBRT with SRS versus SRS alone groups; but the difference for 1-year overall survival was not statistically different. In another trial conducted by Muacevic et al. (2008), local control was not significantly different between surgery with WBRT versus SRS alone in patients with tumors less than 3 cm . However, in the first group, the 2-year local control was lower than the SRS alone.

Based on the available cumulative evidence, the optimal therapy for management of these patients is difficult to know in the absence of sufficient trials regarding the treatment of these patients. General condition of the patient, stage of the disease, histology, age, KPS, and the number, size, and location of the metastases should be considered for selecting the best therapeutic strategy.

Patients with a solitary brain lesion of greater than 3 cm in maximum diameter are regularly treated with resection and when needed, followed by WBRT. SRS has been recommended for solitary lesions of less than 3 cm . In contrast, patients with multiple lesions are poor candidates for surgical resection alone. Surgical resection followed by WBRT for patients with 1-3 metastatic lesions and surgical resections preceded by SRS in patients with 4 or more metastases have led to significant improvement in survival rates. The use of WBRT in combination with SRS has also been proposed for patients with multiple brain metastases (Esmaeilzadeh et al., 2014).

# PROGNOSIS AND SURVIVAL 

In general, the prognosis of esophageal cancer with brain metastasis is poor. The interval between diagnosis of primary esophageal cancer and detection of brain metastasis is between 5.6 to 30 months (Agrawal et al., 2009; Weinberg et al., 2003). A median survival time of 3.8 months has been reported after the diagnosis of brain metastases (Weinberg et al., 2003). Moreover, median survival time after treatment of the brain metastasis has been approximately 7 months in other studies (Esmaeilzadeh et al., 2014). Absence of extracranial metastasis, solitary brain lesion, and KPS of greater than $90 \%$ have been found to be related with better survival in up to $14 \%$ of patients (Go et al., 2011). The prognosis is also affected by the type of primary tumor, the time interval between the diagnosis of primary tumor, the occurrence of brain metastasis, and presence of other systemic metastases (Esmaeilzadeh et al., 2014).

## SUMMARY AND FUTURE DIRECTIONS

Brain metastasis from esophageal cancer is a rare phenomenon with a poor prognosis.
Treatment of these patients does not follow any defined guideline, and the choice of therapies depends on the patients' general condition and the physician's opinion. Early

## I. MOLECULAR MECHANISMSdiagnosis of any metastasis from GI to the brain has a significant influence on the treatment outcome and the quality of life of the patients. Further studies to understand the mechanisms of the development of brain metastasis are necessary. Furthermore, the role of novel therapeutic targets should be considered. Additionally, finding the molecular and genetic moieties which are involved in brain metastasis will be helpful in discovering potential therapeutic targets in these patients.

# References 

Abnet, C.C., 2007. Carcinogenic food contaminants. Cancer Invest. 25, 189-196.
Absi, A., Adelstein, D.J., and Rice, T.W., 2014. Esophageal cancer. Available from: <http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/hematology-oncology/esophageal-cancer/>.
Agrawal, R., Shukla, P., Shukla, V., and Chauhan, A., 2009. Brain metastasis from esophageal carcinoma. J. Cancer Res. Ther. 5, 137-139.
Almasi, S., Bashashati, M., Rezaei, N., and Markazi-Moghaddam, N., 2004. Brain metastasis from esophageal carcinoma. Neurol. India 52, 492-493.
Andrews, D.W., Scott, C.B., Sperduto, P.W., Flanders, A.E., Gaspar, L.E., Schell, M.C., et al., 2004. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363, 1665-1672.
Aoyama, H., Shirato, H., Tago, M., Nakagawa, K., Toyoda, T., Hatano, K., et al., 2006. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. J. Am. Med. Assoc. 295, 2483-2491.
Averbuch, S.D., and Blinder, M.A., 1983. Brain metastasis from esophageal carcinoma. CA. Cancer. J. Clin. 33, 164-166.
Bartelt, S., Momm, F., Weissenberger, C., and Lutterbach, J., 2004. Patients with brain metastases from gastrointestinal tract cancer treated with whole brain radiation therapy: prognostic factors and survival. World J. Gastroenterol. 10, 3345-3348.
Baumert, B.G., Rutten, I., Dehing-Oberije, C., Twijnstra, A., Dirx, M.J., Debougnoux-Huppertz, R.M., et al., 2006. A pathology-based substrate for target definition in radiosurgery of brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 66, 187-194.
Black, P.M., and Johnson, M.D., 2004. Surgical resection for patients with solid brain metastases: current status. J. Neurooncol. 69, 119-124.
Cooper, S.L., Russo, J.K., and Chin, S., 2012. Definitive chemoradiotherapy for esophageal carcinoma. Surg. Clin. North. Am. 92, 1213-1248.
Da Silva, A.N., Nagayama, K., Schlesinger, D., and Sheehan, J.P., 2009. Early brain tumor metastasis reduction following Gamma Knife surgery. J. Neurosurg. 110, 547-552.
Esmaeilzadeh, M., Majlesara, A., Faridar, A., Hafezi, M., Hong, B., Esmaeilnia-Shirvani, H., et al., 2014. Brain metastasis from gastrointestinal cancers: a systematic review. Int. J. Clin. Pract. 68, 890-899.
Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., et al., 2013. Cancer incidence and mortality worldwide. Available from: <http://globocan.iarc.fr>.
Gabrielsen, T.O., Eldevik, O.P., Orringer, M.B., and Marshall, B.L., 1995. Esophageal carcinoma metastatic to the brain: clinical value and cost-effectiveness of routine enhanced head CT before esophagectomy. Am. J. Neuroradiol. 16, 1915-1921.
Go, P.H., Klaassen, Z., Meadows, M.C., and Chamberlain, R.S., 2011. Gastrointestinal cancer and brain metastasis: a rare and ominous sign. Cancer 117, 3630-3640.
Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., and Forman, D., 2011. Global cancer statistics. CA Cancer J. Clin. 61, $69-90$.
Kalkanis, S.N., Kondziolka, D., Gaspar, L.E., Burri, S.H., Asher, A.L., Cobbs, C.S., et al., 2010. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J. Neurooncol. 96, 33-43.
Keditsu, K.K., Jiwnani, S., Karimundackal, G., and Pramesh, C.S., 2013. Multimodality management of esophageal cancer. Indian J. Surg. Oncol. 4, 96-104.
Kesler, K.A., Hammoud, Z.T., Helft, P.R., Rieger, K.M., Pritz, M.B., and Brown, J.W., 2006. Long-term survival after excision of a solitary esophageal cancer brain metastasis. J. Thorac. Cardiovasc. Surg. 131, 497-498.Kim, Y.Z., Kim, K.H., Kim, J.S., Song, Y.J., Kim, K.U., and Kim, H.D., 2009. Clinical analysis of patients who survived for less than 3 months after brain metastatectomy. J. Korean Med. Sci. 24, 641-648.
Kocher, M., Soffietti, R., Abacioglu, U., Villa, S., Fauchon, F., Baumert, B.G., et al., 2011. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J. Clin. Oncol. 29, 134-141.
Koga, H., Mukawa, J., Miyagi, K., Nakasone, S., Kinjo, T., Miyazato, H., et al., 1991. Treatment of metastatic brain tumor from esophageal carcinoma—report of four cases. Neurol. Med. Chir (Tokyo) 31, 518-522.
Kondziolka, D., Lunsford, L.D., and Flickinger, J.C., 2001. Controversies in the management of multiple brain metastases: the roles of radiosurgery and radiation therapy. Forum (Genova) 11, 47-58.
Kondziolka, D., Niranjan, A., Flickinger, J.C., and Lunsford, L.D., 2005. Radiosurgery with or without whole-brain radiotherapy for brain metastases: the patients' perspective regarding complications. Am. J. Clin. Oncol. 28, 173-179.
Kuwano, H., Kato, H., Miyazaki, T., Fukuchi, M., Masuda, N., Nakajima, M., et al., 2005. Genetic alterations in esophageal cancer. Surg. Today 35, 7-18.
Madani, A., Spicer, J., Alcindor, T., David, M., Vanhuyse, M., Asselah, J., et al., 2014. Clinical significance of incidental pulmonary nodules in esophageal cancer patients. J. Gastrointest. Surg. 18, 226-232.
Mao, W.M., Zheng, W.H., and Ling, Z.Q., 2011. Epidemiologic risk factors for esophageal cancer development. Asian Pac. J. Cancer Prev. 12, 2461-2466.
Muacevic, A., Wowra, B., Siefert, A., Tonn, J.C., Steiger, H.J., and Kreth, F.W., 2008. Microsurgery plus whole brain irradiation versus Gamma Knife surgery alone for treatment of single metastases to the brain: a randomized controlled multicentre phase III trial. J. Neurooncol. 87, 299-307.
Murray, L., and Romero, Y., 2009. Role of obesity in Barrett's esophagus and cancer. Surg. Oncol. Clin. N. Am. 18, 439-452.
Natsugoe, S., Nakashima, S., Nakajo, A., Matsumoto, M., Okumura, H., Tokuda, K., et al., 2003. Bone marrow micrometastasis detected by RT-PCR in esophageal squamous cell carcinoma. Oncol. Rep. 10, 1879-1883.
Norden, A.D., Wen, P.Y., and Kesari, S., 2005. Brain metastases. Curr. Opin. Neurol. 18, 654-661.
Odaimi, M., and Ajani, J.A., 1986. Brain metastases and elevated alpha-fetoprotein level in a patient with esophageal carcinoma. South Med. J. 79, 1304-1306.
Ogawa, K., Toita, T., Sueyama, H., Fuwa, N., Kakinohana, Y., Kamata, M., et al., 2002. Brain metastases from esophageal carcinoma: natural history, prognostic factors, and outcome. Cancer 94, 759-764.
Quint, L.E., Hepburn, L.M., Francis, I.R., Whyte, R.I., and Orringer, M.B., 1995. Incidence and distribution of distant metastases from newly diagnosed esophageal carcinoma. Cancer 76, 1120-1125.
Rades, D., Bohlen, G., Pluemer, A., Veninga, T., Hanssens, P., Dunst, J., et al., 2007. Stereotactic radiosurgery alone versus resection plus whole-brain radiotherapy for 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients. Cancer 109, 2515-2521.
Richards, G.M., Khuntia, D., and Mehta, M.P., 2007. Therapeutic management of metastatic brain tumors. Crit. Rev. Oncol. Hematol. 61, 70-78.
Roberge, D., Petrecca, K., El Refae, M., and Souhami, L., 2009. Whole-brain radiotherapy and tumor bed radiosurgery following resection of solitary brain metastases. J. Neurooncol. 95, 95-99.
Sancheti, M., and Fernandez, F., 2012. Management of T2 esophageal cancer. Surg. Clin. North. Am. 92, 1169-1178.
Smith, R.S., and Miller, R.C., 2011. Incidence of brain metastasis in patients with esophageal carcinoma. World J. Gastroenterol. 17, 2407-2410.
Soffietti, R., Ruda, R., and Trevisan, E., 2008. Brain metastases: current management and new developments. Curr. Opin. Oncol. 20, 676-684.
Song, Z., Lin, B., Shao, L., and Zhang, Y., 2014. Brain metastases from esophageal cancer: clinical review of 26 cases. World Neurosurg. 81, 131-135.
Spallone, A., and Izzo, C., 2013. Esophageal cancer presenting as a brain metastasis: a case report. Oncol. Lett. 6, $722-724$.
Syrjanen, K.J., 1982. Histological changes identical to those of condylomatous lesions found in esophageal squamous cell carcinomas. Arch. Geschwulstforsch. 52, 283-292.
van Vliet, E.P., Steyerberg, E.W., Eijkemans, M.J., Kuipers, E.J., and Siersema, P.D., 2007. Detection of distant metastases in patients with oesophageal or gastric cardia cancer: a diagnostic decision analysis. Br. J. Cancer. 97, 868-876.
Viswanatha, B., 2011. Esophageal anatomy. Available from: <http://emedicine.medscape.com/article/1948973overview>.
Weinberg, J.S., Suki, D., Hanbali, F., Cohen, Z.R., Lenzi, R., and Sawaya, R., 2003. Metastasis of esophageal carcinoma to the brain. Cancer 98, 1925-1933.
Yoshida, S., 2007. Brain metastasis in patients with esophageal carcinoma. Surg. Neurol. 67, 288-290.

# I. MOLECULAR MECHANISMS# C H A P T E R 

## 11

## Treatment of Metastatic Melanoma Patients Bearing c-Kit Mutation Using Imatinib Mesylate

Lili Mao and Jun Guo

## O U T L I N E

Introduction
c-Kit Aberration in Melanoma and the Ethnic Differences
Efficacy of Imatinib in Melanoma Treatment
Toxicity of Imatinib in Treating
Melanoma Patients
157
158
159
161

Resistance to Imatinib Treatment
Second-Generation of Tyrosine
Kinase Inhibitors
Perspective
References

References

162
163
164
References

165

## INTRODUCTION

Malignant melanoma (MM) causes most deaths among patients with skin cancer. Up to the end of 2010, the incidence of melanoma in Beijing (China) was 0.89/100,000, which was much lower than that in many Western countries (such as the United States and Australia). Even so, the number of newly diagnosed melanoma patients annually is not small due to the large population in China. Low incidence but high death rates are epidemiological characteristics of melanoma in China. Therefore, more attention should be paid to melanoma.Primary melanoma is classified into four subtypes according to sun exposure and localization: acral melanoma (localized on sun-protected skin such as the palms, soles, or subungual sites); mucosal melanoma (localized on surface of mucosal membrane of the head and neck, the anorectal mucosa and the vulvovaginal mucosa); melanoma on chronically sun-damaged (CSD) skin (showing chronic sun-induced damage as evidenced by marked solar elastosis); and melanoma arising from skin without signs of chronic sun damage (nonSD) (Curtin et al., 2006). The different localization of primary MM may be related to ethnic background. Mucosal and acral melanoma accounts for approximately $65 \%$ of all melanomas in Chinese population, whereas in the Caucasian populations, the main locations are trunk and legs (Chi et al., 2011; Shoo and Kashani-Sabet, 2009).

The outcomes of traditional melanoma chemotherapy are poor, especially for the standard dacarbazine (DTIC)-based classical chemotherapy in metastatic melanoma (Yang and Chapman, 2009). While targeted therapy using inhibitors, such as BRAF and c-Kit, has made great achievements in melanoma treatments, our center, the Department of Renal Cancer and Melanoma in Beijing, has investigated molecular profiling of melanoma and the clinical trials of targeted therapy in Chinese melanoma patients. In this chapter, we summarize the current understanding and our experience of c-Kit-based targeted therapy in melanoma.

# c-Kit Aberration in Melanoma and the Ethnic Differences 

The c-Kit gene encodes a type III transmembrane receptor tyrosine kinase (RTK), also known as CD117, that plays a role in cell survival, proliferation, and differentiation. c-Kit is a cell surface receptor consisting of an extracellular domain, a transmembrane domain (coded by exon 10), a cytoplasmic domain consisting of a juxtamembrane domain (coded by exon 11), and two intracellular tyrosine kinase domains (coded by exons 12-21) (Yarden et al., 1987; Qiu et al., 1988). c-Kit has been identified as a proto-oncogene and regarded as a target in cancer treatments, including gastrointestinal stromal tumor (GIST), leukemia, and melanoma.

Molecular profiling of c-Kit in melanoma suggests that c-Kit aberration is different among subtypes of melanoma. c-Kit mutation and/or an increase in c-Kit copy numbers is/are more common in mucosal, acral, and CSD melanomas, whereas BRAF mutations are highly prevalent in non-CSD melanomas (Curtin et al., 2005, 2006). Curtin et al. (2006) examined 102 primary melanomas and found mutations and/or copy number increases of c-Kit in $39 \%$ of mucosal melanomas, $36 \%$ of acral melanomas, and $28 \%$ of CSD melanomas, but no c-Kit mutation was found in non-CSD melanomas. Beadling et al. (2008) reported that c-Kit mutation was detected in $23 \%$ of acral melanomas, $15.6 \%$ of mucosal melanomas, $7.7 \%$ of conjunctival melanomas, $1.7 \%$ of cutaneous melanomas, and $0 \%$ of choroidal melanomas when studying a cohort of 189 melanomas.

In Chinese melanoma patients examined in our center, c-KIT mutation profile was detected in 502 patients (Kong et al., 2011). The overall incidence of somatic mutations within the c-Kit gene was $10.8 \%$ (54/502), and all subtypes of melanoma contained c-Kit mutations. The frequency of c-Kit mutations in the acral, mucosal, and CSD melanomas were $11.9 \%(23 / 193), 9.6 \%(16 / 167)$, and $20.7 \%(6 / 29)$, respectively. This may be the largest study ever performed for evaluation of the c-Kit mutation in melanoma. Ashida et al. (2009) reported that the frequency of c-Kit mutations in a Japanese cohort, which mainly consisted of metastatic acral melanomas, was approximately $17 \%$. These studies in Asian populationssuggest that although acral and mucosal melanomas are more prevalent in Asian populations, the frequency of c-Kit mutations seems lower than in Caucasian patients. The possible reasons for the differences in c-Kit mutations between Asian and Caucasian populations are unclear, which may be attributed to geographic location that leads to subtype bias of melanoma or to the baseline characteristics of melanoma patients since more metastatic lesions are included in the studies of Asian patients. Shen et al. (2003) have revealed that c-Kit expression tends to be diminished in metastatic lesions. The L576P c-Kit mutation within exon 11 and K642E exon 13 are the most common c-Kit mutations in melanoma ( 30-40\% of mutations) (Beadling et al., 2008). Our study also showed the most frequent c-Kit mutations were L576P (9 cases) and K642E (5 cases) (Kong et al., 2011). Moreover, for the first time, our study suggests that c-Kit aberrations (mutation plus amplification) adversely impact survival of melanoma patients.

Protein expression of c-Kit can be detected in the majority of mucosal melanomas (up to $91 \%$ ) (Satzger et al., 2008) and also in a high percentage of cutaneous melanomas (up to $84 \%$ ) (Chute et al., 2006; Giehl et al., 2007). The association between CD117 protein expression and c-Kit mutation in melanoma has been studied many times. Satzger et al. (2008) found that eight of the nine anorectal melanomas were positive for CD117 expression, with only three samples showing strong expression (one sample contained the L576P c-Kit mutation). Antonescu et al. (2007) reported that $23 \%$ of anal melanomas showed a diffuse and strong reactivity to the antibody of CD117, and only 3 cases with L576P mutation were identified in a total of 20 cases tested. We examined CD117 expression in 502 melanoma patients. Among the 54 cases with c-Kit mutation, 24 cases ( $44.4 \%$ ) were positive for CD117, which was not significantly different from the positive rate of CD117 (39.6\%) detected in the overall population (Kong et al., 2011). We also found that $68.8 \%(11 / 16)$ of mucosal melanomas with c-Kit mutation were positive for CD117, not significantly higher than those in acral melanomas ( $34.8 \%$ ), CSD melanomas ( $16.7 \%$ ), non-CSD melanomas ( $60.0 \%$ ), and melanomas of unknown primary ( $25.0 \%$ ). Ni et al. (2011) examined 40 cases of anorectal melanomas, 16 of them showed diffuse and strong expression of CD117, and one melanoma had weak and focal reactivity. The tumors harboring c-Kit mutation (one tumor with L576P mutation, one tumor with G562V and E583V double mutation, and the third with W557R mutation) showed diffuse and strong expression of CD117. These studies indicate that CD117 protein expression might not correlate with the mutation status of c-Kit, which is consistent with the conclusion by Curtin et al. (2006). They observed increased expression of CD117 in $33 \%$ of melanomas without detectable c-Kit mutation or without increases in copy numbers. In contrast, in the study by Antonescu et al. (2007), three melanomas with c-Kit L576P mutation were strongly immunopositive for CD117. They reported that there was a higher expression of CD117 in anorectal melanomas harboring a potentially gain-of-function c-Kit mutation than that in the tumors without c-Kit mutations.

# Efficacy of Imatinib in Melanoma Treatment 

Imatinib mesylate (Gleevec, formerly STI571) is a selective inhibitor targeting RTKs as Abelson (ABL), platelet-derived growth factor receptor (PDGFR), and c-Kit. It was originally developed by Novartis Pharmaceuticals as a specific inhibitor of the active ABL tyrosine kinase, arising from an acquired $t(9 ; 22)$ genetic translocation (Philadelphia chromosome)in myelogenous leukemia (Natali et al., 1992). GISTs often express mutated forms of c-Kit, and patients with these tumors were also responsive to imatinib mesylate (van Oosterom et al., 2001). Imatinib mesylate was also effective in patients with hypereosinophilic syndrome who harbor a chromosomal deletion that generates an oncogenic fusion protein (FIP1L1-PDGFRA) (Gleich et al., 2002; Cools et al., 2004). Imatinib mesylate is thus considered as an effective agent for many malignancies characterized by aberrant RTK signaling via ABL, c-Kit, and PDGFR. Imatinib as an antitumor agent has been evaluated in melanoma. There are several reasons to support imatinib as a potential therapeutic drug in melanoma. First, it is known that RTK signaling is critical for sustaining melanocyte proliferation in vitro and for migration of melanocytic cells in vivo (Halaban, 2000). In addition, overexpression of RTKs like hepatocyte growth factor receptor is associated with increased susceptibility to melanoma in mice (Noonan et al., 2001). Finally, three known targets of imatinib mesylate (ABL, c-Kit, PDGFR) are generally expressed in melanoma.

Preclinical studies evaluated the sensitivity of melanoma cell lines to imatinib both in vitro and in vivo. Monsel et al. (2010) demonstrated KIT L576P mutation had tumorigenic potential. Pereira et al. (2005) found that all five human uveal melanoma cell lines showed a decrease in proliferation and invasion rates when directly exposed to imatinib mesylate. A report on established murine B16.F10 melanoma xenograft in C57BL/6 mice revealed that the growth of melanomas was potently suppressed by systemic imatinib treatment (Redondo et al., 2004). Tumor growth was inhibited by $77 \%$ at a dose of 0.75 mg 5 times weekly as compared with the control mice treated with saline alone. Jiang et al. (2008) reported that imatinib induced apoptosis and inhibited the activated KIT, MAPK, and PI3K/AKT pathways in M6 cells with c-Kit mutation, but not in the wild-type mucosal melanoma cells. Based on these preclinical studies, imatinib was subsequently trialed in the clinical treatment of metastatic melanoma.

Initially, imatinib showed remarkable efficacy in c-Kit-mutated melanoma patients in several case reports (Hodi et al., 2008; Lutzky et al., 2008); but phase II trials testing imatinib in genetically unselected patients with metastatic melanoma resulted in unsatisfactory outcomes (Eton et al., 2004; Ugurel et al., 2005; Wyman et al., 2006). In one study of 16 patients, only two ( $12 \%$ ) patients (one acral melanoma and one mucosal melanoma) with c-Kit aberration were responsive to imatinib, whereas $13(81 \%)$ patients without c-Kit aberration and one patient with a primary melanoma of the eye responded poorly to imatinib (Wyman et al., 2006). In the trial study by Eton et al. (2004), only patients expressing at least one of the imatinib target proteins (as examined by immunohistochemistry) were included. Of the 21 patients treated with imatinib, 16 had disease progression by 6 weeks and another 4 within 12 weeks. However, one patient with strong c-Kit expression in greater than $75 \%$ of tumor cells later showed to be harboring a deletion in codon 715; this patient had a near-complete response for more than a year. These studies attempt to evaluate imatinib in targeted therapy of melanoma. However, c-Kit mutation or amplification rather than c-Kit protein expression may be relevant for determining susceptibility to imatinib (Hodi et al., 2008; Lutzky et al., 2008; Wyman et al., 2006; Alexis et al., 2005; Carvajal et al., 2009), which might be the reason why phase II trials with imatinib in unselected patients with metastatic cutaneous melanoma were not as promising as expected (Ugurel et al., 2005; Kim et al., 2008).

To test the hypothesis that melanoma patients harboring genetic aberrations in c-Kit are likely to benefit from imatinib treatment, Guo et al. (2011) initiated aclinical trial investigating imatinib in selected metastatic melanoma patients harboring c-Kit mutations or amplifications. In this phase II trial, 43 patients with metastatic melanoma harboring c-Kit aberrations were enrolled. Each patient received a continuous dose of imatinib $400 \mathrm{mg} / \mathrm{d}$. The median progression-free survival (PFS) was 3.5 months, and the 6 -month PFS rate was $36.6 \%$. Rate of total disease control was $53.5 \%$ : 10 patients ( $23.3 \%$ ) achieved partial response (PR), 13 patients ( $30.2 \%$ ) achieved stable disease, and 20 patients ( $46.5 \%$ ) had progressive disease. Notably, additional analysis of the correlation of responses to c-Kit aberrations demonstrated that patients with mutations in exon 11 or exon 13 of c-Kit may be most sensitive to imatinib. The 1-year overall survival (OS) rate was $51.0 \%$. Fifteen patients who experienced progression of disease were allowed to escalate the dose to $800 \mathrm{mg} / \mathrm{d}$, and only one of the 15 patients who received dose escalation to $800 \mathrm{mg} / \mathrm{d}$ achieved stable disease.

Another phase II trial by Carvajal et al. (2011) demonstrated similar results. Twentyeight patients who had advanced unresectable melanoma with c-Kit mutation or amplification were treated with Imatinib mesylate ( 400 mg orally twice daily). Two patients achieved durable complete responses, two achieved durable PRs, two achieved transient PRs, and five achieved stable disease lasting 12 or more weeks. The overall durable response rate (RR) was $16 \%$, with a median time to progression of 12 weeks and a median OS of 46.3 weeks. All six responses occurred in tumors with L576P or K642E mutations, the most common mutations of c-Kit in melanoma (Antonescu et al., 2007).

The third phase II trial was held at Dana-Farber Cancer Institute (Hodi et al., 2013). Twenty-five patients were enrolled and 24 were evaluable. Eight patients (33\%) had tumors with c-Kit mutation, $11(46 \%)$ with c-Kit amplifications, and five ( $21 \%$ ) with both c-Kit aberrations. The median follow-up time was 10.6 months (range: 3.7-27.1 months). The best overall RR was $29 \%$ ( $21 \%$ excluding nonconfirmed responses), which was significantly greater than the hypothesized null of $5 \%$ and statistically significantly different by mutation status ( 7 of 13 or $54 \%$ KIT mutated vs $0 \%$ KIT amplified only). These data demonstrated that there were no statistical differences in rates of progression or survival by mutation status or by melanoma site. The overall disease control rate was $50 \%$ and varied significantly by c-Kit mutation status ( $77 \%$ mutated vs $18 \%$ amplified). Four patients harbored pretreatment NRAS mutations, and one patient acquired increased KIT amplification after treatment. These results suggest that imatinib is a promising agent in selected patients with melanomas with genetic alterations of c-Kit. However, these data may need to be confirmed by phase III trials or reevaluated by meta-analyses.

# Toxicity of Imatinib in Treating Melanoma Patients 

Most of the clinical trials testing imatinib take $800 \mathrm{mg} / \mathrm{d}$ as the study dose. Twenty-six patients were enrolled in a multicenter phase II trial ( 800 mg orally each day). The patients experienced 29 episodes of grade 3 toxicity and 2 episodes of grade 4 toxicity (thrombosis and hyponatremia) (Wyman et al., 2006). Another trial showed that 13 of 28 patients ( $46 \%$ ) required a dose reduction to $400 \mathrm{mg} / \mathrm{d}$ (two of them required a second dose reduction to $300 \mathrm{mg} / \mathrm{d}$ ) (Ugurel et al., 2005). Grade 3 or 4 toxicities were experienced by five patients ( $27.8 \%$ ); dose modifications of imatinib became necessary in seven patients ( $38.9 \%$ ). Three patients ( $16.7 \%$ ) discontinued treatment due to severe adverse events (intestinal perforation,arterial thromboembolism, suicide attempt). In one case, the severe adverse event (intestinal perforation) led to a fatal outcome. In contrast, Kim et al. (2008) proposed $800 \mathrm{mg} / \mathrm{d}$ imatinib was well tolerated: in the phase II trial of 21 patients, no patient required treatment discontinuation caused by toxicity. Fatigue and edema were the only grade 3 or 4 toxicities that occurred in more than $10 \%$ of the patients.

In the study by us, $400 \mathrm{mg} / \mathrm{d}$ was chosen as the basic study dose (Guo et al., 2011). Most patients had more than one adverse event. However, adverse events were generally mild to moderate in severity and were easily managed by dose reduction, dose interruption, or supportive medical treatment. The most common adverse events were edema ( $100 \%$ ), fatigue ( $51.2 \%$ ), anorexia ( $55.8 \%$ ), nausea ( $37.2 \%$ ), neutropenia ( $14 \%$ ), and hepatotoxicity ( $14 \%$ ). Fifteen patients were allowed to escalate to dose $800 \mathrm{mg} / \mathrm{d}$ because of progression of disease, but the toxicity was generally intolerable, which mainly comprised grades 3-4 edema, nausea, and vomiting. Based on the results of significant response, $400 \mathrm{mg} / \mathrm{d}$ may thus be recommended as the most suitable dose for Chinese patients with metastatic melanoma.

Generally, imatinib is well tolerated. From clinical trials, a majority of patients may show at least one event of toxicity, but most toxicity events are mild. Care should be taken when using imatinib since it is a competitive inhibitor of the cytochrome P450 system and may alter concentrations of other drugs.

# Resistance to Imatinib Treatment 

Most results of imatinib resistance arise from experiences in GISTs and chronic myeloid leukemias (CMLs). A meta-analysis summarized 10 eligible studies that included 1083 GIST cases (Lee et al., 2013). Imatinib resistance was found in $35.5 \%$ of PDGFRA-mutant tumors, $27.4 \%$ of c-Kit-mutated tumors, and $33.7 \%$ of wild-type tumors (c-Kit and PDGFRA). Primary imatinib resistance was found in $50 \%$ of PDGFRA-mutant tumors, $33.4 \%$ of wildtype tumors, and $8.9 \%$ of c-Kit-mutated tumors. C-Kit exon 9-mutant tumors showed primary resistance more frequently than exon 11-mutant and other tumors. Regarding secondary resistance associated with second-site mutations of c-Kit, the exon 17 mutation ( $54.5 \%$ ) was most frequent, followed by exon $13(38.3 \%)$ and $14(13.4 \%)$ mutations.

When GIST patients continue to progress within 3-6 months of initiating imatinib therapy, they are regarded as having primary imatinib resistance. In contrast, some GIST patients initially respond to imatinib treatment and develop imatinib resistance within 12-36 months. These patients are classified as having secondary resistance (Wang et al., 2011). In GIST, primary resistance is associated with mutations in c-Kit exon 9 or PDGFRA mutations, many of which can be overcome by increasing drug dosage or switching to an alternative tyrosine kinase inhibitor.

In phase II studies by Guo et al. (2011) and Carvajal et al. (2011), there were seven patients with c-Kit amplification; only one of them had a PR and three had stable diseases (SD). Therefore c-Kit amplification alone may not be a robust predictor of response to imatinib. This observation is not unique in melanoma alone. For example, it is known that nonsmall cell lung cancer overexpresses epidermal growth factor receptor (using immunohistochemistry alone), but the actual putative mutations in exons 19 or 21 are not predictive of response to tyrosine kinase inhibitors, such as erlotinib or gefitinib (Tran and Tawbi, 2012). Carvajal et al. (2011) showed that nonresponders usually harbored specific c-Kitmutations known to confer imatinib resistance in GIST, such as D820Y, N822K, and A829P. In GIST, the development of secondary mutations, especially those in the tyrosine kinase domains encoded by exons 13 and 17 of c-Kit, can lead to secondary resistance ( Heinrich et al., 2006; Lasota et al., 2008), which has not been confirmed in melanoma.

# Second Generation of Tyrosine Kinase Inhibitors 

To meet the demand for treatment of imatinib-resistant melanomas, several secondgeneration inhibitors have been developed. Nilotinib (Tasigna), an imatinib derivative with a 30 -fold higher potency, is type II inhibitor (Weisberg et al., 2005; Blay and von Mehren, 2011). Dasatinib is a type I Src and ABL inhibitor that is 300 -fold more potent than imatinib (Kantarjian et al., 2010; Shah et al., 2004). Both Nilotinib and Dasatinib exploit the increased potency which can cause effective inhibition of the majority of imatinib-resistant tumors.

The development of second-generation tyrosine kinase inhibitors, such as nilotinib and dasatinib, has expanded the treatment of metastatic melanoma with c-Kit mutation. The potential utility of dasatinib in metastatic melanoma with c-Kit mutation was previously investigated by Woodman et al. (2009). Two patients with L576P c-Kit mutation were responsive to dasatinib, and one of them was previously treated with imatinib. A recent phase II study by Kluger et al. (2011) using dasatinib in 39 unselected patients with metastatic melanoma failed to meet its end point of $30 \%$ RR or 6-month PFS. However, one patient achieved PR harboring a c-Kit mutation in exon 13. Another phase II study assessing dasatinib is currently under way, performed by the Eastern Cooperative Oncology Group (ECOG 2607, NCT00700882). This study was recently amended to recruit patients with metastatic melanomas with the primary sites harboring c-Kit mutation.

Nilotinib was originally developed for the treatment of CML patients who had resistance or intolerance to imatinib. It is structurally derived from imatinib. Similar to imatinib, nilotinib competitively inhibits the binding of ATP in the kinase domain of ABL, resulting in the inhibition of phosphorylation of the tyrosine kinase and prevention of cellular signal transduction. Its activity and efficacy in CML patients resistant to imatinib may result from an improved topologic fit (Jarkowski and Sweeney, 2008; Kantarjian et al., 2006, 2007). In addition to binding and inhibiting the kinase domain of ABL with greater infinity, nilotinib also inhibits c-Kit and PDGFRA with greater potency as compared with imatinib (Manley et al., 2007). Nilotinib was used in October 2007 for CML patients resistant to imatinib or in the accelerated phase (Kantarjian et al., 2007). It later got accelerated approval from the Food and Drug Administration (FDA) on June 17, 2010, for the treatment of newly diagnosed chronic phase CML after its superiority to imatinib was established in a randomized phase III study (Saglio et al., 2010).

For c-Kit-mutated patients, the greater potency of nilotinib may cause greater clinical benefits. Cho et al. (2012) published a phase II, single center, open-label, prospective clinical trial, assessing the activity of nilotinib in patients with metastatic melanoma harboring c-Kit mutation. They enrolled patients with either c-Kit mutations and/or gene amplifications. A total of nine patients were evaluated: two patients had PR lasting 8.4 and 10.4 months, and four patients had SD. Consistent with the previous studies, the two responders in this study had missense mutations L576P and V559A in exon 11, and the four patients with SD had c-Kit gene amplification. Although this is a small, single institution study, it providesevidence that nilotinib has activity against a selected group of melanoma patients, which is similar to imatinib trials. Another study published by Sawaki et al. (2011) showed that nilotinib might have even greater activities than imatinib in inhibiting c-Kit mutation-driven tumors. This phase II study evaluated nilotinib as a third-line therapy in patients with GISTs who are resistant or intolerant to both imatinib and sunitinib treatment. It enrolled 35 patients; one patient achieved PR and 23 patients got SD lasting greater than 6 weeks. Although there was only one patient achieving PR, other patients were able to show that this particular patient harbored the D820G mutation in exon 17, a mutation that is known to be resistant to imatinib.

With such inspiring results, multiple clinical trials worldwide are attempting to better define the role of nilotinib in metastatic melanomas with c-Kit alterations (NCT01168050, NCT00788775, NCT01395121, NCT01028222, NCT01099514). Among these trials, the TEAM trial (NCT01028222) involves our center as one of the 29 centers worldwide. By the data cutoff, 877 patients were prescreened for c-Kit mutation, 106 patients were found to harbor the mutations, 78 patients were screened, and 55 patients were enrolled in the study ( 42 nilotinib and 13 DTIC). The primary end point objective response rate (ORR) in the nilotinib group was $26.2 \%$ with $95 \%$ CI ( $13.9 \%, 42.0 \%$ ), which is similar to the ORR of the patients receiving DTIC. The median PFS time ( $95 \% \mathrm{CI}$ ) was 4.1 months (2.1, 8.0), and the estimated PFS rate ( $95 \% \mathrm{CI}$ ) at 6 months was $34.9 \%(20.0 \%, 50.2 \%)$. Median OS was not reached for nilotinib, the estimated OS rate ( $95 \% \mathrm{CI}$ ) at 12 months was $61.5 \%(40.8 \%, 76.8 \%)$. The overall safety profile of nilotinib described in this study remains consistent with the known safety profile of nilotinib in CML and GIST patients. This preliminary analysis might indicate that nilotinib is not yet sufficiently effective to substitute for imatinib in the group of KIT-mutated melanoma patients.

# Perspective 

Before 2011, chemotherapy with DTIC was the standard treatment regimen in advanced melanoma, with RRs ranging between $9.9 \%$ and $18 \%$ (Crosby et al., 2000). In 2011, ipilimumab and vemurafenib were approved by the FDA and European Medicine Agency. Recently, additional drugs have been approved: programmed cell death-1 receptor antibodies (nivolumab and pembrolizumab), new BRAF inhibitor (dabrafenib), and an MEK inhibitor (trametinib). Thus, we have come into a new era for the treatment of melanoma. At our center, patients receive gene mutation analysis before treatment so that we can distinguish melanoma patients into several groups. Patients with BRAF mutation could use vemurafenib, and patients with c-Kit aberration could use imatinib. Nilotinib could be used after failure of imatinib. For patients without these gene mutations, immunotherapy using ipilimumab, nivolumab, and pembrolizumab could be an alternative good choice.

Together, more and more evidence suggests the evolution of a new paradigm in melanoma therapy in which molecular analysis of the tumor will be utilized to assign the most appropriate therapeutic modality for each individual patient. However, a major consideration for physicians is now to determine how to integrate these agents into clinical practice. Therapeutic decisions are complicated for the need to consider patient and disease characteristics, individual treatment goals, and the different efficacy and safety profiles of agents. Treatment paradigm for advanced/metastatic melanoma has been changed these years, long term survival, is now a realistic goal.# References 

Alexis, J.B., Martinez, A.E., and Lutzky, J., 2005. An immunohistochemical evaluation of c-KIT (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients. Melanoma Res. 15, 283-285.
Antonescu, C.R., Busam, K.J., Francone, T.D., et al., 2007. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int. J. Cancer 121, 257-264.
Ashida, A., Takata, M., Murata, H., Kido, K., and Saida, T., 2009. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int. J. Cancer 124, 862-868.
Beadling, C., Jacobson-Dunlop, E., Hodi, F.S., et al., 2008. KIT gene mutation and copy number in melanoma subtypes. Clin. Cancer Res. 14, 6821-6828.
Blay, J.Y., and von Mehren, M., 2011. Nilotinib: a novel, selective tyrosine kinase inhibitor. Semin. Oncol. 38 (Suppl. 1), S3-S9.

Carvajal, R.D., Chapman, B., Wolchok, J.D., et al., 2009. A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. J. Clin. Oncol. 27 (abstract 9001).
Carvajal, R.D., Antonescu, C.R., Wolchok, J.D., et al., 2011. KIT as a therapeutic target in metastatic melanoma. JAMA 305, 2327-2334.
Chi, Z., Li, S., Sheng, X., et al., 2011. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer 11, 85.
Cho, J.H., Kim, K.M., Kwon, M., et al., 2012. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest. New Drugs Invest. 30, 2008-2014.
Chute, D.J., Cousar, J.B., and Mills, S.E., 2006. Anorectal malignant melanoma: morphologic and immunohistochemical features. Am. J. Clin. Pathol. 126, 93-100.
Cools, J., Stover, E.H., Wlodarska, I., et al., 2004. The FIP1L1-PDGFR-alpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr. Opin. Hematol. 11, 51-57.
Crosby, T., Fish, R., Coles, B., and Mason, M.D., 2000. Systemic treatments for metastatic cutaneous melanoma. Cochrane. Database. Syst. Rev. 7.
Curtin, J.A., Fridlyand, J., Kageshita, T., et al., 2005. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135-2147.
Curtin, J.A., Busam, K., Pinkel, D., and Bastian, B.C., 2006. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24, 4340-4346.
Eton, O., Billings, L., Kim, K., et al., 2004. Phase II trial of imatinib mesylate (STI-571) in metastatic melanoma (MM). J. Clin. Oncol. 22 (14S) (abstract 7528).
Gleich, G.J., Leiferman, K.M., Pardanani, A., et al., 2002. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359, 1577-1578.
Giehl, K.A., Nagele, U., Volkenandt, M., and Berking, C., 2007. Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFR-1, c-KIT) in nevi and melanoma. J. Cutan. Pathol. 34, 7-14.
Guo, J., Si, L., Kong, Y., et al., 2011. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J. Clin. Oncol. 29, 2904-2909.
Halaban, R., 2000. The regulation of normal melanocyte proliferation. Pigment. Cell Res. 13, 4-14.
Heinrich, M.C., Corless, C.L., Blanke, C.D., et al., 2006. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J. Clin. Oncol. 24, 4764-4774.
Hodi, F.S., Friedlander, P., Corless, C.L., et al., 2008. Major response to imatinib mesylate in KIT-mutated melanoma. J. Clin. Oncol. 26, 2046-2051.
Hodi, F.S., Corless, C.L., Giobbie-Hurder, A., et al., 2013. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J. Clin. Oncol. 31, 3182-3190.
Jarkowski, A., and Sweeney, R.P., 2008. Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Pharmacotherapy 28, 1374-1382.
Jiang, X., Zhou, J., Yuen, N.K., et al., 2008. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin. Cancer Res. 14, 7726-7732.
Kantarjian, H., Giles, F., Wunderle, L., et al., 2006. Nilotinib in imatinib-resistant CML and Philadelphia chromo-some-positive ALL. N. Engl. J. Med. 354, 2542-2551.
Kantarjian, H., Shah, N.P., Hochhaus, A., et al., 2010. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 362, 2260-2270.Kantarjian, H.M., Giles, F., Gattermann, N., et al., 2007. Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110, 3540-3546.
Kim, K.B., Eton, O., Davis, D.W., et al., 2008. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br. J. Cancer 99, 734-740.
Kluger, H.M., Dudek, A.Z., McCann, C., et al., 2011. A phase 2 trial of dasatinib in advanced melanoma. Cancer 117, 2202-2208.
Kong, Y., Si, L., Zhu, Y., et al., 2011. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin. Cancer Res. 17, 1684-1691.
Lasota, J., Corless, C.L., Heinrich, M.C., et al., 2008. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod. Pathol. 21, $476-484$.
Lee, J.H., Kim, Y., Choi, J.W., et al., 2013. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis. J. Gastrointestin. Liver Dis. 22, 413-418.
Lutzky, J., Bauer, J., and Bastian, B.C., 2008. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment. Cell Melan. Res. 21, 492-493.
Manley, P.W., Bruggen, J., and Fabbro, D., 2007. Extended kinase profiling of the Bcr-Abl inhibitor nilotinib. Proc. Am. Assoc. Cancer Res. 48 (abstract 3249).
Monsel, G., Ortonne, N., Bagot, M., et al., 2010. c-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes. Oncogene 29, 227-236.
Natali, P.G., Nicotra, M.R., Winkler, A.B., et al., 1992. Progression of human cutaneous melanoma is associated with loss of expression of c-KIT proto-oncogene receptor. Int. J. Cancer 52, 197-201.
Ni, S., Huang, D., Chen, X., et al., 2011. c-KIT gene mutation and CD117 expression in human anorectal melanomas. Mod. Pathol. 24, 1031-1035.
Noonan, F.P., Recio, J.A., Takayama, H., et al., 2001. Neonatal sunburn and melanoma in mice. Nature 413, 271-272.
Pereira, P.R., Odashiro, A.N., Marshall, J.C., et al., 2005. The role of c-kit and imatinib mesylate in uveal melanoma. J. Carcinog. 19, 4-19.

Qiu, F.H., Ray, P., Brown, K., et al., 1988. Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family-oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J. $7,1003-1011$.
Redondo, P., Lloret, P., Andreu, E., and Inoges, S., 2004. Imatinib mesylate in cutaneous melanoma. J. Invest. Dermatol. 123, 1208-1209.
Saglio, G., Kim, D.W., Issaragrisil, S., et al., 2010. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 362, 2251-2259.
Satzger, I., Schaefer, T., Kuettler, U., et al., 2008. Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br. J. Cancer 99, 2065-2069.
Sawaki, A., Nishida, T., Doi, T., et al., 2011. Phase 2 study of Nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer 117, 4633-4641.
Shah, N.P., Tran, C., Lee, F.Y., et al., 2004. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science $305,399-401$.
Shen, S.S., Zhang, P.S., Eton, O., and Prieto, V.G., 2003. Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J. Cutan. Pathol. 30, 539-547.
Shoo, B.A., and Kashani-Sabet, M., 2009. Melanoma arising in African-, Asian-, Latino- and Native-American populations. Semin. Cutan. Med. Surg. 28, 96-102.
Tran, A., and Tawbi, H.A., 2012. A potential role for nilotinib in KIT-mutated melanoma. Expert. Opin. Investig. Drugs 21, 861-869.
Ugurel, S., Hildenbrand, R., Zimpfer, A., et al., 2005. Lack of clinical efficacy of imatinib in metastatic melanoma. Br. J. Cancer 92, 1398-1405.
van Oosterom, A.T., Judson, I., Verweij, J., et al., 2001. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358, 1421-1423.
Wang, W.L., Conley, A., Reynoso, D., et al., 2011. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemother. Pharmacol. 67 (Suppl. 1), S15-S24.

# II. TREATMENT AND PROGNOSISWeisberg, E., Manley, P.W., Breitenstein, W., et al., 2005. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7, 129-141.
Woodman, S.E., Trent, J.C., Stemke-Hale, K., et al., 2009. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol. Cancer Ther. 8, 2079-2085.
Wyman, K., Atkins, M.B., Prieto, V., et al., 2006. Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 106, 2005-2011.
Yang, A.S., and Chapman, P.B., 2009. The history and future of chemotherapy for melanoma. Hematol. Oncol. Clin. North Am. 23, 583-597.
Yarden, Y., Kuang, W.J., Yang-Feng, T., et al., 1987. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 6, 3341-3351.# C H A P T E R 

## 12

## Optimal Selection of Targeted Therapies for Melanoma Patients: Role of the Mitogen-Activated Protein Kinase Pathway

Peter Lau and Damien Kee

## O U T L I N E

Introduction
The Mitogen-Activated Protein Kinase Pathway and Molecular Classification of Melanoma
Treatment of BRAF Mutant Melanoma with BRAF Inhibitors
Treatment of BRAF Mutant Melanoma with MEK Inhibitor Monotherapy and in Combination with BRAF Inhibitors

170 Treatment of NRAS Mutant Melanoma
Treatment of KIT Mutant Melanoma
Sequencing Targeted Therapy with Immunotherapy

Conclusions
References

178
178

180

References# INTRODUCTION 

Metastatic melanoma is a chemotherapy refractory disease and historical treatment options have been limited. Dacarbazine was once considered the standard systemic treatment despite a response rate of only $5-15 \%$ and having never demonstrated an improvement in survival (Jilaveanu et al., 2009). Alternative agents such as temozolomide, fotemustine, platinum-based regimens, and combinations with interferon alpha- 2 b or interleukin 2 had consistently failed to make meaningful improvements (Jilaveanu et al., 2009). As such the historical median overall survival for advanced melanoma is in the order of 6-9 months (Balch et al., 2009).

However, since the turn of the decade, advances in our understanding of melanoma driver mutations and immune checkpoint regulation have resulted in two distinct treatment approaches that both offer meaningful improvements in survival. Ipilimumab, an antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), was the first immune checkpoint inhibitor that improved the survival in melanoma. Although response rates to ipilimumab were modest ( $11 \%$ ), it led to improvements in survival with approximately $20 \%$ of patients alive at 3 years (Hodi et al., 2010). Pooled analysis of clinical trial and communitytreated ipilimumab patients has confirmed a plateau in mortality persisting beyond 10 years (Schadendorf et al., 2015). Recently phase III trials of another class of checkpoint inhibitors directed against programmed death-1 (PD-1) have been completed, demonstrating improved response rates and progression-free survival compared to ipilimumab (Larkin et al., 2015; Robert et al., 2015b). Response rates to PD-1 inhibitors, such as pembrolizumab and nivolumab, vary from $33 \%$ to $44 \%$ in phase III trials with significantly less immune-related toxicity in comparison to ipilimumab. Although the overall survival of combination ipilimumab and nivolumab data is pending, PD-1 monotherapy is currently regarded as a standard of care.

Despite these impressive developments in immune-checkpoint inhibitors, there is still a need for alternative agents where immunotherapy is contraindicated or those patients in visceral crisis requiring a rapid response. This chapter will focus on the development of specific targeted agents in response to discoveries characterizing oncogenic drivers in cutaneous melanoma. In particular, mutations resulting in the constitutive activation of the mitogen-activated protein kinase (MAPK) pathway, a key regulator of normal cellular growth and proliferation, appear central to the pathogenesis of the majority of melanomas. Vemurafenib followed closely by dabrafenib are specific BRAF inhibitors that were the first successful agents to target this pathway in cutaneous melanoma. These agents have been augmented with the development of MEK inhibitors such as trametinib and cobimetinib that synergistically inhibit the MAPK pathway. Subsequent studies of BRAF and MEK inhibitor combinations have now established these molecular targeted therapies as an alternative standard of care for BRAF mutant melanoma.

## THE MITOGEN-ACTIVATED PROTEIN KINASE PATHWAY AND MOLECULAR CLASSIFICATION OF MELANOMA

The mitogen-activated protein kinase pathway (MAPK) is a key oncogenic system of melanoma progression. The classical MAPK pathway is a stepwise relay system of kinases: RAS (HRAS, KRAS, NRAS), RAF (ARAF, BRAF, CRAF), MEK (MEK1 and 2), and ERK (ERK1 and 2)![img-71.jpeg](img-71.jpeg)

FIGURE 12.1 Schematic of the mitogen-activated protein kinase pathway and drug inhibitors in melanoma.
(Fig. 12.1). ERK, the terminal step of the MAPK pathway, is hyperactivated in the majority of melanomas and is crucial in signaling of numerous cytoplasmic and nuclear targets regulating processes such as cell proliferation, differentiation, survival, migration, and angiogenesis (Yoon and Seger, 2006).

Initially extracellular ligands bind to specific membrane-bound receptor tyrosine kinases (RTK) to initiate MAPK signaling. Activation of the guanosine triphosphatase (GTPase), RAS results in phosphorylation and activation of RAF. Of the RAF kinases, BRAF is the most frequently mutated gene of the MAPK pathway with approximately $40-50 \%$ of melanoma patients harboring an activating mutation (Platz et al., 2008; Long et al., 2011; Greaves et al., 2013). The most common BRAF mutation is a single valine to glutamine substitution at codon 600 (V600E), which accounts for greater than $75 \%$ of BRAF mutations (Greaves et al., 2013). The resultant protein possesses 10 -fold greater kinase activity than wild-type BRAF and constitutively activates the MAPK pathway (Davies et al., 2002). Other BRAF mutations have been described such as V600K (valine to lysine substitution) accounting for approximately $5-20 \%$ of patients with V600R (valine to arginine) and V600D (valine to aspartic acid) mutations both accounting for less than $5 \%$ of cases (Long et al., 2011; Greaves et al., 2013). These other V600 mutations also exhibit constitutive upregulation of MAPK pathway and confer sensitivity to selective BRAF inhibitors.Exemplifying the importance of MAPK dysregulation in melanoma oncogenesis is the recently proposed molecular classification of cutaneous melanoma into four subtypes: mutant BRAF, mutant RAS, mutant NF-1, and triple wild-type (Network, 2015). While mutant BRAF includes the aforementioned V600 mutations, other loci are also included in this subtype, including V601E, which occur in less than $1 \%$ of patients. Activating mutations of the RAS family occur in $20-30 \%$ of melanoma (Hodis et al., 2012; Xia et al., 2014; Network, 2015), of which NRAS mutations involving Q61, G12, and G13 account for the vast majority ( $>95 \%$ ) (Network, 2015). Neurofibromatosis-1 (NF-1) is a major regulator of NRAS and loss of function mutations account for approximately $10-14 \%$ of melanoma (Xia et al., 2014; Network, 2015). The presence of NRAS or NF-1 mutations in patients is invariably mutually exclusive of BRAF V600 mutations. Wild-type patients are primarily classified by the absence of activating BRAF, NRAS, or NF-1 mutations but may harbor KIT mutations (Network, 2015). In 10-20\% of mucosal and acral melanoma cases, mutations or amplifications of KIT mutations are found (Curtin et al., 2006; Beadling et al., 2008). These KIT mutations are potentially actionable with preexisting and novel inhibitors. Hence identification of these mutations is crucial in individualizing patient therapy in melanoma.

# TREATMENT OF BRAF MUTANT MELANOMA WITH BRAF INHIBITORS 

Vemurafenib was the first selective BRAF inhibitor to show clinical activity in melanoma. Using crystallography, vemurafenib was specifically designed to inhibit the BRAF V600E protein kinase domain and displayed selective inhibition of RAF kinases at nano-molar concentrations. The phase I study of vemurafenib established a maximum tolerated dose of 960 mg twice daily with a response rate of $81 \%$ and progression-free survival of over 7 months-far exceeding benchmarks set in previous chemotherapy studies (Flaherty et al., 2010; Table 12.1). As proof that BRAF V600 mutations lead to constitutive MAPK upregulation, paired tumor biopsies showed strong correlation between tumor response and inhibition of ERK phosphorylation. Additionally, profound inhibition of tumor metabolic activity was shown using $\left[{ }^{18} \mathrm{~F}\right]$ fluorodeoxyglucose positron emission tomography (FDG-PET) on day 15 in all patients treated above the 240 mg twice-daily drug threshold (McArthur et al., 2012).

These developments quickly flowed onto the phase II study (BRIM-2) which confirmed the activity of vemurafenib with an objective response rate of $53 \%$ and progression-free survival of 6.8 months in BRAF V600 mutant melanoma (Sosman et al., 2012). Notably clinical responses were rapid and usually evident on the first scan at 6 weeks. Improved survival in patients receiving vemurafenib was demonstrated in the phase III (BRIM-3) trial (Chapman et al., 2011). A total of 675 patients were randomized to either dacarbazine or vemurafenib with the first interim analysis demonstrating clear improvements in survival in favor of vemurafenib. Risk of death was reduced by $63 \%$ and progression by $74 \%$. On the basis of these results, the trial was terminated early and dacabazine-treated patients were permitted to cross over to vemurafenib. Final analysis at a median follow-up of 10.5 months showed a median overall survival of 13.6 months versus 9.7 months in favor of vemurafenib (HR $=0.70 ; P=0.0008$ ) (McArthur et al., 2014). Objective response rates were far superior with vemurafenib at $57 \%$ versus $9 \%$ in the dacarbazine arm. These results ultimately lead toTABLE 12.1 Main Clinical Trials of Selective RAF Inhibitors in Metastatic Cutaneous Melanoma

| Study/Treatment group | BRAF genotype | Patients <br> (n) | ORR <br> (\%) | Median PFS (months) | Median OS (months) |
| :--: | :--: | :--: | :--: | :--: | :--: |
| PHASE I STUDY OF VEMURAFENIB—DOSE ESCALATION AND COHORT EXTENSION IN PREVIOUSLY TREATED PATIENTS (FLAHERTY ET AL., 2010) |  |  |  |  |  |
| Vemurafenib $>240 \mathrm{mg}$ bd | V600E | 16 | $69 \%$ | NR | NR |
| Vemurafenib 960 mg bd | V600E | 32 | $81 \%$ | $>7.0$ | NR |
| PHASE II STUDY OF VEMURAFENIB IN PREVIOUSLY TREATED PATIENTS (SOSMAN ET AL., 2012) |  |  |  |  |  |
| Vemurafenib 960 mg bd | V600E | 132 | $53 \%$ | 6.8 | 15.9 |
| PHASE III STUDY OF VEMURAFENIB VERSUS DACARBAZINE IN UNTREATED PATIENTS (CHAPMAN ET AL., 2011; MCARTHUR ET AL., 2014) |  |  |  |  |  |
| Vemurafenib 960 mg bd | V600E | 295 | $59 \%$ | 6.9 | 13.3 |
|  | V600K | 33 | $45 \%$ | 5.9 | 14.5 |
| DTIC $1000 \mathrm{mg} / \mathrm{m}^{2} \mathrm{q} 21$ | V600E/K | 338 | $8.6 \%$ | 1.6 | 9.7 |
| PHASE I STUDY OF DABRAFENIB—DOSE ESCALATION AND COHORT EXTENSION IN PREVIOUSLY TREATED PATIENTS (FALCHOOK ET AL., 2012a) |  |  |  |  |  |
| Dabrafenib 35-300 mg bd | V600E | 27 | $78 \%$ | 5.5 | NR |
|  | V600K | 18 | $39 \%$ | 5.6 | NR |
| PHASE II STUDY OF DABRAFENIB IN PREVIOUSLY TREATED PATIENTS (ASCIERTO ET AL., 2013a) |  |  |  |  |  |
| Dabrafenib 150 mg bd | V600E | 76 | $60 \%$ | 6.3 | 13.1 |
|  | V600K | 16 | $13 \%$ | 4.5 | 12.9 |

PHASE III STUDY OF DABRAFENIB VERSUS DACARBAZINE IN UNTREATED PATIENTS (HAUSCHILD ET AL., 2012)

| Dabrafenib 150 mg bd | V600E | 187 | $53 \%$ | 5.1 | NA |
| :-- | :-- | --: | :-- | :-- | :-- |
| DTIC $1000 \mathrm{mg} / \mathrm{m}^{2} \mathrm{q} 21$ | V600E | 63 | $6 \%$ | 2.7 | NA |

Abbreviations: DTIC, dacarbazine; $N A$, not yet available; $N R$, not reported; $O R R$, objective response rate; $O S$, overall survival; PFS, progression-free survival.
approval of vemurafenib in US Food and Drug Administration (FDA) in August 2011 with European Medicine Agency (EMA) approval following in February 2012.

Studies of dabrafenib, another selective BRAF inhibitor, closely followed the development of vemurafenib. Initial phase I studies of dabrafenib demonstrated that a high therapeutic index and dose limiting toxicities were not identified (Falchook et al., 2012b). The phase II dose of 150 mg twice daily was recommended as beyond this there was little improvement in clinical responses and near maximal effects were already observed on pharmacodynamic studies that included tumor biopsies and FDG-PET imaging. The phase III trial (BREAK-3) compared dabrafenib to dacarbazine in patients with untreated BRAF V600E or V600K mutant melanoma with progression-free survival as its primary endpoint (Hauschild et al., 2012). Similarto vemurafenib, dabrafenib exhibited objective response rates of $50 \%$ compared to $6 \%$ in dacarbazine. Progression-free survival was in favor of dabrafenib at 5.1 months compared to 2.7 months for dacarbazine ( $\mathrm{HR}=0.30 ; P<0.0001$ ). Hence, within the span of less than 5 years, two selective BRAF inhibitors had completed successful phase III trials.

Both dabrafenib and vemurafenib are generally well-tolerated medications with less than $5 \%$ of patients discontinued the drug due to toxicity in phase III trials. Common side effects of both drugs are arthralgias, rash, and hyperkeratosis. Of concern is the development of squamo-proliferative skin lesions such as keratoacanthomas or squamous cell carcinoma which occur in 20-26\% (Flaherty et al., 2010; Chapman et al., 2011; Sosman et al., 2012; Larkin et al., 2014) and 6-11\% (Flaherty et al., 2012a; Hauschild et al., 2012; Ascierto et al., 2013a; Long et al., 2015) of patients treated with vemurafenib or dabrafenib, respectively. These squamous cell carcinomas are caused by paradoxical activation of the MAPK pathway via other RAF dimers such as CRAF and wild-type BRAF under the influence of RAF inhibition (Oberholzer et al., 2012). These skin lesions are managed easily with local excision and generally do not lead to long-term sequelae. However, paradoxical reactivation of MAPK has been reported to induce sporadic cases of RAS secondary malignancies including colon, pancreas, and leukemia (Callahan et al., 2012; Andrews et al., 2013; Carlino et al., 2015). The frequency of these events is believed to be low, but may be of greater consequence with long-term or adjuvant use of BRAF inhibitor therapy.

A toxicity specific to vemurafenib is photosensitivity thereby requiring patients to employ sun-protection measures during treatment. In contrast, photosensitivity has not been reported with dabrafenib, but drug-related fever is a common toxicity, often requiring dose interruption. Dabrafenib-related fever was observed at all doses levels during the phase I trial; therefore, dose reductions are not felt to be beneficial in reducing frequency of febrile events (Menzies et al., 2015). Fever often occurs in the first month of treatment and does not appear to influence efficacy. Hence BRAF inhibitor toxicities are manageable through patient education and present a tolerable treatment option for elderly patients.

Given the high response rates and tolerability of selective BRAF inhibitors, their activity in patients with brain metastases was of great interest. Up to $20 \%$ of melanoma patients have CNS metastases on diagnosis and their presence usually heralds a poor prognosis with median overall survival of $4-5$ months (Davies et al., 2011). Intracranial activity of dabrafenib was observed within the initial phase I trial, which quickly prompted a phase II study (BREAK-MB) that enrolled patients with untreated or secondarily progressive melanoma brain metastases (Long et al., 2012). Given standard doses of dabrafenib, patients with untreated BRAF V600E mutant melanoma brain metastases ( $n=139$ ) displayed an intracranial response rate of $39.2 \%$; not dissimilar to response rates in extracranial disease. Progression-free survival was approximately 16 weeks and median overall survival of 31 weeks (Long et al., 2012). Similarly vemurafenib also displayed an intracranial response rate of $42 \%$ ( 10 out of 24 patients) with median progression-free and overall survival of 3.9 and 5.3 months respectively in a similar phase II study (Dummer et al., 2014). Both dabrafenib and vemurafenib were not expected to appreciably cross the blood-brain-barrier; however, disruption of the normal blood-brain barrier by melanoma macrometastases likely facilitates intracranial penetration and activity (Gerstner and Fine, 2007). A pooled analysis of dabrafenib phase I and II trial patients indicates high concordance in extra- and intracranial response rates, which reinforces its place in multidisciplinary management of CNS disease(Azer et al., 2014). Hence, both dabrafenib and vemurafenib display meaningful intracranial activity providing a further treatment option to complement radiotherapy and surgery.

Although the majority of patients benefit from BRAF inhibitor monotherapy, approximately $10 \%$ do not respond and approximately half will develop secondary resistance within 5-8 months (Chapman et al., 2011; Hauschild et al., 2012; Long et al., 2015). In these resistant patients, reactivation of the MAPK pathway is observed in up to $80 \%$ of cases (Rizos et al., 2014; Shi et al., 2014; Van Allen et al., 2014). The precise mechanism of MAPK upregulation is diverse but include splice variants of BRAF that form active BRAF dimers, amplification of BRAF V600, and acquired NRAS mutations. Furthermore overexpression of Cancer Osaka Thyroid (COT) kinase that activates MEK or MEK mutations have also been observed. Sole upregulation of oncogenic pathways other than MAPK such as PI3K can provide another mechanism of resistance, either via loss of PTEN function or AKT mutations, and occur in less than $5 \%$ of patients (Shi et al., 2014). Finally, other mechanisms of resistance include activation of receptor tyrosine kinase receptors including PDGFR, IGF1R, FGFR3, and MET. Hence the mechanisms of BRAF resistance are highly diverse. Given the high proportion of patients with MAPK-mediated upregulation, inhibition of downstream kinases of BRAF, such as MEK, present an attractive molecular target.

# TREATMENT OF BRAF MUTANT MELANOMA WITH MEK INHIBITOR MONOTHERAPY AND IN COMBINATION WITH BRAF INHIBITORS 

Given MEK is the immediate downstream kinase from BRAF, it is a natural molecular target in patients with acquired BRAF resistance or as an alternative agent for selective BRAF inhibitors. Preclinical experiments of BRAF mutant cell lines and xenografts showed strong responses to early MEK inhibitors (Solit et al., 2006; Table 12.2).

Trametinib, an allosteric MEK1/2 inhibitor, was the first agent in its class to establish meaningful clinical activity (Infante et al., 2012). The phase I study of trametinib displayed encouraging response rates of $40 \%$ and a median PFS of 5.3 months in patients with BRAF V600 mutations who were BRAF inhibitor naive (Falchook et al., 2012a). This quickly led to the phase III study (METRIC), where trametinib improved both progression-free ( 4.8 months vs 1.5 months; $\mathrm{HR}=0.45 ; P<0.001$ ) and overall survival when compared to treatment with systemic chemotherapy in BRAF V600E- or V600K-mutated patients (Flaherty et al., 2012b). However, the response rate of $22 \%$ to trametinib was substantially lower compared to vemurafenib or dabrafenib. Trametinib was generally well tolerated with the main dose limiting toxicities being diarrhea, acneiform rash, and lethargy. Uncommon but potentially serious toxicities including ocular disturbances ( $9 \%$ ) such as reversible central serous retinopathy and reductions in cardiac ejection fraction (7\%) were also observed. Nevertheless the trial established trametinib as another efficacious agent in BRAF V600 mutant melanoma and led to FDA approval.

Naturally the activity of trametinib following progression of a BRAF inhibitor was explored in a phase II trial (Kim et al., 2013). Unfortunately, in this cohort of 40 patients, there were no observed responses and a minimal benefit in progression-free survival of 1.6 months. This set the stage for concurrent BRAF and MEK inhibitor studies. The first ofTABLE 12.2 Main Clinical Trials Involving MEK Inhibitors in Metastatic Cutaneous Melanoma

| Study/Treatment group | Genotype | Patients <br> ( $n$ ) | ORR <br> (\%) | Median PFS <br> (months) | Median OS <br> (months) |
| :-- | :-- | :--: | :--: | :--: | :--: |
| PHASE I STUDY OF TRAMETINIB—DOSE ESCALATION AND COHORT EXTENSION IN PATIENTS <br> UNTREATED WITH PRIOR MEKi TREATMENT (INFANTE ET AL., 2012) |  |  |  |  |  |
| Trametinib, no prior BRAFi | BRAF MT | 30 | $40 \%$ | 5.7 | NR |
| Trametinib, prior BRAFi | BRAF MT | 6 | $17 \%$ | NR | NR |
| Trametinib | BRAF WT | 39 | $10 \%$ | 2.0 | NR |
| PHASE II STUDY OF TRAMETINIB IN PATIENTS WITHOUT PRIOR MEKI TREATMENT (KIM ET AL., 2013) |  |  |  |  |  |
| Trametinib, no prior BRAFi | BRAF MT | 57 | $25 \%$ | 4.0 | 14.2 |
| Trametinib, prior BRAFi | BRAF MT | 40 | 0 | 1.8 | 5.8 |
| PHASE III STUDY OF TRAMETINIB VERSUS CHEMOTHERAPY AS SECOND LINE THERAPY IN PATIENTS <br> UNTREATED BY PRIOR RAFi, MEKi OR IPILIMUMAB (FLAHERTY ET AL., 2012B; HAUSCHILD ET AL., 2012) |  |  |  |  |  |
| Trametinib 2 mg daily | V600E/K | 214 | $22 \%$ | 4.8 | NA |
| DTIC $1000 \mathrm{mg} / \mathrm{m}^{2} \mathrm{q} 21$ or Paclitaxel $175 \mathrm{mg} / \mathrm{m}^{2} \mathrm{q} 21$ | V600E/K | 108 | $8 \%$ | 1.5 | NA |
| PHASE II STUDY OF MEK162 IN PATIENTS WITHOUT PRIOR MEKi TREATMENT (ASCIERTO ET AL., 2013b) |  |  |  |  |  |
| MEK162 45 mg bd | NRAS MT | 30 | $20 \%$ | 3.7 | NR |
| MEK162 45 mg bd | BRAF MT | 41 | $20 \%$ | 3.6 | NR |
| PHASE I/II STUDY DABRAFENIB 150MG BD IN COMBINATION WITH TRAMETINIB, EXTENSION COHORT <br> (FLAHERTY ET AL., 2012a) |  |  |  |  |  |
| Dab + Trametinib 0 mg daily | V600E/K | 54 | $54 \%$ | 5.8 | NA |
| Dab + Trametinib 1 mg daily | V600E/K | 54 | $50 \%$ | 9.2 | NA |
| Dab + Trametinib 2 mg daily | V600E/K | 54 | $76 \%$ | 9.4 | NA |
| PHASE III STUDY OF DABRAFENIB 150MG BD IN COMBINATION WITH TRAMETINIB VERSUS <br> DABRAFENIB AND PLACEBO, AS FIRST LINE THERAPY IN PATIENTS UNTREATED BY RAFi, MEKi OR <br> IPILIMUMAB (LONG ET AL., 2014, 2015) |  |  |  |  |  |
| Dab + Trametinib 2 mg daily | V600E/K | 211 | $69 \%$ | 11.0 | 25.1 |
| Dab | V600E/K | 212 | $53 \%$ | 8.8 | 18.7 |
| PHASE III STUDY OF DABRAFENIB 150MG BD IN COMBINATION WITH TRAMETINIB VERSUS <br> VEMURAFENIB, AS FIRST LINE THERAPY IN PATIENTS UNTREATED BY RAFi, MEKi OR IPILIMUMAB <br> (ROBERT ET AL., 2015a) |  |  |  |  |  |
| Dab + Trametinib 2 mg daily | V600E/K | 351 | $64 \%$ | 11.4 | NA |
| Vemurafenib | V600E/K | 350 | $51 \%$ | 7.3 | 17.2 |
| PHASE III STUDY OF VEMURAFENIB 960MG BD IN COMBINATION WITH 60MG COBIMETINIB VERSUS <br> VEMURAFENIB 960MG BD, AS FIRST LINE THERAPY IN PATIENTS UNTREATED BY RAFi, MEKi OR <br> IPILIMUMAB (LARKIN ET AL., 2014) |  |  |  |  |  |
| Vemurafenib + cobimetinib 60 mg daily | V600E/K | 247 | $68 \%$ | 11.3 | NA |
| Vemurafenib | V600E/K | 248 | $45 \%$ | 6.0 | NA |

[^0]
[^0]:    Abbreviations: Dab, dabrafenib; DTIC, dacarbazine; MEKi, MEK inhibitor; MT, mutant; NA, not yet available; NR, not reported; $O R R$, objective response rate; $O S$, overall survival; $P F S$, progression free survival; $R A F i$, RAF inhibitor; $W T$, wild-type.which investigated dabrafenib monotherapy versus combination dabrafenib and trametinib at 1 or 2 mg (Flaherty et al., 2012a). Dabrafenib and 2 mg of trametinib was superior to dabrafenib monotherapy with an improvement in progression-free survival from 5.8 to 9.4 months ( $\mathrm{HR}=0.39 ; P<0.001$ ). While both doses of combination therapy had similar improvements in progression-free survival, those receiving the higher dose of trametinib achieved a higher objective response rate of $76 \%$ versus $50 \%$. Additionally, there was little difference in toxicity between the two doses of trametinib leading to the recommended phase III dose of 2 mg .

The phase III study (COMBI-D) confirmed the additional benefit of trametinib with dabrafenib ( $n=211$ ) over dabrafenib monotherapy ( $n=212$ ). Although the initial analysis showed only an incremental improvement in progression-free survival (Long et al., 2014), by the time of the final analysis, a progression-free survival of 11.0 months versus 8.8 months in favor of the combination was achieved (HR $=0.67 ; P<0.0004$ ) (Long et al., 2015). Objective response rate was significantly higher at $69 \%$ versus $53 \%(P=0.0014)$ in favor of the dabrafenib and trametinib. This translated to an improvement in median overall survival of 25.1 months with combination dabrafenib and trametinib compared to 18.7 months with dabrafenib monotherapy ( $\mathrm{HR}=0.71 ; P=0.0107$ )-despite a higher use of poststudy immunotherapy agents, including ipilimumab, in the latter arm. Key dermatological toxicities such as hyperkeratosis, squamous cell carcinomas, and keratoacanthomas were also reduced, although the incidence of pyrexia and chills was significantly higher with combination therapy. MEK inhibitor-related ocular toxicity such as blurred vision ( $2.4 \%$ ) and chorioretinopathy ( $<1 \%$ ) was uncommon. These improvements in efficacy were replicated in another phase III trial (COMBI-V) of combination dabrafenib and trametinib ( $n=351$ ) compared to vemurafenib monotherapy ( $n=350$ ) (Robert et al., 2015a). Progression-free survival was 11.4 months in the combination arm and 7.3 months in the vemurafenib monotherapy arm ( $H R=0.56 ; P<0.001$ ). The objective response rate was $64 \%$ in the combination therapy group and $51 \%(P<0.001)$ in the vemurafenib group. Hence, two consecutive phase III studies confirmed combination of dabrafenib and trametinib as superior to BRAF inhibitor monotherapy.

Vemurafenib was also partnered with the MEK inhibitor cobimetinib and demonstrated superior efficacy over vemurafenib monotherapy in the phase III study (coBRIM) (Larkin et al., 2014). Progression-free survival of vemurafenib $(n=248)$ was 6.2 months compared to 9.9 months with vemurafenib and cobimetinib $(n=247)$ with a $49 \%$ risk reduction of death or progression. Objective response rate was $68 \%$ compared to $45 \%(P<0.001)$ in favor of the combination. Similar to the results of combination dabrafenib and trametinib, cutaneous toxicities, such as squamous cell carcinomas, keratoacanthomas, and hyperkeratosis, were substantially reduced. However, this was at the expense of increased gastrointestinal, ocular, and cardiac toxicity. The majority of gastrointestinal toxic events were grade 1 or 2 ; however, $11.8 \%$ and $8.2 \%$ of patients experienced chorioretinopathy or retinopathy, respectively. Although the majority of ocular events were asymptomatic, particular attention to visual symptoms is warranted with this combination. Nevertheless the addition of MEK inhibitors such as trametinib and cobimetinib significantly improve response rate, progression-free, and overall survival with the benefit of reduced cutaneous toxicity. As such, upfront combination BRAF and MEK inhibitors have replaced BRAF inhibitor monotherapy in patients with BRAF V600 mutant melanoma.# TREATMENT OF NRAS MUTANT MELANOMA 

NRAS mutations (Q61, G12, G13) occur in approximately 20-30\% of melanoma (Omholt et al., 2003; Platz et al., 2008; Hodis et al., 2012; Xia et al., 2014; Network, 2015) and are associated with similar patterns of metastatic spread to BRAF V600 mutant disease (Jakob et al., 2012; Carlino et al., 2014). The prognostic significance of NRAS mutant melanoma is uncertain with one retrospective analysis (Jakob et al., 2012) indicating worse survival outcomes, which was not replicated in a similar study (Carlino et al., 2014). Unfortunately, developing selective RAS inhibitors has been challenging and remains an area of unfulfilled clinical need.

Intriguingly three different MEK inhibitors have displayed signs of activity in NRAS mutant melanoma. Binimetinib (MEK162) achieved responses in 6 out of the 30 cohort (20\%) with stable disease in a further 13 (43\%) patients (Ascierto et al., 2013b). Another investigational MEK inhibitor, pimasertib, led to one complete response and three partial responses seen within a cohort of 17 patients ( $24 \%$ response rate) (Delord et al., 2012). Lastly within the phase I study of trametinib, two of seven patients treated with NRAS mutant melanoma achieved stable disease, with one receiving treatment for a total of 48 weeks (Falchook et al., 2012a). Given melanomas have a greater dependence on MAPK signaling, this may confer sensitivity to MEK inhibitor monotherapy. Follow-up randomized studies of both binimetinib (NCT01763164) and pimasertib (NCT01693068) versus dacarbazine in NRAS mutant melanoma are currently awaited. Another strategy under investigation includes dual MEK and cyclin-dependent kinase (CDK) inhibition which is currently in progress (NCT01781572).

## TREATMENT OF KIT MUTANT MELANOMA

KIT is a tyrosine kinase receptor that plays a critical role in melanocyte development and continues to be expressed in mature melanocytes. Although rare, overall mutations or amplifications in the KIT gene occur in up to $20 \%$ of mucosal and acral melanomas and provide an alternative mechanism for MAPK activation in melanoma subtypes where aberrations in BRAF or NRAS are less common (Curtin et al., 2006; Beadling et al., 2008).

The importance of mutant KIT as a melanoma oncogene is demonstrated by its association with worse prognosis (Minor et al., 2012) and by consistent reports of meaningful clinical responses to KIT inhibitors including imatinib and nilotinib. Imatinib is the best characterized of these agents with three completed phase II trials in patients with KIT mutations or amplifications (Table 12.3) (Carvajal et al., 2011; Guo et al., 2011; Hodi et al., 2013). Across these studies, response rates were in the order of $16-23 \%$ and median progression-free survival of 2.8-3.7 months. Similar to findings in gastrointestinal stromal tumors, treatment benefit with imatinib was best predicted by the presence of KIT exon 11 or exon 13 K642E mutations and activity in patients solely with KIT amplifications were limited (Kee and Zalcberg, 2012). In these patients, durable responses exceeding 80 weeks have been reported, but median progression occurs after only 4 months (Carvajal et al., 2011). Studies into mechanisms of resistance to imatinib in KIT-mutant melanomas are limited. Primary resistance has been associated with co-occurring NRAS mutations inTABLE 12.3 Clinical Trials of KIT Inhibitors in Melanomas with KIT Mutations or Amplifications

| Drug | KIT <br> alteration | Patients <br> $(\boldsymbol{n})$ | ORR <br> $(\%)$ | DCR <br> $(\%)$ | Median PFS <br> (months) | Median OS <br> (months) |
| :-- | :-- | :-- | :-- | :-- | :-- | :-- |
| NORTH AMERICAN PHASE II STUDY OF IMATINIB 400MG BD (CARVAJAL ET AL., 2011) |  |  |  |  |  |  |
| Imatinib | Any | 25 | $16 \%$ | $72 \%$ | 2.8 | 10.6 |
|  | Ex 11/13 | 14 | $43 \%$ | $86 \%$ | NR | NR |

CHINESE PHASE II STUDY OF IMATINIB 400MG DAILY WITH DOSE ESCALATION ON PROGRESSION (GUO ET AL., 2011)

| Imatinib | Any | 43 | $23 \%$ | $53 \%$ | 3.5 | 14.0 |
| :-- | :-- | :-- | :-- | :-- | :-- | :-- |
|  | Ex 11/13 | 26 | $35 \%$ | $58 \%$ | 4.0 | 14.0 |

NORTH AMERICAN PHASE II STUDY OF IMATINIB 400MG DAILY WITH DOSE ESCALATION ON PROGRESSION (HODI ET AL., 2013)

| Imatinib | Any | 24 | $19 \%$ | $50 \%$ | 3.7 | 12.5 |
| :-- | :-- | :-- | :-- | :-- | :-- | :-- |
|  | Ex 11/13a | 13 | $54 \%$ | $77 \%$ | 3.9 | 12.9 |

NORTH AMERICAN PHASE II STUDY OF SUNITINIB 50MG DAILY, 4 WEEKS ON AND 2 WEEKS OFF (MINOR ET AL., 2012)

| Sunitinib | Any | 10 | $50 \%$ | $50 \%$ | NR | NR |
| :-- | :-- | :-- | :-- | :-- | :-- | :-- |
|  | Ex 11/13 | 4 | $75 \%$ | $75 \%$ | NR | NR |

NORTH AMERICAN PHASE II STUDY OF SECOND LINE NILOTINIB 400MG TWICE DAILY (COHORT A) (CARVAJAL ET AL., 2015)

| Nilotinib | Any | 11 | $20 \%$ | $60 \%$ | 3.3 | 9.1 |
| :-- | :-- | :-- | :-- | :-- | :-- | :-- |
|  | Ex 11/13 | 9 | $25 \%$ | $66 \%$ | NR | NR |

[^0]limited cases and in one patient an increase in KIT copy number was identified at the time of secondary progression (Minor et al., 2012; Hodi et al., 2013). Dose escalation of imatinib from 400 mg daily to 400 mg twice daily appears ineffective in arresting progression (Guo et al., 2011; Hodi et al., 2013).

Nilotinib inhibits KIT with greater potency than imatinib and is active in imatinibresistant chronic myeloid leukemia and GISTs. It was tested in a phase II study in KITaberrant melanoma after progression or intolerance to a prior KIT inhibitor (Carvajal et al., 2015). Although slow accrual necessitated early closer of the trial, 11 previously treated patients received nilotinib with two achieving a partial response of 11.5 and $37.5+$ months' duration. A further four patients had stable disease as their best response. Unfortunately, similar problems with accrual have plagued other studies of KIT inhibitors-including the planned registration trials of imatinib. The rarity of KIT mutant melanoma combined with the emergence of other highly active therapies in the form of ipilimumab and PD-1


[^0]:    Abbreviations: Ex 11/13, exon 11 or 13 mutations only; $D C R$, disease control rate; $N R$, not reported; $O R R$, objective response rate; $O S$, overall survival; PFS, progression free survival.
    ${ }^{a}$ Includes 1 patient with an exon 17 mutation.inhibitors have challenged the feasibility of these studies. For these types of melanomas, immune checkpoint inhibitors have become standard of care with off-label use of KIT inhibitors a valid second-line option.

# SEQUENCING TARGETED THERAPY WITH IMMUNOTHERAPY 

Given the rapid pace of development of BRAF/MEK inhibitor combinations alongside immune checkpoint inhibitors, the optimal sequencing of these two distinct types of systemic treatments is currently unclear. Targeted therapy is typically associated with higher response rates with comparatively less durability while immunotherapies possess lower response rates but potentially offer the prospect of long term disease control.

Therefore, in the absence of direct clinical trial data the choice between molecular targeted therapy or immunotherapy should be made by considering the various treatments' properties in combination with the patient's disease state and treatment goals. Combination BRAF/MEK-inhibition still offers the highest response rates with often-rapid tumor responses that can quickly lead to improvements in patients' symptoms and performance status. It is therefore the preferred first-line option for patients with rapidly progressive symptomatic disease, particularly if there is CNS involvement.

In all other patients who do not require rapid symptom control, first line PD-1 inhibitors are currently favoured due to the prospect of durable disease control. Single agent PD-1 inhibitors are generally better tolerated than combination BRAF/MEK inhibitors with lower frequency of grade 3 or more toxicity ( $9-12 \%$ versus $30-65 \%$ ) and slightly lower discontinuation rates ( $3-7 \%$ versus $9 \%$ ), making these agents preferred for the majority of patients (Larkin et al., 2014; Larkin et al., 2015; Long et al., 2015; Robert et al., 2015b).

Although long term survival data is pending, PD-1 inhibitors have supplanted ipilimumab as first line immunotherapy given its superior response rate ( $33-44 \%$ versus $11-19 \%$ ) and progression free survival (4.1-6.9 months versus 2.8-2.9 months) (Larkin et al. 2015; Robert et al., 2015a). Importantly PD-1 inhibitors are more tolerable compared to ipilimumab with reduced grade 3-4 toxicities ( $10-16 \%$ versus $20-25 \%$ ). Two year survival rates of first line pembrolizumab are approximately $60 \%$ which compares favorably to that of ipilimumab historically (Daud et al., 2015).

Although first line ipilimumab monotherapy has been superseded, it may continue to be employed in combinations, such as with nivolumab. Although the phase III study of combination ipilimumab-nivolumab was not powered for a direct comparison against nivolumab monotherapy, there was improved progression free survival of 11.5 versus 6.9 months (HR $=0.74 ; 95 \%$ CI $0.60-0.92$ ) in favour of the doublet (Larkin et al., 2015). Additionally higher response rates of $58 \%$ versus $44 \%$ were observed. However its significant toxicity (greater than $50 \%$ grade $3-4$ toxicity) indicates that only "fit" patients should be offered this modality. Nevertheless, provided these promising outcomes translate into a superior overall survival advantage, we would anticipate that ipilimumab-nivolumab will become a new standard of care. In anticipation of this, the Intergroup/SWOG Phase III study (EA6134, NCT02224781) will formally examine sequencing of this immunotherapy doublet with dabrafenib-trametinib. This data is eagerly awaited to formally address the pertinent issue of sequencing immunotherapy and molecular targeted therapies.# CONCLUSIONS 

A targetable mutation in the MAPK pathway is now identifiable in around $80 \%$ of melanomas. For BRAF V600 mutant melanoma, the combination of a BRAF and MEK inhibitor has emerged as the preferred targeted therapy. As an alternative, and in non-BRAF, V600 mutant melanomas are the immune checkpoint inhibitors with those targeting PD-1 the lead class of agents. Clinical trials examining the sequencing and combination of these therapies, as well as those targeting NRAS and KIT mutations, are ongoing in a drive to further improve and optimize the treatment of advanced melanoma.

## References

Andrews, M.C., Behren, A., Chionh, F., et al., 2013. BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition. J. Clin. Oncol. 31, e448-e451.
Ascierto, P.A., Minor, D., Ribas, A., et al., 2013a. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J. Clin. Oncol. 31, 3205-3211.
Ascierto, P.A., Schadendorf, D., Berking, C., et al., 2013b. MEK162 for patients with advanced melanoma harboring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 14, 249-256.
Azer, M.W., Menzies, A.M., Haydu, L.E., et al., 2014. Patterns of response and progression in patients with BRAFmutant melanoma metastatic to the brain who were treated with dabrafenib. Cancer 120, 530-536.
Balch, C.M., Gershenwald, J.E., Soong, S.J., et al., 2009. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199-6206.
Beadling, C., Jacobson-Dunlop, E., Hodi, F.S., et al., 2008. KIT gene mutations and copy number in melanoma subtypes. Clin. Cancer Res. 14, 6821-6828.
Callahan, M.K., Rampal, R., Harding, J.J., et al., 2012. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N. Engl. J. Med. 367, 2316-2321.
Carlino, M.S., Haydu, L.E., Kakavand, H., et al., 2014. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. Br. J. Cancer 111, 292-299.
Carlino, M.S., Kwan, V., Miller, D.K., et al., 2015. New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. J. Clin. Oncol. 33, e52-56.
Carvajal, R.D., Antonescu, C.R., Wolchok, J.D., et al., 2011. KIT as a therapeutic target in metastatic melanoma. J Am. Med. Assoc. 305, 2327-2334.
Carvajal, R.D., Lawrence, D.P., Weber, J.S., et al., 2015. Phase II study of nilotinib in melanoma harboring KIT alterations following progression to prior KIT inhibition. Clin. Cancer Res. 21, 2289-2296.
Chapman, P.B., Hauschild, A., Robert, C., et al., 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516.
Curtin, J.A., Busam, K., Pinkel, D., et al., 2006. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24, 4340-4346.
Daud, A., Ribas, A., Robert, C., et al., 2015. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. In: ASCO Meeting Abstracts 33: 9005.
Davies, H., Bignell, G.R., Cox, C., et al., 2002. Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
Davies, M.A., Liu, P., McIntyre, S., et al., 2011. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117, 1687-1696.
Delord, J.P., Houédé, N., Awada, A., et al., 2012. Pimasertib (MSC1936369B/AS703026), a selective oral MEK1/2 inhibitor, shows clinical activity in melanoma. In: EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
Dummer, R., Goldinger, S.M., Turtschi, C.P., et al., 2014. Vemurafenib in patients with BRAF(V600) mutationpositive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur. J. Cancer $50,611-621$.Falchook, G.S., Lewis, K.D., Infante, J.R., et al., 2012a. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 13, 782-789.
Falchook, G.S., Long, G.V., Kurzrock, R., et al., 2012b. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379, 1893-1901.
Flaherty, K.T., Puzanov, I., Kim, K.B., et al., 2010. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819.
Flaherty, K.T., Infante, J.R., Daud, A., et al., 2012a. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703.
Flaherty, K.T., Robert, C., Hersey, P., et al., 2012b. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107-114.
Gerstner, E.R., and Fine, R.L., 2007. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J. Clin. Oncol. 25, 2306-2312.
Greaves, W.O., Verma, S., Patel, K.P., et al., 2013. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J. Mol. Diagn. 15, 220-226.
Guo, J., Si, L., Kong, Y., et al., 2011. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J. Clin. Oncol. 29, 2904-2909.
Hauschild, A., Grob, J.J., Demidov, L.V., et al., 2012. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365.
Hodi, F.S., O'Day, S.J., McDermott, D.F., et al., 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.
Hodi, F.S., Corless, C.L., Giobbie-Hurder, A., et al., 2013. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J. Clin. Oncol. 31, 3182-3190.
Hodis, E., Watson, I.R., Kryukov, G.V., et al., 2012. A landscape of driver mutations in melanoma. Cell 150, 251-263.
Infante, J.R., Fecher, L.A., Falchook, G.S., et al., 2012. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 13, 773-781.
Jakob, J.A., Bassett Jr., R.L., Ng, C.S., et al., 2012. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118, 4014-4023.
Jilaveanu, L.B., Aziz, S.A., and Kluger, H.M., 2009. Chemotherapy and biologic therapies for melanoma: do they work? Clin. Dermatol. 27, 614-625.
Kee, D., and Zalcberg, J.R., 2012. Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors. Ther. Adv. Med. Oncol. 4, 255-270.
Kim, K.B., Kefford, R., Pavlick, A.C., et al., 2013. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J. Clin. Oncol. 31, 482-489.
Larkin, J., Ascierto, P.A., Dreno, B., et al., 2014. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 371, 1867-1876.
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al., 2015. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23-34.
Long, G.V., Menzies, A.M., Nagrial, A.M., et al., 2011. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 29, 1239-1246.
Long, G.V., Trefzer, U., Davies, M.A., et al., 2012. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 1087-1095.
Long, G.V., Stroyakovskiy, D., Gogas, H., et al., 2014. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 371, 1877-1888.
Long, G.V., Stroyakovskiy, D., Gogas, H., et al., 2015. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386, $444-451$.
McArthur, G.A., Puzanov, I., Amaravadi, R., et al., 2012. Marked, homogeneous, and early [18F]fluorodeoxyglu-cose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J. Clin. Oncol. 30, 1628-1634.
McArthur, G.A., Chapman, P.B., Robert, C., et al., 2014. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 15, 323-332.

# II. TREATMENT AND PROGNOSISMenzies, A.M., Ashworth, M.T., Swann, S., et al., 2015. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. Ann. Oncol. 26, $415-421$.
Minor, D.R., Kashani-Sabet, M., Garrido, M., et al., 2012. Sunitinib therapy for melanoma patients with KIT mutations. Clin. Cancer Res. 18, 1457-1463.
Network, and C.G.A., 2015. Genomic classification of cutaneous melanoma. Cell 161, 1681-1696.
Oberholzer, P.A., Kee, D., Dziunycz, P., et al., 2012. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J. Clin. Oncol. 30, 316-321.
Omholt, K., Platz, A., Kanter, L., et al., 2003. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin. Cancer Res. 9, 6483-6488.
Platz, A., Egyhazi, S., Ringborg, U., et al., 2008. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol. Oncol. 1, 395-405.
Rizos, H., Menzies, A.M., Pupo, G.M., et al., 2014. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin. Cancer Res. 20, 1965-1977.
Robert, C., Karaszewska, B., Schachter, J., et al., 2015a. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372, 30-39.
Robert, C., Schachter, J., Long, G.V., et al., 2015b. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521-2532.
Schadendorf, D., Hodi, F.S., Robert, C., et al., 2015. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33, 1889-1894.
Shi, H., Hugo, W., Kong, X., et al., 2014. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 4, 80-93.
Solit, D.B., Garraway, L.A., Pratilas, C.A., et al., 2006. BRAF mutation predicts sensitivity to MEK inhibition. Nature $439,358-362$.
Sosman, J.A., Kim, K.B., Schuchter, L., et al., 2012. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714.
Van Allen, E.M., Wagle, N., Sucker, A., et al., 2014. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 4, 94-109.
Xia, J., Jia, P., Hutchinson, K.E., et al., 2014. A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Mol. Cancer Ther. 13, 1918-1928.
Yoon, S., and Seger, R., 2006. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24, 21-44.# 13 

## Patients with Brain Metastases from Melanoma: Treatment with Surgery and Radiotherapy

Michael N. Khoury, Symeon Missios, Nam D. Tran and Peter A. Forsyth

## O U T L I N E

Introduction 185
Epidemiology 186
Clinical Predictors and Prognostic Factors
of Melanoma Brain Metastasis
Surgical and Radiotherapeutic
Treatment 188

Radiosurgery 188
Whole Brain Radiotherapy 189
Surgery 191
Conclusion 194
References 194

## INTRODUCTION

Chemotherapy has been the mainstay of systemic treatment of malignancy but due to matters largely concerning the blood-brain-barrier and heterogeneity of the tumors it has been largely ineffective in the management of brain metastasis. Instead, surgery and radiation therapy has been the accepted first line treatment in the management of brain metastasis. Up until recently, melanoma was no exception but with the advent of targeted therapy, such as BRAF inhibitors and immune checkpoint inhibitors (CTLA/PD1 blocking antibodies), patients with melanoma brain metastasis have more effective options in disease management. Nonetheless, surgery and radiation therapy continues to play a major role in the care and management of patients with melanoma brain metastasis. Whole brain radiation in particular is associated with long-term cognitive sequelae leading to preferential useof stereotactic radiosurgery (SRS) for selected metastases. This is particularly relevant as patients are experiencing improved outcomes with the targeted and immunotherapies and hence, living long enough to experience the cognitive decline as can be seen in whole brain radiation. In this chapter, we discuss the history of surgical and radiation therapy in melanoma brain metastasis. We will also discuss new modalities such as laser interstitial tumor therapy (AutoLITT).

# Epidemiology 

Metastatic brain tumor is an unfortunate outcome of systemic malignancy with an incidence of greater than 200,000 cases per year in the United States; an incidence much greater than that of primary brain tumors (Patchell, 2003). Melanoma, in particular, is the third most common systemic malignancy to metastasize to the brain ( $5-10 \%$ of all metastatic brain tumors). Brain metastasis is linked with a particularly poor prognosis, with a reported average survival of less than 9 months (Davies et al., 2011).

Melanoma brain metastasis is a frequent outcome of systemic melanoma. Approximately $50 \%$ of patients with stage IV melanoma develop brain metastasis prior to death with autopsy series demonstrating an even higher prevalence of up to $75 \%$ in melanoma patients (Barnholtz-Sloan et al., 2004; Schouten et al., 2002). Moreover, the prognosis of patients with melanoma brain metastasis remains dismal. The median overall survival (OS) from time of diagnosis is only 2 to 9 months (Davies et al., 2011; Fife et al., 2004; Staudt et al., 2010). With this high incidence and grim prognosis in mind, a systemic and multidisciplinary approach should be undertaken. Consideration for chemotherapy, surgery, and radiation in order to manage patients with melanoma and brain metastasis is paramount in improving patient survival and quality of life. Improvements in understanding the tumor biology as well as innovative surgical techniques will dictate the future of effective central nervous system (CNS) tumor control (Fig. 13.1).

## Clinical Predictors and Prognostic Factors of Melanoma Brain Metastasis

To date, a collection of large retrospective studies have identified various clinical and molecular markers associated with development of melanoma brain metastasis. These factors include thickness or ulceration of the primary lesion, site of primary lesion in the head or neck, mucosal or acral lentiginous tumors, nodular primary lesions, and also male gender (Gorantla et al., 2013; Sampson et al., 1998; Zakrzewski et al., 2011). However, on multivariate analysis only primary lesion site involving the head and neck as well as ulceration of primary lesion retained independent predictive significance (Zakrzewski et al., 2011). On a molecular basis, patients with melanoma brain metastasis are equally distributed between mutant BRAF and wild type (48-55.3\% mutant) (Gorantla et al., 2013; Colombino et al., 2012). Similarly, activating mutations of BRAF are found in $40-60 \%$ of patients with primary advanced melanoma (Long et al., 2011; Smalley and Sondak, 2010; Wellbrock and Hurlstone, 2010) (Fig. 13.2).

A recursive partition analysis (RPA) was developed using data of patients with brain metastasis (including a variety of malignancies) from three prospective randomized control trials in the Radiation Therapy Oncology Group (RTOG) (in all, 1200 patients treated with![img-72.jpeg](img-72.jpeg)

FIGURE 13.1 Display of the corticospinal fibers (green), derived from diffusion tensor imaging superimposed on a high resolution T1-volume MRI after gadolinium contrast administration, and their relationship to a right frontal metastatic tumor immediately anterior to the motor cortex.
whole brain radiotherapy (WBRT)) in order to generate risk categories divided into three classes. Class 1 consisted of patients with age less than 65 years, well-controlled primary lesions and no extracranial metastasis, and a Karnofsky performance score (KPS) greater than or equal to 70 . This group had the longest median survival of 7.1 months. The third group, Class 3, was comprised of patients with a KPS less than 70 and had the poorest median survival outcomes of 2.3 months. The second group Class 2 consisted of all other patients and had a median survival of 4.2 months (Gaspar et al., 1997). However, in addition to these factors, it appears that the number of brain metastases plays an important factor in determining OS. It has been repeatedly shown that patients with a solitary brain metastasis have a greater median survival than those with multiple metastases, even with adjustments for other factors (Lutterbach et al., 2002). A more recent analysis of 1960 patients in the![img-73.jpeg](img-73.jpeg)

FIGURE 13.2 Algorithm for management of patients with metastatic melanoma to the brain.

RTOG database was undertaken from which the Graded Prognostic Assessment scale was developed. This scale, unlike the RPA, incorporates the number of metastatic brain lesions into its calculation (Sperduto et al., 2008a,b). However, this data will require a reevaluation to include molecular markers and also to factor the recent progress with the introduction of immunotherapy in the treatment and management of patients with metastatic brain tumors and in particular those of melanoma brain metastasis.

# SURGICAL AND RADIOTHERAPEUTIC TREATMENT 

## Radiosurgery

Melanoma has been considered to be relatively radioresistant to conventional fractionated doses (Barranco et al., 1971; Carlino et al., 2012; Doss and Memula, 1982). SRS involves delivery of radiation as a single ablative dose without fractionation and is favored for its ease, minimal invasiveness, effectiveness, and same-day treatment. In selected patients withlimited CNS disease, good performance status, and lesions less than 3 cm with minimal vasogenic edema and no hydrocephalus or shift, SRS has emerged as a comparable alternative to resection of brain metastases (Gibney et al., 2012). Additionally, the undesirable neurotoxicity associated with whole brain radiation therapy (as discussed below) has made targeted focal radiation therapy a more attractive alternative. The benefit of these targeted systems is the rapid fall-off dose at the tumor margin with minimal radiation delivered to the surrounding normal tissue and hence minimization of adverse cognitive and neurologic sequelae. The additional advantage provided by radiosurgery is the capability to treat locations that are otherwise surgically inaccessible such as brain stem or basal ganglia lesions.

Unlike WBRT, the results following SRS, demonstrate far better OS in addition to fewer neurotoxic effects mentioned earlier. In fact, various series of patients with melanoma brain metastasis undergoing SRS report local tumor control with rates between $72 \%$ and $90 \%$ (Brown et al., 2008; Gaudy-Marqueste et al., 2006; Herfarth et al., 2003; Mathieu et al., 2007; Mori et al., 1998; Powell et al., 2008). Yu and colleagues reported on 122 patients who underwent Gamma Knife SRS for cerebral melanoma metastases and reported median OS of 7 months and identified small tumor volume and inactive systemic disease were predictors of survival (Yu et al., 2002). The capacity for local control and overall improvement in survival are in part dependent on both individual tumor volume as well as the total volume of the SRS treated brain metastasis (Chang et al., 2005; Liew et al., 2011). SRS is in general reserved for patients with metastatic lesions with a diameter less than 3 cm or less than 5 cm and a low number of intracranial metastases (less than 9 lesions); although some practitioners do administer SRS to patients with an intracranial tumor burden of greater than 9 lesions (Liew et al., 2011; Skeie et al., 2011). Moreover, Liew et al. demonstrated that patients with a solitary brain metastasis of malignant melanoma and with controlled extracranial disease have a median survival of 22 months when immunotherapy followed administration of Gamma Knife radiosurgery (Liew et al., 2011). This highlights the importance of patient selection as well as a multispecialty team approach to patient management that includes radiation oncologists, neurosurgeons, as well as oncologists.

The addition of SRS to WBRT has been shown to prolong survival in cerebral metastases. In an RTOG study of patients with 1-3 cerebral metastases ( 333 patients, 14 with melanoma), SRS was associated with improved OS in RPA class 1 patients ( 11.6 vs 9.6 months) and improved KPS at 6 months ( $43 \%$ vs $27 \%$ ) (Kondziolka et al., 1999). Only one randomized control trial attempted to answer the question of SRS versus resection and that was stopped early due to poor accrual (Muacevic et al., 2008). In a comparison of patients with solitary metastasis $<3 \mathrm{~cm}, \mathrm{KPS}>70$, and stable systemic disease, 33 patients were assigned to surgery and 31 to SRS and there was no difference in terms of survival and local recurrence. However, extrapolating the results is difficult because the study is underpowered. In a retrospective study by O'Neil and colleagues of 97 patients with solitary brain metastases there was no difference in the OS in patients who underwent SRS or surgical resection (O'Neill et al., 2003).

# Whole Brain Radiotherapy 

WBRT remains an option in cases where surgical resection or SRS is contraindicated due to tumor size, location, or number (Carlino et al., 2012). The benefits of WBRT include theability to treat both visualized metastatic disease as well as microscopic disease not captured on routine neuroimaging. Typically, patients receive daily fractions of $2-3 G y$ for a total dosage of $30-40 \mathrm{~Gy}$. A higher daily fraction dose or a larger total dose can lead to significant neurotoxicity, as described later in this section. However, in a retrospective study of 184 patients, Rades and colleagues demonstrated improved local control and survival ( 17 vs 13 months) in patients treated with 40 Gy versus 30 Gy (Gibney et al., 2012; Rades et al., 2012). Survival gain from WBRT is modest and its primary role is to palliate symptoms. Carella and colleagues in their series of 60 patients with melanoma cerebral metastases, reported symptomatic improvement in headache, seizures, motor and mentation symptoms in more than $50 \%$ of the patients treated (Carella et al., 1980). The median OS in patients with brain metastasis increased from approximately 2 months to anywhere from 3 to 6 months (Eichler and Loeffler, 2007). However, this data is collected from nonrandomized studies and not specific for melanoma brain metastasis. With this last point in mind, it should be noted that various tumor histology demonstrates greater susceptibility to whole brain radiation than others. Whereas, small cell lung cancer and breast cancer are sensitive to whole brain radiation, melanoma (along with renal cell carcinoma and sarcoma) is generally not (McKay et al., 2003).

WBRT can be used as a primary treatment modality or as an adjuvant treatment after prior surgical resection or treatment with SRS as a means to decrease the possibility of local or distant recurrence. Studies of patients with solid tumor cerebral metastases have suggested that the addition of WBRT after surgical resection or SRS, decreased the chance of recurrence but did not affect OS or functional independence (Carlino et al., 2012; Aoyama et al., 2006; Kocher et al., 2011; Patchell et al., 1998; Andrews et al., 2004). This was also demonstrated in the EORTC 22952-26001 study where a reduction in the 2-year local relapse rates was noted ( $31 \%$ vs $19 \%$ ) and new brain metastases ( $43 \%$ vs $33 \%$ ) (Kocher et al., 2011).

To increase the efficacy of radiation in a largely radioresistant tumor such as melanoma, various investigations have attempted to find cytotoxic agents or radiosensitizers to combine with WBRT in the setting of melanoma brain metastasis. Agents such as fotemustine and temozolmide have been administered concurrently with whole brain radiation. However, there has been no demonstrated improved efficacy compared to whole brain radiation as monotherapy in terms of improvement in OS or local control rates (Atkins et al., 2008; Margolin et al., 2002; Mornex et al., 2003).

Moreover, there is significant neurotoxicity, namely neurocognitive sequelae, in patients receiving WBRT (DeAngelis et al., 1989). In 1989, DeAngelis et al. demonstrated that patients receiving WBRT for metastatic disease in daily fractions greater than 3 Gy (up to 6 Gy ) were at risk of developing significant neurotoxicity in the form of a debilitating dementia in a median of 14 months following the radiation treatment. However, patients receiving daily fractions of less than 3 Gy had a smaller risk of progression to this undesirable neurotoxicity. Nonetheless, it is well established that patients receiving WBRT, even at the lower doses of 3 Gy or less, can develop significant cognitive decline following radiation.

Recently, a large multicenter trial (RTOG 0933) investigated the role of hippocampal sparing WBRT (Gondi et al., 2014). The study's primary end point was the Hopkins Verbal Learning Test-R Delayed Recall (DR) at 4 months and compared to a historical control. In the hippocampus sparing group, $7 \%$ had a significant decline in the HVRLT-R DR scores at 4 months compared to the historical control with $30 \%$ ( $P<0.001$ ). There was also no declinein quality of life scores during this follow-up period. This important study acknowledges the role of the hippocampus in memory formation based on the hypothesis that radiation associated injury to the neural stem cells of the subgranular zone of the hippocampal dentate gyrus is the driving force for the early decline in cognition following radiation therapy (Gondi et al., 2010). However, it does not address the complex pathophysiology of subcortical dementia as evidenced with white matter disease that extends well beyond the hippocampus.

Another attempt on reducing the unfavorable neurocognitive sequelae of WBRT involved the use of memantine as prophylaxis. This study by Brown et al. randomized patients to either receive placebo or memantine ( 20 mg per day), within 3 days of initiating radiotherapy followed by continued daily memantine for 24 weeks (Brown et al., 2013). Patients were evaluated with serial standardized tests measuring cognitive function. In the memantine arm, patients trended toward less decline in delayed recall at 24 weeks $(P=0.059)$. In addition, those taking memantine had significantly longer time to developing measurable cognitive decline (hazard ratio $0.78,95 \%$ confidence interval $0.62-0.99, P=0.01$ ). Finally, patients receiving memantine prophylaxis performed better in executive function testing $(P=0.004)$ at 16 weeks, and also better in processing speed $(P=0.014)$ and delayed recognition at 24 weeks $(P=0.015)$ in comparison to the placebo arm.

With the significant morbidity associated with WBRT and the mostly radioresistant nature of melanoma, in general WBRT should be reserved for patients with multiple brain metastasis that are not amenable to either surgical resection or SRS or to systemic targeted therapy (BRAF inhibitor in a patient with V600 BRAF mutation) or immunological therapy (patient with multiple small largely asymptomatic lesions that do not require steroids). If WBRT is employed, interventions such as hippocampal sparing radiation and memantine prophylaxis should be considered.

# Surgery 

Without medical intervention, patients with brain metastases may have a median survival of only 6 weeks. This dismal prognosis can be extended to 3 months with administration of corticosteroids, thus suggesting an influential role of cerebral edema in OS. In the setting of large brain metastasis, surgery can immediately ameliorate the life-threatening risks and neurologic dysfunction due to tumor-associated edema. Surgery provides an additional benefit in reducing steroid requirements in immunotherapy-directed systemic therapy, where steroid use can render treatments less effective. Surgery also has an advantage over radiotherapy alternatives in providing for a definitive pathologic and molecular diagnosis. This is particularly important in light of the greater recognition of metastatic tumor heterogeneity particularly in the context of an increased use of targeted therapies (Marusyk and Polyak, 2010), or that the newly diagnosed brain tumor can be a primary brain tumor or other metastatic disease in roughly $10 \%$ of cases (Patchell et al., 1990). Despite the potential immediate benefits of surgical intervention, its long-term benefit in patients with brain metastatic disease remains controversial.

The survival advantage that surgery affords in solitary metastatic brain tumors was firmly established by two landmark phase III prospective clinical trials by Patchell (Patchell et al., 1990) and Vecht (Vecht et al., 1993). The Patchell study examined 48 patients withsurgically accessible solitary brain metastasis and KPS $>70$. Those with radiosensitive tumors were excluded. The groups were randomized into two arms with one group receiving biopsy plus WBRT and the second group receiving surgical resection followed by WBRT (Patchell et al., 1990). The patients undergoing surgery plus WBRT demonstrated a significant increase in median survival compared to those receiving biopsy and WBRT ( 40 vs 15 weeks, $P<0.01$ ). In addition, the surgical arm also maintained functional dependence for a longer duration ( 38 vs 8 weeks, $P<0.005$ ) and had a longer time until local tumor recurrence. Vecht and colleagues examined 63 solitary brain metastatic disease who had higher functional status and a life expectancy of greater than 6 months (Vecht et al., 1993). The first arm received complete surgical resection and WBRT, while the second arm received only WBRT. Similar to Patchell's study, he demonstrated a survival benefit in those receiving surgery plus WBRT compared to WBRT alone ( 10 vs 6 months, $P<0.05$ ).

Similar to the Patchell and Vecht studies, Mintz et al. (1996) prospectively studied the benefits of surgery plus radiotherapy alone in 84 patients with solitary, surgically accessible brain metastases. Unlike the previous studies, the inclusion criteria were expanded to include those with KPS 50 or greater. There was also a greater percentage of patients with disseminated systemic disease ( $45 \%$ vs $38 \%$ and $32 \%$, respectively). No statistically significant improvement in survival was found at 24 weeks. Taken together, these studies demonstrate a clear beneficial role for surgery in a select group of patients with surgically accessible, solitary brain metastases, with high functional status and controlled systemic disease.

The criteria for surgical selection in patients with solitary brain metastases should include consideration of (1) tumor radiosensitivity (and melanoma is considered relatively radioresistant), (2) status of systemic metastases, (3) patient's functional status, and (4) surgical accessibility of tumors. Alternatives to surgery should be considered in patients with highly radiosensitive or chemosensitive tumors (i.e., lymphoma). Whether targeted therapies, such as with BRAF inhibitors, may supplant surgery in some cases remains to be determined.

There is no doubt that the extent of systemic metastases plays an important prognostic role for surgery. In both the Patchell and Vecht studies, smaller percentages of patients with disseminated disease showed significant survival benefit from surgery (Patchell et al., 1990; Vecht et al., 1993). In contrast, no surgical survival advantage was seen in the Mintz study population where a higher percentage of patients had disseminated systemic disease (Mintz et al., 1996). Quantifying the degree of systemic or extracranial disease is challenging. Vecht et al. (1993) used life expectancy of greater than 6 months as a surrogate marker of systemic disease. In this era of personalized genomics and immunotargeted therapy, one can argue that the extent of "controllable" systemic disease would be a better defining criteria. For example, melanoma patients with BRAFv600 mutations would have a better prognosis than BRAF wild type patients exhibiting similar systemic tumor burden (Chapman et al., 2011; Hauschild et al., 2012). Patients with a KPS $<70$ are typically deemed poor surgical candidates. The surgical survival advantage was lost when the surgical cohort included patients with KPS as low as 50 . This prognostic criteria is given with a caveat that patients who exhibit low KPS and neurologic dysfunction as a result of tumor mass or edema, would benefit from surgical intervention. Preoperative improvement in clinical symptoms with steroid administration suggests better outcome following surgery.The definition of "surgical accessibility" of metastatic lesion has broadened in part due to advances in neuroimaging and surgical techniques. Tumors in proximity to eloquent locations (e.g., speech or motor cortex) are associated with high risks of neurologic deficit preoperatively and postoperatively. Tumor metastases in these locations were often deemed surgically inaccessible. Our modern neurosurgical armamentarium includes image guided stereotactic navigation, functional MR imaging, diffusion tensor imaging (DTI), and laser interstitial tissue therapy which may all improve surgical outcomes.

Image-guided stereotactic navigation is a technology that has revolutionized brain surgery. By optically matching the patient's anatomic features (e.g., facial features) with a preoperative high-resolution MRI or CT, the location of the tumor can be localized with millimeter accuracy. In addition to tumor localization, this technology aides in identifying critical anatomic landmarks (e.g., motor cortex) in order to minimize the risks of neurologic dysfunction. Identification of topographic anatomy alone is insufficient to determine the resectability of a tumor. Tumor mass or edema can displace or distort brain functional center with much interpatient variability. fMRI is a noninvasive imaging modality that uses changes in blood oxygen levels and cerebral blood flow as a surrogate for changes to neuronal activity while patients are preforming motor or language tasks (Sherman et al., 2011). The sensitivity and specificity of motor cortex localization have been validated in a number of studies (Jack et al., 1994; Krings et al., 2002). Giussani et al. (2010) report that fMRI language localization has sensitivity ranging from $59 \%$ to $100 \%$. DTI is an MRI technique that assesses the directionality and motion of water molecules and provides images of white matter tracts within the CNS (Abdullah et al., 2013; Jellison et al., 2004). DTI allows for mapping of fiber tracts necessary for different functions. Thus, DTI can help minimize surgical damage to neural pathways by predicting the direction of fiber displacement by tumor. A significant limitation of this technique is the potential brain shift that can occur when a craniotomy is performed (Nimsky et al., 2007). Laser interstitial thermal therapy (LITT) is a minimally invasive technique originally introduced by Brown (1983) for percutaneously ablating tumors using laser. Its use in neurosurgical procedures was initially limited due to technical difficulties related to the monitoring and control of the extent of thermal damage induced by the percutaneous laser probe. The development of MR thermography as an imaging modality, and its application to LITT has allowed real-time thermal imaging and feedback control during the laser energy delivery. This has made possible the precise delivery of tissue hyperthermia with minimal morbidity to normal tissues. Currently LITT technology is being investigated for the treatment of difficult to access brain tumors including malignant gliomas and radiosurgery-resistant metastases (Missios et al., 2015). Carpentier and colleagues reported on a series of 15 metastatic tumors treated in seven patients and reported no tumor recurrence within the thermal ablation zone and a median OS of 19.8 months (Carpentier et al., 2011). Hawasli et al. (2013) reported on their experience with use of LITT.

Traditionally oligometastatic disease to the brain has not been considered for surgery. Emergent case reviews and retrospective studies suggested benefit in patients who may have up to four target lesions. Bindal et al. (1993) found a survival advantage in those undergoing surgical resection of up to three metastases compared to unresected controls. Furthermore, those undergoing surgical procedures through multiple craniotomies fared similarly to those undergoing a single craniotomy with no change in morbidity or mortality. Our surgical experience at Moffitt Cancer Center yields similar findings for patients with multiple brain metastasis.# CONCLUSION 

The overall prognosis for patients with brain metastases remains poor. Approximately one-third of patients will die as a result of a progressive intracranial disease. Advances in surgical and radiotherapy treatments for brain metastasis give promise to this grim prognosis. By decreasing morbidity and mortality, greater than 1-year survival is no longer the exception. Furthermore, aggressive treatment of an intracranial disease allows patients time to undergo more novel and promising targeted or immunologic adjunct therapies.

## References

Abdullah, K.G., Lubelski, D., Nucifora, P.G., and Brem, S., 2013. Use of diffusion tensor imaging in glioma resection. Neurosurg. Focus 34, E1.
Andrews, D.W., Scott, C.B., Sperduto, P.W., et al., 2004. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363, 1665-1672.
Aoyama, H., Shirato, H., Tago, M., et al., 2006. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295, 2483-2491.
Atkins, M.B., Sosman, J.A., Agarwala, S., et al., 2008. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer 113, 2139-2145.
Barnholtz-Sloan, J.S., Sloan, A.E., Davis, F.G., Vigneau, F.D., Lai, P., and Sawaya, R.E., 2004. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan detroit cancer surveillance system. J. Clin. Oncol. 22, 2865-2872.

Barranco, S.C., Romsdahl, M.M., and Humphrey, R.M., 1971. The radiation response of human malignant melanoma cells grown in vitro. Cancer Res. 31, 830-833.
Bindal, R.K., Sawaya, R., Leavens, M.E., and Lee, J.J., 1993. Surgical treatment of multiple brain metastases. J. Neurosurg. 79, 210-216.
Brown, S.G., 1983. Phototherapy in tumors. World J. Surg. 7, 700-709.
Brown, P.D., Brown, C.A., Pollock, B.E., Gorman, D.A., and Foote, R.L., 2008. Stereotactic radiosurgery for patients with "radioresistant" brain metastases. Neurosurgery 62 (Suppl. 2), 790-801.
Brown, P.D., Pugh, S., Laack, N.N., et al., 2013. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 15, 1429-1437.
Carella, R.J., Gelber, R., Hendrickson, F., Berry, H.C., and Cooper, J.S., 1980. Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma: Radiation Therapy Oncology Group Brain Metastases Study I and II. Cancer 45, 679-683.
Carlino, M.S., Fogarty, G.B., and Long, G.V., 2012. Treatment of melanoma brain metastases: a new paradigm. Cancer J. 18, 208-212.
Carpentier, A., McNichols, R.J., Stafford, R.J., et al., 2011. Laser thermal therapy: real-time MRI-guided and computer-controlled procedures for metastatic brain tumors. Lasers Surg. Med. 43, 943-950.
Chang, E.L., Selek, U., Hassenbusch, S.J., et al., 2005. Outcome variation among "radioresistant" brain metastases treated with stereotactic radiosurgery. Neurosurgery 56, 936-945.
Chapman, P.B., Hauschild, A., Robert, C., et al., 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516.
Colombino, M., Capone, M., Lissia, A., et al., 2012. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J. Clin. Oncol. 30, 2522-2529.
Davies, M.A., Liu, P., McIntyre, S., et al., 2011. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117, 1687-1696.
DeAngelis, L.M., Delattre, J.Y., and Posner, J.B., 1989. Radiation-induced dementia in patients cured of brain metastases. Neurology 39, 789-796.
Doss, L.L., and Memula, N., 1982. The radioresponsiveness of melanoma. Int. J. Radiat. Oncol. Biol. Phys. 8, $1131-1134$.Eichler, A.F., and Loeffler, J.S., 2007. Multidisciplinary management of brain metastases. Oncologist 12, 884-898.
Fife, K.M., Colman, M.H., Stevens, G.N., et al., 2004. Determinants of outcome in melanoma patients with cerebral metastases. J. Clin. Oncol. 22, 1293-1300.
Gaspar, L., Scott, C., Rotman, M., et al., 1997. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int. J. Radiat. Oncol. Biol. Phys. 37, 745-751.
Gaudy-Marqueste, C., Regis, J.M., Muracciole, X., et al., 2006. Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 65, 809-816.
Gibney, G.T., Forsyth, P.A., and Sondak, V.K., 2012. Melanoma in the brain: biology and therapeutic options. Melanoma Res. 22, 177-183.
Giussani, C., Roux, F.E., Ojemann, J., Sganzerla, E.P., Pirillo, D., and Papagno, C., 2010. Is preoperative functional magnetic resonance imaging reliable for language areas mapping in brain tumor surgery? Review of language functional magnetic resonance imaging and direct cortical stimulation correlation studies. Neurosurgery 66, 113-120.
Gondi, V., Tome, W.A., and Mehta, M.P., 2010. Why avoid the hippocampus? A comprehensive review. Radiother. Oncol. 97, 370-376.
Gondi, V., Pugh, S.L., Tome, W.A., et al., 2014. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J. Clin. Oncol. 32, 3810-3816.
Gorantla, V., Kirkwood, J.M., and Tawbi, H.A., 2013. Melanoma brain metastases: an unmet challenge in the era of active therapy. Curr. Oncol. Rep. 15, 483-491.
Hauschild, A., Grob, J.J., Demidov, L.V., et al., 2012. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365.
Hawasli, A.H., Bagade, S., Shimony, J.S., Miller-Thomas, M., and Leuthardt, E.C., 2013. Magnetic resonance imaging-guided focused laser interstitial thermal therapy for intracranial lesions: single-institution series. Neurosurgery 73, 1007-1017.
Herfarth, K.K., Izwekowa, O., Thilmann, C., et al., 2003. Linac-based radiosurgery of cerebral melanoma metastases. Analysis of 122 metastases treated in 64 patients. Strahlenther. Onkol. 179, 366-371.
Jack Jr., C.R., Thompson, R.M., Butts, R.K., et al., 1994. Sensory motor cortex: correlation of presurgical mapping with functional MR imaging and invasive cortical mapping. Radiology 190, 85-92.
Jellison, B.J., Field, A.S., Medow, J., Lazar, M., Salamat, M.S., and Alexander, A.L., 2004. Diffusion tensor imaging of cerebral white matter: a pictorial review of physics, fiber tract anatomy, and tumor imaging patterns. AJNR Am. J. Neuroradiol. 25, 356-369.

Kocher, M., Soffietti, R., Abacioglu, U., et al., 2011. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J. Clin. Oncol. 29, 134-141.
Kondziolka, D., Patel, A., Lunsford, L.D., Kassam, A., and Flickinger, J.C., 1999. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 45, 427-434.
Krings, T., Schreckenberger, M., Rohde, V., et al., 2002. Functional MRI and 18F FDG-positron emission tomography for presurgical planning: comparison with electrical cortical stimulation. Acta Neurochir. (Wien) 144, 889-899.
Liew, D.N., Kano, H., Kondziolka, D., et al., 2011. Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J. Neurosurg. 114, 769-779.
Long, G.V., Menzies, A.M., Nagrial, A.M., et al., 2011. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 29, 1239-1246.
Lutterbach, J., Bartelt, S., and Ostertag, C., 2002. Long-term survival in patients with brain metastases. J. Cancer Res. Clin. Oncol. 128, 417-425.
Margolin, A., Atkins, B., Thompson, A., et al., 2002. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J. Cancer Res. Clin. Oncol. 128, 214-218.
Marusyk, A., and Polyak, K., 2010. Tumor heterogeneity: causes and consequences. Biochim. Biophys. Acta 1805, $105-117$.
Mathieu, D., Kondziolka, D., Cooper, P.B., et al., 2007. Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery 60, 471-481.
McKay, M.J., Peters, L.J., and Ainslie, J., 2003. Radiotherapy for distant metastases and clinical radiobiology of melanoma. In: Balch, C.M., Houghton, A., Sober, A.J. (Eds.), Cutaneous Melanoma, fourth ed. Quality Medical Publishing, St. Louis, MO, pp. 573-586.

# II. TREATMENT AND PROGNOSISMintz, A.H., Kestle, J., Rathbone, M.P., et al., 1996. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 78, 1470-1476.
Missios, S., Bekelis, K., and Barnett, G.H., 2015. Renaissance of laser interstitial thermal ablation. Neurosurg. Focus 38, E13.
Mori, Y., Kondziolka, D., Flickinger, J.C., Kirkwood, J.M., Agarwala, S., and Lunsford, L.D., 1998. Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int. J. Radiat. Oncol. Biol. Phys. 42, 581-589.
Mornex, F., Thomas, L., Mohr, P., et al., 2003. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res. 13, 97-103.
Muacevic, A., Wowra, B., Siefert, A., Tonn, J.C., Steiger, H.J., and Kreth, F.W., 2008. Microsurgery plus whole brain irradiation versus Gamma Knife surgery alone for treatment of single metastases to the brain: a randomized controlled multicentre phase III trial. J. Neurooncol. 87, 299-307.
Nimsky, C., Ganslandt, O., Hastreiter, P., et al., 2007. Preoperative and intraoperative diffusion tensor imagingbased fiber tracking in glioma surgery. Neurosurgery 61, 178-185.
O'Neill, B.P., Iturria, N.J., Link, M.J., Pollock, B.E., Ballman, K.V., and O'Fallon, J.R., 2003. A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 55, 1169-1176.
Patchell, R.A., 2003. The management of brain metastases. Cancer Treat Rev. 29, 533-540.
Patchell, R.A., Tibbs, P.A., Walsh, J.W., et al., 1990. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 322, 494-500.
Patchell, R.A., Tibbs, P.A., Regine, W.F., et al., 1998. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280, 1485-1489.
Powell, J.W., Chung, C.T., Shah, H.R., et al., 2008. Gamma Knife surgery in the management of radioresistant brain metastases in high-risk patients with melanoma, renal cell carcinoma, and sarcoma. J. Neurosurg. 109, 122-128.
Rades, D., Panzner, A., Dziggel, L., Haatanen, T., Lohynska, R., and Schild, S.E., 2012. Dose-escalation of wholebrain radiotherapy for brain metastasis in patients with a favorable survival prognosis. Cancer 118, 3852-3859.
Sampson, J.H., Carter Jr., J.H., Friedman, A.H., and Seigler, H.F., 1998. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J. Neurosurg. 88, 11-20.
Schouten, L.J., Rutten, J., Huveneers, H.A., and Twijnstra, A., 2002. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94, 2698-2705.
Sherman, J.H., Hoes, K., Marcus, J., Komotar, R.J., Brennan, C.W., and Gutin, P.H., 2011. Neurosurgery for brain tumors: update on recent technical advances. Curr. Neurol. Neurosci. Rep. 11, 313-319.
Skeie, B.S., Skeie, G.O., Enger, P.O., et al., 2011. Gamma Knife surgery in brain melanomas: absence of extracranial metastases and tumor volume strongest indicators of prolonged survival. World Neurosurg. 75, 684-691.
Smalley, K.S., Sondak, V.K., 2010. Melanoma-an unlikely poster child for personalized cancer therapy. N. Engl. J. Med. 363, 876-878.
Sperduto, C.M., Watanabe, Y., Mullan, J., et al., 2008a. A validation study of a new prognostic index for patients with brain metastases: the Graded Prognostic Assessment. J. Neurosurg. 109, 87-89.
Sperduto, P.W., Berkey, B., Gaspar, L.E., Mehta, M., and Curran, W., 2008b. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int. J. Radiat. Oncol. Biol. Phys. 70, 510-514.

Staudt, M., Lasithiotakis, K., Leiter, U., et al., 2010. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br. J. Cancer 102, 1213-1218.
Vecht, C.J., Haaxma-Reiche, H., Noordijk, E.M., et al., 1993. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann. Neurol. 33, 583-590.
Wellbrock, C., and Hurlstone, A., 2010. BRAF as therapeutic target in melanoma. Biochem. Pharmacol. 80, 561-567.
Yu, C., Chen, J.C., Apuzzo, M.L., et al., 2002. Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int. J. Radiat. Oncol. Biol. Phys. 52, 1277-1287.
Zakrzewski, J., Geraghty, L.N., Rose, A.E., et al., 2011. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer 117, $1711-1720$.

# II. TREATMENT AND PROGNOSIS# The Risks and Advantages of Whole Brain Radiation Therapy in Patients with Brain Metastases 

Shivani Bassi, Alexander Engelman, Elizabeth Nichols and Young Kwok

## O U T L I N E

Brain Metastasis Overview
Clinical Presentation
Diagnosis/Prognosis
Medical Symptom Management
Whole Brain Radiotherapy
The Combination of Whole Brain
Radiotherapy and Local Therapy
(Surgery or Stereotactic
Radiosurgery)
Randomized Surgical Resection Trials

197
197
198
199
200

201

202

Local Therapy $\pm$ WBRT: Concluding Thoughts
201
201

209

Randomized Whole Brain
Radiotherapy $\pm$ Stereotactic
Radiosurgery Trials
Local Therapy (Surgery or Stereotactic
Radiosurgery) $\pm$ Whole Brain
Radiotherapy Trials
Local Therapy $\pm$ WBRT: Concluding
Thoughts
209

209

## BRAIN METASTASIS OVERVIEW

## Clinical Presentation

Brain metastasis occurs in approximately $25 \%$ of all cancer patients. The most common primary cancers include lung and breast cancers (Table 14.1) (Wen et al., 2001). Brain metastasis incidence has been rising and this may be attributed to systemic therapy advancementsTABLE 14.1 Epidemiology of Brain Metastasis (Wen et al., 2001)

| PRIMARY SITE |  |
| :-- | :-- |
| Lung | $50 \%$ |
| Breast | $15-20 \%$ |
| Other known primary | $10-15 \%$ |
| Unknown primary | $10-15 \%$ |
| Melanoma | $10 \%$ |
| Colon | $5 \%$ |
| RELEVANT FACTS |  |
| Median survival | $<1$ year |
| Mean age | 60 years |
| Annual US incidence | $>400,000$ |
| Autopsy incidence | $10-30 \%$ |
| Clinical incidence | $15-30 \%$ |
| Metastatic/primary ratio | $10: 1$ |

TABLE 14.2 Clinical Presentation of Brain Metastasis (Posner, 1996)

| Symptom | Percent of patients | Sign | Percent of patients |
| :-- | :-- | :-- | :-- |
| Headache | 49 | Hemiparesis | 59 |
| Mental problems | 32 | Cognitive deficits | 58 |
| Focal weakness | 30 | Sensory deficits | 21 |
| Ataxia | 21 | Papilledema | 20 |
| Seizures | 18 | Ataxia | 19 |
| Speech problems | 12 | Apraxia | 18 |

as well as accessibility to imaging tests such as magnetic resonance imaging (MRI). Headaches, mental problems, focal weaknesses are just a few of the commonly reported complications in patients with brain metastasis (Table 14.2) (Posner, 1996). These neurological symptoms should prompt the clinician to suspect brain metastasis in patients with known cancer although abscess or stroke should also be in the differential.

# Diagnosis/Prognosis 

Initially, computed tomography (CT) scan is typically performed to detect brain metastasis. However, MRI is considered the standard of care due to its high resolution, accuracyTABLE 14.3 RTOG Recursive Partitioning Analysis (Gaspar et al., 1997)

|  | KPS | Other criteria | Average survival |
| :-- | :-- | :-- | :-- |
| RPA class I | $>70$ | Age $<65$ <br> Controlled Primary <br> Brain Mets only | 7.1 months |
| RPA class II | Not meeting criteria <br> of class I or class III |  | 4.2 months |
| RPA class III | $<70$ | 2.3 months |  |

RTOG, Radiation Therapy Oncology Group; RPA, Recursive Partitioning Analysis.
and ability to detect small lesions in the brain which can often be undetectable on the CT scan. Positron emission tomography and CT scan are valuable tests used in a full work-up for brain metastasis.

The prognosis varies depending on the Karnofsky Performance Status (KPS) and extracranial disease status of patients. A study of 1200 patients by the Radiation Oncology Therapy Group (RTOG) reveals the median survival rates of patients in three recursive partitioning analysis (RPA) classes (Table 14.3) (Gaspar et al., 1997). Patients with RPA class I (KPS $\geq 70$, Age $<65$ years, controlled primary, brain metastasis only) had a median survival of 7.1 months while RPA class III (KPS $<70$ ) had a median survival of only 2.3 months. It is important to note that the Grade Prognostic Assessment (GPA) plays a significant role in assessing the prognosis of various cancers. It is a complicated system based on different prognostic factors such as age, KPS, number of metastatic lesions, and presence of extracranial metastases. Different cancers have different prognostic factors which determine the specific treatments that will benefit patients with intracranial metastasis (Sperduto et al., 2011).

# Medical Symptom Management 

## Corticosteroids

Symptomatic patients who are newly diagnosed with brain metastases should undergo initial therapy with corticosteroids such as dexamethasone. This can decrease inflammation and resultant peritumoral edema. Further, it can prevent serious complications such as brain herniation due to mass effect. Because of these antiinflammatory properties, corticosteroids have shown to improve performance status. Vecht and colleagues randomized two groups to two different doses of dexamethasone (Vecht et al., 1994). Both groups were evaluated with different doses of dexamethasone: the first group $(n=47)$ with $8 \mathrm{mg} /$ day versus $16 \mathrm{mg} /$ day initial dexamethasone doses, with tapering schedules over 4 weeks; the second group $(n=49)$ with $4 \mathrm{mg} /$ day versus $16 \mathrm{mg} /$ day over a 28 -day period before tapering. KPS improvements at 7 days and 28 days were $54-70 \%$ and $50-81 \%$, respectively. While all arms were statistically equivalent, this study suggested that the higher initial doses resulted in greater KPS improvements. Based on this study dexamethasone should be started at $2-4 \mathrm{mg}$ every $6-8 \mathrm{~h}$ before tapering in a judicious manner. Corticosteroids should not be in asymptomatic patients.# Anticonvulsants 

While still commonly used, no randomized trial has ever demonstrated an advantage to starting anticonvulsant therapy to prevent a seizure in someone who has never experienced one. Based on four negative randomized trials as well as serious side-effects associated with this class of medications, the American Academy of Neurology first published a consensus statement in 2000 that advises against the use of prophylactic anticonvulsants with patients newly diagnosed with brain tumor who have not experienced seizures (Glantz et al., 2000). It is safe to taper off this medication if the patient has not experienced a seizure.

## Whole Brain Radiotherapy

Whole brain radiotherapy (WBRT) is the current standard of care for patients with five or more brain metastasis. Several studies have explored the different dose and fractionation schedules (Table 14.4) (Graham et al., 2010; Haie-Meder et al., 1993; Murray et al., 1997;

TABLE 14.4 Selected Randomized Trials Examining Various Fractionation Schedules for Brain Metastasis

| Author/Study group [ref] | Dose/ <br> Fractions | N | Median survival | $P$-value |
| :--: | :--: | :--: | :--: | :--: |
| Borgelt/RTOG [4] |  |  |  |  |
| 1st Study (1971-3) | $30 \mathrm{~Gy} / 10$ | 233 | 21 wks | NS |
|  | $30 \mathrm{~Gy} / 15$ | 217 | 18 wks |  |
|  | $40 \mathrm{~Gy} / 15$ | 233 | 18 wks |  |
|  | $40 \mathrm{~Gy} / 20$ | 227 | 16 wks |  |
| 2nd Study (1973-6) | $20 \mathrm{~Gy} / 5$ | 447 | 15 wks | NS |
|  | $30 \mathrm{~Gy} / 10$ | 228 | 15 wks |  |
|  | $40 \mathrm{~Gy} / 15$ | 227 | 18 wks |  |
| Haie-Meder/French [12] (1986-9) | $25 \mathrm{~Gy} / 10$ | 110 | 4.2 mos | NS |
|  | $36 \mathrm{~Gy} / 6^{\mathrm{a}}$ | 106 | 5.3 mos |  |
| Priestman/Royal College [25] of radiology (1990-3) | $30 \mathrm{~Gy} / 10$ | 263 | 84 days | 0.04 |
|  | $12 \mathrm{~Gy} / 2$ | 270 | 77 days |  |
| Murray/RTOG 91-04 [20] (1991-5) | $30 \mathrm{~Gy} / 10$ | 213 | 4.5 mos | NS |
|  | $54.4 \mathrm{~Gy} / 34^{\text {b }}$ | 216 | 4.5 mos |  |
| Graham/Australia [11] (1996-2006) | $40 \mathrm{~Gy} / 20^{\mathrm{c}}$ | 57 | 6.1 mos | NS |
|  | $20 \mathrm{~Gy} / 4$ | 56 | 6.6 mos |  |

ref, reference number. NS, not significant; wks, weeks; mos, months; RTOG, Radiation Therapy Oncology Group.
${ }^{a} 18 \mathrm{~Gy} / 3$ split course with another $18 \mathrm{~Gy} / 3$ within 1 month.
${ }^{b} 54.4 \mathrm{~Gy}$ in 1.6 Gy BID hyperfractionation for the entire course of therapy.
${ }^{c} 40 \mathrm{~Gy}$ in 1.0 Gy BID hyperfractionation for the entire course of therapy.Borgelt et al., 1980). A total dose of 30 Gy in 10 fractions is the most common schedule. However, the decision of the fractionation for a given patient is very complex. Many factors must be considered, including KPS, histology, age, GPA, and RPA.

# Radiosensitizers 

While several have demonstrated improved response rates, no randomized trial has ever demonstrated a survival benefit to concurrent radiosensitizers and WBRT. Therefore, they should not be used outside of a clinical trial (Mehta et al., 2003).

## THE COMBINATION OF WHOLE BRAIN RADIOTHERAPY AND LOCAL THERAPY (SURGERY OR STEREOTACTIC RADIOSURGERY)

## Randomized Surgical Resection Trials

Surgical resection may immediately relieve significant mass effect. The utility of surgical resection in single brain metastasis has been tested in three phase III trials. These trials by Patchell et al. (1990), Noordijk et al. (1994), and Mintz et al. (1996) were conducted to assess the potential impact on overall survival of surgical resection with adjuvant WBRT versus WBRT alone on single brain metastasis. These studies are summarized in Table 14.5. Two of the three trials (Patchell and Noordijik) demonstrated an overall survival benefit to surgery plus WBRT versus WBRT alone. The initial performance status in the patients involved in the studies by Patchell et al. (1990) (KPS > 70) and Noordijk et al. (1994) (WHO < 2) were better than those participating in the study by Mintz et al. (1996) (KPS > 50). Based on these studies good KPS patients, with single brain metastasis causing significant complications, should undergo surgery since this can immediately relieve the mass effect.

## Randomized Whole Brain Radiotherapy $\pm$ Stereotactic Radiosurgery Trials

Stereotactic radiosurgery (SRS) can offer a safe alternative to most patients. The effectiveness of SRS has not been compared to surgical resection in a randomized trial; however it has been proven to result in excellent local control rates of $80-90 \%$ when used in conjunction with WBRT (Andrews et al., 2004). There have been three randomized trials performed that have assessed the effectiveness of WBRT + SRS boost versus WBRT alone (Table 14.6). Two of the trials are difficult to interpret. The Brown University study has never been published in manuscript form (Chougule et al., 2000). The University of Pittsburgh study was prematurely stopped due to poor accruel and used a nonstandard endpoint (i.e., any increase in lesion size on MRI) as measure of recurrence (Kondzioka et al., 1999).

The primary endpoint of overall survival in the third study, RTOG 95-08, was not statistically significant between WBRT + SRS and WBRT alone (Andrews et al., 2004). However, a planned subgroup analysis of patients with a single brain metastasis, and an unplanned subgroup analysis of patients with tumor sizes $>2 \mathrm{~cm}$, RPA class I, squamous/nonsmall cell lung cancer histologies, demonstrated that these patients benefitted from a survival advantage of SRS boost to WBRT.TABLE 14.5 Randomized Trials of Surgical Resection of Single Brain Metastasis

| Author/Study group [ref] | Surgery + RT | RT alone | $P$-value |
| :--: | :--: | :--: | :--: |
| PATCHELL/UNIVERSITY OF KENTUCKY $(N=48)[23]$ |  |  |  |
| Primary endpoint |  | ( $36 \mathrm{~Gy} / 12 \mathrm{fx}$ ) |  |
| Overall survival | 40 wks | 15 wks | $<0.01$ |
| Secondary endpoints |  |  |  |
| Local control |  |  |  |
| Local failure | $20 \%$ | $52 \%$ | $<0.02$ |
| Time to local failure | $>59 \mathrm{wks}$ | 21 wks | $<0.0001$ |
| Time to neurologic death | 62 wks | 26 wks | $<0.0009$ |
| KPS $\geq 70$ maintenance | 38 wks | 8 wks | $<0.005$ |
| NOORDIJK/DUTCH ( $N=63$ ) [21] |  |  |  |
| Primary endpoints |  | $(40 \mathrm{~Gy} / 20 \mathrm{fx})^{a}$ |  |
| Overall survival | 10 mos | 6 mos | 0.04 |
| FIS $^{1}$ | 7.5 mos | 3.5 mos | 0.06 |
| MINTZ/CANADIAN ( $N=84$ ) [18] |  |  |  |
| Primary endpoint |  | ( $30 \mathrm{~Gy} / 10 \mathrm{fx}$ ) |  |
| Overall survival | 5.6 mos | 6.3 mos | NS |
| Secondary endpoints |  |  |  |
| FIS (proportion of days, mean) ${ }^{2}$ | $32 \%$ | $32 \%$ | NS |
| Quality of life (Spitzer score) |  |  |  |
| $1-3$ mos (mean) | 6.38 | 5.36 | NS |
| $4-6$ mos (mean) | 6.32 | 6.15 | NS |

FIS, functionally independent survival as defined by:
${ }^{1}$ WHO performance status $\leq 1$ and neurological condition $\leq 1$.
${ }^{2} \mathrm{KPS} \geq 70$.
RT, whole brain radiotherapy; KPS, Karnofsky performance score; wks, weeks; mos, months;
fx, fraction number; ref, reference number.
${ }^{a} 40$ Gy total in 2 Gy BID hyperfractionation for the entire course of therapy.

# Local Therapy (Surgery or Stereotactic Radiosurgery) $\pm$ Whole Brain Radiotherapy Trials 

The use of WBRT combined with surgical resection or SRS continues to remain controversial. One retrospective study by Sneed and colleagues suggested the complete omission of WBRT after it did not compromise overall survival (Sneed et al., 1999). SecondaryTABLE 14.6 Randomized Trials of Stereotactic Radiosurgery Boost in Brain Metastases

| Author/Study group [ref] | RT + SRS | RT alone | SRS alone | $P$-value |
| :--: | :--: | :--: | :--: | :--: |
| ANDREWS/RTOG 95-08 ( $N=333 ; 1-3$ LESIONS) [1] |  |  |  |  |
| Primary endpoint (overall survival) |  | ( $37.5 \mathrm{~Gy} / 10 \mathrm{fx}$ ) |  |  |
| $1-3$ lesions | 5.7 mos | 6.5 mos |  | NS |
| Single brain metastasis (planned subgroup analysis) | 6.5 mos | 4.9 mos |  | 0.04 |
| Secondary endpoints |  |  |  |  |
| Local control (1 year) | $82 \%$ | $71 \%$ |  | 0.01 |
| Neurologic death rate | $28 \%$ | $31 \%$ |  | NS |
| Performance outcome |  |  |  |  |
| KPS stable/improve |  |  |  |  |
| at 3 mos | $50 \%$ | $33 \%$ |  | 0.02 |
| at 6 mos | $43 \%$ | $27 \%$ |  | 0.03 |
| Mental status |  |  |  | NS |
| Unplanned subgroup analysis (overall survival) |  |  |  |  |
| Largest tumor $>2 \mathrm{~cm}$ | 6.5 mos | 5.3 mos |  | 0.04 |
| RPA class I | 11.6 mos | 9.6 mos |  | 0.05 |
| Squamous/NSCLC | 5.9 mos | 3.9 mos |  | 0.05 |
| Other outcomes |  |  |  |  |
| Response rate (3 mos) |  |  |  |  |
| Tumor | $73 \%$ | $62 \%$ |  | 0.04 |
| Edema | $70 \%$ | $47 \%$ |  | 0.002 |
| KONDZIOLKA/UNIVERSITY OF PITTSBURGH ( $N=27 ; 2-4$ LESIONS) [14] |  |  |  |  |
| Primary endpoint |  | ( $30 \mathrm{~Gy} / 12 \mathrm{fx}$ ) |  |  |
| Local control (1-year) | $92 \%$ | $0 \%$ |  | 0.0016 |
| Time to local failure | 36 mos | 6 mos |  | 0.005 |
| Time to any brain failure | 34 mos | 5 mos |  | 0.002 |
| Secondary endpoints |  |  |  |  |
| Overall survival | 11 mos | 7.5 mos |  | NS |
| Treatment morbidity | 0 | 0 |  |  |
| Progression-free survival | not reported |  |  |  |
| Need for retreatment | not reported |  |  |  |TABLE 14.6 (Continued)

| Author/Study group [ref] | RT + SRS | RT alone | SRS alone | $P$-value |
| :-- | :-- | :-- | :-- | :-- |
| CHOUGULE/BROWN UNIVERSITY ( $N=109 ; 1-3$ LESIONS) [8] |  |  |  |  |
| Endpoints (abstract only) | $(30 \mathrm{~Gy}+20 \mathrm{~Gy}$ SRS) | $(30 \mathrm{~Gy} / 10 \mathrm{fx})$ | $(30 \mathrm{~Gy}$ SRS) |  |
| Overall survival | 5 mos | 9 mos | 7 mos | not reported |
| Local control | $91 \%$ | $62 \%$ | $87 \%$ | not reported |
| New brain lesions | $19 \%$ | $23 \%$ | $43 \%$ | not reported |

RT, whole brain radiotherapy; SRS, stereotactic radiosurgery; RPA, recursive partitioning analysis.NSCLC, nonsmall cell lung cancer; mos, months; NS, not significant; KPS, Karnofsky performance score.fx, fraction number; ref, reference number.
endpoints, such as local controls and local failures, were unfortunately not reported. Another retrospective study by Sneed again explored SRS alone without WBRT. Despite no difference statistically in overall survival, the study revealed that the SRS alone patients fared much worse tumor recurrence and brain disease progression rates (Sneed et al., 2002).

Further, treatment failures are often believed to be detected with follow-ups and close monitoring alone prior to any new onset of symptoms; however these methods have significant risks. Regine et al. (2002) observed 36 patients very closely after initial SRS without WBRT. It was found that even with very close follow-up exams and monitoring with MRI every 3 months, brain failure occurred in approximately $47 \%$ patients with $71 \%$ having symptomatic relapse and $59 \%$ having neurologic dysfunctions. There now have been six randomized studies that have evaluated the effectiveness of WBRT in conjunction with local therapy (surgery or SRS) versus local therapy alone. The results of each study are summarized in Table 14.7.

# Patchell/University of Kentucky (Surgery, Single Lesion) 

Patchell's study randomized 95 patients with single brain lesions into two groups: surgery with WBRT, and surgery alone. An MRI was used to monitor the progress of each patient postoperatively. The primary endpoint of this study was brain tumor recurrence at both original and distant sites, the results of which statistically favored the use of adjuvant WBRT therapy. It demonstrated that patients with surgery (craniotomy) and adjuvant WBRT experienced less total brain recurrences than those with surgery alone, $18 \%$ and $70 \%$, respectively. Secondary endpoint of neurologic cause of death also heavily favored WBRT (14\%) over surgery (44\%). Overall survival, a secondary endpoint, was not statistically different. Overall, this study demonstrated that the use of postoperative WBRT helps to prevent brain failure and neurologic death (Patchell et al., 1998).

## Muacevic/German (Surgery or SRS; 1 Lesion)

This study randomized patients to SRS alone (Gamma Knife) versus surgery and WBRT for those patients with a single brain lesion. However, the study was stopped prematurely due to poor patient accrual ( $n=70$ ). Eligibility was based on the following criteria: brainTABLE 14.7 Randomized Trials of Postoperative/Postradiosurgery Whole Brain Radiotherapy

| Study [ref] | Surgery + RT | Surgery only | $P$-value |
| :--: | :--: | :--: | :--: |
| PATCHELL/UNIVERSITY OF KENTUICKY ( $N=95$; SINGLE LESION) [22] |  |  |  |
| Primary endpoint | (50.4Gy/28 fx) | craniotomy |  |
| Total brain recurrence | $18 \%$ | $70 \%$ | $<0.001$ |
| Original site only | $4 \%$ | $33 \%$ |  |
| Distant site only | $8 \%$ | $24 \%$ |  |
| Original and distant | $6 \%$ | $13 \%$ |  |
| Distant site total | $14 \%$ | $37 \%$ | $<0.01$ |
| Original site total | $10 \%$ | $46 \%$ | $<0.001$ |
| Secondary endpoints |  |  |  |
| Cause of death |  |  |  |
| Neurologic | $14 \%$ | $44 \%$ | 0.003 |
| Systemic | $84 \%$ | $46 \%$ | $<0.001$ |
| Functional independence ${ }^{a}$ | 37 wks | 35 wks | NS |
| Overall survival | 48 wks | 43 wks | NS |
| AOYAMA/JAPANESE JROSG99-1 ( $N=132$; 1-4 LESIONS) [2] |  |  |  |
| Primary endpoint | (30Gy/10 fx) | SRS |  |
| Overall survival |  |  |  |
| 1-year ${ }^{b}$ | $39 \%$ | $28 \%$ | NS |
| Median | 7.5 mos | 8.0 mos | NS |
| Secondary endpoints |  |  |  |
| Brain recurrence (total) ${ }^{b}$ | $47 \%$ | $76 \%$ | $<0.001$ |
| Functional preservation ${ }^{\text {b,a }}$ | $34 \%$ | $27 \%$ | NS |
| Neurologic death | $23 \%$ | $19 \%$ | NS |
| Need for salvage therapy | 10 patients | 29 patients | $<0.001$ |
| Radiation morbidity |  |  |  |
| Acute | 4 patients | 8 patients | NS |
| Late | 7 patients | 3 patients | NS |

(Continued)TABLE 14.7 (Continued)

| Study [ref] | Surgery + RT | Surgery only | $P$-value |
| :--: | :--: | :--: | :--: |
| MUACEVICIGERMAN ( $N=70$; 1 LESION) [19] |  |  |  |
| Primary endpoint | (40Gy/20 fx) | SRS/craniotomy ${ }^{\mathrm{c}}$ |  |
| Overall survival | 9.5 mos | 10.3 mos | NS |
| Secondary endpoint |  |  |  |
| Brain recurrence |  |  |  |
| Local (1 yr) | $3.4 \%$ | $18 \%$ | 0.06 |
| Distant (1 yr) | $3 \%$ | $25.8 \%$ | 0.04 |
| KOCHERIEORTC 22952-26001 ( $N=359$; 1-3 LESIONS) [13] |  |  |  |
| Primary endpoint | (30Gy/10 fx) | SRS or craniotomy |  |
| Functional independence | 9.5 mos | 10 mos | NS |
| Secondary endpoints |  |  |  |
| Brain tumor recurrence |  |  |  |
| Original site—SRS | $19 \%$ | $31 \%$ | 0.040 |
| Distant site-SRS | $33 \%$ | $48 \%$ | 0.023 |
| Original site-S | $27 \%$ | $59 \%$ | $<0.001$ |
| Distant site-S | $23 \%$ | $42 \%$ | 0.008 |
| Progression-free survival | 4.6 mos | 3.4 mos | NS |
| Overall survival | 10.7 mos | 10.9 mos | NS |
| CHANGIMDACC ( $N=58$; 1-3 LESIONS) [7] |  |  |  |
| Primary endpoint | (30Gy/12 fx) | SRS |  |
| Neurocognitive function | $52 \%$ | $24 \%$ | significant |
| (HVLT-R drop) |  | ( $96 \%$ confidence) |  |
| Secondary endpoints |  |  |  |
| Local control (1 yr) | $100 \%$ | $67 \%$ | 0.012 |
| Distant brain control (1 yr) | $73 \%$ | $45 \%$ | 0.02 |
| Overall survival | 5.7 mos | 15.2 mos | 0.003 |
| BROWNINCCTG N0574 ( $N=213$; 1-3 LESIONS) [5] |  |  |  |
| Primary endpoint |  | (30Gy/12 fx) | SRS |
| Cognitive progression |  |  |  |
| (3 mos) | $91.7 \%$ | $63.5 \%$ | 0.0007 |
| (6 mos) | $97.9 \%$ | $77.8 \%$ | 0.032 |TABLE 14.7 (Continued)

| Study [ref] | Surgery + RT | Surgery only | $P$-value |
| :-- | :-- | :-- | :-- |
| Secondary endpoints |  |  |  |
| Local control (6mos) | $88.3 \%$ | $66.1 \%$ | Significant |
| (12mos) | $84.9 \%$ | $50.5 \%$ | Significant |
| Intracranial progression (3mos) | $6.3 \%$ | $24.7 \%$ | $<0.0001$ |
| (6mos) | $11.6 \%$ | $35.4 \%$ | $<0.0001$ |
| Overall survival | 7.5 mos | 10.7 mos | NS |

wks, weeks; Mos, months; yr, year; NS, not significant; KPS, Karnofsky performance score; RT, whole brain radiotherapy;
S, surgery; SRS, stereotactic radiosurgery; MDACC, MD Anderson Cancer Center; NCCTG, North Center Cancer Treatment Group; EORTC, European Organization for Research and Treatment of Cancer; ref, reference.
${ }^{a}$ As defined by KPS $\geq 70$ maintenance.
${ }^{b} 1$-year actuarial rates.
${ }^{c}$ SRS alone vs craniotomy + WBRT.
metastasis $<3 \mathrm{~cm}$, age $18-80$, KPS $>70$, stable systemic disease with 4 months life expectancy. Overall survival and local control was not significantly different between the groups although the distant brain recurrence was more frequently noted in the SRS alone group ( $P=0.04$ ) (Muacevic et al., 2008).

# Aoyama/Japanese JROSG99-1 (SRS; 1-4 Lesions) 

This study assessed neurocognitive function by means of MMSE in 110 patients with 1-4 brain lesions who were randomized between WBRT plus SRS versus SRS alone (Aoyama et al., 2006). The MMSE was both at baseline (prior to treatment) and post-SRS (Aoyama et al., 2007). There was no difference in overall survival. However, there was a significantly higher risk of total brain recurrences in the SRS alone arm. This translated in the significantly delayed MMSE deterioration in the WBRT plus SRS arm ( 15.8 month vs 7.5 months, $P=0.05$ ). Volume greater than 3 cm and peritumoral edema were significant factors that caused changes to the MMSE scores. This study concluded that the tumor control is essential in brain metastasis patients to prevent cognitive decline.

## Chang/MDACC (SRS; 1-3 Lesions)

This study evaluated 58 people with 1-3 lesions, who were randomized to SRS alone and SRS in combination with WBRT ( $30 \mathrm{~Gy} / 12 \mathrm{fx}$ in daily fractions of $2.5 \mathrm{~Gy} /$ day) to assess a primary endpoint of neurocognitive function which was evaluated by the Hopkins Verbal Learning Test-Revised (HVLT-R) total recall at 4 months (drop of five points). Secondary endpoints included local control, distant brain control, and overall survival. Follow-ups were performed with neurological examination, brain MRI, neurocognitive, and quality of life assessments. The WBRT + SRS had significantly better local ( $100 \%$ vs $67 \%, P=0.012$ )and distant ( $73 \%$ vs $45 \%, P=0.02$ ) tumor control. However, the overall survival was noted to be significantly higher in the SRS alone arm compared to the combination arm (15.2 months vs 5.7 months, $P=0.003$ ). The trial was halted by the data monitoring committee who observed a substantial decline in the HVLT-R in the combination arm ( $52 \%$ ) versus those treated with SRS alone ( $24 \%$ ) (Chang et al., 2009).

There are several criticisms of this study (Mahmood et al., 2010). First, there was no established baseline in neurocognition, a primary endpoint, of the patients to identify major changes. Second, the study only used one test to assess neurocognition when ideally a whole battery of tests should be used to evaluate such a complex factor. Lastly, the studies mentioned earlier demonstrate equivalent survival rates with the addition of WBRT to therapies such as SRS and surgery whereas this study concludes with an improbably shorter survival in the combination arm. This study is the first brain metastasis research ever published to demonstrate that worse brain control leads to a better survival outcome. It is possible that improper or inadequate randomization led to this inexplicable finding.

# Kocher/EORTC 22952-26001 (Surgery or SRS; 1-3 Lesions) 

This phase III trial was performed to assess the duration of functional independence with adjuvant WBRT in patients with 1-3 brain lesions who have previously undergone SRS or surgery. Results revealed that overall survival and duration of functional independence in both arms were similar. However, patients who had undergone WBRT after surgery and SRS, had decreased 2-year recurrence rates at initial sites from 59 to $27 \%$ and 31 to $19 \%$ $(P=0.04)$, respectively, and at new sites from 42 to $23 \%$ and 48 to $33 \%(P=0.023)$, respectively. Patients in the WBRT arm of the study required less intracranial salvage therapies. There were three areas that possibly explain the failure of improvement of functional independence duration and overall survival with WBRT. These factors include the subjective grading of the WHO PS scale, the routine use of MRI to detect asymptomatic recurrences, and systemic treatments for brain metastasis that could negatively affect functional status despite initial therapy (Kocher et al., 2011).

## Brown/NCCTG N0574 (SRS; 1-3 Lesions)

The earlier studies have provided level I evidence that adjuvant WBRT after local therapy improves local and distant brain control; however, the preservation of neurocognitive function posttreatment still remains a question. The studies by Aoyama et al. (2006) (MMSE only) and Chang et al. (2009) (HVLT-R only) have been criticized for not including a more thorough neurocognitive battery of tests. These two studies have come to an opposite conclusion regarding the effects of WBRT and, therefore, are difficult to interpret. The NCCTG N0574 included a much more thorough battery of tests.

This study randomized 213 patients to two groups: SRS versus SRS with adjuvant WBRT. The primary endpoint was cognitive progression at 3 months after initial treatment with SRS. Eligible patients had 1-3 metastatic brain lesions $<3 \mathrm{~cm}$, WHO performance status $0-2$, no chemotherapy radiation therapy, and no leptomeningeal disease. Brown defined a decrease in one standard deviation in one cognitive test as cognitive progression. A full neurocognitive battery (HVLT, TMT Part A, TMT Part B, COWA, and GP-D) was established to measure baseline cognitive function and later changes. This study met its primary endpointof cognitive progression at 3 months, with lower rates of cognitive decline in the SRS alone arm HVLT Total Recall ( $P=0.0043$ ), HVLT Delayed Recall ( $P=0.0009$ ), and COWA $(P=0.0098)$ (Brown, 2015).

Secondary endpoints include overall survival which was equivalent in both arms, and total brain failure at 3 months (SRS $24.7 \%$ vs SRS + WBRT $6.3 \%, P<0.0001$ ) and 6 months (SRS $35.4 \%$ vs SRS + WBRT $11.6 \%, P<0.0001$ ) to be significantly lower with the combination arm. The study concludes that although adjuvant WBRT improves brain tumor control, the quality of life, functional well-being, and neurocognitive function are all compromised after WBRT.

# LOCAL THERAPY $\pm$ WBRT: CONCLUDING THOUGHTS 

Whether to add WBRT after local therapy (surgery or SRS) continues to remain controversial. Five of the six trials demonstrated equivalent overall survivals and all of the trials demonstrated superior brain controls with WBRT. Controversy arises from the implication of WBRT on neurocognition. Two trials demonstrate superior outcomes with WBRT (Patchell et al., 1990; Aoyama et al., 2006, 2007) and two trials demonstrate its negative impact (Chang et al., 2009; Brown, 2015) on neurocognition. Regarding the potential neurocognitive outcome, the competing risks are harms from WBRT versus tumor recurrence (Lassman, 2015).

In the trial with the most complete neurocognitive battery (Brown, 2015), the SRS alone arm had superior neurocognitive outcomes despite a worse brain control. Therefore, for patients with 1-3 brain metastases, it is very reasonable to do SRS alone up front without WBRT. However, this recommendation should not be carried to patients with four or more lesions since both the Chang and Brown studies only included patients with 1-3 lesions. Further, the patients treated with SRS alone have a higher brain failure rate and, thus, they need to be followed closely with clinical and MRI exams every 2-3 months (NCCN, 2015).

## References

Andrews, D.W., Scott, C.B., Sperduto, P.W., et al., 2004. Whole brain radiation therapy with and without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomized trial. Lancet $363,1665-1672$.
Aoyama, H., Shirato, H., Tago, M.K., et al., 2006. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases. JAMA 295, 2483-2491.
Aoyama, H., Tago, M., Kato, N., et al., 2007. Neurocognitive function in patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int. J. Radiat. Oncol. Biol. Phys. 68, 1388-1395.
Borgelt, B., Gelber, R., Kramer, S., et al., 1980. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 6, 1-9.
Brown, P.D., 2015. NCCTG N0574 (Alliance): a phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. 2015 ASCO Annual Meeting.
Chang, E.L., Wefel, J.S., Hess, K.R., et al., 2009. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomized controlled trial. Lancet Oncol. 10, $1037-1044$.Chougule, P.B., Burton-Williams, M., Saris, S., et al., 2000. Randomized treatment of brain metastases with Gamma Knife radiosurgery, whole brain radiotherapy or both. Int. J. Radiat. Oncol. Biol. Phys. 48, 114-119.
Gaspar, L., Scott, C., Rotman, M., et al., 1997. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int. J. Radiat. Oncol. Biol. Phys. 37, 745-751.
Glantz, M., Cole, B., Forsyth, P., et al., 2000. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: report of the quality standards subcommittee of the American Academy of Neurology. Neurology 54, 1886.
Graham, P.H., Bucci, J., and Browne, L., 2010. Randomized comparison of whole brain radiotherapy, 20 Gy in four daily fractions versus 40 Gy in 20 twice-daily fractions, for brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 77, $648-654$.
Haie-Meder, C., Pellae-Cosset, B., Laplanche, A., et al., 1993. Results of a randomized clinical trial comparing two radiation schedules in the palliative treatment of brain metastases. Radiother. Oncol. 26, 111-116.
Kocher, M., Soffietti, R., Abacioglu, U., et al., 2011. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J. Clin. Oncol. 29, 134-141.
Kondzioka, D., Patel, A., Lunsford, L.D., et al., 1999. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 45, 427-434.
Lassman, A.B., 2015. Whole Brain Radiotherapy (WBRT) for Brain Metastases (BM): the changing landscapes. 2015 ASCO Annual Meeting.
Mahmood, U., Kwok, Y., Regine, W., et al., 2010. Whole-brain irradiation for patients with brain metastases: still the standard of care. Lancet Oncol. 11, 221-222.
Mehta, M.P., Rodrigus, P., Terhaard, C.H., et al., 2003. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J. Clin. Oncol. 21, 2529-2536.
Mintz, A.H., Kestle, J., Rathbone, M.P., et al., 1996. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 78, 1470-1476.
Muacevic, A., Wowra, B., Siefert, A., et al., 2008. Microsurgery plus whole brain irradiation versus Gamma Knife surgery alone for treatment of single metastases to the brain: a randomized controlled multicentre phase III trial. J. Neurooncol. 87, 299-307.
Murray, K.J., Scott, C., Greenberg, H.M., et al., 1997. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104. Int. J. Radiat. Oncol. Biol. Phys. 39, 571-574.
NCCN Clinical Practice Guidelines in Oncology, 2015. Central nervous system cancers. V.2.2014. Available at: <www.ncen.org/professionals/physician_gls/PDF/cns.pdf>. (accessed 18.08.15).
Noordijk, E.M., Vecht, C.J., Haaxma-Reiche, H., et al., 1994. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int. J. Radiat. Oncol. Biol. Phys. 29, 711-717.
Patchell, R.A., Tibbs, P.A., Walsh, J.W., et al., 1990. A randomized trial of surgery in the treatment of single metastases to the brain. N. Eng. J. Med. 322, 494-500.
Patchell, R.A., Tibbs, P.A., Regine, W.F., et al., 1998. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280, 1485-1489.
Posner, J.B., 1996. Brain metastases: 1995. A brief review. J. Neurooncol. 27, 287-293.
Priestman, T.J., Dunn, J., Brada, M., et al., 1996. Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clin. Oncol. (R. Coll. Radiol.) 8, $308-315$.
Regine, W.F., Huhn, J.L., Patchell, R.A., et al., 2002. Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: results and implications. Int. J. Radiat. Oncol. Biol. Phys. 52, 333-338. Erratum in: Int. J. Radiat. Oncol. Biol. Phys. 53: 259.

Sneed, P.K., Lamborn, K.R., Forstner, J.M., et al., 1999. Radiosurgery for brain metastases: is whole brain radiotherapy necessary? Int. J. Radiat. Oncol. Biol. Phys. 43, 549-558.
Sneed, P.K., Suh, J.H., Goetsch, S.J., et al., 2002. A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int. J. Radiat. Oncol. Biol. Phys. $53,519-526$.Sperduto, P.W., Kased, N., Roberge, D., et al., 2011. Summary report on graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J. Clin. Oncol. 38, 1-7.
Vecht, C.J., Hovestadt, A., Verbiest, H.B., et al., 1994. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4,8 , and 16 mg per day. Neurology 44, $675-680$.
Wen, P.Y., McLaren, B.P., and Loeffler, J.S., 2001. Treatment of metastatic cancer. In: DeVita, V.T., Hellman, S., Rosenberg, S.A. (Eds.), Cancer: Principles and Practice of Oncology Lippincott Williams and Wilkins, Philadelphia, PA, pp. 2655-2670.# Gastrointestinal Stromal Tumors with Intracranial Metastasis: Treatment Strategy and Review of the Literature 

Toshihide Tanaka

## O U T L I N E

Introduction
Clinical Features of GISTs
Neuroradiological Findings
Histopathological Findings of GISTs
Genetic Diagnosis of GISTs
213 Treatment Strategy and Clinical
214
214
217
218

Outcome
Surgery
Radiation
Chemotherapy
Treatment Outcomes
References

## INTRODUCTION

Gastrointestinal stromal tumors (GISTs) are rare mesenchymal neoplasms that arise from precursors of the gastrointestinal tract connective tissue. Approximately $70 \%$ of GISTs are located in the stomach, $20 \%$ in the small bowel, and $5 \%$ in the rectum (Miettinen et al., 2002). Stromal tumors belong to the leiomyosarcoma or leiomyoma group. GISTs arise from precursors of the intestinal cells of Cajal (Chen et al., 2002). Clinically, GISTs are usually diagnosed based on KIT (CD117) expression using immunohistochemical analysis (Hirota et al., 1998). The gain-of-function of c-kit or platelet-derived growth factor receptor alpha (PDGFRA) plays a critical oncogenic role in GISTs (Hirota et al., 1998; Heinrich et al., 2003a). Approximately $70 \%$ of mutations in c-kit are detected in exon 11, particularly in![img-74.jpeg](img-74.jpeg)

FIGURE 15.1 Structure of KIT and platelet-derived growth factor receptor $\alpha$ (PDGFA). The locations of gastrointestinal stromal tumor (GIST)-associated kinase mutations are shown. ATP, adenosine triphosphate.
the $5^{\prime}$ end (Fig. 15.1). The mutational status of $c$-kit is often predictive of the clinical response to imatinib mesylate (Heinrich et al., 2003b). Imatinib mesylate is a competitive inhibitor of multiple tyrosine kinases, including KIT and PDGFRA, and its clinical effectiveness for advanced GISTs has been documented (Demetri et al., 2002).

Most metastases occur in the liver and peritoneum as a result of hematogenous spread and peritoneal seeding. Metastatic GISTs to the central nervous system (CNS) are very rare. Most intracranial metastases are treated surgically with or without additional radiotherapy. Imatinib mesylate is believed to be ineffective for brain metastases because it cannot pass through the blood-brain-barrier (BBB) and does not achieve adequate levels in the brain when administered in lower concentrations (Petzer et al., 2002). Therefore, current clinical practice guidelines recommend surgical resection as a first priority. Adjuvant therapy is considered an option for patients with a substantial risk of relapse (Casali et al., 2010).

According to a PubMed database and literature search, 15 cases of brain metastases from primary GISTs have been reported to date. The list of GISTs in the CNS and their clinical features are given in Table 15.1. Here, we summarize and review the relevant literature regarding intracranial metastasis of GISTs.

# CLINICAL FEATURES OF GISTs 

## Neuroradiological Findings

Common radiological features of GIST metastases include a round mass located in the subcortex, which is occasionally accompanied by perifocal edema, which resemblesTABLE 15.1 List of Published Cases of Metastatic Gastrointestinal Stromal Tumors (GISTs) in the Central Nervous System

| Metastatic GISTs in the central nervous system |  |  |  |  |  |  |  |  |  |  |  |  |
| :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: |
| No. | Age (years) | Sex | Site | Size (cm) | Systemic metastasis | CNS |  | Interval between diagnosis of primary and diagnosis of CNS metastasis | Treatment for CNS tumor | Mutational status | Survival prognosis after diagnosis of CNS metastasis | References |
| 1 | 75 | M | Mesentery | ND | Liver | Both hemispheres | Infiltrative | 14 months | Imatinib $800 \mathrm{mg} /$ day | NA | CR <br> (4 months) | Brooks et al. (2002) |
| 2 | 70 | M | Stomach | $3.5 \times 3$ | Lung | Left occipital lobe | 5.5 | 10 years | Total resection, radiation | NA | 8 months | Inage et al. (2002) |
| 3 | 47 | M | Jejunum | 7.5 | Liver | Left parasagittal | ND | 25 months | Total resection, imatinib $800 \mathrm{mg} /$ day | KIT <br> (exon 9) | 35 months | Hughes et al. (2004) |
| 4 | 60 | M | Small intestine | ND | Lumbosacral vertebrae (L5-S1) | Left cavernous sinus | ND | 7 years | Radiation (54Gy) | NA | 8 months | Akiyama et al. (2004) |
| 5 | 76 | M | Duodenum \& jejunum | 4 | ND | Right parietal, rightcerebellar hemisphere | 2 | 4 months | Imatinib $400 \mathrm{mg} /$ day, radiation(40Gy) | No mutation in KIT (exon 11) | 4 months | Kajikawa et al. (2005) |
| 6 | 68 | F | Perisacral | ND | ND | Right parietal lobe | 3 | 2 years | Total resection, imatinib $800 \mathrm{mg} /$ day | NA | CR | Kaku et al. (2006) |
| 7 | 42 | M | Mesentery | $8 \times 6$ | ND | Right parietal lobe | 3.5 | Mesentery lesion later discovered | Total resection, radiation (60Gy), imatinib $600 \mathrm{mg} /$ day | NA | 10 months | Puri et al. (2006) |
| 8 | 45 | M | Small intestine | ND | ND | Pontomedullary junction, cerebellum, leptomeningeal | 2 | 5 years | Imatinib $800 \mathrm{mg} /$ day | NA | 2 months | Gerin et al. (2007) |TABLE 15.1 (Continued)

| Metastatic GISTs in the central nervous system |  |  |  |  |  |  |  |  |  |  |  |  |
| :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: |
| No. | Age <br> (years) | Sex | Site | Size (cm) | Systemic metastasis | Site | Size (cm) | Interval between diagnosis of primary and diagnosis of CNS metastasis | Treatment for CNS tumor | Mutational status | Survival prognosis after diagnosis of CNS metastasis | References |
| 9 | 49 | F | Mesentery | ND | Liver | Left eye, brain | 0.24 | 3 years | Imatinib $400 \mathrm{mg} /$ day | NA | 9 months | Gentile et al. (2008) |
| 10 | 54 | F | Esophagus | $11 \times 7$ | Liver | Left frontal lobe | 5 | 6 years | Total resection, imatinib $400 \mathrm{mg} /$ day, SRT | KIT <br> (exon 11) | CR <br> (6 months) | Hamada et al. (2010) |
| 11 | 77 | M | Jejunum | 3 | ND | Right cerebral peducle, left occipital lobe | $\begin{aligned} & 2.4 \\ & 2.2 \end{aligned}$ | Jejunum lesion later discovered | Total resection, radiation (39Gy), imatinib $400 \mathrm{mg} /$ day | No <br> mutation <br> in KIT <br> (exon 11, <br> 13, 17, 19), | 4 months | Naoe et al. (2011) |
| 12 | 26 | M | Duodenum | $6 \times 5.4$ | Liver | Left frontotemporal | $6.1 \times 4.1$ | 6 years | Total resection, radiation | NA | CR <br> (4 months) | Wong and Chu (2011) |
| 13 | 15 | M | Stomach | 2.8 | Liver | Right frontoparietal | $4.2 \times 3.3$ | 12 years | Total resection, sorafenib $800 \mathrm{mg} /$ day, sunitinib $37.5 \mathrm{mg} /$ day | No <br> mutation <br> in KIT <br> (exon 9, 11, <br> 13, 17), and <br> PDGFR $\alpha$ <br> (exon 12, <br> 14, 18) | CR <br> (6 months) | Jagannathan et al. (2012) |
| 14 | 74 | M | Jejunum | 5 | Liver | Right prefrontal gyrus | $1.5 \times 1.4$ | 6 years | Sunitinib $50 \mathrm{mg} /$ day, SRS | NA | CR <br> (9 months) | Takeuchi et al. (2013) |
| 15 | 57 | M | Stomach | ND | ND | Left cerebellar, left frontal | 3 | 13 months | Total resection, SRS (18Gy) | NA | CR <br> (15 months) | Drazin et al. (2013) |

CR, complete remission; F, female; M, male; NA, not analyzed; ND, not described; SRS, stereotactic radiosurgery; SRT, stereotactic radiotherapy.![img-75.jpeg](img-75.jpeg)

FIGURE 15.2 Magnetic resonance imaging (MRI) of the metastatic gastrointestinal stromal tumors (GISTs). The tumor was attached to the dura. T1-weighted MRI revealing iso-low intensity in the right frontoparietal lobe (A) with homogenous enhancement by gadolinium-diethylenetriaminepenta-acetic acid in axial (B) and coronal (C). T2-weighted MRI revealing a low intensity with expanding perifocal edema (D). Reproduced from Kaku S, Tanaka T et al., Neurol Med Chir 46:255, 2006. With permission.
meningioma. Typical magnetic resonance imaging shows an isointense T1-weighted and iso- and low intense T2-weighted lesion and homogenous enhancement after gadolinium injection (Fig. 15.2). Rarely, ring enhancement of gadolinium or intratumoral hemorrhages has been noted in intracranial metastatic GISTs (Hamada et al., 2010; Jagannathan et al., 2012).

# Histopathological Findings of GISTs 

Histopathological findings show a tumor with spindle-shaped cells arranged in cords, knitted, and whirlpool patterns that is occasionally accompanied by necrosis and mitoticcells. Tumor cells have abundant cytoplasm and fusiform nuclei. Immunohistochemistry is needed to obtain an accurate diagnosis for determining the appropriate treatment. In general, immunohistochemical analysis is positive for c-kit (CD117), CD34, alpha smooth muscle actin, and vimentin, and negative for desmin, S-100, glial fibrillary acidic protein, neuron-specific enolase, and neurofilament. c-kit in particular is thought to be a specific marker for diagnosis of GISTs.

Puri et al. (2006) described a patient with a mesenteric sarcoma that initially failed to be treated with ifosfamide and epirubicin combination chemotherapy. As histopathology revealed a sarcoma that was positive for c-kit, CD34, and vimentin, the patient was treated with imatinib mesylate, resulting in a reduction in tumor size (Puri et al., 2006). In the present series of intracranial metastatic GISTs, c-kit was positive in almost all tumors. However, expression levels of CD34 and S-100 were different (Table 15.2). No evidence of differences in immunohistochemical findings was found between primary and intracranial metastatic lesions. Finally, tumors with mitotic activity counts exceeding 5 per 50 high-power fields, necrosis, or tumors longer than 5 cm have a high frequency of recurrence and metastasis. In contrast, tumors smaller than 2 cm and those with mitotic activity counts less than 5 per 50 high-power fields are likely to be benign (Miettinen et al., 2002).

# Genetic Diagnosis of GISTs 

Most GISTs constitutively express the activated mutant isoform of KIT kinase or PDGFRA kinase. Mutation in exon 9 , which encodes the extracellular domain, occurs in approximately $15 \%$ of GISTs and includes duplication of $\mathrm{Ala}^{502}$ and $\mathrm{Tyr}^{503}$. These mutations may be a marker for a malignant course of the disease as $71 \%$ of patients with such mutations show a highly malignant course, and $59 \%$ arise exclusively from the small intestine (Miettinen et al., 2002). Recent studies have established that activating mutations in exon $9,11,13$, or 17 of KIT are present in up to $88.2 \%$ of GISTs and likely play a fundamental role in the development of these tumors. Heinrich et al. (2003b) reported that the most common type of mutation is an in-frame deletion of a portion of the juxtamembrane domain (exon 11). The second most common mutation type is an in-frame duplication of nucleotides in exon 9 of KIT. The presence of an exon 11 KIT mutation is the strongest prognostic factor that reduces the risk of adverse clinical events. Less frequently, primary mutations in the adenosine triphos-phate-binding pocket (exon 13) or activation loop (exon 17) are found (Corless et al., 2002; Heinrich et al., 2003b) (Fig. 15.1). Patients with tumors that express an exon 11 mutant KIT isoform show better survival compared with patients with tumors that express an exon 9 mutant KIT isoform or tumors with no detectable mutation of KIT or PDGFRA. A significant difference in survival in favor of the KIT exon 9 mutation subgroup is observed compared with patients with no detectable KIT or PDGFRA mutation. KIT oncoproteins encoded by exon 9 and exon 11 mutations are equally sensitive to imatinib mesylate. However, patients with exon 9 mutations also have a much worse prognosis than those with the more commonly found exon 11 mutations (Heinrich et al., 2003b).

Primary PDGFRA mutations in the juxtamembrane domain (exon 12), the first tyrosine kinase domain (exon 14), and the activation loop (exon 18) are also associated with the pathogenesis of GISTs in a 5-7\% of cases (Cassier et al., 2012; Corless et al., 2005) (Fig. 15.1).TABLE 15.2 Histochemical Findings of Metastatic Gastrointestinal Stromal Tumors (GISTs) in the Central Nervous System

|  |  | Histochemical analysis |  |  |  |  |  |  |  |  |
| :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: |
| No. | References | c-kit <br> (CD117) | CD34 | Vimentin | $\alpha$-SMA | Desmin | S-100 | Cytokeratin | EMA | GFAP |
| 1 | Brooks et al. (2002) | $+$ | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 2 | Inage et al. (2002) | N/A | $+$ | $+$ | $+$ | N/A | - | - | - | N/A |
| 3 | Hughes et al. (2004) | $+$ | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 4 | Akiyama et al. (2004) | $+$ | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 5 | Kajikawa et al. (2005) | $+$ | - | $+$ | - | - | - | N/A | N/A | N/A |
| 6 | Kaku et al. (2006) | $+$ | $+$ | N/A | $+$ | N/A | N/A | N/A | N/A | N/A |
| 7 | Puri et al. (2006) | $+$ | $+$ | N/A | $+$ | - | $+$ | N/A | N/A | N/A |
| 8 | Gerin et al. (2007) | $+$ | $+$ | N/A | $+$ | - | $+$ | N/A | N/A | N/A |
| 9 | Gentile et al. (2008) | $+$ | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 10 | Hamada et al. (2010) | $+$ | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 11 | Naoe et al. (2011) | $+$ | - | N/A | N/A | - | - | N/A | N/A | N/A |
| 12 | Wong and Chu (2011) | $+$ | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 13 | Jagannathan et al. (2012) | $+$ | N/A | N/A | N/A | N/A | N/A | N/A | - | - |
| 14 | Takeuchi et al. (2013) | $+$ | $+$ | N/A | $+$ | - | - | N/A | N/A | N/A |
| 15 | Drazin et al. (2013) | $+$ | $+$ | N/A | - | N/A | N/A | N/A | N/A | - |

EMA, epithelial membrane antigen; GFAP, glial fibrillary acidic protein; N/A, not analyzed; $\alpha$-SMA, alpha smooth muscle actin.These data provide strong evidence of a mechanistic link between expression of an imatinib-sensitive mutant KIT or PDGFRA kinase in GISTs and the clinical response to imatinib.

In the present series of intracranial metastatic GISTs, the mutational status was investigated in 5 out of 15 cases. Mutation in exon 9 and 11 of KIT was detected in one case. No mutation in KIT was found in three cases, and PDGFRA mutation was found in one case. The prognostic significance of KIT or PDGFRA mutations remains controversial for intracranial metastatic GISTs. As given in Table 15.1, the survival prognosis after diagnosis of CNS metastasis in patients without KIT mutation was only 4 months, whereas patients with KIT exon 9 and exon 11 mutations have a more favorable survival prognosis ( 35 months).

# TREATMENT STRATEGY AND CLINICAL OUTCOME 

## Surgery

The current clinical practice guidelines recommend surgical resection for limited disease, especially cortical or subcortical lesions, and adjuvant therapy as an option for patients with a substantial risk of relapse (Casali et al., 2010). Tumor size ( $>5 \mathrm{~cm}$ ) is a prognostic factor for aggressive behavior of GISTs. Surgical treatment is essential to decrease the tumor burden. The aim of surgery is to reduce the tumor volume to provide a cure and to confirm the histopathological diagnosis. Total resection of the tumor is expected to lead to a favorable outcome and prolonged survival.

The advantages of surgery for intracranial metastasis are as follows. Most intracranial metastatic GISTs are located in subcortical regions (Fig. 15.2), which are easy to access for surgery. The boundary between the tumor and the normal brain parenchyma is usually obvious. In the present series, nine patients were treated for intracranial metastasis of GISTs with surgical resection, and good survival outcomes were documented compared with patients treated without surgery (median overall survival: 14.3 vs 5.8 months). Two patients who were treated with surgery and subsequent radiation therapy and two patients who were treated with surgery and subsequent chemotherapy experienced no recurrence (Drazin et al., 2013; Jagannathan et al., 2012; Wong and Chu, 2011; Hamada et al., 2010), whereas patients undergoing surgery alone required a reoperation for recurrence (Hughes et al., 2004; Kaku et al., 2006). These clinical findings suggest that postoperative adjuvant therapy in addition to surgical treatment for intracranial GISTs may be necessary.

## Radiation

The effectiveness of radiation therapy for GISTs has not been proven (De Matteo et al., 2000). GISTs are considered "radioresistant" tumors due to their histological relationship to soft tissue sarcomas, which have a relatively poor responsiveness to radiation therapy. In addition, the increased risk of high-grade dermatologic and mucosal toxicity when other targeted tyrosine kinase inhibitors are used with radiation therapy often precludes physicians from recommending concurrent treatment (Tejwani et al., 2009).

Cuaron et al. (2013) described the importance of radiation therapy for the management of locally advanced and metastatic GISTs. In a series of 18 patients who were treated withradiation therapy, the estimated 6-month local progression-free survival and overall survival were $57.0 \%$ and $57.8 \%$, respectively. Among symptomatic tumors, at least partial palliation was achieved in 17 ( $94.4 \%$ ), and symptoms were completely alleviated in eight ( $44 \%$ ). They concluded that radiation therapy can provide both objective responses and symptomatic relief without detracting dramatically from quality of life, and should be considered in the multidisciplinary care of patients with locally advanced or metastatic GISTs. They insisted that the use of radiation therapy achieves a high degree of palliation with minimal toxicity in heavily pretreated patients with GISTs.

In the current series of GISTs with CNS metastasis, 8 of 15 cases were treated with radiation. In most cases, radiation therapy was used as a concurrent adjuvant therapy. In one case, radiotherapy alone was used to treat metastatic GISTs in the cavernous sinus around the root of the optic nerve, a location that is difficult to access surgically. Partial relief of pain without visual improvement was obtained. The correlation between radiosensitivity and the genetic status has not been investigated, and two cases of intracranial GISTs without mutation in KIT, which were considered to be resistant to imatinib mesylate, were treated with radiotherapy (Naoe et al., 2011; Kajikawa et al., 2005). Radiotherapy may be applicable in patients with unresectable or chemoresistant tumors as described above. Although radiation therapy is not a standard therapy for GISTs, radiotherapy may be effective for controlling refractory residual tumors. The other application may be patients with GISTs that develop imatinib resistance. For selected patients with focally progressive or invasive disease, intensive radiation therapy, such as microplanar beam radiation therapy or photon therapy, may provide palliation pain control and durable freedom from progression.

# Chemotherapy 

Unresectable or metastatic GIST is a fatal disease that is resistant to conventional cytotoxic chemotherapy. Advanced GISTs are also unresponsive to conventional chemotherapy. The development of molecular-targeted anticancer agents has provided a novel approach to the treatment of patients with GIST. GISTs express the cell-surface transmembrane receptor KIT, which has tyrosine kinase activity and is the protein product of the KIT protooncogene. Frequent gain-of-function mutations in KIT are seen in GISTs.

Imatinib mesylate is an orally administered selective inhibitor of tyrosine kinases of the transmembrane receptors KIT, PDGFRA, intracellular Abelson (ABL) kinase, and the chimeric break point cluster-Abelson (BCR-ABL) fusion oncoprotein of chronic myeloid leukemia (Druker et al., 1996; Buchdunger et al., 2000; Heinrich et al., 2000; Demetri et al., 2002). In experiments with human cell lines that are dependent on the KIT pathway, exposure of GISTs to imatinib mesylate blocks the kinase activity of KIT, arrests proliferation, and causes apoptotic cell death (Heinrich et al., 2000; Tuveson et al., 2001). The relationship between mutations in kinases and the clinical response to imatinib has been investigated in patients with advanced GISTs. The mutational status of KIT and PDGFRA is a predictor of the clinical response to imatinib in patients with metastatic GISTs (Heinrich et al., 2003b). These studies emphasize that molecular subclassification of GISTs is crucial in the design and interpretation of clinical trials and in identifying patients who are at high risk for early treatment failure.

All reported GISTs with intracranial metastasis show a poor treatment response to imatinib mesylate for both systemic and regional cerebral lesions. The interval between diagnosis of theprimary tumor and diagnosis of CNS metastasis is quite long in most cases, suggesting that GISTs initially respond to imatinib treatment, and in those with a cranial relapse, the systemic disease was initially controlled. The most important reason is that the CNS provides a site for tumor cells to escape drug therapy because imatinib cannot pass through the BBB and does not achieve adequate levels in the CNS when lower concentrations of imatinib are administered (Petzer et al., 2002). Previous reports have documented that low cerebrospinal fluid levels of imatinib mesylate during therapy for the treatment of chronic myeloid leukemia are associated with cerebral relapse (Abruzzese et al., 2003; Petzer et al., 2002).

Even treatment with higher doses of imatinib fails to control CNS metastases, suggesting inadequate drug penetration or the emergence of a treatment-resistant clone. In contrast, one report has shown intracranial metastatic GISTs that responded well to imatinib therapy (Brooks et al., 2002). Another group postulated that the BBB may be disrupted in some individuals, allowing better penetration of the drug into the brain. The use of imatinib mesylate as a last resort offers an effective treatment option for patients even with advanced GISTs, a malignancy that has been highly resistant to systemic agents.

Another reason for the refractory nature of intracranial GISTs treated with imatinib mesylate may be due to the mutations in KIT or PDGFRA. Unfortunately, the molecular features of most tumors of the present series of intracranial GISTs were not described. Two cases had a mutation in exon 9 or exon 11 in KIT, whereas no mutation in KIT was seen in three cases, and no mutation was seen in PDGFRA in two cases. These results indicated that treatment had no apparent effect on metastatic brain tumors treated with concurrent chemotherapy, probably because the CNS provides a site for the tumors to escape drug therapy rather than because a particular mutation status is needed for acquired resistance.

Alternatively, sunitinib is a promising molecular targeting agent that is an orally active, small-molecule multiple receptor tyrosine kinase inhibitor that selectively blocks vascular endothelial growth factor types 1 through 3, PDGF receptors (alpha and beta), KIT, Fmslike tyrosine kinase-3, and colony stimulating factor-1 receptor. Sunitinib is approved for the treatment of advanced renal cell carcinoma, imatinib-refractory GISTs, and advanced pancreatic neuroendocrine tumors. Sunitinib is thought to penetrate the BBB, and recent reports indicate therapeutic effectiveness in brain metastasis (Takeuchi et al., 2013). The suppressive effect of imatinib for brain metastasis from renal cell carcinoma has been reported, demonstrating a $12 \%$ objective response rate among 321 patients (Gore et al., 2011). Following failure of imatinib mesylate, sunitinib is an effective second-line therapy and is currently approved worldwide for metastatic GISTs in patients with imatinib resistance or intolerance. Based on these findings, sunitinib for metastatic intracranial GISTs will expand the treatment choices for patients with imatinib resistance (Sar Serrano and George, 2014). Currently, sunitinib use in patients with brain metastasis requires careful administration due to a risk of intracerebral hemorrhage. With intensive care regarding hypertension, sunitinib is expected to be a relatively safe and effective treatment modality.

# Treatment Outcomes 

The majority of GISTs are present in older adults with a median age of approximately 60 years at presentation. GISTs rarely affect the pediatric population. Only one pediatric case of metastatic intracranial GISTs has been reported (Jagannathan et al., 2012).The interval between treatment of the primary lesion and diagnosis of CNS metastasis is considerably long ( 14 months to 12 years; mean 4.7 years), and once an intracranial metastasis is diagnosed, the prognosis is dismal. Overall survival has been documented to be 2-35 months (mean 8.6 months).

GISTs mostly metastasize within the abdomen, and the common sites for metastases are the liver ( $46 \%$ ) and peritoneum ( $41 \%$ ). Involvement of the CNS by metastatic GISTs is extremely rare. Patients sometimes have known metastatic disease elsewhere prior to the development of CNS metastases. In the present series, concurrent liver metastasis was seen in seven cases. Nine cases were treated surgically. In 11 cases, patients underwent chemotherapy, including imatinib in nine patients and sunitinib in two patients. Nine patients were treated with radiation as an additional treatment. Seven patients achieved complete remission, and five out of seven patients underwent surgery. Only two out of seven cases showed a response to chemotherapy. The molecular features were unknown in six out of seven cases. Only one case had no mutation in KIT or PDGFRA. In the present series, whether the tumor in the primary lesion and in the CNS metastasis had an identical mutation remains unknown. The ability to identify the responsible gene in GISTs when KIT and $P D G F R A$ are not mutated may lead to novel insights into the nature of GISTs and novel diagnosis and therapy. Currently, the best treatment for intracranial metastatic GISTs is total resection of the tumor with a combination of radiation and chemotherapy.

# References 

Abruzzese, E., Canc Tonetti, M., Morino, L., et al., 2003. CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports. J. Clin. Oncol. 21, $4256-4258$.
Akiyama, K., Numaga, J., Kagaya, F., et al., 2004. Case of optic nerve involvement in metastasis of a gastrointestinal stromal tumor. Jpn. J. Ophthalmol. 48, 166-168.
Brooks, B.J., Bani, J.C., Fletcher, C.D.M., et al., 2002. Challenges in oncology. Case 4. Response of metastatic gastrointestinal stromal tumor including CNS involvement to imatinib mesylate (STI-571). J. Clin. Oncol. 20, 870-872.
Buchdunger, E., Cioffi, C.L., Law, N., et al., 2000. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295, $139-145$.
Casali, P.G., Blay, J.Y., and ESMO/CONTICANET/EUROBONET, 2010. Consensus panel of exprets: soft tissue sarcomas: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann. Onocol. 21 (Suppl. 5), v198-203.
Cassier, P.A., Fumagalli, E., Rutkowski, P., et al., 2012. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin. Cancer Res. 18, $4458-4464$.
Chen, H., Hirota, S., Isozaki, K., et al., 2002. Polyclonal nature of diffuse proliferation of interstitial cells of Cajal in patients with familial and multiple gastrointestinal stromal tumours. Gut 51, 793-796.
Corless, C.L., McGreevey, L., Haley, A., et al., 2002. Gastrointestinal stromal tumours: origin and molecular oncology. Nat. Rev. Cancer 11, 865-878.
Corless, C.L., Schroeder, A., Griffith, D., et al., 2005. PDGFA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J. Clin. Oncol. 23, 5357-5364.
Cuaron, J.J., Godman, K.A., Lee, N., et al., 2013. Extend beam radiation therapy for locally advanced and metastatic gastrointestinal stromal tumors. Radiat. Oncol. 8, 274. Available from: <http://dx.doi.org/10.1186/ 1748-717X-8-274>.
De Matteo, R.P., Lewis, J.J., Leung, D., et al., 2000. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann. Surg. 231, 51-58.Demetri, G.D., Von Mehren, M., Blanke, C.D., et al., 2002. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Eng. J. Med. 347, 472-480.
Drazin, D., Spitler, K., Jeswani, S., et al., 2013. Multiple intracranial metastases from a gastric gastrointestinal stromal tumor. J. Clin. Neurosci. 20, 471-473.
Druker, B.J., Tamura, S., and Buchdunger, E., 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561-566.
Gentile, C.M., Lombardi, A.A., and Croxatto, J.C., 2008. Choroidal metastasis from gastrointestinal stromal tumour: a case report. Br. J. Ophthalmol. 92, 156-157.
Gerin, F., Baloglu, O., Morgan, J.A., et al., 2007. Central nervous system metastases from imatinib mesylate resistant gastrointestinal stromal tumor. J. Neurooncol. 82, 227-228.
Gore, M.E., Hariharan, S., Porta, C., et al., 2011. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 117, 501-509.
Hamada, S., Itami, A., Watanabe, G., et al., 2010. Intracranial metastasis from an esophageal gastrointestinal stromal tumor. Inter. Med 49, 781-785.
Heinrich, M.C., Griffith, D.J., Druker, B.J., et al., 2000. Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood 96, 925-932.
Heinrich, M.C., Corless, C.L., Duensing, A., et al., 2003a. PDGFA activating mutations in gastrointestinal stromal tumors. Science 279, 708-710.
Heinrich, M.C., Corless, C.L., Demetri, G.D., et al., 2003b. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21, 4342-4349.
Hirota, S., Isozaki, K., Moriyama, Y., et al., 1998. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279, 577-580.
Hughes, B., Yip, D., Goldstein, D., et al., 2004. Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: case report. BMC Cancer 4, 74.
Inage, Y., Yamabe, K., Yamamoto, T., et al., 2002. Resection for pulmonary metastasis of pulmonary metastasis of gastrointestinal stromal tumor of the stomach at 10 years after gastrectomy: report of a case. Kyobu Geka 55, 907-911.
Jagannathan, J.P., Ramaiya, N.H., Sinagare, A.B., et al., 2012. Intracranial metastasis from pediatric GI stromal tumor. J. Clin. Oncol. 30, e121-125.
Kajikawa, M., Ishiyama, S., Sawada, K., et al., 2005. Multiple gastrointestinal stromal tumors of duodenum and jejunum accompanied by lymph node and brain metastasis: report of a case. Jpn. J. Gastroenterol. Surg. 38, $632-637$.
Kaku, S., Tanaka, T., Ohtsuka, T., et al., 2006. Perisacral gastrointestinal stromal tumor with intracranial metastasis. Case report. Neurol. Med. Chir.(Tokyo) 46, 254-257.
Miettinen, M., Majidi, M., and Lsota, J., 2002. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur. J. Cancer 38, S38-S51.
Naoe, H., Kaku, E., Ido, Y., et al., 2011. Brain metastasis from gastrointestinal stromal tumor: a case report and review of the literature. Case Rep. Gastroenterol. 5, 583-589.
Petzer, A.L., Gunsilius, E., Hayes, M., et al., 2002. Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br. J. Haematol. 117, 623-625.
Puri, T., Gunabushanam, G., Malik, M., et al., 2006. Mesenteric gastrointestinal stromal tumour presenting as intracranial space occupying lesion. World J. Surg. Oncol. 4, 78.
Sar Serrano, C., and George, S., 2014. Recent advances in the treatment of gastrointestinal stromal tuomrs. Ther. Adv. Med. Oncol. 6 (3), 115-127.
Takeuchi, H., Koike, H., Fujita, T., et al., 2013. Sunitinib treatment for multiple brain metastases from jejunal gastrointestinal stromal tumor: case report Neurol. Med. Chir. (Tokyo). Available from: <http://dx.doi.org/10.2176/ nmc.cr2012-0426>.
Tejwani, A., Wu, S., Jia, Y., et al., 2009. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor inhibitor therapy. Cancer 115, 1286-1299.
Tuveson, D.A., Willis, N.A., Jack, T., et al., 2001. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implication. Oncogene 20, 5054-5058.
Wong, C., and Chu, Y., 2011. Intra-cranial metastasis of gastrointestinal stromal tumor. China Med. J. 124, 3595-3597.

# II. TREATMENT AND PROGNOSIS# C H A P T E R 

## 16

## Brain Metastases from Breast Cancer in Patients Receiving Trastuzumab

Renata Duchnowska and Jacek Jassem

## O U T L I N E

Introduction
HER2 Receptor
HER Family Receptors and Brain
Metastases
Trastuzumab
Brain Metastases in HER2-Positive
Breast Cancer Patients
Brain Metastases in Breast Cancer
Patients Receiving Trastuzumab in
Adjuvant Setting
Brain Metastases in Advanced Breast
Cancer Patients
225
225
226
226
227
227
227
228

Local Treatment of Brain Metastases 230
Anti-HER2 Therapy in Patients with Brain Metastases 230
Intrathecal Trastuzumab Administration for Leptomeningeal Metastases 231
Perspectives of Brain Metastases Prevention 232
Discussion 232
References 233

## INTRODUCTION

## HER2 Receptor

The HER2/neu proto-oncogene is located in chromosome 17q11-q21 (Popescu et al., 1989). In physiological conditions, this gene encodes a glycoprotein with molecular mass of 185 kDa (p185), named HER2 receptor or HER2 protein. HER2 and three structurallyrelated tyrosine kinase receptors-HER1 (epidermal growth factor receptor (EGFR)), HER3 (ErbB3) and HER4 (ErbB4)-constitute the ErbB family. HER2/neu gene amplification and/ or overexpression, which occur in $15-20 \%$ of invasive breast cancers and in up to $60 \%$ of intraductal breast carcinomas, play(s) an important role in signal transduction during cell growth (Slamon et al., 1987). Tumors with HER2/neu gene aberrations, compared to HER2/ neu negative tumors, have a more aggressive clinical behavior, characterized by more frequent recurrences and shorter survival (Hynes and Stern, 1994). Upon activation, HER2 forms homodimers and/or heterodimers with EGFR, HER3, and HER4. This triggers a network of signaling cascades mediated mainly by AKT and MAPK, which regulate cell proliferation, angiogenesis, migration, and survival (Arteaga, 2003). Some studies suggest a dominant role for EGFR and HER3 as key coreceptors driving HER2-amplified breast cancers (Lee-Hoeflich et al., 2008).

# HER Family Receptors and Brain Metastases 

Several studies demonstrated that breast cancer patients who developed brain metastases have a higher proportion of HER2-positive tumors, and that alterations of HER2 family receptors occur more frequently in brain metastases than in primary breast cancers or other metastatic sites (Hohensee et al., 2013; Eichler et al., 2008). In animal models, the overexpression of HER2 in human MDA-MB-231 breast carcinoma subline selected for in vivo brain tropism increased experimental brain metastases 2.5-3-fold, suggesting that HER2 positivity influences the natural history of breast cancer to promote brain colonization (Palmieri et al., 2007). In another study, HER3 overexpression and its downstream pathway activation were found to be implicated in colonization of the brain by breast cancer cells (Da Silva et al., 2010). Notably, in that study, brain metastases from breast and other cancers contained more somatic mutations in EGFR, HRAS, KRAS, NRAS, PIK3CA, and PTEN genes than matched primary tumors. Furthermore, reactive astrocytes driven by activation of the EGFR pathway under pathological conditions appear to be destructive to neurons in the mature brain (Liu and Neufeld, 2007). These data indicate that pathways driven by HER2 family receptors play an important role in pathogenesis of brain metastases from breast cancer and may be potential therapeutic targets.

## Trastuzumab

Trastuzumab (Herceptin, Hoffman La Roche) is a recombinant, humanized monoclonal IgG1 antibody that binds to extracellular subdomain IV of HER2/neu receptor and inhibits the growth of tumor cells. Additionally, this substance is a strong mediator of antibody dependent cellular cytotoxicity, selectively directed against HER2-positive tumor cells (Petricevic et al., 2013). Trastuzumab was also demonstrated to inhibit angiogenesis via modulation of proangiogenic factors, such as vascular endothelial growth factor. Trastuzumab is widely used in combination with chemotherapy or endocrine therapy in adjuvant and metastatic setting in HER2-positive breast cancer patients, and is associated with increased response rates, prolonged disease-free survival, and overall survival (Slamon et al., 2001; Perez et al., 2011; Smith et al., 2007; Joensuu et al., 2006; Slamon et al., 2011). Owing to its high molecular weight, penetration of trastuzumab into the central nervoussystem is extremely low, 1/420th of serum levels (Stemmler et al., 2007). Thus, this compound is ineffective in treating established brain metastases. Approximately $14 \%$ of patients with breast cancer undergo conversion of HER2 status in brain metastases (at a similar rate in both directions), and trastuzumab does not seem to affect the incidence of this phenomenon (Duchnowska et al., 2012a).

# BRAIN METASTASES IN HER2-POSITIVE BREAST CANCER PATIENTS 

## Brain Metastases in Breast Cancer Patients Receiving Trastuzumab in Adjuvant Setting

In a dataset of 9524 early breast cancer patients who were randomized in the International Breast Cancer Study Group clinical trials between 1978 and 1999, the cumulative 10-year incidence of brain metastases in subsets with HER2-positive and HER2negative breast cancer were $2.7 \%$ and $1.0 \%$, respectively, as the first site of relapse, and $6.8 \%$ and $3.5 \%$, respectively, at any time (Pestalozzi et al., 2006). A pooled analysis of five large randomized studies in early breast cancer demonstrated an increased risk of brain metastases in patients administered adjuvant trastuzumab (risk ratio 1.57, $P=0.033$, Table 16.1) (Bria et al., 2008). Several retrospective analyses showed that, compared to historical controls, patients administered adjuvant trastuzumab have a higher incidence of brain metastases. In the Parma Province Cancer Registry including stage I-III breast cancer, at a median follow-up of 4.1 years, brain metastases occurred in $1.3 \%$ of HER2-negative patients, $1.6 \%$ of HER2-positive patients never treated with trastuzumab, and $10.5 \%$ of HER2-positive patients who received trastuzumab at any time before the diagnosis of brain metastases (Musolino et al., 2011). In that study, patients treated with trastuzumab had also significantly worse brain metastasis-free survival ( $P=0.00001$ ). However, among patients with brain metastases at the time of first recurrence, the time to brain relapse was longer in those who did, compared to those who did not, receive adjuvant trastuzumab ( 20.3 vs 10.3 months, respectively). Similar results were reported in another retrospective series (Yap et al., 2012). Delayed onset of brain relapse in patients treated with adjuvant trastuzumab is likely due to its preventive effect at extracranial sites and not a direct activity in the brain.

TABLE 16.1 The Incidence of Brain Metastases in HER2-Positive Breast Cancer Patients Participating in Adjuvant Trastuzumab Randomized Clinical Trials

| Study | Reference | Median follow-up | Control group |  | Trastuzumab group |  |
| :--: | :--: | :--: | :--: | :--: | :--: | :--: |
|  |  |  | N | \% | N | \% |
| HERA | Smith et al. (2007) | 2.0 years | 22 | 1.0 | 26 | 2.0 |
| NSABP B-31 ${ }^{a}$ | Perez et al. (2011) | 3.9 years | 17 | 1.6 | 32 | 3.0 |
| NCCTG N9831 ${ }^{a}$ |  |  | 19 | 2.0 | 29 | 3.0 |

${ }^{a}$ Number of events with brain involvement.# Brain Metastases in Advanced Breast Cancer Patients 

In retrospective studies, the incidence of symptomatic brain metastases among patients with metastatic HER2-positive breast cancer administered trastuzumab was in the range of $10-40 \%$ (Table 16.2). The risk factors in this population include young age, lymph node involvement, estrogen receptor negativity, and early onset of relapse, particularly in visceral organs (Lai et al., 2004; Clayton et al., 2004; Bendell et al., 2003; Yau et al., 2006; Gori et al., 2007; Duchnowska et al., 2009). The incidence of asymptomatic brain metastases in HER2positive advanced breast cancer is in the range of $5 \%$ in patients receiving first-line trastuzumab (Pivot et al., 2011, 2015) and up to $34 \%$ in those receiving trastuzumab in subsequent lines (Niwińska et al., 2007). However, a routine screening for asymptomatic brain metastases in advanced breast cancer patients does not seem to impact overall survival (Niwińska et al., 2010), hence there is no rationale to recommend it as a standard of care.

There are no validated biomarkers predicting the risk of brain relapse in HER2positive advanced breast cancer patients. Recently, higher quantitative HER2 expression (Duchnowska et al., 2012b), expression of DNA double-strand break repair genes, including

TABLE 16.2 The Incidence of Brain Metastases in Retrospective Series of Advanced Breast Cancer Patients Administered Trastuzumab

| Author | N | Median follow-up (months) | Median time to brain metastases (months) | Incidence of brain metastases (\%) |
| :--: | :--: | :--: | :--: | :--: |
| Bendell et al. (2003) | 122 | 22 | 6 | 34 |
| Clayton et al. (2004) | 93 | ND | 10 | 25 |
| Lower et al., (2003) | 87 | ND | ND | 25 |
| Lai et al. (2004) | 79 | ND | ND | 48 |
| Burstein et al. (2005) | 289 | 7 | NR | $10^{a}$ |
| Duchnowska et al. (2009) | 142 | 37 | 13 | 35 |
| Park et al. (2009) | 111 | ND | 15 | 37 |
| Yau et al. (2006) | 87 | 11 | ND | 30 |
| Puente Vázquez et al. (2006) | 86 | ND | 10 | 19 |
| Montagna et al. (2009) | 78 | 35 | 30 | 42 |
| Metro et al. (2007) | 69 | 17 | 17 | 32 |
| Gori et al. (2007) | 122 | 28 | 8 | 35 |
| Ono et al. (2009) | 204 | 54 | 13.5 | 36 |
| Yap et al. (2012) | 176 | 11 | 33 | $22^{\text {b }}$ |

[^0]
[^0]:    NR, not reached; ND, not determined.
    ${ }^{a}$ Responders to trastuzumab therapy.
    ${ }^{\text {b }}$ Brain metastasis at first distant relapse.BARD1 and RAD51(Woditschka et al., 2014) and BRCA1 deficient-like signature (McMullin et al., 2014), have been postulated to increase the risk of brain metastases in this subgroup.

The median time from the onset of trastuzumab treatment (at any line of therapy) for advanced breast cancer to the occurrence of brain metastasis in the retrospective series varied widely from 4 to 33 months (Table 16.2). The administration of trastuzumab seems to increase the time to brain metastases (Dawood et al., 2008; Park et al., 2009). Additionally, despite poor prognosis related to brain metastases in general breast cancer population, there was no significant survival difference in patients who developed brain versus extracranial metastases while on trastuzumab therapy (Lower et al., 2003). An improvement is expected from the introduction of a novel recombinant humanized monoclonal antibody targeting the extracellular dimerization domain (subdomain II) of HER2, pertuzumab (Perjeta, Hoffman La Roche). The addition of pertuzumab to trastuzumab and docetaxel in first-line treatment of advanced breast cancer delayed the occurrence of symptomatic brain metastases as first site of distant relapse (median 15 vs 12 months, respectively; hazard ratio $0.58 ; P=0.005$ ), in addition to increased progression-free survival (Swain et al., 2014).

Approximately $50 \%$ of patients with brain metastases die from progression in the brain, however, the accompanying extracranial disease highly contributes to overall mortality. Thus, the management of these patients should address both intracranial and extracranial diseases.

The efficacy of continuing trastuzumab administration after disease progression to prevent subsequent brain metastases is unclear (Table 16.3). In a randomized study, the occurrence of brain metastases in patients who did and did not continue trastuzumab after first progression was $14 \%$ and $8 \%$, respectively, a nonsignificant difference (von Minckwitz et al., 2011). In that study, overall progression-free survival in patients administered trastuzumab was longer compared to the control group ( 8.2 vs 5.6 months, respectively, hazard ratio 0.69 , $P=0.034$ ).

Another commonly used anti-HER2 agent is lapatinib (Tykerb/Tyverb, GlaxoSmithKline), an oral dual tyrosine kinase inhibitor. This compound interrupts the HER2 and EGFR pathways by binding to the adenosine triphosphate-binding pocket of the EGFR/HER2 protein kinase domain and prevents self-phosphorylation and subsequent activation of the signal mechanism. As opposed to trastuzumab, lapatinib is a small molecule, with relatively better penetration to the brain. However, preliminary data indicate

TABLE 16.3 The Incidence of Brain Metastases in HER2-Positive Advanced Breast Cancer Patients Receiving Second-Line Anti-HER Treatment

| Reference (study) | Therapy | Median follow-up | Incidence of brain metastases | Progression-free survival |
| :--: | :--: | :--: | :--: | :--: |
| Geyer et al. (2006) (EGF100151) | CAP/L vs CAP | ND | 2 vs $6 \% ; P=0.045$ | 8.4 vs 4.4 months; HR $0.49 ; P<0.001$ |
| Von Minckwitz et al. (2011) (BIG 03-05) | CAP/T vs CAP | 21 months | 14 vs $8 \%$; NS | 8.2 vs 5.6 months; HR $0.69 ; P=0.034$ |
| Bian et al. (2013) ${ }^{a}$ | CAP/L vs CAP/T | ND | 3 vs $2 \%$; NS | 6 vs 4.5 months; $P=0.005$ |

[^0]
[^0]:    CAP, capecitabine; L, lapatinib; T, trastuzumab; ND, not determined; HR, hazard ratio; NS, not significant difference.
    ${ }^{a}$ Non randomized study.that the ratio of brain metastasis to serum concentrations of lapatinib is still relatively low and shows a considerable individual variability (Morikawa et al., 2015). In consequence, the drug delivery to the brain may be insufficient in a proportion of patients. In a prospective, nonrandomized controlled study, the occurrence of brain metastases in trastuzumab resistant patients who continued trastuzumab with capecitabine versus those switched to lapatinib plus capecitabine was $12 \%$ versus $3 \%$, respectively ( $P=0.16$ ) (Bian et al., 2013). In a pivotal randomized study including trastuzumab-resistant patients, the occurrence of brain metastases in those administered capecitabine with or without lapatinib was $2 \%$ and $6 \%$, respectively $(P=0.045)$, and the corresponding medians of progression-free survival were 8.4 and 4.4 months, respectively (hazard ratio of $0.49 ; P<0.001$ ) (Geyer et al., 2006).

# Local Treatment of Brain Metastases 

The management of brain metastases originating from breast cancer is highly dependent on patient performance status, the extent of brain involvement, and the coexistence of progressive extracranial metastases (Ramakrishna et al., 2014). In patients with Karnofsky performance status of 70 or more, controlled extracranial disease and 1-3 brain lesions, recommended local therapy includes surgery or stereotactic radiotherapy with or without subsequent whole brain irradiation. Supplemental whole brain irradiation decreases the occurrence of subsequent brain relapse at the expense of increased occurrence of neurocognitive disorders and does not increase survival. Thus, waiving whole brain irradiation necessitates careful monitoring (every $2-3$ months) using magnetic resonance imaging to detect early another brain relapse.

Brain metastases in HER2-positive breast cancer patients are frequently multifocal and thus beyond the scope of surgery or stereotactic radiotherapy (Kaplan et al., 2014; Park et al., 2009; Church et al., 2008; Metro et al., 2007; Gori et al., 2007; Burstein et al., 2005). In such patients, preferred treatment remains whole brain irradiation at a dose of 30 Gy in 10 fractions or 20 Gy in 5 fractions. This therapy is also recommended in patients with Karnofsky performance status below 70 or with accompanying progressive extracranial disease.

## Anti-HER2 Therapy in Patients with Brain Metastases

There are no recommendations for the type of chemotherapy or targeted therapy in patients with brain metastases (Ramakrishna et al., 2014; www.fda.gov). Several retrospective studies have demonstrated increased overall survival in patients who continued trastuzumab treatment after brain relapse (Park et al., 2009; Church et al., 2008; Metro et al., 2007; Gori et al., 2007; Table 16.4). However, owing to low penetrance of trastuzumab through the blood-brain-barrier, this effect is most likely due to better control of extracranial disease and not to a direct anticancer efficacy in the brain. Moreover, the lack of randomization makes these studies a subject of selection bias, since patients in better general condition or with a lower number of metastatic lesions are more likely to continue trastuzumab treatment.

A small retrospective study in patients with brain metastases suggested that compared with trastuzumab-based treatment, a combination of lapatinib and capecitabine improves overall survival (median 19 vs 12 months, $P=0.04$ ), without significant impact on the incidence of cerebral deaths ( $32 \%$ vs $43 \%, P=0.33$ ) (Kaplan et al., 2014). In another studyTABLE 16.4 Overall Survival According to Continued Trastuzumab Therapy After Brain Relapse

|  | Median overall survival (months) |  |
| :-- | :-- | :-- |
| Author | Continued trastuzumab | Terminated trastuzumab |
| Park et al. (2009) | 13.6 | 4 |
| Church et al. (2008) | 11.9 | 3 |
| Metro et al. (2007) | Not reached | 11 |
| Gori et al. (2007) | 30.3 | 9.6 |

including HER2-positive patients who previously underwent cranial irradiation for brain metastases, treatment with lapatinib was associated with modest activity in the brain ( $6 \%$ objective response rate, $42 \%$ stable disease) (Lin et al., 2009). However, among patients who subsequently entered the lapatinib plus capecitabine extension, $20 \%$ experienced an objective response in the brain. One phase II study demonstrated relatively high efficacy of lapatinib plus capecitabine combination as first-line treatment for brain metastases in advanced HER2-positive breast cancer patients who had not received previous whole brain radiation therapy (median time to brain radiotherapy of 8.3 months), however at the expense of relatively high incidence of treatment-related adverse events (Bachelot et al., 2013). On the other hand, a recent CEREBEL study (EGF111438) failed to show the superiority of lapatinib and capecitabine combination compared to trastuzumab and capecitabine for preventing brain metastases in patients with advanced HER2-positive breast cancer (the incidence of brain metastases as site of first relapse 3\% vs 5\%, respectively) (Pivot et al., 2012, 2015).

In the absence of the data from prospective studies, recent ASCO guidelines recommend continued trastuzumab therapy in patients without concomitant progressive extracranial disease at diagnosis of brain metastasis, and switching to another anti-HER2 therapy in those with extracranial progression (Ramakrishna et al., 2014).

Current experience with trastuzumab and lapatinib used as radiosensitizers for established brain metastases is limited. Preclinical studies suggest that both compounds may sensitize cancer cells to radiotherapy and in clinical studies such management provided more than $70 \%$ of objective responses (Lin et al., 2013; Chargari et al., 2011). However, lapatinib therapy in this setting is associated with prohibitive toxicity.

# Intrathecal Trastuzumab Administration for Leptomeningeal Metastases 

Leptomeningeal metastases occur in about 2-5\% of patients with HER2-positive breast cancer (Bendell et al., 2003). A few studies reported clinical and objective improvements after intrathecal administration of trastuzumab at a dose of $5-100 \mathrm{mg}$ weekly or 12.5 mg every 3 weeks, with or without systemic therapy (Platini et al., 2006; Stemmler et al., 2006; Mir et al., 2008; Colozza et al., 2009; Oliveira et al., 2011). The reported duration of response in these studies ranged from 2 to 23 months and overall survival from 3 to 36 months. Notably, trastuzumab has not been originally formulated for intrathecal administration andthe safety of this strategy still warrants careful investigation (Siderov, 2006). Ongoing prospective studies may confirm clinical activity of trastuzumab in this setting and establish its optimal intrathecal delivery.

# Perspectives of Brain Metastases Prevention 

Prophylactic cranial irradiation (PCI) has been shown to effectively decrease the risk of brain metastases in small cell lung cancer and is currently considered a standard procedure in this malignancy. The role of PCI (30Gy in 10 fractions) in HER2-positive advanced breast cancer has been a subject of two clinical studies. A phase I study NCT00916877 (www.clinicaltrials. gov) evaluated the safety of PCI, specifically with respect to neurocognitive function, whereas phase III study NCT00639366 (www.clinicaltrials.gov) evaluated the incidence of symptomatic brain metastases. Both studies have been completed but neither has been reported so far.

The potential of pharmacological inhibition of experimental brain colonization by brain-tropic HER2- and EGFR-positive breast cancer cells (231-HER2-BR) has been investigated in animal models. Inhibitory activity has been shown for lapatinib (Gril et al., 2008) and pazopanib, a small-molecule kinase inhibitor targeting vascular endothelial growth factor receptor types 1-3 (VEGFR1-3), tyrosine-protein kinase Kit (c-Kit or CD117), and platelet-derived growth factor receptor (Gril et al., 2011). Most recently, Palmieri et al. (2014) showed that temozolomide, an oral alkylating agent, may prevent the brain metastases of breast cancer in an $\mathrm{O}^{6}$-methylguanine-DNA methyltransferase (MGMT)-dependent manner, irrespective of breast cancer phenotype. These data provide a rationale for clinical studies using similar approaches in high-risk breast cancer patients.

## DISCUSSION

The development of brain metastasis, irrespective of its origin, is a devastating event, highly deteriorating quality of life and shortening survival. Increasing efficacy of breast cancer treatment has resulted in better control of extracranial disease, whereas brain metastases remain a therapeutic challenge. HER2 overexpressing breast cancer patients constitute a population with relatively high risk of brain metastases. Almost all these patients are currently managed with trastuzumab in adjuvant and/or metastatic setting. This drug, combined with cytotoxics or hormonal agents, considerably improves therapeutic outcomes, yet has also a double-edged impact on brain metastases. On the one hand, improved control of extracranial disease, both in patients treated with curative and palliative intent, decreases the risk of brain metastases, on the other, this paradoxically allows more time for their development. Considering unquestioned survival advantage of trastuzumab treatment, there is an apparent need for a search for molecular risk factors of brain metastases and new methods of prevention in this group of patients.

Greater awareness in the medical community and improved access to modern diagnostic imaging techniques resulted in apparently increased incidence of detected asymptomatic brain metastases within the past decade. However, active screening of asymptomatic patients in general population of HER2-positive breast cancer patients is controversial, as it probably does not translate into improved survival. Such screening might be justifiedthough in the subsets of patients with well-defined high risk of brain metastasis, further supporting the need for reliable predictive biomarkers.

There is no commonly accepted systemic therapy in HER2-positive patients with brain metastases. This concerns in particular the role of continued trastuzumab therapy at brain relapse in patients with otherwise controlled extracranial disease. Owing to poor penetrance of trastuzumab to the central nervous system, its protective effect in the brain is questionable. The efficacy of another anti-HER2 agent, lapatinib, in established brain metastases is also limited, despite its low molecular weight and better penetrance to the central nervous system. More effective is the combination of lapatinib and capecitabine, particularly in patients not exposed to cranial irradiation. However, this regimen is associated with considerable toxicity precluding its wide application.

Preclinical data suggest a potential efficacy of pharmacological brain metastasis prevention in high-risk breast cancer populations. In this respect, identification of reliable clinical and molecular factors predicting brain relapse in breast cancer patients remains a particularly important challenge and an unmet clinical need.

# References 

Arteaga, C.L., 2003. ErbB-targeted therapeutic approaches in human cancer. Exp. Cell Res. 284, 122-130.
Bachelot, T., Romieu, G., Campone, M., et al., 2013. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 14, 64-71.
Bendell, J.C., Domchek, S.M., Burstein, H.J., et al., 2003. Central nervous system metastases in women who receive trastuzumab based therapy for metastatic breast carcinoma. Cancer 97, 2972-2977.
Bian, L., Wang, T., Zhang, S., et al., 2013. Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer. Tumour Biol. 34, 3153-3158.
Bria, E., Cuppone, F., Fornier, M., et al., 2008. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res. Treat. 109, 231-239.
Burstein, H.J., Lieberman, G., Slamon, D.J., et al., 2005. Isolated central nervous system metastases in patients with HER2 overexpressing advanced breast cancer treated with first-line trastuzumab based therapy. Ann. Oncol. 16, $1772-1777$.
Chargari, C., Idrissi, H.R., Pierga, J.Y., et al., 2011. Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 81, $631-636$.
Church, D.N., Modgil, R., Guglani, S., et al., 2008. Extended survival in women with brain metastases from HER2 overexpressing breast cancer. Am. J. Clin. Oncol. 31, 250-254.
Clayton, A.J., Danson, S., Jolly, S., et al., 2004. Incidence of cerebral metastases in patients treated with trastuzumab with trastuzumab for metastatic breast cancer. Br. J. Cancer 16, 639-643.
Colozza, M., Minenza, E., Gori, S., et al., 2009. Extended survival of a HER2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab. Cancer Chemother. Pharmacol. 63, $1157-1159$.
Da Silva, L., Simpson, P.T., Smart, C.E., et al., 2010. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res. 12, R46.
Dawood, S., Broglio, K., Esteva, F.J., et al., 2008. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann. Oncol. 19, 1242-1248.
Duchnowska, R., Dziadziuszko, R., Czartoryska-Arłukowicz, B., et al., 2009. Risk factors for brain relapse in HER2positive metastatic breast cancer patients. Breast Cancer Res. Treat. 117, 297-303.
Duchnowska, R., Dziadziuszko, R., Trojanowski, T., et al., 2012a. Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain. Breast Cancer Res. 14, R119.Duchnowska, R., Biernat, W., Szostakiewicz, B., et al., 2012b. Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumabcontaining therapy. Oncologist 17, 26-35.
Eichler, A.F., Kuter, I., Ryan, P., et al., 2008. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 112, 2359-2367.
Geyer, C.E., Forster, J., Lindquist, D., et al., 2006. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733-2743.
Gori, S., Rimondini, S., De Angelis, V., et al., 2007. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist 12, 766-773.
Gril, B., Palmieri, D., Bronder, J.L., et al., 2008. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J. Natl. Cancer Inst. 100, 1092-1103.
Gril, B., Palmieri, D., Qian, Y., et al., 2011. Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis. Clin. Cancer Res. 17, 142-153.
Hohensee, I., Lamszus, K., Riethdorf, S., et al., 2013. Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases. Am. J. Pathol. 183, 83-95.
Hynes, N.E., and Stern, D.F., 1994. The biology of erbB-2/neu/HER 2 and its role in cancer. Biochim. Biophys. Acta 1198, 165-184.
Joensuu, H., Kellokumpu-Lehtinen, P.L., Bono, P., and FinHer Study Investigators, 2006. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354, 809-820.
Kaplan, M.A., Isikdogan, A., Koca, D., et al., 2014. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology. Breast Cancer 21, 677-683.
Lai, R., Dang, C.T., Malkin, M.G., et al., 2004. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 15, 810-816.
Lee-Hoeflich, S.T., Crocker, L., Yao, E., et al., 2008. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 68, 5878-5887.
Lin, N.U., Diéras, V., Paul, D., et al., 2009. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin.Cancer Res. 15, 1452-1459.
Lin, N.U., Freedman, R.A., Ramakrishna, N., et al., 2013. A phase I study of lapatinib with whole brain radiotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Res. Treat. 142, 405-414.
Liu, B., and Neufeld, A.H., 2007. Activation of epidermal growth factor receptors in astrocytes: from development to neural injury. J. Neurosci. Res. 85, 3523-3529.
Lower, E.E., Drosick, R.D., Blau, R., et al., 2003. Increased rate of brain metastases with trastuzumab therapy not associated with impaired survival. Clin. Breast Cancer 4, 114-119.
McMullin, R.P., Wittner, B.S., Yang, C., et al., 2014. A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity. Breast Cancer Res. 16, R25.
Metro, G., Sperduti, I., Russillo, M., et al., 2007. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer. Oncologist 12, 1467-1469.
Mir, O., Ropert, S., Alexandre, J., et al., 2008. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann. Oncol. 19, 1978-1980.
Montagna, E., Cancello, G., D'Agostino, D., et al., 2009. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab. Cancer Chemother. Pharmacol. 63, 275-280.
Morikawa, A., Peereboom, D.M., Thorsheim, H.R., et al., 2015. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neuro. Oncol. 17, 289-295.
Musolino, A., Ciccolallo, L., Panebianco, M., et al., 2011. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer 117, 1837-1846.
Niwińska, A., Tacikowska, M., and Pieńkowski, T., 2007. Occult brain metastases in HER2-positive breast cancer patients: frequency and response to radiotherapy. Acta Oncol. 46, 1027-1029.
Niwińska, A., Tacikowska, M., and Murawska, M., 2010. The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death. Int. J. Radiat. Oncol. Biol. Phys. 77, 1134-1139.Oliveira, M., Braga, S., Passos-Coelho, J.L., et al., 2011. Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab. Breast Cancer Res. Treat. 127, 841-844.
Ono, M., Ando, M., Yunokawa, M., et al., 2009. Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. Int. J. Clin. Oncol. 14, 48-52.
Palmieri, D., Bronder, J.L., Herring, J.M., et al., 2007. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res. 67, 4190-4198.
Palmieri, D., Duchnowska, R., Woditschka, S., et al., 2014. Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner. Clin. Cancer Res. 20, 2727-2739.
Park, I.H., Ro, J., Lee, K.S., et al., 2009. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Ann. Oncol. 20, 56-62.
Perez, E.A., Romond, E.H., Suman, V.J., et al., 2011. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J. Clin. Oncol. 29, 3366-3373.
Pestalozzi, B.C., Zahrieh, D., Price, K.N., and International Breast Cancer Study Group (IBCSG), 2006. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann. Oncol. 17, 935-944.
Petricevic, B., Laengle, J., Singer, J., et al., 2013. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. J. Transl. Med. 11, 307.
Pivot, X., Hackmann, J., Manikhas, A., et al., 2011. Incidence rate of asymptomatic brain metastases in patients with HER2+ metastatic breast cancer screened for EGF111438/CEREBEL Study. Cancer Res. 71 (24) (Suppl. 3).
Pivot, X., Manikhas, A., Żurawski, B., et al., 2015. CEREBEL (EGF111438): a Phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J. Clin. Oncol. 33, 1564-1573.
Platini, C., Long, J., and Walter, S., 2006. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol. 7, 778-780.
Popescu, N.C., King, C.R., and Kraus, M.H., 1989. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 4, 362-366.
Puente Vázquez, J., López-Tarruella Cobo, S., García-Sáenz, J.A., et al., 2006. Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies. Clin. Transl. Oncol. 8, 50-53.
Ramakrishna, N., Temin, S., Chandarlapaty, S., et al., 2014. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: american society of clinical oncology clinical practice guideline. J. Clin. Oncol. 32, 2100-2108.
Siderov, J., 2006. Care with intrathecal trastuzumab. Lancet Oncol. 7, 888.
Slamon, D., Eiermann, W., and Robert, N., Breast Cancer International Research Group, 2011. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365, 1273-1283.
Slamon, D.J., Clark, G.H., Wong, S.G., et al., 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182.
Slamon, D.J., Leyland-Jones, B., Shak, S., et al., 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792.
Smith, I., Procter, M., Gelber, R.D., and HERA study team, 2007. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369, 29-36.
Stemmler, H.J., Schmitt, M., Harbeck, N., et al., 2006. Application of intrathecal trastuzumab (Herceptin) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol. Rep. 15, $1373-1377$.
Stemmler, H.J., Schmitt, M., Willems, A., et al., 2007. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of the blood-brain barrier. Anticancer Drugs 18, 23-28.
Swain, S.M., Baselga, J., Miles, D., et al., 2014. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann. Oncol. 25, 1116-1121.
von Minckwitz, G., Schwedler, K., Schmidt, M., and GBG 26/BIG 03-05 study group and participating investigators, 2011. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur. J. Cancer 47, 2273-2281.

# II. TREATMENT AND PROGNOSISWoditschka, S., Evans, L., Duchnowska, R., et al., 2014. DNA double-strand break repair genes and oxidative damage in brain metastasis of breast cancer. J. Natl. Cancer Inst. 106 (7).
Yap, Y.S., Cornelio, G.H., Devi, B.C., et al., 2012. Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival. Br. J. Cancer 107, 1075-1082.
Yau, T., Swanton, C., Chua, S., et al., 2006. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol. 45, 196-201.# C H A P T E R 

## 17

## Brain Metastases from Cutaneous Melanoma: Biology and its Implications for More Rational Therapeutic Approaches <br> Stergios J. Moschos, Dimitri Trembath, Frances A. Collichio, Carrie B. Lee, Timothy M. Zagar and Matthew G. Ewend

## O U T L I N E

Introduction238 Treatment of Melanoma Brain

|  | Metastases: Present and Future | 247 |
| :--: | :--: | :--: |
| 239 | Great Improvements Since 2011 | 247 |
| 239 | The Future of the Treatment of Patients |  |
| How Do We Predict Melanoma Brain |  |  |
| 240 | Where Does Radiation Therapy Fit | 249 |
|  | into the Picture? | 250 |
| 241 | References | 251 |# INTRODUCTION 

Cutaneous melanoma is the fifth and seventh most frequently diagnosed cancer in the United States in men and women, respectively, for 2014 (Siegel et al., 2014). In other countries, such as Australia, cutaneous melanoma has reached epidemic proportions. Although it is rare among men and women less than 30 years old, it is the fourth and second most frequently diagnosed cancer in this age group, respectively. Surgery is curative for early, localized, nonmetastatic cutaneous melanomas with a 5-year relative survival rate of $98 \%$. However, the corresponding 5-year rates for patients with regional and distant metastatic melanoma (MM) are $62 \%$ and $16 \%$, respectively. For regional lymph node positive and distant MM, multimodality treatment is frequently used with variable success (McArthur and Ribas, 2013). Over the past 15 years, tremendous progress has been made in identifying histopathologic prognostic factors for patients with cutaneous melanoma. Most of these factors are included in the latest 2009 revision of the American Joint Committee on Cancer (AJCC) staging system, including important histopathologic features associated with primary melanoma, such as Breslow depth of invasion, ulceration, mitotic rate, and tumor infiltrating immune cells as well as features identified in the regional metastases, such as number and size of metastatic lesions within regional lymph nodes (Balch et al., 2009; Thomas et al., 2013). Nevertheless, the current AJCC staging system frequently fails to predict patients with adverse prognosis, in particular patients with regional or distant MM (Balch et al., 2009). To this end, better strategies to quantify and characterize the role of host immune response are expected to further refine existing prognostic factors (Galon et al., 2012). Objective assessment of immune response in tumor tissues is an emerging need given the unique role of host immune response and the therapeutic benefit of several immunotherapies in a subset of patients with regional and distant MM (McArthur and Ribas, 2013). Even less progress has been achieved toward understanding existing or identifying new prognostic factors for patients with established distant metastases, with the exception of the role of metastatic organ site of involvement (lymph nodes and subcutaneous lesions vs lung vs other visceral organ involvement) and serum LDH levels (Balch et al., 2009).

In parallel with the advances in identifying prognostic histopathologic features, considerable progress has been made in understanding the biology of cutaneous melanoma. The discovery of hotspot mutations in the V600 codon of BRAF ( $35-50 \%$ of melanomas) and the G12 and Q61 codons of NRAS ( $10-25 \%$ ) in the 1990s followed by the development of highly selective kinase inhibitors targeting the MAPK pathway in the late 2000s resulted in proof-of-principle clinical trials that led to the FDA approval of three such inhibitors in MM in 2011 and 2013 (McArthur and Ribas, 2013). Recent applications of next generation DNA sequencing technologies in melanoma have shown additional genetic aberrations that not only add further layers of heterogeneity to the biology of this disease, but have also important prognostic and treatment implications (Hodis et al., 2012; Nathanson et al., 2013; Sosman et al., 2014). Research efforts based on large melanoma tissue cohorts, with multiple molecular data platforms and complex integrative analysis, such as the Cancer Genome Atlas Project (TCGA) in cutaneous melanoma, are expected to unravel more robust associations that could better define subgroups with the highest risk for relapse and more personalized systemic treatments (Cancer Genome Atlas Network, 2015).# CHALLENGES OF MELANOMA BRAIN METASTASES IN 2014 

Understand Biology, Predict Future Development, Manage Established Brain Metastases More Effectively and with Less Toxicity.

## Overview and the "Old Wisdom"

Frequency of brain metastasis from melanoma (MBM) follows that of brain metastases from lung, breast, gastrointestinal, and cancers of unknown primary (Preusser et al., 2012). Adjusting for incidence, however, melanoma has the highest propensity for central nervous system (CNS) spread among other metastatic solid tumors (up to $70 \%$ ) and is associated with a worse prognosis than that of distant MM without brain metastases (Balch et al., 2009; Davies et al., 2011; Eigentler et al., 2011; Zakrzewski et al., 2011). In particular, MBM can be the original presentation in $20-30 \%$ patients with newly diagnosed distant MM and their incidence may rise to $60 \%$ over the next two years in patients enduring distant MM (Shapiro and Samlowski, 2011). The grim prognosis of patients with established MBM can be attributed to an approximately $50 \%$ incidence of intracranial hemorrhage, the highest among any other tumor type (Kondziolka et al., 1987). It is important to emphasize, however, that extracranial disease remains the leading cause of death in patients with distant MM, whereas deaths from active MBM are presumably responsible for up to $40 \%$ of all deaths, most frequently as a result of development of new intracranial lesions and other catastrophic events (hemorrhage, seizures) rather than progression of existing intracranial lesions (Mathieu et al., 2007). These clinical observations suggest three fundamental aspects about MM: its inherent high propensity for development of CNS metastases, its high incidence of spontaneous bleeding, and the importance of some organ site-nonspecific factor, presumably from the host, that may play an important role in overall survival (OS).

Treatment of MBM has not significantly changed for decades, with the exception of targeted therapies and immunotherapies directed towards distinct patient subsets that will be discussed later in this chapter (McArthur and Ribas, 2013). External beam irradiation therapy, either in the form of whole brain irradiation or stereotactic radiosurgery, has been the cornerstone therapy for the majority of patients enduring MBM, whereas craniotomy is used for a much more restricted patient subgroup (Gorantla et al., 2013). With respect to systemic treatments, corticosteroids have been the standard "bridge" therapy for most patients, whereas the clinical benefit from any chemotherapy, including agents that adequately penetrate the blood-brain barrier (BBB), has been minimal (Agarwala et al., 2004). Finally, immunotherapies, including the FDA-approved high dose bolus IL-2, had long been avoided for patients with brain metastases due to the increased, at least theoretical, concern of worsening intracranial edema (Chu et al., 2013) for a site that had been, for the most part, considered immune-privileged, at least under physiologic conditions (Gimsa et al., 2013). Lack of clinical studies dedicated for patients with active MBM, limited understanding of the biology of MBM, and even more limited translational research on this tumor site have plagued the field for decades, which may explain the empiricism and paucity of systemic treatment options. Recent and ongoing advances on all three fronts have begun to change the approach to management of MBM, an important priority as patients with distant MMnow live longer than ever, and therefore may more frequently endure brain metastases at some point in the natural history of their disease.

# How Do We Predict Melanoma Brain Metastases? 

As mentioned above, the increased propensity of melanomas to metastasize to the brain has been a long-standing observation. At the moment, our ability to predict patients at risk for the development of MBM has been limited to retrospective analyses of large singleinstitution melanoma patient cohorts for various clinicopathologic parameters, including the incidence of future development of brain metastases. Results from these investigations have shown inconsistent associations between several histopathologic features of the primary melanoma (nodular histology, Breslow thickness of invasion, ulceration), clinical factors (age, primary melanomas from the head and neck), and future development of MBM. Although these data suggest that features from the primary lesion may regulate the CNS tropism of this disease, they do not substantially improve the prognostic value of the existing AJCC staging system (Frankel et al., 2014; Qian et al., 2013; Zakrzewski et al., 2011). Therefore, it is reasonable to postulate that factors linked with the biology of the primary or even premalignant conditions, but not regional lymph node MM (Jackson et al., 2014) may be the culprit. To this end, patients with MM bearing oncogenic mutations in the BRAF and NRAS oncogene were associated with higher frequency of MBM development compared to melanomas that did not bear any hotspot BRAF/NRAS mutations (Jakob et al., 2012). The higher frequency in development of brain metastases for oncogene-driven melanomas can in part explain the worse OS seen in those patients. It also underlies the powerful role of various oncogenes to foster steps leading up to cancer development and progression, such as migration, invasion, survival during hematogenous dissemination, and establishment of brain metastases (Fokas et al., 2013).

The molecular mechanisms, however, that account for this fascinating metastatic organ "tropism" remain speculative. Nevertheless, most melanoma investigators believe that at least two unique, incompletely understood, but established properties of melanoma cells may account for the propensity of melanoma cells for CNS metastases. First, melanoma cells originate from transformed melanocytes, the embryologic derivatives of neural crest cells. This is a transient, highly migratory embryonal cell population that gives rise to several different cell types, including melanocytes. There is growing evidence that genes important for neural crest or embryologic development are overexpressed in a subset of melanomas (Besch and Berking, 2014; Kuphal et al., 2013; Laga et al., 2011; Rao et al., 2010). To this list of neural crest-related genes, it is important to include Rac1, a member of the Ras-related Rho family of GTPases that is important for the maintenance of postmigratory neural crest stem cells. Activating hotspot mutations for Rac1 have been observed in 5-6\% of melanomas (Hodis et al., 2012; Cancer Genome Atlas Network, 2015) and were associated with a worse prognosis (Mar et al., 2014). Second, melanomas can transdifferentiate along the neural pathway. A handful of non-neural crestassociated neuronal proteins have been identified in melanoma cells (Namkoong et al., 2007; Soltani et al., 2005). Apart from these two major properties of melanoma cells, the role of factors other than oncogenic mutations or more specific chemokines in the CNS tropism of melanoma cells is incompletely understood (Izraely et al., 2010). Future translational research that focuses on prospective tumor imaging analysis of primary melanomas for particular neural crest- or neural-associated molecules may help predict metastatic events to the CNS.# Established Melanoma Brain Metastases 

## Translational Research Provides Insights About the Biology of Melanoma Brain Metastases

Before 2011, several single-institution studies have retrospectively investigated prognostic factors for patients with established MBM, such as high systemic tumor burden (serum LDH and S100B), high intracranial tumor burden, successful treatment efforts-local or systemic-to decrease tumor burden, patient's performance status, and age (Davies et al., 2011; Eigentler et al., 2011). Interestingly, presence of BRAF or NRAS mutations in patients with established MBM were found not to be associated with OS, defined as time from first radiographic development of brain metastases to death (Koay et al., 2012). This finding is not surprising and implies that although oncogenes are important to drive the metastatic process to distant organs such as the brain, they may have a less important role in the outcome following the establishment of the lesion at the particular metastatic site. Therefore, other factors related with the "soil," either local (brain microenvironment) or systemic (host immune response), may be important. Nevertheless, presence of such mutations was more frequently associated with symptomatic brain metastases requiring active treatment (Koay et al., 2012).

Translational research using tumor specimens retrospectively collected from patients who have undergone craniotomy for MBM has significantly advanced our knowledge about the pathobiology of MBM. There are obvious limitations to extrapolating conclusions driven by such results to the entire group of patients with MBM; patients who undergo craniotomy may actually have a slightly better prognosis than the entire MBM group (Wronski and Arbit, 2000). In addition, any histopathologic changes observed may actually reflect treatment effect (e.g., previous radiation of a lesion that was becoming symptomatic at the time of craniotomy) and not the true biology of the disease. Nevertheless, systematic histopathologic analysis of tumor specimens from MBM reveals several interesting features (Fig. 17.1). First, melanoma cells are frequently apposed to the abluminal surfaces of vessel walls, a phenomenon that has been previously termed angiotropism (Hung et al., 2013). Second, there is the presence of intratumoral hemorrhage, whose frequency has been previously reported to be the highest in MBM (Kondziolka et al., 1987). Third, there is evidence of infiltration of adjacent glia by melanoma cells, either as single cells or as cell clusters. Fourth, pigmentation is present; this could either be attributed to deposition of hemosiderin secondary to chronic hemorrhage, or due to melanin that is either present within melanoma cells or "ingested" by tissue macrophages, termed melanophages. Fifth, there is the presence of tumor-infiltrating lymphocytes.

We have performed a large retrospective histopathologic analysis of craniotomy specimens obtained from 100 patients who underwent craniotomy for MBM before 2011. The results from this investigation show that the presence of high numbers of lymphocytic infiltrates, in particular peritumoral $\mathrm{CD}^{+}$immune cells, and low levels of intratumoral hemorrhage were associated with prolonged OS, defined as time from craniotomy to death. The prognostic significance of the immune infiltrate in craniotomy specimens in part explains several long-standing clinical observations in MBM research. First, the survival curves in this patient group reach a plateau approximately four years after original diagnosis of MBM. Second, the prognostic significance of tumor burden is inversely proportional to the![img-76.jpeg](img-76.jpeg)

FIGURE 17.1 Histopathologic findings in melanoma brain metastases. Representative tissue sections prepared from craniotomy specimens from patients with MBM that were stained with hematoxylin and eosin (A thru G), or MITF (H, red stain). Images were obtained at $20 \times$ magnification. (A) Immune infiltrate. (B) Hemorrhage. (C) Angiotropism. (D) Reactive glia. (E) Pigmentation. (F) Chronic hemorrhage (Prussian Blue positive; blue stain), (G) and (H) Infiltration of adjacent glia by single melanoma cells (MITF-positive). Abbreviations: tu, tumor; im, immune infiltrate; aHem, acute hemorrhage; cHem, chronic hemorrhage; $g l$, reactive glia; pig, pigment.functioning of the immune system in the overall prognosis of this patient subgroup. Third, the clinical benefit of immunotherapies even in patients with active brain metastases, as will be discussed below (Margolin et al., 2012). In fact, patients with both low intratumoral hemorrhage and high density of immune infiltrates enjoyed the longest OS compared to all other groups. Unfortunately, this favorable histopathologic combination is only present in approximately $20 \%$ of cases, which may in part explain the short OS of patients with MBM. In contrast, the extent of necrosis, melanin, and gliosis did not achieve any prognostic significance (Hamilton et al., 2013). Although the prognostic significance of intracranial hemorrhage quantified by nonhistopathologic methods, has been previously reported (Liew et al., 2011), the significance of immune infiltrates within MBM is new and builds upon a handful of previous underpowered retrospective studies that had previously described lymphocytic infiltrates in craniotomy specimens from patients with MM (Strik et al., 2004).

Most recent studies led by us (Moschos et al., 2014) and others (Berghoff et al., 2014) have further characterized the immune infiltrate in relation to expression of the programmed death ligand 1 (PD-L1), an important co-inhibitory immune checkpoint protein that is frequently upregulated in chronic inflammatory diseases, such as certain infections and cancer (Wherry, 2011). The results from these studies show that PD-L1 is indeed expressed by MBM. To more precisely quantify PD-L1 expression among different cell types (melanoma, stromal cells), sophisticated tumor imaging computer analysis was performed. The results from these studies showed that PD-L1 is not only expressed by melanoma and mononuclear immune cells, but also by the reactive glia, whereas the PD-L1 expression was very low by adjacent normal brain parenchyma (Fig. 17.2). Furthermore, and using OS information to define the "optimal" cut-point between "high" versus "low" expression of PD-L1 by melanoma cells, we found that patients whose melanoma cells in MBM demonstrated high expression of PD-L1 had worse OS compared to "low" expressors (Moschos et al., 2014). The expression of PD-L1 by reactive glia was equally interesting, and, in fact, has been previously described in various intracranial inflammatory states (Jacobs et al., 2009; Phares et al., 2009; Pittet et al., 2011). Expression of PD-L1 by glial cells may constitute a novel mechanism of immunosuppression exerted by the glial microenvironment on melanoma (Gimsa et al., 2013).

Further tumor tissue-based research in craniotomy specimens and/or extracranial metastases from the same melanoma patients has provided additional insights into the biology of MBM. Immunohistochemical analysis of craniotomy melanoma specimens for the presence of BRAFV600E mutation, the most frequent oncogenic mutation in melanoma (Hodis et al., 2012), revealed no association between expression of BRAFV600E and OS, defined as time from craniotomy to death (Capper et al., 2012). The direct investigation of the BRAFV600 mutation status in craniotomy specimens and the lack of differences in OS is in agreement with previous reports and complements data about the prognostic significance of intratumoral hemorrhage and host immune response for MBM. A larger scale search for genetic events unique in MBM via integrated analysis of same-patient brain metastases and extracranial metastases revealed no significant enrichment of MBM specimens for particular mutations or copy number events (Chen et al., 2014; Davies et al., 2009).

Our group has also performed whole genome expression profiling of 29 melanoma specimens from the original 100-patient craniotomy cohort. We focused our analysis on cell processes that were prognostically significant. While several pathways related with immune![img-77.jpeg](img-77.jpeg)

FIGURE 17.2 Expression of various proteins in tissues obtained from craniotomy for MBM. Representative tissue sections were stained with antibodies (red) against PD-L1 (A), HIF1 $\alpha$ (B), PAFAH1B1 (C), and VEGF (D) and counterstained with hematoxylin. Images were obtained at $20 \times$ magnification. Please note differential expression of various proteins by different cells within the melanoma brain metastatic lesions ( $t u$, tumor; im, immune infiltrates; $g l$, reactive glia). (E) Immunoblot analysis of whole cell protein lysates that were prepared from 2 untreated normal human melanocytes (NHM) and 15 untreated melanoma cell lines with various genetic background (BRAFmut, red; NRASmut, green; wild type for BRAF and NRAS, black). Source: Immunoblot images were a courtesy of Drs Janiel Shields and Maria Sambade, University of North Carolina at Chapel Hill.
system function were associated with prolonged OS (e.g., "CD3 complex," "T helper surface molecules," "Lck and Fyn kinases initiate TCR activation"), pathways such as "hypoxiainducible factor," "lissencephaly gene in neuronal migration and development" were associated with worse prognosis (Hamilton et al., 2013). Shown in Fig. 17.2 are representative tissue sections from craniotomy specimens obtained from patients with MBM that were immunohistochemically stained for hypoxia inducible factor 1 alpha (HIF1 $\alpha$ ) and vascular endothelial growth factor-A (VEGF-A), two of the genes that belong to the "hypoxia-inducible factor" Biocarta category, as well as the platelet-activating factor acetylhydrolase 1b, regulatory subunit/lissencephaly-1 protein (PAFAH1B1/LIS1), which belongs to the "lissencephaly gene in neuronal migration and development" Biocarta category. PAFAH1B1/LIS1 is normally involved in the proper activation of Rho GTPases and actin polymerization at the leading edge of neurons. We found that PAFAH1B1/LIS1 was expressed in various melanoma cell lines, irrespective of genetic background (Fig. 17.2E). The expression of proteins (VEGF, HIF1 $\alpha$ ) which can also be regulated by environmental factors (e.g., oxygen) as well as theexpression of "neuronal" proteins by melanoma cells (e.g., PAFAH1B1/LIS1) suggests that, in addition to the "seed", further research should focus on the role of "soil" and its impact on the "seed" to identify better prognostic factors and treatment strategies for patients with MBM (Fidler, 2011).

To further investigate the role of genes whose expression interfaces between oxygen supply, blood vessel density and maturation, angiogenic factors, intratumoral hemorrhage, and melanoma biology, we and others investigated the expression of angiogenic cytokines and vasculature in melanoma biopsies obtained from patients with MBM. Using endoglin (CD105) as a marker for angiogenesis, microvessel density (MVD) was manually counted in brain metastases from melanoma, lung carcinoma, and breast cancer. MVD was significantly smaller in brain metastases from melanoma as opposed to breast cancer whereas no significant differences in the MVD between brain metastases from melanoma and lung cancer were seen (Salgado et al., 2007). These results are interesting because they suggest that MBM may somehow depend on fewer blood vessels for intracranial growth, but this effect alone does not have an impact on OS.

To investigate the prognostic significance of angiogenic factors, quality of blood vessels, and hypoxic markers in MBM as well as their association with adverse histopathologic factors such as intratumoral hemorrhage, we stained representative craniotomy tissues sections for basic fibroblast growth factor (bFGF), a cytokine that is frequently expressed by melanocytes and melanoma cells, VEGF, HIF1 $\alpha$, as well as markers of mature (CD31 ${ }^{+}$SMA ${ }^{+}$) or immature blood vessels (CD31 ${ }^{+}$SMA ${ }^{-}$). Similar to the PD-L1 expression, sophisticated tumor imaging analysis revealed a number of interesting results. First, no correlation between MVD of immature-"leaky" pericyte-free blood vessels with OS as well as with intratumoral hemorrhage was seen. Second, although the MVD of adjacent reactive glia was significantly higher compared to that of normal brain, it was comparable to the MVD of melanoma. Third, although VEGF was indeed expressed by melanoma cells, it was not significantly different from that of adjacent reactive glia or dense mononuclear infiltrates. Fourth, bFGF expression by melanoma cells was significantly higher than that from adjacent reactive glia and dense lymphocytic infiltrates. Fifth, HIF1 $\alpha$ within MBM was predominantly expressed by melanoma and lymphocytic infiltrates, but not by reactive glia or normal brain. Finally, patients who endured MBM longer appeared to have a lower melanoma expression of bFGF and higher expression of HIF1 $\alpha$ by melanoma cells (Moschos et al., 2014).

The favorable prognostic significance of factors associated with hypoxia, such as HIF1 $\alpha$, is counterintuitive and against the common notion that HIF1 $\alpha$ and its downstream effectors that have been previously associated with vasogenic brain edema, such as VEGF (Strugar et al., 1994), play an adverse role in the biology of established MBM. Given that VEGF is expressed to a similar degree by melanoma cells, reactive glia, and mononuclear infiltrates (Moschos et al., 2014) and the adverse prognostic significance of the "hypoxia-inducible factor" pathway, our findings raise the possibility that it is actually the lack of "hypoxic" response that may negatively affect OS, defined as craniotomy to death. Two independent levels of evidence support the latter hypothesis. First, under physiologic conditions, Schwann cell-derived VEGF is important for neurogenesis, neurite extensions, and neurite maturation, in addition to its role in brain angiogenesis; during nervous system damage, VEGF is equally important for new vessel growth and tissue repair (Rosenstein et al., 2010).Second, a large retrospective analysis of patients with a solitary brain metastasis from various solid tumors showed that large peritumoral edema was associated with prolonged OS and with higher immunohistochemical expression of HIF1 $\alpha$ (Rosenstein et al., 2010). These findings may revisit the prevailing clinical assumption that "peritumoral edema = adverse prognosis," and reconsider a prevailing clinical practice that any brain tumor with any degree of peritumoral brain edema must be treated with corticosteroids, an immunosuppressive strategy. Such intriguing results should obviously be confirmed in larger prospective studies.

# Preclinical Studies in Melanoma Brain Metastases; Learning Something More When "Burr-Hole" Surgery and Obtaining Tumor Tissue Is Not an Option 

IN VITRO STUDIES PROVIDE SIGNIFICANT INSIGHTS ABOUT TUMOR-GLIAL INTERACTIONS

Reactive glia is an activated form of nonneuronal cells in response to various stressors imposed upon the CNS. Reactive glia promotes tissue integrity, restricts inflammation, and, possibly, neuronal death (Yang et al., 2013). In our histopathologic analysis of 100 craniotomy specimens, reactive gliosis was not a significant prognostic factor for OS, although only $50 \%$ of specimens had sufficient amount of reactive glia for analysis. Nevertheless, the lack of association may be attributed to the crude histopathologic definition that was used to describe the response of the adjacent brain toward melanoma, namely the presence of reactive astrocytes with abundant eosinophilic cytoplasm and large displaced nucleus in the brain parenchyma near the tumor. Earlier in this chapter we have shown that reactive glia is a major source of angiogenic cytokines, such as VEGF, and immunomodulatory proteins, such as PD-L1 (Moschos et al., 2014). Further in vitro studies using the melanomaastrocyte coculture model have further shown that glia may render melanoma cells less sensitive to systemic treatments. More specifically, coculture between immortalized astrocyte cell lines with melanoma cells revealed that astrocytes form multiple podia in direct contact with tumor cells. Furthermore, treatment of melanoma cells with chemotherapeutic agents attenuated apoptosis when melanoma cells were cocultured with astrocytes (Lin et al., 2010). In a more clinically relevant model, melanoma cell lines were established from MBM from patients who were previously treated with vemurafenib. Treatment of these shortterm cultures with astrocyte-conditioned medium obtained from immortalized human fetal astrocytes lead to significant upregulation of the Akt pathway and stimulated melanoma invasiveness compared with fibroblast conditioned medium (Niessner et al., 2013a,b). The nature of paracrine factor(s) secreted by reactive glia that may influence tumor cell growth is currently under investigation (Valiente et al., 2014).

## Preclinical Animal Models to Study Melanoma Brain Metastases

Most genetically engineered mouse melanoma models rarely develop spontaneous distant metastases. Of those models that develop distant metastases, only two have been reported to induce spontaneous MBM (Kato et al., 1998; Zhu et al., 1998). Admittedly, however, none of the genes that were disrupted in these two models appear to have a direct role in melanoma biology. To overcome this challenge, various melanoma cell lines were either xenografted in different murine organ sites (brain, skin, and orthotopic tumor sites) of immunosuppressedmice (Cruz-Munoz et al., 2008, 2012; Park et al., 2011) or were injected either in the internal carotid artery or intracardially to increase the yield of spontaneous development of brain metastases (Daphu et al., 2013; Huang et al., 2008; Kusters et al., 2002; Stoletov et al., 2013; Zhang et al., 2009). Melanoma cells that were able to establish brain metastases following intracardiac or intracarotid injection were efficient in their ability to adhere to brain endothelial cells and proliferate in the presence of brain-conditioned medium (Cruz-Munoz et al., 2008). Of the molecules that were investigated for their role in MBM biology, others appeared to have a more restricted role in the establishment of MBM (e.g., TGF $\beta 2$, EDNRB/BCL2A1, Cx26) (Cruz-Munoz et al., 2012; Stoletov et al., 2013; Zhang et al., 2009), whereas others affected both melanoma cell growth and the brain microenvironment (e.g., VEGF, SOCS-1) (Huang et al., 2008; Kusters et al., 2002). In addition to the utility of brain xenograft models to study the role of several molecules which regulate development and progression of MBM, several such animal models have been valuable in testing the intracranial antitumor efficacy of various systemic treatments (Cruz-Munoz et al., 2012; Stoletov et al., 2013). Although the immunohistochemical expression of most of these molecules was confirmed in tumor specimens from human craniotomies, the results from these studies should be interpreted with caution due to the inherent lack of a fully functioning host immune system.

A handful of syngeneic models have also been reported in which murine melanoma cell lines were injected either intracerebrally or intracranially to develop MBM (Amit et al., 2013; Kong et al., 2010; Radinsky et al., 1995; Stoletov et al., 2013; Tentori et al., 2003). These models are immunocompetent and therefore overcome the challenges of interpretation of results from xenograft studies. More specifically, these models more closely recapitulate intracranial disease with identification of T cells in MBM and have been used toward testing the effect of immunotherapies in MBM. Their weaknesses stem from the fact that these are essentially murine melanoma models; therefore, the interpretation of the findings for the human disease, including testing human, clinical-grade treatment, may not be possible. Humanized models of melanoma, which will be comprised of immune system reconstituted within immunodeficient mice (e.g., HLA-A2/NSG-hu mice) from $\mathrm{CD} 34^{+}$cells obtained patient, followed by grafting of melanoma tumors from the same patient, are expected to revolutionize in vivo preclinical investigation of MBM, including testing of human, clinicalgrade treatments.

# TREATMENT OF MELANOMA BRAIN METASTASES: PRESENT AND FUTURE 

## Great Improvements Since 2011

In the era before 2011, the greatest progress in the treatment of patients with active MBM was the introduction of stereotactic radiosurgery in the 1990s, which obviated the need for whole brain irradiation, and probably decreased the need for craniotomies. Chemotherapies had little benefit, including drugs with considerable CNS penetration such as temozolomide and fotemustine (Agarwala et al., 2004; Mornex et al., 2003), whereas combinations of chemotherapies with radiation therapies were usually associated with higher toxicity without any definite benefit (Schild et al., 2010). After 2011, significant advances havebeen made toward systemic treatment of MM with the approval of four agents within three years (McArthur and Ribas, 2013). A fifth one that inhibits the co-inhibitory immune checkpoint protein PD1 (pembrilizumab, former lambrolizumab/MK-3475), is expected FDA approval later in 2014 (Robert et al., 2014). It is important to emphasize that all pivotal studies which led to the FDA approval of these agents were conducted in patients without any radiographically detectable MBM. Although these studies cannot address the question of whether the corresponding drugs tested are also effective in patients with active MBM, it is reasonable to postulate that the prolonged progression-free survival and OS that was seen in these randomized phase III trials in favor of these agents was, among other mechanisms, probably secondary to the delay in the development of radiographically detectable MBM. In other words, assuming that several of those patients who were enrolled in these trials were likely to have had nonradiographically detectable microscopic/dormant MBM during study enrollment and initiation, as it has been elegantly shown in experimental brain tumor models (Percy et al., 2011), these agents were able to effectively treat these MBM if truly present. In fact, clinical trials testing the exact same FDA-approved agents in patients with active MBM showed a considerable clinical benefit for the first time in the history of MBM (Dummer et al., 2014; Long et al., 2012; Margolin et al., 2012).

Two important questions were raised following the results from the three trials that were conducted in patients with active MBM (Dummer et al., 2014; Long et al., 2012; Margolin et al., 2012). First, how do these drugs exert their antitumor effect within the brain since preclinical data suggest that they do not penetrate the BBB under physiologic conditions either due to their large size (e.g., monoclonal antibodies; ipilimumab, MK-3475) or due to the activity of drug efflux pumps that operate across the BBB (Mittapalli et al., 2012, 2013; Vaidhyanathan et al., 2014)? Data from limited preclinical animal models of brain metastases suggest that the BBB is disrupted to a variable, but usually minimal, extent such that suboptimal concentrations (in one study it was reported to be as low as $15 \%$ ) of therapeutic agents normally reach intracranial tumors (Lockman et al., 2010). This mechanism may predominantly affect agents that are expected to have a direct antitumor effect, such as the small molecule inhibitors vemurafenib, dabrafenib, and trametinib. In line with this, the BRV116521 study is currently testing dabrafenib plus trametinib in patients with active MBM who have agreed to allow resection of an intracranial lesion in order to assess intratumoral drug levels at the time when both drugs achieve steady-state levels (approximately eight days after treatment initiation; Clinicaltrials.gov identifier: NCT01978236). In addition, other mechanisms may account for the treatment benefit exerted by immunotherapies. Since approximately $50 \%$ of MBM that were collected following craniotomy contain lymphocytic infiltrates (Hamilton et al., 2013) and the fact that under physiologic conditions the brain is constantly surveyed by effector T cells through local configurations of the BBB (Loeffler et al., 2011), it is reasonable to hypothesize that immunotherapies may at least reverse extracranial immunosuppression. Under this concept, more competent lymphocytes from the periphery may be able to infiltrate MBM. This latter concept may well explain a long clinical observation that patients with MBM die more frequently ( $60 \%$ ) from extracranial metastases as opposed to death from intracranial events (e.g., hemorrhage, seizures).

Second, why did all three FDA-approved drugs tested in patients with active MBM exert an inferior benefit compared to their corresponding effect in patients who had solelyextracranial distant metastases? As discussed earlier, it is quite possible that suboptimal drug levels are achieved within the tumor brain parenchyma due to a partially disrupted BBB from the cancer. It is also possible that the brain microenvironment may protect melanoma cells from cell death. The latter was also shown when short-term melanoma cultures established from craniotomy specimens obtained from patients who developed new active MBM following vemurafenib treatment were treated with astrocyte-conditioned medium and showed upregulation of Akt signaling (Niessner et al., 2013a,b).

# The Future of the Treatment of Patients with Metastatic Brain Metastases 

If systemic treatments prolong OS in patients with MM, it is reasonable to speculate that administering such treatments in patients at high risk for development of MM may both prevent development of MM, and MBM in particular. At this time, only immunotherapeutic strategies that broadly activate the immune system, such as type I interferons and CTLA4 blocking antibodies, appear to have clinical benefit. For patients who develop MBM, further clinical benefit is expected if four important concepts are taken into consideration. First, maximal suppression of established oncogenic pathways. In line with this, BRF117277 is a phase II study of concurrent administration of dabrafenib plus trametinib in patients with active MBM (Clinicaltrials.gov identifier: NCT02039947) and aims to maximize the degree of suppression of the MAPK pathway, similar to the considerable progression-free survival benefit that was observed when both drugs were compared against dabrafenib in patients with extracranial MM (Long et al., 2014). Promising targeted treatments are also being developed for patients with NRAS-mutant melanoma (Sosman et al., 2014), another high-risk group for development of MBM (Jakob et al., 2012). Second, identification and targeting of other signaling pathways on which melanoma cells may depend for survival within the brain. The PI3K/Akt pathway appears to play an important role in MBM based on several lines of evidence (Chen et al., 2014; Davies et al., 2009; Niessner et al., 2013a,b). Third, treatment of patients with active MBM with more CNS-penetrant targeted therapies which play an important role in patients with established MBM. In support of this, a proof-of-principle preclinical study of the brain-penetrant pan-PI3K inhibitor BKM120 showed promising intracranial activity (Niessner et al., 2013a,b). Fourth, targeting the brain tumor microenvironment may maximize benefit from direct antitumor strategies. Although little is known about the important components, our and other groups' findings suggest that immunotherapeutic approaches, in particular the PD1-PDL1 pathway, may be beneficial to break immune tolerance within MBM. A pilot study of the PD-1 inhibitor pembrilizumab/MK-3475 in patients with active MBM is under way (Clinicaltrials.gov identifier: NCT02085070). In such a study, safety is also an important concern given the potential important role of the PD1-PDL1 in dampening immune response within organ sites where inflammation and swelling may be deleterious (e.g., brain). Our preliminary data regarding the potential favorable prognostic significance of VEGF/HIF1 $\alpha$ by melanoma cells may raise concerns about treatment strategies that block such pathways and may be important for normal brain homeostasis (e.g., bevacizumab) and may also raise concerns about the frequent indiscriminate use of corticosteroids to treat MBM by clinicians.# Where Does Radiation Therapy Fit into the Picture? 

What would be the role of radiation therapy in MBM in this new era of targeted therapies? Even if no mechanistic data exist about the potential for synergism between radiation treatment and the recent FDA-approved therapies, radiation by itself could potentially increase drug levels within the brain tumor parenchyma by further disrupting the already compromised BBB of patients with brain metastases (Gerstner and Fine, 2007). However, increasing evidence suggests that radiation therapy induces systemic effects beyond its ability to effectively control local disease. It is now established that radiation therapy requires functional immune system for maximum benefit (Lee et al., 2009) by inducing nonapoptotic, immunologic modes of cell death (necrophagy, autophagy). More specifically, molecular signals released by dying cancer cells promote uptake of circulating tumor antigens by dendritic cells. These antigens are in turn cross-presented to T cells and activate effector immune response. In essence, an irradiated tumor is converted into an in situ vaccine. The ability of radiation to induce not only local but also systemic immune response has been described by antitumor responses in tumors outside the radiation field (Frey et al., 2014). In this immunologic phenomenon, co-inhibitor immune checkpoint proteins have shown to play a role in preclinical syngeneic animal models. For example, CTLA-4 blockade and hypofractionated doses of irradiation have shown a synergistic effect (Dewan et al., 2009; Ruocco et al., 2012), whereas ionizing radiation has shown to upregulate PD-L1 which, if inhibited, has a similar synergistic antitumor effect (Deng et al., 2014). Similarly, in a preclinical glioma model, the combination of stereotactic radiotherapy with PD-1 blockade was synergistic (Zeng et al., 2013). Two retrospective analyses of patients with MBM who underwent definitive radiosurgery with or without ipilimumab showed significant progres-sion-free survival in the radiation-ipilimumab group as opposed to radiation therapy alone (Knisely et al., 2012; Silk et al., 2013).

In addition to its immunomodulatory role, radiation therapy may also synergize with small molecule inhibitors. In preclinical studies using BRAF-mutant melanoma cell lines, suppression of the BRAF pathway was synergistic with radiation therapy (Sambade et al., 2011). Case series of patients who undergo radiation therapy for MBM in combination with recently FDA-approved agents have already been reported (Mathew et al., 2013; Narayana et al., 2013), but no systematic studies have been performed and safety should not be taken for granted (du Four et al., 2012; Satzger et al., 2013). Therefore, prospective studies testing the optimal radiation dose and schedule in combination with inhibitors of co-inhibitory immune checkpoint pathways or small molecule inhibitors are anticipated to refine and optimize the use of radiation therapy in the right setting for patients with MBM.

In summary, the treatment landscape of patients with active MBM is rapidly changing. Better understanding of the biology of MBM has already translated into more effective treatments or simply a better understanding of the mechanism of action of existing ones (e.g., radiation therapy). Further improvements in the treatment of MBM should occur on all fronts: better systemic treatments for patients with early stage nonmetastatic disease using appropriate risk stratification and based on evolving knowledge of predictive biomarkers of development of MBM as well as combination strategies between local treatments, mainly radiation therapy, plus targeted or immunotherapeutic strategies.# References 

Agarwala, S.S., Kirkwood, J.M., Gore, M., et al., 2004. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J. Clin. Oncol. 22, 2101-2107.
Amit, M., Laider-Trejo, L., Shalom, V., et al., 2013. Characterization of the melanoma brain metastatic niche in mice and humans. Cancer Med. 2, 155-163.
Balch, C.M., Gershenwald, J.E., Soong, S.J., et al., 2009. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199-6206.
Berghoff, A.K., Kiesel, B., Widhalm, et al. 2014. Tumor-infiltrating lymphocytes (TILs) and expression of PD-L1 in melanoma brain metastases (abstr 9055). In: ASCO Annual Meeting, Chicago, IL.
Besch, R., and Berking, C., 2014. POU transcription factors in melanocytes and melanoma. Eur. J. Cell Biol. 93, 55-60.
Cancer Genome Atlas Network, 2015. Genomic classification of cutaneous Melanoma. Cell. 161, 1681-1696.
Capper, D., Berghoff, A.S., Magerle, M., et al., 2012. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol. 123, 223-233.
Chen, G., Chakravarti, N., Aardalen, K., et al., 2014. Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin. Cancer Res. 20, 5537-5546.
Chu, M.B., Fesler, M.J., Armbrecht, E.S., et al., 2013. High-dose interleukin-2 (HD IL-2) therapy should be considered for treatment of patients with melanoma brain metastases. Chemother. Res. Pract. 2013 2013;2013:726925. http://dx.doi.org/10.1155/2013/726925. (Epub 2013 May 13).
Cruz-Munoz, W., Man, S., Xu, P., and Kerbel, R.S., 2008. Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. Cancer Res. 68, 4500-4505.
Cruz-Munoz, W., Jaramillo, M.L., Man, S., et al., 2012. Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma. Cancer Res. 72, 4909-4919.
Daphu, I., Sundstrom, T., Horn, S., et al., 2013. In vivo animal models for studying brain metastasis: value and limitations. Clin. Exp. Metastasis 30, 695-710.
Davies, M.A., Stemke-Hale, K., Lin, E., et al., 2009. Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin. Cancer Res. 15, 7538-7546.
Davies, M.A., Liu, P., McIntyre, S., Kim, K.B., et al., 2011. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117, 1687-1696.
Deng, L., Liang, H., Burnette, B., et al., 2014. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124, 687-695.
Dewan, M.Z., Galloway, A.E., Kawashima, N., et al., 2009. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res. 15, $5379-5388$.
du Four, S., Wilgenhof, S., Duerinck, J., et al., 2012. Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies. Eur. J. Cancer 48, 3045-3051.
Dummer, R., Goldinger, S.M., Turtschi, C.P., et al., 2014. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur. J. Cancer 50, 611-621.
Eigentler, T.K., Figl, A., Krex, D., et al., 2011. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 117, $1697-1703$.
Fidler, I.J., 2011. The role of the organ microenvironment in brain metastasis. Semin. Cancer Biol. 21, 107-112.
Fokas, E., Steinbach, J.P., and Rodel, C., 2013. Biology of brain metastases and novel targeted therapies: time to translate the research. Biochim. Biophys. Acta 1835, 61-75.
Frankel, T.L., Bamboat, Z.M., Ariyan, C., et al., 2014. Predicting the development of brain metastases in patients with local/regional melanoma. J. Surg. Oncol. 109, 770-774.
Frey, B., Rubner, Y., Kulzer, L., et al., 2014. Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol. Immunother. 63, 29-36.
Galon, J., Pages, F., Marincola, F.M., et al., 2012. The immune score as a new possible approach for the classification of cancer. J. Transl. Med. 10, 1.
Gerstner, E.R., and Fine, R.L., 2007. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J. Clin. Oncol. 25, 2306-2312.
Gimsa, U., Mitchison, N.A., and Brunner-Weinzierl, M.C., 2013. Immune privilege as an intrinsic CNS property: astrocytes protect the CNS against T-cell-mediated neuroinflammation. Mediators Inflamm. 2013, 320519.Gorantla, V., Kirkwood, J.M., and Tawbi, H.A., 2013. Melanoma brain metastases: an unmet challenge in the era of active therapy. Curr. Oncol. Rep. 15, 483-491.
Hamilton, R., Krauze, M., Romkes, M., et al., 2013. Pathologic and gene expression features of metastatic melanomas to the brain. Cancer 119, 2737-2746.
Hodis, E., Watson, I.R., Kryukov, G.V., et al., 2012. A landscape of driver mutations in melanoma. Cell 150, 251-263.
Huang, F.J., Steeg, P.S., Price, J.E., et al., 2008. Molecular basis for the critical role of suppressor of cytokine signal-ing-1 in melanoma brain metastasis. Cancer Res. 68, 9634-9642.
Hung, T., Morin, J., Munday, W.R., et al., 2013. Angiotropism in primary cutaneous melanoma with brain metastasis: a study of 20 cases. Am. J. Dermatopathol. 35, 650-654.
Izraely, S., Klein, A., Sagi-Assif, O., et al., 2010. Chemokine-chemokine receptor axes in melanoma brain metastasis. Immunol. Lett. 130, 107-114.
Jackson, J.E., Burmeister, B.H., Burmeister, E.A., et al., 2014. Melanoma brain metastases: the impact of nodal disease. Clin. Exp. Metastasis 31, 81-85.
Jacobs, J.F., Idema, A.J., Bol, K.F., et al., 2009. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol. 11, 394-402.
Jakob, J.A., Bassett Jr., R.L., Ng, C.S., et al., 2012. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118, 4014-4023.
Kato, M., Liu, W., Yi, H., et al., 1998. The herbal medicine Sho-saiko-to inhibits growth and metastasis of malignant melanoma primarily developed in ret-transgenic mice. J. Invest. Dermatol. 111, 640-644.
Knisely, J.P., Yu, J.B., Flanigan, J., et al., 2012. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J. Neurosurg. 117, 227-233.
Koay, E.J., Bucheit, A.D., Jakob, J.A., et al. 2012. Correlation of BRAF and NRAS mutation status with tumor characteristics and treatment outcomes in melanoma patients with brain metastasis (abstr 8584). In: ASCO Annual Meeting, Chicago, IL.
Kondziolka, D., Bernstein, M., Resch, L., et al., 1987. Significance of hemorrhage into brain tumors: clinicopathological study. J. Neurosurg. 67, 852-857.
Kong, L.Y., Gelbard, A., Wei, J., et al., 2010. Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin. Cancer Res. 16, 2550-2561.
Kuphal, S., Wallner, S., and Bosserhoff, A.K., 2013. Impact of LIF (leukemia inhibitory factor) expression in malignant melanoma. Exp. Mol. Pathol. 95, 156-165.
Kusters, B., Leenders, W.P., Wesseling, P., et al., 2002. Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res. 62, 341-345.
Laga, A.C., Zhan, Q., Weishaupt, C., et al., 2011. SOX2 and nestin expression in human melanoma: an immunohistochemical and experimental study. Exp. Dermatol. 20, 339-345.
Lee, Y., Auh, S.L., Wang, Y., et al., 2009. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114, 589-595.
Liew, D.N., Kano, H., Kondziolka, D., et al., 2011. Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J. Neurosurg. 114, 769-779.
Lin, Q., Balasubramanian, K., Fan, D., et al., 2010. Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia 12, 748-754.
Lockman, P.R., Mittapalli, R.K., Taskar, K.S., et al., 2010. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin. Cancer Res. 16, 5664-5678.
Loeffler, C., Dietz, K., Schleich, A., et al., 2011. Immune surveillance of the normal human CNS takes place in dependence of the locoregional blood-brain barrier configuration and is mainly performed by CD3(+)/CD8(+) lymphocytes. Neuropathology 31, 230-238.
Long, G.V., Trefzer, U., Davies, M.A., et al., 2012. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 1087-1095.
Long, G.V., Stroyakovsky, D.L., Gogas, H., et al. 2014. COMBI-d: a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma (abstr 9011). In: ASCO Annual Meeting, Chicago, IL.
Mar, V.J., Wong, S.Q., Logan, A., et al., 2014. Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma. Pigment Cell Melanoma Res. 27, 1117-1125.

# II. TREATMENT AND PROGNOSISMargolin, K., Ernstoff, M.S., Hamid, O., et al., 2012. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13, 459-465.
Mathew, M., Tam, M., Ott, P.A., et al., 2013. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res. 23, 191-195.
Mathieu, D., Kondziolka, D., Cooper, P.B., et al., 2007. Gamma Knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery 60, 471-481. discussion 481-472.
McArthur, G.A., and Ribas, A., 2013. Targeting oncogenic drivers and the immune system in melanoma. J. Clin. Oncol. 31, 499-506.
Mittapalli, R.K., Vaidhyanathan, S., Sane, R., and Elmquist, W.F., 2012. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J. Pharmacol. Exp. Ther. 342, 33-40.
Mittapalli, R.K., Vaidhyanathan, S., Dudek, A.Z., and Elmquist, W.F., 2013. Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J. Pharmacol. Exp. Ther. 344, 655-664.
Mornex, F., Thomas, L., Mohr, P., et al., 2003. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res. 13, 97-103.
Moschos, S.J., Trembath, D.G., Snavely, A.C., et al. 2014. Prognostic significance of PD-L1 expression, angiogenesis, and hypoxia in melanoma brain metastases (MBM): a histopathologic analysis (abstr 9038). In: ASCO Annual Meeting, Chicago, IL.
Namkoong, J., Shin, S.S., Lee, H.J., et al., 2007. Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res. 67, 2298-2305.
Narayana, A., Mathew, M., Tam, M., et al., 2013. Vemurafenib and radiation therapy in melanoma brain metastases. J. Neurooncol. 113, 411-416.

Nathanson, K.L., Martin, A.M., Wubbenhorst, B., et al., 2013. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin. Cancer Res. 19, 4868-4878.
Niessner, H., Forschner, A., Klumpp, B., et al., 2013a. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med. 2, 76-85.
Niessner, H., Schmitz, J., Schmid, A., et al. 2013b. The PI3K inhibitor BKM120 has potent antitumor activity in melanoma brain metastases in vitro and in vivo. Tenth Anniversary International Congress., Philadelphia, PA.
Park, E.S., Kim, S.J., Kim, S.W., et al., 2011. Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. Proc. Natl. Acad. Sci. U.S.A. 108, 17456-17461.
Percy, D.B., Ribot, E.J., Chen, Y., et al., 2011. In vivo characterization of changing blood-tumor barrier permeability in a mouse model of breast cancer metastasis: a complementary magnetic resonance imaging approach. Invest. Radiol. 46, 718-725.
Phares, T.W., Ramakrishna, C., Parra, G.I., et al., 2009. Target-dependent B7-H1 regulation contributes to clearance of central nervous system infection and dampens morbidity. J. Immunol. 182, 5430-5438.
Pittet, C.L., Newcombe, J., Antel, J.P., and Arbour, N., 2011. The majority of infiltrating CD8 T lymphocytes in multiple sclerosis lesions is insensitive to enhanced PD-L1 levels on CNS cells. Glia 59, 841-856.
Preusser, M., Capper, D., Ilhan-Mutlu, A., et al., 2012. Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol. 123, 205-222.
Qian, M., Ma, M.W., Fleming, N.H., et al., 2013. Clinicopathological characteristics at primary melanoma diagnosis as risk factors for brain metastasis. Melanoma Res. 23, 461-467.
Radinsky, R., Beltran, P.J., Tsan, R., et al., 1995. Transcriptional induction of the melanocyte-stimulating hormone receptor in brain metastases of murine K-1735 melanoma. Cancer Res. 55, 141-148.
Rao, P., Fuller, G.N., and Prieto, V.G., 2010. Expression of Sox-9 in metastatic melanoma-a potential diagnostic pitfall. Am. J. Dermatopathol. 32, 262-266.
Robert, C., Ribas, A., Wolchok, J.D., et al., 2014. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 384, 1109-1117.
Rosenstein, J.M., Krum, J.M., and Ruhrberg, C., 2010. VEGF in the nervous system. Organogenesis 6, 107-114.
Ruocco, M.G., Pilones, K.A., Kawashima, N., et al., 2012. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J. Clin. Invest. 122, 3718-3730.

# II. TREATMENT AND PROGNOSISSalgado, K.B., Toscani, N.V., Silva, L.L., et al., 2007. Immunoexpression of endoglin in brain metastasis secondary to malignant melanoma: evaluation of angiogenesis and comparison with brain metastasis secondary to breast and lung carcinomas. Clin. Exp. Metastasis 24, 403-410.
Sambade, M.J., Peters, E.C., Thomas, N.E., et al., 2011. Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother. Oncol. 98, 394-399.
Satzger, I., Degen, A., Asper, H., et al., 2013. Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy. J. Clin. Oncol. 31, e220-e222.
Schild, S.E., Behl, D., Markovic, S.N., et al., 2010. Brain metastases from melanoma: Is there a role for concurrent temozolomide in addition to whole brain radiation therapy? Am. J. Clin. Oncol. 33, 633-636.
Shapiro, D.G., and Samlowski, W.E., 2011. Management of melanoma brain metastases in the era of targeted therapy. J. Skin Cancer 2011, 845863.
Siegel, R., Ma, J., Zou, Z., and Jemal, A., 2014. Cancer statistics, 2014. CA Cancer J. Clin. 64, 9-29.
Silk, A.W., Bassetti, M.F., West, B.T., et al., 2013. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med. 2, 899-906.
Soltani, M.H., Pichardo, R., Song, Z., et al., 2005. Microtubule-associated protein 2, a marker of neuronal differentiation, induces mitotic defects, inhibits growth of melanoma cells, and predicts metastatic potential of cutaneous melanoma. Am. J. Pathol. 166, 1841-1850.
Sosman, J.A., Kittaneh, M., Lolkema, M.P.J.K., et al. 2014. A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: early encouraging clinical activity (abstr 9009). In: ASCO 2014 Annual Meeting, Chicago, IL.
Stoletov, K., Strnadel, J., Zardouzian, E., et al., 2013. Role of connexins in metastatic breast cancer and melanoma brain colonization. J. Cell Sci. 126, 904-913.
Strik, H.M., Stoll, M., and Meyermann, R., 2004. Immune cell infiltration of intrinsic and metastatic intracranial tumours. Anticancer Res. 24, 37-42.
Strugar, J., Rothbart, D., Harrington, W., and Criscuolo, G.R., 1994. Vascular permeability factor in brain metastases: correlation with vasogenic brain edema and tumor angiogenesis. J. Neurosurg. 81, 560-566.
Tentori, L., Leonetti, C., Scarsella, M., et al., 2003. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin. Cancer Res. 9, 5370-5379.
Thomas, N.E., Busam, K.J., From, L., et al., 2013. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J. Clin. Oncol. 31, 4252-4259.
Vaidhyanathan, S., Mittapalli, R.K., Sarkaria, J.N., and Elmquist, W.F., 2014. Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases. Drug Metab. Dispos. 42, 1292-1300.
Valiente, M., Obenauf, A.C., Jin, X., et al., 2014. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell. 156, 1002-1016.
Wherry, E.J., 2011. T cell exhaustion. Nat. Immunol. 12, 492-499.
Wronski, M., and Arbit, E., 2000. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J. Neurosurg. 93, 9-18.
Yang, C., Rahimpour, S., Yu, A.C., Lonser, R.R., and Zhuang, Z., 2013. Regulation and dysregulation of astrocyte activation and implications in tumor formation. Cell Mol. Life Sci. 70, 4201-4211.
Zakrzewski, J., Geraghty, L.N., Rose, A.E., et al., 2011. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer. 117, $1711-1720$.
Zeng, J., See, A.P., Phallen, J., et al., 2013. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int. J. Radiat. Oncol. Biol. Phys. 86, 343-349.
Zhang, C., Zhang, F., Tsan, R., and Fidler, I.J., 2009. Transforming growth factor-beta2 is a molecular determinant for site-specific melanoma metastasis in the brain. Cancer Res. 69, 828-835.
Zhu, H., Reuhl, K., Zhang, X., et al., 1998. Development of heritable melanoma in transgenic mice. J. Invest. Dermatol. 110, 247-252.

# II. TREATMENT AND PROGNOSIS# C H A P T E R 

## 18

## Treatment of Brain Metastases from Ovarian and Endometrial Carcinomas Using Stereotactic Radiosurgery

Edward A. Monaco III, Gurpreet S. Gandhoke, Ajay Niranjan and L. Dade Lunsford

|  | O U T L I N E |  |  |
| :-- | :-- | :-- | :-- |
| Introduction | 255 | SRS for Endometrial Carcinoma | 261 |
| Stereotactic Radiosurgery Technique | 257 | Conclusions | 263 |
| SRS for Ovarian Carcinoma | 258 | References | 264 |

## INTRODUCTION

Ovarian and endometrial carcinomas together create a substantial cancer burden, combining for nearly $10 \%$ of all cancers in women in the United States (Piura and Piura, 2011, 2012). Despite this figure, the incidence of brain metastases from these primary cancers is quite small: $0.3-2.2 \%$ for ovarian cancer and $0.4-1.2 \%$ for endometrial cancer (Ogawa et al., 2008). However, as is the case with many primary malignancies, the incidence of brain metastases seems to be on the rise due to earlier diagnosis, improved systemic treatments, and prolonged survivals (Nasu et al., 2013). For example, about three quarters of patients with endometrial cancer are diagnosed at an early stage and experience a 5-year survival rate around $90 \%$ after primary therapy (Piura and Piura, 2012). With the widespread useof platinum based therapies for ovarian carcinoma, longer term survival can be achieved in $30 \%$ of patients despite the fact that most women $(\sim 75 \%)$ are initially diagnosed with advanced stage disease (Piura and Piura, 2011). Because of the low rates of central nervous system spread, ovarian and endometrial carcinomas have been described as "neurophobic" (Piura and Piura, 2012). Both tend to recur or spread in a loco-regional fashion through direct extension to adjacent organs or via lymphatic dissemination. Less often these cancers spread hematogenously, and when they do, they tend to spread to the chest (lungs and pleural cavities) and the liver (Bonnefoi et al., 1999; Brezinka et al., 1990; Henriksen, 1975; Nakano and Schoene, 1975). Unlike in melanoma, where brain metastases are often the first site of visceral spread, patients with endometrial and ovarian cancer develop brain metastases late in their course when they have widely disseminated and advanced stage disease. This results in meaningful challenges when deciding on how best to treat brain metastases.

The traditional reflexive approach for the treatment of brain metastases has long been the administration of fractionated whole brain radiation therapy (WBRT). The use of WBRT, for treatment of even a solitary metastasis, has been based on a number of antiquated notions: the absence of treatment alternatives, the widespread availability of delivery devices, the inability of chemotherapeutics to traverse the blood-brain-barrier, the capacity to rapidly begin treatment in the absence of detailed planning, and the presumed benefit of treating potential "micrometastatic disease" not detected on imaging. Despite tremendous improvements in systemic cancer therapies, there have been no meaningful changes in the safety and efficacy of WBRT despite numerous attempts at different fractionation schedules and radiation sensitizers (Komarnicky et al., 1991; Phillips et al., 1995; Sause et al., 1990; Tsao et al., 2006). More than ever, with ever increasing long-term survival from cancers, concerns have begun to mount regarding the delayed toxicities of WBRT. WBRT leads to progressive, irreversible white matter changes, or leukoencephalopathy in long-term survivors of brain metastases (Monaco et al., 2013). Similar changes in the white matter seem to correspond to neurocognitive dysfunction in diseases like vascular dementia and alcoholism (Carmichael et al., 2010; Fazekas et al., 1987; Filley and Kleinschmidt-DeMasters, 2001). In a survey of patients who underwent treatment for brain metastases, patients who had WBRT reported significant difficulties with short- and long-term memory, concentration problems, as well as mood disorders (Kondziolka et al., 2005). Indeed, in the first ever randomized clinical trial of brain metastases treatment using neurocognitive function as a primary outcome, Chang et al. (2009) demonstrated that when therapy included WBRT there was a significantly risk of decline in learning and memory function in as little as 4 months after treatment. In light of these types of findings, the utilization of WBRT ought to be carefully scrutinized in the setting of alternative therapies.

Stereotactic radiosurgery (SRS) has evolved as a safe and efficacious treatment alternative for brain metastases and there is a nearly three decade long experience detailed in the literature. SRS has several advantages over WBRT, including: it is typically performed in a single session, systemic therapies need not be stopped or delayed in the event of an SRS procedure, SRS administers a more radiobiologically effective tumoricidal dose, SRS is not inherently limited by potential toxic dose to normal tissue due to its conformality, and most importantly SRS is a targeted and individualized treatment approach. There is a growing emphasis that the study of brain metastases patients should be tailored to specific histologies or even molecular subtypes rather than the pooling of data from all tumor types.Avoidance of a "one-size-fits-all" approach can eliminate numerous confounding variables. For instance, receptor subtype has a meaningful prognostic significance for breast cancer patients, for some portending survival of greater than 2 years after initial diagnosis of brain metastases (Sperduto et al., 2012). In contrast, for melanoma only performance status and the number of brain metastases seems prognostic (Sperduto et al., 2010). In an often cited landmark randomized clinical trial comparing WBRT plus SRS to SRS alone for patients with brain metastases, $86 \%$ of patients were lung cancer patients (Aoyama et al., 2006). The purpose of this report is to review the limited available data regarding the use of SRS for the treatment of brain metastases from ovarian and endometrial carcinoma.

# STEREOTACTIC RADIOSURGERY TECHNIQUE 

The goals of SRS for brain metastases are several: preservation or improvement in neurological function, prevent interruption of critical treatments for extracranial disease, preservation of quality of life, reduction or elimination of steroid use, and minimization of side effects. The vast majority of the patients treated for brain metastases from gynecologic malignancies have been treating using various iterations of the Gamma Knife device (Lee et al., 2008; Menendez et al., 2012; Monaco et al., 2008; Ogino et al., 2012; Ratner et al., 2009; Shepard et al., 2014). The Gamma Knife SRS procedure begins with the application of an imaging-compatible stereotactic head frame. Rigid immobilization of the target allows for the maximum degree of accuracy and precision when treating intracranial lesions. At our institution this is typically performed with the use of local anesthetic at the pin sites and intravenous sedation. Stereotactic high-resolution magnetic resonance imaging is then performed. The entire brain is imaged with a contrast-enhanced thin-sliced ( $2-\mathrm{mm}$ thick images without any gap) T1-based protocol. Often T2-weighted images are also obtained in order to better appreciate tumor margins and identify reactive changes. These images are then imported into the radiosurgical treatment planning software (i.e., Gamma Plan), from which a team including a neurosurgeon, radiation oncologist, and medical physicist work together to identify the tumor targets and perform direct dose planning (Fig. 18.1).

Historically, dose selection has been based to some degree on the findings of the Radiation Therapy Oncology Group study 90-05 (Shaw et al., 2000). The available literature for ovarian and endometrial cancers indicates that median doses from 16 Gy to 20 Gy are typically utilized (Menendez et al., 2012; Ogino et al., 2012; Shepard et al., 2014). When a patient has had previous WBRT it is our practice to decrease the dose 2 Gy from what we would typically prescribe in order to limit the risk of radiation related toxicity (Monaco et al., 2013). Prescription dose is also decreased $2-4 \mathrm{~Gy}$ when patients are treated for many lesions. Once the final dose plan is created and approved, the patient is positioned on the device's couch with the head attached via the stereotactic head frame. Each tumor is then moved into the path of the focused 192 or 201 beams, depending on the specific unit, until the prescribed dose is achieved. Once all the identified tumors are treated, the patient is removed from the device and the stereotactic head frame is taken off. The patient is typically discharged the same day as the procedure and can return to usual activities the following day.

A fundamental component of SRS treatment is clinical and radiologic follow up after the procedure. For patients with brain metastases this is necessary to confirm treatment![img-78.jpeg](img-78.jpeg)

FIGURE 18.1 Gamma Plan poster shows a conformal radiosurgery dose plan for a 60-year-old woman who was found to have a moderately sized left frontal brain metastasis due to ovarian carcinoma after suffering a generalized seizure. Axial contrast-enhanced magnetic resonance images with coronal and sagittal reconstructions were utilized for planning. A margin dose of 16 Gy was prescribed to the $50 \%$ isodose line.
response, identify new brain metastases, and observe for any adverse radiation effects. In general, SRS alone for brain metastases has proven as effective as SRS plus WBRT at maintaining survival and preserving neurological and cognitive function as long as adequate surveillance is conducted and repeat salvage SRS is performed for new or progressive disease (Aoyama et al., 2006; Chang et al., 2009).

# SRS FOR OVARIAN CARCINOMA 

Kawana et al. (1997) reported the first patient with ovarian cancer brain metastases to be treated by Gamma Knife SRS. Their patient developed brain metastases 36 months after initial diagnosis and underwent SRS for one of her lesions after receiving WBRT. The prescription dose to the tumor margin was 20 Gy . Four months after treatment, there was no evidence of the tumor on computed tomography and at the time of publication the patient was without neurological symptoms or intracranial disease.

Due to the epidemiology of ovarian cancer brain metastases, subsequent reports have been rare. As of 2011, Piura and Piura noted that only a total of 520 patients had been included in reports involving treatment of brain metastases from ovarian cancer (Piura and Piura, 2011). Only 20 or $3.8 \%$ of these patients underwent SRS. Corn et al. reported on a small series ofpatients treated using linear accelerator-based radiosurgery for ovarian carcinoma metastases (Corn et al., 1999). All five patients received WBRT and SRS. The median prescription radiosurgical dose was 15 Gy to the $75 \%$ isodose line. All patients had a Karnofsky performance score (KPS) of $\geq 70$. The median survival of these patients had not been achieved by the time of publication. This is compared to a cohort who received only WBRT and demonstrated a median survival of 4 months. Forty percent of patients showed a complete radiographic response to WBRT plus SRS. One patient had an adverse radiation effect and required a craniotomy for radiation necrosis. In a study of the prognostic factors associated with brain metastases from ovarian carcinoma, Kim et al. identified five patients who underwent SRS for brain metastases (Kim et al., 2007). Four of these patients also underwent WBRT or had multimodality therapy. Details of the radiosurgical methods were not reported. For the patients whose therapy included SRS with the Gamma Knife, median survival was 23 months, compared to 4 months in patients who did not have any SRS. A treatment regimen that included SRS was significantly associated with better prognosis in the entire cohorts, as were KPS, primary disease control, solitary brain metastasis, and better recursive partitioning analysis class. Lee et al. reported on 15 patients with metastatic ovarian carcinoma to the brain with eight receiving WBRT initially and seven SRS (Lee et al., 2008). Of the SRS patients, two went on to have additional fractionated radiation to the head. The median age at the time of treatment was 56 years with a median interval from the time of initial cancer diagnosis to findings of brain metastases of 28 months. The median KPS for the patients who had upfront WBRT was 70 and for the upfront SRS it was 80 . Ninety-three percent of the patients had advanced stage systemic disease. Statistical analysis demonstrated that the use of SRS had a significant impact on survival, as median survival in this cohort was 29 months, whereas it was only 6 months in the group that received upfront WBRT. High KPS was the only other factor associated with survival. Prescription dose and tumor control rate were not reported in this study.

Our group published the largest series to date in 2008, which studied 21 patients with ovarian carcinoma (Monaco et al., 2008). Two-thirds of the patients in this retrospective study, which also included six women with endometrial cancer metastases, had also received WBRT. For the 18 patients with follow-up imaging, the tumor control rate was 100\% (Fig. 18.2). Only one patient developed new brain metastases. Two patients experienced adverse radiation effects. Of the patients with pre-SRS neurological deficits, $88 \%$ had stable or improved deficits after SRS. Median survival for the entire study cohort was 5 months after SRS with 6-month and 1-year survival rates after SRS of 44 and $15 \%$, respectively. Prescription doses were not reported. Navarro-Martín et al. reported on a series of three patients treated with Gamma Knife SRS after failure of prior WBRT (Navarro-Martin et al., 2009). Each patient received prescription margin doses of 15-16Gy. Survival after initial brain involvement was around 24 months. Ratner et al. (2009) reported their series of 24 patients with brain metastases from ovarian carcinoma. Four patients received SRS, three of which also had WBRT. Fourteen other patients in the study underwent WBRT alone. The median survival of patients who underwent WBRT alone was 6 months. The patient who underwent Gamma Knife SRS alone survived for 10 months after treatment. The median survival of the three patients who received combination WBRT and SRS was 20 months. Details of dose planning were not reported, nor were side effects mentioned.

Ogino et al. (2012) reported on 16 patients treated in the Tokyo Gamma Unit from 2006 to 2010. Ten of these patients received SRS alone, while the others had multimodality![img-79.jpeg](img-79.jpeg)

FIGURE 18.2 Axial contrast-enhanced magnetic resonance images of an 86-year-old woman with metastatic ovarian cancer with two brain metastases (arrows). Stereotactic images (A and B) were obtained on the day of Gamma Knife and show moderately sized enhancing tumors. Each tumor was prescribed a marginal dose of 17 Gy . Two months after radiosurgery ( C and D ) the two tumors have dramatically responded with prominent decreases in size by volume (arrows). The patient succumbed to her systemic disease 4 months after radiosurgery without neurological deficit.
therapy including WBRT, SRS, and/or surgery. The median age of the patients at diagnosis of brain tumors was 56.5 years. The median number of tumors treated was two and the median margin prescription dose was 20 Gy . The median KPS was 80 at the time of first SRS. Median survival after SRS was 12.5 months with 6-month and 1-year survivals of 75 and $50 \%$, respectively. Tumor control rate was reportedly $86.4 \%$ but $56 \%$ of patients developed new brain metastases during follow-up. The median time to new intracranial disease was 4.5 months. A KPS $\geq 80$ and total tumor volume $<10 \mathrm{cc}$ were both significantly associated with improved survival after SRS. In a series on the treatment of primary cancers that rarely metastasize to the brain Menendez et al. (2012) identified nine patients who underwent SRS with the Gamma Knife for ovarian tumors. Two patients received WBRT as well as SRS. Four patients had craniotomies prior to SRS. The median Graded Prognostic Assessment (GPA) score for this patient cohort was 3.0. Median dose to the tumor margin was 17 Gy and the median tumor volume was 4.4 cc . Median survival after SRS was 13 months, and two patients had quite prolonged survival periods ( 40 and 80 months, respectively). Three tumors progressed despite SRS and two were retreated. These tumors did not continue to progress. No overall tumor control rate was reported, nor was there mention of complications. The most recent report was published by Shepard et al. (2014). This series includedTABLE 18.1 Summary of Ovarian Cancer Brain Metastases Treated by Stereotactic Radiosurgery

| Report | No. of patients | Other treatments | Margin dose (Gy) | Tumor control | Median survival (months) |
| :--: | :--: | :--: | :--: | :--: | :--: |
| Kawana et al. (1997) | 1 | Craniotomy, WBRT, XRT | 20 | $100 \%$ | Still alive 21 months at time of publication |
| Corn et al. (1999) | 5 | WBRT | 15 | $100 \%$ | Not yet achieved at time of publication |
| Kim et al. (2007) | 5 | Craniotomy, WBRT | NR | NR | 23 |
| Lee et al. (2008) | 7 | WBRT | NR | NR | 29 |
| Monaco et al. (2008) | 21 | Craniotomy, WBRT | NR | $100 \%$ | 5 |
| Navarro-Martin et al. (2009) | 3 | WBRT | $15-16$ | NR | 24 |
| Ratner et al. (2009) | 4 | WBRT | NR | NR | SRS only 10 <br> WBRT + SRS 20 |
| Ogino et al. (2012) | 16 | Craniotomy, WBRT | 20 | $86.4 \%$ | 12.5 |
| Menendez et al. (2012) | 9 | Craniotomy, WBRT | 17 | NR | 13 |
| Shepard et al. (2014) | 8 | WBRT | 20 | $100 \%$ | 22.3 |

NR, not reported; SRS, stereotactic radiosurgery; WBRT, whole brain radiation therapy; XRT, external beam radiation.
eight patients with ovarian carcinoma brain metastases who received SRS with a Gamma Knife. The median marginal dose, which included treatment of eight additional patients with distinct gynecological malignancies, was 20 Gy . The reported tumor control rate was $100 \%$ and the median survival following SRS was 22.3 months. Six of the seven patients with follow-up imaging demonstrated tumor shrinkage after SRS. Three patients developed distant intracranial progression after an average of around a year after SRS. No adverse radiation effects were detected. There were no prognostic factors associated with improved survival in this cohort. Table 18.1 summarizes salient features of select radiosurgical series.

# SRS FOR ENDOMETRIAL CARCINOMA 

Patients harboring brain metastases from endometrial cancer are even less well studied. In a thorough review of brain metastases from endometrial carcinoma published in 2012 only 10 patients in the literature had reportedly received SRS as part of their treatment (Piura and Piura, 2012). Petru et al. (2001) discussed two of the earliest reported patients with such brain metastases treated by SRS. Details of the SRS are not provided but each patient had a solitary brain metastasis that was treated and neither received WBRT. One patient survived 15 months, while the other 171 months. This patient was still alive at the time of publication with no reported evidence of systemic or cranial disease. Shiohara et al.![img-80.jpeg](img-80.jpeg)

FIGURE 18.3 Axial contrast-enhanced magnetic resonance images of a 65-year-old woman who developed acute hemiplegia immediately after resection of an endometrial cancer from the uterus. She was found to have a large left frontal brain metastases that was resection and she was referred for tumor bed radiosurgery 1 month later. The tumor bed was treated with a prescription dose of 18 Gy to the $50 \%$ isodose line. Panel A is an image from the stereotactic study performed on the day of Gamma Knife and shows the tumor bed target (arrow). Panel B is a follow-up image through the same region obtained approximately 1 year later and shows no evidence of active disease at the tumor bed. This patient survived over 2 years after her Gamma Knife procedure.
(2003) reported case of a patient with multiple tumors who received SRS with a Gamma Knife over two procedures. Each tumor was treated with a prescription dose of 16 Gy at the margin. Thirty-eight months after her last SRS treatment there was no evidence of active or recurrent brain disease and the patient was without neurocognitive deficits. In a series of 22 patients identified over a decade with endometrial carcinomas, Chura et al. (2007) noted only one patient who had received SRS at part of her treatment, and this followed WBRT. Insufficient data are presented in this report to comment on the patient's treatment or outcome.

Menendez et al. (2012) reported on five patients who had undergone SRS with Gamma Knife. Only one patient received prior WBRT. The median GPA of these patients was 2.5. The median marginal prescription dose administered was 16.5 Gy to a median volume of 8.55 cc. Six of the seven tumors ( $86 \%$ ) were stabilized or regressed. One tumor progressed 2.5 months after treatment. After Gamma Knife treatment, the reported median survival was 13 months. Shepard et al. (2014) added an additional six patients to the literature. Nine total tumors were treated and two of the patients had previous WBRT. The median prescription dose for all patients, including several with other gynecological malignancies, was 20 Gy. Median KPS was 70. The median survival after SRS was 7 months. The actuarial survival for these patients was $50 \%$ at 6 months and $33 \%$ at 12 months. In our group's original report described above six patients with endometrial cancer had been treated by SRS (Monaco et al., 2008). Outcomes and SRS data were not stratified on the basis of histology. Review of those data, with the addition of six patients treated subsequent to that report, demonstrate a median survival after first SRS of 6.7 months (Fig. 18.3, unpublished data).

Uterine leiomyosarcoma is also exceedingly rarely reported to metastasize to the brain. Munakata et al. (2006) reported the first case of a patient with a metastatic tumor of this histology treated with SRS alone. The patient developed a brain lesion 3 years after systemic treatment with chemotherapy. The authors performed a biopsy that confirmed uterineTABLE 18.2 Summary of Endometrial Cancer Brain Metastases Treated by Stereotactic Radiosurgery

| Report | No. of patients | Other treatments | Margin dose (Gy) | Tumor control | Median survival (months) |
| :--: | :--: | :--: | :--: | :--: | :--: |
| Petru et al. (2001) | 2 | None | NR | $100 \%$ | 93 |
| Shiohara et al. (2003) | 1 | None | 16 | $100 \%$ | Still alive 38 months at time of publication |
| Chura et al. (2007) | 1 | WBRT | NR | NR | NR |
| Monaco et al. (2008) | $12^{a}$ | Craniotomy, WBRT | NR | $100 \%$ | 6.7 |
| Menendez et al. (2012) | 5 | WBRT | 16.5 | $86 \%$ | 13 |
| Shepard et al. (2014) | $\begin{aligned} & 5 \\ & 1^{b} \end{aligned}$ | Craniotomy, WBRT | 20 | $100 \%$ | $7,1^{\text {b }}$ |
| Munakata et al. (2006) | $1^{\text {b }}$ | Biopsy | 20 | NR | NR |
| Yamada et al. (2011) | $1^{\text {b }}$ | Craniotomy | 20 | $100 \%$ | 11 |
| Monaco et al. (unpublished) | $4^{\text {b }}$ | Craniotomy, WBRT | NR | NR | 35 |

NR, not reported; WBRT, whole brain radiation therapy.
${ }^{a}$ This study plus unpublished data.
${ }^{b}$ Leiomyosarcoma cases.
leiomyosarcoma and treated her with Gamma Knife. She was still alive at the time of publication and her final outcome was not reported. Yamada et al. (2011) reported a case of a patient with multiple brain metastases from leiomyosarcoma of the uterus. The patient first underwent resection of two of her tumors and then underwent Gamma Knife SRS for the remainder. Six months post radiosurgery all tumors had regressed dramatically, but a new tumor was apparent. This tumor was treated with Gamma Knife. All tumors received a marginal dose of 20Gy. Overall the patient survived 11 months after initial SRS. Shepard et al. (2014) noted one patient in their gynecological series treated with SRS for leiomyosarcoma brain tumors. A total of three tumors were treated ( 18 cc volume). The patient has a KPS of 20 on presentation and she only survived a month with brain disease. At our institution to date, four patients with brain metastases from uterine leiomyosarcoma have been treated with SRS (unpublished data). Median survival in these patients was 35 months from first SRS treatment. Table 18.2 summarizes the limited studies on endometrial cancer brain metastases.

# CONCLUSIONS 

Overall, the quality of the existing evidence is low. Taken together, the data support the use of SRS in the treatment of patients or ovarian and endometrial carcinoma. Similar to level one prospective data, SRS seems to improve survival in these patients. In theradiosurgery era, most patients are dying from systemic disease and not brain disease. Thus, because patients with ovarian or endometrial carcinoma brain metastases are typically at advanced disease stages, the potential survival benefits of SRS in this population may be underestimated as survival is limited by the systemic disease. Patients with favorable prognostic features tend to do better with SRS. SRS is truly an individualized technique that is tailored to each patient's unique condition and avoids exposure of normal brain tissue to radiation toxicity. Formal quality of life or neurocognitive data are not yet available for this specific population of patients. There are no good data that should limit the use of SRS in patients harboring ovarian or endometrial brain metastases, and extrapolation of high-quality evidence supports a role for withholding WBRT in favor of an "SRS followed by salvage SRS as necessary" approach in most patients. In patients with ovarian or endometrial carcinoma who are in more advanced stages of disease and require ongoing systemic therapy, SRS is particularly advantageous because systemic therapy need not be stopped to receive treatment.

# References 

Aoyama, H., Shirato, H., Tago, M., et al., 2006. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295, 2483-2491.
Bonnefoi, H., A'Hern, R.P., Fisher, C., et al., 1999. Natural history of stage IV epithelial ovarian cancer. J. Clin. Oncol. 17, 767-775.
Brezinka, C., Fend, F., Huter, O., and Plattner, A., 1990. Cerebral metastasis of endometrial carcinoma. Gynecol. Oncol. 38, 278-281.
Carmichael, O., Schwarz, C., Drucker, D., et al., 2010. Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch. Neurol. 67, 1370-1378.
Chang, E.L., Wefel, J.S., Hess, K.R., et al., 2009. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 10, $1037-1044$.
Chura, J.C., Marushin, R., Boyd, A., et al., 2007. Multimodal therapy improves survival in patients with CNS metastasis from uterine cancer: a retrospective analysis and literature review. Gynecol. Oncol. 107, 79-85.
Corn, B.W., Mehta, M.P., Buatti, J.M., et al., 1999. Stereotactic irradiation: potential new treatment method for brain metastases resulting from ovarian cancer. Am. J. Clin. Oncol. 22, 143-146.
Fazekas, F., Chawluk, J.B., Alavi, A., et al., 1987. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. Am. J. Roentgenol. 149, 351-356.
Filley, C.M., and Kleinschmidt-DeMasters, B.K., 2001. Toxic leukoencephalopathy. N. Engl. J. Med. 345, 425-432.
Henriksen, E., 1975. The lymphatic dissemination in endometrial carcinoma. A study of 188 necropsies. Am. J. Obstet. Gynecol. 123, 570-576.
Kawana, K., Yoshikawa, H., Yokota, H., et al., 1997. Successful treatment of brain metastases from ovarian cancer using gamma-knife radiosurgery. Gynecol. Oncol. 65, 357-359.
Kim, T.J., Song, S., Kim, C.K., et al., 2007. Prognostic factors associated with brain metastases from epithelial ovarian carcinoma. Int. J. Gynecol. Cancer 17, 1252-1257.
Komarnicky, L.T., Phillips, T.L., Martz, K., et al., 1991. A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int. J. Radiat. Oncol. Biol. Phys. 20, 53-58.
Kondziolka, D., Niranjan, A., Flickinger, J.C., and Lunsford, L.D., 2005. Radiosurgery with or without whole-brain radiotherapy for brain metastases: the patients' perspective regarding complications. Am. J. Clin. Oncol. 28, $173-179$.
Lee, Y.K., Park, N.H., Kim, J.W., et al., 2008. Gamma-knife radiosurgery as an optimal treatment modality for brain metastases from epithelial ovarian cancer. Gynecol. Oncol. 108, 505-509.Menendez, J.Y., Bauer, D.F., Shannon, C.N., et al., 2012. Stereotactic radiosurgical treatment of brain metastasis of primary tumors that rarely metastasize to the central nervous system. J. Neurooncol. 109, 513-519.
Monaco III, E., Kondziolka, D., Mongia, S., et al., 2008. Management of brain metastases from ovarian and endometrial carcinoma with stereotactic radiosurgery. Cancer 113, 2610-2614.
Monaco III, E.A., Faraji, A.H., Berkowitz, O., et al., 2013. Leukoencephalopathy after whole-brain radiation therapy plus radiosurgery versus radiosurgery alone for metastatic lung cancer. Cancer 119, 226-232.
Munakata, A., Asano, K., Hatayama, T., et al., 2006. Leiomyosarcoma of the uterus metastatic to the brain. No Shinkei Geka 34, 409-413.
Nakano, K.K., and Schoene, W.C., 1975. Endometrial carcinoma with a predominant clear-cell pattern with metastases to the adrenal, posterior mediastinum, and brain. Am. J. Obstet. Gynecol. 122, 529-530.
Nasu, K., Satoh, T., Nishio, S., et al., 2013. Clinicopathologic features of brain metastases from gynecologic malignancies: a retrospective study of 139 cases (KCOG-G1001s trial). Gynecol. Oncol. 128, 198-203.
Navarro-Martin, A., Maitz, A., Manders, M., et al., 2009. Gamma Knife radiosurgery as a primary treatment option for solitary brain metastases from ovarian carcinoma. Clin. Transl. Oncol. 11, 326-328.
Ogawa, K., Yoshii, Y., Aoki, Y., et al., 2008. Treatment and prognosis of brain metastases from gynecological cancers. Neurol. Med. Chir. (Tokyo) 48, 57-62. Discussion 62-63.
Ogino, A., Hirai, T., Fukushima, T., et al., 2012. Gamma knife surgery for brain metastases from ovarian cancer. Acta. Neurochir. (Wien) 154, 1669-1677.
Petru, E., Lax, S., Kurschel, S., et al., 2001. Long-term survival in a patient with brain metastases preceding the diagnosis of endometrial cancer. Report of two cases and review of the literature. J. Neurosurg. 94, 846-848.
Phillips, T.L., Scott, C.B., Leibel, S.A., et al., 1995. Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89-05. Int. J. Radiat. Oncol. Biol. Phys. 33, 339-348.
Piura, E., and Piura, B., 2011. Brain metastases from ovarian carcinoma. I.S.R.N. Oncol. 2011, 527453.
Piura, E., and Piura, B., 2012. Brain metastases from endometrial carcinoma. I.S.R.N. Oncol. 2012, 581749.
Ratner, E.S., Toy, E., O'Malley, D.M., et al., 2009. Brain metastases in epithelial ovarian and primary peritoneal carcinoma. Int. J. Gynecol. Cancer 19, 856-859.
Sause, W.T., Crowley, J.J., Morantz, R., et al., 1990. Solitary brain metastasis: results of an RTOG/SWOG protocol evaluation surgery + RT versus RT alone. Am. J. Clin. Oncol. 13, 427-432.
Shaw, E., Scott, C., Souhami, L., et al., 2000. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int. J. Radiat. Oncol. Biol. Phys. 47, 291-298.
Shepard, M.J., Fezeu, F., Lee, C.C., and Sheehan, J.P., 2014. Gamma knife radiosurgery for the treatment of gynecologic malignancies metastasizing to the brain: clinical article. J. Neurooncol. http://dx.doi.org/10.1007/ s11060-014-1577-0.
Shiohara, S., Ohara, M., Itoh, K., et al., 2003. Successful treatment with stereotactic radiosurgery for brain metastases of endometrial carcinoma: a case report and review of the literature. Int. J. Gynecol. Cancer 13, 71-76.
Sperduto, P.W., Chao, S.T., Sneed, P.K., et al., 2010. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int. J. Radiat. Oncol. Biol. Phys. 77, 655-661.
Sperduto, P.W., Kased, N., Roberge, D., et al., 2012. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 82, 2111-2117.
Tsao, M.N., Lloyd, N., Wong, R., et al., 2006. Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst. Rev. CD003869.
Yamada, S., Yamada, S.M., Nakaguchi, H., et al., 2011. A case of multiple brain metastases of uterine leiomyosarcoma with a literature review. Surg. Oncol. 20, e127-131.# CHAPTER 

## 19

## Prognostic Factors for Survival in Melanoma Patients with Brain Metastases

Isabella C. Glitza, Amy B. Heimberger, Erik P. Sulman and Michael A. Davies

|  | OUTLINE |  |  |
| :--: | :--: | :--: | :--: |
| Introduction | 267 | Whole-Brain Radiation Therapy | 281 |
| Factors Associated with CNS |  | Stereotactic Radiosurgery | 282 |
| Involvement by Melanoma | 269 | Surgery | 283 |
|  |  | Systemic Therapies for Melanoma |  |
| Prognostic Factors for OS in Melanoma |  | Brain Metastases | 284 |
| Patients with Brain Metastases | 273 | Combining Radiation with Systemic |  |
| Treatment-Specific Predictors of |  | Therapy | 291 |
| Outcomes in Melanoma Brain |  | Discussion | 291 |
| Metastasis Patients | 279 | References | 292 |
| Radiation Therapy | 279 |  |  |

## INTRODUCTION

Melanoma is the most aggressive form of the common skin cancers and is the cause of over $75 \%$ of the deaths attributed to skin cancer each year. Worldwide, its incidence is rising, particularly in younger individuals. An estimated 70,000 new cases of melanoma will be diagnosed in the United States alone in 2014 (http://seer.cancer.gov 2014). Melanomagenerally metastasizes regionally first to lymph nodes. While patients with regional lymphatic spread are generally treated with, and can be cured by, surgery, such patients are at high risk for distant metastases. The distant metastatic spread of melanoma cells can affect virtually any site in the body, including the brain parenchyma and/or the leptomeninges. Among common cancers, melanoma is the most likely to metastasize to the brain and is the third-most frequent cause of brain metastases, after breast cancer and lung cancer (Sawaya et al., 2001). The incidence of brain involvement for patients with metastatic melanoma is up to $43 \%$ in the clinical setting and up to $75 \%$ in autopsy series (Davies et al., 2011). While a small subset ( $<10 \%$ ) of melanoma patients with central nervous system (CNS) involvement survive greater than 5 years, the median overall survival (OS) for melanoma patients with CNS metastases is only 4-6 months, which is worse than for any other metastatic site in this disease (Fife et al., 2004; Raizer et al., 2008; Davies et al., 2011). CNS involvement is the cause of death in up to $54 \%$ of patients who die from melanoma (Skibber et al., 1996).

An improved understanding of both the molecular changes that occur in this disease and the factors that regulate the antitumor immune response is now revolutionizing the treatment of patients with metastatic melanoma. Since 2011 three different targeted therapies (vemurafenib, dabrafenib, trametinib) have demonstrated superior outcomes compared to chemotherapy in randomized phase III trials, leading to their regulatory approval (Chapman et al., 2011; Hauschild et al., 2012). In addition, combined treatment with dabrafenib and trametinib was approved based on significant increases in clinical response rates and progression-free survival (PFS) versus single-agent therapy (Flaherty et al., 2012). Notably, each of those agents was approved for use specifically in patients with activating BRAF mutations, which are present in approximately $50 \%$ of patients with cutaneous melanoma (Bucheit et al., 2013). In parallel to these developments in targeted therapy, immunotherapy with ipilimumab, an antibody that blocks the inhibitory CTLA4 receptor on the surface of T cells, was approved for the treatment of patients with metastatic melanoma in 2011. While ipilimumab has a relatively low clinical response rate ( $<10 \%$ ), up to $25 \%$ of patients appear to achieve durable (i.e., $>3$ years) disease control and survival with this treatment (Hodi et al., 2010). More recently, several experimental therapies that target another molecule on the surface of T cells, particularly programmed death-1 (PD-1), have demonstrated clinical responses in $\geq 50 \%$ of metastatic melanoma patients in early-phase clinical trials, with many responses appearing to be long-lasting ( $>2$ years).

These advances and promising results have given rise to a new era and optimism in the management of this highly aggressive disease. However, to date few of these agents have been evaluated systemically in melanoma patients with brain metastases, and the CNS is increasingly a common first site of treatment failure. In this changing landscape of treatment options, understanding the prognostic factors associated with the development of brain metastases, and with survival after their development, will facilitate the appropriate design and interpretation of new clinical trials, and with clinical decisionmaking in individual patients. Thus, this review will summarize the existing literature on prognostic factors for brain metastasis development and survival in patients with melanoma.# FACTORS ASSOCIATED WITH CNS INVOLVEMENT BY MELANOMA 

The cumulative risk of developing brain metastasis within 5 years of a melanoma diagnosis is about 7\% (Cohn-Cedermark et al., 1998). Brain metastases are the first site of distant metastasis in 10-20\% of melanoma patients (Schoenewolf et al., 2014). As summarized in Table 19.1, a number of retrospective studies have investigated factors associated with the risk of or time to the development of brain metastasis in patients with melanoma. These studies were identified using PubMed search terms "melanoma, brain, metastases, prognosis." Most of these studies were single center and conducted between 1976 and 2012. The reported incidences of brain metastasis varied between $8 \%$ and $46 \%$ with most studies reporting an incidence of approximately $10 \%$. No single factor was significantly associated with the risk of brain metastasis universally in these studies, but some associations were identified repeatedly. For example, several studies demonstrated an association for male sex with an increased risk of brain metastasis. Age was only found to be an associated factor in two studies.

The factor associated with the greatest risk for the development of brain metastasis across the studies is primary melanoma location in the head and neck region ( $P<0.001$ to $P=0.05$ ). A number of other primary tumor characteristics known to predict survival in melanoma patients that are incorporated in the 7th edition of the American Joint Committee on Cancer staging system for melanoma (Breslow thickness, ulceration, and mitotic rate, Balch et al., 2009) were also analyzed for an association with brain metastasis. Primary tumors with a higher Breslow thickness had an increased likelihood ( $P<0.0001$ to $P=0.029$ ) of metastatic spread to the brain in six of the eight studies that analyzed this factor. Furthermore, the presence of primary tumor ulceration was also associated with a higher risk of brain metastasis in four of seven studies ( $P<0.0001-0.007$ ). Finally, a higher mitotic index was significantly associated with risk of brain metastasis in all three studies evaluating that factor ( $P<0.0001$ to $P=0.02$ ), and the nodular melanoma subtype showed a similar association in three of the listed studies ( $P<0.0001$ to $P=0.0012$ ). A number of other factors were evaluated in single studies only that did not find an association with the development if brain metastases. These factors included the presence of extracapsular spread ( $P=0.47$ ), nodal stage and nodal region ( $P=0.72$ ), number of involved nodes $(P=0.36)$, size of largest resected lymph node ( $P=0.08$ ), sentinel lymph node biopsy $(P=0.36)$, interval from initial diagnosis to stage IV diagnosis ( $P=$ not reported), race ( $P=$ not reported), and presence of pigmentation ( $P=$ not reported).

Although melanoma patients have historically been risk-stratified by demographics and primary tumor characteristics, recent advances in therapy are increasingly leading to assessments of tumor molecular features as part of routine clinical care. Early data in this area suggests that some of these features may be associated with CNS metastasis. For example, recurrent hot-spot mutations in BRAF ( $40-45 \%$ of cutaneous melanomas) and NRAS (15-20\%) have been assessed in multiple large cohorts of melanoma patients. In a study of 677 patients with stage IV melanoma, $47 \%$ of patients had BRAF mutations, and $20 \%$ had NRAS mutations. Analysis of the sites of involvement at the initial diagnosis of stage IV disease showed that the patients with BRAF or NRAS mutations were more likely to have brain metastasesTABLE 19.1 Factors Associated with the Development of Brain Metastasis in Melanoma Patients

| Reference, No. of patients, years | Brain metastases incidence, median time from diagnosis to brain metastases | Factors significantly ( $P<0.05$ ) associated with development of brain metastases | Factors evaluated but not significantly associated with development of brain metastases |
| :--: | :--: | :--: | :--: |
| Cohn-Cedermark et al. (1998), $\mathrm{n}=2516,1976-1987$ | $8 \%, 31$ months | Female gender, $P<0.001 ; 1^{\circ}$ location: head/neck vs trunk vs extremities, $P<0.001 ; 1^{\circ}$ BT: $0.9-2.0 \mathrm{~mm}$ vs $>2 \mathrm{~mm}, P<0.001,1^{\circ}$ ulceration present, $P<0.001$, $1^{\circ}$ histologic subtype: NM vs SSM, LMM, ALM, $P<$ 0.001 , invasive melanoma vs MIS, $P<0.001$ | Age, $1^{\circ}$ tumor regression |
| Sampson et al. (1998), $\mathrm{n}=702$, 1976-1996 | $11.7 \%, 44$ months | Male gender, $P<0.001 ; 1^{\circ}$ location: mucosal, head and neck, or trunk location, $P<0.001 ; 1^{\circ} \mathrm{BT}:<$ 0.76 mm vs $>4 \mathrm{~mm}, P<0.001 ; 1^{\circ}$ ulceration present: $P<0.001 ; 1^{\circ}$ histologic subtype: ALM, $P<0.001$; lymph node or visceral metastases, $P<0.001$ | Age $<40$ years old ( $P=0.033$ ) but NS as a continuous variable; race; presence of pigmentation |
| Daryanani et al. (2005), $\mathrm{n}=2567$, 1965-2000 | $8 \%$, NR | Male gender, $P=0.025 ; 1^{\circ} \mathrm{BT}:>4 \mathrm{~mm}, P=0.029$; $1^{\circ}$ high mitotic index, $P=0.02$ | $1^{\circ}$ location; $1^{\circ}$ ulceration present; $1^{\circ}$ histologic subtype; $1^{\circ}$ tumor lymphovascular or vascular invasion |
| Zakrzewski et al. (2011), $\mathrm{n}=900$, 2002-2008 | $10 \%, 25$ months | $1^{\circ}$ location: head/neck vs other, $P=0.002 ; 1^{\circ} \mathrm{BT}$ : 1.85 mm vs $0.95 \mathrm{~mm}, P<0.0001 ; 1^{\circ}$ ulceration present: $P<0.0001 ; 1^{\circ}$ histologic subtype: NM, $P<0.0001 ; 1^{\circ}$ high mitotic index, $P<0.0001$ | Age; gender; $1^{\circ}$ tumor regression; $1^{\circ}$ tumor lymphovascular invasion |
| Bedikian et al. (2011), $\mathrm{n}=740,1987-2002$ | $32 \%$, NR | $1^{\circ}$ location: head/neck, $P=0.017$; higher stage of disease, $P<0.0001$; increased lactate dehydrogenase, $P<0.0005$ | Age; gender; $1^{\circ} \mathrm{BT}$; tumor pathologic characteristics; chemosensitive vs chemoresistant disease, $P=0.064$; interval from $1^{\circ}$ diagnosis to stage III/IV disease || Bottoni et al. (2013), <br> $\mathrm{n}=49,1998-2012$ | $3.2 \%, 23$ months | $1^{\circ}$ BT: $>1.01 \mathrm{~mm}, P=0.0076$; SLN positive, $P<0.001$ | Age $>60$ vs younger, $P=0.31$; gender, $P=0.42$; <br> $1^{\circ}$ location; $1^{\circ}$ location: axial vs extremities, <br> $P=0.17 ; 1^{\circ}$ ulceration present, $P=0.06$ |
| :--: | :--: | :--: | :--: |
| Wang et al. (2014), <br> $\mathrm{n}=685,1986-2004$ | $46 \%, 23$ months | $1^{\circ}$ location: trunk/abdomen vs limbs, $P=0.051$; <br> M-stage (M1b vs M1a, $P<0.0001$; M1c vs M1a, <br> $P=0.004$ ) | Age; gender; $1^{\circ}$ BT; lactate dehydrogenase; <br> presence of liver metastases; interval from <br> $1^{\circ}$ diagnosis |
| Gumusay (2014), <br> $\mathrm{n}=470,2000-2012$ | $11.1 \%, 18.3$ months | Age, $P=0.021$; male gender, $P=0.003 ; 1^{\circ}$ location: <br> head/neck, $P=0.002 ; 1^{\circ}$ BT: $>4 \mathrm{~mm}, P=0.008$; <br> $1^{\circ}$ ulceration present, $P=0.007$; pathological N2 <br> and N3 diseases, $P=0.001 ; 1^{\circ}$ high mitotic index, <br> $P=0.001$ | Stage at initial diagnosis |
| Jackson et al. (2014), <br> $\mathrm{n}=474,1995-2010$ | $12.9 \%, 13.8$ months | None | Age, $P=0.34$; gender, $P=0.63 ; 1^{\circ}$ location; <br> presence of extracapsular spread, $P=0.47$; <br> nodal stage; nodal region, $P=0.72$; number <br> of involved nodes, $P=0.36$; size of largest <br> resected lymph node, $P=0.08$, SLN biopsy, <br> $P=0.36$ |
| Schoenewolf et al. <br> (2014), $\mathrm{n}=310$, NR | NR | $1^{\circ}$ histologic subtype: SSM and NM spread to <br> the brain more frequently than ALM and MM <br> melanomas, $P=0.0012$ | Age, date of $1^{\circ}$, TNM-stage, $1^{\circ}$ histological <br> criteria |

BT, Breslow thickness; SSM, superficially spreading melanoma; LMM, lentiginous malignant melanoma; ALM, acral melanoma; NM, nodular melanoma; MIS, melanoma in situ; MM, mucosal melanoma; vs, versus; SLN, sentinel lymph node; NR, not recorded; NS, not significant.( $24 \%$ of those with mutant BRAF and $23 \%$ of those with mutant NRAS) than patients in whom both genes were wild type ( $12 \% ; P=0.008$ ) (Jakob et al., 2012). More recently, an analysis of a cohort of stage IIIB/C melanoma patients failed to identify a significant association between BRAF or NRAS mutation status and time to brain metastasis (Bucheit et al., 2013). However, a significant association was observed between loss of expression of the tumor suppressor PTEN and brain metastasis. Loss-of-function mutations and deletions of PTEN have been detected in $10-30 \%$ of melanomas, commonly in tumors with concurrent BRAF mutations but generally not with NRAS mutations. PTEN is a negative regulator of the PI3KAKT pathway, and loss of PTEN has been shown to result in constitutive activation of the pathway in multiple tumor types, including melanoma. Loss of PTEN expression in the stage III cohort was significantly associated with shorter time to brain metastasis in patients with concurrent activating BRAF mutations $(P=0.03)$ but not in patients with wild-type BRAF and NRAS (Bucheit et al., 2014). Another study has recently also reported the molecular analysis of melanoma brain metastases and extracranial metastases, including a subset of patients with multiple metastases available. Although overall patterns of copy number variations, mRNA expression, and protein expression were similar between within-patient paired samples of brain metastases and extracranial metastases, the brain metastases demonstrated higher expression levels of several activation-specific protein markers in the PI3K/AKT pathway than the extracranial metastases (Chen et al., 2014). Increased activation of the PI3K-AKT pathway was also found in an immunohistochemical analysis of melanoma patients who had undergone synchronous resection of brain and non-CNS metastases (Niessner et al., 2013). Together, these findings suggest that the PI3K-AKT pathway should be further investigated as a potential therapeutic target for melanoma brain metastases.

Murine studies have demonstrated that transfection of constitutively activated signal transducer and activator of transcription 3 (STAT3) enhanced brain metastasis of melanoma, whereas transfection with dominant-negative STAT3 suppressed brain metastasis (Xie et al., 2004). These highly metastatic melanoma cell lines over expressed matrix met-alloproteinases-2 (MMP-2) and blockade of activated STAT3 by expression of dominantnegative STAT3 suppressed MMP-2 expression, prevented invasion, inhibited tumor growth, and prevented metastasis in vivo indicating that there is a central role for STAT3 signaling in the process of metastasis. Further confirmation of the relevance of STAT3 in the process of metastasis comes from tissue microarray studies that have demonstrated higher levels of expression of activated STAT3 in human brain melanoma metastasis specimens compared to primary tumors (Xie et al., 2006). Specifically, in 51 primary and 48 brain metastasis specimens obtained from patients with melanoma, only $43 \%$ of the former had moderate to strong p-STAT3-positive immunohistochemical staining, whereas $81 \%$ of the latter had moderate to strong p-STAT3-positive staining supporting the contention that p-STAT3 is involved in the process of metastasis. We have retrospectively identified 299 patients with stage IV melanoma and assembled a tissue microarray of systemic non-CNS metastasis specimens. Using immunohistochemical analysis to measure the percentage of cells with p-STAT3 expression and Kaplan-Meier survival estimates to analyze the association of p-STAT3 expression with median survival time, time to first CNS metastasis, and development of CNS metastasis, we did not find an association with the development of CNS metastasis; however, p-STAT3 expression was a negative prognostic marker for OS(Lee et al., 2012). A limitation of this study was that the primary tumor that was sampled for p-STAT3 expression may have not reflected the biology of the primary tumor at the time of CNS metastasis or that a minority clone may have been sufficient to initiate metastasis.

In summary, a number of factors have been identified as conferring increased risk of development of CNS metastasis in melanoma. Factors that have been identified in multiple studies include male gender; primary tumor in the head and neck region; and primary tumor Breslow thickness, ulceration, and mitotic index. Clinicians should have a heightened awareness of these factors when discussing prognosis with their patients, and potentially when deciding on appropriate clinical follow-up and monitoring. Moving forward, there will be a need to perform integrated analyses of these factors with emerging molecular markers in this disease.

# PROGNOSTIC FACTORS FOR OS IN MELANOMA PATIENTS WITH BRAIN METASTASES 

Patients with melanoma brain metastases have historically had very poor outcomes. As summarized in Table 19.2, the median survival after the diagnosis of brain metastases across multiple studies has been 4-6 months (Sampson et al., 1998; Meier et al., 2004; Fife et al., 2004; Hofmann et al., 2007; Raizer et al., 2008; Staudt et al., 2010; Vecchio et al., 2014). While patient outcomes are poor overall, some patients do achieve durable long-term survival. Thus, multiple analyses have been undertaken to identify factors that correlate with survival in melanoma patients with CNS involvement.

Most studies of outcomes in melanoma patients with CNS involvement have examined the prognostic significance of the number of brain metastases present. While cutoffs used in these analyses have varied, in general the presence of multiple metastases has predicted shorter OS. As shown in Table 19.2, of the 13 studies that evaluated the number of brain metastases, all but three reported a strong association between single brain metastases and longer OS ( $P<0.0001$ to $P=0.03$ for single metastases and $P=0.07$ to $P=0.61$ for more than one). While it is possible that the presence of multiple brain metastases represents a different biology than single brain metastasis, it is important to note that there is also a strong association between the number of brain metastases and the treatments that patients receive. In multiple series, long-term survival has been observed in some patients who underwent surgical resection as a definitive treatment for their brain metastases (Patchell et al., 1990; Farnell et al., 1996). Long-term survival has also been observed for patients treated with stereotactic radiosurgery (SRS). Historically these treatments have been limited to patients with a small burden of CNS disease, including generally $<3$ brain metastases. Patients with more extensive involvement have generally been treated with whole-brain radiation therapy (WBRT), chemotherapy, or supportive care. Comparison of patients treated with surgery or SRS to those treated with WBRT, chemotherapy, or supportive care have shown that that patients treated with surgery or SRS have better OS (Bedikian et al., 2011). Thus, the effect of the number of metastases on the treatments given may contribute to the significant association with OS observed. However, the possibility of a distinct biology does exist.TABLE 19.2 Prognostic Factors for Survival After the Development of Melanoma Brain Metastases

| Reference, No. of patients, years | Median OS (months) | Association of number of BM with OS | Association of extracranial disease with OS | Other factors associated with OS $(P<0.05)$ | Other factors analyzed |
| :--: | :--: | :--: | :--: | :--: | :--: |
| Sampson et al. (1998), $\mathrm{n}=702$, 1976-1996 | 3.7 | Median survival decreased with increasing number of BM, $P<0.00001$ | Shorter survival for coexistent lung metastasis $(P=0.0014),>1$ additional site of visceral metastasis present $(P=0.0036)$ | Longer survival <br> $1^{\circ}$ location other than head/neck $(P=0.01)$; initial presentation with BM $(P=0.0021)$ in comparison with patients who developed BM $>2$ months after the diagnosis of $1^{\circ}$ | No relationship between the number of BM and the character of the presentation could be delineated |
| Fife et al. (2004), $\mathrm{n}=1137$, 1952-2000 | 4.1 | NE | HR 1.558, $P<0.0001$ | Age (HR 1.010, $P=0.0007$ ); treatment modality of BM, surgery/XRT vs supportive care (HR 0.35, $P<0.0001$ ); interval from $1^{\circ}$ to BM (HR 0.998, CI 0.997-0.999, $P=0.036$ ) | Surgery and radiotherapy vs surgery-alone groups ( $P=0.21$ ); prognosis was marginally better for patients who were younger at the time of diagnosis of BM or who had a longer interval between their melanoma diagnosis and the diagnosis of BM |
| Meier et al. (2004), $\mathrm{n}=100$, 1966-2002 | 4.8 | Longer survival with single vs multiple BM, $P=0.07$ | NE | Longer survival <br> $1^{\circ} \mathrm{BT}>4 \mathrm{~mm}(<1 \mathrm{~mm}, 1.01-2 \mathrm{~mm}, 2-4 \mathrm{~mm}$, $>4 \mathrm{~mm}, P=0.013$, treatment with surgery, $P<0.0001$; stereotactic radiosurgery, $P=0.002$; chemotherapy, $P=0.001$ <br> Shorter survival with <br> Clark level IV-V, $P=0.048$ | Age, $<40,40-60$, and $>60, P=0.91$; gender, $P=0.39 ; 1^{\circ}$ location, $P=0.78 ; 1^{\circ}$ histologic subtype, $P=0.85$; stage at initial diagnosis, $P=0.57$; treatment with temozolomide, $P=0.052$; location of BM, $P=0.11$ |
| Hofmann et al. (2007), $\mathrm{n}=133$, 1995-2003 | 6 | Single vs 2-4 vs $>4$ BM $(P<0.0001$, $P=0.0330)$ | NS, $P=0.5788$ | Longer survival <br> Female gender, $P=0.0163$; systemic therapy and radiotherapy vs systemic therapy only, $P=0.0472$; corticosteroids not required at any point, $P=0.0408$ | No XRT, $P=0.05658$; receiving WBRT, $P=0.1209$ || Staudt et al. (2010), $\mathrm{n}=265$, 1986-2003 | 5.0 | Longer OS for 1 vs $>1$ BM, $P<$ 0.001 | Shorter OS, $P<0.001$ | Age $<45, P=0.004$; supratentorial BM, $P<0.001$; RTOG class I, $P<0.001$; treatment modality, $P<0.001$; response to treatment, $P<0.001$; Karnofsky performance status $>80, P<0.001$; leptomeningeal involvement, $P=0.002$; elevated serum lactate dehydrogenase, $P<0.001$; presence of adrenal gland, spleen, or locoregional metastases, $P=0.05$ | Gender, $P=0.100$; presence of lung metastases, $P=0.121 ; 1^{\circ}$ tumor stage, $P=0.5$; diameter of largest BM $>15 \mathrm{~mm} P=0.05$; symptomatic BM $P=0.05$ |
| :--: | :--: | :--: | :--: | :--: | :--: |
| Sperduto et al. (2010), $\mathrm{n}=483$, 1985-2007 | NR | Single vs $>3$ <br> metastases, $P<0.0001$ | NE | Longer survival <br> Karnofsky performance status of $90-100$ vs $<70, P<0.0001$ | Age $>60$ years |
| Eigentler et al. (2011), $\mathrm{n}=692$, 1986-2007 | 5.0 | Longer survival with single vs multiple BM, $P<0.001$ | Shorter OS, $P=0.056$ | Longer survival <br> Normal pretreatment lactate dehydrogenase, $P<0.001$; normal S-100 level, $P<0.001$; classification according to the RTOG class I $P=0.0485$; stereotactic radiotherapy or neurosurgical metastasectomy vs others; $P=0.036$; Karnofsky performance status ( $70 \%$ vs $<70 \% ; P<0.001)$ | Gender, $P=0.117$; time from primary diagnosis to BM, $P=0.110$; year of diagnosis of BM, $P=0.25$; treatment with temozolomide or fotemustine, $P=0.298$ |
| Zakrzewski et al. (2011), $\mathrm{n}=89$, 2002-2008 | 5.8 | Longer OS for 1 vs $>4$ BM, $P=0.01$ | Shorter OS, $P=0.02$ | Age $>65$ years, $P=0.024$; increased ( $>3$ ) mitotic index, $P=0.009$ ); lymphovascular invasion present, $P<0.0001 ; 1^{\circ}$ ulceration present, $P=0.004$; frontal BM location, $P=0.01$, bilateral BM vs unilateral, $P=0.04$; symptoms (weakness or fatigue), $P<0.0001$; number of neurological symptoms, $P=0.03$ | Location; $1^{\circ} \mathrm{BT} ; 1^{\circ}$ histologic subtype; $1^{\circ}$ tumor regression |

(Continued)TABLE 19.2 Prognostic Factors for Survival After the Development of Melanoma Brain Metastases (Continued)

| Reference, <br> No. of patients, years | Median OS (months) | Association of number of BM with OS | Association of extracranial disease with OS | Other factors associated with OS $(P<0.05)$ | Other factors analyzed |
| :--: | :--: | :--: | :--: | :--: | :--: |
| Raizer et al. (2008), $\mathrm{n}=355$, 1991-2001 | 5.2 | Shorter survival with $>4 \mathrm{BM}$, $P<0.0001$ | Shorter survival, $P=0.0002$ | Longer survival <br> Treatment with temozolomide, $P=0.0009$; surgical resection or stereotactic radiosurgery vs none, $P<0.0001$ <br> Shorter survival <br> Age $>65$ years, $P=0.0044$; presence of BM at stage IV diagnosis, $P=0.0099$; presence of hydrocephalus, $P=0.0005$; presence of leptomeningeal disease, $P=0.0004$; presence of neurologic symptoms at diagnosis of BM, $P=0.0227$ | Gender, $P=0.3575$; stage at initial diagnosis, $P=0.7855$; presence of hemorrhagic lesion, $P=0.8551$ |
| Davies et al. (2011), $\mathrm{n}=330$, 1986-2004 | 4.6 | Single vs $>3$ <br> BM $P=0.0001$, HR 1.57, CI $1.25-1.98$ | BM development after extracranial metastases, $P<0.0001$, HR 1.78, CI 1.38-2.30 | Longer survival <br> BM diagnosed after 01/01/1996, HR 0.75, CI 0.60-0.94, $P=0.01$; leptomeningeal disease present, $P=0.0004$, HR 2.12, CI 1.40-3.23 | Age $</=65$ vs $>65$ years, $P=0.97$, HR 1.01, CI $0.67-1.50$, nonresponders to systemic therapy, $P=0.19$, HR 1.16, CI 0.93-1.46 |
| Miller et al. (2013), $\mathrm{n}=34$, 2000-2010 | NR | Single BM longer survival, $P=0.014$ | Tendency for Longer survival with absence of extracranial disease, $P=0.244$ | Longer survival <br> Isolated intracerebral relapse $P=0.003$ | Age $>65$ or $</=65, P=0.9$; gender, $P=0.413$; Karnofsky performance status $>70, P=0.542$; stage at diagnosis, $P=0.291$; presence of occult primary, $P=0.565$; presence of amelanotic $1^{\mathrm{a}}, P=0.938$; interval from $1^{\mathrm{a}}$ diagnosis to BM, $P=0.098$; BM diameter $>0.3 \mathrm{~cm}, P=0.327$, presence of hemorrhage, $P=0.556$; supratentorial location, $P=0.889$; presentation of BM, $P=0.283$; recursive partitioning analysis class, $P=0.677$ || Hamilton et al. (2013), $\mathrm{n}=115$, 1995-2011 | NR | Single vs multiple, $P=0.61, \mathrm{HR}$ $0.88(0.52-1.44)$ | NS, $P=0.36$, HR 0.82 (0.54-1.26) | Longer survival <br> ECOG performance status, $P=0.024$, HR 1.71 (1.05-2.70); recursive partitioning analysis class I, $P<0.0001$, HR 3.4 (1.976.23); high immune infiltrate, $P=0.006$, HR 0.54 (0.35-0.84); low hemorrhage level, $P=0.04$, HR 1.58 (1.02-2.48) |
| :--: | :--: | :--: | :--: | :--: |
| Gumusay (2014), $\mathrm{n}=470$, 2000-2012 | 4.1 | NS, $P=0.414$ | NS, $P=0.820$ | Longer survival <br> $1^{\circ} \mathrm{BT} \leq 4 \mathrm{~mm}, P=0.001$ <br> Shorter survival <br> Age $>65$ years, $P=0.002$; ECOG $>2$, $P=0.046$ |
| Vecchio et al. (2014), $\mathrm{n}=115$, 1994-2010 | 4.3 | Single vs multiple metastases (HR 1.61, CI 1.05-2.46, $P=0.03$ ) | Shorter survival, especially when visceral and skin involvement (HR 2.35, CI 1.27$4.37, P=0.03$ ) | Longer survival <br> Type of first treatment (surgery, SRS or chemotherapy vs supportive care only, HR 15.46, CI 8.0-29.84, $P<0.001$ ) <br> Shorter survival <br> Symptomatic BM (HR 1.96, CI 1.14-3.36, $P=0.02$ ); Shortened symptoms after treatment (HR 4.18 CI 2.57-6.78, $P<0.001$ ) |

Age $>65$ years, $P=0.33$, HR 1.30 (0.75-2.15); gender, $P=0.1$, HR 1.44 (0.94-2.26); systemic therapy prior to craniotomy, $P=0.66$; systemic therapy after craniotomy, $P=0.13$; local therapy after craniotomy, $P=0.019$; no correlation between survival and gliosis, necrosis and melanin expression

Gender, $P=0.379 ; 1^{\circ}$ ulceration present, $P=0.125$; mitotic index, $P=0.801$; unilateral vs bilateral location, $P=0.466$

Gender, $P=0.20 ; P=0.55 ; 1^{\circ}$ ulceration present, $P=0.72 ; 1^{\circ}$ histology, $P=0.44$; stage at diagnosis, $P=0.88$

BT, Breslow thickness; BM, brain metastases; HR, hazard ratio; CI, confidence interval; OS, overall survival; XRT, radiation therapy; WBRT, whole-brain radiation therapy; LVI, lymphovascular invasion; SRS, stereotactic radiosurgery; NE, not evaluated; NS, not significant.The prognostic significance of concurrent extracranial disease has been evaluated repeatedly in melanoma patients with CNS involvement (Table 19.2). Of the 12 studies that evaluated the prognostic significance of concurrent extracranial disease in patients with melanoma brain metastases, seven found that the presence of other extracranial metastases was associated with significantly shorter OS (in one trial: hazard ratio, 1.558; $P<0.0001$ ). The detrimental effect of uncontrolled extracranial disease on OS in patients with melanoma brain metastases was initially described in 1978 (Amer et al., 1978). The best survival was observed in patients with CNS only disease, without any evidence of other visceral involvement. In one of the largest cohorts of patients examined to date, patients with isolated brain metastasis $(\mathrm{n}=380)$ had a median OS of 135.2 days, while patients with coexisting lung metastasis $(\mathrm{n}=191)$ had a median survival of only 93.8 days $(P=0.0014)$, and patients with more than one additional site of visceral metastasis $(\mathrm{n}=77)$ had a median survival of only 39 days $(P=0.0036)$ (Sampson et al., 1998). Of note, the same group described a small group of 17 patients with metastatic melanoma who survived for more than 3 years, 15 of whom had metastatic disease limited to the CNS alone suggesting that CNS metastasis in of itself is not a sole determinant for survival.

Other factors have also correlated with survival. Good performance status and lower lactate dehydrogenase level at the time of diagnosis of melanoma brain metastases was associated with significantly longer OS in two studies (Staudt et al., 2010; Eigentler et al., 2011). Conversely, patients with neurological symptoms had worse survival (Zakrzewski et al., 2011). The presence of hemorrhage prior to treatment with SRS was a predictor of neurological death and neurological symptoms (Meier et al., 2004; Koc et al., 2005; Neal et al., 2013). The presence of neurological symptoms can be due to large or numerous tumors or to a tumor in an unfavorable location in the brain, all of which were shown to be negatively associated with survival.

Some studies have analyzed the association between primary tumor features and prognosis. In general these analyses have shown mixed results (Table 19.2). While the presence of ulceration of the primary tumor was associated with shorter survival after the development of brain metastases in one study, two other reports did not find a significant association (Zakrzewski et al., 2011). Similarly, primary tumor location, histologic subtype, and mitotic index were associated with shorter survival after brain metastases in some studies but not in others (Saha et al., 1994; Sampson et al., 1998). On a molecular level, genes associated with the T-cell receptor pathway were associated with prolonged OS in patients with melanoma with brain metastases, whereas genes associated with hypoxia and oxidative stress were associated with poor OS in these patients, underlining the importance of immune response in the brain environment (Hamilton et al., 2013).

Overall, these results support that the number of brain metastases and the extracranial disease status are key prognostic factors for OS in melanoma patients with CNS involvement. As discussed previously, these factors have also been significantly associated with the treatment modalities used in patients (Davies et al., 2011). As the treatment landscape for melanoma evolves, it will be important to reevaluate the prognostic significance of these factors. Of note, our single-center experience in patients with brain metastases demonstrated that the OS of these patients has improved over time (median OS 4.14 months for patients diagnosed before 1996 vs 5.92 months diagnosed after January 1, 1996), even priorto the testing and approval of the new, effective systemic therapies (Davies et al., 2011). The development of new focal radiation techniques, such as SRS, may lessen the prognostic impact of the number of brain metastases on survival. Similarly, new therapies with unprecedented rates of disease control also provide hope for the improvement of outcomes in brain metastasis patients with concurrent extracranial disease. Improvements may also be achieved if such systemic therapies also have significant antitumor activity in the brain.

# TREATMENT-SPECIFIC PREDICTORS OF OUTCOMES IN MELANOMA BRAIN METASTASIS PATIENTS 

There are a number of therapeutic options for patients with brain metastases. Broad reviews of outcomes in melanoma patients with brain metastases have demonstrated that OS can be associated with the treatment modality. Of note, these associations may reflect the status of patients' disease. Historically, the selection of different modalities used in patients has been influenced by the pattern of brain involvement. For patients with a limited number of brain metastases (i.e., one to three), surgery was historically considered the primary treatment option. Over time, focused radiation treatments, such as SRS, have emerged and can achieve durable disease control in such patients. Although SRS has traditionally been subject to technical factors that have limited the number of lesions that this modality can treat, newer technologies are being used increasingly in patients with higher numbers of lesions. However, tumor size appears to be critical to the efficacy of focal radiation approaches, and larger lesions may require surgical resection instead (Rodrigues et al., 2014). In addition to focused radiation, WBRT has been commonly used for patients with brain metastases, particularly those for whom surgery and SRS are not options-although WBRT also is sometimes combined with those modalities. A variety of systemic therapies also have been tested in patients with melanoma brain metastases, although no randomized clinical trials of systemic therapy alone have been completed to date in this population. Finally, supportive care alone is often used, likely owing to the low likelihood of significant clinical benefit with many of these treatments and their potential toxicities. As new clinical approaches are considered, particularly combinations that utilize different modalities concurrently (Postow et al., 2012; Golden et al., 2013), an understanding of the factors that predict outcomes with each treatment will be important to consider for appropriately designing and interpreting clinical trials for this patient population.

## Radiation Therapy

Table 19.3 provides an overview of prognostic factors for survival among melanoma patients treated with various radiation therapies.

Recursive partitioning analysis (RPA) can help determine prognosis for patients with brain metastases in general. RPA was developed by the Radiation Therapy Oncology Group (RTOG) and included 1200 patients from three consecutive RTOG trials conducted between 1979 and 1993 (Gaspar et al., 1997). Based on this analysis, the following three classes were defined: Class 1: patients with Karnofsky Performance Scale (KPS) $\geq 70,<65$ years of ageTABLE 19.3 Prognostic Factors for Survival After the Development of Melanoma Brain Metastases in Patients Receiving Radiation Therapy

| Reference, No. of patients, years | Median OS (months) | Association of number of brain metastases with OS | Association of extracranial disease with OS | Other factors associated with longer OS $(P<0.05)$ | Other factors analyzed |
| :--: | :--: | :--: | :--: | :--: | :--: |
| Mori et al. (1998), $\mathrm{n}=60$, 1988-1996 | 7 | Single vs multiple <br> BM, trend toward longer survival, $P=0.07$ | Longer survival with absence of extracranial metastases at the time of SRS, $P=0.004$ | Use of chemotherapy and/or immunotherapy following radiosurgery, $P=0.01$ | Age, $P=0.37$; gender, $P=0.93$; neurological deficit at time of SRS, $P=0.80$; Karnofsky performance status, $P=0.12$; relapse after WBRT, $P=0.24$; volume of BM, $P=0.93$; location of lesion, $P=0.37$; prior hemorrhage, $P=0.54$; prior surgery, $P=0.73$; WBRT before/after SRS, $P=0.26$ |
| $\begin{aligned} & \text { Koc et al. } \\ & (2005), \mathrm{n}=26, \\ & 1999-2003 \end{aligned}$ | 9 | Single vs multiple <br> $\mathrm{BM}, P=0.92$ | Longer survival with absence of extracranial metastases at the time of SRS, $P<0.07$ | Female gender, $P<0.004$; Karnofsky performance status at least 90, $P<0.023$; supratentorial localization, $P<0.001$; absence of neurological symptoms, $P=0.003$; smaller volume of lesions, $P=0.02$ | Age, $P=0.13$; chemotherapy or immunotherapy after SRS, $P=0.17$; receiving WBRT, $P=0.77$ |
| Redmond et al. (2008), $\mathrm{n}=59$, 1998-2007 | NR | Single vs multiple $\mathrm{BM}, P=0.04$ | NS | Lesions without evidence of pre-SRS hemorrhage, $P=0.004$; total tumor volume treated $<4 \mathrm{~cm}^{3}, P=0.02$ | Sex; race; location BM; WBRT; chemotherapy; history of antithrombotic medications; cranial surgery |
| $\begin{aligned} & \text { Skeie et al. } \\ & (2011), \mathrm{n}=77 \text {, } \\ & 1996-2006 \end{aligned}$ | 7 | Single vs multiple $\mathrm{BM}, P=0.062$ | Longer survival with absence of extracranial disease, $P=0.014$ | Karnofsky performance status $>90$, $P=0.024$; tumor volume of less than 5 cc , $P=0.041$; RPA class 1 ( 22 months) than RPA class 2 ( 7 months) and RPA class 3 ( 3 months; $P=0.008$ ) | Presence of cranial nerve deficits, cognitive impairment, or epilepsy had no impact on survival tumor growth arrest vs continued growth, $P=0.625$ |
| Neal et al. (2013), $\mathrm{n}=129$, 2000-2009, | 6.7 | Longer survival with fewer BM at initial SRS, $P=0.02$ | Longer survival with none vs oligometastatic disease, $P=0.02$ | Increased interval to DBF, $P=0.0001$; chemotherapy before SRS, $P=0.02$; treatment with biologic agents before SRS, $P=0.017$; increased interval to DBF, $P=0.0001$ Shorter survival <br> Hemorrhagic BM before SRS, $P=0.0005$; lower marginal dose at the first gamma knife treatment $(P=0.04)$ | WBRT before SRS $(P=0.05)$ were less likely to have local tumor control; pre-SRS hemorrhage did not predict post-SRS hemorrhage ( $P=0.08$ ); hemorrhage of metastases after SRS trended toward significance for DBF $(P=0.06)$ |
| $\begin{aligned} & \text { Partl et al. } \\ & (2013), \mathrm{n}=87 \text {, } \\ & 1988-2009 \end{aligned}$ | 2.6 | Shorter survival with $>2 \mathrm{BM}$, $P=0.005$ | Number of extracranial metastatic locations (>2 vs less), $P=0.430$ | Absence of neurological symptoms, $P=0.027$; lactate dehydrogenase $<240 \mathrm{U} / \mathrm{L}$, $P=0.001$; Karnofsky performance status $>70, P<0.001$ | Age, $P=0.458$; gender, $P=0.626$; intracranial therapy before WBRT vs no prior intracranial therapy, $P=0.38$; local recurrence and lymph node metastases present vs not present, $P=0.123$ |

[^0]
[^0]:    SRS, stereotactic radiosurgery; WBRT, whole-brain radiation therapy; OS, overall survival; RPA, recursive partitioning analysis; DBF, distant brain failure.with controlled primary and no extracranial metastases; Class 3: KPS < 70; Class 2: all others. Median OS varied with each class, with a median OS of 7.1 months for Class I, 4.2 months for Class 2, and only 2.3 months for Class 3 patients. In one study (Gaspar et al., 1997), patients were stratified into three categories estimating survival through a statistical methodology that creates a regression tree. The best survival group had a median OS of 7.1 months, seen in patients younger than 65 years with a Karnofsky performance status of at least 70 and a controlled primary tumor, with the brain as the only site of metastasis.

Recently, researchers suggested including liver and hemorrhagic metastases to the graded prognostic assessment (GPA) index melanoma with brain metastases (Osei-Boateng et al., 2013). The GPA for melanoma is based on the KPS and the number of brain metastases present. This new analysis was based on 90 patients who presented with a median number of brain metastases of 2 (range, 1-11). Their KPS was 90-100 (52\%), 70-80 (43\%), and <70 (6\%) and extracranial metastases was present in 75 patients ( $83 \%$ ). Initial treatment included SRS (49\%), WBRT (8\%), WBRT + SRS (22\%), WBRT + Surgery (S) (14\%), and SRS + (S) (7\%). Number of BM was not associated with OS $(P=0.19)$ but in contrast, KPS $(P=0.02)$, liver ( $P=0.04$ ), and hemorrhagic metastasis $(P=0.02)$ were independently prognostic for OS. The median OS for all patients was 7.8 , but when divided into the three different groups, outcome varied significantly. Patients in the favorable group had a median OS of 12.8 months, while patients in the unfavorable group had a reported median OS of only 4.4 months.

Observations that prognosis and survival can depend on the histology of the primary tumor led to a proposal for diagnosis-specific GPA (Sperduto et al., 2010). While age, presence of extracranial metastases, number of brain metastases, and performance status all influenced the survival categories for disease with lung cancer histology, only the latter two factors affected outcomes in melanoma. Of four survival categories, the least favorable category had a median survival of 3.4 months, and the most favorable category had a median survival of 13.2 months.

One retrospective review of 296 patients with melanoma brain metastases treated with radiation reported that the presence of $B R A F$ and $N R A S$ mutations correlated with inferior local control following radiation compared to patients with a wild-type genotype for both oncogenes. However, the use of radiation (SRS or WBRT) did significantly improve local control for patients with these mutations compared with systemic therapy alone (Koay et al., 2012). Further investigation is warranted to evaluate radiation for brain metastases in conjunction with targeted therapies in melanoma patients with activating BRAF or NRAS mutations.

# Whole-Brain Radiation Therapy 

WBRT has been used for decades as a standard treatment for brain metastases of all histologic types. Studies have demonstrated that WBRT resulted in a median survival of only 2-6 months in patients with melanoma brain metastases but did improve neurologic function and was superior to the use of steroids only (Stridsklev et al., 1984). Melanoma has often been viewed as radioresistant and retrospective analysis of patients treated with WBRT have shown that brain lesions contributed to death nearly in $95 \%$ cases (Sampson et al., 1998). Melanoma brain metastases appear to have worse response and local control to WBRT than brain metastases of other histologies (Nieder et al., 1997). Whole-brainradiation remains the standard of care in the setting of nonoperative large-volume tumors (i.e., $>2 \mathrm{~cm}$ ), numerous brain metastases, and for patients who have failed initial SRS or surgical resection (Ramakrishna and Margolin, 2013).

# Stereotactic Radiosurgery 

In a recent report in patients harboring a median of five brain metastases, treatment with SRS led to a median OS of 6.7 months and a local treatment failure rate of only $4 \%$ (Ojerholm et al., 2014). Larger tumor volume was associated with worse OS, and more than one-third of patients required salvage WBRT after a median of 10.3 months after SRS. The authors postulated that SRS can be substituted for WBRT as the initial treatment for four or more simultaneous brain metastases and thus could spare or delay WBRT in some patients (Ojerholm et al., 2014). A second study showed a high rate of local control with radiosurgery in patients with 10 or more brain metastases (Grandhi et al., 2012). A prospective randomized trial at our institution is currently recruiting melanoma patients with more than three brain metastases to compare SRS with WBRT (NCT01644591).

A few studies have looked specifically at predictors for early distant brain failure after gamma knife radiosurgery. One study found that more than three metastases, stable or poorly controlled extracranial disease, and melanoma histology in the brain lesions predict distant brain failure (Sawrie et al., 2008). Another study found that progressive systemic disease, number of metastases at the time of SRS, discovery of new metastases at the time of SRS, and melanoma histology predicted a shorter time to distant failure (Ayala-Peacock et al., 2014). One study reported that SRS achieves local disease control rates at 1 and 2 years of $86 \%$ and $78 \%$, respectively, for brain metastases ( 44 of the 153 evaluated brain metastases were metastatic melanoma) of 1 cm or less. The local control rates for lesions larger than 1 cm were $56 \%$ and $24 \%$, respectively $(P=0.0016)$ (Chang et al., 2003). SRS may thus be most suitable for smaller lesions and/or for tumors occurring in areas where a surgical approach would be difficult. SRS may also be appropriate for patients who are not surgical candidates due to medical comorbidities. A limitation of these studies is that while they include a substantial number of melanoma patients, they did not evaluate outcomes in melanoma patients specifically.

The combination of WBRT and stereotactic boost treatment appears to improve functional autonomy (Karnofsky performance status) for all patients and survival for patients with a single unresectable brain metastasis (Andrews et al., 2004). This combination also led to lower local and distant recurrence rates than SRS alone (Aoyama et al., 2006). The addition of adjuvant WBRT to SRS or to surgery decreased intracranial relapse rates and reduced the risk of neurological death, and, in patients with no extracranial disease, improved OS (Kocher et al., 2011). In another randomized controlled trial that compared SRS plus WBRT versus SRS alone in 132 patients with one to four brain metastases, WBRT led to a $30 \%$ reduction in local intracranial recurrence and a $22 \%$ reduction in distant intracranial recurrence at 12 months compared with radiosurgery alone ( $P=0.001$ ). The groups did not significantly differ in OS ( 7.5 months with whole-brain radiation and SRS vs 8 months SRS alone) or neurological death (Aoyama et al., 2006). While the addition of WBRT to SRS can improve OS and decrease intracranial relapse rate compared with radiosurgery alone,worsened neurocognitive memory also was reported after using this bimodal approach compared with radiosurgery alone (Chang et al., 2009). The combination of WBRT with SRS has a well-documented risk of $5-10 \%$ for the development of radiation necrosis/treatment effect that can pose a diagnostic dilemma and can cause neurological symptoms in its own right (Schuttrumpf et al., 2014). While the radiosurgery-alone treatment arm had worse local and distant control rates, subsequent salvage therapy appeared to be effective (Chang et al., 2009). Therefore, in selected patients, the radiosurgery-only approach might be appropriate as initial therapy.

Size, number, and location of the lesions as well as patient-specific factors including performance status, comorbidities, and the extent of extracranial disease have to be taken into account by the treating physician when evaluating a patient for either surgery or a radiosurgical approach.

# Surgery 

Surgical removal of brain metastases has been consistently shown to benefit patients with melanoma brain metastases (Staudt et al., 2010; Eigentler et al., 2011). Surgery offers the benefits of confirming the diagnosis, immediate relief of mass effect, and improvement of neurological symptoms. Complete resection provides local control rates as high as $85 \%$ (Essner, 2003). However, the majority of patients with brain metastases treated with surgery do eventually progress and succumb to disease. Retrospective studies have shown OS times of about 7-9 months in patients with melanoma whose brain metastases were surgically removed (Wronski and Arbit, 2000; Fife et al., 2004). Patients with a single brain metastasis and those with a metastasis in the supratentorial region had prolonged survival times. Of note, some patients survive many years after surgery; these tend to be patients with single brain lesions and without extracranial disease (Sampson et al., 1998). In a retrospective study from 2000, the median OS of 91 patients with melanoma who underwent surgical resection for their brain metastases was 6.7 months. Patients with multiple resected brain metastases $(\mathrm{n}=15)$ had shorter survival than the patients who underwent resection of a single lesion $(\mathrm{n}=76$, median 5.4 months vs 7.8 months; $P=0.12$ ). The presence of infratentorial metastases ( 2 months vs 7 months, $P=0.0013$ ) and unresected recurrence of brain metastases ( 20.1 months vs 5 months, $P=0.0003$ ) predicted significantly decreased survival (Wronski and Arbit, 2000). Although postoperative mortality is generally low, one could argue that this is due to selection of patients with better extracranial tumor control and better performance status that were selected for surgery.

When multiple intracranial lesions exist, the role of surgery is less clear. Retrospective data show that if complete surgical resection of all lesions is achieved, then patients with multiple brain lesions, like those with a single lesion only, can derive benefit from surgery. But perhaps the biggest evolution in the surgical management of these patients is the shift away from the prior standard of care of surgical resection followed by whole-brain radiation. In studies described by Patchell et al., the survival time in the surgery and wholebrain radiation group was 40 weeks, whereas it was 15 weeks in the group receiving just radiation. The local recurrence rate dropped to $20 \%$ with combinatorial treatment (Patchell et al., 1990). During an earlier study, 95 brain metastasis patients were randomized to eithersurgery or surgery with whole-brain radiation with the former have a $46 \%$ incidence of local recurrence versus 10\% (Patchell et al., 1998). Furthermore, subsequent studies were unable to substantiate the benefit of whole-brain radiation in post resected patients (Armstrong et al., 1994). Specifically, in a retrospective study at MD Anderson Cancer Center, radiation resistant tumors such as melanoma were not found to benefit from the combination (McPherson et al., 2010). Since then, surgical techniques have evolved to more frequently respect oncological principals of resection with a margin, if feasible, that reduces the local recurrence rate to $20 \%$ (Yoo et al., 2009). The declining use of whole-brain radiation as an immediate follow-up to surgical resection was further accelerated by the associated cognitive issues described for whole-brain radiation and due to the fact that once the option of whole-brain radiation has been used, this potential treatment modality has been eliminated from the therapeutic portfolio.

# Systemic Therapies for Melanoma Brain Metastases 

Responses to systemic chemotherapy regimens have historically been very discouraging for patients with brain metastases in multiple cancers, including melanoma (Table 19.4) (Lombardi et al., 2014). The first agent used to treat brain metastases patients with melanoma was dacarbazine, which was also the first chemotherapeutic agent to gain approval for the treatment of metastatic melanoma. Owing to the limited bioavailability of the drug in the cerebrospinal fluid, however, response rates in the brain were low (Anderson et al., 1995). Temozolomide, a second-generation alkylating agent, with greatly improved penetration into the CNS, is the most commonly used chemotherapeutic agent for the treatment of brain metastases. However, it achieves intracranial response rates of only $10 \%$, similar to the low response rate seen in patients with extracranial disease only (Agarwala et al., 2004). Fotemustine, used mainly in Europe, had an impressive overall response rate of $24 \%$ in one phase II trial and most of the responses were obtained in previously untreated patients and/or those presenting with a single cerebral metastasis, but subsequent trials reported response rates in the same range as those from temozolomide (Mornex et al., 2003). Attempts to combine temozolomide or fotemustine with other agents did not appear to increase response rates in patients with brain metastases from melanoma, with some combinations showing no responses at all (Hwu et al., 2005; Krown et al., 2006; Larkin et al., 2007; Amaravadi et al., 2009).

Sorafenib, a multityrosine kinase inhibitor, also has been evaluated in multiple trials of patients with melanoma. In most of them, sorafenib was combined with other agents, and patients were included in the trial if their brain metastases were stable or asymptomatic (Agarwala et al., 2004; Eisen et al., 2011). Although one trial showed promising improvements in PFS and an OS of 8 months, most of the patients had undergone radiation therapy prior to the initiation of sorafenib, and therefore these results should be interpreted with caution (Amaravadi et al., 2009).

New selective BRAF inhibitors have led to significant improvements in the treatment of metastatic melanoma (Hauschild et al., 2012; Sosman et al., 2012). For dabrafenib, phase I and phase II trials have proven its efficacy in patients with melanoma brain metastases, with intracranial response rates of about $40 \%$ (Falchook et al., 2012; Long et al., 2012). Similar results have been observed with vemurafenib, albeit in a smaller cohort of patients (DzienisTABLE 19.4 Overview of Selected Systemic Treatment Studies

| Reference | Treatment | Number of patients | Median age (range), years | Intracranial response rate | Local tumor control | Median time to progression (range) | Overall survival (range) |
| :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: |
| Margolin et al. (2002) | Temozolomide + WBRT | 31 | NR | $9.70 \%$ |  | 2 months <br> (1 week to 11 months) | 6 months (2-12 months) |
| Buchsbaum et al. (2002) | WBRT alone | 25 | 17 pts $<65$ |  | Local cranial recurrence in $17 \%$ | NR | 2.3 months (0.2-9.6 months) |
|  | Local therapy: surgery or radiosurgery | 10 | 8 pts $<65$ |  | Local cranial recurrence in $20 \%$ |  | 4.8 months (1.2-27.8 months) |
|  | WBRT with local therapy | 36 | 30 pts $<65$ |  | Local cranial recurrence in $49 \%$ |  | 8.8 months (1.8-99.2 months) |
| Mornex et al. (2003) | Fotemustine | 39 | 53.1 (27-77) | $11.10 \%$ |  | 49 days (11-539 days) | 86 days |
|  | Fotemustine + WBRT | 37 | 49.2 (29-70) | $16.70 \%$ |  | 56 days (19-348 days) | 105 days |
| Agarwala et al. (2004) | Temozolomide | 151 | Prior Chemo <br> 53 (20-80), no prior chemo 46.5 (24-66) | Prior Chemo: <br> $3 \%$ PR. <br> Chemo-naïve, <br> 7\% PR |  | NR | 3.5 months |
| Hwu et al. (2005) | Temozolomide + thalidomide | 26 | 60 (27-82) | CR 3\%, PR 6\% | $12 \%$ | 4 months (2-40 months) | 5 months |
| Krown et al. (2006) | Temozolomide + thalidomide | 16 | 54.5 (23-83) | $0 \%$ | $0 \%$ | 7.3 weeks | 23.9 weeks (1.7-40.3 weeks) |
| Larkin et al. (2007) | Temozolomide + lomustine | 26 | 50 (27-63) | $0 \%$ | $0 \%$ | NR | 2 months |TABLE 19.4 Overview of Selected Systemic Treatment Studies (Continued)

| Reference | Treatment | Number of patients | Median age (range), years | Intracranial response rate | Local tumor control | Median time to progression (range) | Overall survival (range) |
| :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: |
| Vestermark et al. (2008) | Thalidomide | 36 | $48(27-70)$ | $0 \%$ | $0 \%$ | 1.7 months | 3.1 months |
| Atkins et al. (2008a,b) | Temozolomide + thalidomide + WBRT | 39 | $49(28-81)$ | $7.50 \%$ | $7.50 \%$ | 7 weeks (1-30 weeks) | 4 months ( 0.5 to 12+ months) |
| Amaravadi et al. (2009) | Temozolomide + sorafenib | 53 | $61(37-83)$ | NR | NR | 3.5 months | 8 |
| Hong et al. (2010) | Adoptive cell transfer (with tumor-infiltrating lymphocytes | 17 | $37(17-61)$ | $41 \%$ |  | NR | 8.5 months |
|  | Adoptive cell transfer with peripheral blood lymphocytes retrovirally transduced to express a T-cell receptor | 9 | $36(25-56)$ | $22 \%$ |  | 15 months | 15 months |
| Weber et al. (2011) | Ipilimumab + budesonide | 5 | 57.2 | $20 \%$ |  | NR | 14 months ( 2.7 to 56.4+ months) |
|  | Ipilimumab | 7 | 54.9 | $14 \%$ |  |  |  |
| Knisely et al. (2012) | SRS | 50 | 59.3 (55.1-63.4) | NR | NR | NR | 4.9 months (3.3-10.4 months) |
|  | Ipilimumab + SRS | 27 | 53.2 (49.9-56.4) |  |  |  | 21.3 months (6.43-26.7 months) || Devito (2011) | Temozolomide + WBRT | 29 | $58(30-83)$ | NR | NR | 20.4 weeks (16.630.9 weeks) | 44.4 weeks (30.6-74.7 weeks) |
| :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: |
| Falchook et al. (2012) | Dabrafenib | 10 | $62.5(29-65)$ | 80 |  | 4.2 | NR |
| Di Giacomo et al. (2012) | Ipilimumab + fotemustine | 20 | $54(43-66)$ |  | 50\% disease control rate | 4.5 months (0.3-8.7 months) | 13.4 months (10.0 months to not evaluable) |
| Long (2012) | Dabrafenib (patients without previous local treatment for brain metastases: 74 with V600E mutation; 15 with V600K mutation) | 89 | $52(43-63)$ | BRAF V600E $39.2 \%, \mathrm{~V} 600 \mathrm{~K}$ $6.7 \%$ |  | BRAF V600E, <br> 16.1 months; BRAF V600K, 8.1 months | BRAF V600E, <br> 33.1 months; BRAF V600K, 16.3 months |
|  | Dabrafenib (patients with previous local treatment for brain metastases: 65 with V600E mutation; 18 with V600K mutation) | 83 | $53(44-62)$ | BRAF V600E $30.8 \%, \mathrm{~V} 600 \mathrm{~K}$ $22.2 \%$ |  | BRAF V600E, <br> 16.6 months; BRAF V600K, 15.9 months | BRAF V600E, <br> 31.4 months; BRAF V600K, 21.9 months |
| Rompoti et al. (2013) | Vemurafenib + WBRT | 3 | 70 (64-79) | 40\% mixed response, 20\% SD | 40\% mixed response, 20\% stable disease | NR | NR |
|  | Vemurafenib + SRS | 2 |  |  |  |  |  |
| Silk et al. (2013) | Ipilimumab + SRS | 17 | 56.6 | NR | NR | 2.6 months (1.2 months to not estimable) | 19.9 months (15.9 months to not estimable) |
|  | Ipilimumab + WBRT | 16 |  |  |  | 2.7 months (1.0-8.2 months) | 3.1 months (1.9 months to not estimable) |TABLE 19.4 Overview of Selected Systemic Treatment Studies (Continued)

| Reference | Treatment | Number of patients | Median age (range), years | Intracranial response rate | Local tumor control | Median time to progression (range) | Overall survival (range) |
| :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: |
| Mathew et al. (2013) | SRS | 33 | $57(27-91)$ | NR | NR | 6-month local control, $65 \%$ | 6-month OS, $45 \%$ |
|  | Ipilimumab + SRS | 25 | $62(27-87)$ |  |  | 6-month local control, $63 \%$ | 6-month OS, $56 \%$ |
| Chu et al. (2013) | High-dose Interleukin-2 | 8 | $52.2(26.8-61.1)$ | 0.125 | 0.125 | NR | 6.7 months (2.1-18.2 months) |
| Dzienis and Atkinson (2014) | Vemurafenib | 22 | $49(21-76)$ | $50 \%$ | $50 \%$ | Responders, 23 weeks; nonresponders, 12 weeks | Responders, 46 weeks; nonresponders, 21 weeks |
| Konstantinou et al. (2014) | Ipilimumab | 38 | $50(44-64.7)$ | $8 \%$ (CR + PR), disease control rate $21 \%$ | $8 \%$ (CR + PR), disease control rate $21 \%$ | NR | 101 days (54-154 days) |
| Margolin et al. (2012) | Ipilimumab, asymptomatic patients | 51 | $59(33-79)$ | $15.70 \%$ | $15.70 \%$ | 1.5 months | 7 months |
|  | Ipilimumab, symptomatic patients | 21 | $57(30-74)$ | $5 \%$ | $5 \%$ | 1.2 months | 3.7 months |
| Queirolo et al. (2014) | Ipilimumab | 146 | $54(17-78)$ | $3 \%$ irCR, $9 \%$ irPR | $27 \%$ | 3.1 months (2.7-3.5 months) | 4.3 months (3.4-5.2 months) |

Pts, patients; irCR, immune-related complete response; irPR, immune-related partial response; CR, complete response; PR, partial response; NR, no response; SRS, stereotactic radiosurgery; chemo, thermotherapy; WBRT, whole-brain radiation therapy; OS, overall survival.and Atkinson, 2014). Outcomes with BRAF inhibitors appears to be better in patients with a BRAF V600E mutation, which represents $\sim 70 \%$ of the observed substitutions in melanoma, compared to patients with a V600K mutation, which represents approximately $20 \%$ of BRAF mutations (Menzies et al., 2012; Bucheit et al., 2013). For melanoma patients without previous treatments for brain metastases, the median progression-free and OS with dabrafenib treatment were 16.1 weeks and 33.1 weeks for patients with a V600E mutation and 8.1 and 16.3 weeks for patients with a V600K mutation. For patients with prior CNS surgery or radiation, median PFS and OS were 16.6 weeks and 31.4 weeks for V600E and 15.9 and 21.9 weeks for V600K patients. Notably, inferior results for metastatic melanoma patients with BRAF V600K mutations have also been reported in other trials with dabrafenib, and these mutations are associated with older age at diagnosis, male gender, and more aggressive clinical course (Hauschild et al., 2012; Menzies et al., 2012; Bucheit et al., 2013).

There are a number of potential combinatorial strategies to improve the efficacy of BRAF inhibitors in melanoma patients with CNS metastases. Studies in metastatic melanoma patients without active CNS disease have shown that combined treatment with BRAF and MEK inhibitors is well-tolerated and more effective than either agent alone (Flaherty et al., 2012). Studies are now planned and/or ongoing to test this combination in melanoma patients with active CNS disease. As described earlier, evidence of increased activation of the PI3K-AKT pathway in brain metastases supports the rationale to test inhibitors against it in this patient population. Furthermore, the efficacy and safety of combining BRAF inhibitors and radiation therapy need to be assessed in larger trials, given a recent report showing significant skin toxicity in patients who received this combination (Satzger et al., 2013).

Immunotherapy-based regimens have been used for decades in the treatment of metastatic melanoma. High-dose interleukin-2 is associated with a low rate of responses and can cause significant toxic effects but also can induce long-term responses in a small subset of patients. In an analysis of 274 patients with melanoma who received high-dose interleukin-2, 20 had brain metastases. Although the overall response rate was $15.5 \%$, only one of the patients with brain metastases had an objective response ( $P=0.056$ ) (Phan et al., 2001). This result suggested that the presence of brain metastases was the most significant predictor of a lack of clinical response to interleukin-2. In addition, one has to consider the risk of elevated intracranial pressure in patients who receive this treatment. Small series support that inter-leukin-2 can be used safely in melanoma patients with CNS involvement, and can achieve durable clinical benefit (Chu et al., 2013; Powell and Dudek, 2009).

Interleukin-2 has also been studied in the context of biochemotherapy regimens for melanoma patients. In such regimens, interleukin-2 is given as a continuous infusion, and is combined with both interferon and multiagent chemotherapy. Randomized clinical trials comparing biochemotherapy to multiagent chemotherapy failed to demonstrate significant improvements in OS (Atkins et al., 2008a,b) but retrospective single-institution studies have shown durable (i.e., 5-10 years) OS rates of 15-20\% (Kim et al., 2004; Bedikian et al., 2008). One study of 20 patients found that the outcomes of a biochemotherapy were similar in patients with and without brain metastases if the brain metastases were controlled with multidisciplinary treatment. The median survival from the time of the diagnosis of metastatic melanoma was 15.8 months for patients with brain metastases and 11.1 months for those without CNS involvement ( $P=0.26$ ), and prolonged survival was achieved in approximately $15 \%$ of patients, regardless of CNS involvement (Majer et al., 2007).Ipilimumab, an inhibitory antibody against the CTLA4 receptor on the surface of T cells, was the first agent to ever show a significant improvement in OS in a randomized phase III clinical trial in melanoma. Ipilimumab was approved for the treatment of patients with metastatic melanoma in 2011. In a nonrandomized phase II trial of 72 melanoma patients with brain metastases, patients were divided into a group of patients who were neurologically asymptomatic and were not receiving corticosteroid treatment at study entry (Cohort A) and a group experiencing neurological symptoms and requiring a stable dose of corticosteroids (Cohort B). Ipilimumab (given intravenously at $10 \mathrm{mg} / \mathrm{kg}$ every 3 weeks a total of 4 times) achieved disease control in 13 patients ( $25 \%$ ) in Cohort A and two ( $10 \%$ ) in Cohort B by immune-related response criteria (irRC). The irRC response rates were $15.7 \%$ for Cohort A and 5\% for Cohort B. Median OS times were 7.0 months ( $95 \%$ confidence interval, $4.1-10.8$ months) in Cohort A and 3.7 months (1.6-7.3 months) in Cohort B. The survival rates at $6,12,18$, and $24 \mathrm{months}$ were $55,31,26$, and $26 \%$ for Cohort A, and $38,19,19$, and $10 \%$ for Cohort B, supporting that a subgroup of patients will derive long-term benefit from treatment with ipilimumab, particularly those with tumors that do not require steroids. Notably, the overall antitumor activity, 2-year survival rate, and safety in this study were similar to what has been reported in melanoma patients without brain metastases who were treated with ipilimumab (Margolin et al., 2012). Another author reported a brain control rate of $16 \%$ and a response rate of $8 \%$ in 38 patients with melanoma brain metastases who were treated with ipilimumab as part of the extended access program (Konstantinou et al., 2014).

Adding fotemustine to ipilimumab could further increase clinical benefit (Di Giacomo et al., 2012). Ten of the twenty patients with brain metastases a phase II trial of this combination achieved immune-related disease control (all had asymptomatic disease), with five patients showing a reduction in or stabilization of brain lesions on imaging and with another five patients showing complete metastatic resolution. With a median follow-up of 10.8 months (interquartile range, 4.3-14.2 months), median immune-related PFS was longer for all patients ( 5.3 months, $95 \%$ confidence interval $3.4-7.1$ months) than for just those with brain metastases ( 4.5 months, $0.3-8.7$ months). In this report, the median brain PFS in the 66 patients with no evidence of brain metastases at baseline was 9.5 months (4.7-14.2 months), and the median OS of patients with brain metastases at baseline was 13.4 months, but some patients were still alive at the time of analysis ( 10.0 months to not evaluable).

While the outcomes with, and approval of, ipilimumab represent a breakthrough in melanoma, recent results suggest that other immunotherapies may be even more beneficial. Response rates of $30-50 \%$ have been reported for new immunotherapies that target the PD-1 receptor which, similar to CTLA4 blockade, result in checkpoint release of T cells and augmented antitumor immunity (Hamid et al., 2013; Topalian et al., 2014). In addition to high response rates, the PD-1 blocking antibodies appear to have very low rates of significant autoimmune toxicity, which is a key limitation of ipilimumab therapy. While initial clinical trials with both nivolumab and pembrolizumab excluded melanoma patients with activate brain metastases, new trials are open and planned to test their safety and efficacy in these patients (NCT02085070).

Adoptive cell therapy (ACT) has also been shown to benefit advanced melanoma patients, with response rates of about $50 \%$. However this is a time-consuming, logistically demanding process, requiring the patient be fit for the nonmyeloablative, lymphodepleting preparative regimen and for treatment with interleukin-2 following the reinfusion ofthe autologous cell product (Radvanyi et al., 2012). One trial reported that 7 of 17 patients with brain metastases treated with ACT obtained complete remission and that six additional patients obtained an overall partial response (Hong et al., 2010). Five of these responses were continuing in the brain at $4-44$ months at the time of the trial report's publication. Two of the patients who experienced a complete response in the brain for 6 months ultimately developed diseases at new sites in the brain as well as at extracranial sites. Given that number of brain metastases is a negative predictor of survival, it is notable that most patients in this trial had more than two brain metastases. In addition, all of the patients had extensive extracranial metastatic disease. Six of the seven patients with complete responses in the brain achieved an overall partial response. While the patients in this study were highly selected, the promising results support that ACT should be explored further for patients with melanoma brain metastases.

# Combining Radiation with Systemic Therapy 

Combining whole-brain radiation with chemotherapy or immunotherapy has been another subject of investigation. Neither the addition of temozolomide or other chemotherapy agents to WBRT have improved the intracranial response rates of melanoma metastases compared with single-agent temozolomide, but the combined modalities may slightly increase OS in these patients (Margolin et al., 2002; Atkins et al., 2008a,b; Vestermark et al., 2008; Devito et al., 2011). Promising results have been reported when ipilimumab was added either prior to or after SRS or WBRT (Silk et al., 2013). Another group described a median survival times of 21.3 months in the ipilimumab plus SRS group and 4.9 months in patients who received radiosurgery alone (Knisely et al., 2012). This survival benefit translated into 2-year survival rates of $47.2 \%$ in the ipilimumab group and $19.7 \%$ in the radio-surgery-alone group. An independent study failed to confirm this survival benefit but did show the safety of the combination (Mathew et al., 2013). While these findings suggest that checkpoint blockade and radiation therapy are safe and improve survival for patients with melanoma brain metastases, prospective studies are warranted to confirm these findings and are ongoing (NCT01703507, NCT02115139, and NCT02097732).

## DISCUSSION

The prevention and control of CNS involvement remains one of the biggest challenges in the management of patients with melanoma. In this review, we have discussed factors associated with the development of melanoma brain metastases, prognostic factors associated with survival once brain metastases have developed, and the outcomes with many of the treatments available for such patients. The factors presented here are all retrospectively collected, and some studies included patients treated over five decades ago. It remains to be seen how recent advances in surgery, radiation, and systemic therapy will change the overall outcomes of melanoma patients with CNS involvement, and the prognostic factors that have been defined by these studies. Although the literature on local therapies for patients with melanoma brain metastases also has been mainly retrospective and current recommendations often are extrapolated from studies of cancers with nonmelanomahistology, treatment with surgery or SRS remain effective options for patients with limited brain disease. While historically patients with more extensive involvement have been managed with WBRT or more conservative measures, recent technical advances with focal radiation approaches (i.e., gamma knife) and systemic therapies with unprecedented activity suggest that this paradigm may need to be tested and to evolve. Interestingly, as the outcomes achieved by new radiation approaches appear to be predicted more by lesion size than number, and systemic therapies may be affected significantly by the molecular biology of the tumors, it is possible that prognostic factors for survival in patients with melanoma brain metastases will evolve in parallel to the treatments used for them.

While most studies cited here have focused on parenchymal brain metastases, melanoma can also involve the lining of the brain, an entity known as leptomeningeal disease (LMD). LMD is very challenging to diagnoses, and even more difficult to treat. The presence of LMD has been associated with shorter survival in melanoma patients with brain metastases (Davies et al., 2011). It is likely that distinct therapeutic approaches may be needed for patients with LMD versus those with parenchymal metastases only.

There remains a critical unmet need for new therapies and clinical trials for patients with melanoma brain metastasis. The multiple recent laboratory and clinical advances in this disease support that rational and more effective treatments may be developed in the near future. In particular, there is a tremendous opportunity to combine the different treatments and treatment modalities that have been used to optimize outcomes. This opportunity is matched by the challenge of identifying factors that will allow for appropriate stratification and analysis of these trials, and ultimately for personalized treatment selection for patients. While this challenge is large, the rapidly advancing treatment landscape for this disease supports that such efforts have tremendous promise and potential to meaningfully impact survival in the near future for patients with this highly aggressive disease.

# References 

Agarwala, S.S., Kirkwood, J.M., Gore, M., Dreno, B., Thatcher, N., Czarnetski, B., et al., 2004. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J. Clin. Oncol. 22, $2101-2107$.
Amaravadi, R.K., Schuchter, L.M., McDermott, D.F., Kramer, A., Giles, L., Gramlich, K., et al., 2009. Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin. Cancer Res. $15,7711-7718$.
Amer, M.H., Al-Sarraf, M., Baker, L.H., and Vaitkevicius, V.K., 1978. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 42, 660-668.
Anderson, C.M., Buzaid, A.C., and Legha, S.S., 1995. Systemic treatments for advanced cutaneous melanoma. Oncology 9, 1149-1158.
Andrews, D.W., Scott, C.B., Sperduto, P.W., Flanders, A.E., Gaspar, L.E., Schell, M.C., et al., 2004. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363, 1665-1672.
Aoyama, H., Shirato, H., Tago, M., Nakagawa, K., Toyoda, T., Hatano, K., et al., 2006. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295 (21), 2483-2491.
Armstrong, J.G., Wronski, M., Galicich, J., Arbit, E., Leibel, S.A., and Burt, M., 1994. Postoperative radiation for lung cancer metastatic to the brain. J. Clin. Oncol. 12 (11), 2340-2344.
Atkins, M.B., Hsu, J., Lee, S., Cohen, G.I., Flaherty, L.E., Sosman, J.A., et al., 2008a. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa- 2 b withcisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. 26, 5748-5754.
Atkins, M.B., Sosman, J.A., Agarwala, S., Logan, T., Clark, J.I., Ernstoff, M.S., et al., 2008b. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer 113, 2139-2145.
Ayala-Peacock, D.N., Peiffer, A.M., Lucas, J.T., Isom, S., Kuremsky, J.G., Urbanic, J.J., et al., 2014. A nomogram for predicting distant brain failure in patients treated with gamma knife stereotactic radiosurgery without whole brain radiotherapy. Neuro. Oncol. 16 (9), 1283-1288.
Balch, C.M., Gershenwald, J.E., Soong, S.J., Thompson, J.F., Atkins, M.B., Byrd, D.R., et al., 2009. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27 (36), 6199-6206.
Bedikian, A.Y., Johnson, M.M., Warneke, C.L., McIntyre, S., Papadopoulos, N., Hwu, W.J., et al., 2008. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival. J. Immunotoxicol. 5 (2), 201-207.

Bedikian, A.Y., Wei, C., Detry, M., Kim, K.B., Papadopoulos, N.E., Hwu, W.J., et al., 2011. Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma. Am. J. Clin. Oncol. 34 (6), 603-610.
Bottoni, U., Clerico, R., Paolino, G., Ambrifi, M., Corsetti, P., Calvieri, S., 2013. Predictors and survival in patients with melanoma brain metastases. Med. Oncol. 30 (466), 1-6.
Bucheit, A.D., Syklawer, E., Jakob, J.A., Bassett Jr., R.L., Curry, J.L., Gershenwald, J.E., et al., 2013. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer 119, $3821-3829$.
Bucheit, A.D., Chen, G., Siroy, A., Tetzlaff, M.T., Broaddus, R., Milton, D., et al., 2014. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin. Cancer Res. 20 (21), 5527-5536.
Buchsbaum, J.C., Suh, J.H., Lee, S.Y., Chidel, M.A., Greskovich, J.F., and Barnett, G.H., 2002. Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer 94, 2265-2272.
Chang, E.L., Hassenbusch III, S.J., Shiu, A.S., Lang, F.F., Allen, P.K., Sawaya, R., et al., 2003. The role of tumor size in the radiosurgical management of patients with ambiguous brain metastases. Neurosurgery 53, 272-280. Discussion 280-271.
Chang, E.L., Wefel, J.S., Hess, K.R., Allen, P.K., Lang, F.F., Kornguth, D.G., et al., 2009. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 10, 1037-1044.
Chapman, P.B., Hauschild, A., Robert, C., Haanen, J.B., Ascierto, P., Larkin, J., et al., 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516.
Chen, G., Chakravarti, N., Aardalen, K., Lazar, A.J., Tetzlaff, M., Wubberhorst, B., et al., 2014. Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin. Cancer Res. 21, 5537-5546.
Chu, M.B., Fesler, M.J., Armbrecht, E.S., Fosko, S.W., Hsueh, E., and Richart, J.M., 2013. High-Dose Interleukin-2 (HD IL-2) therapy should be considered for treatment of patients with melanoma brain metastases. Chemother. Res. Pract. 2013 (726925), 1-7.
Cohn-Cedermark, G., Mansson-Brahme, E., Rutqvist, L.E., Larsson, O., Johansson, H., and Ringborg, U., 1998. Central nervous system metastases of cutaneous malignant melanoma- a population-based study. Acta Oncol. $37(5), 463-470$.
Daryanani, D., Plukker, J.T., de Jong, M.A., Haaxma-Reiche, H., Nap, R., Kuiper, H., et al., 2005. Increased incidence of brain metastases in cutaneous head and neck melanoma. Melanoma Res. 15, 119-124.
Davies, M.A., Liu, P., McIntyre, S., Kim, K.B., Papadopoulos, N., Hwu, W.J., et al., 2011. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117, 1687-1696.
Devito, N., Yu, M., Chen, R., and Pan, E., 2011. Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide. Anticancer Res. 31, 4537-4543.
Di Giacomo, A.M., Ascierto, P.A., Pilla, L., Santinami, M., Ferrucci, P.F., Giannarelli, D., et al., 2012. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 13, 879-886.
Dzienis, M.R., and Atkinson, V.G., 2014. Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases: a retrospective review. Melanoma Res. 4, 349-353.Eigentler, T.K., Figl, A., Krex, D., Mohr, P., Mauch, C., Rass, K., et al., 2011. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 117, 1697-1703.
Eisen, T., Marais, R., Affolter, A., Lorigan, P., Robert, C., Corrie, P., et al., 2011. Sorafenib and dacarbazine as firstline therapy for advanced melanoma: phase I and open-label phase II studies. Br. J. Cancer 105, 353-359.
Essner, R., 2003. Surgical treatment of malignant melanoma. Surg. Clin. North Am. 83, 109-156.
Falchook, G.S., Long, G.V., Kurzrock, R., Kim, K.B., Arkenau, T.H., Brown, M.P., et al., 2012. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379, 1893-1901.
Farnell, G.F., Buckner, J.C., Cascino, T.L., O'Connell, M.J., Schomberg, and P.J., Suman, V., 1996. Brain metastases from colorectal carcinoma. The long term survivors. Cancer 78, 711-716.
Fife, K.M., Colman, M.H., Stevens, G.N., Firth, I.C., Moon, D., Shannon, K.F., et al., 2004. Determinants of outcome in melanoma patients with cerebral metastases. J. Clin. Oncol. 22, 1293-1300.
Flaherty, K.T., Infante, J.R., Daud, A., Gonzalez, R., Kefford, R.F., Sosman, J., et al., 2012. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703.
Gaspar, L., Scott, C., Rotman, M., Asbell, S., Phillips, T., Wasserman, T., et al., 1997. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int. J. Radiat. Oncol. Biol. Phys. 37, 745-751.
Golden, E.B., Demaria, S., Schiff, P.B., Chachoua, A., and Formenti, S.C., 2013. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol. Res. 1, 365-372.
Grandhi, R., Kondziolka, D., Panczykowski, D., Monaco III, E.A., Kano, H., Niranjan, A., et al., 2012. Stereotactic radiosurgery using the Leksell Gamma Knife Perfexion unit in the management of patients with 10 or more brain metastases. J. Neurosurg. 117, 237-245.
Gumusay, O., Coskun, U., Akman, T., Ekinci, A.S., Kocar, M., Erceleb, O.B., et al., 2014. Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology. J. Cancer Res. Clin. Oncol. 140, 151-157.
Hamid, O., Robert, C., Daud, A., Hodi, F.S., Hwu, W.J., Kefford, R., et al., 2013. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134-144.
Hamilton, R., Krauze, M., Romkes, M., Omolo, B., Konstantinopoulos, P., Reinhart, T., et al., 2013. Pathologic and gene expression features of metastatic melanomas to the brain. Cancer 119, 2737-2746.
Hauschild, A., Grob, J.J., Demidov, L.V., Jouary, T., Gutzmer, R., Millward, M., et al., 2012. Dabrafenib in BRAFmutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365.
Hofmann, M.A., Coll, S.H., Kuchler, I., Kiecker, F., Wurm, R., Sterry, W., et al., 2007. Prognostic factors and impact of treatment in melanoma brain metastases: better prognosis for women? Dermatology 215, 10-16.
Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al., 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363 (8), 711-723.
Hong, J.J., Rosenberg, S.A., Dudley, M.E., Yang, J.C., White, D.E., Butman, J.A., et al., 2010. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin. Cancer Res. 16, 4892-4898.
Hwu, W.J., Lis, E., Menell, J.H., Panageas, K.S., Lamb, L.A., Merrell, J., et al., 2005. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 103, 2590-2597.
Jackson, J.E., Burmeister, B.H., Burmeister, E.A., Foote, M.C., Thomas, J.M., Meakin, J.A., et al., 2014. Melanoma brain metastases: the impact of nodal disease. Clin. Exp. Metastasis 31, 81-85.
Jakob, J.A., Bassett Jr., R.L., Ng, C.S., Curry, J.L., Joseph, R.W., Alvarado, G.C., et al., 2012. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118, 4014-4023.
Kim, K.B., Eton, O., East, M.J., Hodges, C., Papadopoulos, N.E., Grimm, E.A., et al., 2004. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma. Cancer 101, 596-603.
Knisely, J.P., Yu, J.B., Flanigan, J., Sznol, M., Kluger, H.M., and Chiang, V.L., 2012. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J. Neurosurg. 117, 227-233.
Koay, E.U., Bucheit, A.D., Jakob, J.A., Hyun, E.D., Settle, S.H., Brown, P.D., et al., 2012. Correlation of BRAF and NRAS mutation status with tumor characteristics and treatment outcomes in melanoma patients with brain metastasis. J. Clin. Oncol. 30 (suppl; abstr 8584).
Koc, M., McGregor, J., Grecula, J., Bauer, C.J., Gupta, N., and Gahbauer, R.A., 2005. Gamma Knife radiosurgery for intracranial metastatic melanoma: an analysis of survival and prognostic factors. J. Neurooncol. 71, 307-313.

# II. TREATMENT AND PROGNOSISKocher, M., Soffietti, R., Abacioglu, U., Villa, S., Fauchon, F., Baumert, B.G., et al., 2011. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J. Clin. Oncol. 29, 134-141.
Konstantinou, M.P., Dutriaux, C., Gaudy-Marqueste, C., Mortier, L., Bedane, C., Girard, C., et al., 2014. Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients. Acta Derm. Venereol. 94, 45-49.
Krown, S.E., Niedzwiecki, D., Hwu, W.J., Hodgson, L., Houghton, A.N., and Haluska, F.G., 2006. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer 107, 1883-1890.
Larkin, J.M., Hughes, S.A., Beirne, D.A., Patel, P.M., Gibbens, I.M., Bate, S.C., et al., 2007. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. Br. J. Cancer 96, 44-48.
Lee, I., Fox, P.S., Ferguson, S.D., Bassett, R., Kong, L.Y., Schacherer, C.W., et al., 2012. The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival. Oncotarget 3, 336-344.
Lombardi, G., Di Stefano, A.L., Farina, P., Zagonel, V., and Tabouret, E., 2014. Systemic treatments for brain metastases from breast Cancer, non-small cell lung Cancer, melanoma and renal cell carcinoma: an overview of the literature. Cancer Treat. Rev. 8, 951-959.
Long, G.V., Trefzer, U., Davies, M.A., Kefford, R.F., Ascierto, P.A., Chapman, P.B., et al., 2012. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 1087-1095.
Majer, M., Jensen, R.L., Shrieve, D.C., Watson, G.A., Wang, M., Leachman, S.A., et al., 2007. Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases. Cancer 110, 1329-1337.
Margolin, K., Atkins, B., Thompson, A., Ernstoff, S., Weber, J., Flaherty, L., et al., 2002. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J. Cancer Res. Clin. Oncol. 128, 214-218.
Margolin, K., Ernstoff, M.S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., et al., 2012. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13, 459-465.
Mathew, M., Tam, M., Ott, P.A., Pavlick, A.C., Rush, S.C., Donahue, B.R., et al., 2013. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res. 23, 191-195.
McPherson, C.M., Suki, D., Feiz-Erfan, I., Mahajan, A., Chang, E., Sawaya, R., et al., 2010. Adjuvant whole-brain radiation therapy after surgical resection of single brain metastases. Neuro. Oncol. 12, 711-719.
Meier, S., Baumert, B.G., Maier, T., Wellis, G., Burg, G., Seifert, B., et al., 2004. Survival and prognostic factors in patients with brain metastases from malignant melanoma. Onkologie 27, 145-149.
Menzies, A.M., Haydu, L.E., Visintin, L., Carlino, M.S., Howle, J.R., Thompson, J.F., et al., 2012. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin. Cancer Res. $18,3242-3249$.
Miller, D., Zappala, V., El Hindy, N., Livingstone, E., Schadendorf, D., Sure, U., et al., 2013. Intracerebral metastases of malignant melanoma and their recurrences- a clinical analysis. Clin. Neurol. Neurosurg. 115, 1721-1728.
Mori, Y., Kondziolka, D., Flickinger, J.C., Kirkwood, J.M., Agarwala, S., and Lunsford, L.D., 1998. Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int. J. Radiat. Oncol. Biol. Phys. 42, 581-589.
Mornex, F., Thomas, L., Mohr, P., Hauschild, A., Delaunay, M.M., Lesimple, T., et al., 2003. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res. 13, 97-103.
Neal, M.T., Chan, M.D., Lucas Jr., J.T., Loganathan, A., Dillingham, C., Pan, E., et al., 2013. Predictors of survival, neurologic death, local failure, and distant failure after gamma knife radiosurgery for melanoma brain metastases. World Neurosurg. [Epub ahead of print].
Nieder, C., Berberich, W., and Schnabel, K., 1997. Tumor-related prognostic factors for remission of brain metastases after radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 39, 25-30.
Niessner, H., Forschner, A., Klumpp, B., Honegger, J.B., Witte, M., Bornemann, A., et al., 2013. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med. 2, 76-85.
Ojerholm, E., Lee, J.Y., Kolker, J., Lustig, R., Dorsey, J.F., and Alonso-Basanta, M., 2014. Gamma Knife radiosurgery to four or more brain metastases in patients without prior intracranial radiation or surgery. Cancer Med. 3, $565-571$.Osei-Boateng, V.A., Dahiya, S., Du, L., Garje, R., Elson, P., Chao, S.T., et al., 2013. Graded prognostic assessment index for melanoma with brain metastases (MBM). J. Clin. Oncol. 31 (suppl; abstr 9086).
Partl, R., Richtig, E., Avian, A., Berghold, A., and Kapp, K.S., 2013. Karnofsky performance status and lactate dehydrogenase predict the benefit of palliative whole-brain irradiation in patients with advanced intra- and extracranial metastases from malignant melanoma. Int. J. Radiat. Oncol. Biol. Phys. 85, 662-666.
Patchell, R.A., Tibbs, P.A., Regine, W.F., Dempsey, R.J., Mohiuddin, M., Kryscio, R.J., et al., 1998. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280, 1485-1489.
Patchell, R.A., Tibbs, P.A., Walsh, J.W., Dempsey, R.J., Maruyama, Y., Kryscio, R.J., et al., 1990. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 322, 494-500.
Phan, G.Q., Attia, P., Steinberg, S.M., White, D.E., and Rosenberg, S.A., 2001. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J. Clin. Oncol. 19, 3477-3482.
Postow, M.A., Callahan, M.K., Barker, C.A., Yamada, Y., Yuan, J., Kitano, S., et al., 2012. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366, 925-931.
Powell, S., and Dudek, A.Z., 2009. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases. Anticancer Res. 29, 4189-4193.
Queirolo, P., Spagnolo, F., Ascierto, P.A., Simeone, E., Marchetti, P., Scoppola, A., et al., 2014. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J. Neurooncol. 118, 109-116.
Radvanyi, L.G., Bernatchez, C., Zhang, M., Fox, P.S., Miller, P., Chacon, J., et al., 2012. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 18, 6758-6770.
Raizer, J.J., Hwu, W.J., Panageas, K.S., Wilton, A., Baldwin, D.E., Bailey, E., et al., 2008. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro. Oncol. 10, 199-207.
Ramakrishna, N., and Margolin, K.A., 2013. Multidisciplinary approach to brain metastasis from melanoma; local therapies for central nervous system metastases. Am. Soc. Clin. Oncol. Educ. Book, 399-403.
Redmond, A.J., Diluna, M.L., Hebert, R., Moliterno, J.A., Desai, R., Anisely, J.P., et al., 2008. Gamma Knife surgery for the treatment of melanoma metastases: the effect of intratumoral hemorrhage on survival. J. Neurosurg. 109 (Suppl.), 99-105.
Rodrigues, G., Warner, A., Zindler, J., Slotman, B., and Lagerwaard, F., 2014. A clinical nomogram and recursive partitioning analysis to determine the risk of regional failure after radiosurgery alone for brain metastases. Radiother. Oncol. 111, 52-58.
Rompoti, N., Schilling, B., Livingstone, E., Griewank, K., Hillen, U., Sauerwein, W., et al., 2013. Combination of BRAF inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicity. J. Clin. Oncol. 31, 3844-3850.
Saha, S., Meyer, M., Krementz, E.T., Hoda, S., Carter, R.D., Muchmore, J., et al., 1994. Prognostic evaluation of intracranial metastasis in malignant melanoma. Ann. Surg. Oncol. 1, 38-44.
Sampson, J.H., Carter Jr., J.H., Friedman, A.H., and Seigler, H.F., 1998. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J. Neurosurg. 88, 11-20.
Satzger, I., Degen, A., Asper, H., Kapp, A., Hauschild, A., and Gutzmer, R., 2013. Reply to N. Rompoti et al. J. Clin. Oncol. 31, 3845-3846.
Sawaya, R.B., Lang, R., and Abi-Said, F.F., 2001. Metastatic brain tumors. In: Kaye, A.H., Laws Jr, E.R. (Eds.), Brain Tumors, second ed. Churchill Livingstone, Philadelphia, pp. 999-1026.
Sawrie, S.M., Guthrie, B.L., Spencer, S.A., Nordal, R.A., Meredith, R.F., Markert, J.M., et al., 2008. Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone. Int. J. Radiat. Oncol. Biol. Phys. 70, 181-186.
Schoenewolf, N.L., Belloni, B., Simcock, M., Tonolla, S., Vogt, P., Scherrer, E., et al., 2014. Clinical implications of distinct metastasizing preferences of different melanoma subtypes. Eur. J. Dermatol. 2, 236-241.
Schuttrumpf, L.H., Niyazi, M., Nachbichler, S.B., Manapov, F., Jansen, N., Siefert, A., et al., 2014. Prognostic factors for survival and radiation necrosis after stereotactic radiosurgery alone or in combination with whole brain radiation therapy for 1-3 cerebral metastases. Radiat. Oncol. 9 (105), 1-8.
Silk, A.W., Bassetti, M.F., West, B.T., Tsien, C.I., and Lao, C.D., 2013. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med. 2, 899-906.
Skeie, B.S., Skeie, G.O., Enger, P.O., Ganz, J.C., Heggdal, J.I., Ystevik, B., et al., 2011. Gamma knife surgery in brain melanomas: absence of extracranial metastases and tumor volume strongest indicators of prolonged survival. World Neurosurg. 75, 684-691.

# II. TREATMENT AND PROGNOSISSkibber, J.M., Soong, S.J., Austin, L., Balch, C.M., and Sawaya, R.E., 1996. Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann. Surg. Oncol. 3, 118-123.
Sosman, J.A., Kim, K.B., Schuchter, L., Gonzalez, R., Pavlick, A.C., Weber, J.S., et al., 2012. Survival in BRAF V600mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714.
Sperduto, P.W., Chao, S.T., Sneed, P.K., Luo, X., Suh, J., Roberge, D., et al., 2010. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int. J. Radiat. Oncol. Biol. Phys. 77, 655-661.
Staudt, M., Lasithiotakis, K., Leiter, U., Meier, F., Eigentler, T., Bamberg, M., et al., 2010. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br. J. Cancer 102, 1213-1218.
Stridsklev, I.C., Hagen, S., and Klepp, O., 1984. Radiation therapy for brain metastases from malignant melanoma. Acta Radiol. Oncol. 23, 231-235.
Topalian, S.L., Sznol, M., McDermott, D.F., Kluger, H.M., Carvajal, R.D., Sharfman, W.H., et al., 2014. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32, 1020-1030.
Vecchio, S., Spagnolo, F., Merlo, D.F., Signori, A., Acquati, M., Pronzato, P., et al., 2014. The treatment of melanoma brain metastases before the advent of targeted therapies: associations between therapeutic choice, clinical symptoms and outcome with survival. Melanoma Res. 24, 61-67.
Vestermark, L.W., Larsen, S., Lindelov, B., and Bastholt, L., 2008. A phase II study of thalidomide in patients with brain metastases from malignant melanoma. Acta Oncol. 47, 1526-1530.
Wang, J., Wei, C., Noor, R., Burke, A., McIntyre, S., and Bedikian, A.Y., 2014. Surveillance for brain metastases in patients receiving systemic therapy for advanced melanoma. Melanoma Res. 24, 54-60.
Weber, J.S., Amin, A., Minor, D., Siegel, J., Berman, D., and O'Day, S.J., 2011. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res. 21, 530-534.
Wronski, M., and Arbit, E., 2000. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J. Neurosurg. 93, 9-18.
Xie, T.X., Wei, D., Liu, M., Gao, A.C., Ali-Osman, F., Sawaya, R., et al., 2004. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23, 3550-3560.
Xie, T.X., Huang, F.J., Aldape, K.D., Kang, S.H., Liu, M., Gershenwald, J.E., et al., 2006. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res. 66, 3188-3196.
Yoo, H., Kim, Y.Z., Nam, B.H., Shin, S.H., Yang, H.S., Lee, J.S., et al., 2009. Reduced local recurrence of a single brain metastasis through microscopic total resection. J. Neurosurg. 110, 730-736.
Zakrzewski, J., Geraghty, L.N., Rose, A.E., Christos, P.J., Mazumdar, M., Polsky, D., et al., 2011. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer 117, 1711-1720.# C H A P T E R 

## 20

## Management of Melanoma Therapy-Associated Toxicities

Sarah A. Weiss, Juraj Kavecansky and Anna C. Pavlick

## O U T L I N E

Introduction ..... 300
Immune Checkpoint Inhibitors ..... 300
Anticytotoxic T-Lymphocyte Antigen-4 Antibody ..... 300
Anti-Programmed Death-1 Receptor Antibodies ..... 301
Ipilimumab and Nivolumab in Combination ..... 301
Immune-Related Adverse Events ..... 302
Dermatitis ..... 302
Diarrhea ..... 302
Hepatitis ..... 304
Endocrinopathies ..... 305
Neuropathy ..... 306
Pancreatitis ..... 306
Pneumonitis ..... 307
Renal Toxicity ..... 307
Ocular Toxicity ..... 307
Immunotherapy Treatment-Related Morbidity and Mortality ..... 307
Targeted Therapy ..... 308
Vemurafenib ..... 308
Dabrafenib ..... 309
Combination BRAF and MEK Inhibition ..... 309
Targeted Therapy-Associated Adverse Events ..... 309
Dermatologic Toxicity ..... 309
Arthralgias ..... 314
Pyrexia ..... 314
Fatigue ..... 314
Hepatotoxicity ..... 315
Cardiotoxicity ..... 315
Other Toxicities ..... 316
Conclusion ..... 316
References ..... 317# INTRODUCTION 

There has been a dramatic shift in the treatment of advanced cutaneous melanoma within the last 5 years. Until 2011, the only FDA-approved therapies for metastatic melanoma were dacarbazine chemotherapy or high-dose interleukin-2 (IL-2) immunotherapy, which each have limited efficacy and can carry significant toxicity. While response rates may range as high as $20 \%$, dacarbazine generally fails to prolong overall survival (OS) (Eggermont and Kirkwood, 2004) and has typical chemotherapy-associated toxicities including bone marrow suppression, alopecia, nausea, vomiting, and fatigue that worsen patient quality of life. IL-2 has a $16 \%$ response rate, with $6 \%$ of patients achieving a complete response. Although IL-2 induces durable responses in a minority of patients, the trade-off is the toxic adverse events, which can be severe, including a septic shock-like presentation with hypotension, fevers, oliguria, nausea, and vomiting with a drug-related death rate of 2\% (Atkins et al., 1999). IL-2 administration requires thorough monitoring in an intensive care unit in the event that vasoactive pressors are required. Elderly patients or those with significant medical comorbidities or poor performance status are not IL-2 candidates.

Newly available advanced melanoma therapies have enhanced efficacy over dacarbazine and IL-2 since FDA approval of the immunotherapies ipilimumab in 2011, followed by pembrolizumab and nivolumab in 2014, as well as the BRAF inhibitors vemurafenib in 2011 and dabrafenib in 2013. With these new therapies comes a unique set of adverse events that are manageable when promptly recognized and addressed.

## IMMUNE CHECKPOINT INHIBITORS

## Anticytotoxic T-Lymphocyte Antigen-4 Antibody

Ipilimumab is an anticytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody that blocks the immune-inhibitory action of CTLA-4 and thereby promotes an immune response. Ipilimumab was initially studied in a phase II clinical trial that randomized previously treated advanced melanoma patients to three doses of ipilimumab: 10,3 , or $0.3 \mathrm{mg} / \mathrm{kg}$ every 3 weeks. Overall response rates (ORR) were $11.1 \%, 4.2 \%$, and $0 \%$, respectively, with drug-related adverse events becoming more prominent with increasing dose (Wolchok et al., 2010). The phase III trial randomized patients to three treatment arms: ipilimumab $3 \mathrm{mg} / \mathrm{kg}$ plus a gp100 peptide vaccine, ipilimumab $3 \mathrm{mg} / \mathrm{kg}$ plus a placebo vaccine, or gp100 vaccine alone. Ipilimumab with or without vaccine demonstrated prolonged OS ( 10 and 10.1 months, respectively), compared to vaccine alone ( 6.4 months) (Hodi et al., 2010). In these trials and in a retrospective analysis of 14 completed phase I-III trials that enrolled melanoma patients to receive ipilimumab, drug-related adverse events occurred in up to $80 \%$ of patients. At least $60 \%$ of the toxicities were immune-mediated, most commonly manifesting as dermatitis ( $49 \%$ ) including pruritis or rash, gastrointestinal effects ( $31 \%$ ) including diarrhea and hepatitis, fatigue, and endocrinopathies (Hodi et al., 2010; O'Day et al., 2010; Wolchok et al., 2010; Ibrahim et al., 2011). Up to $25 \%$ of patients experienced grade 3 or 4 events (Hodi et al., 2010; Ibrahim et al., 2011). Less than $1 \%$ of patients had rare immune-related adverse events (irAEs) such as uveitis, pneumonitis, pancreatitis, and nephritis (Ibrahim et al., 2011).# Anti-Programmed Death-1 Receptor Antibodies 

Programmed death-1 (PD-1) receptor monoclonal antibodies pembrolizumab and nivolumab came on the market after ipilimumab, for both single agent use or as combination therapy in the case of ipilimumab and nivolumab. Pembrolizumab, compared to ipilimumab, demonstrated improved response rates ( $33 \%$ vs $12 \%$ ), progression-free survival (PFS) and OS in advanced melanoma patients with a decreased rate of grade 3-5 drugrelated adverse events (Robert et al., 2015b). For pembrolizumab treated patients, adverse events had later onset times when compared to ipilimumab and there was a decreased rate of drug discontinuation. The most common adverse events for pembrolizumab are fatigue (20\%), diarrhea (15\%), rash (14\%), and pruritis (14\%) (Robert et al., 2015b). Similarly, singleagent nivolumab has also demonstrated efficacy in advanced melanoma with a $25 \%$ ORR (Weber et al. 2013) and 1 year OS rates ranging from $62 \%$ to $73 \%$ (Topalian et al., 2014; Robert et al., 2015a). Nivolumab is similarly well tolerated, with the most common adverse events being fatigue ( $20 \%$ ), pruritis ( $17 \%$ ), and nausea ( $17 \%$ ). Only $7 \%$ of patients needed to discontinue nivolumab due to adverse events (Robert et al., 2015a).

## Ipilimumab and Nivolumab in Combination

Currently, the combination of ipilimumab and nivolumab has demonstrated a robust ORR of $40-61 \%$ which is higher than for either agent alone, with impressive 2 year OS rates of 88\% (Wolchok et al., 2013; Larkin et al., 2015; Postow et al., 2015). While the combination therapy is extremely promising in terms of potential for durable responses, it carries significantly increased toxicity, with $93 \%$ of patients experiencing treatment-related adverse events, and thus candidates for combination immunotherapy must be carefully selected. Grade 3-4 treatment-related adverse events occurred in $53 \%$ of patients in the phase I combination therapy trial, most commonly reported as elevated serum lipase (13\%), aspartate aminotransferase (AST) (13\%), and alanine aminotransferase (ALT) (11\%). The combination group also demonstrated higher rates of rash (55\%), pruritis (47\%), fatigue (38\%), and diarrhea (34\%) compared to single-agent immunotherapy alone (Wolchok et al., 2013). Furthermore, a significant percentage of patients ( $21-36 \%$ ) on combination ipilimumab/nivolumab require discontinuation of therapy due to adverse events (Wolchok et al., 2013; Larkin et al., 2015).

Despite some of the varying safety profiles between anti-CTLA-4 antibodies, anti-PD-1 antibodies, and combination immunotherapy, irAEs should be recognized and managed similarly for each agent. The time to onset of irAEs are generally similar among the immunotherapies, although irAEs associated with anti-PD-1 agents may be later in time of onset and slower to resolve than irAEs associated with anti-CTLA-4 agents. Chronologically, dermatologic manifestations are usually the first to arise, followed by diarrhea or colitis, which typically present after the first 1-3 cycles of immunotherapy. Liver toxicity usually occurs later, at least after the third cycle of therapy, and endocrinopathies present as late irAEs, even when the patient may have been off immunotherapy for months or even years (Weber et al., 2015). Grade 3 or 4 treatment-related adverse events occur with highest incidence in patients treated with ipilimumab/nivolumab combination therapy (55\%), and less frequently for single agent ipilimumab (27\%), nivolumab (16\%), or pembrolizumab (10\%) (Larkin et al., 2015; Robert et al., 2015b).# IMMUNE-RELATED ADVERSE EVENTS 

## Dermatitis

Dermatologic toxicity of immunotherapy usually arises early after the first or second cycle of therapy, tends to be mild, and presents as a maculopapular erythematous rash or as pruritis (Fecher et al., 2013). Pruritis and rash occur in up to $24 \%$ and $19 \%$ of ipilimumabtreated patients, respectively (Hodi et al., 2010), while skin disorders of any grade arise in $70 \%$ of patients treated with combination ipilimumab/nivolumab, although the majority are grade 1-2 (Wolchok et al., 2013; Larkin et al., 2015). Pruritis may occur to a slightly lesser degree with pembrolizumab compared to ipilimumab (Robert et al., 2015b).

Grade 1-2 pruritis and rash do not require dose reductions and usually resolve with administration of oral antipruritics, such as diphenhydramine or hydroxyzine, taken as needed and/or topical corticosteroids, such as betamethasone $0.1 \%$ cream or urea-containing creams, applied to the affected area (Weber et al., 2012). If the rash does not improve within 1 week with these conservative therapies, oral corticosteroids should be considered. Vitiligo may also appear as a dermatologic irAE and is permanent, however is thought to represent a surrogate of response to treatment (Fecher et al., 2013). Rarely, severe or life threatening grade 3-5 immune-mediated dermatitis can occur, as represented by StevensJohnson syndrome, toxic epidermal necrolysis, or appearance of a bullous, ulcerated, or hemorrhagic rash which occurs in less than $1 \%$ of patients (Fecher et al., 2013). Grade 3 dermatologic irAEs are treated by holding the next immunotherapy dose and initiating oral corticosteroids dosed as prednisone $1 \mathrm{mg} / \mathrm{kg}$ daily, to be tapered over 4 weeks (Weber et al., 2012). Grade 4 dermatologic irAEs mandate permanent discontinuation of immunotherapy and again, oral corticosteroid administration with $1-2 \mathrm{mg} / \mathrm{kg}$ of prednisone daily with a prolonged taper of 4 weeks or more is indicated (Weber et al., 2012) (Figs. 20.1 and 20.2).

## Diarrhea

Diarrhea is a common irAE, occurring in $32 \%$ of ipilimumab-treated patients enrolled on the phase III trial, with 5\% of patients experiencing grade 3 diarrhea (Hodi et al., 2010). The degree of diarrhea appears to be dose-dependent as shown in the phase II ipilimumab trial in which grade 3-4 diarrhea occurred in $14 \%$ of patients on ipilimumab $10 \mathrm{mg} / \mathrm{kg}$ but in only $1 \%$ of patients on $3 \mathrm{mg} / \mathrm{kg}$ (Wolchok et al., 2010). Diarrhea also occurs with the anti-PD-1 antibodies, but to a lesser extent and decreased severity, with an incidence of $15 \%$ for both nivolumab and pembrolizumab (Robert et al., 2015a,b). Patients on combination ipilimumab/nivolumab do experience higher rates of diarrhea of any grade (34-44\%) (Wolchok et al., 2013; Larkin et al., 2015).

Onset of diarrhea usually occurs after the second cycle of immunotherapy, at a median time of 7.4 weeks after treatment initiation for ipilimumab. Grade 1 diarrhea consisting of less than 4 diarrheal bowel movements over baseline in 24 h should be managed with the antimotility agent loperamide. Patients should follow the American Dietary Association colitis diet, increase fluid hydration, and receive electrolyte repletion as needed (Weber et al., 2012; Della Vittoria Scarpati et al., 2014). Grade 2 diarrhea defined as 4-6 diarrheal stools per day over baseline should prompt an infectious work-up consisting of stool culture![img-81.jpeg](img-81.jpeg)

FIGURE 20.1 Vitiligo secondary to immunotherapy.
![img-82.jpeg](img-82.jpeg)

FIGURE 20.2 Erythematous, macular rash due to immunotherapy.
and examination for fecal leukocytes and Clostridium difficile and oral atropine/diphenoxylate four times daily can be added. If symptoms persist longer than 1 week, systemic corticosteroids at a dose of $0.5 \mathrm{mg} / \mathrm{kg} /$ day should be started and endoscopic exam should be considered to look for colitis, inflammatory bowel disease, or infection (Weber et al., 2012; Della Vittoria Scarpati et al., 2014).

For grade 3-4 diarrhea defined as at least 7 diarrheal bowel movements over baseline in 24 h , immunotherapy should be permanently discontinued. Intravenous fluid hydration and methylprednisolone 125 mg IV should be initiated. Oral prednisone $1-2 \mathrm{mg} / \mathrm{kg}$ daily or dexamethasone 4 mg every 4 h should follow as a slow taper over at least 4 weeks (Weber et al., 2012, Della Vittoria Scarpati et al., 2014). Average time to resolution of grade 2 or higher diarrhea treated with a median dose of prednisone 80 mg daily was 2.3 weeks foripilimumab treated patients (Hodi et al., 2010). For patients who do not demonstrate symptomatic improvement within $48-72 \mathrm{~h}$ of high dose steroid initiation, the tumor necrosis factor alpha monoclonal antibody infliximab should be administered at a dose of $5 \mathrm{mg} / \mathrm{kg}$ (Weber et al., 2012). Infliximab can be administered once every 2 weeks as necessary for persistent symptoms, but is contraindicated in patients with bowel perforation or sepsis. In the phase III ipilimumab study, four patients required infliximab for treatment of grade 3 or higher diarrhea and colitis (Hodi et al., 2010). If possible, tuberculosis testing is recommended prior to infliximab use (Fecher et al., 2013). If diarrheal symptoms worsen again while on decreasing doses of a steroid taper, the steroids should be increased back to a dose of $80-100 \mathrm{mg}$ per day and then more slowly tapered and inflimximab can be reinitiated if necessary (Weber et al., 2012). Although diarrheal prophylaxis has been investigated in patients receiving ipilimumab, a phase II trial demonstrated that prophylactic budesonide does not prevent grade 2 or higher ipilimumab-induced diarrhea and so prophylactic measures have not been recommended (Weber et al., 2009).

Abdominal pain and presence of stool blood or mucous can be a sign of colitis, which can progress to bowel obstruction and rarely perforation ( $<1 \%$ ) if not promptly addressed (Hodi et al., 2010; Robert et al., 2011; Weber et al., 2012). Surgical consult should be requested if the patient develops an ileus with severe diarrhea (Fecher et al., 2013). Anti-PD-1 agents have a lower rate of grade $3-5$ colitis ( $1-3 \%$ ) compared to ipilimumab (7\%) (Robert et al., 2015b).

# Hepatitis 

Immune-mediated hepatic impairment is uncommon and occurs in approximately $4 \%$ of ipilimumab treated patients (Hodi et al., 2010) and $2 \%$ of pembrolizumab treated patients (Robert et al., 2015b) usually occurring after the second cycle of immunotherapy (Fecher et al., 2013). Incidence of hepatic toxicity is $15-23 \%$ in patients treated with the ipilimumab/ nivolumab combination, and $15 \%$ of cases are grade 3-4 (Wolchok et al., 2013; Larkin et al., 2015). The hepatitis usually presents as an asymptomatic rise in serum liver transaminases or bilirubin or can involve fatigue and fever (Weber et al., 2012; Della Vittoria Scarpati et al., 2014) and while infrequent, hepatitis can be severe and must be urgently managed (Chmiel et al., 2011). Baseline liver function tests should be performed prior to each cycle of immunotherapy and clinicians should consider screening for hepatitis B or C prior to immunotherapy initiation, particularly given that immunotherapy trials typically exclude patients with active hepatitis B or C (Fecher et al., 2013). Clinicians should counsel patients against active alcohol use and ingestion of hepatotoxic drugs while on immunotherapy (Chmiel et al., 2011).

Upon any noted rise in liver function tests, clinicians should suspect disease progression, medication toxicity, or viral hepatitis, all of which should be ruled out before diagnosing immunotherapy-mediated hepatitis. Once serum levels rise to greater than or equal to 2 times the upper limit of normal, repeat testing is recommended every 1-3 days until stabilization or a decrease is noted, and autoimmune hepatitis evaluation including antinuclear, antismooth muscle, antimitochondrial, and antiliver-kidney microsomal antibodies should be checked (Fecher et al., 2013). Immunotherapy should be held for grade 2 hepatotoxicity, defined as elevation of AST or ALT to greater than $2.5-5$ times the upper limit of normal or elevation of total bilirubin to $1.5-3$ times the upper limit of normal, and should bepermanently discontinued for hepatotoxicity grade 3 or above (Weber et al., 2012). Grade $3-5$ hepatotoxicity consisting of elevated AST or ALT above 5 times the upper limit of normal or elevated total bilirubin above 3 times the upper limit of normal should be managed with $24-48 \mathrm{~h}$ of high-dose intravenous glucocorticoids followed by oral prednisone $1-2 \mathrm{mg} / \mathrm{kg}$ tapered over at least 4 weeks. Liver function tests should be monitored at least weekly, and daily if the levels are greater than 8 times the normal. Although immunother-apy-induced hepatitis is usually responsive to steroids, mycophenolate mofetil 500 mg orally every 12 h can be administered if liver function tests do not begin to improve 48 h after steroid initiation and consultation with a hepatologist at that time is recommended (Weber et al., 2012; Fecher et al., 2013; Della Vittoria Scarpati et al., 2014). In a rare cases refractory to these therapies, antithymocyte globulin has been effectively used (Chmiel et al., 2011).

# Endocrinopathies 

Endocrinopathies including hypothyroidism, hypopituitarism, hypophysitis, adrenal insufficiency, increase in serum thyrotropin level, and decrease in serum corticotropin level were all reported in total in $8 \%$ of patients on the ipilimumab arm of the phase III trial. Grade 3 events included one case of hypopituitarism and two cases of hypophysitis. Grade 4 events consisted of hypopituitarism and decrease in serum corticotropin level (Hodi et al., 2010). In patients on combination ipilimumab/nivolumab in the phase I trial, $13 \%$ developed immune-mediated endocrinopathies (Wolchok et al., 2013).

Immunotherapy-induced hypophysitis typically involves the anterior pituitary, which secretes thyroid stimulating hormone (TSH), adrenocorticotropic hormone (ACTH), leutinizing hormone (LH), follicle stimulating hormone (FSH), prolactin, and growth hormone. The most common immunotherapy-related endocrinopathy is hypophysitis and usually presents after the third cycle of ipilimumab (Fecher et al., 2013). In a retrospective analysis from Memorial Sloan Kettering Cancer Center (MSKCC), the incidence of ipilimumabtreated patients developing hypophysitis was $8 \%$ with a median time to onset of 4 months after therapy initiation, however distant cases can occur, as hypophysitis developed in two patients at 8 and 19 months postipilimumab initiation (Ryder et al., 2014). Symptoms of hypophysitis can often be vague and include headaches, visual changes, fatigue, nausea, abdominal pain, mental status changes, and altered bowel habits. Of the 19 patients in the MSKCC analysis who developed hypophysitis, 16 had secondary adrenal insufficiency which presents as hypotension and electrolyte abnormalities (hyponatremia, hyperkalemia), 11 had abnormal thyroid function tests, and 3 had loss of ACTH secretion. Brain MRI in these patients will demonstrate pituitary enlargement and/or abnormal enhancement (Ryder et al., 2014).

Treatment of hypophysitis first involves recognition, which can often be difficult as the symptoms are nonspecific and may mimic other common melanoma issues such as brain metastases, which are important to rule out. TSH, free T4, and electrolytes should be checked prior to each immunotherapy cycle. For symptomatic patients in which an endocrinopathy is suspected, blood should be drawn prior to steroid initiation for cortisol, ACTH, free T3, free T4, TSH, as well as testosterone in males and FSH, LH, and prolactin in females (Weber et al., 2012). Immunotherapy should be held for any grade 3-4 endocrinopathy or in patients with symptomatic pan-hypopituitarism (Weber et al., 2012).Intravenous high dose steroids with mineralocorticoid activity such as methylprednisolone $1-2 \mathrm{mg} / \mathrm{kg}$ should be initiated, followed by oral prednisone $1-2 \mathrm{mg} / \mathrm{kg}$ daily with at least a 4 week taper. Importantly, evidence of severe dehydration or hypotension should make the clinician suspect an adrenal crisis, which is also managed with rapid initiation of high dose methylprednisolone. Infectious causes should be ruled out and an endocrinology consult is recommended. Immunotherapy should be permanently discontinued in the event of adrenal crisis. Patients with secondary adrenal insufficiency require physiologic hydrocortisone replacement and given that pituitary dysfunction can be long-lasting or permanent, patients should be informed that steroid maintenance may be life-long (Weber et al., 2012; Fecher et al., 2013; Ryder et al., 2014). In the MSKCC analysis, 9/19 patients did not recover pituitary functioning, while three regained secretion of ACTH and two recovered LH and FSH secretion (Ryder et al., 2014).

Hypothyroidism occurs at a rate of $6-10 \%$ in patients on ipilimumab, pembrolizumab, or nivolumab (Topalian et al., 2014; Robert et al., 2015b). Time onset is variable, ranging from months to years after the initiation of immunotherapy (Ryder et al., 2014). Pembrolizumab has a slightly increased rate of both hypothyroidism ( $9 \%$ vs $2 \%$ ) and hyperthyroidism ( $3 \%$ vs $2 \%$ ) compared to ipilimumab (Robert et al., 2015b). Most patients are either asymptomatic or present with fatigue and this usually resolves with initiation of hormone supplementation (Ryder et al., 2014).

# Neuropathy 

Neurologic irAEs are rare complications of immunotherapy, usually related to anti-CTLA-4 therapy, and are mostly documented as case reports but should be suspected in patients treated with immunotherapy who present with new sensory or motor deficits (Liao et al., 2014; Gaudy-Marqueste et al., 2013). Reported immune-mediated neurologic deficits include neuropathy, chronic inflammatory demyelinating polyneuropathy, transverse myelitis, myasthenia gravis, and Guillane-Barre syndrome (Gaudy-Marqueste et al., 2013; Liao et al., 2014; Thaipisuttikul et al., 2015). Peripheral neuropathies may be only slightly symptomatic and can resolve spontaneously, although persistent grade 2 neuropathy is treated by withholding the next dose of therapy and administering a prednisone or dexamethasone taper over 4 weeks (Weber et al., 2012). For more serious neuropathies and other neurologic irAEs, treatment involves discontinuation of immunotherapy and high dose steroid initiation such as prednisone $1-2 \mathrm{mg} / \mathrm{kg}$ daily. Some patients have required infliximab or plasmapheresis (Liao et al., 2014; Thaipisuttikul et al., 2015).

## Pancreatitis

Immune-mediated pancreatitis is rare, with an incidence of $1 \%$ or less in ipilimumab and pembrolizumab treated patients (Robert et al., 2014a; Weber et al., 2015); however, some clinicians note an increased incidence in patients receiving ipilimumab/nivolumab combination therapy. Pancreatitis usually presents as asymptomatic elevations in amylase and/or lipase and sometimes includes fevers, malaise, or abdominal discomfort (Weber et al., 2012). Grade 1 or 2 pancreatitis may slowly resolve without intervention (Tirumani et al., 2015); however, grade 3 or 4 pancreatitis requires discontinuation of immunotherapy. Oral steroid tapers canbe considered however amylase and lipase elevations may not immediately respond and should slowly decrease over time upon withdrawal of therapy (Weber et al., 2012).

# Pneumonitis 

Incidence of pneumonitis is also very rare in ipilimumab-treated patients ( $<1 \%$ ) and may be slightly higher in patients treated with pembrolizumab ( $2 \%$ ) (Robert et al., 2015b) or combination ipilimumab/nivolumab (6\%) (Wolchok et al., 2013). While grade 3 or 4 pneumonitis is rare, it can be severe and diagnosis may be delayed by initially attributing patient symptoms to other causes. Pneumonitis presents as dyspnea, cough, and occasionally hypoxemia with CT chest imaging that demonstrates bilateral patchy infiltrates and consolidation, ground glass opacities, and can resemble a cryptogenic organizing pneumonia, interstitial pneumonia, or acute respiratory distress syndrome. Symptoms and radiographic findings usually resolve with high-dose steroid treatment and discontinuation of the immunotherapeutic agent, but this can take several months and patients may symptomatically improve ahead of normalization of imaging findings (Barjaktarevic et al., 2013; Nishino et al., 2015; Tirumani et al., 2015; Weber et al., 2015).

## Renal Toxicity

In the phase I trial ipilimumab/nivolumab combination trial, there were reports of increased creatinine ( $6 \%$ ), acute renal failure ( $4 \%$ ), renal failure ( $2 \%$ ), and tubulointerstitial nephritis ( $2 \%$ ) of any grade (Wolchok et al., 2013). Nephritis has been reported in less than $1 \%$ of patients on pembrolizumab and can occur months after therapy initiation. Renal function usually recovers with high-dose corticosteroids. Prednisone at a dose of at least 40 mg daily followed by a slow taper is indicated for grade 2 or higher renal irAEs. For grade 2 irAEs, clinicians can consider withholding the next immunotherapy dose, while grade 3-4 renal irAEs require permanent discontinuation of immunotherapy (Merck).

## Ocular Toxicity

Ocular toxicity related to immunotherapy is very rare, reported in less than $1 \%$ of cases, and is documented mostly by case reports. Uveitis and episcleritis can present with blurred vision, flashes, floaters, and/or photophobia and usually arise after at least the second cycle of therapy. Grade 1-2 ocular irAEs are treated with topical steroids such as $1 \%$ prednisolone acetate with expected resolution of symptoms within 1 week. Grade 3-4 ocular irAEs require systemic steroids and discontinuation of immunotherapy (Weber et al., 2012; Della Vittoria Scarpati et al., 2014; Nallapaneni et al., 2014; Papavasileiou et al., 2015).

## Immunotherapy Treatment-Related Morbidity and Mortality

High dose steroids are often mandatory to suppress the enhanced immune activation and resultant unleashed inflammation caused by the immune checkpoint inhibitors. However, clinicians should recognize side effects of long-term, high dose steroids and carefully time the length of steroid therapy to achieve a balance fully treating irAEs without inducingsteroid-related issues, which include myopathy, hyperglycemia, increased appetite, depression, insomnia, increased risk of infection (Fecher et al., 2013). Any patient on long term steroids should receive prophylaxis for Pneumocystis jiroveci pneumonia, and in individual cases, should be considered for prophylaxis against herpes simplex virus and fungal organisms.

Treatment-related deaths are rarely reported in immunotherapy trials because irAEs, once recognized, are manageable with high dose steroids and/or withdrawal of therapy. One patient in the phase II ipilimumab trial died as a result of liver failure after not receiving systemic steroids rapidly enough and four other potential treatment-related deaths included multiorgan failure, acute myeloid leukemia, acute glomerulonephritis, and hypovolemic shock (O'Day et al., 2010). In the phase III ipilimumab trial, death due to study drugs occurred in 14 patients ( $2.1 \%$ ) and seven of these deaths were associated with irAEs (Hodi et al., 2010). Other reported causes of immunotherapy-related deaths include neutropenia from nivolumab and cardiac arrest related to ipilimumab (Larkin et al., 2015). Combination therapy-related deaths have been attributed to ventricular arrhythmia in the setting of a patient's known cardiovascular disease and iatrogenic pneumothorax in the setting of pneumonitis (Postow et al., 2015). There were no treatment-related deaths in the CheckMate 067 combination immunotherapy trial (Larkin et al., 2015).

# TARGETED THERAPY 

The discovery of driver mutations in melanoma and the drugs targeting those mutations have led to significant gains in therapeutic options and survival outcomes over the past 5 years. The rapidly accelerated fibrosarcoma kinase B (BRAF) V600 activating mutation in the mitogen-activated protein kinase (MAPK) pathway is involved in melanoma pathogenesis and is effectively targeted by BRAF inhibitors vemurafenib and dabrafenib, although resistance usually develops after 6-7 months of therapy (Hauschild et al., 2012; Sosman et al., 2012). When compared to dacarbazine chemotherapy in a phase III trial, vemurafenib improved 6 month OS rates ( $84 \%$ vs $64 \%$ ) and response rates ( $48 \%$ vs $5 \%$ ) in patients with advanced melanoma with the BRAF V600E mutation (Chapman et al., 2011). Similarly, dabrafenib was compared to dacarbazine in a phase III trial and demonstrated improved PFS ( 5.1 vs 2.7 months) and achieved an ORR of $53 \%$ in BRAF V600E mutated advanced melanoma patients (Hauschild et al., 2012).

## Vemurafenib

The most common adverse events of any grade associated with vemurafenib are skin manifestations including rash ( $49 \%$ ), pruritis ( $12 \%$ ), and development of keratoacanthomas and cutaneous squamous cell carcinoma which occurred in $18 \%$ of patients on the phase III vemurafenib trial (Chapman et al., 2011; Larkin et al., 2014a). Other common vemurafenib toxicities include arthralgias (39\%), fatigue (34\%), photosensitivity (31\%), alopecia (26\%), nausea (19\%), diarrhea ( $16 \%$ ), and pyrexia ( $11 \%$ ). In the phase III trial, $38 \%$ of patients underwent dose reduction or interruptions due to adverse events (Chapman et al., 2011). The standard dose for vemurafenib is 960 mg twice daily. First dose reduction for toxicity is recommendedto give 720 mg twice daily and a second dose reduction is recommended to give 480 mg twice daily. Beyond two dose reductions with vemurafenib, the therapeutic efficacy is unclear and so intermittent dosing or a switch to dabrafenib is recommended (Welsh and Corrie, 2015).

# Dabrafenib 

The toxicity of profile of dabrafenib is somewhat different from vemurafenib in that development of keratoacanthomas and cutaneous squamous cell carcinomas occur at a lower rate $(6 \%)$, as does photosensitivity ( $3 \%$ ), however there is a much higher incidence of pyrexia (Chapman et al., 2011; Hauschild et al., 2012; Long et al., 2012). In the phase III trial, dabrafenib dose reduction and drug discontinuation was required in $28 \%$ and $3 \%$ of patients, respectively due to adverse events, with pyrexia as the most common reason for dose reduction (Falchook et al., 2012; Hauschild et al., 2012; Long et al., 2012; Ascierto et al., 2013). Standard dabrafenib dosing is 150 mg twice daily. The first recommended dose reduction for toxicity is to decrease to 100 mg twice daily, followed by a second dose reduction to 75 mg twice daily, and a third dose reduction to 50 mg twice daily if necessary (Welsh and Corrie, 2015).

## Combination BRAF and MEK Inhibition

Reactivation of the MAPK pathway is a resistance mechanism by which melanomas escape control of BRAF inhibition. This was the rationale to combine dabrafenib with trametinib, a selective MAPK (MEK) inhibitor in phase I/II trial that established that this combination was safe and effective at full doses 150 mg bid and 2 mg daily, respectively (Flaherty et al., 2012). This led to two phase III combination therapy trials in previously untreated patients with BRAF V600E/K mutant metastatic melanoma. COMBI-v demonstrated that dabrafenib plus trametinib compared with vemurafenib alone improved PFS (11.4 vs 7.3 months) and 12 month OS rates ( $72 \%$ vs $65 \%$ ) (Robert et al., 2014b). COMBI-d showed improved PFS for dabrafenib plus trametinib ( 9.3 months) compared to dabrafenib and placebo ( 8.8 months) (Long et al., 2014) as well as improved median OS ( 25.1 vs 18.7 months) for patients treated with the combination (Long et al., 2015). Finally, the coBRIM trial demonstrated improved PFS with vemurafnib and cobimetinib combination therapy ( 9.9 month) compared to vemurafenib and placebo ( 6.2 months) in advanced melanoma patients with a BRAF V600 mutation (Larkin et al., 2014b).

## TARGETED THERAPY-ASSOCIATED ADVERSE EVENTS

## Dermatologic Toxicity

## Rash

Rash occurs in $49 \%$ of patients on vemurafenib, $30 \%$ of patients on dabrafenib, and present less frequently in the combination therapy ( $24 \%$ ). Grade 3 or 4 rashes occur in $5-9 \%$ of patients on vemurafenib, however, they are uncommon in patients treated with dabrafenib or combination dabrafenib/trametinib (Hauschild et al., 2012; Larkin et al., 2014a; Long et al., 2015). The typical rash seen with BRAF inhibitors is centered around hair follicles andforms erythematous papules, although the appearance can be variable. The rash may coalesce into broader areas on the extensor surfaces of limbs, back, and abdomen (Boyd et al., 2012; Sinha et al., 2012). Rashes tend to present in the first 2 weeks after treatment initiation and for this reason patients need to be closely clinically monitored and examined over the first 1-2 months of therapy to ensure they are on optimal therapeutic dose without significant dermatologic AEs (Belum et al., 2013; Welsh and Corrie, 2015).

Grade 1 symptomatic rashes should be managed with topical steroid creams including hydrocortisone $1-2.5 \%$, triamcinolone $0.025 \%$, or antibiotic creams such as clindamycin $1 \%$. Further symptomatic relief can be achieved with cold compresses, moisturizing creams, and oral antihistamines such as diphenhydramine or hydroxyzine in the case of pruritis. Patients should be advised to avoid skin irritants that may be part of detergents and soaps they use (Belum et al., 2013). Depending on severity, grade 2 rashes, defined as affecting less than $50 \%$ of skin surface, can be managed with topical or low dose oral corticosteroids in addition to the therapies for grade 1 rash, with BRAF inhibitor dose reduction or interruption the rash does not improve to grade 1 . If there is a suspected folliculitis contributing to the rash, topical clindamycin or oral doxycycline can be of benefit (Sinha et al., 2012). Grade 3 rashes, defined as covering more than $50 \%$ of the skin surface, should be treated with oral corticosteroids such as prednisone $0.5 \mathrm{mg} / \mathrm{kg} /$ day for a dose of up to 60 mg daily for at least 5-7 days. BRAF inhibitor dosing should be held until the rash severity decreases to grade 1 and should be reinitiated at the next lower dose (Boussemart et al., 2013; Welsh and Corrie, 2015). If a severe grade 4 rash appears, treatment includes permanent discontinuation of the BRAF inhibitor, obtaining a dermatology consult, and considering hospitalization for patients in need of intravenous hydration or electrolyte repletion (Welsh and Corrie, 2015) (Figs. 20.3 and 20.4).

# Photosensitivity 

Photosensitivity, defined as significant burning or irritation after sun exposure, is a frequent toxicity seen with vemurafenib, noted in $30 \%$ of patients, with $3 \%$ of patients having severe grade 3 or 4 toxicity (Chapman et al., 2011). Photosensitivity is uncommon with dabrafenib (Hauschild et al., 2012). Photosensitivity can be seen as early as several days after
![img-83.jpeg](img-83.jpeg)

FIGURE 20.3 Folliculitis due to BRAF inhibitors.![img-84.jpeg](img-84.jpeg)

FIGURE 20.4 Macular rash due to BRAF inhibitors.
initiation of BRAF inhibitor therapy and can occur after only minimal exposure to sunlight. Patients should be counseled on sun protection upon starting vemurafenib, as prevention is the major role in management. Photosensitivity with vemurafenib occurs from exposure to UVA light, which can pass through glass, and thus patients need sun protection even when sitting indoors near a window. Prevention includes daily sunscreen application with at least SPF 30 with both UVA and UVB protective ingredients, application of lip balm with SPF protection, and covering up exposed skin with sun-protective clothing and hats. If photosensitivity from vemurafenib is an intolerable or unacceptable toxicity for patients, dabrafenib is an appropriate alternate choice given the low incidence of photosensitivity (Sinha et al., 2012; Welsh and Corrie, 2015) (Fig. 20.5).

# Benign Squamoproliferative Lesions and Cutnaeus Squamous Cell Carcinoma 

New skin lesions present in up to $90 \%$ of patients on vemurafenib and dabrafenib and therefore all patients on BRAF inhibitors should have skin exams at each visit and should follow regularly with a dermatologist (Anforth et al., 2013; Lacouture et al., 2013). BRAF inhibitors paradoxically activate the MAPK pathway in normal keratinocytes, which are BRAF wild type, and thus increase $C R A F$ activation and signaling that leads to keratinocyte proliferation and development of cutaneous squamous cell carcinomas. This mechanism helps to explain why patients who concurrently receive a MEK inhibitor with a BRAF inhibitor have reduced rates of hyperkeratosis and cutaneous squamous cell carcinomas (2-3\%) (Su et al., 2012; Sanlorenzo et al., 2014). Benign squamoproliferative lesions resulting from BRAF inhibition include papillomas, verrucous keratosis, verrucae, and actinic and seborrheic keratosis. If necessary, these lesions are removed with cryotherapy, electrocautery, or surgical excision or shave removal and do not require BRAF inhibitor dose reduction or discontinuation (Belum et al., 2013). Squamous cell carcinomas occur between 6 and 24 weeks after treatment initiation (Anforth et al., 2012). BRAF inhibitor-associated lesions, compared to spontaneous cutaneous squamous cell carcinomas, are well-differentiated and are![img-85.jpeg](img-85.jpeg)

FIGURE 20.5 Photosensitivity.
![img-86.jpeg](img-86.jpeg)

FIGURE 20.6 Cutaneous squamous cell carcinoma.
surgically excised without $B R A F$ inhibitor dose reduction or disruption of therapy (Anforth et al., 2012; Mattei et al., 2013) (Figs. 20.6 and 20.7).

# Palmar-Plantar Erythrodysesthesia and Hyperkeratosis 

Palmar-plantar erythrodysesthesia (PPE), otherwise known as hand-foot syndrome, commonly occurs with targeted therapies including BRAF inhibitors dabrafenib (8\%) (Hauschild) and vemurafenib ( $8 \%$ ) and manifests as palmar and plantar pain, erythema, edema, and abnormal sensation (Hauschild et al., 2012; Belum et al., 2013; Lacouture et al., 2013). Palmar-plantar hyperkeratosis develops as painful callouses on pressure points of the soles at sites of friction and occurs more frequently in dabrafenib treated patients (12\%)![img-87.jpeg](img-87.jpeg)

FIGURE 20.7 Verrucous keratosis.
![img-88.jpeg](img-88.jpeg)

FIGURE 20.8 Plantar hyperkeratosis.
compared to those patients on vemurafenib (6\%) and more commonly on the soles than palms (Chapman et al., 2011; Hauschild et al., 2012; Belum et al., 2013). The pain from plantar hyperkeratosis may resolve spontaneously over several weeks; however, PPE often negatively affects patient quality of life and may progress to formation of blisters, ulceration, or cracking of the skin (Anforth et al., 2012; Belum et al., 2013). Patients should be advised to wear comfortable shoes with cushioning that minimize unnecessary friction to the skin and can apply keratolytic skin moisturizers such as $10 \%$ urea cream up to three times daily as a prophylactic measure. Grade 1 PPE presents as skin erythema without pain and is managed by application of skin moisturizers with urea, salicylic acid or ammonium lactate. Grade 2 PPE occurs with pain and topical corticosteroids and a lidocaine anesthetic cream should be added as adjunctive therapy. For grade 3 or higher PPE that affects daily functioning, the BRAF inhibitor should be held and pain control with non-steroidal anti-inflammatories (NSAIDs), gabapentin, and/or opioids is often necessary (Belum et al., 2013) (Fig. 20.8).# Arthralgias 

Arthralgias of any grade, defined as significant pain in one or multiple joints, occur in $20-40 \%$ of patients on vemurafenib, with grade 3-4 arthralgias occurring in only $3 \%$ of cases (Chapman et al., 2011; Larkin et al., 2014a). Arthralgias are less common in patients on dabrafenib, with an incidence of $5-20 \%$ for dabrafenib monotherapy and $15-24 \%$ for combined dabrafenib/trametinib therapy and almost all are grade 2 or less. The onset of arthralgias was noted several weeks to a few months from onset of therapy (Hauschild et al., 2012; Robert et al., 2014b; Long et al., 2015).

Grade 1 arthralgias defined as mild pain that does not affect activities of daily living (ADL) can typically be conservatively managed with NSAIDs or acetaminophen without disruption of the BRAF inhibitor. For grade 2 arthralgias defined as moderate pain that limits some ADLs, BRAF inhibitor therapy should be interrupted until the arthralgias decrease to a grade 1 level and patients may require dose reduction at time of BRAF inhibitor reinitiation. If arthralgias reoccur, a short course of low dose corticosteroids can be considered for symptomatic management in addition to NSAIDs or acetaminophen. For grade 3-4 arthralgias defined as severe pain that significantly limit ADLs, the same approach regarding dose holding and dose reduction should be taken. While most arthralias are self-limited and improve with holding the dose of BRAF inhibitor and/or dose reduction, persistent symptoms may require patients to switch to a different class of BRAF inhibitor or may necessitate rheumatologic consultation (Welsh and Corrie, 2015).

## Pyrexia

Pyrexia is a common therapy-associated toxicity with a $15-30 \%$ incidence in patients treated with dabrafenib, and up to $50 \%$ incidence in patients on dabrafenib/trametinib combination therapy, but rare in vemurafenib-treated patients. The mechanism of pyrexia associated with BRAF inhibition is not well understood. The median time of onset of fevers is 11 days after initiation of dabrafenib, and median duration of fever is 3 days (Long et al., 2012; Welsh and Corrie, 2015). Any development of fever and/or chills should prompt an infectious work-up including a complete blood count to assess for neutropenia. Once infection is ruled out, grade 1 pyrexia $\left(100.4^{\circ} \mathrm{F}-102.2^{\circ} \mathrm{F}\right)$ is treated with acetaminophen and NSAIDs. If fever persists, dabrafenib should be held until resolution of fevers, low dose corticosteroids can be considered, and dabrafenib can be reinitiated at a lower dose once the fever resolves. For grade $2\left(102.3^{\circ} \mathrm{F}-104^{\circ} \mathrm{F}\right)$ and $3(>104 \mathrm{~F}$ for $<24 \mathrm{~h})$ pyrexia, dabrafenib should be similarly held, treated with acetaminophen, NSAIDs, and low dose corticosteroids, and hospitalization should be considered for further management and intravenous hydration. If refractory pyrexia mandates dabrafenib discontinuation, switch to vemurafenib is an appropriate alternative (Welsh and Corrie, 2015). For patients with dabrafenib-associated pyrexia, premedication prophylaxis prior to each dose with acetaminophen or ibuprofen can often control the pyrexia and can be tapered over several weeks, often without fever recurrence.

## Fatigue

Subjective fatigue often has a multifactorial etiology in patients with advanced melanoma and can be under recognized, although it has been noted in patients on clinical trialswith BRAF inhibitors, in $13 \%$ of patients on vemurafenib and $6 \%$ of patients on dabrafenib (Chapman et al., 2011; Hauschild et al., 2012). After ruling out and treating other possible medical causes of fatigue, dose reduction of the BRAF inhibitor or use of low dose corticosteroids may be effective in improving patients' energy level (Welsh and Corrie, 2015).

# Hepatotoxicity 

Asymptomatic liver function test abnormalities, including elevated transaminases, bilirubin, or alkaline phosphatase are reported patients treated with vemurafenib (36\%), dabrafenib (5\%), and combination dabrafenib/trametinib (11\%) (McArthur et al., 2014; Long et al., 2015). Of cautionary note, a phase I study examining the combination of vemurafenib and ipilimumab in advanced melanoma patients with BRAF V600 mutations noted multiple episodes of grade 3 hepatotoxicity, representing dose-limiting toxic effects, and as a result the study was closed early (Ribas et al., 2013). Vemurafenib is also noted to synergistically-induce hepatotoxicity when combined with palliative radiotherapy, and thus it is recommended that BRAF inhibitors are not administered for at least 7 days before and after planned radiotherapy (Anker et al., 2013).

Grade 1 BRAF -associated hepatotoxicity involves careful monitoring of liver function tests with withdrawal of any hepatotoxic drugs and advising against alcohol intake. For grade 2 hepatotoxicity or for grade 1 hepatotoxicity that does not resolve, the BRAF inhibitor should be held, although MEK inhibitor therapy can be continued as long as the liver function tests do not worsen. Investigations for alternate causes of hepatitis and elevated bilirubin should be ruled out, including viral hepatitis, CMV and EBV infections, and autoimmune hepatitis. If the liver chemistries resolve to less than grade 1, the BRAF inhibitor can be reinstituted at a lower dose. Grade 3 or 4 hepatotoxicity requires blood monitoring every 1-3 days, permanent discontinuation of the BRAF inhibitor, and consultation with a hepatologist (Welsh and Corrie, 2015).

## Cardiotoxicity

## Cardiomyopathy

Trametinib and combination dabrafenib/trametinib has been associated with a up to $10 \%$ rate of cardiomyopathy including decrease in left ventricular ejection fraction (LVEF), defined as LVEF below the lower limit of normal or an absolute decrease in LVEF greater than or equal to $10 \%$ below baseline. Patients are often asymptomatic and hemodynamically stable and while peripheral edema also occurs in up to $30 \%$ of patients on combination therapy, it is unclear if this is related to cardiac dysfunction (FDA; Robert et al., 2014b; Long et al., 2015; Welsh and Corrie, 2015). Routine echocardiograms for patients on combination therapy are probably not necessary except in the cases of preexisting cardiac disease or patients who present with heart failure symptoms, however the package inserts for both dabrafenib and trametinib recommend a baseline echocardiogram, with follow-up imaging after 2-3 months of therapy. For grade 1 or 2 decreases in LVEF defined as up to a $20 \%$ drop from baseline, BRAF and MEK inhibitors should be held for 4 weeks and can be reinstituted at a lower dose if repeat echocardiogram demonstrates near improvement. For grade 3 or 4cardiomyopathy that is symptomatic or greater than a $20 \%$ LVEF decrease from baseline, therapy should be permanently discontinued and cardiac dysfunction usually resolves with cessation of therapy (FDA; Welsh and Corrie, 2015).

# QTc Prolongation 

QTc prolongation is a rare toxicity of BRAF inhibitors, seen in $3 \%$ of patients on dabrafenib and $2 \%$ of patients on vemurafenib (Flaherty et al., 2012; Larkin et al., 2015). Electrocardiogram should be checked at baseline and therapy is contraindicated for a QTc interval $>500 \mathrm{~ms}$. For QTc intervals that prolong to $>500 \mathrm{msec}$, the BRAF inhibitor should be held, electrolyte abnormalities corrected, and cardiac risk factors addressed. With QTc interval improvement, the BRAF inhibitor can be reinitiated with a dose reduction, however if two dose reductions are required without decrease in QTc interval, the BRAF inhibitor should be discontinued (Welsh and Corrie, 2015).

## Other Toxicities

Ocular toxicities such as uveitis occur in 1-2\% of patients on BRAF inhibitors and tend to develop over time, with longer exposure times to therapy. Uveitis is treated with topical steroids, dose interruption, and ophthalmologic evaluation. Other very rare ocular toxicities include retinal vein occlusion, retinal detachment and central serous retinopathy that have been noted with trametinib therapy. Any patient on trametinib with ocular symptoms including blurry vision, loss of vision, or ocular pain should immediately see an ophthalmologist and hold treatment until the issue resolves. While central serous retinopathy is thought to be reversible, retinal vein occlusion may not be, even with discontinuation of the drug (Welsh and Corrie, 2015).

Other notable toxicities include hypertension which occurs in up to $22 \%$ of patients on the combination therapy, with $12 \%$ of patients having grade 3 or 4 hypertension (Flaherty et al., 2012). Blood pressure should thus be routinely monitored, and antihypertensives should be titrated along with possible interruptions in BRAF and MEK inhibitors to allow normalization of blood pressure (Welsh and Corrie, 2015). Hyperglycemia is another rare side effect seen in $6 \%$ of patients on combination dabrafenib/trametinib and is usually exacerbated in known diabetics (Flaherty, 2012). Close monitoring of glucose in diabetic patients undergoing targeted therapy and aggressive titration of diabetic medications is thus warranted.

## CONCLUSION

Success in managing melanoma therapy-related toxicities is directly dependent on close clinical monitoring and suspicion, patient-provider communication, and prompt recognition, with swift initiation of steroids in the event of irAE development and/or other adjunctive agents needed for symptomatic control of immunotherapy and targeted therapy-related adverse events (Weber et al., 2015). All patients should be extensively counseled on possible side effects and encouraged to call their providers early with development of unusual symptoms. Providers should be educated on algorithms to follow for many of the common melanoma therapy-related toxicities to avoid delay in timing of therapy and to limit the severity of the adverse events.# References 

Anforth, R., Fernandez-Penas, P., and Long, G.V., 2013. Cutaneous toxicities of RAF inhibitors. Lancet Oncol. 14 (1), e11-18.
Anforth, R.M., Blumetti, T.C., Kefford, R.F., et al., 2012. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br. J. Dermatol. 167 (5), 1153-1160.
Anker, C.J., Ribas, A., Grossmann, A.H., et al., 2013. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J. Clin. Oncol. 31 (17), e283-287.
Ascierto, P.A., Minor, D., Ribas, A., et al., 2013. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J. Clin. Oncol. 31 (26), 3205-3211.
Atkins, M.B., Lotze, M.T., Dutcher, J.P., et al., 1999. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17 (7), 2105-2116.
Barjaktarevic, I.Z., Qadir, N., Suri, A., Santamauro, J.T., and Stover, D., 2013. Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. Chest 143 (3), 858-861.
Belum, V.R., Fischer, A., Choi, J.N., and Lacouture, M.E., 2013. Dermatological adverse events from BRAF inhibitors: a growing problem. Curr. Oncol. Rep. 15 (3), 249-259.
Boussemart, L., Routier, E., Mateus, C., et al., 2013. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann. Oncol. 24 (6), 1691-1697.
Boyd, K.P., Vincent, B., Andea, A., Conry, R.M., and Hughey, L.C., 2012. Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma. J. Am. Acad. Dermatol. 67 (6), 1375-1379. Bristol-Myers Squibb. Ipilimumab package insert. <http://packageinserts.bms.com/pi/pi_yervoy.pdf> accessed 02.07.15.).

Chapman, P.B., Hauschild, A., Robert, C., et al., 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364 (26), 2507-2516.
Chmiel, K.D., Suan, D., Liddle, C., et al., 2011. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J. Clin. Oncol. 29 (9), e237-240.
Della Vittoria Scarpati, G., Fusciello, C., Perri, F., Sabbatino, F., Ferrone, S., Carlomagno, C., et al., 2014. Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco. Targets Ther. 7, 203-209.
Eggermont, A.M., and Kirkwood, J.M., 2004. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur. J. Cancer 40 (12), 1825-1836.
Falchook, G.S., Long, G.V., Kurzrock, R., et al., 2012. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379 (9829), 1893-1901.
FDA, Trametinib package insert. <http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204114s000lbl. pdf> (accessed 06.07.15.).
FDA, Dabrafenib package insert. <http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202806s000lbl. pdf> (accessed 06.07.15.).
Fecher, L.A., Agarwala, S.S., Hodi, F.S., and Weber, J.S., 2013. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 18 (6), 733-743.
Flaherty, K.T., 2012. Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets. Clin. Exp. Metastasis 29 (7), 841-846.
Flaherty, K.T., Infante, J.R., Daud, A., et al., 2012. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367 (18), 1694-1703.
Gaudy-Marqueste, C., Monestier, S., Franques, J., Cantais, E., Richard, M.A., and Grob, J.J., 2013. A severe case of ipilimumab-induced guillain-barre syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J. Immunother. 36 (1), 77-78.
Hauschild, A., Grob, J.J., Demidov, L.V., et al., 2012. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380 (9839), 358-365.
Hodi, F.S., O'Day, S.J., McDermott, D.F., et al., 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363 (8), 711-723.
Ibrahim, R.A., Berman, D.M., DePril, V., Humphrey, R.W., et al., 2011. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J. Clin. Oncol. 29 (suppl; abstr 8583).
Lacouture, M.E., Duvic, M., Hauschild, A., et al., 2013. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 18 (3), 314-322.
Larkin, J., Del Vecchio, M., Ascierto, P.A., et al., 2014a. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 15 (4), 436-444.Larkin, J., Ascierto, P.A., Dreno, B., et al., 2014b. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 371 (20), 1867-1876.
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al., 2015. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373 (1), 23-34.
Liao, B., Shroff, S., Kamiya-Matsuoka, C., and Tummala, S., 2014. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol. 16 (4), 589-593.
Long, G.V., Trefzer, U., Davies, M.A., et al., 2012. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 13 (11), 1087-1095.
Long, G.V., Stroyakovskiy, D., Gogas, H., et al., 2014. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 371 (20), 1877-1888.
Long, G.V., Stroyakovskiy, D., Gogas, H., et al., 2015. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386 (9992), 444-451.

Mattei, P.L., Alora-Palli, M.B., Kraft, S., Lawrence, D.P., Flaherty, K.T., and Kimball, A.B., 2013. Cutaneous effects of BRAF inhibitor therapy: a case series. Ann. Oncol. 24 (2), 530-537.
McArthur, G.A., Chapman, P.B., Robert, C., et al., 2014. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 15 (3), 323-332.
Merck, Pembrolizumab package insert. <http://www.merck.com/product/usa/pi_circulars/k/keytruda/ keytruda_pi.pdf> (accessed 13.07.15.).
Nallapaneni, N.N., Mourya, R., Bhatt, V.R., Malhotra, S., Ganti, A.K., and Tendulkar, K.K., 2014. Ipilimumabinduced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash. J. Natl. Compr. Canc. Netw. 12 (8), 1077-1081.
Nishino, M., Sholl, L.M., Hodi, F.S., Hatabu, H., and Ramaiya, N.H., 2015. Anti-PD-1-related pneumonitis during cancer immunotherapy. N. Engl. J. Med. 373 (3), 288-290.
O'Day, S.J., Maio, M., Chiarion-Sileni, V., et al., 2010. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann. Oncol. 21 (8), 1712-1717.
Papavasileiou, E., Prasad, S., Freitag, S.K., Sobrin, L., and Lobo, A.M., 2015. Ipilimumab-induced ocular and orbital Inflammation-A case series and review of the literature. Ocul. Immunol. Inflamm., 1-7. Available from: http://dx.doi.org/10.3109/09273948.2014.1001858.
Postow, M.A., Chesney, J., Pavlick, A.C., et al., 2015. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372 (21), 2006-2017.
Ribas, A., Hodi, F.S., Callahan, M., Konto, C., and Wolchok, J., 2013. Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 368 (14), 1365-1366.
Robert, C., Thomas, L., Bondarenko, I., et al., 2011. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364 (26), 2517-2526.
Robert, C., Ribas, A., Wolchok, J.D., et al., 2014a. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384 (9948), 1109-1117.
Robert, C., Karaszewska, B., Schachter, J., et al., 2014b. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372 (1), 30-39.
Robert, C., Long, G.V., Brady, B., et al., 2015a. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372 (4), 320-330.
Robert, C., Schachter, J., Long, G.V., et al., 2015b. Pembrolizumab versus Ipilimumab in advanced melanoma. N. Engl. J. Med. 372 (26), 2521-2532.
Ryder, M., Callahan, M., Postow, M.A., Wolchok, J., and Fagin, J.A., 2014. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr. Relat. Cancer 21 (2), 371-381.
Sanlorenzo, M., Choudhry, A., Vujic, I., et al., 2014. Comparative profile of cutaneous adverse events: BRAF/ MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J. Am. Acad. Dermatol. 71 (6), 1102-1109. e1101.
Sinha, R., Edmonds, K., Newton-Bishop, J.A., Gore, M.E., Larkin, J., and Fearfield, L., 2012. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br. J. Dermatol. 167 (5), 987-994.

# II. TREATMENT AND PROGNOSISSosman, J.A., Kim, K.B., Schuchter, L., et al., 2012. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366 (8), 707-714.
Su, F., Viros, A., Milagre, C., et al., 2012. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366 (3), 207-215.
Thaipisuttikul, I., Chapman, P., and Avila, E.K., 2015. Peripheral neuropathy associated with ipilimumab: a report of 2 cases. J. Immunother. 38 (2), 77-79.
Tirumani, S.H., Ramaiya, N.H., Keraliya, A., et al., 2015. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol. Res. 3 (10), 1185-1192.
Topalian, S.L., Sznol, M., McDermott, D.F., et al., 2014. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32 (10), 1020-1030.
Weber, J., Thompson, J.A., Hamid, O., et al., 2009. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin. Cancer Res. 15 (17), 5591-5598.
Weber, J.S., Kahler, K.C., and Hauschild, A., 2012. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30 (21), 2691-2697.
Weber, J.S., Kudchadkar, R.R., Yu, B., et al., 2013. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J. Clin. Oncol. 31 (34), 4311-4318.
Weber, J.S., Yang, J.C., Atkins, M.B., and Disis, M.L., 2015. Toxicities of immunotherapy for the practitioner. J. Clin. Oncol. 33 (18), 2092-2099.
Welsh, S.J., and Corrie, P.G., 2015. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther. Adv. Med. Oncol. 7 (2), 122-136.
Wolchok, J.D., Neyns, B., Linette, G., et al., 2010. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 11 (2), 155-164.
Wolchok, J.D., Kluger, H., Callahan, M.K., et al., 2013. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369 (2), 122-133.# C H A P T E R 

## 21

## Brain Metastases from Breast Cancer: Focus on Risk Factors, Treatment, and Clinical Outcome <br> Caterina Fontanella, Etin-Osa Osa and Fabio Puglisi

## O U T L I N E

Introduction
Risk Factors for Brain Metastases
Development
Mechanisms of Brain Dissemination
Prognosis of Breast Cancer Patients with Brain Metastases
321
322
323

324

## INTRODUCTION

Among the worldwide female population, breast cancer accounts for $29 \%$ of the total new cancer cases diagnosed and $15 \%$ of the cancer deaths. To date, breast cancer is the most frequently diagnosed tumor and the second leading cause of cancer death among women (Siegel et al., 2016).The American Cancer Society assessed that 160,000 women in the United States are living with metastatic breast cancer with an estimated median survival rate within the range of 3 years. Over the last four decades, the survival of breast cancer patients has increased mainly due to early detection and improvement in adjuvant treatment. Initial reports suggested an improvement in metastatic breast cancer survival between 1974 and 2000 (Giordano et al., 2004). However, starting from the late 1990s, a significant shift toward more unfavorable risk factors was observed in metastatic breast cancer, and patients developing metastatic disease seem to have a more aggressive disease (Ufen et al., 2014).

The vast majority of brain metastases are detected due to symptoms suggesting central nervous system (CNS) involvement, such as headache, vomiting, dizziness, and ataxia (Minisini et al., 2013). According to the literature, the incidence of brain metastases in breast cancer patients ranges from $10 \%$ to $16 \%$ (Lin et al., 2004); however, the total incidence of brain metastases may be underestimated. The CEREBEL trial, a trial specifically testing whether lapatinib plus capecitabine was superior to trastuzumab plus capecitabine in prevention of CNS lesions in metastatic breast cancer patients after trastuzumab failure, carefully screened asymptomatic patients for brain metastases. Asymptomatic brain metastases were detected in almost $20 \%$ of patients (Pivot et al., 2011).

A review of the literature showed that the risk of developing brain metastases increased with increasing stage at the initial diagnosis. Only $2.5 \%$ of patients diagnosed with early disease developed CNS disease, whereas $7.6 \%$ of patients diagnosed with regional disease and $13.4 \%$ of patients presenting with stage IV disease were found to have brain involvement (Lin et al., 2004).

More than $80 \%$ of brain metastases were detected later during the course of metastatic disease. The diagnosis of CNS involvement as first manifestation of breast cancer or synchronously with first diagnosis of systemic disease could be considered a relatively rare event. Overall, one-third of patients were diagnosed with polymetastatic brain disease (four or more metastatic lesions), one-third with oligometastatic brain disease (between two and three lesions), and one-third with one single brain lesion (Barnholtz-Sloan et al., 2004).

# RISK FACTORS FOR BRAIN METASTASES DEVELOPMENT 

A large study with a median follow up of 15 years showed that the incidence of brain metastases varied in different breast cancer subtypes. Patients with epidermal growth factor receptor 2 (HER2)-positive disease had the highest incidence of CNS involvement, followed by triple negative (hormone receptor (HR)-negative and HER2-negative) both basal-like and nonbasal-like, luminal B-like (HR-positive, HER2-negative, high proliferation rate), and luminal A-like (HR-positive, HER2-negative, low proliferation rate) subtypes (Kennecke et al., 2012).

In the Graesslin nomogram (Graesslin et al., 2010), age, histological grade, HR status, HER2 status, number of noncentral nervous system metastatic sites, and interval between date of primary diagnosis and date of first metastases were associated with the risk of developing brain lesions. Several data supported the same results (Minisini et al., 2013) and young women with HR-negative, high proliferation rate, and/or HER2-positive disease were confirmed to be the subgroup with the higher risk of developing brain metastases.A study that evaluated the correlation between quantitative HER2 protein expression ratio by fluorescence in situ hybridization and risk for brain metastases in 142 consecutive patients who received trastuzumab (a humanized monoclonal antibody directed at the HER2 ectodomain)-based therapy for HER2-positive metastatic breast cancer showed that time to brain metastases strongly correlate with total HER2 protein expression (Duchnowska et al., 2012a). HER2 positivity seems to be the strongest risk factor for brain metastases (Minisini et al., 2013). Indeed, among 413 patients who died during follow-up on the HERA (HERceptin adjuvant) trial, $47 \%$ were diagnosed with CNS relapse in the trastuzumab arm and $57 \%$ in the control arm (Pestalozzi et al., 2013). Moreover, among patients with HER2positive breast cancer, the risk of brain metastases is further elevated in the setting of HR negativity. In a recent retrospective analysis of 473 metastatic breast cancer patients (Minisini et al., 2013), estrogen receptor (ER) and progesterone receptor (PR) negativity were associated with an increased risk of development of CNS lesions (odds ratio (OR) 4.06, 95\% CI $2.38-6.91 ; P<0.001$ and OR $2.21,95 \%$ CI $1.31-3.71 ; P=0.003$, respectively).

The loss of HR positivity seems to be a common event in brain metastases. Duchnowska and colleagues evaluated the conversion rate of ER and PR receptor from primary tumor to corresponding brain metastases in a consecutive series of 120 breast cancer patients (Duchnowska et al., 2012b) and found the conversion rate of ER and PR in brain metastases was $29 \%$, mostly from positive to negative. Apparently, patients who received endocrine therapy had the highest conversion rate from hormone receptor positive to negative disease. However, it is important to note that the conversion did not affect survival. The authors also investigated HER2 status; conversion of HER2 occurred in $14 \%$ of patients and it was more balanced either way. No impact of the use of chemotherapy or trastuzumab was observed. Patients with metastatic triple-negative breast cancer were also at high risk of brain metastases, with an estimated incidence from $25 \%$ to $46 \%$ (Lin et al., 2008).

One of the major differences between HER2-positive and triple-negative breast cancer patients seems to be the time to brain relapse. A hospital-based tumor registry of 2441 women with breast cancer treated between 1998 and 2006 showed that the median time to development of brain metastases was shortest in the triple-negative group ( 22 months), followed by the HER2-positive group ( 30 months), followed by the luminal group ( 63.5 months) (Heitz et al., 2009). In contrast, brain involvement in patients with triple-negative disease frequently occurs simultaneously with extracranial disease progression (Park et al., 2012). There is also evidence to suggest that once brain metastases are discovered, patients with triple-negative tumor have a shorter time to death.

# MECHANISMS OF BRAIN DISSEMINATION 

The number of different genes expressed among subtypes of breast cancer confirms that the underline biology of the subtypes is different. This heterogeneity also plays an important role in the metastatic potential and pattern of relapse of the different subtypes. For example, brain metastases occur most frequently in nonluminal subtypes, liver relapse is associated with HER2-positive tumors, and lung relapse occurs often within the basal-like subtypes.

The mechanisms underlying brain dissemination remain poorly understood. Through comparative genome-wide expression analysis, a 17 -gene signature was identified asassociated to brain dissemination in two independent breast cancer datasets (Nam et al., 2008). In particular, ST6GALNAC5, a sialyltransferase, was found to facilitate transmigration across the blood-brain-barrier and to be specifically involved in the brain metastatic potential, whereas the cyclooxygenase (COX) 2 and the epidermal growth factor receptor (EGFR) ligand HBEGF also conferred lung metastatic potential. Other intracellular pathways associated with metastases to the brain include CXCR4/CXCL12, VEGF, PI3K, and Notch. An extensive analysis detected 37 proteins differentially expressed between primary breast tumors with brain metastases and primary breast tumors without brain metastases. In particular, the combination of GRP94, FN14, and inhibin was observed to have a higher probability to predict brain metastases compared with HER2 alone (SanzPamplona et al., 2011).

Once tumor cells have migrated across the blood-brain-barrier, an essential step of metastases formation is at the vascular branch points. The brain microenvironment represents a unique system of stromal elements, such as pericytes, astrocytes, and glial cells, which may interfere with both metastatic colonization and therapeutic response. In particular, in vitro culture experiments suggest that a brain inflammatory response with extensive reactive gliosis may play a role in promoting brain metastases colonization and growth (Fitzgerald et al., 2008).

# PROGNOSIS OF BREAST CANCER PATIENTS WITH BRAIN METASTASES 

In clinical practice, the patient's overall general condition is generally defined by the performance status, using either the Karnofsky performance status (KPS) score or the Eastern Cooperative Oncology Group (ECOG) system. The Radiation Therapy Oncology Group (RTOG) Recursive Partitioning Analysis (RPA) was developed to assist in assigning patients with newly diagnosed brain metastases to the appropriate prognostic group to guide treatment decision making and clinical trial design. The scale assigns patients with brain metastases to RPA class 1, 2, or 3 based on KPS, age, and burden of disease. Patients with KPS score 70-100, age less than 65, controlled primary, and metastases to the brain only are classified as RPA class 1 ; patients with KPA less than 70 are classified as RPA class 3 ; and all others are classified as RPA class 2. According to the literature, patients in class 1 have a median survival of 7.1 months, class 2, 4.2 months, and class 3, 2.3 months (Le Scodan et al., 2007).

More modern prognostic scales have been developed including the graded prognostic assessment (GPA). This scale assigns a score of $0,0.5$, or 1 for age, KPS, number of CNS lesions, and presence or absence of extracranial metastases. The sum score is then used to determine the median survival in months, ranging from 2.6 months for a score of $0-1$ to 11 months for a score of 3.5-4.0. Comparison of the RPA, GPA, and other prognostic indices found the GPA and RPA to have the most statistically significant difference between categories. In addition, the GPA was the least subjective, most quantitative, and easiest to use. The GPA has been further refined and a diagnosis-specific GPA for breast cancer assigns scores based on KPS, age greater than or less than 60, and breast cancer subtype (Sperduto et al., 2012) (Table 21.1). The sum of the points for each prognostic factor is the GPA for anTABLE 21.1 GPA to Estimate Survival from Brain Metastases from Breast Cancer

| Prognostic factor value | $\mathbf{0}$ | $\mathbf{0 . 5}$ | $\mathbf{1 . 0}$ | $\mathbf{1 . 5}$ | $\mathbf{2 . 0}$ |
| :-- | :-- | :-- | :-- | :-- | :-- |
| KPS | $\leq 50$ | 60 | $70-80$ | $90-100$ | N/A |
| Subtype | Triple-negative | N/A | Luminal A | HER2-positive | Luminal B |
| Age (in years) | $\geq 60$ | $<60$ | N/A | N/A | N/A |

Modified from Sperduto et al. (2012).
The sum of the points for each prognostic factor is the GPA for an individual patient:

- GPA $0-1.0=$ median survival time (mST) of 3.4 months.
- GPA $1.5-2.0=$ mST of 7.7 months.
- GPA $2.5-3.0=$ mST of 15.1 months.
- GPA $3.5-4.0=$ mST of 25.3 months.
individual patient. Patients with a GPA score of $0-1.0$ have a median survival time (mST) of 3.4 months, patients with a GPA score of $1.5-2.0$ have an mST of 7.7 months, patients with a GPA score of $2.5-3.0$ have an mST of 15.1 months, and patients with a GPA score of $3.5-4.0$ have an mST of 25.3 months.


# TREATMENT OF BRAIN METASTASES 

Brain metastases continue to be a challenge for the oncology team and contribute significantly to the morbidity and mortality of breast cancer. Without treatment, the median length of survival following the diagnosis of brain metastases is approximately 1 month, and increases to $2-3$ months with corticosteroids and supportive treatment. Over the last century, a number of loco-regional treatments have become available and overall survival of breast cancer patients with brain metastatic lesions has remarkably increased.

## Loco-Regional Approach

## Whole-Brain Radiotherapy

In the 1950s, Chao and colleagues reported the first evidence of a beneficial effect of whole-brain radiotherapy (WBRT) for brain metastases (Chao et al., 1954). Subsequently, WBRT emerged as the standard of care for the management of brain metastases, resulting in a median survival of 4-6 months and a clinical response rates ranging from $50 \%$ to $75 \%$ (Tsao et al., 2012).

The most commonly used dose and fractionation scheme is 30 Gray (Gy) delivered over 10 fractions. This regimen emerged partly from the RTOG phase III trials demonstrating improved outcomes and side effect profile with such fractionation schemes compared to more rapid fractionation treatments (Borgelt et al., 1980). However, shorter fractionationschemes, such as 20 Gy in 5 fractions, should be considered in cases of high burden of systemic disease and visceral metastases, chemotherapy refractory disease or patients with reduced general condition or RPA class 3. Acute side effects of WBRT include fatigue, headache, nausea, vomiting, alopecia, and scalp erythema. Long-term side effects can occur 6 months to several years following WBRT and include neurocognitive decline, urinary incontinence, and ataxia. Given the high rate of local recurrence with WBRT, especially for lesions greater than 3 cm , the management of brain metastases has evolved over time and currently can involve any combination of surgical resection and radiotherapy via WBRT or stereotactic radiosurgery (SRS).

# Surgical Resection 

Patients diagnosed with a single brain lesion or with oligometastatic disease should be assessed for suitability for radical surgical resection. The superiority of surgical resection of brain metastases followed by WBRT compared to WBRT alone in this subset of patients was demonstrated in three randomized studies. Patchell et al. (1990) randomized 48 patients with a single lesion to undergo either surgical resection followed by WBRT ( 36 Gy in 20 fractions) or needle biopsy only followed by WBRT. In this trial, the local recurrence rate at the initial site of brain metastasis was lower in the surgical group compared with the WBRT alone group ( $20 \%$ vs $52 \% ; P=0.02$ ). Moreover, the median overall survival was significantly longer in the surgical group compared with the WBRT alone group ( 40 vs 15 weeks; $P=0.01$ ), and patients treated with surgery remained functionally independent longer ( 38 vs 8 weeks; $P=0.005$ ). The occurrence of distant brain metastases was not significantly different between the two groups ( $20 \%$ in the surgical group vs $13 \%$ in the radiation group, $P=0.52$ ). Similar results were obtained by Noordijk and colleagues (Noordijk et al., 1994) in 66 patients with single brain metastases from different solid tumors. The combined treatment led to a longer overall survival compared with WBRT alone ( 10 vs 6 months; $P=$ 0.04). In this trial, patients with active extracranial disease showed no significantly difference in median overall survival, irrespective of given treatment. The third study by Mintz and colleagues was not able to detect significant superiority of combined treatment against whole-brain irradiation alone, but it has been criticized due to an enrollment of a patient population with poorer performance status and a relatively high rate of nonadherence to the assigned treatment (Mintz et al., 1996).

Patchell and colleagues subsequently studied whether WBRT could be omitted following surgical resection (Patchell et al., 1998). They randomly assigned 95 patients with a single brain metastasis to surgical resection followed by either WBRT ( 50.4 Gy in 28 fractions) or observation. There was no difference in overall survival or duration of functional independence, but the addition of radiation therapy improved local control and decreased the risk of neurologic death. A similar phase III trial of the European Organization of Research and Treatment in Cancer (EORTC) showed that the addition of WBRT following surgical resection or SRS for patients with one to three brain metastases failed to improve the duration of functional independence or overall survival, but decreased 6- and 12-month intracranial progression and neurologic death (Mintz et al., 1996). Radiation therapy following surgical resection continues to be the standard of care.

Recently, a retrospective study on breast cancer patients with solitary or limited number of brain metastases treated by surgical resection confirmed that surgical resection could bean effective treatment in selected patients (Tabouret et al., 2013). Moreover, mini mental status test, number of systemic metastases, and the use of postoperative systemic treatment seemed to be significantly associated with better outcome. In contrast, hormonal receptor status, HER2 status, and molecular subtype were not significantly correlated to survival.

Involved field radiation therapy (IFRT) delivering radiotherapy to the surgical bed only as opposed to WBRT following surgical resection of a single brain metastasis in wellselected patients has also been studied. The main benefit of this approach is it allows WBRT and its concomitant side effects, including neurocognitive decline, to be delayed until WBRT is deemed necessary. Connolly et al. (2013) reported on 33 patients who underwent IFRT to a dose of 40.5 Gy in 15 fractions following surgical resection of a single brain metastasis with a known primary site. About $30 \%$ of the patient had breast cancer as the primary site. At 12 months, they obtained a local control rate of $90.3 \%$, distant brain recurrence-free survival rate of $60.7 \%$, and overall survival rate of $65.6 \%$. Overall, $15 \%$ of patients developed recurrence at the resection cavity and $39 \%$ at a new intracranial site.

# Stereotactic Radiotherapy 

SRS, a noninvasive alternative to surgical resection, is typically reserved for metastatic brain lesions equal to or smaller than 3 cm in patients who are medically or technically inoperable, such as patients with metastases in deep, eloquent regions of the brain. The risks of SRS include radiation necrosis and peritumoral edema requiring long-term steroid treatment. The advantages of SRS over surgery include short hospital stay, minimal risk of bleeding and infection, lower risk of complications, no general anesthesia, and the fact that it is not limited or by medical comorbidities in general. No randomized controlled trials have compared surgical resection to SRS, but SRS-treated lesions have similar recurrence rates as surgically resected lesions, and SRS can have local control rates up to $80-90 \%$ when added to WBRT (Errico, 2014).

The benefit of adding SRS to WBRT was studied in a phase III randomized controlled trial by the RTOG (Andrews et al., 2004). Over 300 patients with one to three brain metastases, less than or equal to 4 cm , were randomized to WBRT ( 37.5 Gy in 15 fractions) or WBRT ( 37.5 Gy in 15 fractions) plus SRS ( $15-24 \mathrm{~Gy}$ ). At 1 year, there was better control of the treated lesion with the addition of SRS ( $82 \%$ vs $71 \%, P=0.01$ ). The addition of SRS did not improve survival for patients with two to three brain metastasis, but for patients with one lesion, the overall survival improved from 4.9 to 6.5 months, $(P=0.04)$. SRS also significantly improved or maintained KPS at 6 months and allowed for less steroid use. Therefore, for patients with single metastases who undergo WBRT, SRS boost is considered standard of care.

In an attempt to avoid the neurocognitive side effects of WBRT, several groups have studied whether WBRT can be omitted if SRS is performed. Aoyama and colleagues performed a randomized controlled trial comparing WBRT ( 30 Gy in 10 fractions) followed by SRS (18-25Gy) to SRS alone (18-25Gy) in 132 patients with one to four brain metastases, each less than 3 cm and KPS greater than or equal to 70 (Aoyama et al., 2006). The primary endpoint was overall survival. There was no significant difference in mSTs between the WBRT plus SRS group and the SRS alone group, 7.5 versus 8 months, respectively ( $P=0.42$ ). There was also no difference in neurologic or KPS preservation, or mini mental status exam between the two groups. The actuarial local tumor control rate at 12 months was significantly higher in the WBRT plus SRS group compared to the SRS alone group, $88.7 \%$ versus $72.5 \%$, respectively ( $P=0.002$ ), and the WBRT plus SRS group required less salvage brain treatment.In a similar randomized controlled trial, Chang and colleagues randomly assigned 58 patients with one to three brain metastases and KPS greater than or equal to 70 to SRS alone (15-24Gy) or SRS (15-24Gy) followed by WBRT (30Gy in 12 fractions) (Chang et al., 2009). The primary endpoint was neurocognitive function based on the Hopkins Verbal Learning Test. The WBRT group displayed worse neurocognitive decline at 4 months despite better 1-year local control and 1-year distant brain tumor control with WBRT. The SRS alone group also had a statistically significant increased 1-year overall survival compared to the SRS plus WBRT group ( $63 \%$ vs $21 \%, P=0.003$ ). This study has been criticized for inappropriate patient stratification as there was no stratification based on baseline neurocognitive function. Also, the primary end-point, neurocognitive function based on the HVLT, was assessed at a single time point of 4 months which may have biased the trial against WBRT as transient decline in verbal memory following WBRT is known to nadir at 4 months with recovery by 1 year. Nonetheless, these studies highlight the benefit in local and distant brain tumor control with WBRT and the need for increased salvage treatments with SRS alone.

Different breast cancer subtypes exhibit different outcomes and patterns of failure following treatment with SRS. Patients with triple-negative breast cancer were found to have worse overall survival and a higher chance of distant brain failure after SRS. In addition, breast cancer subtype predicted for distant brain failure rate, with triple-negative breast cancer having the highest distant failure rate.

# Systemic Approach 

The role of systemic therapy in the management of patients with brain metastases is not well defined and to date, no systemic therapies have obtained the regulatory approval for the treatment of brain metastases from solid tumors and. However, data supporting the efficacy of systemic therapies in the management of brain metastases from breast cancer are available from published clinical trials.

## HER2-Positive Disease

Several retrospective studies have demonstrated improved survival with trastuzumab in HER2-positive metastatic breast cancer patients with CNS metastases. However, the impact on survival seems to be mainly due to control of systemic disease rather than brain lesions. Consensus guidelines on systemic treatment after brain metastases in HER2-positive breast cancer patients are lacking.

Historically, it has been thought that trastuzumab crosses neither the blood-brain-barrier nor the blood-tumor-barrier because of its large molecular size. This idea was supported by the evidence that about $50 \%$ of metastatic breast cancer patients treated with trastuzumab develop brain metastases with controlled disease outside the CNS. However, increased trastuzumab levels were found in cerebrospinal fluid after radiotherapy in patients with breast cancer (Pestalozzi and Brignoli, 2000). Moreover, a significant uptake of ${ }^{89}$ zirconium-labeled trastuzumab was detected by in vivo positron emission tomography imaging in brain metastases (Dijkers et al., 2010). Due to the relatively small number of patients and the minimal amounts of trastuzumab detected in the brain metastases, these data did not provide information about the proportion of brain metastases that were permeable to trastuzumab. Nonetheless, these data suggest that more potent formulations, such as trastuzumab emtansine (T-DM1), could have a more favorable therapeutic profile.Recently, an exploratory analyses of the CLEOPATRA trial showed that metastatic breast cancer patients treated with pertuzumab added to trastuzumab plus docetaxel had a longer median time to development of CNS metastases as first site of disease progression compared with patients treated only with trastuzumab plus docetaxel ( 15.0 vs 11.9 months; $P=0.0049$ ) (Swain et al., 2014).

Small molecule inhibitors of HER2, including lapatinib and neratinib, have also been investigated in this setting. Lapatinib is a small molecule tyrosine kinase inhibitor of both the EGFR and HER2 with the important ability to cross the blood-brain-barrier. In preclinical models, lapatinib level in normal brain tissue was $1.3-2.8 \%$ of plasma concentrations, whereas in brain metastases, the brain metastases/plasma concentration ratio reached $26 \%$ overall (Lockman et al., 2010). In a presurgical resection study of metastatic breast cancer with brain lesions, lapatinib demonstrated marked accumulation in brain metastases, reaching up to 10 -fold greater levels that in the serum (Morikawa et al., 2013). These findings strongly agree with clinical data. For example, the combination of capecitabine plus lapatinib showed a response rate of $18-38 \%$ in patients with brain progression after radiotherapy. In the LANDSCAPE trial, patients with untreated CNS metastases received lapatinib plus capecitabine before whole-brain irradiation; the brain response rate was $66 \%$ and the 1-year survival more than $70 \%$ (Bachelot et al., 2013). By contrast, Gori et al. (2014) found low concentrations of lapatinib in the cerebrospinal fluid of two metastatic breast cancer patients treated with lapatinib and concluded that lapatinib concentration in cerebrospinal fluid may not be a surrogate of its distribution in CNS (Gori et al., 2014).

An increasing body of evidence shows that the combination of trastuzumab and lapatinib, either concomitantly or sequentially, leads to a longer survival in metastatic breast cancer patients with brain metastases. Metro and colleagues showed that patients treated with sequential combination of a trastuzumab-based regimen followed by lapatinib plus capecitabine had about a 10 -month significantly longer survival compared with patients treated with a trastuzumab-based regimen alone ( 27.9 vs 16.7 months; $P=0.01$ ) (Metro et al., 2001). Consistently, the combination of trastuzumab and lapatinib was shown to be associated with a longer overall survival compared with trastuzumab alone (HR $0.279 ; P=0.012$ ) in another retrospective single center study (Sutherland et al., 2010). Neratinib, an irreversible inhibitor of EGFR and HER2, is under investigation as both monotherapy and in combination with capecitabine in breast cancer patients with progressive brain metastases (trial protocol number NCT01494662 and NCT01441596, respectively). Finally, two phase I studies are evaluating the optimal dose as well as safety and efficacy of intrathecal trastuzumab (NCT01373710, NCT01325207). Taken together, these findings suggest an important role for systemic treatments in improving the outcome of HER2-positive breast cancer with brain involvement.

# Triple-Negative Disease 

Systemic treatment in triple-negative tumors is limited to chemotherapy in both the metastatic and early setting. Thus, in triple-negative breast cancer patients, the integrity of the blood-brain-barrier, which may limit the delivery of large and hydrophilic drugs to the site of brain metastases, is crucial. In preclinical animal models, brain metastases were more permeable than normal brain tissue. Approximately $10 \%$ of brain lesions showed a free uptake of radiolabeled paclitaxel $>50$-fold greater than normal brain, $76 \%$ of lesions demonstrated a free uptake between 50 -fold and slightly greater than normal brain, and $14 \%$of lesions had drug uptake statistically indistinct from normal brain tissue (Lockman et al., 2010). However, only the $10 \%$ of lesions with the highest permeability showed an objective response to paclitaxel.

Several methodologies have been proposed to increase blood-brain metastases permeability, including blood-brain-barrier disruption using ultrasound, radiotherapy, or development of new drugs conjugated with brain tissue vectors. ANG1005 is a novel formulation of paclitaxel conjugated to the angiopep-2 vector, which is supposed to facilitate passage across the blood-brain-barrier (Regina et al., 2008). In an ongoing phase II trial, patients with breast cancer brain metastases were initially treated at a $650 \mathrm{mg} / \mathrm{m}^{2}$ starting dose; however, the protocol was subsequently amended to test a $550 \mathrm{mg} / \mathrm{m}^{2}$ due to an exceeding rate of fatigue, pancytopenia, and peripheral neuropathy. The interim efficacy analysis showed a CNS response in one-third of patients.

Classic chemotherapy combinations against metastatic breast cancer show brain objective response rates from $0 \%$ to $55 \%$. Over the last 15 years, cisplatin and carboplatin in combination with different drugs have shown response rates of $34-40 \%$. In particular, the combination of cisplatin and etoposide demonstrated a brain complete response of $13 \%$ and a partial response of $25 \%$ among breast cancer patients with brain lesions (Franciosi et al., 1999). The response rate observed with topotecan for newly diagnosed brain metastases was $37 \%$; however, the drug showed a nonfavorable hematologic safety profile with $37 \%$ of grade 3-4 neutropenia, $21 \%$ of grade 3-4 thrombocytopenia, and $16 \%$ of grade 3-4 anemia, and the use of this regimen in elderly and poor performance status patients was not recommended (Lorusso et al., 2006). Temozolomide showed no activity in breast cancer with brain metastases neither as a single agent nor in combination with vinorelbine and only moderate activity in combination with cisplatin.

Although the data are limited primarily to phase II studies not specific for triple-negative breast tumors, classic chemotherapy regimens such as cyclophosphamide/methotrexate/ 5-fluorouracil (CMF) or 5-fluorouracil/doxorubicin/cyclophosphamide (FAC), or carboplatin-based regimens should be considered in triple-negative patients with brain lesions who have not previously received these chemotherapy combinations.

In preclinical models, antiangiogenic agents have been shown to lead to a regression of highly vascularized metastatic lesions. However, in human clinical trials, patients with brain metastases have historically been excluded from studies of antiangiogenic agents due to the fear of intracranial hemorrhage. Recently, the preliminary results of two prospective phase II trials evaluating the role of bevacizumab, a humanized antivascular endothelial growth factor (VEGF) monoclonal antibody, in combination with chemotherapy for patients with breast cancer brain metastases showed a CNS response rates higher than 60\% (Lu et al., 2012; Lin et al., 2013).

Sunitinib and sorafenib, small molecule inhibitors of multiple kinases including VEGF receptor (VEGFR) kinases, were also evaluated in with patients with solid tumors and brain metastases. Although sunitinib showed a significant reduction in the occurrence of CNS lesions in patients with metastatic renal cancer, to date, no data are available regarding treatment with sorafenib or sunitinib in breast cancer patients with CNS lesions.

# Luminal-Like Disease 

Brain metastases in luminal-like breast cancer, defined as HR-positive/HER2-negative tumors, are a relatively rare and late event compared with HER2-positive and triple-negative subtypes, with a median time interval from primary diagnosis to development of CNS lesionsof almost 55 months (Park et al., 2012). In one retrospective series, the median survival from primary breast cancer diagnosis of patients with metastatic luminal-like subtype was consistently longer than the median survival of patients with triple-negative subtype ( 72.7 vs 39.6 months, $P<0.01$ ), although the difference in median survival after brain metastasis diagnosis was less than 3 months ( 10.0 vs 7.6 months, respectively, $P<0.01$ ) (Sperduto et al., 2013).

In a retrospective study, systemic treatment prolonged median overall survival after brain metastases in luminal-like patients: 14.3 months in patients who received systemic chemotherapy with or without endocrine treatment versus 7.1 months in patients who did not received systemic treatment after whole-brain irradiation ( $P=0.003$ ) (Kaplan et al., 2012).

Historical data with tamoxifen and megestrol acetate showed activity against brain lesions in HR-positive disease. In particular, tamoxifen has been reported to attain a 46 -fold higher concentration in brain metastases and in brain tissue than in serum (Smitherman and Sontheimer, 2001). Moreover, a response in brain lesions was also reported with the aromatase inhibitors in letrozole and anastrozole (Madhup et al., 2006; Ito et al., 2009).

# References 

Andrews, D.W., Scott, C.B., Sperduto, P.W., et al., 2004. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363, 1665-1672.
Aoyama, H., Shirato, H., Tago, M., et al., 2006. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295, 2483-2491.
Bachelot, T., Romieu, G., Campone, M., et al., 2013. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 14, 64-71.
Barnholtz-Sloan, J.S., Sloan, A.E., Davis, F.G., et al., 2004. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J. Clin. Oncol. 22, 2865-2872.
Borgelt, B., Gelber, R., Kramer, S., et al., 1980. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 6, 1-9.
Chang, E.L., Wefel, J.S., Hess, K.R., et al., 2009. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 10, $1037-1044$.
Chao, J.H., Phillips, R., and Nickson, J.J., 1954. Roentgen-ray therapy of cerebral metastases. Cancer 7, 682-689.
Connolly, E.P., Mathew, M., Tam, M., et al., 2013. Involved field radiation therapy after surgical resection of solitary brain metastases-mature results. Neuro. Oncol. 15, 589-594.
Dijkers, E.C., Oude Munnink, T.H., Kosterink, J.G., et al., 2010. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin. Pharmacol. Ther. 87, 586-592.
Duchnowska, R., Biernat, W., Szostakiewicz, B., et al., 2012a. Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2? Advanced breast cancer patients receiving trastuzumabcontaining therapy. Oncologist 17, 26-35.
Duchnowska, R., Dziadziuszko, R., Trojanowski, T., et al., 2012b. Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain. Breast Cancer Res. 14, R119.
Errico, A., 2014. Surgery: stereotactic radiosurgery—new options for multiple brain metastases? Nat. Rev. Clin. Oncol. 11, 242.
Fitzgerald, D.P., Palmieri, D., Hua, E., et al., 2008. Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin. Exp. Metastases 25, 799-810.
Franciosi, V., Cocconi, G., Michiara, M., et al., 1999. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 85, 1599-1605.Giordano, S.H., Buzdar, A.U., Smith, T.L., et al., 2004. Is breast cancer survival improving? Cancer 100, 44-52.
Graesslin, O., Abdulkarim, B.S., Coutant, C., et al., 2010. Nomogram to predict subsequent brain metastases in patients with metastatic breast cancer. J. Clin. Oncol. 28, 2032-2037.
Gori, S., Lunardi, G., Inno, A., et al., 2014. Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases. Ann. Oncol. 25, 912-913.
Heitz, F., Harter, P., Lueck, H.J., et al., 2009. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur. J. Cancer 45, 2792-2798.
Ito, K., Ito, T., Okada, T., et al., 2009. A case of brain metastases from breast cancer that responded to anastrozole monotherapy. Breast J. 15, 435-437.
Kaplan, M.A., Isikdogan, A., Koca, D., et al., 2012. Biological subtypes and survival outcomes in breast cancer patients with brain metastases (Study of the Anatolian Society of Medical Oncology). Oncology 83, 141-150.
Kennecke, H., Yerushalmi, R., Woods, R., et al., 2012. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol. 28, 3271-3277.
Le Scodan, R., Massard, C., Mouret-Fourme, E., et al., 2007. Brain metastases from breast carcinoma: validation of the radiation therapy oncology group recursive partitioning analysis classification and proposition of a new prognostic score. Int. J. Radiat. Oncol. Biol. Phys. 69, 839-845.
Lin, N.U., Bellon, J.R., and Winer, E.P., 2004. CNS metastases in breast cancer. J. Clin. Oncol. 22, 3608-3617.
Lin, N.U., Claus, E., Sohl, J., et al., 2008. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 13, 2638-2645.
Lin, N.U., Gelman, R., Younger, J., et al., 2013. Phase II trial of carboplatin (C) and bevacizumab (BEV) in patients (Pts) with breast cancer brain metastases (BCBM). J. Clin. Oncol. 31. (abstract 513)
Lorusso, V., Galetta, D., Giotta, F., et al., 2006. Topotecan in the treatment of the brain metastases. A phase II study of GOIM (Gruppo Oncologico dell'Italia Meridionale). Anticancer Res. 26, 2259-2263.
Lockman, P.R., Mittapalli, R.K., Taskar, K.S., et al., 2010. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin. Cancer Res. 16, 5664-5678.
Lu, Y.S., Chen, W.W., Ling, C.H., et al., 2012. Bevacizumab, etoposide, and cisplatin (BEEP) in brain metastases of breast cancer progressing from radiotherapy: results of the first stage of a multicenter phase II study. J. Clin. Oncol. 30, 1079. (abstract 1079)
Madhup, R., Kirti, S., Bhatt, M.L., et al., 2006. Letrozole for brain and scalp metastases from breast cancer-a case report. Breast 15, 440-442.
Metro, G., Foglietta, J., Russillo, M., et al., 2001. Clinical outcome of patients with brain metastases from HER2positive breast cancer treated with lapatinib and capecitabine. Ann. Oncol. 22, 625-630.
Minisini, A.M., Moroso, S., Gerratana, L., et al., 2013. Risk factors and survival outcomes in patients with brain metastases from breast cancer. Clin. Exp. Metastases 30, 951-956.
Mintz, A.H., Kestle, J., Rathbone, M.P., et al., 1996. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastases. Cancer 78, 1470-1476.
Morikawa, A., Peereboom, D.M., Smith, Q.R., et al., 2013. Clinical evidence for drug penetration of capecitabine and lapatinib uptake in resected brain metastases from women with metastatic breast cancer. J. Clin. Oncol. 31 Abstract nr 514.
Nam, B.H., Kim, S.Y., Han, H.S., et al., 2008. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res. 10, R20.
Noordijk, E.M., Vecht, C.J., Haaxma-Reiche, H., et al., 1994. The choice of treatment of single brain metastases should be based on extracranial tumor activity and age. Int. J. Radiat. Oncol. Biol. Phys. 29, 711-717.
Park, Y.H., Ahn, H.K., Park, S., et al., 2012. Time to brain metastases (TTBM) from initial diagnosis of distant metastases in breast cancer: prediction of TTBM according to breast cancer subtypes and treatment effect. J. Clin. Oncol. 30. (abstract 644)
Patchell, R.A., Tibbs, P.A., Walsh, J.W., et al., 1990. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 322, 494-500.
Patchell, R.A., Tibbs, P.A., Regine, W.F., et al., 1998. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280, 1485-1489.
Pestalozzi, B.C., and Brignoli, S., 2000. Trastuzumab in CSF. J. Clin. Oncol. 18, 2349-2351.
Pivot, X., Hackmann, J., Manikhas, A., et al., 2011. Incidence rate of asymptomatic CNS lesions in patients with HER2? Metastatic breast cancer screened for GF111438/CEREBEL study. Cancer Res. SABCS11-P4-17-03.

# II. TREATMENT AND PROGNOSISRegina, A., Demeule, M., Che, C., et al., 2008. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br. J. Pharmacol. 155, 185-197.
Sanz-Pamplona, R., Aragues, R., Driouch, K., et al., 2011. Expression of endoplasmic reticulum stress proteins is a candidate marker of brain metastases in both ErbB-2? And ErbB-2- primary breast tumors. Am. J. Pathol. 79, $564-579$.
Siegel, R.L., Miller, K.D., and Jemal, A., 2016. Cancer statistics, 2016. CA Cancer. J. Clin. 66, 7-30.
Smitherman, K.A., and Sontheimer, H., 2001. Inhibition of glial $\mathrm{Na}^{+}$and $\mathrm{K}^{+}$currents by tamoxifen. J. Membr. Biol. $181,125-135$.
Sperduto, P.W., Kased, N., Roberge, D., et al., 2012. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J. Clin. Oncol. 30, $419-425$.
Sperduto, P.W., Kased, N., Roberge, D., et al., 2013. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. J. Neuro. Oncol. 112, 467-472.
Sutherland, S., Ashley, S., Miles, D., et al., 2010. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases-the UK experience. Br. J. Cancer 102, 995-1002.
Swain, S.M., Baselga, J., Miles, D., et al., 2014. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann. Oncol. 25, 1116-1121.
Tabouret, E., Metellus, P., Tallet-Richard, A., et al., 2013. Surgical resection of brain metastases from breast cancer in the modern era: clinical outcome and prognostic factors. Anticancer Res. 33, 2159-2167.
Tsao, M.N., Lloyd, N., Wong, R.K., et al., 2012. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst. Rev. 4, CD003869.
Ufen, M.P., Köhne, C.H., Wischneswky, M., et al., 2014. Metastatic breast cancer: Are we treating the same patients as in the past? Ann. Oncol. 25, 95-100.# Index 

Note: Page numbers followed by " $f$ " and " $t$ " refer to figures and tables, respectively.

## A

ABCB1. See P-glycoprotein (P-gp)
Abelson (ABL), 159-160, 221
ACD gene. See Adrenocortical dysplasia homologue gene (ACD gene)
ACT. See Adoptive cell therapy (ACT)
ACTH. See Adrenocorticotropic hormone (ACTH)
Activities of daily living (ADL), 314
Adenosine triphosphate (ATP), 25-26
Adjuvant IFN- $\alpha$ trials in melanoma, 51, $53 t$
HDI trials, 51-52
E2696 trial, 52
ECOG and U.S. Intergroup E1690 trial, 52
pooled analysis of E1684 and E1690, 53
US Intergroup E1694 trial, 52
IFN- $\alpha$ studies evaluated varying dose levels, routes, and duration, $54-55$
meta-analyses of IFN- $\alpha$ trials, $56,56 t$
ADL. See Activities of daily living (ADL)
Adoptive cell therapy (ACT), 290-291
Adrenocortical dysplasia homologue gene (ACD gene), 108
Adrenocorticotropic hormone (ACTH), 305
Advanced breast cancer patients, brain metastases in, $228-230,228 t$
Advanced glycation end products (AGEs), $123-125$
AEDs. See Antiepileptic drugs (AEDs)
AGEs. See Advanced glycation end products (AGEs)
Aging process, 3
AJCC staging system. See American Joint Committee on Cancer (AJCC) staging system
Alanine aminotransferase (ALT), 301
Albumin, 22-23
ALK. See Anaplastic lymphoma kinase (ALK)
ALT. See Alanine aminotransferase (ALT)
AMCG trial. See Austrian trial (AMCG trial)
American Cancer Society, 322
American Joint Committee on Cancer (AJCC) staging system, 50, 238
Aminooxyacetate (AOA), 134
Anaplastic lymphoma kinase (ALK), 32
Androgen-responsive element (ARE), 137

ANG1005, 330
Angiopoietin-like 4 (ANGPTL4), 136
Animal models, 226
Anti-HER2 therapy, 230-231
Anti-PD1 antibodies, 79
Anti-programmed death-1 receptor antibodies, 301
Anticonvulsants, 200
Antiepileptic drugs (AEDs), 29
ANZMTG. See Australia and New Zealand Melanoma Trials Group (ANZMTG)
AOA. See Aminooxyacetate (AOA)
Aoyama/Japanese JROSG99-1, 207
Ara-C. See Cytarabine (Ara-C)
Arc based intensity modulated radiotherapy techniques, 70
ARE. See Androgen-responsive element (ARE)
Area under the curve (AUC), 59
Arthralgias, 314
Aspartate aminotransferase (AST), 301
AST. See Aspartate aminotransferase (AST)
ATP. See Adenosine triphosphate (ATP)
AUC. See Area under the curve (AUC)
Australia and New Zealand Melanoma Trials Group (ANZMTG), 71-72
Austrian trial (AMCG trial), 55
Autolaser interstitial tumor therapy (AutoLITT), $185-186$

## B

B-lymphocytes, 92
BAP1. See BRCA1-Associated protein-1 (BAP1)
Basic fibroblast growth factor (bFGF), 245
Batson's vertebral venous plexus, 15
BAX. See Bcl-2 associated X protein (BAX)
BBB. See Blood-brain-barrier (BBB)
BCA. See $\beta$-cyanoalanine (BCA)
Bcl-2 associated X protein (BAX), 135
BCRP. See Breast cancer resistance protein (BCRP)
BCT. See Biochemotherapy (BCT)
Benign squamoproliferative lesions, 311-312
Beta-catenin (CTNNB1), 93-94
$\beta$-cyanoalanine (BCA), 134
Bevacizumab, 13bFGF. See Basic fibroblast growth factor (bFGF)
Binimetinib, 178
Biochemotherapy (BCT), 51
Blood pressure, 316
Blood-brain-barrier (BBB), 8, 21-22, 38, 68, 86, 214, 239-240
molecular changes in, 24-25
structure, 22-24
Bone-modifying agents, 14
BRAF. See Rapidly accelerated fibrosarcoma kinase B (BRAF)
Brain
control, 207-208
dissemination mechanisms, 323-324
imaging, 149
microenvironment, 89-90
Brain metastases, 6, 21-22, 38, 74, 146, 256. See also
Melanoma brain metastases (MBM)
clinical presentation, 197-198, 198t
development, risk factors for, 322-323
diagnosis/prognosis, 198-199
epidemiology, $198 t$
epigenetics in, 94
and esophageal cancer, 149-150
clinical presentations from, 146-147, 147t
diagnosis and staging, 149
histology, 148
incidence from, 146
risk factors, 148
evolution in animal models, 92-93
local treatment, 230
medical symptom management, 199-200
in melanoma patients, $271 t$
microRNAS in, 94-95
pathogenesis, 38-39
prognosis of breast cancer patients with, 324-325
prognostic factors for OS in melanoma patients with, 273-279, 274t-277t
risk factors for development, 322-323
ROS and, 90
RTOG RPA, $199 t$
treatment, 325
loco-regional approach, 325-328
systemic approach, 328-331
WBRT, 200-201
Brain-metastasizing melanoma cells, 8
BRCA1-Associated protein-1 (BAP1), 105-106
Breast cancer, 12, 30-31, 321. See also Esophageal cancer (EC)
brain dissemination mechanisms, 323-324
brain metastases development, risk factors for, $322-323$
CEREBEL trial, 322
disease-free interval, 12
genetics in brain metastases, 93
prognosis of patients with brain metastases, 324-325
treatment, $12-14$
Breast cancer resistance protein (BCRP), 74-75
Brown/NCCTG N0574, 208-209
"Burr-hole" surgery, 246

## C

c-Jun N-terminal kinase (JNK), 135, 138
c-Kit-based targeted therapy in melanoma, 158
c-Kit aberration in melanoma, 158-159
ethnic differences, 158-159
imatinib
efficacy in melanoma treatment, 159-161
resistance to treatment, 162-163
toxicity in treating melanoma patients, 161-162
perspective, 164
second-generation of tyrosine kinase inhibitors, $163-164$
CAF. See Cancer-associated fibroblasts (CAF)
Camptothecin-derived drugs, 24
Cancer, 3-4. See also Breast cancer
cases and deaths in United States, $4,4 t$
development, 4-5
incidence of, 4
Cancer Genome Atlas Project (TCGA), 238
Cancer Osaka Thyroid (COT), 175
Cancer stem cells (CSC), 87
Cancer-associated fibroblasts (CAF), 88
Cancer-associated localized hypermethylation, 94
Candidate 9p21 locus, 102-103
Carcinoma of unknown primary origin (CUP), 15
Cardiomyopathy, 315-316
Cardiotoxicity
cardiomyopathy, 315-316
QTc prolongation, 316
CAT. See Cysteine aminotransferase (CAT)
CBS. See Cystathionine $\beta$-synthase (CBS)
CBS-derived $\mathrm{H}_{2} \mathrm{~S}, 136$
CBT-1, 26-27
CCR4 ligands, 8
CD117. See Receptor tyrosine kinase (RTK)
CDH1. See E-cadherin (CDH1)
CDK. See Cyclin Dependent Kinase (CDK)
CDKN2. See p16 locus
CDKN2A
melanoma predisposition gene identification, 102-103
mutations, 103-105
Cellular heterogeneity, 87
Central nervous system (CNS), 7-8, 24, 67, 86, 186, 214, $239,267-268,322$CEREBEL trial, 322
Cerebellar brain metastases incidence, 42
Cerebellar colorectal cancer metastases incidence, 42-43
Cerebellar malignant melanomas metastases incidence, 42
Cerebellar metastases, 40
Cerebrospinal fluid (CSF), 28-29
CGL. See Cystathionine $\gamma$-lyase (CSE)
Chang/MDACC, 207-208
Check point inhibitors, 78-79
Chemokines, 8
Chemotherapeutic/chemotherapy, 16, 75-76, 151, 185-186, 221-222, 268, 273, 289, 291. See also
Immunotherapy
agents, 38
regime, 30
Chronic myeloid leukemias (CMLs), 162
Chronically sun-damaged (CSD) skin, 158
CLEOPATRA trial, 329
CMF. See Cyclophosphamide/methotrexate/ 5-fluorouracil (CMF)
CMLs. See Chronic myeloid leukemias (CMLs)
CNS. See Central nervous system (CNS)
Colorectal cancer, 40
Combination therapies, 151-152
Complete response (CR), 76
Computerized tomography (CT), 149, 198-199
Corticosteroids, 29-30, 199
COT. See Cancer Osaka Thyroid (COT)
COX. See Cyclooxygenase (COX)
CR. See Complete response (CR)
Craniotomy specimens, 241-243, 246
CSC. See Cancer stem cells (CSC)
CSD skin. See Chronically sun-damaged (CSD) skin
CSE. Cystathionine $\gamma$-lyase (CSE)
$\mathrm{CSE} / \mathrm{H}_{2} \mathrm{~S}$ signaling, 137
CSF. See Cerebrospinal fluid (CSF)
CSF-1, 88
CT. See Computerized tomography (CT)
CTH. See Cystathionase (CTH)
CTL. See Cytotoxic T lymphocytes (CTL)
CTLA-4. See Cytotoxic T-lymphocyte antigen 4 (CTLA-4)
CTNNB1. See Beta-catenin (CTNNB1)
CUP. See Carcinoma of unknown primary origin (CUP)
Cutaneous melanoma, 238
challenges of melanoma brain metastases, 239
old wisdom, 239-240
MBM, 240
histopathologic findings in, $242 f$
preclinical animal models, 246-247
preclinical studies, 246
prediction, 240
translational research, 241-246
treatment, 247-251
Cutaneous squamous cell carcinoma, 311-312
Cyclin Dependent Kinase (CDK), 178
CDK4
mutation, 105
protein, 103
Cyclooxygenase (COX), 323-324
Cyclophosphamide/methotrexate/5-fluorouracil (CMF), 330
Cystathionase (CTH), 140-141
Cystathionine $\beta$-synthase (CBS), 134
evidence for in cancer, 135-138
Cystathionine $\gamma$-lyase (CSE), 134
evidence for in cancer, 135-138
and melanoma, 138-141
Cysteine aminotransferase (CAT), 134
Cytarabine (Ara-C), 24
Cytotoxic T lymphocytes (CTL), 91
Cytotoxic T-lymphocyte antigen 4 (CTLA-4), 9, 32-33, 170,300
inhibition, 78-79

## D

D9S126 markers, 102-103
Dabrafenib, 76-78, 173-174, 309, 315-316
Dasatinib, 163
DATS. See Diallyl trisulfide (DATS)
DC. See Dendritic cell (DC)
DeCOG trial. See Dermatologic Cooperative Group (DeCOG) trial
Delayed Recall (Dr), 190-191
Dendritic cell (DC), 11, 51
Dermatitis, 302
Dermatologic Cooperative Group (DeCOG) trial, 55
Dermatologic toxicity
benign squamoproliferative lesions, 311-312
cutaneous squamous cell carcinoma, 311-312
hyperkeratosis, 312-313
photosensitivity, 310-311, $312 f$
plantar hyperkeratosis, $313 f$
PPE, 312-313
rash, 309-310
verrucous keratosis, $313 f$
Diagnosis/prognosis, 198-199
Diallyl trisulfide (DATS), 139
Diarrhea, 302-304
Diffusion tensor imaging (DTI), 68-69, 193
Diffusion-weighted MRI (DWI), 15
Dihydropyridines, 26-27
Disease-free interval, 12
Dishevelled-1 (DVL1), 93-94
Dishevelled-3 (DVL3), 93-94Dissemination, 89
Distant metastasis-free interval (DMFS), 55
DMFS. See Distant metastasis-free interval (DMFS)
DNA
hypomethylation, 94
methylation, 111-114
Docetaxel, 13
Dr. See Delayed Recall (Dr)
DTI. See Diffusion tensor imaging (DTI)
DVL1. See Dishevelled-1 (DVL1)
DWI. See Diffusion-weighted MRI (DWI)

## E

E-cadherin (CDH1), 93-94
E-cadherin-catenin molecular complex (ECCC), 88-89
EAC. See Esophageal adenocarcinoma (EAC)
Eastern Cooperative Oncology Group (ECOG), $52,163,324$
EC. See Esophageal cancer (EC)
ECCC. See E-cadherin-catenin molecular complex (ECCC)
ECM. See Extracellular matrix (ECM)
ECOG. See Eastern Cooperative Oncology Group (ECOG)
EGF receptor (EGFr), 32
EGFR. See Epidermal growth factor receptor (EGFR)
EGJ. See Esophagogastric junction (EGJ)
EGJA. See Esophagogastric junction adenocarcinoma (EGJA)
Elacridar, 26-27
EMA. See European Medicine Agency (EMA)
EMEA. See European Medicine Agency (EMA)
EMT. See Epithelial-mesenchymal transition (EMT)
Endocrinopathies, 305-306
Endometrial carcinoma
brain metastases treated by SRS, $263 t$
SRS for, 261-263
EORTC. See European Organization for Research and Treatment of Cancer (EORTC)
Epidemiology, 186
Epidermal growth factor receptor (EGFR), 30-31, 138, 225-226, 323-324
Epigenetics in brain metastases, 94
Epithelial cells, 87
Epithelial-mesenchymal transition (EMT), 87-88
ER. See Estrogen receptor (ER)
Eribulin mesilate monotherapy, 13-14
ERK1/2. See Extracellular-signal-regulated kinase $1 / 2$ (ERK1/2)
Erythematous, $303 f$
ESCC. See Esophageal squamous cell carcinoma (ESCC)
Esophageal adenocarcinoma (EAC), 14, 146, 148
Esophageal cancer (EC), 14, 145. See also Breast cancer

Batson's vertebral venous plexus, 15
brain metastasis, 146, 149-150
clinical presentations from, 146-147, 147t
diagnosis and staging, 149
histology, 148
incidence from, 146
risk factors, 148
CUP, 15
DWI, 15
oncological anatomy, 149-150
prognosis and survival, 152
smoking and alcohol consumption, 14
treatment, 15-17, 150
chemotherapy, 151
combination therapies, 151-152
SRS, 151
surgical resection, 150
WBRT, 151
Esophageal carcinoma, 146-147
Esophageal squamous cell carcinoma (ESCC), 14, 146, 148
Esophagogastric junction (EGJ), 149
Esophagogastric junction adenocarcinoma (EGJA), 17
Estrogen receptor (ER), 30-31, 323
Ethnic differences, 158-159
European Medicine Agency (EMA), 55, 172-173
European Organization for Research and Treatment of Cancer (EORTC), 54, 326
EORTC 18952 trial, 55
EORTC 18991 trial, 55
Exogenous hydrogen sulfide ( NaHS ), 137
Extracellular matrix (ECM), 87
Extracellular-signal-regulated kinase $1 / 2$ (ERK1/2), 138

## F

FAC. See 5-Fluorouracil/doxorubicin/ cyclophosphamide (FAC)
FAK. See Focal adhesion kinase (FAK)
Fatigue, 314-315
FCGM trial. See French trial (FCGM trial)
FDA. See US Food and Drug Administration (FDA)
FDG-PET. See Fluorodeoxyglucose positron emission tomography (FDG-PET)
Fibroblasts, 89-90
Fixed-dose capecitabine, 13
Fluorodeoxyglucose positron emission tomography (FDG-PET), 172
5-Fluorouracil (5-FU), 24
5-Fluorouracil/doxorubicin/cyclophosphamide (FAC), 330
fMRI. See functional MRI (fMRI)
Focal adhesion kinase (FAK), 88-89
Follicle stimulating hormone (FSH), 305Fotemustine, 75-76
Frame-based stereotactic approaches, 70
Frameless stereotactic system, 69
French trial (FCGM trial), 55
FSH. See Follicle stimulating hormone (FSH)
5-FU. See 5-Fluorouracil (5-FU)
functional MRI (fMRI), 68-69

## G

Gamma knife radiosurgery (GKRS), 151
Gastrointestinal (GI) bleeding, 146-147
Gastrointestinal stromal tumor (GIST), 158, 213-214
clinical features
genetic diagnosis, 218-220
histopathological findings, 217-218
neuroradiological findings, 214-217
in CNS, $215 t-216 t, 219 t$
treatment strategy and clinical outcome
chemotherapy, 221-222
radiation, $220-221$
surgery, 220
treatment outcomes, 222-223
Gemcitabine, 24
17-Gene signature, 323-324
Genetics
in breast cancer brain metastases, 93
in lung cancer brain metastases, 93-94
Genome-wide association studies (GWAS), 111
on melanoma predisposition, 111
GI bleeding. See Gastrointestinal (GI) bleeding
GIST. See Gastrointestinal stromal tumor (GIST)
GKRS. See Gamma knife radiosurgery (GKRS)
Glembatumumab vedotin monoclonal antibody, 13
Glial cells, 89-90
Glutathione (GSH), 135
gp100 peptide vaccine, 9
Graded Prognostic Assessment (GPA), 22, 199, 259-261, 281, 324-325, $325 t$
GSH. See Glutathione (GSH)
GWAS. See Genome-wide association studies (GWAS)

## H

$\mathrm{H}_{2} \mathrm{~S}$. See Hydrogen sulfide $\left(\mathrm{H}_{2} \mathrm{~S}\right)$
$\mathrm{H}_{2} \mathrm{~S}_{2} \mathrm{O}_{3}$. See Thiosulfate $\left(\mathrm{H}_{2} \mathrm{~S}_{2} \mathrm{O}_{3}\right)$
HA. See Hydroxylamine (HA)
Hand-foot syndrome, 312-313
HCC. See Hepatocellular carcinoma (HCC)
HDI. See High-dose IFN- $\alpha-2 b$ (HDI)
HDI trials. See High dose IFN- $\alpha$ (HDI) trials
Hellenic Oncology group trial, 54
Heparanase (HPSE), 24-25, 89
Hepatitis, 304-305
Hepatocellular carcinoma (HCC), 138

Hepatotoxicity, 315
HER family receptors and brain metastases, 226
HER2. See Human epidermal growth factor receptor-2 (HER2)
HIF-1. See Hypoxia-inducible factor 1 (HIF-1)
High dose IFN- $\alpha$ (HDI) trials, 51-52
E2696 trial, 52
ECOG, 52
and U.S. Intergroup E1690 trial, 52
pooled analysis of E1684 and E1690, 53
US Intergroup E1694 trial, 52
High mobility group box 1 (HMGB1) protein, 123, 125
High performance liquid chromatography (HPLC), $26-27$
High-dose IFN- $\alpha-2 b$ (HDI), 58
High-risk melanoma predisposition genes
BAP1, 105-106
CDK4 mutation, 105
CDKN2A
melanoma predisposition gene identification, $102-103$
mutations, 103-105
variants associated with melanoma predisposition, $104 t$
HMGB1 protein. See High mobility group box 1 (HMGB1) protein
Hopkins Verbal Learning Test-Revised (HVLT-R), 207-208
Hormone receptor (HR), 322
HPLC. See High performance liquid chromatography (HPLC)
HPSE. See Heparanase (HPSE)
HPV. See Human papillomavirus (HPV)
HR. See Hormone receptor (HR)
Human epidermal growth factor receptor-2 (HER2), 12, $30-31,225-226$
brain metastases in HER2-positive breast cancer patients
anti-HER2 therapy, 230-231
brain metastases in advanced breast cancer patients, 228-230, $228 t$
intrathecal trastuzumab administration for leptomeningeal metastases, 231-232
local treatment of brain metastases, 230
perspectives of brain metastases prevention, 232
trastuzumab in adjuvant setting, 227
HER2-positive disease, 328-329
HER2/neu proto-oncogene, 225-226
receptor, $225-226$
Human papillomavirus (HPV), 148
Human telomeres, 106
HVLT-R. See Hopkins Verbal Learning Test-Revised (HVLT-R)Hydrogen sulfide $\left(\mathrm{H}_{2} \mathrm{~S}\right), 133$
and cancer, 135
CSE and melanoma, 138-141
evidence for role of CBS and CSE, 135-138
donors, 136, 139
synthesis, metabolism, and general functions, $133-135$
Hydroxylamine (HA), 134
Hyperglycemia, 316
Hyperkeratosis, 312-313
Hypothyroidism, 306
Hypoxia, 25
Hypoxia-inducible factor 1 (HIF-1), 25
HIF1 $\alpha, 243-245$

## I

IFN- $\alpha$. See Interferon- $\alpha$ (IFN- $\alpha$ )
IFNA markers, 102-103
IFRT. See Involved field radiation therapy (IFRT)
Ig-like receptors. See Immunoglobulin (Ig)-like receptors
IgG4. See Immunoglobulin G4 (IgG4)
IHC. See Immunohistochemical staining (IHC)
IL-2. See Interleukin-2 (IL-2)
Image-guided approaches, 70
Image-guided stereotactic navigation, 193
Imatinib, 178-179
efficacy in melanoma treatment, 159-161
mesylate, 159-160, 213-214, 221
resistance to treatment, 162-163
toxicity in treating melanoma patients, 161-162
Immortality, 3
Immune-checkpoint inhibitors, 170
anti-programmed death-1 receptor antibodies, 301
CTLA-4, 300
ipilimumab and nivolumab in combination, 301
Immune-mediated pancreatitis, 306-307
Immune-related adverse events (irAEs), 300. See also
Targeted therapy-associated adverse events
dermatitis, 302
diarrhea, 302-304
endocrinopathies, 305-306
erythematous, $303 f$
hepatitis, 304-305
immunotherapy treatment-related morbidity and mortality, 307-308
neuropathy, 306
ocular toxicity, 307
pancreatitis, 306-307
pneumonitis, 307
renal toxicity, 307
vitiligo secondary to immunotherapy, $303 f$
Immune-related response criteria (irRC), 78-79, 290

Immunoglobulin G4 (IgG4), 9-10
Immunoglobulin (Ig)-like receptors, 121
Immunohistochemical staining (IHC), 25-26
Immunotherapy, 189. See also Chemotherapeutic/ chemotherapy
check point inhibitors, 78-79
IL-2, 78
immunotherapy-based regimens, 289
immunotherapy-induced hypophysitis, 305
sequencing targeted therapy with, 180
treatment-related morbidity and mortality, 307-308
In vitro assays, 92-93
Iniparib plus chemotherapy, 13
Integrins, 88-89
Interferon- $\alpha$ (IFN- $\alpha$ ), 50
adjuvant IFN- $\alpha$ trials in melanoma, 51
adjuvant trials testing IFN- $\alpha$ in combination, 56-57
HDI trials, 51-53
IFN- $\alpha$ studies evaluated varying dose levels, routes, and duration, 54-55
meta-analyses of IFN- $\alpha$ trials, 56, $56 t$
biology and clinical applications in cancer, 50-51
biomarkers of clinical benefit with, 58-60
neoadjuvant IFN- $\alpha$ and other agents in melanoma, $57-58$
studies in stage IV inoperable melanoma, 51
Interleukin-2 (IL-2), 9, 78, 289, 300
Interleukin-8 (IL-8), 91
Intracranial metastasis, 214, 220-222
Intracranial metastatic lesions, 6
Intrathecal trastuzumab administration for
leptomeningeal metastases, 231-232
Intratumoral immunotherapy (ITIT), 11
Intravenously (IV), 52
Involved field radiation therapy (IFRT), 327
Ipilimumab, 9, 180, 268, 290, 300
and nivolumab in combination, 301
irAEs. See Immune-related adverse events (irAEs)
Irinotecan, 22-24
irRC. See Immune-related response criteria (irRC)
ITIT. See Intratumoral immunotherapy (ITIT)
IV. See Intravenously (IV)

## J

JNK. See c-Jun N-terminal kinase (JNK)

## K

Karnofsky performance score (KPS), 22, 151, 186-188, 199, 258-259, 324
Ki-67, 24
KIT receptor, 213-214, $214 f$
KIT-inhibitors in melanomas, $179 t$
mutant melanoma treatment, 178-180Kocher/EORTC 22952-26001, 208
KPS. See Karnofsky performance score (KPS)

## L

Lambrolizumab, 10
LANDSCAPE trial, 30-31, 329
Lapatinib, 13, 229-232, 329
Laser interstitial thermal therapy (LITT), 193
Left ventricular ejection fraction (LVEF), 315-316
Lenalidomide, 11
Leptomeningeal metastases, intrathecal trastuzumab administration for, 231-232
Leutinizing hormone (LH), 305
LH. See Leutinizing hormone (LH)
LINE-1 hypermethylation, 111-114
Linear incision, 69
LIS1. See Lissencephaly-1 protein (LIS1)
Lissencephaly-1 protein (LIS1), 243-245
LITT. See Laser interstitial thermal therapy (LITT)
LND. See Lymph node dissection (LND)
Local and supportive treatments, 29-30
Local invasion, 88
Local therapy and WBRT combination, 202-204
Aoyama/Japanese JROSG99-1, 207
Brown/NCCTG N0574, 208-209
Chang/MDACC, 207-208
Kocher/EORTC 22952-26001, 208
Muacevic/German, 204-207
patchell/university of Kentucky, 204
randomized trials
of single brain metastasis surgical resection, $202 t$
of stereotactic radiosurgery boost, 203t-204t
surgical resection trials, 201
WBRT/SRS trials, 201
Loco-regional approach
SRS, 327-328
surgical resection, 326-327
WBRT, 325-326
Low evidence genes, 110-111
Luminal-like disease, 330-331
Lung adenocarcinoma, 31-32
Lung cancer, 21-22
genetics in lung cancer brain metastases, 93-94
LVEF. See Left ventricular ejection fraction (LVEF)
Lymph node dissection (LND), 52

## M

Macrophages, 90-91
Magnetic resonance (MR), 16
Magnetic resonance imaging (MRI), 24, 149, 197-198, $217 f$
Malignant melanoma (MM), 157
Malignant melanomas (M. melanomas), 40

MAPK pathway. See Mitogen activated protein kinase (MAPK) pathway
MAPKp38. See Mitogen-activated protein kinase p38 (MAPKp38)
Mass effect, 199, 201
Matrix metalloproteinases (MMP), 24-25
MMP-2, 272-273
MBM. See Melanoma brain metastases (MBM)
MBT. See Metastatic brain tumors (MBT)
MC1R, 109
MC1R gene. See Melanocortin-1-receptor (MC1R) gene
MD Anderson Cancer Center, 73
Medical symptom management
anticonvulsants, 200
corticosteroids, 199
Melanocortin-1-receptor (MC1R) gene, 103-105
Melanoma, 7, 32-33, 49, 101-102, 119-120, 138, 157, 267-268. See also Cutaneous melanoma
adjuvant IFN- $\alpha$ trials in, 51-57
BRAF, 8
complications, $7-8$
CSE and, 138-141
factors with CNS by, 269
BRAF mutations, 269-272
clinicians, 273
development of brain metastasis in melanoma patients, $271 t$
murine studies, 272-273
MAPK pathway and molecular classification, $170-172$
neoadjuvant IFN- $\alpha$ and other agents in, 57-58
pigmented tissues, 7
predisposition, 101-102
genomic map, $113 f$
GWAS on, 111
high-risk melanoma predisposition genes, 102-106
low evidence genes, 110-111
pigmentation trait genes, 109-110
telomere regulating genes, 106-109
prognostic factors for OS in, 273-279, 274t-277t
RAGE, 122-123
ligands, $123-130,124 t$
treatment, 8-12
treatment-specific predictors of outcomes in brain metastasis patients, 279
combining radiation with systemic therapy, 291
radiation therapy, 279-281
selected systemic treatment studies, $285 t-288 t$
SRS, 282-283
surgery, 283-284
systemic therapies for melanoma brain metastases, 284-291
WBRT, 281-282Melanoma brain metastases (MBM), 4-5, 5f, 186, 240. See also brain metastases
algorithm for management of patients, $188 f$
clinical predictors and prognostic factors, 186-188
epidemiology, 186
histopathologic findings in, $242 f$
preclinical animal models, 246-247
preclinical studies, 246
prediction, 240
prognostic factors for patients with, 66
radiation therapy, 70
current role, 74
minimizing risk of neurological deficit, 73-74
multiple metastases, 74
SRS, $70-71$
WBRT, 71-73
surgery, 66-67
complications, 69-70
current indications, 68
historical role, 67-68
technical aspects of surgical resection, 68-69
surgical and radiotherapeutic treatment
radiosurgery, 188-189
surgery, 191-193
WBRT, 189-191
systemic therapies, $74-75,75 t, 78 t$
chemotherapy, 75-76
immunotherapy, 78-79
small molecule targeted therapies, 76-78
suggested approach to management, 79-80
translational research, 241-246
genes, 245
HIF1 $\alpha, 245-246$
PD-L1, 243
using tumor specimens, 241
tumor tissue-based research, 243
treatment
future of treatment of patients, 249
great improvements since 2011, 247-249
radiation therapy, 250
Melanoma metastases
cerebellar metastases, 40
epidemiology, 38
histology of primary cancer, 39-40
OUH, 40-41
cerebellar colorectal cancer metastases incidence, $42-43$
cerebellar malignant melanomas metastases incidence, 42
cerebellar vs. supratentorial brain metastases incidence, 42
clinical setting, 41
origin of primary tumor, 41 statistics, 41
pathogenesis of brain metastasis, 38-39
Melanoma therapy
FDA-approved therapies for metastatic melanoma, 300
immune checkpoint inhibitors
anti-programmed death-1 receptor antibodies, 301
CTLA-4, 300
ipilimumab and nivolumab in combination, 301
irAEs, 302-308
targeted therapy, 308-309
targeted therapy-associated adverse events, 309-316
MelJuSo melanoma cell lines, 123
Memorial Sloan Kettering Cancer Center (MSKCC), 305
3-Mercaptopyruvate sulfurtransferase (3-MST), 134
Metastases, 4-5, 21-22, 24-25
Metastatic brain cancer. See Metastatic cancers to brain
Metastatic brain tumors (MBT), 6, 86, 186
Metastatic cancers to brain, 6, 21-22
BBB structure, 22-24
local and supportive treatments, 29-30
molecular changes in BBB with metastatic lesions, $24-25$
P-gp, 25-29
systemic and targeted therapies
breast cancer, 30-31
general principles, 30
lung adenocarcinoma, 31-32
melanoma, 32-33
Metastatic colonization, 4-5
Metastatic dissemination, 4-5
Metastatic melanoma (MM), 170, 238
in brain, 66
Metastatic niche, 4-5
Methylthioadenosine phosphorylase (MTAP), 59-60
MGMT deletion, 110-111
Microglia, 90
Micrometastatic disease, 256
Microphthalmia-associated transcription factor (MITF), $109-110$
microRNAS in brain metastases, 94-95, 95f, $96 f$
Microsurgical technique, 69
Microvessel density (MVD), 245
Mini craniotomy, 69
MITF. See Microphthalmia-associated transcription factor (MITF)
Mitogen activated protein kinase (MAPK) pathway, 170,308
BRAF mutant melanoma treatment with BRAF inhibitors, 172-175
BRAF inhibitors combination, 175-177
with MEK inhibitor monotherapy, 175-177, $176 t$
and drug inhibitors in melanoma, $171 f$KIT mutant melanoma treatment, 178-180, $179 t$ and melanoma molecular classification, 170-172
NRAS mutant melanoma treatment, 178
sequencing targeted therapy with immunotherapy, 180
Mitogen-activated protein kinase p38 (MAPKp38), 135
MM. See Malignant melanoma (MM)Metastatic melanoma (MM)
MMP. See Matrix metalloproteinases (MMP)
Modified World Health Organization (mWHO), 78-79
MPRAGE sequence. See Multiplanar rapid acquisition gradient echo (MPRAGE) sequence
MR. See Magnetic resonance (MR)
MRI. See Magnetic resonance imaging (MRI)
MRP. See Multidrug resistance-associated proteins (MRP)
MSKCC. See Memorial Sloan Kettering Cancer Center (MSKCC)
3-MST. See 3-Mercaptopyruvate sulfurtransferase (3-MST)
MTAP. See Methylthioadenosine phosphorylase (MTAP)
MTS1. See p16 locus
Muacevic/German, 204-207
Multidrug resistance-associated proteins (MRP), 22-23
Multiplanar rapid acquisition gradient echo (MPRAGE) sequence, 68-69
Multiple metastases, 74
Multisource cobalt system, 70
Murine studies, 272-273
MVD. See Microvessel density (MVD)
mWHO. See Modified World Health Organization (mWHO)

## N

$\mathrm{Na}_{2} \mathrm{~S}$. See Sodium sulfide $\left(\mathrm{Na}_{2} \mathrm{~S}\right)$
NACT. See Neoadjuvant chemoradiotherapy (NACT)
NaHS. See Exogenous hydrogen sulfide ( NaHS )
Natural Killer cells, 91
Natural product chemotherapy agents (NPCAs), 22-23
NCCTG. See North Central Cancer Treatment Group (NCCTG)
Neoadjuvant chemoradiotherapy (NACT), 150
Neoadjuvant IFN- $\alpha$ and other agents in melanoma, 57-58. See also Adjuvant IFN- $\alpha$ trials in melanoma Neratinib, 329
Neurofibromatosis-1 (NF-1), 172
Neuropathy, 306
Neurosurgery, 6, 8-9
Neurotrophins, 89
Neutrophils, 91
NF-1. See Neurofibromatosis-1 (NF-1)
NF-кB. See Nuclear factor kappa beta (NF-кB)

Nilotinib, 163, 179-180
Nitric oxide (NO), 90
Nivolumab, 9-10
and ipilimumab in combination, 301
NNT. See Number needed to treat (NNT)
NO. See Nitric oxide (NO)
Non-steroidal anti-inflammatories (NSAIDs), 312-313
Nonsmall cell lung cancer (NSCLC), 21-22, 32
North Central Cancer Treatment Group (NCCTG), $51-52$
NPCAs. See Natural product chemotherapy agents (NPCAs)
NRAS mutant melanoma treatment, 178
NSAIDs. See Non-steroidal anti-inflammatories (NSAIDs)
NSCLC. See Nonsmall cell lung cancer (NSCLC)
Nuclear factor kappa beta (NF-кB), 135, 137
Number needed to treat (NNT), 56

## O

OB domain. See Oligonucleotide-/oligosaccharidebinding (OB) domain
Objective response rate (ORR), 164
Ocular toxicities, 307, 316
Odds ratio (OR), 323
Old wisdom, 239-240
Oligometastases, 70-73
Oligonucleotide-/oligosaccharide-binding (OB) domain, 107-108
"One-size-fits-all" approach, 256-257
OR. See Odds ratio (OR)
ORR. See Objective response rate (ORR)Overall response rates (ORR)
OS. See Overall survival (OS)
Oslo University Hospital (OUH), 40-41
cerebellar malignant melanomas metastases incidence, 42
cerebellar vs. supratentorial brain metastases incidence, 42
clinical setting, 41
origin of primary tumor, 41
statistics, 41
OUH. See Oslo University Hospital (OUH)
Ovarian and endometrial carcinomas, 255-256
Ovarian carcinoma, SRS for, 258
brain metastases treated by SRS, $261 t$
retrospective study, 259
tumor control rate, 259-261
Overall response rates (ORR), 300
Overall survival (OS), 22, 51, 72, 160-161, 186, 239, $267-268,300$
prognostic factors in melanoma patients, 273-279, $274 t-277 t$## $\mathbf{P}$

P-glycoprotein (P-gp), 22-23, 25-26
CSF, 28-29
inhibitors, 26-27
PK studies, 27-28
P-gp. See P-glycoprotein (P-gp)
p.N249S, 108
p.R364X mutations, 108
p.V272M, 108
p13K pathway. See Phosphoinositol 3-kinase (p13K) pathway
p14, 103
3p14p13, 110
p16 locus, 102-103
P5P. See Pyridoxal-5'-phosphate (P5P)
Paclitaxel, 27-28, $28 f$
PAFAH1B1. See Platelet-activating factor acetylhydrolase 1b, regulatory subunit (PAFAH1B1)
Palmar-plantar erythrodysesthesia (PPE), 312-313
Pancreatitis, 306-307
Parenchymal metastases, 39
PARP inhibitors. See Poly-Adenosine Ribose
Polymerase (PARP) inhibitors
Partial response (PR), 76
Patchell/university of Kentucky, 204
Pathobiology of brain metastasis, 86-87
brain metastasis animal models, evolution in, 92-93
brain's microenvironment, 89-90
cellular heterogeneity and proliferation, 87
dissemination, 89
ECCC, 88-89
EMT, 87-88
epigenetics in brain metastases, 94
genetics
in breast cancer brain metastases, 93
in lung cancer brain metastases, 93-94
integrins, 88-89
local invasion, 88
microRNAS in brain metastases, 94-95
ROS and brain metastasis, 90
systemic immune cells contribution to metastasis proliferation, 90-92
tumor stroma, interaction with, 88
PCI. See Prophylactic cranial irradiation (PCI)
PD-1. See Programmed death-1 (PD-1)
PD-1/PDL-1 Axis inhibition, 78-79
PD-L1. See Programmed cell death ligand 1 (PD-L1)
pDC precursors. See plasmacytoid Dendritic cell (pDC) precursors
PDGFR. See Platelet-derived growth factor receptor (PDGFR)
PDGFRA. See Platelet-derived growth factor receptor alpha (PDGFRA)

Pembrolizumab, 10
Perfusion-weighted magnetic resonance, 16
Pertuzumab, 13
PFS. Progression-free survival (PFS)
Pharmacokinetic (PK) studies, 27-28
Phase II studies, 162-163
Phosphoinositol 3-kinase (p13K) pathway, 12
Photosensitivity, 310-311, $312 f$
Pigmentation trait genes, 109. See also Telomere regulating genes
MC1R, 109
MITF gene, 110
PK studies. See Pharmacokinetic (PK) studies
Plantar hyperkeratosis, $313 f$
plasmacytoid Dendritic cell (pDC) precursors, 50
Platelet-activating factor acetylhydrolase 1b, regulatory subunit (PAFAH1B1), 243-245
Platelet-derived growth factor receptor (PDGFR), $159-160$
Platelet-derived growth factor receptor alpha (PDGFRA), 213-214, $214 f$
Platelets, 92
Pneumonitis, 307
Poly-Adenosine Ribose Polymerase (PARP) inhibitors, 31
Pomalidomide, 11
POT1 gene. See Protection of telomeres 1 (POT1) gene
PPE. See Palmar-plantar erythrodysesthesia (PPE)
PPG. See Propargyl glycine (PPG)
PR. See Partial response (PR)Progesterone receptor (PR)
Preclinical studies, 160
in MBM, 246
Prescription dose, 257
Primary cancers, 38
histology, 39-40
Primary gliomas, 24-25
Primary melanoma, 158
Primary tumor
origin of, 41
ulceration, 6-7
Progesterone receptor (PR), 30-31, 323
Programmed cell death ligand 1 (PD-L1), 9-10, 243
Programmed cell death ligand 2 (PD-L2), 9-10
Programmed death-1 (PD-1), 9-10, 170, 268, 301 receptor, 79, 119-120
Progression-free survival (PFS), 160-161, 268, 301
Proliferation, 87
Promoter hypermethylation, 111-114
Propargyl glycine (PPG), 134
Prophylactic cranial irradiation (PCI), 232
Prostate-specific antigen (PSA), 137
Protection of telomeres 1 (POT1) gene, 107-108
Proton spectroscopy magnetic resonance, 16PSA. See Prostate-specific antigen (PSA)
PubMed database, 214
Pyrexia, 314
Pyridoxal-5'-phosphate (P5P), 134
Pyruvate acid, 134

## Q

QTc prolongation, 316
Quinone pool (Q), 134

## R

$R A D 51 B$ nonsense mutation, 111
Radiation, 220-221
Radiation therapy, 185-186, 250, 279-281
Radiation therapy for melanoma brain metastases,
70. See also Systemic therapies
current role, 74
minimizing risk of neurological deficit, 73-74
multiple metastases, 74
SRS, $70-71$
WBRT, 71-73
Radiation Therapy Oncology Group (RTOG), 70, 186-188, 199, 279-281, 324
Radiosensitizers, 201
Radiosurgery, 70, 188-189
RAGE. See Receptor for advanced glycation end products (RAGE)
Randomized controlled trials (RCTs), 56
Rapidly accelerated fibrosarcoma kinase B (BRAF), 13 inhibitors, $76-78$
inhibitors combination, 175-177
and MEK inhibition combination, 309
mutant melanoma treatment
with BRAF inhibitors, 172-175
with MEK inhibitor monotherapy, 175-177, $176 t$
Rapidly accelerated fibrosarcoma kinase B (BRAF), 308
Rash, 309-310
RCTs. See Randomized controlled trials (RCTs)
Reactive glia, 246
Reactive oxygen species (ROS), 90, 135
and brain metastasis, 90
Receptor for advanced glycation end products (RAGE), 120
ligands in melanoma, 123, $124 t$
AGEs, 124-125
HMGB1, 125
S100 proteins, 125, 129
S100A2, 126-127
S100A4, 127-128
S100A6, 128
S100A8, 129
S100A9, 129
S100B, 125-126
in melanoma, 122-123
physiological role, 120
and S100 protein ligands in melanoma tumors, $123 f$
signaling, 122
structure and isoforms, 121-122, $121 f$
Receptor tyrosine kinase (RTK), 158, 171
RECIST. See Response Evaluation Criteria in Solid Tumors (RECIST)
Recursive partitioning analysis (RPA), 22, 70, 186-188, 199, 279-281, 324
Regulator of T-cells (T-Reg Cells), 32-33
Relapse-free survival (RFS), 52
Renal toxicity, 307
Response Evaluation Criteria in Solid Tumors (RECIST), 76
Response rate (RR), 75-76
Retrospective studies, 186, 228
RFS. See Relapse-free survival (RFS)
ROS. See Reactive oxygen species (ROS)
RPA. See Recursive partitioning analysis (RPA)
RR. See Response rate (RR)
RTK. See Receptor tyrosine kinase (RTK)
RTOG. See Radiation Therapy Oncology Group (RTOG)
RTOG 90-05 study, 71

## S

S100 proteins, 125
S100A2 protein, 126-127
S100A4 protein, 127-128
S100A6 protein, 128
S100A8 protein, 129
S100A9 protein, 129
S100A10 protein, 129
S100A11 protein, 129
S100B protein, 125-126
SC. See Subcutaneously (SC)
SCLC. See Small cell lung cancer (SCLC)
SD. See Stable disease (SD)
SDO. See Sulfur dioxygenase (SDO)
Seed and soil hypothesis, 39, 86-87
Seizure, 22
Sequencing targeted therapy with immunotherapy, 180
Shelterin complex genes, 108
Signal transducer and activator of transcription (STAT) signaling, 51, 272-273
Single metastases, 70-73
Single-nucleotide polymorphisms (SNPs), 110, $112 t$
SK-Mel28 melanoma cell lines, 123
Skin cancer, 101-102, 267-268
Slow aging, 3
Small cell lung cancer (SCLC), 21-22, 39
Small molecule targeted therapies, 76
BRAF inhibitors, 76-78SNPs. See Single-nucleotide polymorphisms (SNPs)
SOD. See Superoxide dismutase (SOD)
Sodium sulfide $\left(\mathrm{Na}_{2} \mathrm{~S}\right), 139$
Sorafenib, 13, 284
South West Oncology Group (SWOG), 56-57
Splicing isoforms, 122
SQR. See Sulfide:quinone oxidoreductases (SQR)
SR. See Surgical resection (SR)
sRAGE, 121-122
SRS. See Stereotactic radiosurgery (SRS)
ST. See Sulfur transferase (ST)
Stable disease (SD), 78-79
STAT signaling. See Signal transducer and activator of transcription (STAT) signaling
Stereotactic navigation, 69
Stereotactic radiosurgery (SRS), 6, 30, 66, 70-71, 151, 185-186, 201, 256-257, 273, 282-283, 325-328
for endometrial carcinoma, 261-263
for ovarian carcinoma, 258, $261 t$
retrospective study, 259
tumor control rate, 259-261
technique, 257-258
Subcutaneously (SC), 52
Sulfide:quinone oxidoreductases (SQR), 134
Sulfur dioxygenase (SDO), 134
Sulfur transferase (ST), 134
Sunitinib, 222
Superoxide dismutase (SOD), 135
Supratentorial brain metastases incidence, 42
Surgery, 185-186, 191, 220. See also Stereotactic radiosurgery (SRS)
oligometastatic disease, 193
Patchell and Vecht studies, 192
Patchell study, 191-192
"surgical accessibility" of metastatic lesion, 193
Surgical resection (SR), 150-152, 326-327
Surgical resectioning, 16
SWOG. See South West Oncology Group (SWOG)
Systemic approach, 328
HER2-positive disease, 328-329
luminal-like disease, 330-331
triple negative disease, 329-330
Systemic therapies, 328. See also Radiation therapy for melanoma brain metastases
chemotherapy, 75-76
combining radiation with, 291
immunotherapy, 78-79
check point inhibitors, 78-79
IL-2, 78
for melanoma brain metastases, $74-75,75 t, 78 t$
for melanoma brain metastases, 284-291
small molecule targeted therapies, 76-78
BRAF inhibitors, 76-78
suggested approach to management, 79-80

## T

T helper (Th) cells, 91
T-DM1. See Trastuzumab emtansine (T-DM1)
T-lymphocytes, 91
T-Reg Cells. See Regulator of T-cells (T-Reg Cells)
Tamoxifen, 27-28
everolimus, 13
TAMs. See Tumor associated macrophages (TAMs)
Tanespimycin plus trastuzumab, 12
Targeted therapy, 308
combination BRAF and MEK inhibition, 309
dabrafenib, 309
vemurafenib, 308-309
Targeted therapy-associated adverse events. See also
Immune-related adverse events (irAEs)
arthralgias, 314
cardiotoxicity, 315-316
dermatologic toxicity, 309-314
fatigue, 314-315
hepatotoxicity, 315
hyperglycemia, 316
ocular toxicities, 316
pyrexia, 314
TCGA. See Cancer Genome Atlas Project (TCGA)
Telomerase reverse transcriptase (TERT) gene, 107
Telomere regulating genes, 106. See also Pigmentation trait genes
germline mutations, 106-107
POT1 gene, 107-108
shelterin complex genes, 108
TERT gene, 107
Telomeric repeat binding factor 2, interacting protein (TERF2IP) gene, 108
Temozolomide (TMZ), 25-26, 31-32, 75-76, 284
TERF2IP gene. See Telomeric repeat binding factor 2, interacting protein (TERF2IP) gene
TERT gene. See Telomerase reverse transcriptase (TERT) gene
TGF- $\alpha$. See Transforming Growth Factor alpha (TGF- $\alpha$ )
Th cells. See T helper (Th) cells
Thiosulfate $\left(\mathrm{H}_{2} \mathrm{~S}_{2} \mathrm{O}_{3}\right), 134$
Thyroid stimulating hormone (TSH), 305
TIMP-1. See Tissue Inhibitor of Metalloproteinases 1 (TIMP-1)
Tissue Inhibitor of Metalloproteinases 1 (TIMP-1), 59
Tissue microarray (TMA), 136
TKI. See Tyrosine kinase inhibitor (TKI)
TLR 4. See Toll like receptor 4 (TLR 4)
TMA. See Tissue microarray (TMA)
TMZ. See Temozolomide (TMZ)
TNF-RII. See Tumor Necrosis Factor alpha Receptor II (TNF-RII)
Toll like receptor 4 (TLR 4), 125
Topotecan, 22-24Trametinib, 175, 315-316
Trans-Tasman Radiation Oncology Group (TROG), $71-72$
Transforming Growth Factor alpha (TGF- $\alpha$ ), 59
Translational research, 241
genes, 245
HIF1 $\alpha, 245-246$
PD-L1, 243
using tumor specimens, 241
tumor tissue-based research, 243
Trastuzumab, 13, 226-227
in adjuvant setting, 227
HER2-positive breast cancer patients, $227 t$
Trastuzumab plus anthracycline, 13
Trastuzumab plus Everolimus, 12
Trastuzumab emtansine (T-DM1), 12, 328
Tremelimumab, 10
Triple negative disease, 329-330
"Triple-negative" breast cancer, 31
TROG. See Trans-Tasman Radiation Oncology Group (TROG)
TSGs. See Tumor suppressor genes (TSGs)
TSH. See Thyroid stimulating hormone (TSH)
Tumor associated macrophages (TAMs), 91
Tumor cells, 87, 324
Tumor Necrosis Factor alpha Receptor II (TNF-RII), 59
Tumor stroma, interaction with, 88
Tumor suppressor genes (TSGs), 93-94
Tumor-related inflammation, 7-8
Tyrosine kinase inhibitor (TKI), 30-31

## U

US Food and Drug Administration (FDA), 172-173
US Intergroup E1697 trial, 54
Uterine leiomyosarcoma, 262-263
Uveitis, 316

## V

Vascular endothelial growth factor (VEGF), 25, 136, 330 VEGF-A, 243-245
Vascular endothelial growth factor receptor (VEGFR), 330
Vemurafenib, 9-11, 76-78, 172, 174, 177, 308-309
Verrucous keratosis, $313 f$
Vitiligo secondary to immunotherapy, $303 f$

## W

WBXRT. See Whole brain radiation therapy (WBRT)
Whole brain radiation therapy (WBRT), 6, 11, 30, 66, 71-73, 151, 186-191, 200-201, 256, 273, 281-282, $325-326$
advantages and limitations, 6
and local therapy combination, 202-204
Aoyama/Japanese JROSG99-1, 207
Brown/NCCTG N0574, 208-209
Chang/MDACC, 207-208
Kocher/EORTC 22952-26001, 208
Muacevic/German, 204-207
patchell/university of Kentucky, 204
randomized surgical resection trials, 201
randomized trials of single brain metastasis
surgical resection, $202 t$
randomized trials of stereotactic radiosurgery boost, 203t-204t
randomized WBRT/SRS trials, 201
minimizing risk of neurological deficit following, $73-74$
radiosensitizers, 201
randomized trials of postoperative/ postradiosurgery, 205t-207t
selected randomized trials, $200 t$
Whole brain radiotherapy. See Whole brain radiation therapy (WBRT)
Wnt pathway, 137-138